data_2fn5_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2fn5 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.548 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 48.4 tt0 . . . . . 0 N--CA 1.425 -1.706 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -90.79 108.39 19.8 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.822 -1.548 . . . . 0.0 106.822 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -123.13 140.71 34.17 Favored Pre-proline 0 C--N 1.293 -1.881 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -171.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -86.7 131.71 3.37 Favored 'Trans proline' 0 C--N 1.314 -1.267 0 C-N-CA 123.05 2.5 . . . . 0.0 111.928 174.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.3 t -124.32 105.79 15.85 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.302 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 175.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.587 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.1 tt0 -91.32 103.33 16.0 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 175.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.495 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.2 OUTLIER -91.85 143.7 26.24 Favored 'General case' 0 N--CA 1.421 -1.884 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 -174.556 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -112.05 87.92 2.68 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.79 0.805 . . . . 0.0 109.684 175.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.444 ' HG2' HD11 ' A' ' 10' ' ' LEU . 2.1 mmtp -84.87 -178.95 6.98 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -178.222 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.491 ' CG ' ' H ' ' A' ' 14' ' ' GLU . 18.9 t70 -76.08 -176.7 3.61 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 113.568 -1.651 . . . . 0.0 109.845 -178.577 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.491 ' H ' ' CG ' ' A' ' 13' ' ' ASP . 12.0 pt-20 -82.02 -19.86 39.57 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.809 -1.087 . . . . 0.0 109.936 -176.288 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -69.26 -47.46 64.59 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.73 -128.31 4.4 Favored Glycine 0 N--CA 1.425 -2.039 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.078 -177.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mt -103.81 -49.49 3.64 Favored 'General case' 0 CA--C 1.495 -1.139 0 O-C-N 122.351 -0.499 . . . . 0.0 110.151 -174.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 71.74 31.91 64.55 Favored Glycine 0 N--CA 1.428 -1.858 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -175.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 18.5 pt -111.01 167.82 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 C-N-CA 120.151 -0.62 . . . . 0.0 110.399 -179.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.4 m -131.47 154.38 48.78 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.303 -177.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -123.34 170.04 14.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 C-N-CA 123.334 0.654 . . . . 0.0 109.352 -178.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.428 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.1 tt -136.37 131.41 48.38 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 C-N-CA 120.569 -0.452 . . . . 0.0 110.208 176.298 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.509 ' HA2' HD12 ' A' ' 37' ' ' ILE . . . -95.63 104.24 3.08 Favored Glycine 0 CA--C 1.477 -2.305 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.412 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 19.4 ptm -145.75 98.17 3.08 Favored 'General case' 0 C--N 1.29 -1.992 0 CA-C-N 115.389 -0.406 . . . . 0.0 110.699 -179.049 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.036 0 O-C-N 124.36 1.038 . . . . 0.0 111.32 -178.162 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 3.4 pp . . . . . 0 N--CA 1.434 -1.251 0 CA-C-O 120.957 0.408 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -109.8 32.59 6.62 Favored Glycine 0 C--N 1.281 -2.509 0 C-N-CA 120.19 -1.005 . . . . 0.0 111.329 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.509 HD12 ' HA2' ' A' ' 23' ' ' GLY . 28.4 mm -93.06 100.4 11.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-O 121.732 0.777 . . . . 0.0 110.064 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -97.24 166.65 11.46 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.336 178.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.0 t -80.95 131.37 34.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 175.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.4 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -93.27 -49.61 5.88 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.477 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.3 m -150.69 161.03 43.4 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 -176.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.407 HG13 ' HG3' ' A' ' 49' ' ' GLN . 57.7 t -132.66 160.39 42.6 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.662 0 N-CA-C 104.9 -2.259 . . . . 0.0 104.9 175.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.1 t . . . . . 0 N--CA 1.433 -1.287 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 173.412 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.467 ' O ' ' HB2' ' A' ' 51' ' ' ASP . . . . . . . . 0 C--O 1.187 -2.204 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -95.95 -57.07 2.45 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -176.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.407 ' HG3' HG13 ' A' ' 42' ' ' VAL . 25.6 mt-30 -80.92 -12.99 59.31 Favored 'General case' 0 CA--C 1.502 -0.874 0 C-N-CA 119.349 -0.94 . . . . 0.0 109.853 177.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.494 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 5.8 mmp_? -92.17 -9.83 40.95 Favored 'General case' 0 N--CA 1.427 -1.599 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.891 173.062 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.467 ' HB2' ' O ' ' A' ' 47' ' ' ALA . 13.2 t70 -70.54 -64.74 0.84 Allowed 'General case' 0 N--CA 1.481 1.12 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 171.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 115.54 -25.66 9.55 Favored Glycine 0 N--CA 1.431 -1.655 0 C-N-CA 120.383 -0.913 . . . . 0.0 114.297 175.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -80.48 -36.0 34.04 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 117.903 0.851 . . . . 0.0 109.149 -177.581 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.4 tt -92.97 149.55 4.18 Favored 'Isoleucine or valine' 0 C--O 1.254 1.303 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 23.5 mt-30 -130.8 167.43 18.91 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.156 0.503 . . . . 0.0 111.031 179.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.98 -8.81 11.48 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.165 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.641 178.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 10.3 p30 -106.38 12.62 29.59 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-O 121.423 0.63 . . . . 0.0 110.764 -177.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -91.28 -174.4 3.93 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.613 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.56 ' O ' HG21 ' A' ' 91' ' ' ILE . 30.6 tt0 -135.09 126.13 27.78 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.765 -176.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.448 ' HA ' HG12 ' A' ' 91' ' ' ILE . 47.0 mm -73.65 114.45 13.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.014 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.681 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 74.0 t -93.26 -49.95 12.5 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-O 121.675 0.75 . . . . 0.0 109.928 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.43 ' HG3' ' H ' ' A' ' 67' ' ' SER . 26.1 tt0 -151.27 126.73 10.06 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.464 178.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 5.0 t -118.43 130.65 72.96 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.048 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 174.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 16.6 t70 62.69 16.71 9.16 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 124.205 1.002 . . . . 0.0 111.623 174.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.89 15.81 78.37 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.209 -179.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.4 tt -79.86 -16.83 12.93 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.115 0 O-C-N 122.347 -0.502 . . . . 0.0 112.064 -175.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.43 ' H ' ' HG3' ' A' ' 62' ' ' GLU 0.282 0.8 OUTLIER 39.34 80.97 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 114.728 1.381 . . . . 0.0 114.728 -175.553 . . . . . . . . 4 4 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.43 ' H ' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -92.24 36.78 0.99 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.859 -176.73 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.66 91.41 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.713 -177.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 107.4 33.17 3.21 Favored Glycine 0 C--N 1.303 -1.276 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.79 176.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.9 m -103.97 175.96 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 120.249 -0.58 . . . . 0.0 111.152 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 40.3 p -91.89 176.0 6.68 Favored 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 178.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.35 -25.18 64.96 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.404 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 -65.32 -48.16 74.04 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.457 ' O ' HG21 ' A' ' 79' ' ' VAL . 29.5 t80 -64.44 -51.85 61.07 Favored 'General case' 0 N--CA 1.432 -1.331 0 CA-C-N 114.577 -1.192 . . . . 0.0 109.124 -178.208 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.77 -44.99 96.05 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.558 -177.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.5 -34.1 73.58 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.039 0.447 . . . . 0.0 110.066 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.461 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 76.8 m -65.75 -45.06 84.01 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.525 176.477 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.457 HG21 ' O ' ' A' ' 75' ' ' PHE . 41.1 t -60.62 -52.33 62.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 C-N-CA 122.229 0.212 . . . . 0.0 110.527 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -70.7 0.07 7.78 Favored 'General case' 0 CA--C 1.552 1.049 0 CA-C-O 121.406 0.622 . . . . 0.0 112.154 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.461 ' HB3' ' O ' ' A' ' 78' ' ' THR . 25.9 ttm180 -100.14 -38.18 8.63 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 124.024 0.93 . . . . 0.0 108.986 174.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.17 -10.26 59.3 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.122 -175.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.3 p -71.58 161.23 31.34 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 113.183 0.808 . . . . 0.0 113.183 -178.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -118.9 -161.24 0.84 Allowed 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.23 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.59 -63.42 5.3 Favored Glycine 0 N--CA 1.439 -1.12 0 O-C-N 123.544 0.528 . . . . 0.0 113.323 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.495 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 17.9 m120 -82.14 108.82 15.91 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.8 t -119.7 136.66 56.1 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.677 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.721 -176.433 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 84.2 mtt180 -102.63 97.38 7.58 Favored 'General case' 0 C--N 1.288 -2.103 0 CA-C-O 121.4 0.619 . . . . 0.0 109.993 173.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.44 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 92.8 m-85 -89.36 106.16 18.27 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.735 177.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.681 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.4 t -95.65 88.77 2.13 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.743 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 175.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.56 HG21 ' O ' ' A' ' 59' ' ' GLN . 82.2 mt -101.09 149.68 6.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.678 0 CA-C-N 114.613 -1.176 . . . . 0.0 108.566 179.094 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.548 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -138.05 128.73 4.32 Favored Glycine 1 N--CA 1.393 -4.196 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 -178.638 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 15.7 ttp180 -157.9 162.1 38.28 Favored 'General case' 0 N--CA 1.414 -2.24 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 -175.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.285 -2.212 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 175.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 . . . . . 0 CA--C 1.479 -1.751 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.402 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.5 mm? -86.43 134.28 33.71 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 123.752 0.658 . . . . 0.0 109.884 -177.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 10.7 p90 -141.57 144.36 33.11 Favored Pre-proline 0 C--N 1.293 -1.865 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.802 -178.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -84.61 130.17 4.36 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 C-N-CA 122.57 2.18 . . . . 0.0 113.168 179.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.458 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 26.1 t -115.65 107.65 23.23 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.228 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 174.034 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -88.42 107.02 18.64 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 177.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -100.48 139.27 36.4 Favored 'General case' 0 N--CA 1.423 -1.802 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -176.157 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -109.76 81.77 1.49 Allowed 'General case' 0 N--CA 1.426 -1.641 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 173.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.527 ' HZ2' HG22 ' A' ' 43' ' ' THR . 2.0 mmtt -77.9 171.72 14.56 Favored 'General case' 0 N--CA 1.409 -2.52 0 CA-C-N 115.05 -0.977 . . . . 0.0 113.426 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -72.96 167.98 19.93 Favored 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 126.06 1.744 . . . . 0.0 108.617 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -68.58 -21.41 64.53 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-O 121.412 0.625 . . . . 0.0 110.289 179.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -64.14 -32.43 74.0 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.418 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.23 -158.8 14.05 Favored Glycine 0 N--CA 1.434 -1.472 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -178.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.407 ' HG ' ' OG1' ' A' ' 83' ' ' THR . 17.6 mt -83.64 -48.78 9.84 Favored 'General case' 0 CA--C 1.49 -1.352 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -177.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.32 32.01 71.85 Favored Glycine 0 N--CA 1.431 -1.67 0 O-C-N 124.515 1.134 . . . . 0.0 110.677 -175.093 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.8 pt -98.91 -177.79 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.567 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.403 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.8 m -138.13 149.09 45.58 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 122.766 0.426 . . . . 0.0 110.011 -178.01 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.407 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.5 pp -119.04 161.39 18.15 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 C-N-CA 123.324 0.65 . . . . 0.0 109.73 -177.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 15.6 tt -128.94 128.72 67.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 174.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.457 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -93.71 96.39 2.07 Favored Glycine 0 N--CA 1.432 -1.61 0 C-N-CA 120.468 -0.872 . . . . 0.0 112.77 -175.526 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 91.9 mmm -104.15 164.52 11.66 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -2.35 0 C-N-CA 119.969 -1.11 . . . . 0.0 110.653 177.36 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.6 pt? . . . . . 0 N--CA 1.436 -1.136 0 CA-C-O 121.738 0.78 . . . . 0.0 111.054 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -114.26 19.99 16.78 Favored Glycine 0 N--CA 1.412 -2.964 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 174.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.457 HD11 ' HA2' ' A' ' 23' ' ' GLY . 30.5 mm -77.7 116.53 21.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 177.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -114.92 165.88 12.39 Favored 'General case' 0 C--N 1.269 -2.924 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.7 t -77.96 132.37 32.66 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 176.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.448 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -95.89 -44.0 7.58 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 121.396 0.617 . . . . 0.0 110.049 -178.715 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.8 m -155.66 160.13 40.15 Favored 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 -178.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 64.0 t -129.11 148.8 33.29 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.621 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 176.114 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.527 HG22 ' HZ2' ' A' ' 12' ' ' LYS . 15.3 t . . . . . 0 C--O 1.254 1.292 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 176.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.5 ' HB1' ' HA ' ' A' ' 12' ' ' LYS . . . . . . . . 0 CA--C 1.563 1.463 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.456 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -77.88 -57.34 3.85 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -75.16 -12.61 60.34 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 119.764 -0.774 . . . . 0.0 112.085 175.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.487 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 20.5 mmm180 -73.4 -40.99 63.88 Favored 'General case' 0 CA--C 1.507 -0.689 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -62.36 -57.69 10.39 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.965 0.79 . . . . 0.0 109.603 176.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 83.25 -5.74 75.49 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 115.539 0.976 . . . . 0.0 115.539 173.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -78.36 -30.99 48.29 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 19.7 tt -89.11 152.6 3.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 175.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -133.03 -177.57 4.57 Favored 'General case' 0 N--CA 1.42 -1.962 0 CA-C-O 121.508 0.67 . . . . 0.0 111.019 -179.297 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.9 p -97.9 -5.06 9.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 121.822 0.82 . . . . 0.0 109.548 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -117.2 16.96 14.88 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.433 -174.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.415 ' OD1' HD12 ' A' ' 91' ' ' ILE . 3.0 p30 -100.66 -168.37 1.56 Allowed 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.167 177.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.468 ' O ' HG22 ' A' ' 91' ' ' ILE . 11.8 tt0 -131.39 117.6 19.11 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.374 -176.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.469 ' HA ' HG12 ' A' ' 91' ' ' ILE . 46.0 mm -68.83 106.85 1.24 Allowed 'Isoleucine or valine' 0 C--O 1.21 -1.024 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.761 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 89.3 t -87.76 -50.87 13.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-O 121.607 0.718 . . . . 0.0 110.326 -177.769 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.478 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.9 tt0 -145.62 133.32 21.04 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.31 129.56 71.98 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 176.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 31.3 t70 64.2 16.95 10.41 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 124.739 1.274 . . . . 0.0 111.143 172.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 72.2 26.03 73.16 Favored Glycine 0 N--CA 1.433 -1.525 0 CA-C-N 114.825 -1.08 . . . . 0.0 112.483 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.5 tt -85.09 -15.1 10.9 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 CA-C-O 121.417 0.627 . . . . 0.0 109.389 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.449 ' HA ' ' HG3' ' A' ' 62' ' ' GLU . 23.2 p 49.01 83.84 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 124.951 1.3 . . . . 0.0 112.704 -175.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.449 ' O ' HG21 ' A' ' 71' ' ' VAL . 1.9 pp -97.88 14.02 28.6 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 122.22 1.01 . . . . 0.0 109.313 -177.682 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 22.4 t -56.13 93.43 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-N 113.836 -1.529 . . . . 0.0 110.356 176.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.74 14.52 19.24 Favored Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 116.032 -0.531 . . . . 0.0 113.3 176.571 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.449 HG21 ' O ' ' A' ' 68' ' ' LEU . 21.0 m -88.16 176.14 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 O-C-N 122.335 -0.509 . . . . 0.0 111.836 -179.426 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.6 p -92.16 176.72 6.39 Favored 'General case' 0 N--CA 1.428 -1.545 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.185 177.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.407 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -66.98 -23.87 65.98 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.07 179.895 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 19.6 m-80 -63.53 -50.92 67.68 Favored 'General case' 0 CA--C 1.484 -1.581 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.41 ' O ' HG23 ' A' ' 79' ' ' VAL . 38.8 t80 -68.5 -50.56 51.31 Favored 'General case' 0 N--CA 1.415 -2.182 0 CA-C-N 114.067 -1.424 . . . . 0.0 110.093 -175.748 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.5 -44.45 95.96 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.29 -16.48 64.07 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-O 121.232 0.539 . . . . 0.0 111.063 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.4 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 60.2 m -85.04 -42.22 15.06 Favored 'General case' 0 N--CA 1.417 -2.107 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.944 176.678 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.415 ' O ' HG22 ' A' ' 83' ' ' THR . 38.7 t -62.85 -53.14 50.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 122.211 0.204 . . . . 0.0 110.588 178.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -68.59 -1.93 7.86 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-O 121.571 0.701 . . . . 0.0 112.434 -179.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.4 ' HB3' ' O ' ' A' ' 78' ' ' THR . 33.4 ttm180 -97.34 -43.41 7.32 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-O 121.922 0.868 . . . . 0.0 108.93 174.495 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 11.5 m-80 -83.78 8.59 14.22 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 114.338 -1.301 . . . . 0.0 112.794 -174.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.415 HG22 ' O ' ' A' ' 79' ' ' VAL . 2.2 p -65.6 176.99 1.31 Allowed 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 123.86 0.864 . . . . 0.0 112.679 177.785 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -139.25 -155.57 0.6 Allowed 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.31 -175.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -71.77 -68.77 1.53 Allowed Glycine 0 N--CA 1.444 -0.786 0 O-C-N 123.66 0.6 . . . . 0.0 111.834 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.442 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 43.8 m-80 -87.28 104.12 16.1 Favored 'General case' 0 CA--C 1.498 -1.044 0 CA-C-O 121.638 0.732 . . . . 0.0 110.079 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.409 ' HB ' ' CE1' ' A' ' 89' ' ' PHE . 3.0 t -116.74 133.17 64.25 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 CA-C-N 115.261 -0.881 . . . . 0.0 109.76 -175.454 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 70.0 mtp180 -97.79 101.97 13.6 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 173.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.458 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 91.1 m-85 -92.74 107.36 19.16 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 176.416 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.761 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 42.8 t -96.05 86.26 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.268 -2.951 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.469 HG12 ' HA ' ' A' ' 60' ' ' ILE . 88.8 mt -96.08 158.73 3.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.25 0 C-N-CA 125.314 1.445 . . . . 0.0 108.689 -179.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.402 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -136.53 149.32 20.11 Favored Glycine 0 N--CA 1.398 -3.884 0 C-N-CA 119.565 -1.303 . . . . 0.0 111.267 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.23 135.18 54.44 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.078 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.291 -1.972 0 C-N-CA 124.335 1.054 . . . . 0.0 112.893 -175.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 . . . . . 0 N--CA 1.429 -1.485 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.402 HD12 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -87.31 128.6 35.17 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -140.43 144.08 35.49 Favored Pre-proline 0 C--N 1.307 -1.269 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -178.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -83.01 126.23 4.34 Favored 'Trans proline' 0 C--N 1.327 -0.594 0 C-N-CA 123.092 2.528 . . . . 0.0 113.393 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 41.4 t -118.05 99.94 9.08 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.018 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 175.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.511 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 34.0 tt0 -85.2 109.67 18.47 Favored 'General case' 0 N--CA 1.432 -1.372 0 C-N-CA 119.544 -0.863 . . . . 0.0 108.72 176.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.416 HD13 ' O ' ' A' ' 47' ' ' ALA . 0.1 OUTLIER -99.83 145.37 27.82 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -177.694 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -111.24 90.26 3.28 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 173.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.493 ' HA ' ' HB1' ' A' ' 47' ' ' ALA . 3.3 mtpm? -80.56 -176.63 5.84 Favored 'General case' 0 N--CA 1.423 -1.777 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -178.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -72.83 173.02 9.75 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 112.338 -2.21 . . . . 0.0 111.679 -173.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -61.29 -26.66 67.93 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.303 -0.862 . . . . 0.0 112.42 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -67.52 -45.52 75.51 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-O 121.494 0.664 . . . . 0.0 109.879 176.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.36 -114.3 2.34 Favored Glycine 0 N--CA 1.426 -2.025 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.73 -176.069 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.415 ' HG ' HG23 ' A' ' 19' ' ' ILE . 9.9 tp -108.1 -62.77 1.4 Allowed 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 117.349 0.575 . . . . 0.0 111.656 -173.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.87 36.25 92.87 Favored Glycine 0 N--CA 1.44 -1.034 0 O-C-N 123.889 0.743 . . . . 0.0 113.139 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.415 HG23 ' HG ' ' A' ' 17' ' ' LEU . 20.9 pt -102.17 178.48 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.519 177.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.8 m -130.79 148.79 52.61 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.498 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -118.66 162.86 16.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.453 -177.335 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 15.6 tt -126.9 125.55 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.938 0 C-N-CA 120.269 -0.573 . . . . 0.0 110.435 174.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.414 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -86.96 105.63 3.06 Favored Glycine 0 N--CA 1.431 -1.66 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.753 -178.417 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.467 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 9.0 ptp -137.03 176.96 8.24 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 122.668 0.387 . . . . 0.0 111.891 176.239 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.277 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.804 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.6 pt? . . . . . 0 N--CA 1.446 -0.627 0 CA-C-O 121.405 0.621 . . . . 0.0 111.438 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -124.41 33.0 3.94 Favored Glycine 0 N--CA 1.412 -2.909 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 174.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.526 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 32.8 mm -89.5 107.76 18.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 176.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -104.21 168.66 8.96 Favored 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.9 t -78.72 121.63 32.16 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 176.014 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.464 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.1 OUTLIER -86.73 -49.19 7.65 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.503 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.09 157.65 43.68 Favored 'General case' 0 N--CA 1.417 -2.11 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.72 151.07 32.43 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.952 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 176.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.6 t . . . . . 0 N--CA 1.444 -0.726 0 CA-C-O 121.583 0.706 . . . . 0.0 112.132 -173.524 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.493 ' HB1' ' HA ' ' A' ' 12' ' ' LYS . . . . . . . . 0 CA--C 1.55 0.943 0 N-CA-C 115.301 1.593 . . . . 0.0 115.301 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.29 -63.13 1.47 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 -70.6 -21.9 62.61 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 120.616 -0.434 . . . . 0.0 112.125 176.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 40.2 mmt180 -68.54 -33.71 74.58 Favored 'General case' 0 CA--C 1.522 -0.103 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -70.48 -64.98 0.79 Allowed 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.353 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.62 -10.97 57.84 Favored Glycine 0 N--CA 1.437 -1.278 0 C-N-CA 120.549 -0.834 . . . . 0.0 115.115 175.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.651 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -76.72 -33.63 58.16 Favored 'General case' 0 C--O 1.239 0.507 0 CA-C-N 118.65 1.225 . . . . 0.0 108.448 178.404 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.3 tt -90.82 154.47 3.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 178.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -134.96 -163.43 1.38 Allowed 'General case' 0 N--CA 1.428 -1.57 0 C-N-CA 119.772 -0.771 . . . . 0.0 110.972 -174.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.9 p -115.16 11.43 7.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-O 122.81 1.29 . . . . 0.0 107.564 176.25 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -121.94 -7.34 8.95 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.435 -1.257 . . . . 0.0 110.655 -174.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.499 ' OD1' HD13 ' A' ' 91' ' ' ILE . 3.9 p30 -86.92 -165.29 1.25 Allowed 'General case' 0 C--O 1.255 1.358 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.425 -177.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.526 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 62.9 tt0 -142.04 121.55 13.27 Favored 'General case' 0 N--CA 1.416 -2.14 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.38 -175.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.42 ' HA ' HG12 ' A' ' 91' ' ' ILE . 42.3 mm -70.16 107.0 1.71 Allowed 'Isoleucine or valine' 0 C--O 1.212 -0.872 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 179.149 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.684 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 93.5 t -88.28 -52.26 11.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 CA-C-O 121.649 0.738 . . . . 0.0 110.724 -177.178 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.502 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 29.4 tt0 -146.15 110.53 5.07 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.75 -178.199 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 t -105.15 131.0 55.44 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.919 0 O-C-N 122.033 -0.417 . . . . 0.0 111.455 176.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 33.5 t70 61.65 16.75 8.02 Favored 'General case' 0 N--CA 1.484 1.273 0 O-C-N 124.722 1.264 . . . . 0.0 111.242 174.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.37 19.01 75.05 Favored Glycine 0 N--CA 1.443 -0.898 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.232 -179.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.4 tt -80.18 -30.23 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 O-C-N 122.36 -0.494 . . . . 0.0 110.971 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 19.4 t 54.59 95.24 0.02 OUTLIER 'General case' 0 C--N 1.345 0.392 0 C-N-CA 125.035 1.334 . . . . 0.0 110.5 -175.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.47 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.7 OUTLIER -101.65 20.35 16.35 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 122.204 1.002 . . . . 0.0 109.734 -176.144 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 39.0 t -61.84 93.56 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-N 114.496 -1.229 . . . . 0.0 111.343 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 117.07 5.77 14.68 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.697 176.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.47 HG22 ' O ' ' A' ' 68' ' ' LEU . 16.3 m -87.72 179.51 0.49 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.57 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -177.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 14.9 p -94.21 176.18 6.41 Favored 'General case' 0 C--O 1.255 1.376 0 CA-C-O 121.463 0.649 . . . . 0.0 109.9 177.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.498 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -62.81 -38.37 90.44 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 114.713 -1.131 . . . . 0.0 111.246 178.071 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -68.65 -32.76 72.84 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 111.768 0.284 . . . . 0.0 111.768 -177.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -68.28 -51.83 40.59 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 176.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.419 ' CB ' HG22 ' A' ' 37' ' ' ILE . . . -59.84 -44.64 93.98 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.463 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.58 -18.48 63.93 Favored 'General case' 0 C--O 1.22 -0.467 0 C-N-CA 122.995 0.518 . . . . 0.0 111.266 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 78.3 m -83.67 -49.66 8.94 Favored 'General case' 0 N--CA 1.416 -2.125 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 175.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.434 ' O ' HG23 ' A' ' 83' ' ' THR . 38.4 t -59.57 -54.82 29.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 CA-C-O 120.462 0.172 . . . . 0.0 110.831 -178.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -67.95 -2.77 8.12 Favored 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 123.331 0.652 . . . . 0.0 112.033 -179.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 38.5 ttt180 -98.8 -43.46 6.76 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 174.221 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -73.08 -11.73 60.65 Favored 'General case' 0 C--O 1.24 0.588 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.142 -174.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.434 HG23 ' O ' ' A' ' 79' ' ' VAL . 15.9 p -75.14 140.18 43.2 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-O 121.588 0.709 . . . . 0.0 112.464 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.465 ' O ' HG23 ' A' ' 87' ' ' VAL . 71.0 mmtt -107.07 -167.5 1.28 Allowed 'General case' 0 C--N 1.292 -1.908 0 CA-C-N 114.432 -1.258 . . . . 0.0 109.044 176.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -40.14 -58.57 2.33 Favored Glycine 0 C--O 1.216 -0.971 0 O-C-N 124.631 1.207 . . . . 0.0 115.761 -176.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -87.62 100.32 12.72 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 117.747 0.773 . . . . 0.0 111.399 -174.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.535 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 1.6 t -119.43 128.7 75.86 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.36 -175.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 42.3 mtp180 -92.31 99.46 12.23 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 173.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.535 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 97.1 m-85 -92.06 101.09 13.63 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 177.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.684 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.8 t -91.08 92.44 3.94 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 105.963 -1.865 . . . . 0.0 105.963 175.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.499 HD13 ' OD1' ' A' ' 58' ' ' ASP . 97.2 mt -110.56 153.39 12.35 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.777 0 CA-C-N 114.293 -1.321 . . . . 0.0 107.968 179.336 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.402 ' HA3' HD12 ' A' ' 5' ' ' LEU . . . -124.42 150.5 17.08 Favored Glycine 0 N--CA 1.401 -3.662 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.938 179.053 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.416 ' C ' ' HD2' ' A' ' 93' ' ' ARG . 4.3 tmm_? -113.9 134.95 54.49 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 -177.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 . . . . . 0 C--N 1.309 -1.165 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.436 179.721 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 . . . . . 0 N--CA 1.436 -1.155 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -90.45 120.39 31.52 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 177.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -135.1 146.64 59.21 Favored Pre-proline 0 C--N 1.304 -1.398 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -175.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -80.28 126.89 6.42 Favored 'Trans proline' 0 N--CA 1.444 -1.431 0 C-N-CA 122.244 1.963 . . . . 0.0 112.488 175.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.45 103.26 15.21 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.076 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 173.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.46 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.1 tt0 -88.17 103.57 15.89 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.494 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -98.28 145.71 26.38 Favored 'General case' 0 N--CA 1.426 -1.625 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 -175.819 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -116.48 95.85 5.25 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-O 121.66 0.743 . . . . 0.0 109.188 175.18 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.453 ' CD ' ' HB2' ' A' ' 47' ' ' ALA . 1.9 mmmp? -92.49 -169.96 2.35 Favored 'General case' 0 N--CA 1.419 -1.991 0 CA-C-N 114.911 -1.041 . . . . 0.0 112.564 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -78.49 167.19 21.66 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 113.864 -1.516 . . . . 0.0 107.805 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -67.88 -20.11 65.09 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.325 0.584 . . . . 0.0 109.807 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -65.69 -31.77 72.96 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 114.697 -1.138 . . . . 0.0 109.707 177.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.73 -130.4 9.06 Favored Glycine 0 N--CA 1.413 -2.838 0 CA-C-N 114.841 -1.072 . . . . 0.0 111.613 177.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.469 ' HB3' HG22 ' A' ' 19' ' ' ILE . 20.7 mt -108.49 -63.68 1.31 Allowed 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.836 -174.587 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.62 23.27 36.87 Favored Glycine 0 N--CA 1.424 -2.1 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -172.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.469 HG22 ' HB3' ' A' ' 17' ' ' LEU . 22.7 pt -89.23 178.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.349 0.547 0 C-N-CA 120.446 -0.502 . . . . 0.0 110.908 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.1 m -139.17 147.59 42.05 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.414 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -126.8 162.4 31.44 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 C-N-CA 122.814 0.446 . . . . 0.0 110.108 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.417 ' HB ' ' CG ' ' A' ' 40' ' ' LYS . 13.5 tt -130.96 135.0 60.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.473 174.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.477 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.18 102.48 2.86 Favored Glycine 0 N--CA 1.427 -1.945 0 C-N-CA 120.722 -0.751 . . . . 0.0 111.792 -178.017 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.633 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 93.8 mmm -116.87 93.48 4.21 Favored 'General case' 0 C--N 1.291 -1.96 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -179.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.915 0 O-C-N 123.839 0.712 . . . . 0.0 111.743 -179.002 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.5 pp . . . . . 0 N--CA 1.43 -1.45 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.633 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -129.59 34.37 2.79 Favored Glycine 0 C--N 1.283 -2.38 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 172.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.477 HD13 ' HA2' ' A' ' 23' ' ' GLY . 26.8 mm -86.72 100.19 9.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.828 0 CA-C-O 121.556 0.693 . . . . 0.0 110.992 -175.405 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -93.16 160.3 14.91 Favored 'General case' 0 C--N 1.287 -2.134 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.211 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 49.3 t -83.63 130.52 35.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.417 ' CG ' ' HB ' ' A' ' 22' ' ' ILE . 20.3 mmmt -87.77 -53.09 4.95 Favored 'General case' 0 CA--C 1.491 -1.3 0 CA-C-O 121.661 0.743 . . . . 0.0 110.266 178.184 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -144.28 160.26 41.3 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 -176.107 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.401 ' O ' ' HB ' ' A' ' 43' ' ' THR . 60.9 t -131.53 86.95 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.473 -1.995 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -178.297 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.401 ' HB ' ' O ' ' A' ' 42' ' ' VAL 0.257 95.9 m . . . . . 0 CA--C 1.583 2.248 0 O-C-N 124.542 1.151 . . . . 0.0 110.182 179.381 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.453 ' HB2' ' CD ' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.201 -1.494 0 N-CA-C 115.114 1.524 . . . . 0.0 115.114 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.35 -60.42 2.25 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 179.075 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 44.1 mt-30 -70.64 -24.3 62.69 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.065 -0.516 . . . . 0.0 112.333 176.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 40.0 mmt180 -69.72 -37.46 76.54 Favored 'General case' 0 CA--C 1.504 -0.806 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.589 174.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -59.81 -48.73 80.52 Favored 'General case' 0 C--N 1.352 0.691 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.61 -10.61 36.94 Favored Glycine 0 N--CA 1.439 -1.116 0 N-CA-C 115.286 0.874 . . . . 0.0 115.286 172.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.462 ' O ' ' HD3' ' A' ' 53' ' ' ARG . 0.1 OUTLIER -75.46 -27.77 59.01 Favored 'General case' 0 C--O 1.221 -0.426 0 CA-C-N 118.57 1.185 . . . . 0.0 108.401 -179.782 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.0 tt -97.81 149.29 5.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 177.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 48.2 mt-30 -132.71 170.34 15.38 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-O 121.839 0.828 . . . . 0.0 112.499 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.4 p -83.26 -3.61 7.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.763 -179.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -103.85 15.98 27.42 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 122.6 1.191 . . . . 0.0 108.332 -178.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.416 ' HB3' HG21 ' A' ' 91' ' ' ILE . 68.5 m-20 -93.23 177.9 5.9 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.223 -0.899 . . . . 0.0 112.335 -178.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -136.7 122.46 19.89 Favored 'General case' 0 N--CA 1.416 -2.174 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 47.5 mm -74.11 111.95 10.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 -175.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.701 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 99.4 t -92.12 -51.22 11.77 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-O 121.771 0.796 . . . . 0.0 110.28 -177.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.481 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.4 tt0 -152.04 110.09 3.69 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.33 0.586 . . . . 0.0 111.066 -178.338 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.01 129.08 53.9 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 O-C-N 122.005 -0.434 . . . . 0.0 110.983 177.299 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 18.2 t70 65.11 10.52 6.42 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 124.764 1.226 . . . . 0.0 111.772 174.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.32 19.9 68.11 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.421 -177.428 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 9.7 tt -76.33 -18.96 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 CA-C-O 121.058 0.456 . . . . 0.0 110.357 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.437 ' HB3' ' OE2' ' A' ' 62' ' ' GLU . 31.4 p 48.2 84.96 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 124.875 1.27 . . . . 0.0 112.004 -175.189 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 1.5 pp -97.12 16.92 18.31 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.669 0.747 . . . . 0.0 110.084 -175.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 45.6 t -58.16 97.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.171 174.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.22 53.55 1.0 Allowed Glycine 0 N--CA 1.431 -1.652 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.551 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.6 m -134.32 173.87 13.91 Favored 'Isoleucine or valine' 0 C--O 1.244 0.796 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 176.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 14.5 p -92.45 175.53 6.8 Favored 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 122.873 0.469 . . . . 0.0 110.965 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.414 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -66.38 -31.17 71.77 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.276 -179.36 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -69.56 -36.94 76.77 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 120.783 -0.367 . . . . 0.0 111.166 -179.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.402 ' O ' HG22 ' A' ' 79' ' ' VAL . 44.1 t80 -68.02 -51.15 50.3 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.21 -47.14 86.45 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.036 -0.983 . . . . 0.0 111.693 -177.659 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.22 -37.07 74.12 Favored 'General case' 0 C--O 1.212 -0.9 0 O-C-N 122.94 0.15 . . . . 0.0 110.641 179.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 65.3 m -64.75 -42.75 94.93 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.088 176.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.402 HG22 ' O ' ' A' ' 75' ' ' PHE . 47.8 t -61.12 -51.56 71.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 177.327 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -69.73 -2.34 11.63 Favored 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.448 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 3.4 tmt_? -99.51 -30.09 12.35 Favored 'General case' 0 C--N 1.312 -1.061 0 C-N-CA 123.667 0.787 . . . . 0.0 109.329 175.388 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -86.81 0.19 55.28 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 123.344 0.658 . . . . 0.0 112.004 -177.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.3 p -65.96 148.83 51.18 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.596 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.71 -157.48 0.72 Allowed 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 124.79 1.236 . . . . 0.0 108.587 178.76 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.27 -76.97 0.17 Allowed Glycine 0 C--N 1.315 -0.613 0 O-C-N 123.542 0.527 . . . . 0.0 113.963 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.494 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.3 m-80 -78.79 109.83 13.41 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.329 0.585 . . . . 0.0 111.537 -179.309 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 7.2 t -121.73 131.12 73.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.457 -178.46 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -98.58 98.71 9.84 Favored 'General case' 0 C--N 1.284 -2.271 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 174.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.434 ' CE1' ' HB ' ' A' ' 87' ' ' VAL . 89.8 m-85 -89.42 103.06 15.73 Favored 'General case' 0 CA--C 1.486 -1.481 0 CA-C-N 114.643 -1.162 . . . . 0.0 107.942 177.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.701 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.7 t -89.03 95.39 5.37 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.987 0 N-CA-C 106.6 -1.629 . . . . 0.0 106.6 177.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.416 HG21 ' HB3' ' A' ' 58' ' ' ASP . 96.7 mt -112.4 154.02 13.93 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.682 0 CA-C-N 114.143 -1.39 . . . . 0.0 108.248 176.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -120.91 149.72 17.38 Favored Glycine 0 N--CA 1.416 -2.657 0 C-N-CA 118.946 -1.597 . . . . 0.0 111.507 179.139 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 25.2 tpt180 -121.22 136.8 54.91 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 120.959 0.409 . . . . 0.0 110.859 179.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 . . . . . 0 N--CA 1.424 -1.755 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.171 176.611 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.475 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 42.1 tt0 . . . . . 0 CA--C 1.489 -1.373 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -87.09 116.21 25.0 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 174.333 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -132.07 137.19 29.57 Favored Pre-proline 0 N--CA 1.417 -2.113 0 CA-C-O 121.896 0.855 . . . . 0.0 113.237 -173.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -82.31 128.47 5.57 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.972 2.448 . . . . 0.0 112.144 175.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.421 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 38.4 t -118.95 112.92 39.81 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.491 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 174.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.48 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.2 tt0 -96.11 105.2 17.22 Favored 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 176.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.414 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -92.93 143.46 26.23 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -175.02 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -108.34 90.73 3.38 Favored 'General case' 0 C--N 1.291 -1.941 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 174.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.8 mmmp? -87.05 -175.46 5.35 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 113.966 1.099 . . . . 0.0 113.966 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.434 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.2 p-10 -89.32 -172.39 3.61 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 126.285 1.834 . . . . 0.0 111.179 -178.248 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -82.1 -6.44 59.18 Favored 'General case' 0 N--CA 1.465 0.286 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -175.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.434 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 11.3 t70 -82.16 -34.09 29.24 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 122.005 0.907 . . . . 0.0 108.757 176.001 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 121.37 -109.95 1.59 Allowed Glycine 0 N--CA 1.415 -2.735 0 CA-C-N 114.146 -1.388 . . . . 0.0 110.118 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.495 ' HG ' HG22 ' A' ' 19' ' ' ILE . 14.1 tp -117.31 -62.75 1.53 Allowed 'General case' 0 C--N 1.291 -1.939 0 O-C-N 122.341 -0.505 . . . . 0.0 109.878 -177.216 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.56 33.55 55.75 Favored Glycine 0 N--CA 1.434 -1.496 0 O-C-N 124.175 0.922 . . . . 0.0 113.157 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.495 HG22 ' HG ' ' A' ' 17' ' ' LEU . 27.5 pt -101.02 172.6 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 C-N-CA 119.892 -0.723 . . . . 0.0 110.279 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 34.8 m -119.33 145.98 45.69 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -179.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.401 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -122.71 164.38 20.09 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -178.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.6 tt -132.53 132.78 60.09 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 174.361 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.479 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.58 105.73 3.29 Favored Glycine 0 N--CA 1.428 -1.9 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.926 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.464 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 16.7 ptm -143.65 85.22 1.82 Allowed 'General case' 0 C--N 1.291 -1.948 0 CA-C-O 121.585 0.707 . . . . 0.0 110.8 179.264 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.519 0 CA-C-N 114.013 -1.449 . . . . 0.0 113.845 -176.248 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.414 -2.253 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.464 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -131.67 35.48 2.39 Favored Glycine 0 N--CA 1.414 -2.781 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.039 176.255 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.479 HD13 ' HA2' ' A' ' 23' ' ' GLY . 26.7 mm -94.81 105.72 17.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 C-N-CA 119.405 -0.918 . . . . 0.0 109.547 -179.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -102.17 161.54 13.61 Favored 'General case' 0 C--N 1.276 -2.604 0 CA-C-N 114.721 -1.127 . . . . 0.0 110.191 -179.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 29.0 t -77.5 117.81 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.087 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 176.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 56.3 tptt -84.64 -51.33 6.92 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -178.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -149.51 160.69 43.26 Favored 'General case' 0 N--CA 1.427 -1.61 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 -179.777 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.428 ' HB ' ' OE1' ' A' ' 49' ' ' GLN . 16.8 t -122.75 162.36 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.151 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 178.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.1 t . . . . . 0 N--CA 1.422 -1.83 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.332 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.413 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 C--O 1.201 -1.473 0 N-CA-C 115.424 1.638 . . . . 0.0 115.424 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.89 -53.25 10.58 Favored 'General case' 0 N--CA 1.465 0.275 0 O-C-N 121.46 -0.775 . . . . 0.0 109.952 -178.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.428 ' OE1' ' HB ' ' A' ' 42' ' ' VAL . 27.8 mt-30 -78.46 -13.89 59.63 Favored 'General case' 0 CA--C 1.508 -0.66 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.739 176.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.413 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 13.5 mmm180 -74.45 -41.06 61.46 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 174.614 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.436 ' OD1' ' HB2' ' A' ' 53' ' ' ARG . 12.2 t70 -60.29 -59.03 6.06 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.461 177.065 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.4 -9.35 77.79 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 115.03 0.772 . . . . 0.0 115.03 174.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.436 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -69.35 -37.27 77.56 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.545 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.9 tt -81.93 152.33 4.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -178.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 30.3 mt-30 -127.88 161.6 28.69 Favored 'General case' 0 C--N 1.312 -1.061 0 C-N-CA 120.031 -0.668 . . . . 0.0 109.303 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.9 p -89.64 16.82 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 CA-C-O 121.747 0.784 . . . . 0.0 110.531 -177.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -137.59 20.38 2.9 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 122.236 1.017 . . . . 0.0 110.11 -177.021 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -103.72 -175.19 2.73 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.234 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.441 ' O ' HG22 ' A' ' 91' ' ' ILE . 33.6 tt0 -120.68 132.65 55.2 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.132 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.462 ' HA ' HG12 ' A' ' 91' ' ' ILE . 47.2 mm -76.73 101.45 2.91 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.128 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.7 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 81.2 t -80.8 -48.06 19.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 CA-C-O 121.233 0.539 . . . . 0.0 110.571 -175.32 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.426 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 39.5 tt0 -156.64 112.91 3.02 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-O 121.015 0.436 . . . . 0.0 110.639 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.519 ' C ' ' H ' ' A' ' 65' ' ' GLY . 4.8 t -102.26 131.08 51.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.566 175.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.3 t70 73.03 -22.56 0.23 Allowed 'General case' 0 N--CA 1.503 2.22 0 C-N-CA 125.747 1.619 . . . . 0.0 112.975 176.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.519 ' H ' ' C ' ' A' ' 63' ' ' VAL . . . 110.36 12.41 17.4 Favored Glycine 0 C--N 1.274 -2.911 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -173.323 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.3 tt -70.02 -19.51 22.56 Favored 'Isoleucine or valine' 0 C--N 1.344 0.326 0 C-N-CA 122.885 0.474 . . . . 0.0 110.903 -178.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 12.3 p 49.03 81.57 0.05 Allowed 'General case' 0 C--O 1.233 0.19 0 C-N-CA 124.26 1.024 . . . . 0.0 112.88 -176.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.407 ' O ' HG21 ' A' ' 71' ' ' VAL . 0.0 OUTLIER -95.58 30.22 2.36 Favored 'General case' 0 N--CA 1.423 -1.778 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.381 -178.625 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 47.9 t -73.45 97.04 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-N 114.974 -1.012 . . . . 0.0 109.585 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 108.26 33.07 3.05 Favored Glycine 0 C--N 1.294 -1.799 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 176.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.407 HG21 ' O ' ' A' ' 68' ' ' LEU . 19.7 m -109.39 174.53 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 119.917 -0.713 . . . . 0.0 111.461 -178.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 22.2 p -91.29 172.82 8.27 Favored 'General case' 0 N--CA 1.418 -2.049 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.794 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.401 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -66.97 -32.01 72.96 Favored 'General case' 0 C--O 1.204 -1.293 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.018 -179.682 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -71.44 -31.6 67.39 Favored 'General case' 0 CA--C 1.516 -0.362 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.82 -178.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -70.38 -51.67 28.03 Favored 'General case' 0 N--CA 1.443 -0.819 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 177.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.408 ' CB ' HG23 ' A' ' 37' ' ' ILE . . . -62.56 -42.16 99.37 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.031 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.09 -11.4 48.52 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 121.23 0.538 . . . . 0.0 111.102 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 58.0 m -89.75 -47.13 8.12 Favored 'General case' 0 N--CA 1.415 -2.204 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.862 174.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.488 ' O ' HG22 ' A' ' 83' ' ' THR . 31.4 t -61.86 -54.27 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -68.41 0.42 3.96 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.617 0.767 . . . . 0.0 112.716 -178.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -104.07 -45.95 4.59 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 174.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 -80.83 7.36 10.64 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 114.405 -1.27 . . . . 0.0 113.142 -173.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.488 HG22 ' O ' ' A' ' 79' ' ' VAL . 1.7 p -60.45 154.22 21.18 Favored 'General case' 0 C--N 1.29 -2.013 0 C-N-CA 124.854 1.261 . . . . 0.0 111.405 175.047 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 31.8 mmtp -111.51 -164.91 0.95 Allowed 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.061 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.32 -67.59 2.12 Favored Glycine 0 N--CA 1.439 -1.152 0 O-C-N 123.657 0.598 . . . . 0.0 112.886 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.414 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 15.6 m120 -82.52 117.07 22.25 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.2 t -125.04 127.79 72.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.453 -177.326 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -91.68 104.33 16.8 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-O 120.877 0.37 . . . . 0.0 110.169 172.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.421 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.7 m-85 -95.6 103.99 15.88 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 175.234 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.7 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 47.7 t -92.85 91.48 3.37 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.921 0 N-CA-C 104.781 -2.303 . . . . 0.0 104.781 174.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.462 HG12 ' HA ' ' A' ' 60' ' ' ILE . 74.8 mt -108.0 157.05 8.33 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.09 178.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -131.78 143.66 15.22 Favored Glycine 0 N--CA 1.397 -3.913 0 C-N-CA 119.404 -1.379 . . . . 0.0 111.093 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.443 ' C ' ' HD2' ' A' ' 93' ' ' ARG . 5.2 tmm_? -108.22 128.47 54.75 Favored 'General case' 0 C--N 1.291 -1.97 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -178.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 . . . . . 0 C--N 1.311 -1.095 0 O-C-N 123.353 0.408 . . . . 0.0 110.459 178.961 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 . . . . . 0 CA--C 1.498 -1.031 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -91.72 127.87 37.34 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.761 -1.199 . . . . 0.0 107.761 173.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.488 ' O ' ' HA ' ' A' ' 90' ' ' VAL . 20.9 p90 -133.21 137.59 29.67 Favored Pre-proline 0 C--N 1.283 -2.295 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -175.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -84.21 121.67 2.75 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 123.472 2.781 . . . . 0.0 112.146 176.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 35.8 t -112.17 98.47 7.07 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.048 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 175.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.614 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 31.6 tt0 -83.8 101.54 11.69 Favored 'General case' 0 N--CA 1.421 -1.899 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 176.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -93.23 133.67 36.21 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 -175.948 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -101.15 92.98 5.23 Favored 'General case' 0 N--CA 1.419 -2.016 0 CA-C-O 121.995 0.903 . . . . 0.0 109.282 175.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.561 ' CD ' ' HB2' ' A' ' 47' ' ' ALA . 2.0 mmmp? -92.95 -175.45 3.89 Favored 'General case' 0 N--CA 1.421 -1.921 0 CA-C-N 114.302 -1.317 . . . . 0.0 113.218 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.459 ' OD1' ' HB3' ' A' ' 15' ' ' ASP . 1.7 p30 -77.31 176.62 8.63 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-N 112.784 -2.007 . . . . 0.0 110.743 178.063 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -82.94 -6.65 59.56 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.612 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.459 ' HB3' ' OD1' ' A' ' 13' ' ' ASP . 9.6 t70 -81.77 -41.94 20.45 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 175.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.32 -123.26 2.6 Favored Glycine 0 N--CA 1.42 -2.381 0 C-N-CA 120.136 -1.031 . . . . 0.0 112.909 175.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 mt -108.36 -45.1 3.97 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 122.211 -0.582 . . . . 0.0 110.569 -172.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.67 28.45 70.89 Favored Glycine 0 N--CA 1.426 -2.014 0 O-C-N 124.336 1.023 . . . . 0.0 110.663 -174.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 20.4 pt -106.38 -176.95 0.58 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.293 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.797 -178.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.3 m -144.22 151.86 40.05 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.475 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.6 pp -125.0 162.67 26.84 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -178.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 12.1 tt -134.59 130.42 53.3 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.833 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 176.703 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.467 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -98.01 104.92 3.05 Favored Glycine 0 CA--C 1.481 -2.034 0 C-N-CA 120.357 -0.925 . . . . 0.0 111.744 -178.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.485 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 18.4 ptm -147.16 96.41 2.72 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 120.643 0.258 . . . . 0.0 111.562 -179.469 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.704 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.315 -178.914 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.465 ' HB3' ' N ' ' A' ' 70' ' ' GLY . 1.8 pt? . . . . . 0 N--CA 1.448 -0.561 0 CA-C-O 122.254 1.026 . . . . 0.0 111.985 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -131.66 32.04 2.99 Favored Glycine 0 N--CA 1.41 -3.076 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.873 175.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.553 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 23.8 mm -90.1 98.61 8.41 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 119.778 -0.769 . . . . 0.0 109.098 178.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -96.98 162.5 13.37 Favored 'General case' 0 C--N 1.273 -2.744 0 CA-C-N 115.047 -0.979 . . . . 0.0 108.914 -178.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 40.9 t -79.71 122.71 35.44 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.537 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -81.15 -49.92 10.24 Favored 'General case' 0 C--N 1.293 -1.86 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.331 -177.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -154.31 161.23 41.89 Favored 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 -178.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 51.0 t -136.25 147.54 27.88 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 N-CA-C 105.415 -2.068 . . . . 0.0 105.415 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.2 t . . . . . 0 C--O 1.257 1.465 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 173.967 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.561 ' HB2' ' CD ' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.197 -1.704 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.42 -54.74 27.94 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.239 0.542 . . . . 0.0 110.662 -176.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 42.8 mt-30 -76.45 -7.79 55.81 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.772 178.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -90.44 -23.29 21.06 Favored 'General case' 0 N--CA 1.437 -1.085 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.12 176.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -61.01 -54.9 39.17 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 170.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 105.3 -26.55 21.46 Favored Glycine 0 N--CA 1.432 -1.576 0 CA-C-N 115.164 -0.925 . . . . 0.0 114.746 174.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -72.93 -31.5 64.66 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 118.446 1.123 . . . . 0.0 109.666 -176.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.9 tt -97.09 146.96 6.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -179.193 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . 0.421 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 97.0 mt-30 -136.57 162.52 32.9 Favored 'General case' 0 N--CA 1.436 -1.13 0 CA-C-O 121.331 0.586 . . . . 0.0 110.945 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.4 p -75.71 -15.34 15.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 C-N-CA 124.085 0.954 . . . . 0.0 111.298 -178.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -95.06 9.84 38.01 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.455 0.645 . . . . 0.0 111.557 -175.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.421 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 39.9 m-20 -97.84 -172.68 2.43 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.691 -177.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.553 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.6 tt0 -134.91 133.21 39.38 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.836 -177.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.408 ' HA ' HG12 ' A' ' 91' ' ' ILE . 44.1 mm -78.4 115.15 20.04 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.001 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 -177.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.64 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.2 t -94.49 -51.8 10.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-O 121.679 0.752 . . . . 0.0 110.552 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.536 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 21.4 tt0 -147.55 110.01 4.62 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.92 -177.427 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.5 t -103.39 126.54 57.78 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 O-C-N 122.018 -0.427 . . . . 0.0 110.204 175.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.5 t70 62.19 17.52 9.29 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 124.452 1.101 . . . . 0.0 112.215 174.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 83.09 8.75 85.15 Favored Glycine 0 N--CA 1.442 -0.915 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.975 -179.214 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.7 tt -75.25 -16.62 15.91 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 O-C-N 122.571 -0.37 . . . . 0.0 110.845 -176.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 31.3 m 49.09 79.71 0.07 Allowed 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 124.876 1.27 . . . . 0.0 112.706 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.498 ' O ' HG23 ' A' ' 71' ' ' VAL . 2.3 pp -96.16 11.73 33.32 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 122.322 1.058 . . . . 0.0 110.074 -175.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.427 HG21 HD21 ' A' ' 35' ' ' LEU . 5.2 p -58.11 92.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.294 -1.841 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.497 173.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . 0.465 ' N ' ' HB3' ' A' ' 35' ' ' LEU . . . 113.79 21.42 5.71 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.829 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 68' ' ' LEU . 20.4 m -103.48 176.97 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 O-C-N 121.978 -0.719 . . . . 0.0 110.965 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.3 p -93.7 171.71 8.71 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.026 177.034 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.475 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -64.78 -28.83 69.84 Favored 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.775 -176.337 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.82 -30.49 66.94 Favored 'General case' 0 CA--C 1.512 -0.492 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.358 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.432 ' O ' HG21 ' A' ' 79' ' ' VAL . 31.2 t80 -77.32 -52.01 9.91 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 177.686 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -56.25 -50.12 72.23 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.274 -0.876 . . . . 0.0 112.364 -177.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.15 -36.41 75.21 Favored 'General case' 0 C--O 1.214 -0.786 0 CA-C-O 120.505 0.193 . . . . 0.0 110.796 -179.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 84.0 m -62.88 -42.75 99.88 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.301 177.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.432 HG21 ' O ' ' A' ' 75' ' ' PHE . 31.6 t -64.27 -51.78 64.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 178.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -63.58 -18.28 63.72 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.841 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.13 -26.44 23.62 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 123.276 0.631 . . . . 0.0 110.32 174.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -88.67 6.17 39.68 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-O 121.48 0.657 . . . . 0.0 112.251 -178.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 36.4 p -74.89 -178.2 3.64 Favored 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.043 177.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.18 -163.0 1.52 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.166 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -49.25 -73.3 0.37 Allowed Glycine 0 CA--C 1.531 1.036 0 O-C-N 123.884 0.74 . . . . 0.0 114.49 178.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.464 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 19.0 m120 -82.99 104.74 13.42 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 117.667 0.734 . . . . 0.0 111.628 -178.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.614 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -114.71 137.51 47.89 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.503 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 90.6 mtt180 -99.64 99.04 9.83 Favored 'General case' 0 C--N 1.283 -2.304 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.476 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 91.9 m-85 -92.2 101.45 13.96 Favored 'General case' 0 CA--C 1.489 -1.386 0 CA-C-N 114.895 -1.048 . . . . 0.0 108.555 177.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.64 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 60.8 t -92.32 94.76 4.96 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.89 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.498 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.463 HG23 ' O ' ' A' ' 59' ' ' GLN . 90.6 mt -106.3 163.19 4.92 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.929 0 CA-C-N 114.104 -1.407 . . . . 0.0 108.543 178.532 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -139.07 161.23 25.94 Favored Glycine 0 N--CA 1.412 -2.912 0 C-N-CA 119.489 -1.338 . . . . 0.0 112.162 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 37.0 ttp-105 -142.58 144.17 32.76 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 . . . . . 0 C--N 1.302 -1.485 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 176.291 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 . . . . . 0 N--CA 1.43 -1.473 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -93.1 127.55 38.68 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 175.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 19.6 p90 -137.25 141.34 33.79 Favored Pre-proline 0 C--N 1.297 -1.684 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -175.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -82.24 123.9 4.1 Favored 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 122.76 2.307 . . . . 0.0 112.21 177.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 38.9 t -109.44 95.99 4.29 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.688 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 174.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 29.7 tt0 -83.37 102.72 12.21 Favored 'General case' 0 N--CA 1.423 -1.825 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -98.44 140.43 32.7 Favored 'General case' 0 N--CA 1.411 -2.386 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 -175.025 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -108.86 95.74 5.85 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 173.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.9 mmmp? -84.72 174.21 10.09 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 114.381 1.252 . . . . 0.0 114.381 -178.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -92.12 179.91 5.45 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 112.714 -2.039 . . . . 0.0 111.032 -176.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -68.81 -15.51 63.52 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -173.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -77.3 -28.03 53.17 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 121.572 0.701 . . . . 0.0 109.411 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.12 -125.62 6.61 Favored Glycine 0 CA--C 1.482 -1.997 0 N-CA-C 108.513 -1.835 . . . . 0.0 108.513 -179.275 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt -103.79 -50.24 3.46 Favored 'General case' 0 CA--C 1.483 -1.609 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 176.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.94 27.33 64.77 Favored Glycine 0 N--CA 1.434 -1.491 0 O-C-N 124.642 1.214 . . . . 0.0 110.773 -176.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 21.6 pt -102.54 -179.51 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.817 -177.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.3 t -138.72 153.23 48.49 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -178.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.474 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.6 pp -125.75 163.43 27.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -177.304 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.51 ' HB ' ' HG2' ' A' ' 40' ' ' LYS . 11.3 tt -130.96 132.69 63.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-O 120.536 0.208 . . . . 0.0 110.686 174.503 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.477 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -93.15 103.83 3.1 Favored Glycine 0 N--CA 1.426 -1.978 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.5 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.415 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 16.5 ptm -143.94 91.3 2.21 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 178.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.34 0.799 0 CA-C-N 114.184 -1.371 . . . . 0.0 113.018 -177.421 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.6 pp . . . . . 0 N--CA 1.428 -1.568 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.415 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -118.79 30.88 5.74 Favored Glycine 0 N--CA 1.417 -2.583 0 C-N-CA 119.684 -1.246 . . . . 0.0 110.303 176.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.477 HD11 ' HA2' ' A' ' 23' ' ' GLY . 30.3 mm -91.95 100.97 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.868 0 CA-C-O 121.553 0.692 . . . . 0.0 110.998 -176.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.404 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 96.2 m-85 -96.98 165.0 12.29 Favored 'General case' 0 C--N 1.285 -2.209 0 CA-C-N 115.075 -0.966 . . . . 0.0 108.532 177.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 47.1 t -81.41 128.17 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.14 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.51 ' HG2' ' HB ' ' A' ' 22' ' ' ILE . 15.9 mmmt -85.36 -57.34 3.11 Favored 'General case' 0 CA--C 1.473 -2.015 0 CA-C-O 121.567 0.698 . . . . 0.0 109.332 177.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.48 163.6 34.19 Favored 'General case' 0 C--N 1.291 -1.978 0 CA-C-N 114.241 -1.345 . . . . 0.0 107.789 -176.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 86.6 t -129.68 157.26 42.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.23 0 N-CA-C 104.9 -2.259 . . . . 0.0 104.9 174.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 14.9 t . . . . . 0 N--CA 1.435 -1.193 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 175.939 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.423 -1.799 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -95.1 -55.8 2.95 Favored 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 115.795 -0.638 . . . . 0.0 109.608 -175.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -79.08 -16.19 57.1 Favored 'General case' 0 N--CA 1.438 -1.044 0 C-N-CA 119.301 -0.96 . . . . 0.0 110.037 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 36.0 mmt180 -78.43 -25.32 45.95 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.55 171.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -70.91 -61.0 1.92 Allowed 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 172.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.77 2.07 84.67 Favored Glycine 0 N--CA 1.437 -1.247 0 N-CA-C 115.055 0.782 . . . . 0.0 115.055 173.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -85.23 -36.37 20.99 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 176.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.6 tt -88.04 146.71 5.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -128.71 177.56 6.97 Favored 'General case' 0 N--CA 1.431 -1.377 0 C-N-CA 120.163 -0.615 . . . . 0.0 111.406 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 5.2 t -90.47 -9.99 10.29 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.774 0 CA-C-O 121.936 0.874 . . . . 0.0 109.46 -175.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -103.56 7.56 37.67 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.699 -176.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -83.25 -177.93 6.91 Favored 'General case' 0 C--O 1.247 0.954 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.537 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.422 ' O ' HG21 ' A' ' 91' ' ' ILE . 63.9 tt0 -133.32 128.3 35.41 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-N 115.112 -0.949 . . . . 0.0 108.746 -177.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 49.4 mm -76.83 109.99 11.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -176.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.664 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 88.1 t -92.64 -47.66 13.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 CA-C-O 121.242 0.544 . . . . 0.0 111.137 -176.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.477 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 38.7 tt0 -155.2 102.17 2.28 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-O 121.623 0.725 . . . . 0.0 110.541 -178.456 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.8 t -94.61 129.3 45.02 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 O-C-N 121.921 -0.487 . . . . 0.0 111.089 177.095 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 38.5 t70 65.32 11.72 7.52 Favored 'General case' 0 N--CA 1.487 1.394 0 CA-C-O 122.234 1.016 . . . . 0.0 111.55 172.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.35 15.47 78.31 Favored Glycine 0 N--CA 1.441 -1.026 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.084 -178.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.2 tt -76.41 -20.53 15.07 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.798 0 CA-C-O 121.215 0.531 . . . . 0.0 110.683 -177.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . 0.267 13.1 p 47.97 76.48 0.11 Allowed 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 124.708 1.203 . . . . 0.0 113.879 -177.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.443 ' O ' HG21 ' A' ' 71' ' ' VAL . 0.0 OUTLIER -88.9 32.2 0.82 Allowed 'General case' 0 N--CA 1.432 -1.367 0 CA-C-N 114.432 -1.258 . . . . 0.0 111.287 -177.063 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 46.3 t -69.69 95.81 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 CA-C-N 114.799 -1.092 . . . . 0.0 110.385 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 105.44 19.74 10.24 Favored Glycine 0 C--N 1.31 -0.901 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.574 176.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.443 HG21 ' O ' ' A' ' 68' ' ' LEU . 23.9 m -93.1 179.21 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 177.496 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.9 p -94.54 171.0 9.07 Favored 'General case' 0 N--CA 1.416 -2.163 0 CA-C-O 121.221 0.534 . . . . 0.0 110.349 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.474 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.17 -34.64 70.53 Favored 'General case' 0 C--N 1.294 -1.814 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.916 178.126 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.27 -36.97 74.75 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.332 -178.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.469 ' O ' HG23 ' A' ' 79' ' ' VAL . 45.9 t80 -66.99 -49.42 65.41 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.48 -45.58 93.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.758 -179.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -64.11 -16.84 62.67 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 120.915 0.388 . . . . 0.0 111.425 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 66.3 m -85.93 -44.81 12.08 Favored 'General case' 0 N--CA 1.426 -1.631 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.625 174.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 75' ' ' PHE . 47.1 t -58.11 -51.5 70.15 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.627 0 N-CA-C 110.091 -0.336 . . . . 0.0 110.091 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -70.24 3.21 3.01 Favored 'General case' 0 CA--C 1.556 1.194 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.769 179.08 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 1.3 tmt_? -114.95 -17.76 11.43 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 123.373 0.669 . . . . 0.0 109.682 177.186 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -92.0 -7.46 48.83 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.279 0.632 . . . . 0.0 110.319 177.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.442 HG21 ' O ' ' A' ' 79' ' ' VAL . 2.5 p -64.5 161.48 17.21 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 115.061 -0.972 . . . . 0.0 113.444 -177.58 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 43.5 mmtm -113.42 -163.41 0.86 Allowed 'General case' 0 C--N 1.293 -1.875 0 CA-C-N 114.434 -1.257 . . . . 0.0 109.282 -178.066 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.87 -60.4 6.14 Favored Glycine 0 N--CA 1.424 -2.113 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 171.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -76.39 106.93 8.31 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-O 121.2 0.524 . . . . 0.0 110.168 177.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.0 t -121.87 132.36 71.05 Favored 'Isoleucine or valine' 0 CA--C 1.484 -1.571 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 -178.005 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 79.5 mtt180 -102.42 96.77 7.15 Favored 'General case' 0 C--N 1.283 -2.314 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 173.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -87.35 102.53 14.61 Favored 'General case' 0 CA--C 1.491 -1.312 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 177.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.664 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.1 t -90.99 90.87 3.42 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.625 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 177.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.422 HG21 ' O ' ' A' ' 59' ' ' GLN . 86.2 mt -104.12 156.49 5.64 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.689 0 CA-C-N 114.248 -1.342 . . . . 0.0 108.189 179.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.65 166.81 22.89 Favored Glycine 0 N--CA 1.406 -3.344 0 C-N-CA 119.42 -1.371 . . . . 0.0 110.926 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 46.1 ttp180 -142.59 141.32 31.95 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 . . . . . 0 N--CA 1.431 -1.414 0 N-CA-C 106.087 -1.82 . . . . 0.0 106.087 170.204 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 . . . . . 0 C--O 1.212 -0.909 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -90.11 136.12 33.24 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 20.8 p90 -145.99 140.63 15.76 Favored Pre-proline 0 C--N 1.303 -1.421 0 CA-C-O 121.079 0.466 . . . . 0.0 112.141 -178.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -81.4 126.58 5.51 Favored 'Trans proline' 0 C--O 1.248 1.022 0 C-N-CA 123.29 2.66 . . . . 0.0 113.081 177.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 26.2 t -120.83 102.87 13.01 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 175.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.54 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 37.4 tt0 -84.24 105.98 15.5 Favored 'General case' 0 N--CA 1.427 -1.592 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.633 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 12.9 tp -89.91 155.08 19.37 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 -174.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -120.29 93.05 3.92 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 175.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -89.65 176.16 6.97 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 115.278 1.584 . . . . 0.0 115.278 -179.304 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -77.25 168.33 20.23 Favored 'General case' 0 N--CA 1.428 -1.547 0 CA-C-N 111.934 -2.393 . . . . 0.0 107.435 -179.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -74.01 -10.48 59.68 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-O 121.217 0.532 . . . . 0.0 110.967 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -63.55 -33.16 74.97 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 172.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.4 -130.87 9.08 Favored Glycine 0 N--CA 1.413 -2.897 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 13.7 tp -103.5 -61.51 1.41 Allowed 'General case' 0 C--N 1.285 -2.219 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 -177.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.445 ' O ' ' HB ' ' A' ' 43' ' ' THR . . . 71.32 37.85 62.88 Favored Glycine 0 N--CA 1.429 -1.786 0 O-C-N 124.284 0.99 . . . . 0.0 112.854 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 15.5 pt -107.95 167.51 3.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 118.949 -1.101 . . . . 0.0 111.435 176.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.3 m -117.08 148.54 41.43 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 -177.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.422 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -125.41 166.34 21.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -177.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.432 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 11.9 tt -130.35 132.15 65.03 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.877 0 C-N-CA 120.701 -0.4 . . . . 0.0 110.575 175.706 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.445 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -89.61 95.77 2.13 Favored Glycine 0 N--CA 1.424 -2.14 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.589 -178.58 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 95.1 mmm -109.3 173.72 6.19 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 176.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.292 -1.916 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 177.743 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.428 -1.535 0 CA-C-O 120.806 0.336 . . . . 0.0 110.153 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -124.07 25.13 6.15 Favored Glycine 0 N--CA 1.414 -2.771 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 174.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.445 HD11 ' HA2' ' A' ' 23' ' ' GLY . 33.4 mm -85.02 100.71 8.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 121.525 0.679 . . . . 0.0 109.524 -179.809 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -97.43 164.39 12.47 Favored 'General case' 0 C--N 1.278 -2.502 0 CA-C-N 115.252 -0.885 . . . . 0.0 108.917 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.556 ' HB ' ' O ' ' A' ' 56' ' ' VAL . 39.7 t -78.83 127.98 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.19 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 176.2 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 55.6 tptt -89.13 -44.13 10.55 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -178.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -161.18 162.82 31.42 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 89.1 t -127.35 152.52 35.49 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.167 0 N-CA-C 106.223 -1.769 . . . . 0.0 106.223 178.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.445 ' HB ' ' O ' ' A' ' 18' ' ' GLY . 10.6 t . . . . . 0 N--CA 1.428 -1.557 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.434 ' HA ' ' CG ' ' A' ' 50' ' ' ARG . . . . . . . . 0 CA--C 1.557 1.235 0 N-CA-C 115.542 1.682 . . . . 0.0 115.542 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.97 -50.38 16.86 Favored 'General case' 0 C--O 1.215 -0.728 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -80.54 -3.59 50.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 120.285 -0.566 . . . . 0.0 111.101 176.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.434 ' CG ' ' HA ' ' A' ' 47' ' ' ALA . 36.1 mmt180 -82.65 -39.09 22.56 Favored 'General case' 0 CA--C 1.507 -0.691 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 171.283 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -53.83 -60.42 3.35 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 114.856 -1.065 . . . . 0.0 112.088 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.48 -17.56 56.55 Favored Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 120.316 -0.945 . . . . 0.0 114.353 175.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.408 ' HE ' ' C ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -88.69 -46.77 8.75 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.68 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.0 tt -73.67 145.13 11.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . 0.416 ' HB2' ' OD1' ' A' ' 58' ' ' ASP . 35.6 mt-30 -138.79 -172.66 3.36 Favored 'General case' 0 C--N 1.316 -0.868 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.843 -176.26 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.556 ' O ' ' HB ' ' A' ' 39' ' ' VAL . 49.0 t -93.22 -34.55 5.94 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.104 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.413 -178.258 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -92.24 20.67 5.79 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -174.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.416 ' OD1' ' HB2' ' A' ' 55' ' ' GLN . 4.2 m-20 -101.75 -172.9 2.23 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.967 177.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.461 ' O ' HG23 ' A' ' 91' ' ' ILE . 63.7 tt0 -128.54 126.51 40.52 Favored 'General case' 0 C--N 1.313 -0.995 0 O-C-N 122.089 -0.382 . . . . 0.0 111.328 -175.137 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.489 ' HA ' HG12 ' A' ' 91' ' ' ILE . 48.2 mm -74.93 104.36 3.27 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.016 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.735 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.2 t -91.41 -50.15 12.85 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-O 121.694 0.759 . . . . 0.0 111.315 -175.166 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.481 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 32.1 tt0 -149.0 105.74 3.56 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.398 0.618 . . . . 0.0 110.226 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.424 ' C ' ' H ' ' A' ' 65' ' ' GLY . 3.0 t -98.02 126.98 50.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.146 177.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 26.9 t70 71.42 -9.96 0.86 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 125.599 1.56 . . . . 0.0 112.702 173.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.424 ' H ' ' C ' ' A' ' 63' ' ' VAL . . . 103.61 12.96 29.21 Favored Glycine 0 N--CA 1.424 -2.151 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.126 -175.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 11.0 tt -72.98 -18.07 18.24 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-O 121.077 0.465 . . . . 0.0 111.198 -178.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.402 ' HB3' ' OE2' ' A' ' 62' ' ' GLU . 29.6 p 50.87 81.41 0.07 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.985 1.314 . . . . 0.0 112.92 -175.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.44 ' O ' HG23 ' A' ' 71' ' ' VAL . 1.8 pp -96.12 14.91 22.33 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-O 122.092 0.948 . . . . 0.0 109.94 -176.114 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 61.2 t -57.62 98.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.427 174.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.51 35.03 3.68 Favored Glycine 0 N--CA 1.438 -1.223 0 CA-C-N 115.54 -0.754 . . . . 0.0 112.457 176.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.44 HG23 ' O ' ' A' ' 68' ' ' LEU . 20.6 m -115.02 177.55 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 117.14 0.47 . . . . 0.0 111.221 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 12.9 p -91.31 172.56 8.45 Favored 'General case' 0 N--CA 1.433 -1.318 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.605 178.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.422 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -65.37 -32.04 73.47 Favored 'General case' 0 C--O 1.205 -1.24 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.232 -178.638 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -71.58 -35.4 70.53 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 120.861 -0.336 . . . . 0.0 110.985 -178.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.462 ' O ' HG21 ' A' ' 79' ' ' VAL . 29.7 t80 -65.86 -52.19 52.39 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 176.472 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.83 -46.27 89.79 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.135 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.04 -33.96 69.56 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.795 0.331 . . . . 0.0 110.73 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 97.8 m -68.07 -45.57 73.46 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.069 176.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.462 HG21 ' O ' ' A' ' 75' ' ' PHE . 32.7 t -61.56 -51.85 67.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 C-N-CA 122.632 0.373 . . . . 0.0 110.902 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -68.52 -4.57 15.59 Favored 'General case' 0 CA--C 1.542 0.65 0 CA-C-O 121.237 0.541 . . . . 0.0 112.364 -179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.41 ' HD3' ' C ' ' A' ' 81' ' ' ARG . 0.7 OUTLIER -99.73 -32.52 11.0 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.218 0.533 . . . . 0.0 109.796 172.868 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 8.7 m-80 -80.13 6.68 10.99 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 121.794 0.807 . . . . 0.0 111.856 -178.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.0 p -70.61 170.21 12.69 Favored 'General case' 0 N--CA 1.408 -2.551 0 CA-C-N 114.536 -1.211 . . . . 0.0 111.562 175.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.445 ' HE3' ' O ' ' A' ' 86' ' ' ASN . 0.0 OUTLIER -147.81 -161.3 1.31 Allowed 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 124.898 1.279 . . . . 0.0 107.831 -175.036 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -55.88 -75.15 0.26 Allowed Glycine 0 CA--C 1.525 0.696 0 O-C-N 123.524 0.515 . . . . 0.0 114.016 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.633 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.5 m120 -88.79 105.93 18.03 Favored 'General case' 0 CA--C 1.497 -1.061 0 CA-C-N 117.637 0.718 . . . . 0.0 111.482 -177.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.9 t -116.22 136.29 53.68 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.09 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.994 -175.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 46.8 mtp180 -92.89 99.97 12.52 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 175.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.486 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 97.3 m-85 -92.38 103.26 15.72 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 176.597 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.735 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 40.3 t -92.45 86.52 2.28 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.858 0 N-CA-C 104.984 -2.228 . . . . 0.0 104.984 175.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.489 HG12 ' HA ' ' A' ' 60' ' ' ILE . 64.1 mt -101.25 159.11 4.05 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 CA-C-N 113.989 -1.46 . . . . 0.0 109.174 -179.2 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -130.61 158.04 22.36 Favored Glycine 1 N--CA 1.385 -4.724 0 C-N-CA 119.85 -1.167 . . . . 0.0 110.329 176.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 4.9 tpp180 -133.31 138.79 46.54 Favored 'General case' 0 C--N 1.286 -2.154 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 . . . . . 0 N--CA 1.416 -2.167 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.051 174.098 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 . . . . . 0 C--O 1.214 -0.783 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.435 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -88.14 126.99 35.41 Favored 'General case' 0 C--O 1.249 1.052 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -138.97 142.73 34.45 Favored Pre-proline 0 C--N 1.306 -1.316 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -176.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -79.27 125.85 6.62 Favored 'Trans proline' 0 C--O 1.25 1.122 0 C-N-CA 122.929 2.419 . . . . 0.0 113.357 177.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.412 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 46.5 t -118.71 105.2 17.23 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 174.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.411 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 45.3 tt0 -88.71 102.45 15.0 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.541 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 15.3 tp -90.94 153.13 20.4 Favored 'General case' 0 N--CA 1.422 -1.827 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 -176.107 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -125.39 78.41 1.72 Allowed 'General case' 0 C--N 1.289 -2.049 0 CA-C-O 122.062 0.934 . . . . 0.0 108.757 177.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.46 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 5.5 mmtt -68.92 -169.72 0.19 Allowed 'General case' 0 N--CA 1.402 -2.842 0 CA-C-N 113.56 -1.654 . . . . 0.0 113.047 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.406 ' H ' ' CD ' ' A' ' 12' ' ' LYS . 9.1 m-20 -91.79 176.37 6.55 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 124.619 1.168 . . . . 0.0 108.346 -174.231 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -63.61 -22.46 66.91 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -176.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -72.0 -32.53 67.29 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.62 0.724 . . . . 0.0 110.151 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.423 ' O ' ' HD2' ' A' ' 12' ' ' LYS . . . 108.82 -140.07 15.45 Favored Glycine 0 N--CA 1.414 -2.831 0 N-CA-C 107.49 -2.244 . . . . 0.0 107.49 -173.21 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.458 ' HG ' ' OG1' ' A' ' 83' ' ' THR . 14.7 mt -91.18 -60.9 1.78 Allowed 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.208 179.292 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.58 33.92 60.45 Favored Glycine 0 N--CA 1.424 -2.117 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -173.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.433 ' HB ' ' O ' ' A' ' 41' ' ' THR . 30.6 pt -96.56 177.78 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 C-N-CA 120.369 -0.532 . . . . 0.0 111.018 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.4 m -120.4 150.11 41.3 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 115.252 -0.885 . . . . 0.0 109.092 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.447 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -125.84 162.98 28.17 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 -179.038 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.8 tt -136.13 126.31 41.1 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.256 176.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.489 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -85.37 104.95 2.86 Favored Glycine 0 N--CA 1.435 -1.38 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.657 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.574 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 89.6 mmm -120.98 88.92 3.03 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.314 -0.689 0 O-C-N 123.918 0.761 . . . . 0.0 112.528 -177.622 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.1 pt? . . . . . 0 N--CA 1.44 -0.959 0 CA-C-O 121.406 0.622 . . . . 0.0 111.122 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.574 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -122.07 26.6 6.39 Favored Glycine 0 N--CA 1.417 -2.609 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 173.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.489 HD11 ' HA2' ' A' ' 23' ' ' GLY . 17.9 mm -85.36 101.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 121.547 0.689 . . . . 0.0 109.981 -178.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -95.12 161.93 13.92 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.315 179.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -77.6 122.85 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.202 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -85.54 -49.79 7.76 Favored 'General case' 0 C--N 1.291 -1.96 0 CA-C-O 121.333 0.587 . . . . 0.0 110.501 -177.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.433 ' O ' ' HB ' ' A' ' 19' ' ' ILE . 0.7 OUTLIER -150.84 156.49 41.34 Favored 'General case' 0 N--CA 1.421 -1.876 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.59 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 64.8 t -125.88 145.96 32.45 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.431 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 176.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 8.4 t . . . . . 0 C--O 1.253 1.289 0 O-C-N 123.556 0.535 . . . . 0.0 109.773 176.019 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.46 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . . . . . . 0 CA--C 1.552 1.052 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -116.56 -65.56 1.17 Allowed 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 174.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -74.09 -26.06 60.15 Favored 'General case' 0 N--CA 1.464 0.239 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.111 175.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.531 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 2.0 mmp_? -69.09 -26.94 65.18 Favored 'General case' 0 CA--C 1.503 -0.828 0 CA-C-O 121.053 0.454 . . . . 0.0 110.058 173.128 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -73.74 -57.18 4.16 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 178.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.09 -20.73 48.79 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.505 -0.855 . . . . 0.0 114.262 174.68 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.513 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -73.66 -22.86 59.83 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-O 121.648 0.737 . . . . 0.0 109.114 -177.757 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.8 tt -104.85 148.98 8.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 26.7 mm-40 -129.54 165.98 20.6 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-O 121.168 0.509 . . . . 0.0 111.906 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -83.45 -8.94 11.49 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.892 0 CA-C-O 122.166 0.984 . . . . 0.0 108.621 176.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -102.43 16.85 25.1 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 122.286 1.041 . . . . 0.0 109.443 -175.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -102.05 -179.62 4.05 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.009 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.48 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 33.4 tt0 -128.72 124.96 36.93 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 46.1 mm -76.36 95.39 1.24 Allowed 'Isoleucine or valine' 0 C--O 1.206 -1.192 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 -176.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.689 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 60.6 t -79.42 -42.09 22.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 CA-C-O 121.59 0.71 . . . . 0.0 111.159 -175.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.495 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 36.8 tt0 -151.07 131.14 13.44 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.0 t -123.51 126.05 72.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 172.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 24.3 t70 69.47 5.47 5.18 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-O 122.356 1.074 . . . . 0.0 111.804 172.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.99 13.3 62.44 Favored Glycine 0 N--CA 1.434 -1.493 0 CA-C-N 115.362 -0.836 . . . . 0.0 111.624 -176.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.2 tt -77.34 -16.73 14.41 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.774 0 O-C-N 122.793 -0.239 . . . . 0.0 110.44 -178.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.6 m 39.74 80.67 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.985 1.714 . . . . 0.0 112.7 -176.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.458 ' O ' HG23 ' A' ' 71' ' ' VAL . 0.0 OUTLIER -89.53 31.82 0.9 Allowed 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 122.216 1.007 . . . . 0.0 111.959 -175.606 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 47.8 t -70.52 106.16 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.075 0 CA-C-N 115.199 -0.91 . . . . 0.0 109.288 178.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.93 15.89 20.81 Favored Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.913 176.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 68' ' ' LEU . 19.1 m -96.63 175.83 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.973 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.711 178.434 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 8.4 p -91.54 172.86 8.22 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.99 178.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.447 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -61.24 -33.65 73.86 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.509 -179.488 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -73.09 -33.05 65.38 Favored 'General case' 0 CA--C 1.512 -0.507 0 C-N-CA 121.072 -0.251 . . . . 0.0 111.568 -176.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 33.4 t80 -69.94 -49.71 49.14 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -58.1 -49.22 77.7 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.516 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -55.87 -36.7 67.89 Favored 'General case' 0 C--O 1.216 -0.682 0 C-N-CA 122.467 0.307 . . . . 0.0 110.957 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.404 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 86.9 m -63.39 -45.51 90.75 Favored 'General case' 0 CA--C 1.55 0.957 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.086 176.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 31.0 t -65.1 -49.92 76.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.663 0.268 . . . . 0.0 110.788 178.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -69.77 -4.87 21.83 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.224 0.61 . . . . 0.0 111.993 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.404 ' HB3' ' O ' ' A' ' 78' ' ' THR . 59.5 ttt180 -92.15 -46.62 7.67 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 124.055 0.942 . . . . 0.0 108.541 174.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -77.41 5.68 8.33 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.326 -1.306 . . . . 0.0 113.366 -174.322 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.458 ' OG1' ' HG ' ' A' ' 17' ' ' LEU . 16.8 p -63.45 154.19 32.97 Favored 'General case' 0 C--N 1.294 -1.806 0 C-N-CA 123.832 0.853 . . . . 0.0 112.711 176.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.0 mmtt -120.24 -161.92 0.91 Allowed 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 114.567 -1.197 . . . . 0.0 108.501 176.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.05 -68.03 1.89 Allowed Glycine 0 N--CA 1.444 -0.824 0 O-C-N 123.818 0.699 . . . . 0.0 111.901 176.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.541 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.7 m120 -83.06 118.57 23.63 Favored 'General case' 0 C--N 1.307 -1.268 0 O-C-N 122.244 -0.562 . . . . 0.0 110.635 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.417 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 4.4 t -130.75 130.0 64.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.504 -176.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 22.1 mtp180 -94.33 100.59 12.6 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-O 121.186 0.517 . . . . 0.0 110.917 174.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.476 ' HB3' HG13 ' A' ' 91' ' ' ILE . 89.0 m-85 -95.12 112.0 23.76 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 176.101 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.689 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 10.7 t -100.48 65.54 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.476 HG13 ' HB3' ' A' ' 89' ' ' PHE . 76.4 mt -77.14 153.8 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.516 0 CA-C-N 112.796 -2.002 . . . . 0.0 109.909 -177.683 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.435 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -131.07 149.3 19.15 Favored Glycine 1 N--CA 1.385 -4.709 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 177.386 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -111.25 133.0 53.92 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 -178.626 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 . . . . . 0 C--N 1.309 -1.185 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 177.968 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 . . . . . 0 N--CA 1.437 -1.094 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.42 HD11 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -87.86 125.17 34.33 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -132.02 140.66 38.81 Favored Pre-proline 0 C--N 1.287 -2.112 0 CA-C-O 121.461 0.648 . . . . 0.0 112.061 -176.286 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -83.11 125.85 4.18 Favored 'Trans proline' 0 C--N 1.301 -1.927 0 C-N-CA 122.535 2.157 . . . . 0.0 112.188 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.44 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 36.9 t -109.04 109.05 26.89 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.593 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 172.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.481 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 45.3 tt0 -92.89 103.23 15.58 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.406 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.5 OUTLIER -103.38 154.21 19.65 Favored 'General case' 0 N--CA 1.395 -3.182 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 -175.669 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -123.06 100.56 6.94 Favored 'General case' 0 N--CA 1.409 -2.483 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 177.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.479 ' HD2' ' HB2' ' A' ' 47' ' ' ALA . 3.3 mmmp? -92.48 178.92 5.67 Favored 'General case' 0 C--N 1.284 -2.282 0 CA-C-N 114.524 -1.217 . . . . 0.0 109.486 176.254 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.535 ' OD2' ' HG2' ' A' ' 14' ' ' GLU . 19.6 t70 -101.41 -160.01 0.77 Allowed 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -176.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.535 ' HG2' ' OD2' ' A' ' 13' ' ' ASP . 11.0 pt-20 -75.77 -13.08 60.29 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -171.305 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -71.07 -43.9 66.84 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.213 0.53 . . . . 0.0 110.254 177.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 125.1 -131.02 7.57 Favored Glycine 0 CA--C 1.481 -2.066 0 N-CA-C 108.28 -1.928 . . . . 0.0 108.28 -177.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.427 ' CD1' HD13 ' A' ' 80' ' ' LEU . 14.3 mt -100.7 -60.94 1.43 Allowed 'General case' 0 CA--C 1.476 -1.902 0 C-N-CA 119.012 -1.075 . . . . 0.0 109.462 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.12 29.94 39.65 Favored Glycine 0 N--CA 1.419 -2.472 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -174.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 24.5 pt -104.54 176.87 0.94 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.987 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.4 m -135.42 150.08 49.78 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 -177.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.554 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -120.16 166.02 15.0 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 C-N-CA 123.303 0.641 . . . . 0.0 110.098 -177.242 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 11.9 tt -140.94 127.93 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.014 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 174.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.434 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -93.57 109.48 3.81 Favored Glycine 0 CA--C 1.484 -1.869 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -177.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.612 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 88.7 mmm -125.99 92.92 3.69 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.397 0 N-CA-C 114.77 0.668 . . . . 0.0 114.77 -175.523 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.3 pp . . . . . 0 N--CA 1.44 -0.927 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.612 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -121.98 30.62 5.21 Favored Glycine 0 N--CA 1.422 -2.281 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.75 178.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.48 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 23.5 mm -82.25 103.65 9.74 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 CA-C-O 121.847 0.832 . . . . 0.0 110.537 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -99.32 164.33 12.16 Favored 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.0 t -82.6 131.04 34.69 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.484 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 177.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.492 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.4 OUTLIER -91.7 -45.39 8.47 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.137 0.494 . . . . 0.0 109.832 -178.692 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.0 m -154.66 162.24 41.21 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -127.11 160.98 35.13 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.15 0 N-CA-C 105.363 -2.088 . . . . 0.0 105.363 178.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.6 t . . . . . 0 C--N 1.293 -1.883 0 CA-C-O 121.908 0.861 . . . . 0.0 111.007 -178.599 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.479 ' HB2' ' HD2' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.211 -0.942 0 N-CA-C 115.685 1.735 . . . . 0.0 115.685 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.435 ' HB3' ' CE ' ' A' ' 12' ' ' LYS . . . -82.38 -56.79 3.68 Favored 'General case' 0 N--CA 1.488 1.461 0 CA-C-N 118.974 0.806 . . . . 0.0 110.91 -176.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -73.9 -16.99 61.09 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.561 0.696 . . . . 0.0 110.45 177.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.504 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 3.9 mmp_? -83.14 -17.03 44.42 Favored 'General case' 0 N--CA 1.432 -1.353 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.092 174.073 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -61.43 -61.75 2.32 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.964 0.411 . . . . 0.0 109.987 173.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.92 -9.86 74.75 Favored Glycine 0 N--CA 1.44 -1.073 0 C-N-CA 120.575 -0.821 . . . . 0.0 114.849 173.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -89.35 -45.35 9.55 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 178.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.7 tt -74.9 150.51 6.96 Favored 'Isoleucine or valine' 0 C--O 1.252 1.225 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 176.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -134.87 160.35 38.51 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.7 p -73.27 -17.0 17.7 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.139 0 CA-C-O 121.79 0.805 . . . . 0.0 109.743 176.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -90.32 -6.37 55.16 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.389 -173.327 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -95.07 -176.12 3.73 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 113.249 0.833 . . . . 0.0 113.249 -174.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.498 ' O ' HG21 ' A' ' 91' ' ' ILE . 32.4 tt0 -116.99 127.43 54.18 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.102 -174.365 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.434 ' HA ' HG12 ' A' ' 91' ' ' ILE . 50.4 mm -73.4 105.57 2.87 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.627 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.626 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 97.9 t -90.04 -49.46 13.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 CA-C-O 121.664 0.745 . . . . 0.0 111.008 -176.006 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.441 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 37.4 tt0 -151.99 104.15 2.96 Favored 'General case' 0 C--N 1.296 -1.751 0 CA-C-O 121.518 0.675 . . . . 0.0 109.834 -178.181 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.8 t -91.75 123.04 43.73 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.061 0 CA-C-O 121.322 0.582 . . . . 0.0 111.717 176.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 24.5 t70 65.86 4.66 3.05 Favored 'General case' 0 C--N 1.311 -1.067 0 C-N-CA 126.813 2.045 . . . . 0.0 112.769 174.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.98 12.34 57.84 Favored Glycine 0 N--CA 1.429 -1.771 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.613 -177.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 9.6 tt -73.01 -17.8 18.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-O 121.185 0.517 . . . . 0.0 110.408 -179.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.44 ' HB3' ' OE2' ' A' ' 62' ' ' GLU . 9.7 p 49.69 82.83 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 124.826 1.25 . . . . 0.0 113.259 -176.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.534 ' O ' HG23 ' A' ' 71' ' ' VAL . 1.8 pp -93.03 14.43 17.78 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.572 -177.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 58.6 t -57.75 102.5 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.5 176.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.62 -5.25 24.54 Favored Glycine 0 N--CA 1.442 -0.941 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.433 176.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 68' ' ' LEU . 11.5 m -83.98 178.15 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.247 0.925 0 CA-C-O 121.245 0.545 . . . . 0.0 111.69 -175.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.4 p -101.12 170.53 8.2 Favored 'General case' 0 N--CA 1.415 -2.18 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.116 176.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.554 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -56.13 -33.5 65.21 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-N 114.51 -1.223 . . . . 0.0 112.256 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -74.4 -22.36 59.2 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 111.744 0.275 . . . . 0.0 111.744 -177.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.428 ' O ' ' HB ' ' A' ' 78' ' ' THR . 38.6 t80 -80.85 -50.14 10.17 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 174.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.64 -47.99 80.71 Favored 'General case' 0 C--O 1.22 -0.459 0 CA-C-N 114.719 -1.128 . . . . 0.0 112.12 -178.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -56.74 -33.22 66.34 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 120.89 0.376 . . . . 0.0 110.687 179.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.428 ' HB ' ' O ' ' A' ' 75' ' ' PHE . 53.0 m -68.62 -47.15 67.4 Favored 'General case' 0 N--CA 1.435 -1.205 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.904 176.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 44.3 t -58.82 -50.27 79.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 110.097 -0.335 . . . . 0.0 110.097 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.427 HD13 ' CD1' ' A' ' 17' ' ' LEU . 3.6 mm? -67.67 -10.62 53.93 Favored 'General case' 0 CA--C 1.551 1.014 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.681 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -97.7 -23.05 16.11 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.256 0.551 . . . . 0.0 110.43 176.082 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -83.84 -23.18 31.47 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.092 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.4 p -63.99 156.62 27.42 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 113.646 0.98 . . . . 0.0 113.646 -178.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.75 -145.97 0.36 Allowed 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 114.685 -1.143 . . . . 0.0 109.764 -176.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.8 -67.64 1.91 Allowed Glycine 0 C--N 1.295 -1.719 0 O-C-N 123.671 0.607 . . . . 0.0 112.603 -177.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.406 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 0.9 OUTLIER -77.25 109.73 11.37 Favored 'General case' 0 CA--C 1.497 -1.079 0 C-N-CA 119.937 -0.705 . . . . 0.0 110.118 178.657 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -124.09 144.53 33.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.82 98.26 7.78 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 173.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.44 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 86.5 m-85 -90.42 98.4 11.75 Favored 'General case' 0 C--N 1.279 -2.498 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 178.134 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.626 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 58.9 t -89.3 91.8 3.77 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.433 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 178.168 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.498 HG21 ' O ' ' A' ' 59' ' ' GLN . 81.6 mt -106.52 156.67 7.04 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.073 0 CA-C-N 114.0 -1.454 . . . . 0.0 108.096 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.42 ' HA3' HD11 ' A' ' 5' ' ' LEU . . . -134.25 164.47 24.53 Favored Glycine 1 N--CA 1.393 -4.182 0 C-N-CA 119.566 -1.302 . . . . 0.0 109.931 178.595 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -149.46 131.06 14.91 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . 0.26 0.0 OUTLIER . . . . . 0 N--CA 1.411 -2.377 0 CA-C-O 118.436 -0.792 . . . . 0.0 110.671 175.218 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 . . . . . 0 N--CA 1.438 -1.026 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -81.73 130.55 35.1 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 178.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -137.11 141.53 34.84 Favored Pre-proline 0 C--N 1.284 -2.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.324 -179.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -77.89 128.71 9.4 Favored 'Trans proline' 0 N--CA 1.443 -1.474 0 C-N-CA 122.368 2.046 . . . . 0.0 112.418 178.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 21.7 t -119.11 94.99 3.34 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.258 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 174.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.535 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 40.7 tt0 -78.33 112.44 15.34 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 175.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -97.43 123.07 41.15 Favored 'General case' 0 N--CA 1.405 -2.701 0 N-CA-C 105.444 -2.058 . . . . 0.0 105.444 178.617 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.455 ' HG3' ' OD1' ' A' ' 86' ' ' ASN . 30.9 tt0 -94.44 90.45 6.23 Favored 'General case' 0 C--N 1.281 -2.373 0 CA-C-O 121.839 0.828 . . . . 0.0 109.005 179.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 2.8 mmmp? -93.82 -175.4 3.72 Favored 'General case' 0 N--CA 1.428 -1.563 0 CA-C-N 114.263 -1.335 . . . . 0.0 111.778 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.568 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.5 p-10 -88.27 -172.42 3.78 Favored 'General case' 0 C--N 1.28 -2.452 0 C-N-CA 126.8 2.04 . . . . 0.0 112.384 -177.386 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -77.45 -20.21 54.82 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 114.705 -1.134 . . . . 0.0 111.577 -179.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.568 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 18.8 t70 -73.95 -35.64 64.55 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 118.25 -124.58 6.11 Favored Glycine 0 CA--C 1.486 -1.747 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.661 172.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.444 ' HB3' HG23 ' A' ' 19' ' ' ILE . 31.7 mt -112.76 -54.54 2.61 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.1 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.55 27.51 69.32 Favored Glycine 0 N--CA 1.425 -2.062 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.818 -173.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.444 HG23 ' HB3' ' A' ' 17' ' ' LEU . 27.0 pt -94.67 176.32 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.26 -178.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 49.0 m -132.33 150.31 52.18 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.882 -178.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -120.05 159.89 20.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.46 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 15.4 tt -124.13 132.01 72.01 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 C-N-CA 120.063 -0.655 . . . . 0.0 110.045 175.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.466 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.82 92.45 1.78 Allowed Glycine 0 N--CA 1.427 -1.94 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.852 -177.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 91.8 mmm -108.26 -179.07 3.78 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.284 -2.354 0 C-N-CA 120.087 -1.054 . . . . 0.0 112.333 179.913 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.523 HD21 ' HA ' ' A' ' 69' ' ' VAL . 3.2 pp . . . . . 0 N--CA 1.44 -0.969 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -116.47 32.54 5.51 Favored Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 175.172 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.466 HD13 ' HA2' ' A' ' 23' ' ' GLY . 29.7 mm -81.31 103.87 9.01 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.867 0 CA-C-O 121.624 0.726 . . . . 0.0 110.14 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -102.21 160.16 14.76 Favored 'General case' 0 C--N 1.275 -2.645 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.296 176.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 40.5 t -74.32 123.97 30.84 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 175.293 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.402 ' HB2' ' HB ' ' A' ' 22' ' ' ILE . 53.5 tptt -89.29 -48.61 7.25 Favored 'General case' 0 C--N 1.293 -1.871 0 CA-C-O 121.118 0.485 . . . . 0.0 110.28 -176.762 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -150.25 159.15 44.65 Favored 'General case' 0 N--CA 1.422 -1.874 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -177.401 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 23.3 t -121.24 174.16 6.17 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.522 0 N-CA-C 104.894 -2.261 . . . . 0.0 104.894 175.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 3.2 t . . . . . 0 CA--C 1.561 1.377 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 173.831 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.413 ' O ' ' HB2' ' A' ' 51' ' ' ASP . . . . . . . . 0 C--O 1.193 -1.921 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.57 -60.11 2.44 Favored 'General case' 0 C--N 1.35 0.59 0 C-N-CA 123.551 0.74 . . . . 0.0 110.059 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -70.5 -27.46 64.22 Favored 'General case' 0 CA--C 1.511 -0.536 0 C-N-CA 120.14 -0.624 . . . . 0.0 111.029 178.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.415 ' HD3' ' HA ' ' A' ' 50' ' ' ARG . 37.1 mmt180 -78.45 -19.5 53.01 Favored 'General case' 0 N--CA 1.44 -0.975 0 C-N-CA 120.04 -0.664 . . . . 0.0 111.778 175.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 47' ' ' ALA . 11.1 t70 -66.7 -64.01 0.94 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 172.058 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.89 -10.11 70.4 Favored Glycine 0 N--CA 1.44 -1.092 0 C-N-CA 120.557 -0.83 . . . . 0.0 115.13 173.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.08 -21.56 43.2 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -179.817 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.6 tt -105.05 164.59 3.91 Favored 'Isoleucine or valine' 0 C--O 1.254 1.305 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 175.164 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 63.1 mt-30 -136.17 -156.72 0.73 Allowed 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 119.033 0.833 . . . . 0.0 110.923 -177.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.2 p -123.94 18.21 4.77 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 174.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -132.91 -8.43 3.09 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.758 0.789 . . . . 0.0 111.206 -174.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.546 ' OD2' HD12 ' A' ' 91' ' ' ILE . 7.1 p-10 -83.18 179.24 7.78 Favored 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 124.571 1.148 . . . . 0.0 110.919 -177.357 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.46 ' O ' HG21 ' A' ' 91' ' ' ILE . 31.1 tt0 -119.76 126.08 50.18 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.087 -176.054 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 50.8 mm -74.36 114.71 14.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.089 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.693 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 84.7 t -98.37 -48.92 11.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.85 0.834 . . . . 0.0 111.022 -178.164 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.498 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 26.9 tt0 -150.28 114.88 5.23 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -178.614 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.4 t -110.1 128.13 66.51 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.821 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.589 178.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.7 t70 72.58 -8.84 1.15 Allowed 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 125.265 1.426 . . . . 0.0 112.348 175.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.83 13.43 31.98 Favored Glycine 0 C--N 1.286 -2.203 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.686 -174.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.4 tt -74.97 -17.44 16.2 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 17.4 m 45.83 84.56 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 125.659 1.584 . . . . 0.0 111.585 -176.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.411 ' HB2' ' CG2' ' A' ' 71' ' ' VAL . 0.7 OUTLIER -93.06 20.98 6.19 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.659 0.742 . . . . 0.0 110.671 -175.317 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.523 ' HA ' HD21 ' A' ' 35' ' ' LEU . 59.1 t -52.77 100.63 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 CA-C-N 114.691 -1.141 . . . . 0.0 111.77 177.474 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.59 21.7 25.89 Favored Glycine 0 N--CA 1.443 -0.844 0 CA-C-N 115.47 -0.786 . . . . 0.0 114.131 174.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.411 ' CG2' ' HB2' ' A' ' 68' ' ' LEU . 20.5 m -93.43 -178.66 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 117.497 0.649 . . . . 0.0 111.173 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.9 p -98.37 178.97 4.87 Favored 'General case' 0 C--O 1.251 1.146 0 CA-C-O 121.037 0.446 . . . . 0.0 110.377 177.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.92 -25.31 66.3 Favored 'General case' 0 C--O 1.204 -1.337 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.337 179.638 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 25.6 m-80 -63.02 -48.57 78.22 Favored 'General case' 0 CA--C 1.483 -1.603 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.183 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -68.61 -47.79 65.78 Favored 'General case' 0 N--CA 1.426 -1.633 0 CA-C-N 114.76 -1.109 . . . . 0.0 109.698 -175.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -62.94 -40.29 97.21 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.167 -178.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -69.08 -18.19 63.97 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.229 0.537 . . . . 0.0 110.426 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 83.3 m -84.01 -47.5 10.91 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.457 176.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.44 HG11 HD22 ' A' ' 80' ' ' LEU . 3.9 p -62.78 -48.6 87.36 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 N-CA-C 112.943 0.72 . . . . 0.0 112.943 177.323 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.44 HD22 HG11 ' A' ' 79' ' ' VAL . 3.9 mm? -67.2 -12.22 59.48 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.531 0.682 . . . . 0.0 112.056 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -84.47 -46.05 12.04 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 176.249 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -79.56 -11.09 59.89 Favored 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 114.388 1.255 . . . . 0.0 114.388 -171.188 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.427 HG22 ' O ' ' A' ' 79' ' ' VAL . 12.0 p -68.45 140.7 55.76 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -135.93 141.75 44.54 Favored 'General case' 0 CA--C 1.482 -1.659 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.096 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 47.67 -88.13 0.01 OUTLIER Glycine 0 CA--C 1.474 -2.508 0 O-C-N 126.039 2.087 . . . . 0.0 113.696 178.081 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.455 ' OD1' ' HG3' ' A' ' 11' ' ' GLU . 3.0 m-20 -97.94 102.0 13.63 Favored 'General case' 0 C--N 1.247 -3.849 0 CA-C-N 113.804 -1.198 . . . . 0.0 110.52 -173.283 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.535 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 40.2 t -113.15 124.82 70.16 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 CA-C-N 115.021 -0.991 . . . . 0.0 111.611 -173.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.59 104.18 16.61 Favored 'General case' 0 CA--C 1.49 -1.364 0 C-N-CA 120.204 -0.598 . . . . 0.0 109.944 174.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -93.49 100.19 12.52 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 175.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.693 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.8 t -89.5 92.99 4.13 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.82 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 177.282 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.546 HD12 ' OD2' ' A' ' 58' ' ' ASP . 96.5 mt -108.62 163.84 5.79 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.375 0 C-N-CA 125.485 1.514 . . . . 0.0 107.494 179.486 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -133.75 159.82 23.83 Favored Glycine 0 N--CA 1.411 -2.97 0 C-N-CA 118.557 -1.782 . . . . 0.0 113.301 -177.146 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 35.5 ttt180 -114.32 137.41 51.84 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 123.321 0.648 . . . . 0.0 109.533 177.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? . . . . . 0 C--N 1.294 -1.834 0 CA-C-O 119.395 -0.336 . . . . 0.0 110.976 -178.445 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.411 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 35.2 tt0 . . . . . 0 N--CA 1.44 -0.961 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -84.14 131.89 34.74 Favored 'General case' 0 CA--C 1.5 -0.963 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -140.58 138.5 18.73 Favored Pre-proline 0 N--CA 1.42 -1.971 0 CA-C-O 121.507 0.67 . . . . 0.0 112.012 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -81.47 124.27 4.64 Favored 'Trans proline' 0 C--N 1.314 -1.263 0 C-N-CA 122.856 2.37 . . . . 0.0 112.781 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.418 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 25.0 t -113.61 106.14 20.13 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 175.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.496 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 30.8 tt0 -89.64 109.13 20.11 Favored 'General case' 0 N--CA 1.416 -2.132 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 177.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -100.91 149.34 23.99 Favored 'General case' 0 C--N 1.289 -2.063 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 -176.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -120.44 93.03 3.91 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 171.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.426 ' HD2' ' HA ' ' A' ' 12' ' ' LYS . 3.0 mmmp? -82.73 172.86 12.43 Favored 'General case' 0 N--CA 1.421 -1.92 0 CA-C-O 122.63 1.205 . . . . 0.0 114.177 -179.046 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -72.78 171.23 13.03 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 112.077 -2.329 . . . . 0.0 108.564 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -68.83 -16.93 63.92 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.345 0.593 . . . . 0.0 110.373 178.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.05 -33.02 72.65 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 122.023 0.916 . . . . 0.0 109.986 174.462 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.59 -138.38 14.93 Favored Glycine 0 N--CA 1.41 -3.095 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt -89.46 -43.91 10.52 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 119.734 -0.786 . . . . 0.0 109.735 -179.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 66.64 28.0 73.52 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 124.547 1.155 . . . . 0.0 111.013 -174.23 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 20.7 pt -109.0 177.07 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.452 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.0 m -138.64 153.81 48.61 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -177.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -122.39 166.72 16.76 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 -178.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 13.7 tt -135.08 133.57 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.79 0 C-N-CA 120.026 -0.67 . . . . 0.0 111.435 176.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.478 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -92.93 103.44 3.05 Favored Glycine 0 N--CA 1.413 -2.886 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 18.1 ptm -140.85 86.94 2.08 Favored 'General case' 0 C--N 1.288 -2.079 0 CA-C-O 121.584 0.707 . . . . 0.0 109.77 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.44 -1.09 0 CA-C-N 114.066 -1.425 . . . . 0.0 112.966 -176.058 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.24 0.597 0 CA-C-O 121.664 0.745 . . . . 0.0 112.6 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -120.02 47.43 1.03 Allowed Glycine 0 N--CA 1.413 -2.877 0 N-CA-C 109.961 -1.255 . . . . 0.0 109.961 175.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.577 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 28.9 mm -109.12 111.43 36.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 177.659 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -110.49 170.41 8.1 Favored 'General case' 0 C--N 1.269 -2.909 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.385 -178.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 38.9 t -83.47 128.21 39.0 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.076 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.5 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -92.92 -47.12 7.17 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 120.944 0.402 . . . . 0.0 110.165 -176.884 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.1 m -150.36 163.46 38.3 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 -178.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 61.0 t -136.38 148.4 27.29 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 N-CA-C 105.007 -2.22 . . . . 0.0 105.007 178.347 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.6 t . . . . . 0 C--O 1.251 1.176 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 175.277 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.487 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 CA--C 1.56 1.342 0 N-CA-C 114.825 1.417 . . . . 0.0 114.825 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.43 -59.33 2.82 Favored 'General case' 0 C--O 1.219 -0.535 0 O-C-N 121.745 -0.597 . . . . 0.0 109.993 -176.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -74.34 -15.12 60.96 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.387 175.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.487 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 24.2 mmm180 -73.12 -34.02 65.88 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 172.219 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -59.53 -58.63 7.75 Favored 'General case' 0 N--CA 1.473 0.681 0 O-C-N 123.565 0.54 . . . . 0.0 109.813 173.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.82 -12.81 67.68 Favored Glycine 0 C--N 1.312 -0.782 0 C-N-CA 120.319 -0.943 . . . . 0.0 114.879 173.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 63.5 ttt180 -80.18 -40.77 26.59 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.4 tt -86.23 143.73 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.99 0 CA-C-N 114.335 -1.302 . . . . 0.0 107.857 179.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -138.5 175.85 9.21 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-O 121.258 0.551 . . . . 0.0 110.665 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.7 p -81.38 -3.25 6.57 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.49 -177.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -105.38 6.89 32.97 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.638 0.732 . . . . 0.0 110.545 -174.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -93.01 -173.66 3.34 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 115.186 -0.916 . . . . 0.0 111.08 -176.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.577 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 27.5 tt0 -131.86 127.45 36.56 Favored 'General case' 0 C--N 1.322 -0.608 0 C-N-CA 123.488 0.715 . . . . 0.0 111.001 -177.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.43 ' HA ' HG12 ' A' ' 91' ' ' ILE . 48.9 mm -77.21 106.45 7.29 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.852 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.45 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.711 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.1 t -89.18 -49.5 13.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-O 122.219 1.009 . . . . 0.0 110.116 -176.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.47 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 23.8 tt0 -148.64 126.84 12.13 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.496 179.225 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.37 127.69 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.641 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.118 176.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.9 t70 63.94 15.15 8.95 Favored 'General case' 0 N--CA 1.477 0.886 0 O-C-N 124.744 1.277 . . . . 0.0 111.081 173.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.93 17.32 67.83 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.855 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.1 tt -77.23 -18.68 14.34 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.156 0 CA-C-N 117.166 0.483 . . . . 0.0 111.283 -179.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.438 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 16.8 p 49.56 83.88 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.419 1.488 . . . . 0.0 113.126 -174.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -97.87 17.36 18.34 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.582 0.706 . . . . 0.0 110.805 -175.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 44.6 t -57.06 94.13 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.134 174.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.96 52.74 0.93 Allowed Glycine 0 N--CA 1.436 -1.355 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.866 178.29 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 23.5 m -130.05 178.71 4.93 Favored 'Isoleucine or valine' 0 C--O 1.243 0.723 0 CA-C-O 120.97 0.414 . . . . 0.0 111.107 178.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 15.5 p -98.31 174.61 6.41 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.425 178.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.45 -27.38 66.99 Favored 'General case' 0 C--O 1.2 -1.541 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.395 -178.61 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -71.81 -30.87 65.96 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.064 -179.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -74.64 -48.39 26.57 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 176.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.426 ' O ' HD22 ' A' ' 80' ' ' LEU . . . -61.72 -42.15 98.57 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.733 -179.115 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.1 -33.22 71.8 Favored 'General case' 0 C--O 1.204 -1.32 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 177.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 92.0 m -71.67 -48.7 45.8 Favored 'General case' 0 N--CA 1.434 -1.25 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.185 178.658 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.421 HG13 HD23 ' A' ' 80' ' ' LEU . 3.4 p -62.23 -45.59 98.4 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 178.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.426 HD22 ' O ' ' A' ' 76' ' ' ALA . 3.8 mm? -70.68 -7.82 47.4 Favored 'General case' 0 CA--C 1.549 0.918 0 CA-C-O 121.053 0.454 . . . . 0.0 111.597 178.283 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.9 tmt_? -97.44 -28.12 14.14 Favored 'General case' 0 C--O 1.214 -0.799 0 C-N-CA 122.73 0.412 . . . . 0.0 110.773 176.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -84.92 -2.52 57.96 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -177.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.0 p -76.82 159.85 29.74 Favored 'General case' 0 C--N 1.288 -2.072 0 CA-C-O 121.655 0.741 . . . . 0.0 112.866 -177.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 33.2 mmtp -118.39 -162.51 0.89 Allowed 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 114.931 -1.031 . . . . 0.0 108.639 177.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -53.04 -62.71 5.69 Favored Glycine 0 C--O 1.217 -0.953 0 O-C-N 123.846 0.716 . . . . 0.0 113.228 174.258 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.16 115.2 18.67 Favored 'General case' 0 C--O 1.245 0.867 0 CA-C-N 117.597 0.699 . . . . 0.0 110.014 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.0 t -132.24 136.43 56.44 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.907 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.213 -177.712 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 65.2 mtp180 -99.2 99.71 10.72 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 171.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.418 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 95.9 m-85 -90.31 102.78 15.51 Favored 'General case' 0 CA--C 1.486 -1.493 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 175.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.711 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 47.5 t -93.65 87.28 2.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.694 0 N-CA-C 105.326 -2.102 . . . . 0.0 105.326 178.164 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.471 HG22 ' O ' ' A' ' 59' ' ' GLN . 76.9 mt -104.11 153.22 6.24 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.785 0 CA-C-N 113.684 -1.598 . . . . 0.0 109.223 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.411 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -126.08 155.74 19.37 Favored Glycine 1 N--CA 1.384 -4.778 0 N-CA-C 108.405 -1.878 . . . . 0.0 108.405 177.135 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 64.7 ttt-85 -141.03 137.48 32.98 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 119.169 -1.012 . . . . 0.0 112.83 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 . . . . . 0 C--N 1.311 -1.102 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 173.585 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 . . . . . 0 CA--C 1.498 -1.029 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -85.54 130.98 34.45 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 176.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -138.79 142.41 33.83 Favored Pre-proline 0 C--N 1.288 -2.065 0 CA-C-O 121.214 0.531 . . . . 0.0 111.802 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -83.87 123.48 3.23 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.667 2.244 . . . . 0.0 112.732 177.21 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.2 t -114.65 105.38 18.55 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 174.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.527 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 27.6 tt0 -93.7 97.54 10.52 Favored 'General case' 0 N--CA 1.417 -2.121 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 -179.384 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -87.67 158.36 18.86 Favored 'General case' 0 N--CA 1.397 -3.105 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -174.778 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -124.04 98.93 6.01 Favored 'General case' 0 C--N 1.274 -2.681 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.229 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.458 ' O ' ' HA2' ' A' ' 85' ' ' GLY . 2.3 mmmp? -100.73 -170.0 1.79 Allowed 'General case' 0 N--CA 1.409 -2.512 0 CA-C-N 114.518 -1.219 . . . . 0.0 112.696 -179.791 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.56 157.12 36.02 Favored 'General case' 0 N--CA 1.413 -2.312 0 CA-C-N 113.03 -1.896 . . . . 0.0 106.534 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -72.48 -8.95 57.75 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 121.438 0.637 . . . . 0.0 110.253 176.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -72.22 -38.47 68.97 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 175.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.59 -145.14 16.74 Favored Glycine 0 N--CA 1.42 -2.411 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.624 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.401 ' CD1' HD12 ' A' ' 80' ' ' LEU . 18.3 mt -104.53 -46.47 4.35 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.44 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.85 29.7 37.82 Favored Glycine 0 N--CA 1.422 -2.242 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.874 -175.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.2 pt -102.42 -174.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 120.059 -0.656 . . . . 0.0 112.357 -177.293 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 21.8 m -135.66 153.04 51.75 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.551 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -126.63 164.99 25.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 123.393 0.677 . . . . 0.0 109.336 -177.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.9 tt -135.41 130.02 50.17 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-O 120.811 0.338 . . . . 0.0 110.487 175.062 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.433 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.33 107.28 3.32 Favored Glycine 0 N--CA 1.428 -1.861 0 C-N-CA 121.085 -0.578 . . . . 0.0 112.029 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.412 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.2 mmm -121.94 174.53 6.84 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.645 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.29 -1.989 0 C-N-CA 119.418 -1.372 . . . . 0.0 112.171 179.616 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.464 HD21 ' HA ' ' A' ' 69' ' ' VAL . 2.0 pp . . . . . 0 N--CA 1.437 -1.084 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -116.8 33.71 4.95 Favored Glycine 0 C--N 1.288 -2.103 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 173.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.513 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 26.3 mm -84.58 105.49 13.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 121.407 0.622 . . . . 0.0 110.337 -177.09 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -99.25 162.98 12.74 Favored 'General case' 0 C--N 1.279 -2.46 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 177.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.89 128.01 38.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.407 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.472 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -91.74 -39.07 12.02 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.303 0.573 . . . . 0.0 110.455 -177.049 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.7 m -159.65 161.0 34.9 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 17.5 t -117.62 167.73 10.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.216 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.9 t . . . . . 0 C--N 1.305 -1.364 0 C-N-CA 123.044 0.538 . . . . 0.0 109.965 178.566 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.401 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 C--O 1.203 -1.392 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.55 -62.56 1.65 Allowed 'General case' 0 C--O 1.214 -0.807 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.4 mt-30 -72.73 -13.73 61.4 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.783 0.661 . . . . 0.0 112.783 176.208 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.401 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 27.4 mmt180 -81.17 -26.33 36.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 172.299 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -54.94 -57.55 11.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 123.743 0.652 . . . . 0.0 111.368 177.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.73 -13.15 56.48 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.225 -0.988 . . . . 0.0 114.352 175.322 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.568 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -93.74 -59.93 1.88 Allowed 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 118.082 0.941 . . . . 0.0 108.573 176.878 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.568 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 15.3 tt -64.29 143.67 15.47 Favored 'Isoleucine or valine' 0 C--O 1.246 0.893 0 O-C-N 123.707 0.63 . . . . 0.0 110.672 -175.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -142.52 172.76 12.26 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.029 0.442 . . . . 0.0 111.617 -178.377 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.7 p -76.68 -9.52 12.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.653 0 CA-C-O 121.889 0.852 . . . . 0.0 110.503 -177.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -92.22 -2.75 56.32 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.592 0.711 . . . . 0.0 110.288 -176.087 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 -82.29 174.94 10.68 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 121.988 0.899 . . . . 0.0 112.328 -176.173 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.513 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.3 tt0 -128.6 125.48 38.27 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.497 178.309 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 48.8 mm -77.16 104.74 5.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -178.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.773 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 86.1 t -87.13 -48.07 15.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.844 0.831 . . . . 0.0 110.82 -176.469 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.484 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 33.1 tt0 -151.66 125.95 9.35 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 t -115.64 128.05 73.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 175.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.1 t70 72.97 -9.15 1.16 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 125.23 1.412 . . . . 0.0 112.671 173.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.93 11.56 36.94 Favored Glycine 0 C--N 1.29 -2.011 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.763 -174.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.0 tt -70.95 -21.21 22.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-O 120.728 0.299 . . . . 0.0 111.36 -177.614 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 57.7 p 51.01 88.52 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.036 1.334 . . . . 0.0 112.192 -177.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.48 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.4 pp -100.29 17.9 20.22 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 122.29 1.043 . . . . 0.0 109.931 -175.595 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.464 ' HA ' HD21 ' A' ' 35' ' ' LEU . 39.2 t -60.69 98.49 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.297 178.234 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 112.75 9.67 18.34 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.609 177.538 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.48 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.7 m -95.56 174.21 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.485 -179.408 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 p -95.02 175.45 6.63 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.54 177.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.551 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.23 -34.35 72.1 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.628 -179.385 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.7 -36.87 73.48 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.439 -177.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.447 ' O ' HG22 ' A' ' 79' ' ' VAL . 35.4 t80 -70.68 -49.1 50.76 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.808 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.19 -45.07 94.38 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.399 -178.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -54.91 -43.29 73.14 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 122.716 0.406 . . . . 0.0 110.307 178.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 90.3 m -61.35 -41.78 97.61 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.981 177.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.447 HG22 ' O ' ' A' ' 75' ' ' PHE . 47.4 t -62.98 -51.82 67.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 178.022 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.401 HD12 ' CD1' ' A' ' 17' ' ' LEU . 3.5 mm? -68.26 -5.36 17.99 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-O 121.342 0.591 . . . . 0.0 111.63 179.525 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -102.47 -22.44 14.05 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.901 0.881 . . . . 0.0 110.891 176.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -90.44 0.85 57.13 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 121.253 0.549 . . . . 0.0 111.628 178.295 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 15.6 p -61.83 155.38 23.33 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.172 -0.922 . . . . 0.0 112.739 178.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.49 -157.55 0.8 Allowed 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.626 -1.17 . . . . 0.0 108.241 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 12' ' ' LYS . . . -51.61 -82.04 0.05 OUTLIER Glycine 0 CA--C 1.531 1.033 0 N-CA-C 114.601 0.6 . . . . 0.0 114.601 177.489 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -77.12 102.13 6.42 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.122 0.486 . . . . 0.0 111.419 -176.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 41.8 t -115.52 119.42 61.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.16 -178.323 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.34 104.49 15.22 Favored 'General case' 0 CA--C 1.487 -1.447 0 C-N-CA 120.282 -0.567 . . . . 0.0 109.963 173.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -93.33 101.33 13.57 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 174.445 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.773 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.9 t -91.53 85.77 2.3 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 N-CA-C 105.337 -2.098 . . . . 0.0 105.337 176.553 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 78.0 mt -102.68 155.37 5.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 CA-C-N 113.765 -1.561 . . . . 0.0 108.85 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -128.85 155.59 20.72 Favored Glycine 0 N--CA 1.4 -3.748 0 C-N-CA 119.747 -1.215 . . . . 0.0 110.479 177.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -132.15 152.17 51.41 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 121.551 0.691 . . . . 0.0 112.864 -178.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 . . . . . 0 C--N 1.299 -1.606 0 C-N-CA 127.231 2.212 . . . . 0.0 105.505 174.381 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 . . . . . 0 CA--C 1.498 -1.029 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -85.54 130.98 34.45 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -138.79 142.41 33.83 Favored Pre-proline 0 C--N 1.288 -2.065 0 CA-C-O 121.214 0.531 . . . . 0.0 111.802 -179.176 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -83.87 123.48 3.23 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.667 2.244 . . . . 0.0 112.732 177.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.2 t -114.65 105.38 18.55 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 174.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.527 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 27.6 tt0 -93.7 97.54 10.52 Favored 'General case' 0 N--CA 1.417 -2.121 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 -179.384 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -87.67 158.36 18.86 Favored 'General case' 0 N--CA 1.397 -3.105 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -174.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -124.04 98.93 6.01 Favored 'General case' 0 C--N 1.274 -2.681 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.229 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.458 ' O ' ' HA2' ' A' ' 85' ' ' GLY . 2.3 mmmp? -100.73 -170.0 1.79 Allowed 'General case' 0 N--CA 1.409 -2.512 0 CA-C-N 114.518 -1.219 . . . . 0.0 112.696 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.56 157.12 36.02 Favored 'General case' 0 N--CA 1.413 -2.312 0 CA-C-N 113.03 -1.896 . . . . 0.0 106.534 174.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -72.48 -8.95 57.75 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 121.438 0.637 . . . . 0.0 110.253 176.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -72.22 -38.47 68.97 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 175.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.59 -145.14 16.74 Favored Glycine 0 N--CA 1.42 -2.411 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.624 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.401 ' CD1' HD12 ' A' ' 80' ' ' LEU . 18.3 mt -104.53 -46.47 4.35 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.85 29.7 37.82 Favored Glycine 0 N--CA 1.422 -2.242 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.874 -175.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.2 pt -102.42 -174.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 120.059 -0.656 . . . . 0.0 112.357 -177.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 21.8 m -135.66 153.04 51.75 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.551 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -126.63 164.99 25.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 123.393 0.677 . . . . 0.0 109.336 -177.539 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.9 tt -135.41 130.02 50.17 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-O 120.811 0.338 . . . . 0.0 110.487 175.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.433 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.33 107.28 3.32 Favored Glycine 0 N--CA 1.428 -1.861 0 C-N-CA 121.085 -0.578 . . . . 0.0 112.029 -178.292 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.412 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.2 mmm -121.94 174.53 6.84 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.29 -1.989 0 C-N-CA 119.418 -1.372 . . . . 0.0 112.171 179.616 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.464 HD21 ' HA ' ' A' ' 69' ' ' VAL . 2.0 pp . . . . . 0 N--CA 1.437 -1.084 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -116.8 33.71 4.95 Favored Glycine 0 C--N 1.288 -2.103 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 173.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.513 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 26.3 mm -84.58 105.49 13.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 121.407 0.622 . . . . 0.0 110.337 -177.09 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -99.25 162.98 12.74 Favored 'General case' 0 C--N 1.279 -2.46 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 177.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.89 128.01 38.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.472 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -91.74 -39.07 12.02 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.303 0.573 . . . . 0.0 110.455 -177.049 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.7 m -159.65 161.0 34.9 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 17.5 t -117.62 167.73 10.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.9 t . . . . . 0 C--N 1.305 -1.364 0 C-N-CA 123.044 0.538 . . . . 0.0 109.965 178.566 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.401 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 C--O 1.203 -1.392 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.55 -62.56 1.65 Allowed 'General case' 0 C--O 1.214 -0.807 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.4 mt-30 -72.73 -13.73 61.4 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.783 0.661 . . . . 0.0 112.783 176.208 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.401 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 27.4 mmt180 -81.17 -26.33 36.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 172.299 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -54.94 -57.55 11.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 123.743 0.652 . . . . 0.0 111.368 177.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.73 -13.15 56.48 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.225 -0.988 . . . . 0.0 114.352 175.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.568 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -93.74 -59.93 1.88 Allowed 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 118.082 0.941 . . . . 0.0 108.573 176.878 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.568 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 15.3 tt -64.29 143.67 15.47 Favored 'Isoleucine or valine' 0 C--O 1.246 0.893 0 O-C-N 123.707 0.63 . . . . 0.0 110.672 -175.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -142.52 172.76 12.26 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.029 0.442 . . . . 0.0 111.617 -178.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.7 p -76.68 -9.52 12.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.653 0 CA-C-O 121.889 0.852 . . . . 0.0 110.503 -177.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -92.22 -2.75 56.32 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.592 0.711 . . . . 0.0 110.288 -176.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 -82.29 174.94 10.68 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 121.988 0.899 . . . . 0.0 112.328 -176.173 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.513 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.3 tt0 -128.6 125.48 38.27 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.497 178.309 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 48.8 mm -77.16 104.74 5.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -178.582 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.773 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 86.1 t -87.13 -48.07 15.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.844 0.831 . . . . 0.0 110.82 -176.469 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.484 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 33.1 tt0 -151.66 125.95 9.35 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 t -115.64 128.05 73.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 175.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.1 t70 72.97 -9.15 1.16 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 125.23 1.412 . . . . 0.0 112.671 173.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.93 11.56 36.94 Favored Glycine 0 C--N 1.29 -2.011 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.763 -174.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.0 tt -70.95 -21.21 22.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-O 120.728 0.299 . . . . 0.0 111.36 -177.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 57.7 p 51.01 88.52 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.036 1.334 . . . . 0.0 112.192 -177.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.48 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.4 pp -100.29 17.9 20.22 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 122.29 1.043 . . . . 0.0 109.931 -175.595 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.464 ' HA ' HD21 ' A' ' 35' ' ' LEU . 39.2 t -60.69 98.49 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.297 178.234 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 112.75 9.67 18.34 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.609 177.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.48 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.7 m -95.56 174.21 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.485 -179.408 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 p -95.02 175.45 6.63 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.54 177.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.551 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.23 -34.35 72.1 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.628 -179.385 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.7 -36.87 73.48 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.439 -177.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.447 ' O ' HG22 ' A' ' 79' ' ' VAL . 35.4 t80 -70.68 -49.1 50.76 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.808 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.19 -45.07 94.38 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.399 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -54.91 -43.29 73.14 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 122.716 0.406 . . . . 0.0 110.307 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 90.3 m -61.35 -41.78 97.61 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.981 177.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.447 HG22 ' O ' ' A' ' 75' ' ' PHE . 47.4 t -62.98 -51.82 67.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 178.022 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.401 HD12 ' CD1' ' A' ' 17' ' ' LEU . 3.5 mm? -68.26 -5.36 17.99 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-O 121.342 0.591 . . . . 0.0 111.63 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -102.47 -22.44 14.05 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.901 0.881 . . . . 0.0 110.891 176.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -90.44 0.85 57.13 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 121.253 0.549 . . . . 0.0 111.628 178.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 15.6 p -61.83 155.38 23.33 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.172 -0.922 . . . . 0.0 112.739 178.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.49 -157.55 0.8 Allowed 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.626 -1.17 . . . . 0.0 108.241 179.377 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 12' ' ' LYS . . . -51.61 -82.04 0.05 OUTLIER Glycine 0 CA--C 1.531 1.033 0 N-CA-C 114.601 0.6 . . . . 0.0 114.601 177.489 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -77.12 102.13 6.42 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.122 0.486 . . . . 0.0 111.419 -176.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 41.8 t -115.52 119.42 61.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.16 -178.323 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.34 104.49 15.22 Favored 'General case' 0 CA--C 1.487 -1.447 0 C-N-CA 120.282 -0.567 . . . . 0.0 109.963 173.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -93.33 101.33 13.57 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 174.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.773 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.9 t -91.53 85.77 2.3 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 N-CA-C 105.337 -2.098 . . . . 0.0 105.337 176.553 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 78.0 mt -102.68 155.37 5.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 CA-C-N 113.765 -1.561 . . . . 0.0 108.85 179.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -128.85 155.59 20.72 Favored Glycine 0 N--CA 1.4 -3.748 0 C-N-CA 119.747 -1.215 . . . . 0.0 110.479 177.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -132.15 152.17 51.41 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 121.551 0.691 . . . . 0.0 112.864 -178.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 . . . . . 0 C--N 1.299 -1.606 0 C-N-CA 127.231 2.212 . . . . 0.0 105.505 174.381 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.401 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 40.9 tt0 . . . . . 0 CA--C 1.496 -1.12 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -86.82 128.74 35.05 Favored 'General case' 0 C--N 1.313 -0.994 0 O-C-N 123.648 0.592 . . . . 0.0 110.007 -176.755 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 33.3 p90 -142.91 141.86 20.84 Favored Pre-proline 0 N--CA 1.423 -1.782 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -178.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -81.18 122.58 4.23 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.826 2.351 . . . . 0.0 112.107 176.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.486 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 47.2 t -103.03 100.35 10.23 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.98 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 174.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 35.9 tt0 -81.58 102.03 10.37 Favored 'General case' 0 N--CA 1.427 -1.587 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 174.174 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.539 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -104.04 134.49 47.22 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 -175.449 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -102.78 97.59 7.73 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 175.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.0 mmmp? -84.42 177.53 8.09 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 115.115 1.524 . . . . 0.0 115.115 -177.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -80.66 -174.47 4.73 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 112.759 -2.019 . . . . 0.0 110.457 -175.041 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -71.79 -26.62 62.49 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.742 176.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -59.11 -41.99 89.48 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.504 178.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 120.2 -114.12 2.61 Favored Glycine 0 N--CA 1.413 -2.888 0 N-CA-C 108.044 -2.023 . . . . 0.0 108.044 -175.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.427 ' HG ' HG21 ' A' ' 19' ' ' ILE . 10.5 tp -113.63 -64.41 1.31 Allowed 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -178.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 79.75 28.64 50.46 Favored Glycine 0 N--CA 1.437 -1.259 0 O-C-N 124.183 0.927 . . . . 0.0 113.014 177.021 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.427 HG21 ' HG ' ' A' ' 17' ' ' LEU . 18.0 pt -104.99 172.11 1.66 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.826 0 C-N-CA 119.543 -0.863 . . . . 0.0 111.278 179.649 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.1 m -123.81 147.4 47.61 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.854 -179.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.528 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -117.66 162.2 15.87 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -178.248 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.451 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.9 tt -128.96 132.83 67.05 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.116 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 174.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.413 ' HA2' HD12 ' A' ' 37' ' ' ILE . . . -93.22 106.69 3.45 Favored Glycine 0 N--CA 1.42 -2.405 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.029 -177.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.422 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.7 mmm -115.82 156.2 26.5 Favored 'General case' 0 C--N 1.289 -2.052 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 177.414 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.286 -2.195 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 176.498 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.423 ' O ' ' HG ' ' A' ' 35' ' ' LEU . 1.0 OUTLIER . . . . . 0 N--CA 1.447 -0.617 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 . . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -117.91 34.59 4.42 Favored Glycine 0 N--CA 1.416 -2.655 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.922 173.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.451 ' HA ' ' O ' ' A' ' 22' ' ' ILE . 29.3 mm -87.15 99.04 7.88 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 119.83 -0.748 . . . . 0.0 109.868 179.491 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -97.09 159.34 14.97 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 115.13 -0.941 . . . . 0.0 109.724 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.7 t -77.17 115.41 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.544 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 176.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -87.15 -51.4 6.01 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.858 -175.229 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -143.43 157.16 44.68 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 -179.006 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 50.0 t -126.85 151.01 33.14 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 N-CA-C 105.984 -1.858 . . . . 0.0 105.984 175.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.4 t . . . . . 0 N--CA 1.433 -1.325 0 CA-C-O 121.869 0.842 . . . . 0.0 109.942 178.253 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.461 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 C--O 1.195 -1.768 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.06 -53.69 9.43 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -76.66 -6.31 51.56 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.743 175.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.461 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 1.8 mmp_? -86.95 -38.27 16.81 Favored 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 172.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.537 ' OD1' ' HB2' ' A' ' 53' ' ' ARG . 11.4 t70 -66.13 -46.0 79.06 Favored 'General case' 0 C--O 1.217 -0.631 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 176.523 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.86 -17.44 11.33 Favored Glycine 0 N--CA 1.469 0.841 0 N-CA-C 114.54 0.576 . . . . 0.0 114.54 173.096 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.537 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 6.7 ttm180 -64.05 -40.37 96.14 Favored 'General case' 0 C--N 1.316 -0.85 0 C-N-CA 124.285 1.034 . . . . 0.0 110.238 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.8 tt -83.04 162.54 3.19 Favored 'Isoleucine or valine' 0 C--O 1.257 1.451 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 -178.465 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -125.74 -171.74 2.45 Favored 'General case' 0 N--CA 1.423 -1.805 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.308 -178.309 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.9 p -123.51 16.46 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.042 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 173.312 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 34.9 p30 -134.4 16.23 3.72 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 122.591 1.186 . . . . 0.0 109.923 -174.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -112.89 -169.89 1.57 Allowed 'General case' 0 C--N 1.27 -2.865 0 CA-C-N 113.69 -1.596 . . . . 0.0 109.943 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.444 ' O ' HG23 ' A' ' 91' ' ' ILE . 62.7 tt0 -132.39 132.35 42.74 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 116.72 -0.218 . . . . 0.0 110.595 -173.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.425 ' HA ' HG12 ' A' ' 91' ' ' ILE . 50.5 mm -74.38 104.83 3.15 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.961 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.013 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.701 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 94.1 t -86.33 -49.22 15.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 121.292 0.568 . . . . 0.0 110.139 -176.622 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.429 ' OE1' ' HB3' ' A' ' 67' ' ' SER . 34.8 tt0 -154.39 116.67 4.29 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.254 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.2 t -108.83 129.98 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.209 0 N-CA-C 111.765 0.283 . . . . 0.0 111.765 177.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 15.6 t70 62.09 17.06 8.79 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 124.922 1.289 . . . . 0.0 111.441 174.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.9 10.98 85.69 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 115.65 -0.705 . . . . 0.0 112.422 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.0 tt -73.83 -14.81 16.54 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 O-C-N 122.528 -0.395 . . . . 0.0 111.171 -176.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.429 ' HB3' ' OE1' ' A' ' 62' ' ' GLU . 8.9 p 42.95 79.59 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 124.801 1.24 . . . . 0.0 113.357 -176.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.47 ' O ' HG23 ' A' ' 71' ' ' VAL . 1.5 pp -90.84 14.14 14.46 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.739 -174.435 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.411 ' HA ' HD22 ' A' ' 35' ' ' LEU . 48.7 t -58.84 98.0 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 114.736 -1.12 . . . . 0.0 109.586 173.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 112.96 18.24 7.44 Favored Glycine 0 N--CA 1.435 -1.42 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.781 177.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 68' ' ' LEU . 15.6 m -105.33 175.72 1.13 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.518 0 CA-C-N 117.205 0.502 . . . . 0.0 110.578 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.6 p -94.65 179.37 5.28 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-O 121.633 0.73 . . . . 0.0 110.012 178.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.528 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -65.87 -35.29 80.23 Favored 'General case' 0 N--CA 1.419 -1.975 0 CA-C-N 114.803 -1.089 . . . . 0.0 111.055 -179.619 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -70.17 -27.68 64.72 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.492 -177.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 36.6 t80 -75.47 -51.8 12.18 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 175.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.2 -44.06 92.25 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.448 -0.797 . . . . 0.0 112.218 -178.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.46 -10.66 36.08 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.335 0.654 . . . . 0.0 111.59 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.417 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 98.3 m -93.01 -49.18 6.15 Favored 'General case' 0 N--CA 1.412 -2.355 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.668 175.224 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.526 ' O ' HG23 ' A' ' 83' ' ' THR . 38.5 t -59.64 -52.07 65.34 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.649 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.404 HD23 HG23 ' A' ' 60' ' ' ILE . 3.6 mm? -68.62 3.39 1.88 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.611 0.764 . . . . 0.0 112.228 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.417 ' HB3' ' O ' ' A' ' 78' ' ' THR . 11.7 ttm180 -109.91 -41.02 4.6 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 121.99 0.9 . . . . 0.0 109.109 176.334 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -80.31 -4.83 54.92 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 114.496 -1.229 . . . . 0.0 112.182 -174.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.526 HG23 ' O ' ' A' ' 79' ' ' VAL . 7.5 p -60.7 147.68 41.3 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 123.759 0.824 . . . . 0.0 112.194 177.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.85 -172.88 2.17 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.852 177.157 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -38.93 -73.74 0.15 Allowed Glycine 0 C--O 1.217 -0.94 0 O-C-N 124.484 1.115 . . . . 0.0 115.067 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.539 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 36.3 m-80 -83.05 105.11 13.76 Favored 'General case' 0 CA--C 1.497 -1.062 0 CA-C-N 118.0 0.9 . . . . 0.0 110.956 -179.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -104.24 143.38 16.0 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 CA-C-N 115.44 -0.8 . . . . 0.0 108.927 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 60.3 mtp180 -107.27 97.28 7.06 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 173.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.486 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 81.6 m-85 -94.67 104.76 16.68 Favored 'General case' 0 CA--C 1.483 -1.6 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 177.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.701 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 62.5 t -87.65 94.74 4.71 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.609 0 N-CA-C 105.108 -2.182 . . . . 0.0 105.108 173.198 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.444 HG23 ' O ' ' A' ' 59' ' ' GLN . 93.9 mt -114.49 153.76 15.95 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.671 0 CA-C-N 114.894 -1.048 . . . . 0.0 108.245 177.515 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -118.02 157.88 14.96 Favored Glycine 1 N--CA 1.393 -4.221 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.534 177.459 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.424 HH21 ' HG2' ' A' ' 94' ' ' GLU . 8.1 tpm_? -129.48 123.66 32.09 Favored 'General case' 0 C--N 1.29 -2.005 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.569 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.424 ' HG2' HH21 ' A' ' 93' ' ' ARG . 16.5 pt-20 . . . . . 0 N--CA 1.428 -1.567 0 N-CA-C 105.886 -1.894 . . . . 0.0 105.886 171.014 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.427 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 39.1 tt0 . . . . . 0 N--CA 1.439 -0.99 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -89.93 120.33 31.06 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 177.346 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -131.63 143.64 50.01 Favored Pre-proline 0 C--N 1.29 -1.987 0 CA-C-O 121.322 0.582 . . . . 0.0 112.356 -174.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -84.01 127.45 4.1 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.914 2.409 . . . . 0.0 112.273 175.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 23.6 t -117.52 104.63 16.68 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.271 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 174.381 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.427 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 36.4 tt0 -91.48 102.41 15.08 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.741 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.505 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -91.23 144.51 25.54 Favored 'General case' 0 N--CA 1.422 -1.866 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 -173.983 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -113.12 84.54 2.01 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 170.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.447 ' HE2' ' H ' ' A' ' 48' ' ' ALA . 5.1 mmtt -71.89 165.5 24.04 Favored 'General case' 0 N--CA 1.417 -2.077 0 N-CA-C 114.071 1.137 . . . . 0.0 114.071 -179.243 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -84.38 -175.18 5.67 Favored 'General case' 0 N--CA 1.433 -1.308 0 CA-C-N 113.613 -1.631 . . . . 0.0 111.123 -176.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -78.21 -9.27 59.13 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 -172.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -77.72 -45.47 24.67 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 121.746 0.784 . . . . 0.0 108.889 176.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.85 -160.28 21.75 Favored Glycine 0 N--CA 1.422 -2.271 0 N-CA-C 108.551 -1.82 . . . . 0.0 108.551 -176.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.8 mt -75.52 -50.8 14.57 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 118.011 0.905 . . . . 0.0 109.599 -176.346 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 68.1 27.97 73.52 Favored Glycine 0 N--CA 1.433 -1.56 0 CA-C-N 114.695 -1.139 . . . . 0.0 110.453 -176.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 18.1 pt -99.57 171.02 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.832 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.165 -178.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.1 m -133.35 148.34 51.86 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -177.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -115.41 161.59 14.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.424 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 15.3 tt -129.14 131.84 67.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 C-N-CA 120.611 -0.436 . . . . 0.0 109.895 174.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.434 ' HA2' HD12 ' A' ' 37' ' ' ILE . . . -90.65 97.08 2.28 Favored Glycine 0 CA--C 1.494 -1.238 0 C-N-CA 120.974 -0.631 . . . . 0.0 112.138 -177.719 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.437 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 95.1 mmm -111.73 -175.72 2.76 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.282 -2.43 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 174.107 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.467 HD21 HG23 ' A' ' 69' ' ' VAL . 2.2 pt? . . . . . 0 N--CA 1.436 -1.132 0 CA-C-O 121.377 0.608 . . . . 0.0 110.933 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -110.49 19.07 26.92 Favored Glycine 0 N--CA 1.417 -2.592 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 175.152 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.605 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 35.9 mm -85.73 104.04 13.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-O 121.498 0.666 . . . . 0.0 110.457 -177.551 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.422 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 96.6 m-85 -101.65 163.31 12.33 Favored 'General case' 0 C--N 1.281 -2.4 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.484 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 47.0 t -77.35 116.29 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 N-CA-C 106.935 -1.505 . . . . 0.0 106.935 175.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.47 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.2 OUTLIER -83.44 -39.03 21.11 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 -177.621 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -157.56 158.23 35.23 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 4.3 p -137.52 97.81 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 CA-C-O 121.456 0.646 . . . . 0.0 111.557 178.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.8 t . . . . . 0 CA--C 1.563 1.478 0 C-N-CA 127.221 2.208 . . . . 0.0 113.933 178.307 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.408 ' HB2' ' HA ' ' A' ' 12' ' ' LYS . . . . . . . . 0 CA--C 1.548 0.894 0 N-CA-C 115.178 1.547 . . . . 0.0 115.178 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.447 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -80.48 -58.01 3.32 Favored 'General case' 0 C--O 1.214 -0.796 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 43.0 mt-30 -63.27 -29.83 71.09 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.948 173.421 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 31.0 mmm180 -66.78 -34.37 77.68 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.863 176.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 48' ' ' ALA . 11.6 t70 -56.3 -52.15 65.57 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.719 176.607 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.19 -7.14 72.83 Favored Glycine 0 C--N 1.313 -0.737 0 N-CA-C 114.944 0.737 . . . . 0.0 114.944 173.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -86.57 -43.69 12.5 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.3 tt -78.54 152.12 5.11 Favored 'Isoleucine or valine' 0 C--O 1.243 0.736 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 177.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . 0.538 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 19.5 mt-30 -140.69 171.06 14.63 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 121.02 0.438 . . . . 0.0 110.019 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.7 p -83.24 -11.91 11.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.419 1.104 . . . . 0.0 108.587 175.288 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -88.65 3.24 51.33 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.786 -172.152 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.538 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 13.0 m-20 -109.6 -165.99 1.06 Allowed 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -174.254 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.605 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 18.9 tt0 -136.41 129.19 30.82 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 123.683 0.793 . . . . 0.0 111.261 -176.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.499 ' HA ' HG12 ' A' ' 91' ' ' ILE . 46.9 mm -73.88 108.33 5.25 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.877 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -179.331 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.765 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 97.3 t -92.41 -49.87 12.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 CA-C-O 121.854 0.835 . . . . 0.0 110.403 -178.349 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.543 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.2 tt0 -146.13 127.89 15.3 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.442 ' C ' ' H ' ' A' ' 65' ' ' GLY . 2.7 t -117.78 126.39 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.917 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.612 175.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.4 t70 72.51 -13.67 0.62 Allowed 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 125.391 1.476 . . . . 0.0 112.97 173.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.442 ' H ' ' C ' ' A' ' 63' ' ' VAL . . . 111.0 11.41 18.68 Favored Glycine 0 C--N 1.288 -2.099 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.003 -176.177 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.5 tt -75.33 -18.35 15.96 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.733 0 CA-C-O 120.777 0.323 . . . . 0.0 110.617 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.451 ' HA ' ' HG3' ' A' ' 62' ' ' GLU . 25.7 m 49.19 87.15 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.257 1.423 . . . . 0.0 111.54 -176.262 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.455 ' O ' HG23 ' A' ' 71' ' ' VAL . 2.1 pp -103.93 15.58 28.29 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-O 122.246 1.022 . . . . 0.0 109.484 -176.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.467 HG23 HD21 ' A' ' 35' ' ' LEU . 6.3 p -62.66 79.62 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 114.001 -1.454 . . . . 0.0 111.324 175.819 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 118.17 49.35 0.37 Allowed Glycine 0 N--CA 1.433 -1.505 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.048 -178.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 68' ' ' LEU . 32.4 m -127.02 178.08 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.242 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 13.3 p -91.08 174.66 7.29 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 120.933 0.397 . . . . 0.0 111.27 179.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.26 -35.35 80.76 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.026 -179.301 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -70.36 -31.14 68.28 Favored 'General case' 0 CA--C 1.511 -0.519 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.695 -177.604 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -71.52 -54.22 11.27 Favored 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.44 -48.25 79.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.419 -0.809 . . . . 0.0 112.022 -178.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.05 -25.75 65.59 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 -179.149 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 71.4 m -76.22 -44.14 39.01 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.485 176.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.407 ' O ' HG22 ' A' ' 83' ' ' THR . 33.5 t -61.75 -51.74 69.08 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.621 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -68.12 -3.82 11.67 Favored 'General case' 0 CA--C 1.556 1.188 0 CA-C-O 121.341 0.591 . . . . 0.0 112.448 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 36.4 ttt180 -95.64 -40.79 9.23 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 175.642 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 23.1 m-80 -89.01 8.06 31.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 114.241 -1.345 . . . . 0.0 113.88 -171.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.407 HG22 ' O ' ' A' ' 79' ' ' VAL . 1.3 p -75.9 154.38 36.05 Favored 'General case' 0 C--N 1.28 -2.431 0 C-N-CA 123.596 0.758 . . . . 0.0 112.332 178.689 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.29 -170.38 1.63 Allowed 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.984 176.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -50.41 -62.87 4.79 Favored Glycine 0 N--CA 1.473 1.116 0 N-CA-C 115.341 0.896 . . . . 0.0 115.341 -176.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.505 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 20.7 m120 -81.49 104.6 12.04 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 117.436 0.618 . . . . 0.0 110.992 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.427 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.3 t -113.75 128.76 70.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.195 -176.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.14 104.23 16.26 Favored 'General case' 0 C--N 1.293 -1.872 0 C-N-CA 119.979 -0.689 . . . . 0.0 109.474 170.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.423 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 93.2 m-85 -94.8 100.66 12.51 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 174.53 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.765 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 27.2 t -93.62 83.82 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.434 0 N-CA-C 105.288 -2.116 . . . . 0.0 105.288 177.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.514 HG23 ' O ' ' A' ' 59' ' ' GLN . 64.7 mt -97.61 158.36 3.31 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.588 0 CA-C-N 113.335 -1.757 . . . . 0.0 109.563 -178.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -133.3 147.83 19.13 Favored Glycine 1 N--CA 1.393 -4.187 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.607 176.836 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 24.8 tpt180 -115.73 119.2 35.27 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 . . . . . 0 N--CA 1.413 -2.315 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 173.717 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 . . . . . 0 N--CA 1.434 -1.259 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -85.32 130.37 34.61 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.245 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 24.8 p90 -139.37 139.85 24.0 Favored Pre-proline 0 N--CA 1.426 -1.667 0 CA-C-O 121.454 0.645 . . . . 0.0 112.157 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -82.77 121.94 3.37 Favored 'Trans proline' 0 N--CA 1.446 -1.273 0 C-N-CA 122.765 2.31 . . . . 0.0 112.844 177.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.0 t -111.28 105.08 18.11 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 176.24 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.621 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.1 tt0 -85.39 105.28 15.91 Favored 'General case' 0 N--CA 1.42 -1.956 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 174.674 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.553 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 15.9 tp -95.76 151.35 19.45 Favored 'General case' 0 N--CA 1.41 -2.471 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 -176.719 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -115.27 92.59 3.97 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 177.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.401 ' HA ' ' HB1' ' A' ' 47' ' ' ALA . 2.6 mmmp? -84.24 177.61 8.12 Favored 'General case' 0 C--N 1.289 -2.032 0 CA-C-O 122.498 1.142 . . . . 0.0 113.675 178.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.401 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.0 p-10 -88.86 172.06 9.46 Favored 'General case' 0 C--N 1.286 -2.178 0 CA-C-N 112.835 -1.984 . . . . 0.0 109.536 179.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -64.32 -18.22 64.42 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -174.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.401 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 23.3 t70 -68.61 -32.98 73.24 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.778 0.799 . . . . 0.0 110.209 178.652 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.97 -124.44 5.94 Favored Glycine 0 CA--C 1.477 -2.285 0 N-CA-C 108.706 -1.758 . . . . 0.0 108.706 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.42 HD22 HG22 ' A' ' 87' ' ' VAL . 25.7 mt -104.27 -52.58 2.89 Favored 'General case' 0 CA--C 1.462 -2.407 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.45 178.499 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.2 24.55 76.53 Favored Glycine 0 N--CA 1.426 -2.003 0 O-C-N 124.678 1.236 . . . . 0.0 110.911 -175.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 28.0 pt -101.27 176.48 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.482 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 23.7 m -132.65 148.59 52.35 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -176.489 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -119.82 167.11 13.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.439 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.2 tt -133.36 132.26 57.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.668 177.391 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.428 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.1 102.07 2.79 Favored Glycine 0 N--CA 1.435 -1.43 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.607 -177.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 95.5 mmm -115.68 173.41 6.56 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.295 -1.702 0 C-N-CA 120.121 -1.038 . . . . 0.0 112.469 179.162 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.46 HD21 ' HA ' ' A' ' 69' ' ' VAL . 2.5 pp . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -110.47 27.48 11.39 Favored Glycine 0 N--CA 1.423 -2.213 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 172.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.439 ' HA ' ' O ' ' A' ' 22' ' ' ILE . 35.3 mm -83.67 102.84 10.18 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 CA-C-O 121.47 0.652 . . . . 0.0 110.068 -178.626 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -96.83 169.2 10.02 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 177.232 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.0 t -83.43 129.33 37.67 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 175.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 55.6 tptt -93.64 -46.37 7.3 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.248 -177.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.8 m -151.72 161.45 42.64 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 -179.258 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 40.6 t -137.58 141.4 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.115 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 177.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 14.1 t . . . . . 0 C--N 1.29 -1.98 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.115 -178.036 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.495 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 CA--C 1.555 1.173 0 N-CA-C 114.179 1.177 . . . . 0.0 114.179 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -98.23 -62.99 1.17 Allowed 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -179.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -75.87 -28.9 58.33 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.679 0.752 . . . . 0.0 109.312 176.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.495 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 19.1 mmm180 -63.35 -32.65 74.13 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.473 -1.239 . . . . 0.0 109.63 172.595 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -70.4 -63.21 1.13 Allowed 'General case' 0 C--O 1.241 0.64 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 173.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.26 -17.28 40.82 Favored Glycine 0 N--CA 1.436 -1.356 0 N-CA-C 115.435 0.934 . . . . 0.0 115.435 175.049 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.501 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.3 OUTLIER -79.21 -25.69 42.66 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 118.816 1.308 . . . . 0.0 109.341 -177.914 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.9 tt -94.44 150.76 3.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . 0.591 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 23.6 mt-30 -136.64 166.11 24.3 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 121.232 0.539 . . . . 0.0 111.598 -176.327 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -86.88 -12.44 10.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.392 178.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -92.99 3.42 55.79 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 122.214 1.007 . . . . 0.0 110.647 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.591 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 24.9 m-20 -101.98 -174.54 2.61 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.268 -177.48 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.443 ' O ' HG23 ' A' ' 91' ' ' ILE . 61.5 tt0 -129.26 131.97 47.12 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.813 -176.017 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 49.1 mm -75.43 106.56 5.31 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.783 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.686 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 98.5 t -87.87 -44.65 15.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 120.967 0.413 . . . . 0.0 111.344 -177.09 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.46 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 37.6 tt0 -156.85 120.96 4.34 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 120.67 0.271 . . . . 0.0 110.544 178.281 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.3 t -112.62 129.04 68.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 111.575 0.213 . . . . 0.0 111.575 176.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.3 t70 66.95 7.52 5.41 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 125.737 1.615 . . . . 0.0 111.294 174.54 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.65 20.7 61.23 Favored Glycine 0 N--CA 1.434 -1.472 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.296 -175.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.4 tt -79.44 -22.68 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 CA-C-O 121.197 0.522 . . . . 0.0 110.267 -179.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.453 ' HB3' ' OE2' ' A' ' 62' ' ' GLU . 63.8 p 48.68 81.95 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.356 1.462 . . . . 0.0 111.935 -176.003 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.457 ' O ' HG23 ' A' ' 71' ' ' VAL . 0.0 OUTLIER -87.33 30.71 0.77 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 122.515 1.15 . . . . 0.0 111.283 -175.997 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.46 ' HA ' HD21 ' A' ' 35' ' ' LEU . 42.4 t -74.71 103.87 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.585 -179.424 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.08 26.83 6.84 Favored Glycine 0 N--CA 1.434 -1.436 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.784 179.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.457 HG23 ' O ' ' A' ' 68' ' ' LEU . 11.0 m -112.63 170.4 4.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 C-N-CA 120.391 -0.524 . . . . 0.0 110.071 177.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.9 p -93.6 172.2 8.41 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.323 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.494 ' N ' HE21 ' A' ' 73' ' ' GLN . 0.0 OUTLIER -60.98 -28.43 69.01 Favored 'General case' 0 C--O 1.205 -1.269 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.751 -179.141 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -73.44 -36.03 65.87 Favored 'General case' 0 CA--C 1.522 -0.122 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.557 -178.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 30.1 t80 -70.43 -49.8 45.05 Favored 'General case' 0 CA--C 1.506 -0.712 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 178.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.29 -46.73 87.76 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.934 -178.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.48 -34.19 72.26 Favored 'General case' 0 C--O 1.209 -1.036 0 CA-C-O 120.472 0.177 . . . . 0.0 110.554 179.391 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 77.6 m -65.91 -44.45 85.16 Favored 'General case' 0 N--CA 1.435 -1.217 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.755 177.219 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.413 ' O ' HG22 ' A' ' 83' ' ' THR . 39.3 t -61.89 -53.08 52.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 178.553 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -67.98 -2.23 7.19 Favored 'General case' 0 CA--C 1.564 1.509 0 CA-C-O 121.393 0.616 . . . . 0.0 112.183 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.23 -34.02 10.51 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 123.556 0.743 . . . . 0.0 109.714 175.132 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -82.0 -13.68 57.06 Favored 'General case' 0 CA--C 1.498 -1.019 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -175.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.413 HG22 ' O ' ' A' ' 79' ' ' VAL . 5.4 p -60.54 146.67 44.19 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.647 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.89 -161.28 0.75 Allowed 'General case' 0 C--N 1.297 -1.709 0 CA-C-N 114.88 -1.055 . . . . 0.0 109.238 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -51.21 -74.93 0.24 Allowed Glycine 0 CA--C 1.536 1.379 0 N-CA-C 115.399 0.92 . . . . 0.0 115.399 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.553 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 15.9 m120 -81.65 99.99 9.2 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 117.872 0.836 . . . . 0.0 112.18 -177.534 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.621 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.8 t -108.54 135.49 47.17 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.044 -175.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -94.05 101.49 13.52 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 172.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.49 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 98.8 m-85 -94.8 103.92 15.82 Favored 'General case' 0 CA--C 1.48 -1.741 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.206 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.686 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 60.8 t -88.81 93.31 4.26 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.89 0 N-CA-C 105.416 -2.068 . . . . 0.0 105.416 174.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.443 HG23 ' O ' ' A' ' 59' ' ' GLN . 88.7 mt -107.43 155.51 8.14 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.265 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.21 175.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -129.83 149.39 18.77 Favored Glycine 0 N--CA 1.406 -3.331 0 C-N-CA 119.376 -1.393 . . . . 0.0 111.673 -178.771 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 22.9 tpt180 -123.85 116.23 22.61 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 -178.313 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 . . . . . 0 N--CA 1.441 -0.92 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 173.879 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.427 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 82.9 tt0 . . . . . 0 N--CA 1.431 -1.404 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -87.31 125.78 34.43 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -178.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -140.48 145.66 41.78 Favored Pre-proline 0 C--N 1.294 -1.845 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -176.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -82.64 125.48 4.35 Favored 'Trans proline' 0 N--CA 1.442 -1.511 0 C-N-CA 122.62 2.213 . . . . 0.0 112.202 175.635 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 23.7 t -111.14 102.77 14.44 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.58 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 175.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.498 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 28.7 tt0 -82.22 108.83 15.98 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 174.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.473 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -103.79 135.97 44.34 Favored 'General case' 0 C--N 1.279 -2.469 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 -177.772 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -106.99 97.73 7.48 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.521 -1.289 . . . . 0.0 107.521 171.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.415 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 2.7 mmmp? -83.71 173.78 11.04 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-O 122.406 1.098 . . . . 0.0 113.839 -177.329 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -88.15 172.68 9.32 Favored 'General case' 0 N--CA 1.423 -1.803 0 CA-C-N 112.818 -1.992 . . . . 0.0 110.026 -178.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -67.75 -9.29 42.64 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 114.197 1.184 . . . . 0.0 114.197 -173.188 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -73.49 -34.05 65.13 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.95 -127.14 6.98 Favored Glycine 0 CA--C 1.475 -2.452 0 N-CA-C 107.533 -2.227 . . . . 0.0 107.533 -177.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 18.2 mt -99.65 -48.92 4.56 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 175.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 73.94 31.03 60.48 Favored Glycine 0 N--CA 1.418 -2.524 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 -177.038 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 22.2 pt -110.84 178.35 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.3 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.641 -178.44 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 34.8 m -140.09 154.65 47.1 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -178.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -125.84 166.58 21.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -177.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 14.0 tt -140.23 134.6 35.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 C-N-CA 120.58 -0.448 . . . . 0.0 110.681 177.251 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.445 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -92.96 107.58 3.55 Favored Glycine 0 N--CA 1.425 -2.079 0 C-N-CA 120.965 -0.635 . . . . 0.0 111.794 -179.239 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.653 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 93.0 mmm -122.58 97.88 5.66 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.308 -1.015 0 C-N-CA 120.98 -0.629 . . . . 0.0 113.428 -175.651 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.5 pp . . . . . 0 N--CA 1.436 -1.136 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.653 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -115.12 32.85 5.58 Favored Glycine 0 N--CA 1.424 -2.16 0 C-N-CA 118.919 -1.61 . . . . 0.0 111.797 178.14 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.518 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 25.6 mm -91.04 98.73 8.71 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.779 0 CA-C-O 122.018 0.913 . . . . 0.0 110.117 -178.764 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -93.11 162.44 14.03 Favored 'General case' 0 C--N 1.277 -2.559 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.395 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 46.7 t -79.44 126.83 39.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 175.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 58.3 tptt -88.64 -50.45 6.25 Favored 'General case' 0 C--N 1.294 -1.811 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.806 -177.087 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -150.87 162.62 40.43 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 -177.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 61.4 t -128.02 159.55 38.93 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.134 0 N-CA-C 105.959 -1.867 . . . . 0.0 105.959 175.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 6.6 t . . . . . 0 CA--C 1.544 0.714 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 171.659 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.415 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.204 -1.333 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.472 ' O ' ' HB3' ' A' ' 51' ' ' ASP . . . -87.55 -55.06 3.95 Favored 'General case' 0 CA--C 1.486 -1.483 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -175.82 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -76.46 -22.3 54.76 Favored 'General case' 0 N--CA 1.433 -1.319 0 C-N-CA 118.586 -1.246 . . . . 0.0 110.87 176.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 25.7 mmm180 -69.0 -23.59 64.12 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.192 171.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.472 ' HB3' ' O ' ' A' ' 48' ' ' ALA . 12.1 t70 -71.39 -64.92 0.82 Allowed 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.099 -1.075 . . . . 0.0 108.099 170.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.71 -5.54 84.63 Favored Glycine 0 C--O 1.245 0.794 0 C-N-CA 121.24 -0.505 . . . . 0.0 113.792 174.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.62 -32.85 21.82 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 178.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.6 tt -93.52 143.46 11.49 Favored 'Isoleucine or valine' 0 C--O 1.251 1.148 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 170.164 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 62.0 mt-30 -139.05 178.42 7.18 Favored 'General case' 0 C--N 1.308 -1.225 0 O-C-N 122.183 -0.323 . . . . 0.0 111.412 -179.513 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.2 p -84.64 -14.96 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-O 121.66 0.743 . . . . 0.0 110.838 -176.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -91.24 7.9 38.51 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-O 122.107 0.956 . . . . 0.0 109.502 -176.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -88.47 -175.4 4.96 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.8 -176.063 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.518 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 30.9 tt0 -141.53 129.14 21.48 Favored 'General case' 0 N--CA 1.423 -1.795 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.007 -179.03 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 46.8 mm -77.2 105.31 5.96 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.786 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -178.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.755 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 94.2 t -85.07 -48.96 16.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-O 121.957 0.884 . . . . 0.0 109.357 -177.665 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.515 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 28.8 tt0 -150.87 135.1 16.89 Favored 'General case' 0 N--CA 1.419 -2.015 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.078 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 t -121.52 128.71 75.9 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 173.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 37.0 t70 71.23 -11.49 0.68 Allowed 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 125.3 1.44 . . . . 0.0 113.261 176.603 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.11 15.4 28.33 Favored Glycine 0 C--N 1.277 -2.729 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -174.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 9.3 tt -72.7 -21.02 19.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 CA-C-O 121.452 0.644 . . . . 0.0 110.046 -179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.409 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 62.9 p 49.25 88.2 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 125.399 1.48 . . . . 0.0 111.89 -175.407 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.404 ' O ' HG23 ' A' ' 71' ' ' VAL . 1.3 pp -98.11 20.1 12.94 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-O 122.429 1.109 . . . . 0.0 109.573 -176.775 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 50.4 t -57.6 94.26 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-N 114.025 -1.443 . . . . 0.0 110.944 175.549 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 107.77 27.35 5.21 Favored Glycine 0 N--CA 1.441 -1.003 0 CA-C-N 115.408 -0.815 . . . . 0.0 112.603 175.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.404 HG23 ' O ' ' A' ' 68' ' ' LEU . 20.2 m -105.73 176.15 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.885 -179.439 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 12.4 p -93.0 172.76 8.11 Favored 'General case' 0 C--O 1.254 1.327 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.546 179.08 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.97 -30.81 71.43 Favored 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.666 -178.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -73.73 -26.37 60.65 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.686 -177.5 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 40.3 t80 -75.27 -53.13 9.29 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.62 -48.8 78.42 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.054 -177.177 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -55.76 -36.96 67.89 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.642 0.258 . . . . 0.0 110.624 179.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 89.0 m -65.62 -44.64 85.85 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.854 177.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 34.7 t -61.93 -51.2 75.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -64.01 -20.2 65.73 Favored 'General case' 0 C--O 1.214 -0.794 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.423 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.82 -25.63 24.47 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 122.934 0.494 . . . . 0.0 110.927 177.177 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -89.02 3.62 51.06 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 112.747 0.647 . . . . 0.0 112.747 -178.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 38.9 p -73.49 -178.33 3.01 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.78 0.8 . . . . 0.0 111.846 177.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.23 -165.9 1.56 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 125.534 1.533 . . . . 0.0 107.045 -179.186 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -39.51 -78.27 0.06 OUTLIER Glycine 0 C--O 1.22 -0.719 0 O-C-N 124.504 1.128 . . . . 0.0 115.204 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.473 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 20.9 m120 -81.57 114.97 20.63 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 118.075 0.938 . . . . 0.0 111.272 -177.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.4 t -124.37 140.48 47.54 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.458 -179.112 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 20.2 mtp85 -100.41 100.7 11.51 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 120.907 0.384 . . . . 0.0 110.831 171.35 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.432 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 95.4 m-85 -93.09 105.02 17.17 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 176.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.755 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 41.0 t -95.86 86.19 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.274 -2.686 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 178.369 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 94.0 mt -104.92 160.82 5.06 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.49 0 CA-C-N 113.841 -1.527 . . . . 0.0 109.252 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -122.47 152.88 16.86 Favored Glycine 0 N--CA 1.409 -3.134 0 C-N-CA 119.666 -1.254 . . . . 0.0 110.613 177.015 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 14.8 tpp180 -95.55 123.15 38.96 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -176.255 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 . . . . . 0 C--N 1.303 -1.449 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 172.354 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 . . . . . 0 N--CA 1.442 -0.869 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -85.87 123.52 31.31 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-O 120.877 0.37 . . . . 0.0 110.468 -177.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -133.5 143.71 49.11 Favored Pre-proline 0 C--N 1.29 -1.979 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.72 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.43 126.08 5.96 Favored 'Trans proline' 0 N--CA 1.437 -1.817 0 C-N-CA 122.148 1.899 . . . . 0.0 112.4 177.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.439 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 61.1 t -107.0 98.87 7.49 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.677 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 173.527 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.5 tt0 -88.72 103.38 15.9 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -99.36 137.74 37.44 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -173.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -100.28 103.98 15.43 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 171.286 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.497 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.9 mmmp? -98.35 173.57 6.91 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -175.413 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -63.05 167.2 5.07 Favored 'General case' 0 C--N 1.313 -0.996 0 C-N-CA 126.917 2.087 . . . . 0.0 109.069 178.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -64.47 -24.48 67.63 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.646 0.736 . . . . 0.0 109.719 176.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -58.78 -45.96 88.6 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 114.501 -1.227 . . . . 0.0 110.333 177.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.74 -118.24 3.28 Favored Glycine 0 N--CA 1.413 -2.864 0 N-CA-C 107.834 -2.107 . . . . 0.0 107.834 -176.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 18.6 mt -105.76 -50.89 3.09 Favored 'General case' 0 CA--C 1.475 -1.911 0 CA-C-N 118.153 0.976 . . . . 0.0 110.305 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 71.27 30.49 67.15 Favored Glycine 0 N--CA 1.422 -2.291 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 -174.392 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 21.5 pt -107.32 172.04 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 119.708 -0.797 . . . . 0.0 110.195 179.166 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.3 m -124.67 150.53 46.0 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -177.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -124.92 160.68 29.83 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 -177.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.3 tt -133.55 126.13 51.21 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 177.023 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.444 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -89.26 96.53 2.22 Favored Glycine 0 N--CA 1.429 -1.786 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.504 -176.184 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.466 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 79.1 mmm -115.13 76.75 1.02 Allowed 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.619 0 O-C-N 124.407 1.067 . . . . 0.0 113.093 -176.464 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.622 HD13 ' O ' ' A' ' 60' ' ' ILE . 0.5 OUTLIER . . . . . 0 N--CA 1.451 -0.408 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.466 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -110.56 30.52 8.1 Favored Glycine 0 C--N 1.298 -1.569 0 C-N-CA 119.837 -1.173 . . . . 0.0 111.578 176.206 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.444 HD11 ' HA2' ' A' ' 23' ' ' GLY . 20.5 mm -90.56 112.03 24.35 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.125 0 CA-C-O 121.509 0.671 . . . . 0.0 110.628 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -104.92 159.88 15.46 Favored 'General case' 0 C--N 1.282 -2.341 0 CA-C-N 115.153 -0.93 . . . . 0.0 109.805 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 44.8 t -75.0 122.05 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 176.08 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 84.6 tttt -86.5 -47.8 8.94 Favored 'General case' 0 C--N 1.286 -2.178 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.623 -177.196 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -152.98 162.34 41.44 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 -179.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 47.8 t -130.02 151.84 36.48 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.052 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.2 t . . . . . 0 C--N 1.314 -0.966 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 176.629 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.497 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.209 -1.055 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.402 ' HB1' ' CE ' ' A' ' 12' ' ' LYS . . . -65.56 -59.59 3.81 Favored 'General case' 0 N--CA 1.504 2.274 0 CA-C-N 118.719 0.691 . . . . 0.0 110.423 -175.799 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.1 mt-30 -78.02 6.8 7.12 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.349 177.437 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 26.0 mmm180 -95.59 -27.72 15.2 Favored 'General case' 0 N--CA 1.428 -1.568 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 171.697 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -66.65 -37.22 84.36 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 173.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.58 -31.74 4.13 Favored Glycine 0 N--CA 1.458 0.119 0 CA-C-N 115.471 -0.786 . . . . 0.0 113.985 172.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 2.7 ttm180 -61.55 -54.79 38.52 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 124.975 1.31 . . . . 0.0 111.401 -176.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.5 tt -84.82 141.55 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 CA-C-N 115.033 -0.985 . . . . 0.0 108.832 -176.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.7 mt-30 -143.0 -179.83 6.6 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 119.991 -0.684 . . . . 0.0 111.875 178.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.2 t -62.81 -30.69 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.701 178.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 35.3 m-80 -83.53 18.55 1.83 Allowed 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 113.252 0.834 . . . . 0.0 113.252 -175.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -104.57 175.43 5.49 Favored 'General case' 0 C--O 1.252 1.187 0 CA-C-O 121.491 0.662 . . . . 0.0 111.715 177.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.41 ' O ' HG21 ' A' ' 91' ' ' ILE . 62.3 tt0 -127.46 136.27 51.57 Favored 'General case' 0 N--CA 1.422 -1.827 0 CA-C-N 114.848 -1.069 . . . . 0.0 108.453 177.268 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.622 ' O ' HD13 ' A' ' 35' ' ' LEU . 49.0 mm -75.62 139.84 18.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 178.473 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.703 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 90.5 t -119.26 -53.71 3.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 CA-C-O 121.545 0.688 . . . . 0.0 109.805 177.57 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.494 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 32.0 tt0 -151.7 102.91 2.9 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 -177.617 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.8 t -96.41 127.61 48.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.762 -0.586 . . . . 0.0 111.38 179.185 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 35.2 t70 61.51 19.51 10.4 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 124.847 1.259 . . . . 0.0 111.17 173.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.17 20.24 79.69 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 114.891 -1.05 . . . . 0.0 112.505 -178.575 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.9 tt -81.33 -14.42 12.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 O-C-N 122.418 -0.46 . . . . 0.0 110.282 -179.269 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 17.8 m 45.33 81.23 0.04 OUTLIER 'General case' 0 C--N 1.351 0.642 0 C-N-CA 125.479 1.512 . . . . 0.0 112.172 -178.004 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.425 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.5 OUTLIER -91.4 18.31 7.36 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 121.88 0.848 . . . . 0.0 111.409 -174.901 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 57.2 t -57.95 104.67 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.941 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.264 173.426 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.47 29.27 6.36 Favored Glycine 0 N--CA 1.437 -1.261 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.633 179.028 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 68' ' ' LEU . 15.7 m -113.88 176.1 2.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 C-N-CA 120.166 -0.614 . . . . 0.0 110.735 176.704 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -104.06 173.27 6.38 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.734 178.008 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.28 -33.48 71.12 Favored 'General case' 0 C--O 1.204 -1.314 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.035 -176.616 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -66.09 -32.65 74.23 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 123.695 0.798 . . . . 0.0 111.967 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 51.3 t80 -78.92 -49.33 13.01 Favored 'General case' 0 N--CA 1.444 -0.752 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 177.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.42 -43.41 96.79 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.243 -177.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.437 ' O ' ' HB2' ' A' ' 81' ' ' ARG . . . -63.38 -22.59 66.97 Favored 'General case' 0 C--O 1.218 -0.592 0 CA-C-O 121.028 0.442 . . . . 0.0 110.798 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 52.9 m -80.96 -45.44 16.66 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.827 177.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.529 ' O ' HG21 ' A' ' 83' ' ' THR . 40.0 t -62.45 -52.71 56.63 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.571 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 178.338 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -70.13 6.82 1.14 Allowed 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 123.968 0.907 . . . . 0.0 112.213 -178.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.437 ' HB2' ' O ' ' A' ' 77' ' ' ALA . 41.5 ttt180 -109.12 -47.61 3.4 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 174.169 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -79.76 -10.76 59.83 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 113.99 -1.459 . . . . 0.0 114.021 -172.121 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.529 HG21 ' O ' ' A' ' 79' ' ' VAL . 12.5 p -63.14 138.43 58.55 Favored 'General case' 0 C--O 1.248 1.014 0 CA-C-O 120.418 0.151 . . . . 0.0 110.838 177.419 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.8 mmtt -131.17 132.38 44.69 Favored 'General case' 0 CA--C 1.487 -1.453 0 N-CA-C 113.516 0.932 . . . . 0.0 113.516 -175.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.46 -73.17 0.0 OUTLIER Glycine 0 CA--C 1.479 -2.179 0 C-N-CA 127.895 2.664 . . . . 0.0 115.079 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 19.2 m120 -102.53 100.19 10.27 Favored 'General case' 0 C--N 1.253 -3.63 0 CA-C-O 121.376 0.607 . . . . 0.0 109.417 -172.366 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.514 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 5.6 t -114.5 127.67 71.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.058 -172.388 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 37.7 mtm-85 -99.99 97.78 8.61 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-O 121.026 0.441 . . . . 0.0 109.942 175.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . 0.439 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 80.8 m-85 -87.56 100.75 13.02 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.703 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.4 t -85.66 94.25 4.02 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.634 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 175.745 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.41 HG21 ' O ' ' A' ' 59' ' ' GLN . 90.3 mt -112.84 158.58 13.17 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.257 0 CA-C-N 114.05 -1.432 . . . . 0.0 107.749 176.807 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.47 167.34 14.29 Favored Glycine 0 N--CA 1.405 -3.405 0 C-N-CA 118.903 -1.617 . . . . 0.0 112.276 -178.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 2.6 tmt_? -113.59 128.55 56.48 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 176.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 . . . . . 0 C--N 1.302 -1.477 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 178.236 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.45 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 35.3 tt0 . . . . . 0 CA--C 1.499 -0.988 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -87.85 117.34 26.63 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -132.38 140.67 38.66 Favored Pre-proline 0 C--N 1.294 -1.816 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -177.167 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -77.78 125.0 7.16 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.525 2.15 . . . . 0.0 111.855 176.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 26.3 t -111.73 97.19 5.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -80.0 104.29 10.47 Favored 'General case' 0 N--CA 1.425 -1.691 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -98.4 141.22 31.55 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 -177.374 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -112.88 85.29 2.14 Favored 'General case' 0 N--CA 1.416 -2.133 0 C-N-CA 119.077 -1.049 . . . . 0.0 108.924 172.078 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.532 ' HA ' ' HB2' ' A' ' 47' ' ' ALA . 4.3 mmtt -68.69 168.67 12.72 Favored 'General case' 0 N--CA 1.409 -2.511 0 CA-C-N 114.402 -1.272 . . . . 0.0 114.398 -179.374 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -67.04 164.94 16.73 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 113.721 -1.582 . . . . 0.0 107.506 -178.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -70.25 -12.82 61.86 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.41 0.624 . . . . 0.0 111.712 -177.03 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -68.21 -43.87 77.06 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.186 174.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.462 ' O ' ' HD2' ' A' ' 12' ' ' LYS . . . 132.64 -152.48 20.29 Favored Glycine 0 N--CA 1.426 -1.98 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -176.292 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.585 ' O ' ' HB ' ' A' ' 43' ' ' THR . 22.8 mt -89.14 -49.49 6.72 Favored 'General case' 0 CA--C 1.489 -1.398 0 CA-C-N 117.678 0.739 . . . . 0.0 109.967 -177.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 73.11 23.82 76.93 Favored Glycine 0 N--CA 1.425 -2.054 0 CA-C-N 114.752 -1.113 . . . . 0.0 111.062 -174.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.408 HG21 ' HA ' ' A' ' 42' ' ' VAL . 19.5 pt -101.17 178.95 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.747 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.7 m -145.58 156.49 43.72 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.522 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -116.71 162.1 14.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 C-N-CA 122.83 0.452 . . . . 0.0 110.556 -176.065 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.4 tt -132.6 125.36 52.96 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.821 0 CA-C-O 120.965 0.412 . . . . 0.0 110.107 174.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.483 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.55 101.18 2.71 Favored Glycine 0 N--CA 1.417 -2.595 0 CA-C-N 115.743 -0.662 . . . . 0.0 112.013 -178.488 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 94.9 mmm -107.1 165.32 11.45 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 177.483 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.287 -2.166 0 C-N-CA 119.207 -1.473 . . . . 0.0 111.414 -179.852 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.504 ' CD2' ' HA ' ' A' ' 69' ' ' VAL . 1.6 pp . . . . . 0 N--CA 1.451 -0.411 0 CA-C-O 120.63 0.252 . . . . 0.0 110.867 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -106.52 30.19 9.88 Favored Glycine 0 N--CA 1.431 -1.662 0 C-N-CA 120.009 -1.091 . . . . 0.0 111.229 177.038 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.554 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 24.8 mm -82.83 100.68 6.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 121.537 0.684 . . . . 0.0 110.038 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -99.28 167.35 10.72 Favored 'General case' 0 C--N 1.277 -2.545 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.482 179.306 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.1 t -83.21 113.62 22.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 56.6 tptt -76.74 -45.73 28.05 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.897 -176.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.4 m -152.37 162.92 40.49 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -175.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.408 ' HA ' HG21 ' A' ' 19' ' ' ILE . 59.6 t -134.27 158.08 41.88 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.066 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.309 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.585 ' HB ' ' O ' ' A' ' 17' ' ' LEU . 10.1 t . . . . . 0 CA--C 1.546 0.792 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 171.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.532 ' HB2' ' HA ' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.201 -1.457 0 N-CA-C 115.254 1.575 . . . . 0.0 115.254 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.504 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -74.05 -58.99 2.93 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.217 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -69.84 -24.4 63.45 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 119.83 -0.748 . . . . 0.0 112.133 175.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.477 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 13.1 mmt180 -66.37 -36.77 83.72 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 174.017 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -57.23 -59.66 4.78 Favored 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.607 0.567 . . . . 0.0 109.728 177.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.06 -20.75 35.14 Favored Glycine 0 N--CA 1.437 -1.244 0 C-N-CA 120.222 -0.989 . . . . 0.0 114.442 174.37 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.543 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -77.11 -60.95 2.15 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.814 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.543 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 17.5 tt -69.08 140.75 18.33 Favored 'Isoleucine or valine' 0 C--O 1.245 0.831 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.428 -175.518 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 16.4 mm-40 -137.18 173.36 11.76 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-O 121.641 0.734 . . . . 0.0 111.669 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.6 p -81.77 23.75 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.227 0 CA-C-O 122.309 1.052 . . . . 0.0 110.362 -178.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -134.79 13.43 3.68 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 122.432 1.111 . . . . 0.0 108.816 -178.324 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -92.47 -177.4 4.6 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.151 -0.932 . . . . 0.0 110.806 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.554 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 32.3 tt0 -134.31 125.02 26.81 Favored 'General case' 0 N--CA 1.434 -1.229 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.303 179.156 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 45.1 mm -77.63 113.8 17.29 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.908 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -177.143 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.655 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 84.9 t -97.17 -49.14 12.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-O 121.65 0.738 . . . . 0.0 111.093 -177.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.551 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 28.6 tt0 -149.39 115.77 5.82 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.9 t -108.9 125.95 65.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.688 176.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 21.1 t70 69.98 1.62 3.56 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 124.807 1.243 . . . . 0.0 112.162 173.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.54 16.84 38.31 Favored Glycine 0 N--CA 1.427 -1.908 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.608 -176.185 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.8 tt -74.24 -32.85 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.786 0 O-C-N 122.343 -0.504 . . . . 0.0 110.357 179.109 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.407 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 20.8 t 58.0 93.45 0.03 OUTLIER 'General case' 0 C--N 1.344 0.327 0 C-N-CA 125.015 1.326 . . . . 0.0 110.038 -176.207 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.469 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.6 OUTLIER -105.27 21.0 17.91 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 121.747 0.784 . . . . 0.0 109.883 -174.954 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.504 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 21.4 t -56.31 96.22 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.287 -2.129 0 CA-C-N 114.532 -1.213 . . . . 0.0 112.046 179.091 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 108.49 6.86 30.77 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.859 175.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.469 HG22 ' O ' ' A' ' 68' ' ' LEU . 21.3 m -82.7 -177.26 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 117.245 0.522 . . . . 0.0 112.005 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 p -97.89 173.77 6.91 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.003 176.489 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.522 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -61.3 -35.11 76.47 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.437 -1.256 . . . . 0.0 111.706 179.044 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -71.33 -32.15 68.23 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 121.059 -0.257 . . . . 0.0 111.364 -178.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -70.75 -47.12 61.34 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 176.434 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.416 ' O ' HD21 ' A' ' 80' ' ' LEU . . . -61.14 -42.88 99.35 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.915 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.405 ' O ' ' HB3' ' A' ' 81' ' ' ARG . . . -59.26 -38.08 79.18 Favored 'General case' 0 C--O 1.212 -0.911 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 176.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 88.1 m -65.15 -50.95 64.01 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.099 178.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.403 ' O ' HG23 ' A' ' 83' ' ' THR . 5.6 p -63.65 -45.2 98.15 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.577 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 178.731 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.416 HD21 ' O ' ' A' ' 76' ' ' ALA . 4.0 mm? -67.29 -25.47 66.06 Favored 'General case' 0 C--O 1.216 -0.709 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.405 ' HB3' ' O ' ' A' ' 77' ' ' ALA . 0.4 OUTLIER -86.38 -23.54 26.11 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-O 120.857 0.36 . . . . 0.0 111.657 177.544 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -86.49 5.29 36.03 Favored 'General case' 0 N--CA 1.483 1.211 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 179.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.403 HG23 ' O ' ' A' ' 79' ' ' VAL . 31.2 p -70.08 178.05 2.94 Favored 'General case' 0 C--N 1.291 -1.965 0 CA-C-O 121.711 0.767 . . . . 0.0 112.348 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.77 -159.04 0.97 Allowed 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 125.01 1.324 . . . . 0.0 108.045 -179.014 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.12 -76.01 0.22 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 114.467 0.547 . . . . 0.0 114.467 -179.223 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -78.75 112.14 15.58 Favored 'General case' 0 CA--C 1.497 -1.076 0 O-C-N 122.654 -0.321 . . . . 0.0 110.427 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 83.0 t -132.36 128.05 57.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.153 -178.374 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.68 108.38 19.78 Favored 'General case' 0 CA--C 1.496 -1.098 0 C-N-CA 119.715 -0.794 . . . . 0.0 109.903 172.133 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -93.63 98.92 11.46 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 174.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.655 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.7 t -84.55 96.39 4.58 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.06 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 176.062 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.444 HG23 ' O ' ' A' ' 59' ' ' GLN . 95.0 mt -112.91 153.75 14.44 Favored 'Isoleucine or valine' 0 C--N 1.262 -3.202 0 CA-C-N 113.796 -1.547 . . . . 0.0 108.608 177.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.45 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -119.76 153.65 16.71 Favored Glycine 0 N--CA 1.403 -3.554 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 177.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.5 ' NH1' ' HG3' ' A' ' 94' ' ' GLU . 4.3 tmt_? -135.19 152.39 51.54 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -176.835 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.5 ' HG3' ' NH1' ' A' ' 93' ' ' ARG . 7.2 pt-20 . . . . . 0 C--N 1.321 -0.641 0 O-C-N 124.247 0.967 . . . . 0.0 110.771 177.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.19 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 17.8 p80 -146.15 142.05 28.1 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 54.7 ttp -77.99 109.44 12.06 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 121.295 0.569 . . . . 0.0 109.602 179.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.548 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 48.4 tt0 -87.9 114.47 24.55 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.904 -1.044 . . . . 0.0 108.737 -178.507 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -90.79 108.39 19.8 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.822 -1.548 . . . . 0.0 106.822 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -123.13 140.71 34.17 Favored Pre-proline 0 C--N 1.293 -1.881 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -171.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -86.7 131.71 3.37 Favored 'Trans proline' 0 C--N 1.314 -1.267 0 C-N-CA 123.05 2.5 . . . . 0.0 111.928 174.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.3 t -124.32 105.79 15.85 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.302 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 175.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.587 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.1 tt0 -91.32 103.33 16.0 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 175.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.495 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.2 OUTLIER -91.85 143.7 26.24 Favored 'General case' 0 N--CA 1.421 -1.884 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 -174.556 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -112.05 87.92 2.68 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.79 0.805 . . . . 0.0 109.684 175.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.444 ' HG2' HD11 ' A' ' 10' ' ' LEU . 2.1 mmtp -84.87 -178.95 6.98 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -178.222 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.491 ' CG ' ' H ' ' A' ' 14' ' ' GLU . 18.9 t70 -76.08 -176.7 3.61 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 113.568 -1.651 . . . . 0.0 109.845 -178.577 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.491 ' H ' ' CG ' ' A' ' 13' ' ' ASP . 12.0 pt-20 -82.02 -19.86 39.57 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.809 -1.087 . . . . 0.0 109.936 -176.288 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -69.26 -47.46 64.59 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.73 -128.31 4.4 Favored Glycine 0 N--CA 1.425 -2.039 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.078 -177.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mt -103.81 -49.49 3.64 Favored 'General case' 0 CA--C 1.495 -1.139 0 O-C-N 122.351 -0.499 . . . . 0.0 110.151 -174.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 71.74 31.91 64.55 Favored Glycine 0 N--CA 1.428 -1.858 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -175.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 18.5 pt -111.01 167.82 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 C-N-CA 120.151 -0.62 . . . . 0.0 110.399 -179.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.4 m -131.47 154.38 48.78 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.303 -177.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -123.34 170.04 14.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 C-N-CA 123.334 0.654 . . . . 0.0 109.352 -178.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.428 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.1 tt -136.37 131.41 48.38 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 C-N-CA 120.569 -0.452 . . . . 0.0 110.208 176.298 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.509 ' HA2' HD12 ' A' ' 37' ' ' ILE . . . -95.63 104.24 3.08 Favored Glycine 0 CA--C 1.477 -2.305 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.412 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 19.4 ptm -145.75 98.17 3.08 Favored 'General case' 0 C--N 1.29 -1.992 0 CA-C-N 115.389 -0.406 . . . . 0.0 110.699 -179.049 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.7 111.36 1.2 Allowed Glycine 0 CA--C 1.497 -1.036 0 O-C-N 124.36 1.038 . . . . 0.0 111.32 -178.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -75.6 116.5 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.682 0 CA-C-O 121.779 0.8 . . . . 0.0 112.482 -174.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.73 75.07 2.05 Favored Glycine 0 N--CA 1.433 -1.538 0 N-CA-C 108.516 -1.834 . . . . 0.0 108.516 173.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.449 ' C ' ' H ' ' A' ' 30' ' ' ALA . . . -58.13 -20.76 42.89 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 124.575 1.15 . . . . 0.0 113.554 -175.188 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.2 t70 76.13 -32.07 0.2 Allowed 'General case' 0 N--CA 1.495 1.825 0 C-N-CA 124.879 1.271 . . . . 0.0 111.681 176.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.449 ' H ' ' C ' ' A' ' 28' ' ' ALA . . . -60.76 -33.05 72.37 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 125.046 1.338 . . . . 0.0 111.596 178.556 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 123.71 -28.47 5.45 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 119.806 -1.188 . . . . 0.0 112.696 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.0 mp -71.94 -60.93 1.98 Allowed 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -177.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 60.03 75.79 0.39 Allowed 'General case' 0 CA--C 1.505 -0.753 0 CA-C-O 122.452 1.12 . . . . 0.0 110.31 176.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -72.06 -171.04 0.67 Allowed 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 113.161 -1.836 . . . . 0.0 111.175 -176.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 3.4 pp -50.82 143.3 10.13 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.018 174.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -109.8 32.59 6.62 Favored Glycine 0 C--N 1.281 -2.509 0 C-N-CA 120.19 -1.005 . . . . 0.0 111.329 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.509 HD12 ' HA2' ' A' ' 23' ' ' GLY . 28.4 mm -93.06 100.4 11.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-O 121.732 0.777 . . . . 0.0 110.064 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -97.24 166.65 11.46 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.336 178.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.0 t -80.95 131.37 34.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 175.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.4 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -93.27 -49.61 5.88 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.477 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.3 m -150.69 161.03 43.4 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 -176.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.407 HG13 ' HG3' ' A' ' 49' ' ' GLN . 57.7 t -132.66 160.39 42.6 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.662 0 N-CA-C 104.9 -2.259 . . . . 0.0 104.9 175.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.1 t -59.31 155.6 14.2 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 173.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -48.54 -31.4 6.44 Favored 'General case' 0 C--O 1.241 0.613 0 C-N-CA 124.384 1.074 . . . . 0.0 112.826 -176.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -163.53 -62.53 0.02 OUTLIER Glycine 0 N--CA 1.417 -2.591 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.755 175.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 43.56 -112.12 0.51 Allowed Glycine 0 N--CA 1.421 -2.308 0 C-N-CA 125.28 1.419 . . . . 0.0 110.891 -170.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.467 ' O ' ' HB2' ' A' ' 51' ' ' ASP . . . -129.6 7.92 5.33 Favored 'General case' 0 C--N 1.258 -3.398 0 CA-C-N 112.853 -1.673 . . . . 0.0 108.938 175.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -95.95 -57.07 2.45 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -176.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.407 ' HG3' HG13 ' A' ' 42' ' ' VAL . 25.6 mt-30 -80.92 -12.99 59.31 Favored 'General case' 0 CA--C 1.502 -0.874 0 C-N-CA 119.349 -0.94 . . . . 0.0 109.853 177.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.494 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 5.8 mmp_? -92.17 -9.83 40.95 Favored 'General case' 0 N--CA 1.427 -1.599 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.891 173.062 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.467 ' HB2' ' O ' ' A' ' 47' ' ' ALA . 13.2 t70 -70.54 -64.74 0.84 Allowed 'General case' 0 N--CA 1.481 1.12 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 171.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 115.54 -25.66 9.55 Favored Glycine 0 N--CA 1.431 -1.655 0 C-N-CA 120.383 -0.913 . . . . 0.0 114.297 175.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -80.48 -36.0 34.04 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 117.903 0.851 . . . . 0.0 109.149 -177.581 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.4 tt -92.97 149.55 4.18 Favored 'Isoleucine or valine' 0 C--O 1.254 1.303 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 23.5 mt-30 -130.8 167.43 18.91 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.156 0.503 . . . . 0.0 111.031 179.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.98 -8.81 11.48 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.165 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.641 178.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 10.3 p30 -106.38 12.62 29.59 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-O 121.423 0.63 . . . . 0.0 110.764 -177.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -91.28 -174.4 3.93 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.613 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.56 ' O ' HG21 ' A' ' 91' ' ' ILE . 30.6 tt0 -135.09 126.13 27.78 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.765 -176.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.448 ' HA ' HG12 ' A' ' 91' ' ' ILE . 47.0 mm -73.65 114.45 13.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.014 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.681 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 74.0 t -93.26 -49.95 12.5 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-O 121.675 0.75 . . . . 0.0 109.928 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.43 ' HG3' ' H ' ' A' ' 67' ' ' SER . 26.1 tt0 -151.27 126.73 10.06 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.464 178.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 5.0 t -118.43 130.65 72.96 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.048 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 174.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 16.6 t70 62.69 16.71 9.16 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 124.205 1.002 . . . . 0.0 111.623 174.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.89 15.81 78.37 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.209 -179.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.4 tt -79.86 -16.83 12.93 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.115 0 O-C-N 122.347 -0.502 . . . . 0.0 112.064 -175.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.43 ' H ' ' HG3' ' A' ' 62' ' ' GLU 0.282 0.8 OUTLIER 39.34 80.97 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 114.728 1.381 . . . . 0.0 114.728 -175.553 . . . . . . . . 4 4 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.43 ' H ' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -92.24 36.78 0.99 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.859 -176.73 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.66 91.41 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.713 -177.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 107.4 33.17 3.21 Favored Glycine 0 C--N 1.303 -1.276 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.79 176.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.9 m -103.97 175.96 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 120.249 -0.58 . . . . 0.0 111.152 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 40.3 p -91.89 176.0 6.68 Favored 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 178.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.35 -25.18 64.96 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.404 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 -65.32 -48.16 74.04 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.457 ' O ' HG21 ' A' ' 79' ' ' VAL . 29.5 t80 -64.44 -51.85 61.07 Favored 'General case' 0 N--CA 1.432 -1.331 0 CA-C-N 114.577 -1.192 . . . . 0.0 109.124 -178.208 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.77 -44.99 96.05 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.558 -177.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.5 -34.1 73.58 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.039 0.447 . . . . 0.0 110.066 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.461 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 76.8 m -65.75 -45.06 84.01 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.525 176.477 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.457 HG21 ' O ' ' A' ' 75' ' ' PHE . 41.1 t -60.62 -52.33 62.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 C-N-CA 122.229 0.212 . . . . 0.0 110.527 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -70.7 0.07 7.78 Favored 'General case' 0 CA--C 1.552 1.049 0 CA-C-O 121.406 0.622 . . . . 0.0 112.154 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.461 ' HB3' ' O ' ' A' ' 78' ' ' THR . 25.9 ttm180 -100.14 -38.18 8.63 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 124.024 0.93 . . . . 0.0 108.986 174.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.17 -10.26 59.3 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.122 -175.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.3 p -71.58 161.23 31.34 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 113.183 0.808 . . . . 0.0 113.183 -178.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -118.9 -161.24 0.84 Allowed 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.23 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.59 -63.42 5.3 Favored Glycine 0 N--CA 1.439 -1.12 0 O-C-N 123.544 0.528 . . . . 0.0 113.323 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.495 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 17.9 m120 -82.14 108.82 15.91 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.8 t -119.7 136.66 56.1 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.677 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.721 -176.433 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 84.2 mtt180 -102.63 97.38 7.58 Favored 'General case' 0 C--N 1.288 -2.103 0 CA-C-O 121.4 0.619 . . . . 0.0 109.993 173.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.44 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 92.8 m-85 -89.36 106.16 18.27 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.735 177.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.681 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.4 t -95.65 88.77 2.13 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.743 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 175.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.56 HG21 ' O ' ' A' ' 59' ' ' GLN . 82.2 mt -101.09 149.68 6.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.678 0 CA-C-N 114.613 -1.176 . . . . 0.0 108.566 179.094 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.548 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -138.05 128.73 4.32 Favored Glycine 1 N--CA 1.393 -4.196 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 -178.638 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 15.7 ttp180 -157.9 162.1 38.28 Favored 'General case' 0 N--CA 1.414 -2.24 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 -175.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.285 -2.212 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 175.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.496 -1.129 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 54.3 m80 55.42 63.41 2.09 Favored 'General case' 0 CA--C 1.508 -0.666 0 CA-C-O 121.73 0.776 . . . . 0.0 111.093 -177.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' MET . . . . . 0.515 ' HA ' ' O ' ' A' ' 93' ' ' ARG 0.273 43.7 ttm 69.38 93.81 0.08 Allowed 'General case' 0 N--CA 1.432 -1.336 0 CA-C-N 113.736 -1.574 . . . . 0.0 113.236 -178.317 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -85.25 115.46 23.03 Favored 'General case' 0 C--N 1.288 -2.09 0 CA-C-N 112.901 -1.954 . . . . 0.0 108.117 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.402 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.5 mm? -86.43 134.28 33.71 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 123.752 0.658 . . . . 0.0 109.884 -177.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 10.7 p90 -141.57 144.36 33.11 Favored Pre-proline 0 C--N 1.293 -1.865 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.802 -178.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -84.61 130.17 4.36 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 C-N-CA 122.57 2.18 . . . . 0.0 113.168 179.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.458 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 26.1 t -115.65 107.65 23.23 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.228 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 174.034 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -88.42 107.02 18.64 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 177.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -100.48 139.27 36.4 Favored 'General case' 0 N--CA 1.423 -1.802 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -176.157 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -109.76 81.77 1.49 Allowed 'General case' 0 N--CA 1.426 -1.641 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 173.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.527 ' HZ2' HG22 ' A' ' 43' ' ' THR . 2.0 mmtt -77.9 171.72 14.56 Favored 'General case' 0 N--CA 1.409 -2.52 0 CA-C-N 115.05 -0.977 . . . . 0.0 113.426 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -72.96 167.98 19.93 Favored 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 126.06 1.744 . . . . 0.0 108.617 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -68.58 -21.41 64.53 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-O 121.412 0.625 . . . . 0.0 110.289 179.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -64.14 -32.43 74.0 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.418 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.23 -158.8 14.05 Favored Glycine 0 N--CA 1.434 -1.472 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -178.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.407 ' HG ' ' OG1' ' A' ' 83' ' ' THR . 17.6 mt -83.64 -48.78 9.84 Favored 'General case' 0 CA--C 1.49 -1.352 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -177.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.32 32.01 71.85 Favored Glycine 0 N--CA 1.431 -1.67 0 O-C-N 124.515 1.134 . . . . 0.0 110.677 -175.093 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.8 pt -98.91 -177.79 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.567 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.403 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.8 m -138.13 149.09 45.58 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 122.766 0.426 . . . . 0.0 110.011 -178.01 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.407 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.5 pp -119.04 161.39 18.15 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 C-N-CA 123.324 0.65 . . . . 0.0 109.73 -177.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 15.6 tt -128.94 128.72 67.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 174.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.457 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -93.71 96.39 2.07 Favored Glycine 0 N--CA 1.432 -1.61 0 C-N-CA 120.468 -0.872 . . . . 0.0 112.77 -175.526 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 91.9 mmm -104.15 164.52 11.66 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.8 73.97 0.36 Allowed Glycine 0 N--CA 1.421 -2.35 0 C-N-CA 119.969 -1.11 . . . . 0.0 110.653 177.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.4 p -101.33 94.77 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.405 0 CA-C-O 122.473 1.13 . . . . 0.0 108.939 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.469 ' CA ' ' HA ' ' A' ' 33' ' ' GLU . . . -148.13 -75.49 0.02 OUTLIER Glycine 0 N--CA 1.424 -2.154 0 C-N-CA 119.671 -1.252 . . . . 0.0 112.715 -173.779 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.32 -33.91 77.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.806 0.812 . . . . 0.0 109.81 -179.24 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -71.67 -19.22 62.12 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 114.225 -1.352 . . . . 0.0 111.481 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.99 -33.88 11.98 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 121.608 0.718 . . . . 0.0 109.241 177.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.14 -32.14 7.66 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.759 179.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.6 mp -78.83 -36.57 42.3 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.865 0.364 . . . . 0.0 110.991 -177.368 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.469 ' HA ' ' CA ' ' A' ' 27' ' ' GLY . 44.5 mt-10 64.22 97.15 0.04 OUTLIER 'General case' 0 CA--C 1.509 -0.605 0 C-N-CA 124.436 1.094 . . . . 0.0 113.393 -175.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -142.95 -179.42 6.34 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 172.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -57.71 151.56 17.2 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-O 121.738 0.78 . . . . 0.0 111.054 176.199 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -114.26 19.99 16.78 Favored Glycine 0 N--CA 1.412 -2.964 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 174.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.457 HD11 ' HA2' ' A' ' 23' ' ' GLY . 30.5 mm -77.7 116.53 21.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 177.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -114.92 165.88 12.39 Favored 'General case' 0 C--N 1.269 -2.924 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.7 t -77.96 132.37 32.66 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 176.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.448 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -95.89 -44.0 7.58 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 121.396 0.617 . . . . 0.0 110.049 -178.715 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.8 m -155.66 160.13 40.15 Favored 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 -178.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 64.0 t -129.11 148.8 33.29 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.621 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 176.114 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.527 HG22 ' HZ2' ' A' ' 12' ' ' LYS . 15.3 t -54.44 140.04 35.38 Favored 'General case' 0 C--O 1.254 1.292 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 176.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -68.89 -35.39 76.81 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -171.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -152.32 77.81 0.21 Allowed Glycine 0 CA--C 1.46 -3.373 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.289 -178.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -137.69 174.09 22.0 Favored Glycine 1 N--CA 1.366 -5.979 0 N-CA-C 103.422 -3.871 . . . . 0.0 103.422 173.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.5 ' HB1' ' HA ' ' A' ' 12' ' ' LYS . . . -61.73 -1.2 0.56 Allowed 'General case' 0 C--N 1.273 -2.74 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 -174.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.456 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -77.88 -57.34 3.85 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -75.16 -12.61 60.34 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 119.764 -0.774 . . . . 0.0 112.085 175.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.487 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 20.5 mmm180 -73.4 -40.99 63.88 Favored 'General case' 0 CA--C 1.507 -0.689 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -62.36 -57.69 10.39 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.965 0.79 . . . . 0.0 109.603 176.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 83.25 -5.74 75.49 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 115.539 0.976 . . . . 0.0 115.539 173.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -78.36 -30.99 48.29 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 19.7 tt -89.11 152.6 3.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 175.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -133.03 -177.57 4.57 Favored 'General case' 0 N--CA 1.42 -1.962 0 CA-C-O 121.508 0.67 . . . . 0.0 111.019 -179.297 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.9 p -97.9 -5.06 9.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 121.822 0.82 . . . . 0.0 109.548 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -117.2 16.96 14.88 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.433 -174.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.415 ' OD1' HD12 ' A' ' 91' ' ' ILE . 3.0 p30 -100.66 -168.37 1.56 Allowed 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.167 177.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.468 ' O ' HG22 ' A' ' 91' ' ' ILE . 11.8 tt0 -131.39 117.6 19.11 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.374 -176.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.469 ' HA ' HG12 ' A' ' 91' ' ' ILE . 46.0 mm -68.83 106.85 1.24 Allowed 'Isoleucine or valine' 0 C--O 1.21 -1.024 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.761 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 89.3 t -87.76 -50.87 13.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-O 121.607 0.718 . . . . 0.0 110.326 -177.769 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.478 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.9 tt0 -145.62 133.32 21.04 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.31 129.56 71.98 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 176.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 31.3 t70 64.2 16.95 10.41 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 124.739 1.274 . . . . 0.0 111.143 172.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 72.2 26.03 73.16 Favored Glycine 0 N--CA 1.433 -1.525 0 CA-C-N 114.825 -1.08 . . . . 0.0 112.483 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.5 tt -85.09 -15.1 10.9 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 CA-C-O 121.417 0.627 . . . . 0.0 109.389 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.449 ' HA ' ' HG3' ' A' ' 62' ' ' GLU . 23.2 p 49.01 83.84 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 124.951 1.3 . . . . 0.0 112.704 -175.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.449 ' O ' HG21 ' A' ' 71' ' ' VAL . 1.9 pp -97.88 14.02 28.6 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 122.22 1.01 . . . . 0.0 109.313 -177.682 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 22.4 t -56.13 93.43 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-N 113.836 -1.529 . . . . 0.0 110.356 176.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.74 14.52 19.24 Favored Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 116.032 -0.531 . . . . 0.0 113.3 176.571 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.449 HG21 ' O ' ' A' ' 68' ' ' LEU . 21.0 m -88.16 176.14 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 O-C-N 122.335 -0.509 . . . . 0.0 111.836 -179.426 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.6 p -92.16 176.72 6.39 Favored 'General case' 0 N--CA 1.428 -1.545 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.185 177.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.407 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -66.98 -23.87 65.98 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.07 179.895 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 19.6 m-80 -63.53 -50.92 67.68 Favored 'General case' 0 CA--C 1.484 -1.581 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.41 ' O ' HG23 ' A' ' 79' ' ' VAL . 38.8 t80 -68.5 -50.56 51.31 Favored 'General case' 0 N--CA 1.415 -2.182 0 CA-C-N 114.067 -1.424 . . . . 0.0 110.093 -175.748 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.5 -44.45 95.96 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.29 -16.48 64.07 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-O 121.232 0.539 . . . . 0.0 111.063 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.4 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 60.2 m -85.04 -42.22 15.06 Favored 'General case' 0 N--CA 1.417 -2.107 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.944 176.678 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.415 ' O ' HG22 ' A' ' 83' ' ' THR . 38.7 t -62.85 -53.14 50.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 122.211 0.204 . . . . 0.0 110.588 178.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -68.59 -1.93 7.86 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-O 121.571 0.701 . . . . 0.0 112.434 -179.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.4 ' HB3' ' O ' ' A' ' 78' ' ' THR . 33.4 ttm180 -97.34 -43.41 7.32 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-O 121.922 0.868 . . . . 0.0 108.93 174.495 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 11.5 m-80 -83.78 8.59 14.22 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 114.338 -1.301 . . . . 0.0 112.794 -174.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.415 HG22 ' O ' ' A' ' 79' ' ' VAL . 2.2 p -65.6 176.99 1.31 Allowed 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 123.86 0.864 . . . . 0.0 112.679 177.785 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -139.25 -155.57 0.6 Allowed 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.31 -175.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -71.77 -68.77 1.53 Allowed Glycine 0 N--CA 1.444 -0.786 0 O-C-N 123.66 0.6 . . . . 0.0 111.834 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.442 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 43.8 m-80 -87.28 104.12 16.1 Favored 'General case' 0 CA--C 1.498 -1.044 0 CA-C-O 121.638 0.732 . . . . 0.0 110.079 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.409 ' HB ' ' CE1' ' A' ' 89' ' ' PHE . 3.0 t -116.74 133.17 64.25 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 CA-C-N 115.261 -0.881 . . . . 0.0 109.76 -175.454 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 70.0 mtp180 -97.79 101.97 13.6 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 173.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.458 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 91.1 m-85 -92.74 107.36 19.16 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 176.416 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.761 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 42.8 t -96.05 86.26 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.268 -2.951 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.469 HG12 ' HA ' ' A' ' 60' ' ' ILE . 88.8 mt -96.08 158.73 3.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.25 0 C-N-CA 125.314 1.445 . . . . 0.0 108.689 -179.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.402 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -136.53 149.32 20.11 Favored Glycine 0 N--CA 1.398 -3.884 0 C-N-CA 119.565 -1.303 . . . . 0.0 111.267 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.515 ' O ' ' HA ' ' A' ' 3' ' ' MET . 0.0 OUTLIER -115.23 135.18 54.44 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.078 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.291 -1.972 0 C-N-CA 124.335 1.054 . . . . 0.0 112.893 -175.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.28 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 31.2 t60 -154.19 139.73 17.84 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -178.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 49.7 ttm -160.41 112.09 1.94 Allowed 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 174.079 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -99.48 114.91 28.15 Favored 'General case' 0 C--N 1.285 -2.197 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.479 -178.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.402 HD12 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -87.31 128.6 35.17 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -140.43 144.08 35.49 Favored Pre-proline 0 C--N 1.307 -1.269 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -178.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -83.01 126.23 4.34 Favored 'Trans proline' 0 C--N 1.327 -0.594 0 C-N-CA 123.092 2.528 . . . . 0.0 113.393 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 41.4 t -118.05 99.94 9.08 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.018 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 175.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.511 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 34.0 tt0 -85.2 109.67 18.47 Favored 'General case' 0 N--CA 1.432 -1.372 0 C-N-CA 119.544 -0.863 . . . . 0.0 108.72 176.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.416 HD13 ' O ' ' A' ' 47' ' ' ALA . 0.1 OUTLIER -99.83 145.37 27.82 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -177.694 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -111.24 90.26 3.28 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 173.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.493 ' HA ' ' HB1' ' A' ' 47' ' ' ALA . 3.3 mtpm? -80.56 -176.63 5.84 Favored 'General case' 0 N--CA 1.423 -1.777 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -178.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -72.83 173.02 9.75 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 112.338 -2.21 . . . . 0.0 111.679 -173.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -61.29 -26.66 67.93 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.303 -0.862 . . . . 0.0 112.42 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -67.52 -45.52 75.51 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-O 121.494 0.664 . . . . 0.0 109.879 176.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.36 -114.3 2.34 Favored Glycine 0 N--CA 1.426 -2.025 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.73 -176.069 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.415 ' HG ' HG23 ' A' ' 19' ' ' ILE . 9.9 tp -108.1 -62.77 1.4 Allowed 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 117.349 0.575 . . . . 0.0 111.656 -173.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.87 36.25 92.87 Favored Glycine 0 N--CA 1.44 -1.034 0 O-C-N 123.889 0.743 . . . . 0.0 113.139 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.415 HG23 ' HG ' ' A' ' 17' ' ' LEU . 20.9 pt -102.17 178.48 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.519 177.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.8 m -130.79 148.79 52.61 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.498 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -118.66 162.86 16.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.453 -177.335 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 15.6 tt -126.9 125.55 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.938 0 C-N-CA 120.269 -0.573 . . . . 0.0 110.435 174.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.414 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -86.96 105.63 3.06 Favored Glycine 0 N--CA 1.431 -1.66 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.753 -178.417 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.467 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 9.0 ptp -137.03 176.96 8.24 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 122.668 0.387 . . . . 0.0 111.891 176.239 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.43 94.96 0.49 Allowed Glycine 0 C--N 1.303 -1.277 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 p -87.56 94.12 4.43 Favored 'Isoleucine or valine' 0 C--O 1.257 1.483 0 CA-C-O 122.238 1.018 . . . . 0.0 113.433 -176.031 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.4 76.31 0.59 Allowed Glycine 0 N--CA 1.435 -1.399 0 CA-C-N 114.182 -1.372 . . . . 0.0 115.724 173.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.76 -18.78 34.03 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 172.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -100.92 9.73 41.96 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.346 -1.297 . . . . 0.0 109.512 177.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.09 13.38 34.29 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 112.977 0.732 . . . . 0.0 112.977 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.09 -50.91 3.42 Favored Glycine 0 C--N 1.306 -1.099 0 C-N-CA 119.948 -1.12 . . . . 0.0 114.821 174.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 26.8 mt -71.78 -44.92 63.17 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-O 120.623 0.249 . . . . 0.0 111.067 -173.227 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 54.64 77.32 0.21 Allowed 'General case' 0 CA--C 1.511 -0.52 0 O-C-N 124.301 1.0 . . . . 0.0 111.544 178.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.443 ' HD3' ' H ' ' A' ' 34' ' ' LYS . 0.0 OUTLIER -128.21 179.24 5.72 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.685 -178.786 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -53.73 155.71 3.07 Favored 'General case' 0 C--N 1.321 -0.638 0 O-C-N 124.413 1.071 . . . . 0.0 111.438 -179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -124.41 33.0 3.94 Favored Glycine 0 N--CA 1.412 -2.909 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 174.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.526 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 32.8 mm -89.5 107.76 18.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 176.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -104.21 168.66 8.96 Favored 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.9 t -78.72 121.63 32.16 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 176.014 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.464 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.1 OUTLIER -86.73 -49.19 7.65 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.503 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.09 157.65 43.68 Favored 'General case' 0 N--CA 1.417 -2.11 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.72 151.07 32.43 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.952 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 176.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.6 t -53.58 140.16 29.53 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-O 121.583 0.706 . . . . 0.0 112.132 -173.524 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -53.35 -44.12 68.28 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 126.184 1.793 . . . . 0.0 113.794 -174.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -159.76 36.66 0.47 Allowed Glycine 0 CA--C 1.458 -3.517 0 C-N-CA 118.541 -1.79 . . . . 0.0 113.997 -179.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -86.48 179.27 49.19 Favored Glycine 1 N--CA 1.365 -6.097 0 N-CA-C 106.497 -2.641 . . . . 0.0 106.497 170.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.493 ' HB1' ' HA ' ' A' ' 12' ' ' LYS . . . -56.61 -8.12 0.52 Allowed 'General case' 0 C--N 1.259 -3.344 0 N-CA-C 115.301 1.593 . . . . 0.0 115.301 -174.265 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.29 -63.13 1.47 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 -70.6 -21.9 62.61 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 120.616 -0.434 . . . . 0.0 112.125 176.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 40.2 mmt180 -68.54 -33.71 74.58 Favored 'General case' 0 CA--C 1.522 -0.103 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -70.48 -64.98 0.79 Allowed 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.353 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.62 -10.97 57.84 Favored Glycine 0 N--CA 1.437 -1.278 0 C-N-CA 120.549 -0.834 . . . . 0.0 115.115 175.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.651 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -76.72 -33.63 58.16 Favored 'General case' 0 C--O 1.239 0.507 0 CA-C-N 118.65 1.225 . . . . 0.0 108.448 178.404 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.3 tt -90.82 154.47 3.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 178.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -134.96 -163.43 1.38 Allowed 'General case' 0 N--CA 1.428 -1.57 0 C-N-CA 119.772 -0.771 . . . . 0.0 110.972 -174.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.9 p -115.16 11.43 7.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-O 122.81 1.29 . . . . 0.0 107.564 176.25 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -121.94 -7.34 8.95 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.435 -1.257 . . . . 0.0 110.655 -174.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.499 ' OD1' HD13 ' A' ' 91' ' ' ILE . 3.9 p30 -86.92 -165.29 1.25 Allowed 'General case' 0 C--O 1.255 1.358 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.425 -177.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.526 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 62.9 tt0 -142.04 121.55 13.27 Favored 'General case' 0 N--CA 1.416 -2.14 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.38 -175.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.42 ' HA ' HG12 ' A' ' 91' ' ' ILE . 42.3 mm -70.16 107.0 1.71 Allowed 'Isoleucine or valine' 0 C--O 1.212 -0.872 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 179.149 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.684 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 93.5 t -88.28 -52.26 11.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 CA-C-O 121.649 0.738 . . . . 0.0 110.724 -177.178 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.502 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 29.4 tt0 -146.15 110.53 5.07 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.75 -178.199 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 t -105.15 131.0 55.44 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.919 0 O-C-N 122.033 -0.417 . . . . 0.0 111.455 176.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 33.5 t70 61.65 16.75 8.02 Favored 'General case' 0 N--CA 1.484 1.273 0 O-C-N 124.722 1.264 . . . . 0.0 111.242 174.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.37 19.01 75.05 Favored Glycine 0 N--CA 1.443 -0.898 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.232 -179.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.4 tt -80.18 -30.23 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 O-C-N 122.36 -0.494 . . . . 0.0 110.971 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 19.4 t 54.59 95.24 0.02 OUTLIER 'General case' 0 C--N 1.345 0.392 0 C-N-CA 125.035 1.334 . . . . 0.0 110.5 -175.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.47 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.7 OUTLIER -101.65 20.35 16.35 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 122.204 1.002 . . . . 0.0 109.734 -176.144 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 39.0 t -61.84 93.56 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-N 114.496 -1.229 . . . . 0.0 111.343 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 117.07 5.77 14.68 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.697 176.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.47 HG22 ' O ' ' A' ' 68' ' ' LEU . 16.3 m -87.72 179.51 0.49 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.57 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -177.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 14.9 p -94.21 176.18 6.41 Favored 'General case' 0 C--O 1.255 1.376 0 CA-C-O 121.463 0.649 . . . . 0.0 109.9 177.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.498 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -62.81 -38.37 90.44 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 114.713 -1.131 . . . . 0.0 111.246 178.071 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -68.65 -32.76 72.84 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 111.768 0.284 . . . . 0.0 111.768 -177.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -68.28 -51.83 40.59 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 176.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.419 ' CB ' HG22 ' A' ' 37' ' ' ILE . . . -59.84 -44.64 93.98 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.463 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.58 -18.48 63.93 Favored 'General case' 0 C--O 1.22 -0.467 0 C-N-CA 122.995 0.518 . . . . 0.0 111.266 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 78.3 m -83.67 -49.66 8.94 Favored 'General case' 0 N--CA 1.416 -2.125 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 175.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.434 ' O ' HG23 ' A' ' 83' ' ' THR . 38.4 t -59.57 -54.82 29.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 CA-C-O 120.462 0.172 . . . . 0.0 110.831 -178.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -67.95 -2.77 8.12 Favored 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 123.331 0.652 . . . . 0.0 112.033 -179.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 38.5 ttt180 -98.8 -43.46 6.76 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 174.221 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -73.08 -11.73 60.65 Favored 'General case' 0 C--O 1.24 0.588 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.142 -174.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.434 HG23 ' O ' ' A' ' 79' ' ' VAL . 15.9 p -75.14 140.18 43.2 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-O 121.588 0.709 . . . . 0.0 112.464 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.465 ' O ' HG23 ' A' ' 87' ' ' VAL . 71.0 mmtt -107.07 -167.5 1.28 Allowed 'General case' 0 C--N 1.292 -1.908 0 CA-C-N 114.432 -1.258 . . . . 0.0 109.044 176.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -40.14 -58.57 2.33 Favored Glycine 0 C--O 1.216 -0.971 0 O-C-N 124.631 1.207 . . . . 0.0 115.761 -176.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -87.62 100.32 12.72 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 117.747 0.773 . . . . 0.0 111.399 -174.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.535 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 1.6 t -119.43 128.7 75.86 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.36 -175.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 42.3 mtp180 -92.31 99.46 12.23 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 173.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.535 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 97.1 m-85 -92.06 101.09 13.63 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 177.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.684 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.8 t -91.08 92.44 3.94 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 105.963 -1.865 . . . . 0.0 105.963 175.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.499 HD13 ' OD1' ' A' ' 58' ' ' ASP . 97.2 mt -110.56 153.39 12.35 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.777 0 CA-C-N 114.293 -1.321 . . . . 0.0 107.968 179.336 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.402 ' HA3' HD12 ' A' ' 5' ' ' LEU . . . -124.42 150.5 17.08 Favored Glycine 0 N--CA 1.401 -3.662 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.938 179.053 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.416 ' C ' ' HD2' ' A' ' 93' ' ' ARG . 4.3 tmm_? -113.9 134.95 54.49 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 -177.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 . . . . . 0 C--N 1.309 -1.165 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.436 179.721 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.507 -0.457 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 59.9 m80 -68.78 131.87 45.87 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 177.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 45.0 ttp -137.59 132.89 33.75 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-O 121.089 0.471 . . . . 0.0 112.248 -174.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -102.14 120.0 39.73 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -90.45 120.39 31.52 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 177.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -135.1 146.64 59.21 Favored Pre-proline 0 C--N 1.304 -1.398 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -175.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -80.28 126.89 6.42 Favored 'Trans proline' 0 N--CA 1.444 -1.431 0 C-N-CA 122.244 1.963 . . . . 0.0 112.488 175.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.45 103.26 15.21 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.076 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 173.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.46 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.1 tt0 -88.17 103.57 15.89 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.494 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -98.28 145.71 26.38 Favored 'General case' 0 N--CA 1.426 -1.625 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 -175.819 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -116.48 95.85 5.25 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-O 121.66 0.743 . . . . 0.0 109.188 175.18 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.453 ' CD ' ' HB2' ' A' ' 47' ' ' ALA . 1.9 mmmp? -92.49 -169.96 2.35 Favored 'General case' 0 N--CA 1.419 -1.991 0 CA-C-N 114.911 -1.041 . . . . 0.0 112.564 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -78.49 167.19 21.66 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 113.864 -1.516 . . . . 0.0 107.805 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -67.88 -20.11 65.09 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.325 0.584 . . . . 0.0 109.807 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -65.69 -31.77 72.96 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 114.697 -1.138 . . . . 0.0 109.707 177.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.73 -130.4 9.06 Favored Glycine 0 N--CA 1.413 -2.838 0 CA-C-N 114.841 -1.072 . . . . 0.0 111.613 177.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.469 ' HB3' HG22 ' A' ' 19' ' ' ILE . 20.7 mt -108.49 -63.68 1.31 Allowed 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.836 -174.587 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.62 23.27 36.87 Favored Glycine 0 N--CA 1.424 -2.1 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -172.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.469 HG22 ' HB3' ' A' ' 17' ' ' LEU . 22.7 pt -89.23 178.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.349 0.547 0 C-N-CA 120.446 -0.502 . . . . 0.0 110.908 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.1 m -139.17 147.59 42.05 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.414 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -126.8 162.4 31.44 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 C-N-CA 122.814 0.446 . . . . 0.0 110.108 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.417 ' HB ' ' CG ' ' A' ' 40' ' ' LYS . 13.5 tt -130.96 135.0 60.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.473 174.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.477 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.18 102.48 2.86 Favored Glycine 0 N--CA 1.427 -1.945 0 C-N-CA 120.722 -0.751 . . . . 0.0 111.792 -178.017 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.633 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 93.8 mmm -116.87 93.48 4.21 Favored 'General case' 0 C--N 1.291 -1.96 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -179.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.93 107.07 0.56 Allowed Glycine 0 C--O 1.247 0.915 0 O-C-N 123.839 0.712 . . . . 0.0 111.743 -179.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.5 p -137.58 163.19 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -177.246 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 114.71 -9.49 21.61 Favored Glycine 0 N--CA 1.419 -2.471 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.7 177.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.92 -41.68 61.73 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -71.73 -30.96 66.19 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.921 0.867 . . . . 0.0 108.949 178.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.54 -29.28 66.83 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.403 175.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.53 24.43 28.46 Favored Glycine 0 N--CA 1.442 -0.934 0 C-N-CA 121.219 -0.515 . . . . 0.0 112.638 178.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -117.32 -38.94 3.25 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 122.546 -0.385 . . . . 0.0 111.013 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 54.45 82.88 0.09 Allowed 'General case' 0 C--O 1.238 0.495 0 CA-C-O 122.104 0.954 . . . . 0.0 110.377 -172.182 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -126.63 -155.6 0.7 Allowed 'General case' 0 C--N 1.297 -1.695 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.958 -175.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.5 pp -73.57 150.72 41.25 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 178.105 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.633 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -129.59 34.37 2.79 Favored Glycine 0 C--N 1.283 -2.38 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 172.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.477 HD13 ' HA2' ' A' ' 23' ' ' GLY . 26.8 mm -86.72 100.19 9.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.828 0 CA-C-O 121.556 0.693 . . . . 0.0 110.992 -175.405 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -93.16 160.3 14.91 Favored 'General case' 0 C--N 1.287 -2.134 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.211 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 49.3 t -83.63 130.52 35.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.417 ' CG ' ' HB ' ' A' ' 22' ' ' ILE . 20.3 mmmt -87.77 -53.09 4.95 Favored 'General case' 0 CA--C 1.491 -1.3 0 CA-C-O 121.661 0.743 . . . . 0.0 110.266 178.184 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -144.28 160.26 41.3 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 -176.107 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.401 ' O ' ' HB ' ' A' ' 43' ' ' THR . 60.9 t -131.53 86.95 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.473 -1.995 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -178.297 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.52 HG23 ' N ' ' A' ' 44' ' ' GLU 0.257 95.9 m 53.91 -170.5 0.05 Allowed 'General case' 0 CA--C 1.583 2.248 0 O-C-N 124.542 1.151 . . . . 0.0 110.182 179.381 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.52 ' N ' HG23 ' A' ' 43' ' ' THR . 11.8 pt-20 -81.84 -153.37 0.11 Allowed 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 104.887 -2.264 . . . . 0.0 104.887 161.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -93.78 57.41 2.22 Favored Glycine 0 C--N 1.287 -2.176 0 C-N-CA 118.796 -1.668 . . . . 0.0 111.047 177.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.414 ' O ' ' HG2' ' A' ' 50' ' ' ARG . . . -94.33 -160.38 34.41 Favored Glycine 1 N--CA 1.393 -4.215 0 N-CA-C 108.722 -1.751 . . . . 0.0 108.722 173.942 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.453 ' HB2' ' CD ' ' A' ' 12' ' ' LYS . . . -58.67 -17.78 25.37 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 115.114 1.524 . . . . 0.0 115.114 -171.544 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.35 -60.42 2.25 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 179.075 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 44.1 mt-30 -70.64 -24.3 62.69 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.065 -0.516 . . . . 0.0 112.333 176.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.414 ' HG2' ' O ' ' A' ' 46' ' ' GLY . 40.0 mmt180 -69.72 -37.46 76.54 Favored 'General case' 0 CA--C 1.504 -0.806 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.589 174.771 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -59.81 -48.73 80.52 Favored 'General case' 0 C--N 1.352 0.691 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.61 -10.61 36.94 Favored Glycine 0 N--CA 1.439 -1.116 0 N-CA-C 115.286 0.874 . . . . 0.0 115.286 172.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.462 ' O ' ' HD3' ' A' ' 53' ' ' ARG . 0.1 OUTLIER -75.46 -27.77 59.01 Favored 'General case' 0 C--O 1.221 -0.426 0 CA-C-N 118.57 1.185 . . . . 0.0 108.401 -179.782 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.0 tt -97.81 149.29 5.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 177.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 48.2 mt-30 -132.71 170.34 15.38 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-O 121.839 0.828 . . . . 0.0 112.499 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.4 p -83.26 -3.61 7.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.763 -179.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -103.85 15.98 27.42 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 122.6 1.191 . . . . 0.0 108.332 -178.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.416 ' HB3' HG21 ' A' ' 91' ' ' ILE . 68.5 m-20 -93.23 177.9 5.9 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.223 -0.899 . . . . 0.0 112.335 -178.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -136.7 122.46 19.89 Favored 'General case' 0 N--CA 1.416 -2.174 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 47.5 mm -74.11 111.95 10.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 -175.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.701 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 99.4 t -92.12 -51.22 11.77 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-O 121.771 0.796 . . . . 0.0 110.28 -177.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.481 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.4 tt0 -152.04 110.09 3.69 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.33 0.586 . . . . 0.0 111.066 -178.338 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.01 129.08 53.9 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 O-C-N 122.005 -0.434 . . . . 0.0 110.983 177.299 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 18.2 t70 65.11 10.52 6.42 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 124.764 1.226 . . . . 0.0 111.772 174.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.32 19.9 68.11 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.421 -177.428 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 9.7 tt -76.33 -18.96 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 CA-C-O 121.058 0.456 . . . . 0.0 110.357 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.437 ' HB3' ' OE2' ' A' ' 62' ' ' GLU . 31.4 p 48.2 84.96 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 124.875 1.27 . . . . 0.0 112.004 -175.189 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 1.5 pp -97.12 16.92 18.31 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.669 0.747 . . . . 0.0 110.084 -175.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 45.6 t -58.16 97.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.171 174.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.22 53.55 1.0 Allowed Glycine 0 N--CA 1.431 -1.652 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.551 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.6 m -134.32 173.87 13.91 Favored 'Isoleucine or valine' 0 C--O 1.244 0.796 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 176.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 14.5 p -92.45 175.53 6.8 Favored 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 122.873 0.469 . . . . 0.0 110.965 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.414 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -66.38 -31.17 71.77 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.276 -179.36 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -69.56 -36.94 76.77 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 120.783 -0.367 . . . . 0.0 111.166 -179.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.402 ' O ' HG22 ' A' ' 79' ' ' VAL . 44.1 t80 -68.02 -51.15 50.3 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.21 -47.14 86.45 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.036 -0.983 . . . . 0.0 111.693 -177.659 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.22 -37.07 74.12 Favored 'General case' 0 C--O 1.212 -0.9 0 O-C-N 122.94 0.15 . . . . 0.0 110.641 179.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 65.3 m -64.75 -42.75 94.93 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.088 176.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.402 HG22 ' O ' ' A' ' 75' ' ' PHE . 47.8 t -61.12 -51.56 71.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 177.327 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -69.73 -2.34 11.63 Favored 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.448 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 3.4 tmt_? -99.51 -30.09 12.35 Favored 'General case' 0 C--N 1.312 -1.061 0 C-N-CA 123.667 0.787 . . . . 0.0 109.329 175.388 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -86.81 0.19 55.28 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 123.344 0.658 . . . . 0.0 112.004 -177.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.3 p -65.96 148.83 51.18 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.596 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.71 -157.48 0.72 Allowed 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 124.79 1.236 . . . . 0.0 108.587 178.76 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.27 -76.97 0.17 Allowed Glycine 0 C--N 1.315 -0.613 0 O-C-N 123.542 0.527 . . . . 0.0 113.963 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.494 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.3 m-80 -78.79 109.83 13.41 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.329 0.585 . . . . 0.0 111.537 -179.309 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 7.2 t -121.73 131.12 73.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.457 -178.46 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -98.58 98.71 9.84 Favored 'General case' 0 C--N 1.284 -2.271 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 174.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.434 ' CE1' ' HB ' ' A' ' 87' ' ' VAL . 89.8 m-85 -89.42 103.06 15.73 Favored 'General case' 0 CA--C 1.486 -1.481 0 CA-C-N 114.643 -1.162 . . . . 0.0 107.942 177.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.701 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.7 t -89.03 95.39 5.37 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.987 0 N-CA-C 106.6 -1.629 . . . . 0.0 106.6 177.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.416 HG21 ' HB3' ' A' ' 58' ' ' ASP . 96.7 mt -112.4 154.02 13.93 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.682 0 CA-C-N 114.143 -1.39 . . . . 0.0 108.248 176.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -120.91 149.72 17.38 Favored Glycine 0 N--CA 1.416 -2.657 0 C-N-CA 118.946 -1.597 . . . . 0.0 111.507 179.139 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 25.2 tpt180 -121.22 136.8 54.91 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 120.959 0.409 . . . . 0.0 110.859 179.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 . . . . . 0 N--CA 1.424 -1.755 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.171 176.611 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.503 -0.676 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 17.5 t-80 -92.61 10.02 32.27 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 122.858 1.314 . . . . 0.0 108.361 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 25.7 ttt -152.32 120.21 6.16 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 105.028 -2.212 . . . . 0.0 105.028 174.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.475 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 42.1 tt0 -88.22 104.4 16.68 Favored 'General case' 0 C--N 1.289 -2.054 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 -178.324 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -87.09 116.21 25.0 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 174.333 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -132.07 137.19 29.57 Favored Pre-proline 0 N--CA 1.417 -2.113 0 CA-C-O 121.896 0.855 . . . . 0.0 113.237 -173.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -82.31 128.47 5.57 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.972 2.448 . . . . 0.0 112.144 175.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.421 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 38.4 t -118.95 112.92 39.81 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.491 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 174.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.48 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.2 tt0 -96.11 105.2 17.22 Favored 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 176.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.414 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -92.93 143.46 26.23 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -175.02 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -108.34 90.73 3.38 Favored 'General case' 0 C--N 1.291 -1.941 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 174.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.8 mmmp? -87.05 -175.46 5.35 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 113.966 1.099 . . . . 0.0 113.966 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.434 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.2 p-10 -89.32 -172.39 3.61 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 126.285 1.834 . . . . 0.0 111.179 -178.248 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -82.1 -6.44 59.18 Favored 'General case' 0 N--CA 1.465 0.286 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -175.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.434 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 11.3 t70 -82.16 -34.09 29.24 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 122.005 0.907 . . . . 0.0 108.757 176.001 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 121.37 -109.95 1.59 Allowed Glycine 0 N--CA 1.415 -2.735 0 CA-C-N 114.146 -1.388 . . . . 0.0 110.118 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.495 ' HG ' HG22 ' A' ' 19' ' ' ILE . 14.1 tp -117.31 -62.75 1.53 Allowed 'General case' 0 C--N 1.291 -1.939 0 O-C-N 122.341 -0.505 . . . . 0.0 109.878 -177.216 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.56 33.55 55.75 Favored Glycine 0 N--CA 1.434 -1.496 0 O-C-N 124.175 0.922 . . . . 0.0 113.157 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.495 HG22 ' HG ' ' A' ' 17' ' ' LEU . 27.5 pt -101.02 172.6 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 C-N-CA 119.892 -0.723 . . . . 0.0 110.279 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 34.8 m -119.33 145.98 45.69 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -179.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.401 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -122.71 164.38 20.09 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -178.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.6 tt -132.53 132.78 60.09 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 174.361 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.479 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.58 105.73 3.29 Favored Glycine 0 N--CA 1.428 -1.9 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.926 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.464 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 16.7 ptm -143.65 85.22 1.82 Allowed 'General case' 0 C--N 1.291 -1.948 0 CA-C-O 121.585 0.707 . . . . 0.0 110.8 179.264 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.21 112.99 2.58 Favored Glycine 0 C--O 1.24 0.519 0 CA-C-N 114.013 -1.449 . . . . 0.0 113.845 -176.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.3 p -129.17 166.93 25.55 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 105.39 -18.49 41.64 Favored Glycine 0 N--CA 1.435 -1.411 0 C-N-CA 121.165 -0.54 . . . . 0.0 111.916 176.04 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.45 -39.84 74.08 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 120.649 0.261 . . . . 0.0 110.547 -177.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -65.91 -37.08 85.15 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.249 177.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.74 -26.73 66.28 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.998 178.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.78 -8.12 42.68 Favored Glycine 0 N--CA 1.443 -0.871 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.457 179.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.7 mp -84.89 -32.64 23.05 Favored 'General case' 0 C--N 1.312 -1.029 0 O-C-N 122.938 -0.154 . . . . 0.0 111.062 -178.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 57.77 78.46 0.24 Allowed 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 122.146 0.975 . . . . 0.0 110.01 -175.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.0 tptt -100.59 176.63 5.26 Favored 'General case' 0 N--CA 1.405 -2.7 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -175.243 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -77.39 170.63 16.22 Favored 'General case' 0 N--CA 1.414 -2.253 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 170.197 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.464 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -131.67 35.48 2.39 Favored Glycine 0 N--CA 1.414 -2.781 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.039 176.255 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.479 HD13 ' HA2' ' A' ' 23' ' ' GLY . 26.7 mm -94.81 105.72 17.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 C-N-CA 119.405 -0.918 . . . . 0.0 109.547 -179.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -102.17 161.54 13.61 Favored 'General case' 0 C--N 1.276 -2.604 0 CA-C-N 114.721 -1.127 . . . . 0.0 110.191 -179.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 29.0 t -77.5 117.81 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.087 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 176.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 56.3 tptt -84.64 -51.33 6.92 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -178.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -149.51 160.69 43.26 Favored 'General case' 0 N--CA 1.427 -1.61 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 -179.777 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.428 ' HB ' ' OE1' ' A' ' 49' ' ' GLN . 16.8 t -122.75 162.36 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.151 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 178.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.1 t -74.48 141.36 44.94 Favored 'General case' 0 N--CA 1.422 -1.83 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.463 ' HA ' ' NE2' ' A' ' 49' ' ' GLN . 44.3 tt0 -95.91 -31.08 13.29 Favored 'General case' 0 C--N 1.27 -2.864 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -175.247 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -106.09 49.3 0.89 Allowed Glycine 0 CA--C 1.478 -2.273 0 CA-C-N 114.288 -1.324 . . . . 0.0 111.757 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -152.83 150.87 22.73 Favored Glycine 1 N--CA 1.368 -5.863 0 N-CA-C 107.309 -2.317 . . . . 0.0 107.309 178.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.413 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -58.59 0.59 0.07 Allowed 'General case' 0 C--N 1.279 -2.467 0 N-CA-C 115.424 1.638 . . . . 0.0 115.424 -176.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.89 -53.25 10.58 Favored 'General case' 0 N--CA 1.465 0.275 0 O-C-N 121.46 -0.775 . . . . 0.0 109.952 -178.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.463 ' NE2' ' HA ' ' A' ' 44' ' ' GLU . 27.8 mt-30 -78.46 -13.89 59.63 Favored 'General case' 0 CA--C 1.508 -0.66 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.739 176.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.413 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 13.5 mmm180 -74.45 -41.06 61.46 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 174.614 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.436 ' OD1' ' HB2' ' A' ' 53' ' ' ARG . 12.2 t70 -60.29 -59.03 6.06 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.461 177.065 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.4 -9.35 77.79 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 115.03 0.772 . . . . 0.0 115.03 174.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.436 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -69.35 -37.27 77.56 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.545 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.9 tt -81.93 152.33 4.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -178.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 30.3 mt-30 -127.88 161.6 28.69 Favored 'General case' 0 C--N 1.312 -1.061 0 C-N-CA 120.031 -0.668 . . . . 0.0 109.303 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.9 p -89.64 16.82 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 CA-C-O 121.747 0.784 . . . . 0.0 110.531 -177.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -137.59 20.38 2.9 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 122.236 1.017 . . . . 0.0 110.11 -177.021 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -103.72 -175.19 2.73 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.234 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.441 ' O ' HG22 ' A' ' 91' ' ' ILE . 33.6 tt0 -120.68 132.65 55.2 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.132 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.462 ' HA ' HG12 ' A' ' 91' ' ' ILE . 47.2 mm -76.73 101.45 2.91 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.128 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.7 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 81.2 t -80.8 -48.06 19.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 CA-C-O 121.233 0.539 . . . . 0.0 110.571 -175.32 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.426 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 39.5 tt0 -156.64 112.91 3.02 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-O 121.015 0.436 . . . . 0.0 110.639 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.519 ' C ' ' H ' ' A' ' 65' ' ' GLY . 4.8 t -102.26 131.08 51.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.566 175.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.3 t70 73.03 -22.56 0.23 Allowed 'General case' 0 N--CA 1.503 2.22 0 C-N-CA 125.747 1.619 . . . . 0.0 112.975 176.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.519 ' H ' ' C ' ' A' ' 63' ' ' VAL . . . 110.36 12.41 17.4 Favored Glycine 0 C--N 1.274 -2.911 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -173.323 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.3 tt -70.02 -19.51 22.56 Favored 'Isoleucine or valine' 0 C--N 1.344 0.326 0 C-N-CA 122.885 0.474 . . . . 0.0 110.903 -178.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 12.3 p 49.03 81.57 0.05 Allowed 'General case' 0 C--O 1.233 0.19 0 C-N-CA 124.26 1.024 . . . . 0.0 112.88 -176.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.407 ' O ' HG21 ' A' ' 71' ' ' VAL . 0.0 OUTLIER -95.58 30.22 2.36 Favored 'General case' 0 N--CA 1.423 -1.778 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.381 -178.625 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 47.9 t -73.45 97.04 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-N 114.974 -1.012 . . . . 0.0 109.585 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 108.26 33.07 3.05 Favored Glycine 0 C--N 1.294 -1.799 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 176.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.407 HG21 ' O ' ' A' ' 68' ' ' LEU . 19.7 m -109.39 174.53 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 119.917 -0.713 . . . . 0.0 111.461 -178.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 22.2 p -91.29 172.82 8.27 Favored 'General case' 0 N--CA 1.418 -2.049 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.794 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.401 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -66.97 -32.01 72.96 Favored 'General case' 0 C--O 1.204 -1.293 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.018 -179.682 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -71.44 -31.6 67.39 Favored 'General case' 0 CA--C 1.516 -0.362 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.82 -178.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -70.38 -51.67 28.03 Favored 'General case' 0 N--CA 1.443 -0.819 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 177.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.408 ' CB ' HG23 ' A' ' 37' ' ' ILE . . . -62.56 -42.16 99.37 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.031 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.09 -11.4 48.52 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 121.23 0.538 . . . . 0.0 111.102 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 58.0 m -89.75 -47.13 8.12 Favored 'General case' 0 N--CA 1.415 -2.204 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.862 174.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.488 ' O ' HG22 ' A' ' 83' ' ' THR . 31.4 t -61.86 -54.27 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -68.41 0.42 3.96 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.617 0.767 . . . . 0.0 112.716 -178.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -104.07 -45.95 4.59 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 174.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 -80.83 7.36 10.64 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 114.405 -1.27 . . . . 0.0 113.142 -173.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.488 HG22 ' O ' ' A' ' 79' ' ' VAL . 1.7 p -60.45 154.22 21.18 Favored 'General case' 0 C--N 1.29 -2.013 0 C-N-CA 124.854 1.261 . . . . 0.0 111.405 175.047 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 31.8 mmtp -111.51 -164.91 0.95 Allowed 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.061 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.32 -67.59 2.12 Favored Glycine 0 N--CA 1.439 -1.152 0 O-C-N 123.657 0.598 . . . . 0.0 112.886 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.414 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 15.6 m120 -82.52 117.07 22.25 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.2 t -125.04 127.79 72.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.453 -177.326 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -91.68 104.33 16.8 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-O 120.877 0.37 . . . . 0.0 110.169 172.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.421 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.7 m-85 -95.6 103.99 15.88 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 175.234 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.7 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 47.7 t -92.85 91.48 3.37 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.921 0 N-CA-C 104.781 -2.303 . . . . 0.0 104.781 174.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.462 HG12 ' HA ' ' A' ' 60' ' ' ILE . 74.8 mt -108.0 157.05 8.33 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.09 178.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -131.78 143.66 15.22 Favored Glycine 0 N--CA 1.397 -3.913 0 C-N-CA 119.404 -1.379 . . . . 0.0 111.093 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.443 ' C ' ' HD2' ' A' ' 93' ' ' ARG . 5.2 tmm_? -108.22 128.47 54.75 Favored 'General case' 0 C--N 1.291 -1.97 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -178.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 . . . . . 0 C--N 1.311 -1.095 0 O-C-N 123.353 0.408 . . . . 0.0 110.459 178.961 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.576 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 53.1 t-80 -128.91 127.22 41.35 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 117.351 0.576 . . . . 0.0 110.365 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 44.0 ttp -91.6 128.66 37.52 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.012 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -88.3 109.43 19.95 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -179.168 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -91.72 127.87 37.34 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.761 -1.199 . . . . 0.0 107.761 173.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.488 ' O ' ' HA ' ' A' ' 90' ' ' VAL . 20.9 p90 -133.21 137.59 29.67 Favored Pre-proline 0 C--N 1.283 -2.295 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -175.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -84.21 121.67 2.75 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 123.472 2.781 . . . . 0.0 112.146 176.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 35.8 t -112.17 98.47 7.07 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.048 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 175.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.614 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 31.6 tt0 -83.8 101.54 11.69 Favored 'General case' 0 N--CA 1.421 -1.899 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 176.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -93.23 133.67 36.21 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 -175.948 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -101.15 92.98 5.23 Favored 'General case' 0 N--CA 1.419 -2.016 0 CA-C-O 121.995 0.903 . . . . 0.0 109.282 175.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.561 ' CD ' ' HB2' ' A' ' 47' ' ' ALA . 2.0 mmmp? -92.95 -175.45 3.89 Favored 'General case' 0 N--CA 1.421 -1.921 0 CA-C-N 114.302 -1.317 . . . . 0.0 113.218 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.459 ' OD1' ' HB3' ' A' ' 15' ' ' ASP . 1.7 p30 -77.31 176.62 8.63 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-N 112.784 -2.007 . . . . 0.0 110.743 178.063 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -82.94 -6.65 59.56 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.612 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.459 ' HB3' ' OD1' ' A' ' 13' ' ' ASP . 9.6 t70 -81.77 -41.94 20.45 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 175.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.32 -123.26 2.6 Favored Glycine 0 N--CA 1.42 -2.381 0 C-N-CA 120.136 -1.031 . . . . 0.0 112.909 175.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 mt -108.36 -45.1 3.97 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 122.211 -0.582 . . . . 0.0 110.569 -172.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.67 28.45 70.89 Favored Glycine 0 N--CA 1.426 -2.014 0 O-C-N 124.336 1.023 . . . . 0.0 110.663 -174.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 20.4 pt -106.38 -176.95 0.58 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.293 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.797 -178.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.3 m -144.22 151.86 40.05 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.475 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.6 pp -125.0 162.67 26.84 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -178.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 12.1 tt -134.59 130.42 53.3 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.833 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 176.703 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.467 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -98.01 104.92 3.05 Favored Glycine 0 CA--C 1.481 -2.034 0 C-N-CA 120.357 -0.925 . . . . 0.0 111.744 -178.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.485 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 18.4 ptm -147.16 96.41 2.72 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 120.643 0.258 . . . . 0.0 111.562 -179.469 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.36 107.69 0.55 Allowed Glycine 0 C--O 1.243 0.704 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.315 -178.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -74.69 88.44 0.63 Allowed 'Isoleucine or valine' 0 C--O 1.252 1.201 0 N-CA-C 114.039 1.126 . . . . 0.0 114.039 -174.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 74.54 -71.96 1.53 Allowed Glycine 0 N--CA 1.439 -1.136 0 CA-C-N 114.376 -1.284 . . . . 0.0 115.926 171.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . 64.06 26.23 13.97 Favored 'General case' 0 C--N 1.35 0.597 0 CA-C-O 122.651 1.215 . . . . 0.0 107.979 -171.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -104.16 -42.45 5.52 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 113.775 -1.557 . . . . 0.0 111.594 -173.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.32 -29.7 70.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.897 -177.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.57 -20.29 10.25 Favored Glycine 0 CA--C 1.498 -1.011 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.78 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.2 mp -67.81 -47.14 69.88 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 53.66 72.84 0.41 Allowed 'General case' 0 C--O 1.247 0.955 0 C-N-CA 124.379 1.072 . . . . 0.0 112.081 174.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.2 ptpt -109.84 177.65 4.66 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 178.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.465 ' HB3' ' N ' ' A' ' 70' ' ' GLY . 1.8 pt? -56.0 170.9 0.28 Allowed 'General case' 0 C--N 1.305 -1.346 0 CA-C-O 122.254 1.026 . . . . 0.0 111.985 173.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -131.66 32.04 2.99 Favored Glycine 0 N--CA 1.41 -3.076 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.873 175.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.553 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 23.8 mm -90.1 98.61 8.41 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 119.778 -0.769 . . . . 0.0 109.098 178.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -96.98 162.5 13.37 Favored 'General case' 0 C--N 1.273 -2.744 0 CA-C-N 115.047 -0.979 . . . . 0.0 108.914 -178.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 40.9 t -79.71 122.71 35.44 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.537 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -81.15 -49.92 10.24 Favored 'General case' 0 C--N 1.293 -1.86 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.331 -177.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -154.31 161.23 41.89 Favored 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 -178.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 51.0 t -136.25 147.54 27.88 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 N-CA-C 105.415 -2.068 . . . . 0.0 105.415 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.2 t -54.48 132.88 45.5 Favored 'General case' 0 C--O 1.257 1.465 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 173.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 16.5 tp10 -55.4 -58.34 8.15 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 124.759 1.223 . . . . 0.0 111.218 -172.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -144.36 39.36 1.24 Allowed Glycine 0 N--CA 1.421 -2.315 0 C-N-CA 120.094 -1.051 . . . . 0.0 112.744 179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -63.39 -48.21 80.64 Favored Glycine 0 C--O 1.221 -0.667 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 175.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.561 ' HB2' ' CD ' ' A' ' 12' ' ' LYS . . . 170.44 -25.61 0.0 OUTLIER 'General case' 0 C--O 1.197 -1.704 0 C-N-CA 124.999 1.32 . . . . 0.0 109.797 177.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.42 -54.74 27.94 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.239 0.542 . . . . 0.0 110.662 -176.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 42.8 mt-30 -76.45 -7.79 55.81 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.772 178.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -90.44 -23.29 21.06 Favored 'General case' 0 N--CA 1.437 -1.085 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.12 176.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -61.01 -54.9 39.17 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 170.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 105.3 -26.55 21.46 Favored Glycine 0 N--CA 1.432 -1.576 0 CA-C-N 115.164 -0.925 . . . . 0.0 114.746 174.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -72.93 -31.5 64.66 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 118.446 1.123 . . . . 0.0 109.666 -176.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.9 tt -97.09 146.96 6.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -179.193 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . 0.421 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 97.0 mt-30 -136.57 162.52 32.9 Favored 'General case' 0 N--CA 1.436 -1.13 0 CA-C-O 121.331 0.586 . . . . 0.0 110.945 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.4 p -75.71 -15.34 15.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 C-N-CA 124.085 0.954 . . . . 0.0 111.298 -178.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -95.06 9.84 38.01 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.455 0.645 . . . . 0.0 111.557 -175.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.421 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 39.9 m-20 -97.84 -172.68 2.43 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.691 -177.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.553 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.6 tt0 -134.91 133.21 39.38 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.836 -177.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.408 ' HA ' HG12 ' A' ' 91' ' ' ILE . 44.1 mm -78.4 115.15 20.04 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.001 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 -177.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.64 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.2 t -94.49 -51.8 10.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-O 121.679 0.752 . . . . 0.0 110.552 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.536 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 21.4 tt0 -147.55 110.01 4.62 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.92 -177.427 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.5 t -103.39 126.54 57.78 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 O-C-N 122.018 -0.427 . . . . 0.0 110.204 175.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.5 t70 62.19 17.52 9.29 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 124.452 1.101 . . . . 0.0 112.215 174.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 83.09 8.75 85.15 Favored Glycine 0 N--CA 1.442 -0.915 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.975 -179.214 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.7 tt -75.25 -16.62 15.91 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 O-C-N 122.571 -0.37 . . . . 0.0 110.845 -176.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 31.3 m 49.09 79.71 0.07 Allowed 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 124.876 1.27 . . . . 0.0 112.706 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.498 ' O ' HG23 ' A' ' 71' ' ' VAL . 2.3 pp -96.16 11.73 33.32 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 122.322 1.058 . . . . 0.0 110.074 -175.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.427 HG21 HD21 ' A' ' 35' ' ' LEU . 5.2 p -58.11 92.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.294 -1.841 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.497 173.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . 0.465 ' N ' ' HB3' ' A' ' 35' ' ' LEU . . . 113.79 21.42 5.71 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.829 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 68' ' ' LEU . 20.4 m -103.48 176.97 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 O-C-N 121.978 -0.719 . . . . 0.0 110.965 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.3 p -93.7 171.71 8.71 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.026 177.034 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.475 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -64.78 -28.83 69.84 Favored 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.775 -176.337 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.82 -30.49 66.94 Favored 'General case' 0 CA--C 1.512 -0.492 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.358 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.432 ' O ' HG21 ' A' ' 79' ' ' VAL . 31.2 t80 -77.32 -52.01 9.91 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 177.686 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -56.25 -50.12 72.23 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.274 -0.876 . . . . 0.0 112.364 -177.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.15 -36.41 75.21 Favored 'General case' 0 C--O 1.214 -0.786 0 CA-C-O 120.505 0.193 . . . . 0.0 110.796 -179.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 84.0 m -62.88 -42.75 99.88 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.301 177.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.432 HG21 ' O ' ' A' ' 75' ' ' PHE . 31.6 t -64.27 -51.78 64.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 178.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -63.58 -18.28 63.72 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.841 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.13 -26.44 23.62 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 123.276 0.631 . . . . 0.0 110.32 174.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -88.67 6.17 39.68 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-O 121.48 0.657 . . . . 0.0 112.251 -178.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 36.4 p -74.89 -178.2 3.64 Favored 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.043 177.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.18 -163.0 1.52 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.166 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -49.25 -73.3 0.37 Allowed Glycine 0 CA--C 1.531 1.036 0 O-C-N 123.884 0.74 . . . . 0.0 114.49 178.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.464 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 19.0 m120 -82.99 104.74 13.42 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 117.667 0.734 . . . . 0.0 111.628 -178.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.614 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -114.71 137.51 47.89 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.503 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 90.6 mtt180 -99.64 99.04 9.83 Favored 'General case' 0 C--N 1.283 -2.304 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.476 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 91.9 m-85 -92.2 101.45 13.96 Favored 'General case' 0 CA--C 1.489 -1.386 0 CA-C-N 114.895 -1.048 . . . . 0.0 108.555 177.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.64 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 60.8 t -92.32 94.76 4.96 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.89 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.498 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.463 HG23 ' O ' ' A' ' 59' ' ' GLN . 90.6 mt -106.3 163.19 4.92 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.929 0 CA-C-N 114.104 -1.407 . . . . 0.0 108.543 178.532 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -139.07 161.23 25.94 Favored Glycine 0 N--CA 1.412 -2.912 0 C-N-CA 119.489 -1.338 . . . . 0.0 112.162 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 37.0 ttp-105 -142.58 144.17 32.76 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 . . . . . 0 C--N 1.302 -1.485 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 176.291 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.5 -0.902 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 58.2 m80 -93.99 94.83 8.67 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 26.6 ttt -84.05 111.82 19.64 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 119.003 -1.079 . . . . 0.0 108.964 176.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -95.66 117.38 30.38 Favored 'General case' 0 C--N 1.287 -2.115 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 -179.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -93.1 127.55 38.68 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 175.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 19.6 p90 -137.25 141.34 33.79 Favored Pre-proline 0 C--N 1.297 -1.684 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -175.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -82.24 123.9 4.1 Favored 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 122.76 2.307 . . . . 0.0 112.21 177.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 38.9 t -109.44 95.99 4.29 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.688 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 174.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 29.7 tt0 -83.37 102.72 12.21 Favored 'General case' 0 N--CA 1.423 -1.825 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -98.44 140.43 32.7 Favored 'General case' 0 N--CA 1.411 -2.386 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 -175.025 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -108.86 95.74 5.85 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 173.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.9 mmmp? -84.72 174.21 10.09 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 114.381 1.252 . . . . 0.0 114.381 -178.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -92.12 179.91 5.45 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 112.714 -2.039 . . . . 0.0 111.032 -176.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -68.81 -15.51 63.52 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -173.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -77.3 -28.03 53.17 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 121.572 0.701 . . . . 0.0 109.411 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.12 -125.62 6.61 Favored Glycine 0 CA--C 1.482 -1.997 0 N-CA-C 108.513 -1.835 . . . . 0.0 108.513 -179.275 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt -103.79 -50.24 3.46 Favored 'General case' 0 CA--C 1.483 -1.609 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 176.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.94 27.33 64.77 Favored Glycine 0 N--CA 1.434 -1.491 0 O-C-N 124.642 1.214 . . . . 0.0 110.773 -176.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 21.6 pt -102.54 -179.51 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.817 -177.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.3 t -138.72 153.23 48.49 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -178.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.474 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.6 pp -125.75 163.43 27.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -177.304 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.51 ' HB ' ' HG2' ' A' ' 40' ' ' LYS . 11.3 tt -130.96 132.69 63.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-O 120.536 0.208 . . . . 0.0 110.686 174.503 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.477 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -93.15 103.83 3.1 Favored Glycine 0 N--CA 1.426 -1.978 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.5 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.415 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 16.5 ptm -143.94 91.3 2.21 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 178.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -51.82 109.98 0.98 Allowed Glycine 0 C--N 1.34 0.799 0 CA-C-N 114.184 -1.371 . . . . 0.0 113.018 -177.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -135.3 164.12 34.06 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.922 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -175.155 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 81.17 59.51 2.41 Favored Glycine 0 N--CA 1.432 -1.58 0 C-N-CA 121.22 -0.514 . . . . 0.0 113.381 173.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -109.04 -1.74 18.68 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 174.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -59.71 -41.2 90.26 Favored 'General case' 0 C--N 1.312 -1.023 0 C-N-CA 126.151 1.78 . . . . 0.0 111.909 -172.199 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.64 3.7 55.08 Favored 'General case' 0 C--N 1.31 -1.141 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.402 -178.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 89.83 8.79 66.91 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.831 -0.7 . . . . 0.0 114.02 177.025 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -90.77 -44.22 9.59 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 117.791 0.795 . . . . 0.0 113.057 -178.271 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 61.55 84.35 0.14 Allowed 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -171.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -96.38 -173.91 2.91 Favored 'General case' 0 N--CA 1.422 -1.865 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.266 -171.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.6 pp -64.95 146.35 55.1 Favored 'General case' 0 C--N 1.296 -1.735 0 CA-C-N 114.996 -1.002 . . . . 0.0 109.054 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.415 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -118.79 30.88 5.74 Favored Glycine 0 N--CA 1.417 -2.583 0 C-N-CA 119.684 -1.246 . . . . 0.0 110.303 176.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.477 HD11 ' HA2' ' A' ' 23' ' ' GLY . 30.3 mm -91.95 100.97 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.868 0 CA-C-O 121.553 0.692 . . . . 0.0 110.998 -176.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.404 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 96.2 m-85 -96.98 165.0 12.29 Favored 'General case' 0 C--N 1.285 -2.209 0 CA-C-N 115.075 -0.966 . . . . 0.0 108.532 177.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 47.1 t -81.41 128.17 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.14 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.51 ' HG2' ' HB ' ' A' ' 22' ' ' ILE . 15.9 mmmt -85.36 -57.34 3.11 Favored 'General case' 0 CA--C 1.473 -2.015 0 CA-C-O 121.567 0.698 . . . . 0.0 109.332 177.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.48 163.6 34.19 Favored 'General case' 0 C--N 1.291 -1.978 0 CA-C-N 114.241 -1.345 . . . . 0.0 107.789 -176.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 86.6 t -129.68 157.26 42.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.23 0 N-CA-C 104.9 -2.259 . . . . 0.0 104.9 174.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 14.9 t -61.54 150.9 34.59 Favored 'General case' 0 N--CA 1.435 -1.193 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 175.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -54.44 -30.99 54.4 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -172.06 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -149.74 -62.08 0.01 OUTLIER Glycine 0 N--CA 1.417 -2.573 0 C-N-CA 119.653 -1.26 . . . . 0.0 111.769 174.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 43.24 -103.99 0.05 OUTLIER Glycine 0 CA--C 1.477 -2.324 0 C-N-CA 125.325 1.441 . . . . 0.0 110.095 -170.096 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -141.1 6.35 1.96 Allowed 'General case' 0 C--N 1.257 -3.419 0 CA-C-N 113.083 -1.559 . . . . 0.0 108.646 173.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -95.1 -55.8 2.95 Favored 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 115.795 -0.638 . . . . 0.0 109.608 -175.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -79.08 -16.19 57.1 Favored 'General case' 0 N--CA 1.438 -1.044 0 C-N-CA 119.301 -0.96 . . . . 0.0 110.037 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 36.0 mmt180 -78.43 -25.32 45.95 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.55 171.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -70.91 -61.0 1.92 Allowed 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 172.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.77 2.07 84.67 Favored Glycine 0 N--CA 1.437 -1.247 0 N-CA-C 115.055 0.782 . . . . 0.0 115.055 173.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -85.23 -36.37 20.99 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 176.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.6 tt -88.04 146.71 5.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -128.71 177.56 6.97 Favored 'General case' 0 N--CA 1.431 -1.377 0 C-N-CA 120.163 -0.615 . . . . 0.0 111.406 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 5.2 t -90.47 -9.99 10.29 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.774 0 CA-C-O 121.936 0.874 . . . . 0.0 109.46 -175.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -103.56 7.56 37.67 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.699 -176.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -83.25 -177.93 6.91 Favored 'General case' 0 C--O 1.247 0.954 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.537 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.422 ' O ' HG21 ' A' ' 91' ' ' ILE . 63.9 tt0 -133.32 128.3 35.41 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-N 115.112 -0.949 . . . . 0.0 108.746 -177.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 49.4 mm -76.83 109.99 11.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -176.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.664 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 88.1 t -92.64 -47.66 13.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 CA-C-O 121.242 0.544 . . . . 0.0 111.137 -176.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.477 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 38.7 tt0 -155.2 102.17 2.28 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-O 121.623 0.725 . . . . 0.0 110.541 -178.456 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.8 t -94.61 129.3 45.02 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 O-C-N 121.921 -0.487 . . . . 0.0 111.089 177.095 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 38.5 t70 65.32 11.72 7.52 Favored 'General case' 0 N--CA 1.487 1.394 0 CA-C-O 122.234 1.016 . . . . 0.0 111.55 172.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.35 15.47 78.31 Favored Glycine 0 N--CA 1.441 -1.026 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.084 -178.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.2 tt -76.41 -20.53 15.07 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.798 0 CA-C-O 121.215 0.531 . . . . 0.0 110.683 -177.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . 0.267 13.1 p 47.97 76.48 0.11 Allowed 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 124.708 1.203 . . . . 0.0 113.879 -177.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.443 ' O ' HG21 ' A' ' 71' ' ' VAL . 0.0 OUTLIER -88.9 32.2 0.82 Allowed 'General case' 0 N--CA 1.432 -1.367 0 CA-C-N 114.432 -1.258 . . . . 0.0 111.287 -177.063 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 46.3 t -69.69 95.81 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 CA-C-N 114.799 -1.092 . . . . 0.0 110.385 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 105.44 19.74 10.24 Favored Glycine 0 C--N 1.31 -0.901 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.574 176.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.443 HG21 ' O ' ' A' ' 68' ' ' LEU . 23.9 m -93.1 179.21 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 177.496 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.9 p -94.54 171.0 9.07 Favored 'General case' 0 N--CA 1.416 -2.163 0 CA-C-O 121.221 0.534 . . . . 0.0 110.349 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.474 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.17 -34.64 70.53 Favored 'General case' 0 C--N 1.294 -1.814 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.916 178.126 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.27 -36.97 74.75 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.332 -178.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.469 ' O ' HG23 ' A' ' 79' ' ' VAL . 45.9 t80 -66.99 -49.42 65.41 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.48 -45.58 93.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.758 -179.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -64.11 -16.84 62.67 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 120.915 0.388 . . . . 0.0 111.425 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 66.3 m -85.93 -44.81 12.08 Favored 'General case' 0 N--CA 1.426 -1.631 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.625 174.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 75' ' ' PHE . 47.1 t -58.11 -51.5 70.15 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.627 0 N-CA-C 110.091 -0.336 . . . . 0.0 110.091 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -70.24 3.21 3.01 Favored 'General case' 0 CA--C 1.556 1.194 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.769 179.08 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 1.3 tmt_? -114.95 -17.76 11.43 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 123.373 0.669 . . . . 0.0 109.682 177.186 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -92.0 -7.46 48.83 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.279 0.632 . . . . 0.0 110.319 177.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.442 HG21 ' O ' ' A' ' 79' ' ' VAL . 2.5 p -64.5 161.48 17.21 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 115.061 -0.972 . . . . 0.0 113.444 -177.58 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 43.5 mmtm -113.42 -163.41 0.86 Allowed 'General case' 0 C--N 1.293 -1.875 0 CA-C-N 114.434 -1.257 . . . . 0.0 109.282 -178.066 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.87 -60.4 6.14 Favored Glycine 0 N--CA 1.424 -2.113 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 171.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -76.39 106.93 8.31 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-O 121.2 0.524 . . . . 0.0 110.168 177.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.0 t -121.87 132.36 71.05 Favored 'Isoleucine or valine' 0 CA--C 1.484 -1.571 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 -178.005 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 79.5 mtt180 -102.42 96.77 7.15 Favored 'General case' 0 C--N 1.283 -2.314 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 173.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -87.35 102.53 14.61 Favored 'General case' 0 CA--C 1.491 -1.312 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 177.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.664 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.1 t -90.99 90.87 3.42 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.625 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 177.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.422 HG21 ' O ' ' A' ' 59' ' ' GLN . 86.2 mt -104.12 156.49 5.64 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.689 0 CA-C-N 114.248 -1.342 . . . . 0.0 108.189 179.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.65 166.81 22.89 Favored Glycine 0 N--CA 1.406 -3.344 0 C-N-CA 119.42 -1.371 . . . . 0.0 110.926 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 46.1 ttp180 -142.59 141.32 31.95 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 . . . . . 0 N--CA 1.431 -1.414 0 N-CA-C 106.087 -1.82 . . . . 0.0 106.087 170.204 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.503 -0.718 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 72.3 m-70 -103.54 104.16 14.19 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 117.228 0.514 . . . . 0.0 110.761 179.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 57.3 tpp -119.91 134.13 55.34 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -104.71 111.43 24.14 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -90.11 136.12 33.24 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 20.8 p90 -145.99 140.63 15.76 Favored Pre-proline 0 C--N 1.303 -1.421 0 CA-C-O 121.079 0.466 . . . . 0.0 112.141 -178.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -81.4 126.58 5.51 Favored 'Trans proline' 0 C--O 1.248 1.022 0 C-N-CA 123.29 2.66 . . . . 0.0 113.081 177.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 26.2 t -120.83 102.87 13.01 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 175.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.54 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 37.4 tt0 -84.24 105.98 15.5 Favored 'General case' 0 N--CA 1.427 -1.592 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.633 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 12.9 tp -89.91 155.08 19.37 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 -174.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -120.29 93.05 3.92 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 175.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -89.65 176.16 6.97 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 115.278 1.584 . . . . 0.0 115.278 -179.304 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -77.25 168.33 20.23 Favored 'General case' 0 N--CA 1.428 -1.547 0 CA-C-N 111.934 -2.393 . . . . 0.0 107.435 -179.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -74.01 -10.48 59.68 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-O 121.217 0.532 . . . . 0.0 110.967 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -63.55 -33.16 74.97 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 172.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.4 -130.87 9.08 Favored Glycine 0 N--CA 1.413 -2.897 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 13.7 tp -103.5 -61.51 1.41 Allowed 'General case' 0 C--N 1.285 -2.219 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 -177.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.445 ' O ' ' HB ' ' A' ' 43' ' ' THR . . . 71.32 37.85 62.88 Favored Glycine 0 N--CA 1.429 -1.786 0 O-C-N 124.284 0.99 . . . . 0.0 112.854 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 15.5 pt -107.95 167.51 3.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 118.949 -1.101 . . . . 0.0 111.435 176.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.3 m -117.08 148.54 41.43 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 -177.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.422 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -125.41 166.34 21.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -177.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.432 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 11.9 tt -130.35 132.15 65.03 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.877 0 C-N-CA 120.701 -0.4 . . . . 0.0 110.575 175.706 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.445 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -89.61 95.77 2.13 Favored Glycine 0 N--CA 1.424 -2.14 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.589 -178.58 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 95.1 mmm -109.3 173.72 6.19 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 176.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -130.31 61.74 0.66 Allowed Glycine 0 C--N 1.292 -1.916 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 177.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.7 p -69.17 133.4 31.93 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.394 0.616 . . . . 0.0 110.246 -177.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 78.06 0.45 76.35 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 115.848 -0.615 . . . . 0.0 113.277 178.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.49 -58.64 3.22 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 117.733 0.766 . . . . 0.0 110.517 -178.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -66.46 -29.96 70.2 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.515 178.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.64 -31.41 72.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.471 178.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 119.26 5.57 11.4 Favored Glycine 0 C--O 1.239 0.431 0 C-N-CA 119.389 -1.386 . . . . 0.0 114.851 176.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 4.4 mp -92.51 -47.82 6.94 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 117.386 0.593 . . . . 0.0 109.949 -178.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 60.01 82.86 0.15 Allowed 'General case' 0 C--O 1.248 1.001 0 C-N-CA 124.446 1.098 . . . . 0.0 111.081 -172.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 26.2 ttmt -128.41 176.26 7.86 Favored 'General case' 0 N--CA 1.385 -3.71 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 178.085 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -68.74 147.65 51.5 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 120.806 0.336 . . . . 0.0 110.153 -178.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -124.07 25.13 6.15 Favored Glycine 0 N--CA 1.414 -2.771 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 174.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.445 HD11 ' HA2' ' A' ' 23' ' ' GLY . 33.4 mm -85.02 100.71 8.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 121.525 0.679 . . . . 0.0 109.524 -179.809 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -97.43 164.39 12.47 Favored 'General case' 0 C--N 1.278 -2.502 0 CA-C-N 115.252 -0.885 . . . . 0.0 108.917 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.556 ' HB ' ' O ' ' A' ' 56' ' ' VAL . 39.7 t -78.83 127.98 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.19 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 176.2 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 55.6 tptt -89.13 -44.13 10.55 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -178.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -161.18 162.82 31.42 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 89.1 t -127.35 152.52 35.49 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.167 0 N-CA-C 106.223 -1.769 . . . . 0.0 106.223 178.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.445 ' HB ' ' O ' ' A' ' 18' ' ' GLY . 10.6 t -63.6 143.63 57.67 Favored 'General case' 0 N--CA 1.428 -1.557 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.648 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.596 ' HA ' ' NE2' ' A' ' 49' ' ' GLN . 34.7 tt0 -79.54 -52.44 8.01 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -176.269 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -104.29 64.61 0.34 Allowed Glycine 0 CA--C 1.455 -3.707 0 CA-C-N 114.556 -1.202 . . . . 0.0 110.889 -178.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -145.33 148.51 20.3 Favored Glycine 1 N--CA 1.366 -6.002 0 N-CA-C 105.569 -3.012 . . . . 0.0 105.569 172.589 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.434 ' HA ' ' CG ' ' A' ' 50' ' ' ARG . . . -58.73 0.87 0.07 Allowed 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 115.542 1.682 . . . . 0.0 115.542 -175.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.97 -50.38 16.86 Favored 'General case' 0 C--O 1.215 -0.728 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.596 ' NE2' ' HA ' ' A' ' 44' ' ' GLU . 27.7 mt-30 -80.54 -3.59 50.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 120.285 -0.566 . . . . 0.0 111.101 176.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.434 ' CG ' ' HA ' ' A' ' 47' ' ' ALA . 36.1 mmt180 -82.65 -39.09 22.56 Favored 'General case' 0 CA--C 1.507 -0.691 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 171.283 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -53.83 -60.42 3.35 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 114.856 -1.065 . . . . 0.0 112.088 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.48 -17.56 56.55 Favored Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 120.316 -0.945 . . . . 0.0 114.353 175.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.408 ' HE ' ' C ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -88.69 -46.77 8.75 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.68 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.0 tt -73.67 145.13 11.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . 0.416 ' HB2' ' OD1' ' A' ' 58' ' ' ASP . 35.6 mt-30 -138.79 -172.66 3.36 Favored 'General case' 0 C--N 1.316 -0.868 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.843 -176.26 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.556 ' O ' ' HB ' ' A' ' 39' ' ' VAL . 49.0 t -93.22 -34.55 5.94 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.104 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.413 -178.258 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -92.24 20.67 5.79 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -174.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.416 ' OD1' ' HB2' ' A' ' 55' ' ' GLN . 4.2 m-20 -101.75 -172.9 2.23 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.967 177.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.461 ' O ' HG23 ' A' ' 91' ' ' ILE . 63.7 tt0 -128.54 126.51 40.52 Favored 'General case' 0 C--N 1.313 -0.995 0 O-C-N 122.089 -0.382 . . . . 0.0 111.328 -175.137 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.489 ' HA ' HG12 ' A' ' 91' ' ' ILE . 48.2 mm -74.93 104.36 3.27 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.016 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.735 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.2 t -91.41 -50.15 12.85 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-O 121.694 0.759 . . . . 0.0 111.315 -175.166 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.481 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 32.1 tt0 -149.0 105.74 3.56 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.398 0.618 . . . . 0.0 110.226 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.424 ' C ' ' H ' ' A' ' 65' ' ' GLY . 3.0 t -98.02 126.98 50.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.146 177.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 26.9 t70 71.42 -9.96 0.86 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 125.599 1.56 . . . . 0.0 112.702 173.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.424 ' H ' ' C ' ' A' ' 63' ' ' VAL . . . 103.61 12.96 29.21 Favored Glycine 0 N--CA 1.424 -2.151 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.126 -175.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 11.0 tt -72.98 -18.07 18.24 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-O 121.077 0.465 . . . . 0.0 111.198 -178.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.402 ' HB3' ' OE2' ' A' ' 62' ' ' GLU . 29.6 p 50.87 81.41 0.07 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.985 1.314 . . . . 0.0 112.92 -175.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.44 ' O ' HG23 ' A' ' 71' ' ' VAL . 1.8 pp -96.12 14.91 22.33 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-O 122.092 0.948 . . . . 0.0 109.94 -176.114 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 61.2 t -57.62 98.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.427 174.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.51 35.03 3.68 Favored Glycine 0 N--CA 1.438 -1.223 0 CA-C-N 115.54 -0.754 . . . . 0.0 112.457 176.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.44 HG23 ' O ' ' A' ' 68' ' ' LEU . 20.6 m -115.02 177.55 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 117.14 0.47 . . . . 0.0 111.221 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 12.9 p -91.31 172.56 8.45 Favored 'General case' 0 N--CA 1.433 -1.318 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.605 178.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.422 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -65.37 -32.04 73.47 Favored 'General case' 0 C--O 1.205 -1.24 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.232 -178.638 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -71.58 -35.4 70.53 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 120.861 -0.336 . . . . 0.0 110.985 -178.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.462 ' O ' HG21 ' A' ' 79' ' ' VAL . 29.7 t80 -65.86 -52.19 52.39 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 176.472 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.83 -46.27 89.79 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.135 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.04 -33.96 69.56 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.795 0.331 . . . . 0.0 110.73 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 97.8 m -68.07 -45.57 73.46 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.069 176.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.462 HG21 ' O ' ' A' ' 75' ' ' PHE . 32.7 t -61.56 -51.85 67.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 C-N-CA 122.632 0.373 . . . . 0.0 110.902 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -68.52 -4.57 15.59 Favored 'General case' 0 CA--C 1.542 0.65 0 CA-C-O 121.237 0.541 . . . . 0.0 112.364 -179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.41 ' HD3' ' C ' ' A' ' 81' ' ' ARG . 0.7 OUTLIER -99.73 -32.52 11.0 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.218 0.533 . . . . 0.0 109.796 172.868 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 8.7 m-80 -80.13 6.68 10.99 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 121.794 0.807 . . . . 0.0 111.856 -178.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.0 p -70.61 170.21 12.69 Favored 'General case' 0 N--CA 1.408 -2.551 0 CA-C-N 114.536 -1.211 . . . . 0.0 111.562 175.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.445 ' HE3' ' O ' ' A' ' 86' ' ' ASN . 0.0 OUTLIER -147.81 -161.3 1.31 Allowed 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 124.898 1.279 . . . . 0.0 107.831 -175.036 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -55.88 -75.15 0.26 Allowed Glycine 0 CA--C 1.525 0.696 0 O-C-N 123.524 0.515 . . . . 0.0 114.016 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.633 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.5 m120 -88.79 105.93 18.03 Favored 'General case' 0 CA--C 1.497 -1.061 0 CA-C-N 117.637 0.718 . . . . 0.0 111.482 -177.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.9 t -116.22 136.29 53.68 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.09 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.994 -175.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 46.8 mtp180 -92.89 99.97 12.52 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 175.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.486 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 97.3 m-85 -92.38 103.26 15.72 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 176.597 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.735 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 40.3 t -92.45 86.52 2.28 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.858 0 N-CA-C 104.984 -2.228 . . . . 0.0 104.984 175.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.489 HG12 ' HA ' ' A' ' 60' ' ' ILE . 64.1 mt -101.25 159.11 4.05 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 CA-C-N 113.989 -1.46 . . . . 0.0 109.174 -179.2 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -130.61 158.04 22.36 Favored Glycine 1 N--CA 1.385 -4.724 0 C-N-CA 119.85 -1.167 . . . . 0.0 110.329 176.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 4.9 tpp180 -133.31 138.79 46.54 Favored 'General case' 0 C--N 1.286 -2.154 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 . . . . . 0 N--CA 1.416 -2.167 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.051 174.098 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.289 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 39.6 m-70 69.53 102.64 0.06 Allowed 'General case' 0 CA--C 1.503 -0.844 0 C-N-CA 124.373 1.069 . . . . 0.0 113.354 -178.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 25.3 ttt 68.92 115.45 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 O-C-N 124.614 1.196 . . . . 0.0 112.361 176.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -92.45 108.72 20.18 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.435 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -88.14 126.99 35.41 Favored 'General case' 0 C--O 1.249 1.052 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -138.97 142.73 34.45 Favored Pre-proline 0 C--N 1.306 -1.316 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -176.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -79.27 125.85 6.62 Favored 'Trans proline' 0 C--O 1.25 1.122 0 C-N-CA 122.929 2.419 . . . . 0.0 113.357 177.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.412 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 46.5 t -118.71 105.2 17.23 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 174.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.411 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 45.3 tt0 -88.71 102.45 15.0 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.541 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 15.3 tp -90.94 153.13 20.4 Favored 'General case' 0 N--CA 1.422 -1.827 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 -176.107 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -125.39 78.41 1.72 Allowed 'General case' 0 C--N 1.289 -2.049 0 CA-C-O 122.062 0.934 . . . . 0.0 108.757 177.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.46 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 5.5 mmtt -68.92 -169.72 0.19 Allowed 'General case' 0 N--CA 1.402 -2.842 0 CA-C-N 113.56 -1.654 . . . . 0.0 113.047 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.406 ' H ' ' CD ' ' A' ' 12' ' ' LYS . 9.1 m-20 -91.79 176.37 6.55 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 124.619 1.168 . . . . 0.0 108.346 -174.231 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -63.61 -22.46 66.91 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -176.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -72.0 -32.53 67.29 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.62 0.724 . . . . 0.0 110.151 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.423 ' O ' ' HD2' ' A' ' 12' ' ' LYS . . . 108.82 -140.07 15.45 Favored Glycine 0 N--CA 1.414 -2.831 0 N-CA-C 107.49 -2.244 . . . . 0.0 107.49 -173.21 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.458 ' HG ' ' OG1' ' A' ' 83' ' ' THR . 14.7 mt -91.18 -60.9 1.78 Allowed 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.208 179.292 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.58 33.92 60.45 Favored Glycine 0 N--CA 1.424 -2.117 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -173.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.433 ' HB ' ' O ' ' A' ' 41' ' ' THR . 30.6 pt -96.56 177.78 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 C-N-CA 120.369 -0.532 . . . . 0.0 111.018 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.4 m -120.4 150.11 41.3 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 115.252 -0.885 . . . . 0.0 109.092 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.447 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -125.84 162.98 28.17 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 -179.038 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.8 tt -136.13 126.31 41.1 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.256 176.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.489 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -85.37 104.95 2.86 Favored Glycine 0 N--CA 1.435 -1.38 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.657 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.574 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 89.6 mmm -120.98 88.92 3.03 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -56.11 112.09 3.0 Favored Glycine 0 C--N 1.314 -0.689 0 O-C-N 123.918 0.761 . . . . 0.0 112.528 -177.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.8 p -111.76 38.09 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 CA-C-O 123.284 1.516 . . . . 0.0 108.239 -178.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -62.09 130.87 45.07 Favored Glycine 0 N--CA 1.442 -0.922 0 CA-C-N 113.612 -1.631 . . . . 0.0 112.313 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . 71.64 -47.2 0.66 Allowed 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 126.104 1.761 . . . . 0.0 113.679 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -73.13 5.57 3.36 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -176.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.31 -12.37 21.6 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 173.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 81.77 -53.24 4.69 Favored Glycine 0 C--N 1.335 0.481 0 CA-C-O 121.952 0.751 . . . . 0.0 111.342 -177.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.2 mp -78.2 -25.5 47.1 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 114.512 -0.844 . . . . 0.0 110.399 -179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 55.85 92.12 0.03 OUTLIER 'General case' 0 C--N 1.349 0.567 0 C-N-CA 123.989 0.916 . . . . 0.0 111.261 -170.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.41 ' HD3' ' N ' ' A' ' 34' ' ' LYS . 0.1 OUTLIER -134.06 -176.02 4.05 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 177.855 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -58.97 161.01 5.34 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 124.136 0.897 . . . . 0.0 111.122 178.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.574 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -122.07 26.6 6.39 Favored Glycine 0 N--CA 1.417 -2.609 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 173.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.489 HD11 ' HA2' ' A' ' 23' ' ' GLY . 17.9 mm -85.36 101.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 121.547 0.689 . . . . 0.0 109.981 -178.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -95.12 161.93 13.92 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.315 179.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -77.6 122.85 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.202 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -85.54 -49.79 7.76 Favored 'General case' 0 C--N 1.291 -1.96 0 CA-C-O 121.333 0.587 . . . . 0.0 110.501 -177.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.433 ' O ' ' HB ' ' A' ' 19' ' ' ILE . 0.7 OUTLIER -150.84 156.49 41.34 Favored 'General case' 0 N--CA 1.421 -1.876 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.59 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 64.8 t -125.88 145.96 32.45 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.431 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 176.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 8.4 t -56.84 147.99 21.92 Favored 'General case' 0 C--O 1.253 1.289 0 O-C-N 123.556 0.535 . . . . 0.0 109.773 176.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -43.83 -68.62 0.18 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 126.73 2.012 . . . . 0.0 115.126 -169.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -154.35 53.17 0.45 Allowed Glycine 0 CA--C 1.471 -2.701 0 C-N-CA 118.828 -1.653 . . . . 0.0 113.756 -174.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.418 ' C ' ' H ' ' A' ' 48' ' ' ALA . . . -94.83 -165.26 35.66 Favored Glycine 1 N--CA 1.386 -4.664 0 N-CA-C 107.298 -2.321 . . . . 0.0 107.298 169.661 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.46 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . -74.82 33.54 0.1 Allowed 'General case' 0 C--N 1.27 -2.849 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -173.122 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.418 ' H ' ' C ' ' A' ' 46' ' ' GLY . . . -116.56 -65.56 1.17 Allowed 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 174.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -74.09 -26.06 60.15 Favored 'General case' 0 N--CA 1.464 0.239 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.111 175.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.531 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 2.0 mmp_? -69.09 -26.94 65.18 Favored 'General case' 0 CA--C 1.503 -0.828 0 CA-C-O 121.053 0.454 . . . . 0.0 110.058 173.128 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -73.74 -57.18 4.16 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 178.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.09 -20.73 48.79 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.505 -0.855 . . . . 0.0 114.262 174.68 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.513 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -73.66 -22.86 59.83 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-O 121.648 0.737 . . . . 0.0 109.114 -177.757 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.8 tt -104.85 148.98 8.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 26.7 mm-40 -129.54 165.98 20.6 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-O 121.168 0.509 . . . . 0.0 111.906 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -83.45 -8.94 11.49 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.892 0 CA-C-O 122.166 0.984 . . . . 0.0 108.621 176.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -102.43 16.85 25.1 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 122.286 1.041 . . . . 0.0 109.443 -175.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -102.05 -179.62 4.05 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.009 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.48 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 33.4 tt0 -128.72 124.96 36.93 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 46.1 mm -76.36 95.39 1.24 Allowed 'Isoleucine or valine' 0 C--O 1.206 -1.192 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 -176.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.689 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 60.6 t -79.42 -42.09 22.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 CA-C-O 121.59 0.71 . . . . 0.0 111.159 -175.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.495 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 36.8 tt0 -151.07 131.14 13.44 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.0 t -123.51 126.05 72.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 172.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 24.3 t70 69.47 5.47 5.18 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-O 122.356 1.074 . . . . 0.0 111.804 172.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.99 13.3 62.44 Favored Glycine 0 N--CA 1.434 -1.493 0 CA-C-N 115.362 -0.836 . . . . 0.0 111.624 -176.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.2 tt -77.34 -16.73 14.41 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.774 0 O-C-N 122.793 -0.239 . . . . 0.0 110.44 -178.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.6 m 39.74 80.67 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.985 1.714 . . . . 0.0 112.7 -176.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.458 ' O ' HG23 ' A' ' 71' ' ' VAL . 0.0 OUTLIER -89.53 31.82 0.9 Allowed 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 122.216 1.007 . . . . 0.0 111.959 -175.606 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 47.8 t -70.52 106.16 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.075 0 CA-C-N 115.199 -0.91 . . . . 0.0 109.288 178.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.93 15.89 20.81 Favored Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.913 176.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 68' ' ' LEU . 19.1 m -96.63 175.83 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.973 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.711 178.434 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 8.4 p -91.54 172.86 8.22 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.99 178.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.447 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -61.24 -33.65 73.86 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.509 -179.488 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -73.09 -33.05 65.38 Favored 'General case' 0 CA--C 1.512 -0.507 0 C-N-CA 121.072 -0.251 . . . . 0.0 111.568 -176.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 33.4 t80 -69.94 -49.71 49.14 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -58.1 -49.22 77.7 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.516 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -55.87 -36.7 67.89 Favored 'General case' 0 C--O 1.216 -0.682 0 C-N-CA 122.467 0.307 . . . . 0.0 110.957 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.404 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 86.9 m -63.39 -45.51 90.75 Favored 'General case' 0 CA--C 1.55 0.957 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.086 176.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 31.0 t -65.1 -49.92 76.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.663 0.268 . . . . 0.0 110.788 178.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -69.77 -4.87 21.83 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.224 0.61 . . . . 0.0 111.993 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.404 ' HB3' ' O ' ' A' ' 78' ' ' THR . 59.5 ttt180 -92.15 -46.62 7.67 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 124.055 0.942 . . . . 0.0 108.541 174.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -77.41 5.68 8.33 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.326 -1.306 . . . . 0.0 113.366 -174.322 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.458 ' OG1' ' HG ' ' A' ' 17' ' ' LEU . 16.8 p -63.45 154.19 32.97 Favored 'General case' 0 C--N 1.294 -1.806 0 C-N-CA 123.832 0.853 . . . . 0.0 112.711 176.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.0 mmtt -120.24 -161.92 0.91 Allowed 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 114.567 -1.197 . . . . 0.0 108.501 176.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.05 -68.03 1.89 Allowed Glycine 0 N--CA 1.444 -0.824 0 O-C-N 123.818 0.699 . . . . 0.0 111.901 176.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.541 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.7 m120 -83.06 118.57 23.63 Favored 'General case' 0 C--N 1.307 -1.268 0 O-C-N 122.244 -0.562 . . . . 0.0 110.635 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.417 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 4.4 t -130.75 130.0 64.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.504 -176.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 22.1 mtp180 -94.33 100.59 12.6 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-O 121.186 0.517 . . . . 0.0 110.917 174.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.476 ' HB3' HG13 ' A' ' 91' ' ' ILE . 89.0 m-85 -95.12 112.0 23.76 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 176.101 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.689 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 10.7 t -100.48 65.54 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.476 HG13 ' HB3' ' A' ' 89' ' ' PHE . 76.4 mt -77.14 153.8 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.516 0 CA-C-N 112.796 -2.002 . . . . 0.0 109.909 -177.683 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.435 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -131.07 149.3 19.15 Favored Glycine 1 N--CA 1.385 -4.709 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 177.386 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -111.25 133.0 53.92 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 -178.626 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 . . . . . 0 C--N 1.309 -1.185 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 177.968 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.498 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -92.7 161.67 14.46 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 175.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' MET . . . . . 0.403 ' O ' HD23 ' A' ' 5' ' ' LEU . 22.5 ttt -164.65 138.99 5.28 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 177.575 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -90.9 101.37 14.13 Favored 'General case' 0 C--N 1.294 -1.828 0 C-N-CA 119.396 -0.922 . . . . 0.0 108.898 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.42 HD11 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -87.86 125.17 34.33 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -132.02 140.66 38.81 Favored Pre-proline 0 C--N 1.287 -2.112 0 CA-C-O 121.461 0.648 . . . . 0.0 112.061 -176.286 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -83.11 125.85 4.18 Favored 'Trans proline' 0 C--N 1.301 -1.927 0 C-N-CA 122.535 2.157 . . . . 0.0 112.188 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.44 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 36.9 t -109.04 109.05 26.89 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.593 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 172.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.481 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 45.3 tt0 -92.89 103.23 15.58 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.406 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.5 OUTLIER -103.38 154.21 19.65 Favored 'General case' 0 N--CA 1.395 -3.182 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 -175.669 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -123.06 100.56 6.94 Favored 'General case' 0 N--CA 1.409 -2.483 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 177.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.479 ' HD2' ' HB2' ' A' ' 47' ' ' ALA . 3.3 mmmp? -92.48 178.92 5.67 Favored 'General case' 0 C--N 1.284 -2.282 0 CA-C-N 114.524 -1.217 . . . . 0.0 109.486 176.254 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.535 ' OD2' ' HG2' ' A' ' 14' ' ' GLU . 19.6 t70 -101.41 -160.01 0.77 Allowed 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -176.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.535 ' HG2' ' OD2' ' A' ' 13' ' ' ASP . 11.0 pt-20 -75.77 -13.08 60.29 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -171.305 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -71.07 -43.9 66.84 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.213 0.53 . . . . 0.0 110.254 177.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 125.1 -131.02 7.57 Favored Glycine 0 CA--C 1.481 -2.066 0 N-CA-C 108.28 -1.928 . . . . 0.0 108.28 -177.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.427 ' CD1' HD13 ' A' ' 80' ' ' LEU . 14.3 mt -100.7 -60.94 1.43 Allowed 'General case' 0 CA--C 1.476 -1.902 0 C-N-CA 119.012 -1.075 . . . . 0.0 109.462 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.12 29.94 39.65 Favored Glycine 0 N--CA 1.419 -2.472 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -174.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 24.5 pt -104.54 176.87 0.94 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.987 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.4 m -135.42 150.08 49.78 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 -177.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.554 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -120.16 166.02 15.0 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 C-N-CA 123.303 0.641 . . . . 0.0 110.098 -177.242 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 11.9 tt -140.94 127.93 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.014 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 174.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.434 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -93.57 109.48 3.81 Favored Glycine 0 CA--C 1.484 -1.869 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -177.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.612 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 88.7 mmm -125.99 92.92 3.69 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -56.74 97.9 0.06 OUTLIER Glycine 0 CA--C 1.52 0.397 0 N-CA-C 114.77 0.668 . . . . 0.0 114.77 -175.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.6 p -91.11 41.48 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 CA-C-O 123.18 1.467 . . . . 0.0 108.732 178.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.35 105.39 2.9 Favored Glycine 0 N--CA 1.432 -1.625 0 CA-C-N 114.367 -1.288 . . . . 0.0 110.904 -179.202 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.489 ' H ' ' HG3' ' A' ' 33' ' ' GLU . . . 68.44 66.09 0.32 Allowed 'General case' 0 CA--C 1.493 -1.232 0 C-N-CA 125.016 1.326 . . . . 0.0 109.766 -178.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -134.81 -64.63 0.66 Allowed 'General case' 0 N--CA 1.428 -1.538 0 CA-C-N 114.578 -1.192 . . . . 0.0 111.47 -174.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.36 9.94 7.3 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 -171.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.27 -7.93 48.07 Favored Glycine 0 CA--C 1.502 -0.721 0 C-N-CA 119.194 -1.479 . . . . 0.0 112.505 178.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.4 mp -80.61 -46.34 15.84 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.489 ' HG3' ' H ' ' A' ' 28' ' ' ALA . 0.4 OUTLIER 40.27 70.63 0.23 Allowed 'General case' 0 C--N 1.348 0.517 0 C-N-CA 124.871 1.268 . . . . 0.0 113.616 178.05 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 17.8 ptmt -160.02 -163.42 1.13 Allowed 'General case' 0 N--CA 1.424 -1.751 0 CA-C-N 115.158 -0.928 . . . . 0.0 108.94 -174.238 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.3 pp -56.95 150.54 16.53 Favored 'General case' 0 N--CA 1.44 -0.927 0 O-C-N 124.175 0.922 . . . . 0.0 109.183 174.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.612 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -121.98 30.62 5.21 Favored Glycine 0 N--CA 1.422 -2.281 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.75 178.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.48 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 23.5 mm -82.25 103.65 9.74 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 CA-C-O 121.847 0.832 . . . . 0.0 110.537 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -99.32 164.33 12.16 Favored 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.0 t -82.6 131.04 34.69 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.484 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 177.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.492 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.4 OUTLIER -91.7 -45.39 8.47 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.137 0.494 . . . . 0.0 109.832 -178.692 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.0 m -154.66 162.24 41.21 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -127.11 160.98 35.13 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.15 0 N-CA-C 105.363 -2.088 . . . . 0.0 105.363 178.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.6 t -72.51 146.21 46.96 Favored 'General case' 0 C--N 1.293 -1.883 0 CA-C-O 121.908 0.861 . . . . 0.0 111.007 -178.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -102.78 -0.33 31.64 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-O 123.742 1.734 . . . . 0.0 107.305 176.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -70.28 -30.27 69.54 Favored Glycine 0 C--N 1.294 -1.776 0 CA-C-N 112.541 -2.118 . . . . 0.0 114.467 -177.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 142.81 150.63 5.34 Favored Glycine 0 N--CA 1.426 -2.031 0 C-N-CA 119.351 -1.404 . . . . 0.0 113.217 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.479 ' HB2' ' HD2' ' A' ' 12' ' ' LYS . . . 73.92 -34.86 0.29 Allowed 'General case' 0 C--N 1.311 -1.088 0 C-N-CA 126.822 2.049 . . . . 0.0 115.685 171.345 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.435 ' HB3' ' CE ' ' A' ' 12' ' ' LYS . . . -82.38 -56.79 3.68 Favored 'General case' 0 N--CA 1.488 1.461 0 CA-C-N 118.974 0.806 . . . . 0.0 110.91 -176.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -73.9 -16.99 61.09 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.561 0.696 . . . . 0.0 110.45 177.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.504 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 3.9 mmp_? -83.14 -17.03 44.42 Favored 'General case' 0 N--CA 1.432 -1.353 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.092 174.073 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -61.43 -61.75 2.32 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.964 0.411 . . . . 0.0 109.987 173.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.92 -9.86 74.75 Favored Glycine 0 N--CA 1.44 -1.073 0 C-N-CA 120.575 -0.821 . . . . 0.0 114.849 173.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -89.35 -45.35 9.55 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 178.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.7 tt -74.9 150.51 6.96 Favored 'Isoleucine or valine' 0 C--O 1.252 1.225 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 176.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -134.87 160.35 38.51 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.7 p -73.27 -17.0 17.7 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.139 0 CA-C-O 121.79 0.805 . . . . 0.0 109.743 176.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -90.32 -6.37 55.16 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.389 -173.327 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -95.07 -176.12 3.73 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 113.249 0.833 . . . . 0.0 113.249 -174.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.498 ' O ' HG21 ' A' ' 91' ' ' ILE . 32.4 tt0 -116.99 127.43 54.18 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.102 -174.365 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.434 ' HA ' HG12 ' A' ' 91' ' ' ILE . 50.4 mm -73.4 105.57 2.87 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.627 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.626 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 97.9 t -90.04 -49.46 13.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 CA-C-O 121.664 0.745 . . . . 0.0 111.008 -176.006 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.441 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 37.4 tt0 -151.99 104.15 2.96 Favored 'General case' 0 C--N 1.296 -1.751 0 CA-C-O 121.518 0.675 . . . . 0.0 109.834 -178.181 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.8 t -91.75 123.04 43.73 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.061 0 CA-C-O 121.322 0.582 . . . . 0.0 111.717 176.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 24.5 t70 65.86 4.66 3.05 Favored 'General case' 0 C--N 1.311 -1.067 0 C-N-CA 126.813 2.045 . . . . 0.0 112.769 174.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.98 12.34 57.84 Favored Glycine 0 N--CA 1.429 -1.771 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.613 -177.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 9.6 tt -73.01 -17.8 18.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-O 121.185 0.517 . . . . 0.0 110.408 -179.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.44 ' HB3' ' OE2' ' A' ' 62' ' ' GLU . 9.7 p 49.69 82.83 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 124.826 1.25 . . . . 0.0 113.259 -176.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.534 ' O ' HG23 ' A' ' 71' ' ' VAL . 1.8 pp -93.03 14.43 17.78 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.572 -177.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 58.6 t -57.75 102.5 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.5 176.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.62 -5.25 24.54 Favored Glycine 0 N--CA 1.442 -0.941 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.433 176.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 68' ' ' LEU . 11.5 m -83.98 178.15 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.247 0.925 0 CA-C-O 121.245 0.545 . . . . 0.0 111.69 -175.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.4 p -101.12 170.53 8.2 Favored 'General case' 0 N--CA 1.415 -2.18 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.116 176.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.554 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -56.13 -33.5 65.21 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-N 114.51 -1.223 . . . . 0.0 112.256 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -74.4 -22.36 59.2 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 111.744 0.275 . . . . 0.0 111.744 -177.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.428 ' O ' ' HB ' ' A' ' 78' ' ' THR . 38.6 t80 -80.85 -50.14 10.17 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 174.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.64 -47.99 80.71 Favored 'General case' 0 C--O 1.22 -0.459 0 CA-C-N 114.719 -1.128 . . . . 0.0 112.12 -178.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -56.74 -33.22 66.34 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 120.89 0.376 . . . . 0.0 110.687 179.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.428 ' HB ' ' O ' ' A' ' 75' ' ' PHE . 53.0 m -68.62 -47.15 67.4 Favored 'General case' 0 N--CA 1.435 -1.205 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.904 176.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 44.3 t -58.82 -50.27 79.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 110.097 -0.335 . . . . 0.0 110.097 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.427 HD13 ' CD1' ' A' ' 17' ' ' LEU . 3.6 mm? -67.67 -10.62 53.93 Favored 'General case' 0 CA--C 1.551 1.014 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.681 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -97.7 -23.05 16.11 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.256 0.551 . . . . 0.0 110.43 176.082 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -83.84 -23.18 31.47 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.092 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.4 p -63.99 156.62 27.42 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 113.646 0.98 . . . . 0.0 113.646 -178.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.75 -145.97 0.36 Allowed 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 114.685 -1.143 . . . . 0.0 109.764 -176.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.8 -67.64 1.91 Allowed Glycine 0 C--N 1.295 -1.719 0 O-C-N 123.671 0.607 . . . . 0.0 112.603 -177.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.406 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 0.9 OUTLIER -77.25 109.73 11.37 Favored 'General case' 0 CA--C 1.497 -1.079 0 C-N-CA 119.937 -0.705 . . . . 0.0 110.118 178.657 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -124.09 144.53 33.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.82 98.26 7.78 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 173.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.44 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 86.5 m-85 -90.42 98.4 11.75 Favored 'General case' 0 C--N 1.279 -2.498 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 178.134 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.626 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 58.9 t -89.3 91.8 3.77 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.433 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 178.168 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.498 HG21 ' O ' ' A' ' 59' ' ' GLN . 81.6 mt -106.52 156.67 7.04 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.073 0 CA-C-N 114.0 -1.454 . . . . 0.0 108.096 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.42 ' HA3' HD11 ' A' ' 5' ' ' LEU . . . -134.25 164.47 24.53 Favored Glycine 1 N--CA 1.393 -4.182 0 C-N-CA 119.566 -1.302 . . . . 0.0 109.931 178.595 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -149.46 131.06 14.91 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . 0.26 0.0 OUTLIER . . . . . 0 N--CA 1.411 -2.377 0 CA-C-O 118.436 -0.792 . . . . 0.0 110.671 175.218 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.428 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 36.6 t60 68.59 138.73 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.682 1.193 . . . . 0.0 109.827 -175.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' MET . . . . . 0.431 ' O ' HD21 ' A' ' 5' ' ' LEU . 24.8 ttt -84.75 103.79 14.15 Favored 'General case' 0 N--CA 1.427 -1.595 0 C-N-CA 119.142 -1.023 . . . . 0.0 109.472 -179.319 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -79.86 104.56 10.52 Favored 'General case' 0 C--N 1.295 -1.801 0 CA-C-N 114.792 -1.094 . . . . 0.0 108.597 -179.211 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.431 HD21 ' O ' ' A' ' 3' ' ' MET . 1.8 mm? -81.73 130.55 35.1 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 178.628 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -137.11 141.53 34.84 Favored Pre-proline 0 C--N 1.284 -2.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.324 -179.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -77.89 128.71 9.4 Favored 'Trans proline' 0 N--CA 1.443 -1.474 0 C-N-CA 122.368 2.046 . . . . 0.0 112.418 178.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 21.7 t -119.11 94.99 3.34 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.258 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 174.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.535 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 40.7 tt0 -78.33 112.44 15.34 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 175.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -97.43 123.07 41.15 Favored 'General case' 0 N--CA 1.405 -2.701 0 N-CA-C 105.444 -2.058 . . . . 0.0 105.444 178.617 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.455 ' HG3' ' OD1' ' A' ' 86' ' ' ASN . 30.9 tt0 -94.44 90.45 6.23 Favored 'General case' 0 C--N 1.281 -2.373 0 CA-C-O 121.839 0.828 . . . . 0.0 109.005 179.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 2.8 mmmp? -93.82 -175.4 3.72 Favored 'General case' 0 N--CA 1.428 -1.563 0 CA-C-N 114.263 -1.335 . . . . 0.0 111.778 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.568 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.5 p-10 -88.27 -172.42 3.78 Favored 'General case' 0 C--N 1.28 -2.452 0 C-N-CA 126.8 2.04 . . . . 0.0 112.384 -177.386 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -77.45 -20.21 54.82 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 114.705 -1.134 . . . . 0.0 111.577 -179.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.568 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 18.8 t70 -73.95 -35.64 64.55 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 118.25 -124.58 6.11 Favored Glycine 0 CA--C 1.486 -1.747 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.661 172.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.444 ' HB3' HG23 ' A' ' 19' ' ' ILE . 31.7 mt -112.76 -54.54 2.61 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.1 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.55 27.51 69.32 Favored Glycine 0 N--CA 1.425 -2.062 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.818 -173.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.444 HG23 ' HB3' ' A' ' 17' ' ' LEU . 27.0 pt -94.67 176.32 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.26 -178.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 49.0 m -132.33 150.31 52.18 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.882 -178.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -120.05 159.89 20.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.46 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 15.4 tt -124.13 132.01 72.01 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 C-N-CA 120.063 -0.655 . . . . 0.0 110.045 175.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.466 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.82 92.45 1.78 Allowed Glycine 0 N--CA 1.427 -1.94 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.852 -177.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 91.8 mmm -108.26 -179.07 3.78 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -133.59 93.16 0.26 Allowed Glycine 0 C--N 1.284 -2.354 0 C-N-CA 120.087 -1.054 . . . . 0.0 112.333 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.1 p -97.68 75.21 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 123.601 1.667 . . . . 0.0 110.08 174.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.34 -164.52 15.53 Favored Glycine 0 N--CA 1.41 -3.058 0 CA-C-N 113.746 -1.57 . . . . 0.0 110.394 -178.429 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.461 ' H ' ' HG2' ' A' ' 33' ' ' GLU . . . 62.17 -83.57 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 125.125 1.37 . . . . 0.0 112.299 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -93.72 -12.5 29.08 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-O 122.409 1.1 . . . . 0.0 109.405 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.458 ' C ' ' H ' ' A' ' 32' ' ' LEU . . . -95.65 99.86 11.66 Favored 'General case' 0 N--CA 1.399 -2.98 0 N-CA-C 104.265 -2.495 . . . . 0.0 104.265 174.712 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -45.59 20.34 0.0 OUTLIER Glycine 0 N--CA 1.497 2.755 0 C-N-CA 128.608 3.004 . . . . 0.0 118.972 -175.519 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.458 ' H ' ' C ' ' A' ' 30' ' ' ALA . 19.8 mt -106.13 -37.56 6.56 Favored 'General case' 0 C--N 1.278 -2.515 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.097 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.461 ' HG2' ' H ' ' A' ' 28' ' ' ALA . 44.2 mt-10 49.5 73.88 0.22 Allowed 'General case' 0 C--O 1.247 0.97 0 CA-C-N 115.128 -0.942 . . . . 0.0 113.508 -179.076 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 17.7 ptmt -154.52 -172.03 4.06 Favored 'General case' 0 N--CA 1.406 -2.662 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 -179.211 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.523 HD21 ' HA ' ' A' ' 69' ' ' VAL . 3.2 pp -63.02 152.35 37.17 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 124.31 1.006 . . . . 0.0 110.066 179.066 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -116.47 32.54 5.51 Favored Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 175.172 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.466 HD13 ' HA2' ' A' ' 23' ' ' GLY . 29.7 mm -81.31 103.87 9.01 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.867 0 CA-C-O 121.624 0.726 . . . . 0.0 110.14 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -102.21 160.16 14.76 Favored 'General case' 0 C--N 1.275 -2.645 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.296 176.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 40.5 t -74.32 123.97 30.84 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 175.293 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.402 ' HB2' ' HB ' ' A' ' 22' ' ' ILE . 53.5 tptt -89.29 -48.61 7.25 Favored 'General case' 0 C--N 1.293 -1.871 0 CA-C-O 121.118 0.485 . . . . 0.0 110.28 -176.762 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -150.25 159.15 44.65 Favored 'General case' 0 N--CA 1.422 -1.874 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -177.401 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 23.3 t -121.24 174.16 6.17 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.522 0 N-CA-C 104.894 -2.261 . . . . 0.0 104.894 175.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 3.2 t -61.07 178.23 0.27 Allowed 'General case' 0 CA--C 1.561 1.377 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 173.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -56.01 -31.09 62.77 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 124.065 0.946 . . . . 0.0 110.251 176.771 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . 0.493 ' HA2' HE21 ' A' ' 49' ' ' GLN . . . -169.64 -73.87 0.04 OUTLIER Glycine 0 N--CA 1.402 -3.627 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.752 178.303 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 55.13 -177.51 0.42 Allowed Glycine 1 N--CA 1.382 -4.931 0 CA-C-O 123.398 1.554 . . . . 0.0 113.003 -173.163 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.413 ' O ' ' HB2' ' A' ' 51' ' ' ASP . . . -71.26 -4.93 28.5 Favored 'General case' 1 C--N 1.237 -4.291 0 CA-C-N 113.398 -1.401 . . . . 0.0 109.977 172.445 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.57 -60.11 2.44 Favored 'General case' 0 C--N 1.35 0.59 0 C-N-CA 123.551 0.74 . . . . 0.0 110.059 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.493 HE21 ' HA2' ' A' ' 45' ' ' GLY . 26.5 mt-30 -70.5 -27.46 64.22 Favored 'General case' 0 CA--C 1.511 -0.536 0 C-N-CA 120.14 -0.624 . . . . 0.0 111.029 178.087 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.415 ' HD3' ' HA ' ' A' ' 50' ' ' ARG . 37.1 mmt180 -78.45 -19.5 53.01 Favored 'General case' 0 N--CA 1.44 -0.975 0 C-N-CA 120.04 -0.664 . . . . 0.0 111.778 175.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 47' ' ' ALA . 11.1 t70 -66.7 -64.01 0.94 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 172.058 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.89 -10.11 70.4 Favored Glycine 0 N--CA 1.44 -1.092 0 C-N-CA 120.557 -0.83 . . . . 0.0 115.13 173.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.08 -21.56 43.2 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -179.817 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.6 tt -105.05 164.59 3.91 Favored 'Isoleucine or valine' 0 C--O 1.254 1.305 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 175.164 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 63.1 mt-30 -136.17 -156.72 0.73 Allowed 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 119.033 0.833 . . . . 0.0 110.923 -177.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.2 p -123.94 18.21 4.77 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 174.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -132.91 -8.43 3.09 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.758 0.789 . . . . 0.0 111.206 -174.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.546 ' OD2' HD12 ' A' ' 91' ' ' ILE . 7.1 p-10 -83.18 179.24 7.78 Favored 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 124.571 1.148 . . . . 0.0 110.919 -177.357 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.46 ' O ' HG21 ' A' ' 91' ' ' ILE . 31.1 tt0 -119.76 126.08 50.18 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.087 -176.054 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 50.8 mm -74.36 114.71 14.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.089 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.693 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 84.7 t -98.37 -48.92 11.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.85 0.834 . . . . 0.0 111.022 -178.164 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.498 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 26.9 tt0 -150.28 114.88 5.23 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -178.614 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.4 t -110.1 128.13 66.51 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.821 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.589 178.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.7 t70 72.58 -8.84 1.15 Allowed 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 125.265 1.426 . . . . 0.0 112.348 175.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.83 13.43 31.98 Favored Glycine 0 C--N 1.286 -2.203 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.686 -174.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.4 tt -74.97 -17.44 16.2 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 17.4 m 45.83 84.56 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 125.659 1.584 . . . . 0.0 111.585 -176.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.411 ' HB2' ' CG2' ' A' ' 71' ' ' VAL . 0.7 OUTLIER -93.06 20.98 6.19 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.659 0.742 . . . . 0.0 110.671 -175.317 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.523 ' HA ' HD21 ' A' ' 35' ' ' LEU . 59.1 t -52.77 100.63 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 CA-C-N 114.691 -1.141 . . . . 0.0 111.77 177.474 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.59 21.7 25.89 Favored Glycine 0 N--CA 1.443 -0.844 0 CA-C-N 115.47 -0.786 . . . . 0.0 114.131 174.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.411 ' CG2' ' HB2' ' A' ' 68' ' ' LEU . 20.5 m -93.43 -178.66 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 117.497 0.649 . . . . 0.0 111.173 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.9 p -98.37 178.97 4.87 Favored 'General case' 0 C--O 1.251 1.146 0 CA-C-O 121.037 0.446 . . . . 0.0 110.377 177.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.92 -25.31 66.3 Favored 'General case' 0 C--O 1.204 -1.337 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.337 179.638 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 25.6 m-80 -63.02 -48.57 78.22 Favored 'General case' 0 CA--C 1.483 -1.603 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.183 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -68.61 -47.79 65.78 Favored 'General case' 0 N--CA 1.426 -1.633 0 CA-C-N 114.76 -1.109 . . . . 0.0 109.698 -175.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -62.94 -40.29 97.21 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.167 -178.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -69.08 -18.19 63.97 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.229 0.537 . . . . 0.0 110.426 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 83.3 m -84.01 -47.5 10.91 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.457 176.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.44 HG11 HD22 ' A' ' 80' ' ' LEU . 3.9 p -62.78 -48.6 87.36 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 N-CA-C 112.943 0.72 . . . . 0.0 112.943 177.323 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.44 HD22 HG11 ' A' ' 79' ' ' VAL . 3.9 mm? -67.2 -12.22 59.48 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.531 0.682 . . . . 0.0 112.056 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -84.47 -46.05 12.04 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 176.249 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -79.56 -11.09 59.89 Favored 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 114.388 1.255 . . . . 0.0 114.388 -171.188 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.427 HG22 ' O ' ' A' ' 79' ' ' VAL . 12.0 p -68.45 140.7 55.76 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -135.93 141.75 44.54 Favored 'General case' 0 CA--C 1.482 -1.659 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.096 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 47.67 -88.13 0.01 OUTLIER Glycine 0 CA--C 1.474 -2.508 0 O-C-N 126.039 2.087 . . . . 0.0 113.696 178.081 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.455 ' OD1' ' HG3' ' A' ' 11' ' ' GLU . 3.0 m-20 -97.94 102.0 13.63 Favored 'General case' 0 C--N 1.247 -3.849 0 CA-C-N 113.804 -1.198 . . . . 0.0 110.52 -173.283 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.535 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 40.2 t -113.15 124.82 70.16 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 CA-C-N 115.021 -0.991 . . . . 0.0 111.611 -173.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.59 104.18 16.61 Favored 'General case' 0 CA--C 1.49 -1.364 0 C-N-CA 120.204 -0.598 . . . . 0.0 109.944 174.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -93.49 100.19 12.52 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 175.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.693 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.8 t -89.5 92.99 4.13 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.82 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 177.282 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.546 HD12 ' OD2' ' A' ' 58' ' ' ASP . 96.5 mt -108.62 163.84 5.79 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.375 0 C-N-CA 125.485 1.514 . . . . 0.0 107.494 179.486 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -133.75 159.82 23.83 Favored Glycine 0 N--CA 1.411 -2.97 0 C-N-CA 118.557 -1.782 . . . . 0.0 113.301 -177.146 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 35.5 ttt180 -114.32 137.41 51.84 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 123.321 0.648 . . . . 0.0 109.533 177.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? . . . . . 0 C--N 1.294 -1.834 0 CA-C-O 119.395 -0.336 . . . . 0.0 110.976 -178.445 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.359 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 32.4 m-70 -83.68 103.33 12.9 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-O 121.066 0.46 . . . . 0.0 110.732 176.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' MET . . . . . 0.529 ' SD ' ' HG3' ' A' ' 94' ' ' GLU . 57.3 tpp -70.42 127.47 32.84 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 177.221 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.411 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 35.2 tt0 -85.61 102.52 13.63 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 177.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -84.14 131.89 34.74 Favored 'General case' 0 CA--C 1.5 -0.963 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -140.58 138.5 18.73 Favored Pre-proline 0 N--CA 1.42 -1.971 0 CA-C-O 121.507 0.67 . . . . 0.0 112.012 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -81.47 124.27 4.64 Favored 'Trans proline' 0 C--N 1.314 -1.263 0 C-N-CA 122.856 2.37 . . . . 0.0 112.781 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.418 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 25.0 t -113.61 106.14 20.13 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 175.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.496 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 30.8 tt0 -89.64 109.13 20.11 Favored 'General case' 0 N--CA 1.416 -2.132 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 177.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -100.91 149.34 23.99 Favored 'General case' 0 C--N 1.289 -2.063 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 -176.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -120.44 93.03 3.91 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 171.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.426 ' HD2' ' HA ' ' A' ' 12' ' ' LYS . 3.0 mmmp? -82.73 172.86 12.43 Favored 'General case' 0 N--CA 1.421 -1.92 0 CA-C-O 122.63 1.205 . . . . 0.0 114.177 -179.046 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -72.78 171.23 13.03 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 112.077 -2.329 . . . . 0.0 108.564 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -68.83 -16.93 63.92 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.345 0.593 . . . . 0.0 110.373 178.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.05 -33.02 72.65 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 122.023 0.916 . . . . 0.0 109.986 174.462 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.59 -138.38 14.93 Favored Glycine 0 N--CA 1.41 -3.095 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt -89.46 -43.91 10.52 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 119.734 -0.786 . . . . 0.0 109.735 -179.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 66.64 28.0 73.52 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 124.547 1.155 . . . . 0.0 111.013 -174.23 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 20.7 pt -109.0 177.07 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.452 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.0 m -138.64 153.81 48.61 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -177.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -122.39 166.72 16.76 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 -178.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 13.7 tt -135.08 133.57 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.79 0 C-N-CA 120.026 -0.67 . . . . 0.0 111.435 176.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.478 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -92.93 103.44 3.05 Favored Glycine 0 N--CA 1.413 -2.886 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 18.1 ptm -140.85 86.94 2.08 Favored 'General case' 0 C--N 1.288 -2.079 0 CA-C-O 121.584 0.707 . . . . 0.0 109.77 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -57.98 110.08 2.22 Favored Glycine 0 N--CA 1.44 -1.09 0 CA-C-N 114.066 -1.425 . . . . 0.0 112.966 -176.058 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.1 p -97.23 146.66 7.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -100.71 -151.9 25.65 Favored Glycine 0 N--CA 1.422 -2.291 0 C-N-CA 120.269 -0.967 . . . . 0.0 113.618 -177.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.409 ' CB ' ' HG2' ' A' ' 33' ' ' GLU . . . -90.7 -17.32 26.97 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.438 -0.881 . . . . 0.0 111.39 -177.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -66.44 -33.02 74.76 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 121.713 0.768 . . . . 0.0 110.171 -174.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -84.38 -5.1 59.24 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.403 -179.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 87.94 11.21 68.08 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.103 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.48 ' O ' ' HE3' ' A' ' 34' ' ' LYS . 4.0 mm? -88.81 -59.22 2.29 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 120.858 -0.337 . . . . 0.0 111.452 -179.208 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.409 ' HG2' ' CB ' ' A' ' 28' ' ' ALA . 40.1 mt-10 62.32 33.22 16.62 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.254 0.622 . . . . 0.0 111.669 177.05 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.48 ' HE3' ' O ' ' A' ' 32' ' ' LEU . 15.0 ptpt -155.02 -164.41 1.79 Allowed 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.814 -175.622 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -48.8 150.02 1.6 Allowed 'General case' 0 C--O 1.24 0.597 0 C-N-CA 124.984 1.314 . . . . 0.0 112.6 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -120.02 47.43 1.03 Allowed Glycine 0 N--CA 1.413 -2.877 0 N-CA-C 109.961 -1.255 . . . . 0.0 109.961 175.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.577 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 28.9 mm -109.12 111.43 36.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 177.659 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -110.49 170.41 8.1 Favored 'General case' 0 C--N 1.269 -2.909 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.385 -178.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 38.9 t -83.47 128.21 39.0 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.076 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.5 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -92.92 -47.12 7.17 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 120.944 0.402 . . . . 0.0 110.165 -176.884 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.1 m -150.36 163.46 38.3 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 -178.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 61.0 t -136.38 148.4 27.29 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 N-CA-C 105.007 -2.22 . . . . 0.0 105.007 178.347 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.6 t -59.34 142.04 53.06 Favored 'General case' 0 C--O 1.251 1.176 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 175.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.54 ' HA ' ' NE2' ' A' ' 49' ' ' GLN . 12.0 pt-20 -82.77 -27.51 30.97 Favored 'General case' 0 C--N 1.277 -2.568 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.261 -175.65 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -137.42 70.8 0.48 Allowed Glycine 0 CA--C 1.471 -2.696 0 CA-C-O 122.1 0.833 . . . . 0.0 112.402 -175.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -150.42 170.21 30.34 Favored Glycine 1 N--CA 1.372 -5.583 0 N-CA-C 105.032 -3.227 . . . . 0.0 105.032 174.77 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.487 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -59.59 -3.66 0.51 Allowed 'General case' 0 C--N 1.277 -2.557 0 N-CA-C 114.825 1.417 . . . . 0.0 114.825 -176.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.43 -59.33 2.82 Favored 'General case' 0 C--O 1.219 -0.535 0 O-C-N 121.745 -0.597 . . . . 0.0 109.993 -176.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.54 ' NE2' ' HA ' ' A' ' 44' ' ' GLU . 41.2 mt-30 -74.34 -15.12 60.96 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.387 175.626 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.487 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 24.2 mmm180 -73.12 -34.02 65.88 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 172.219 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -59.53 -58.63 7.75 Favored 'General case' 0 N--CA 1.473 0.681 0 O-C-N 123.565 0.54 . . . . 0.0 109.813 173.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.82 -12.81 67.68 Favored Glycine 0 C--N 1.312 -0.782 0 C-N-CA 120.319 -0.943 . . . . 0.0 114.879 173.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 63.5 ttt180 -80.18 -40.77 26.59 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.4 tt -86.23 143.73 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.99 0 CA-C-N 114.335 -1.302 . . . . 0.0 107.857 179.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -138.5 175.85 9.21 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-O 121.258 0.551 . . . . 0.0 110.665 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.7 p -81.38 -3.25 6.57 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.49 -177.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -105.38 6.89 32.97 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.638 0.732 . . . . 0.0 110.545 -174.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -93.01 -173.66 3.34 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 115.186 -0.916 . . . . 0.0 111.08 -176.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.577 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 27.5 tt0 -131.86 127.45 36.56 Favored 'General case' 0 C--N 1.322 -0.608 0 C-N-CA 123.488 0.715 . . . . 0.0 111.001 -177.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.43 ' HA ' HG12 ' A' ' 91' ' ' ILE . 48.9 mm -77.21 106.45 7.29 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.852 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.45 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.711 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.1 t -89.18 -49.5 13.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-O 122.219 1.009 . . . . 0.0 110.116 -176.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.47 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 23.8 tt0 -148.64 126.84 12.13 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.496 179.225 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.37 127.69 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.641 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.118 176.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.9 t70 63.94 15.15 8.95 Favored 'General case' 0 N--CA 1.477 0.886 0 O-C-N 124.744 1.277 . . . . 0.0 111.081 173.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.93 17.32 67.83 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.855 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.1 tt -77.23 -18.68 14.34 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.156 0 CA-C-N 117.166 0.483 . . . . 0.0 111.283 -179.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.438 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 16.8 p 49.56 83.88 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.419 1.488 . . . . 0.0 113.126 -174.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -97.87 17.36 18.34 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.582 0.706 . . . . 0.0 110.805 -175.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 44.6 t -57.06 94.13 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.134 174.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.96 52.74 0.93 Allowed Glycine 0 N--CA 1.436 -1.355 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.866 178.29 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 23.5 m -130.05 178.71 4.93 Favored 'Isoleucine or valine' 0 C--O 1.243 0.723 0 CA-C-O 120.97 0.414 . . . . 0.0 111.107 178.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 15.5 p -98.31 174.61 6.41 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.425 178.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.45 -27.38 66.99 Favored 'General case' 0 C--O 1.2 -1.541 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.395 -178.61 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -71.81 -30.87 65.96 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.064 -179.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -74.64 -48.39 26.57 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 176.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.426 ' O ' HD22 ' A' ' 80' ' ' LEU . . . -61.72 -42.15 98.57 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.733 -179.115 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.1 -33.22 71.8 Favored 'General case' 0 C--O 1.204 -1.32 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 177.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 92.0 m -71.67 -48.7 45.8 Favored 'General case' 0 N--CA 1.434 -1.25 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.185 178.658 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.421 HG13 HD23 ' A' ' 80' ' ' LEU . 3.4 p -62.23 -45.59 98.4 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 178.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.426 HD22 ' O ' ' A' ' 76' ' ' ALA . 3.8 mm? -70.68 -7.82 47.4 Favored 'General case' 0 CA--C 1.549 0.918 0 CA-C-O 121.053 0.454 . . . . 0.0 111.597 178.283 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.9 tmt_? -97.44 -28.12 14.14 Favored 'General case' 0 C--O 1.214 -0.799 0 C-N-CA 122.73 0.412 . . . . 0.0 110.773 176.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -84.92 -2.52 57.96 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -177.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.0 p -76.82 159.85 29.74 Favored 'General case' 0 C--N 1.288 -2.072 0 CA-C-O 121.655 0.741 . . . . 0.0 112.866 -177.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 33.2 mmtp -118.39 -162.51 0.89 Allowed 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 114.931 -1.031 . . . . 0.0 108.639 177.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -53.04 -62.71 5.69 Favored Glycine 0 C--O 1.217 -0.953 0 O-C-N 123.846 0.716 . . . . 0.0 113.228 174.258 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.16 115.2 18.67 Favored 'General case' 0 C--O 1.245 0.867 0 CA-C-N 117.597 0.699 . . . . 0.0 110.014 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.0 t -132.24 136.43 56.44 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.907 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.213 -177.712 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 65.2 mtp180 -99.2 99.71 10.72 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 171.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.418 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 95.9 m-85 -90.31 102.78 15.51 Favored 'General case' 0 CA--C 1.486 -1.493 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 175.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.711 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 47.5 t -93.65 87.28 2.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.694 0 N-CA-C 105.326 -2.102 . . . . 0.0 105.326 178.164 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.471 HG22 ' O ' ' A' ' 59' ' ' GLN . 76.9 mt -104.11 153.22 6.24 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.785 0 CA-C-N 113.684 -1.598 . . . . 0.0 109.223 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.411 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -126.08 155.74 19.37 Favored Glycine 1 N--CA 1.384 -4.778 0 N-CA-C 108.405 -1.878 . . . . 0.0 108.405 177.135 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 64.7 ttt-85 -141.03 137.48 32.98 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 119.169 -1.012 . . . . 0.0 112.83 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.529 ' HG3' ' SD ' ' A' ' 3' ' ' MET . 39.6 mt-10 . . . . . 0 C--N 1.311 -1.102 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 173.585 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.502 -0.722 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -70.43 102.28 2.15 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 26.1 ttt 71.47 118.86 0.04 OUTLIER 'General case' 0 C--N 1.342 0.281 0 C-N-CA 124.389 1.076 . . . . 0.0 111.19 -178.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -85.26 106.47 16.7 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -178.511 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -85.54 130.98 34.45 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 176.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -138.79 142.41 33.83 Favored Pre-proline 0 C--N 1.288 -2.065 0 CA-C-O 121.214 0.531 . . . . 0.0 111.802 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -83.87 123.48 3.23 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.667 2.244 . . . . 0.0 112.732 177.21 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.2 t -114.65 105.38 18.55 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 174.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.527 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 27.6 tt0 -93.7 97.54 10.52 Favored 'General case' 0 N--CA 1.417 -2.121 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 -179.384 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -87.67 158.36 18.86 Favored 'General case' 0 N--CA 1.397 -3.105 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -174.778 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -124.04 98.93 6.01 Favored 'General case' 0 C--N 1.274 -2.681 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.229 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.458 ' O ' ' HA2' ' A' ' 85' ' ' GLY . 2.3 mmmp? -100.73 -170.0 1.79 Allowed 'General case' 0 N--CA 1.409 -2.512 0 CA-C-N 114.518 -1.219 . . . . 0.0 112.696 -179.791 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.56 157.12 36.02 Favored 'General case' 0 N--CA 1.413 -2.312 0 CA-C-N 113.03 -1.896 . . . . 0.0 106.534 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -72.48 -8.95 57.75 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 121.438 0.637 . . . . 0.0 110.253 176.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -72.22 -38.47 68.97 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 175.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.59 -145.14 16.74 Favored Glycine 0 N--CA 1.42 -2.411 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.624 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.401 ' CD1' HD12 ' A' ' 80' ' ' LEU . 18.3 mt -104.53 -46.47 4.35 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.44 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.85 29.7 37.82 Favored Glycine 0 N--CA 1.422 -2.242 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.874 -175.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.2 pt -102.42 -174.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 120.059 -0.656 . . . . 0.0 112.357 -177.293 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 21.8 m -135.66 153.04 51.75 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.551 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -126.63 164.99 25.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 123.393 0.677 . . . . 0.0 109.336 -177.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.9 tt -135.41 130.02 50.17 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-O 120.811 0.338 . . . . 0.0 110.487 175.062 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.433 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.33 107.28 3.32 Favored Glycine 0 N--CA 1.428 -1.861 0 C-N-CA 121.085 -0.578 . . . . 0.0 112.029 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.412 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.2 mmm -121.94 174.53 6.84 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.645 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.58 99.36 0.59 Allowed Glycine 0 C--N 1.29 -1.989 0 C-N-CA 119.418 -1.372 . . . . 0.0 112.171 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.0 p -96.63 91.9 2.89 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-O 122.723 1.249 . . . . 0.0 110.4 176.583 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.445 ' HA2' ' HA ' ' A' ' 33' ' ' GLU . . . -105.21 -116.81 4.26 Favored Glycine 0 N--CA 1.423 -2.213 0 CA-C-N 114.804 -1.089 . . . . 0.0 114.58 -174.194 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.97 -23.59 62.24 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 113.377 0.88 . . . . 0.0 113.377 -171.559 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -66.11 -28.14 68.58 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.476 0.655 . . . . 0.0 111.227 -177.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.2 -22.14 13.44 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.159 177.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.29 27.7 17.29 Favored Glycine 0 CA--C 1.494 -1.223 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -178.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.43 ' HB3' ' HG2' ' A' ' 34' ' ' LYS . 31.1 mt -109.75 -64.78 1.21 Allowed 'General case' 0 N--CA 1.423 -1.798 0 C-N-CA 120.051 -0.659 . . . . 0.0 111.541 -174.226 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.445 ' HA ' ' HA2' ' A' ' 27' ' ' GLY . 47.4 mt-10 65.93 35.21 6.65 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 122.414 1.102 . . . . 0.0 111.689 -178.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.43 ' HG2' ' HB3' ' A' ' 32' ' ' LEU . 2.5 ptpp? -111.48 -162.64 0.81 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-N 114.672 -1.149 . . . . 0.0 107.905 174.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.464 HD21 ' HA ' ' A' ' 69' ' ' VAL . 2.0 pp -57.56 145.67 32.8 Favored 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 123.904 0.882 . . . . 0.0 109.906 177.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -116.8 33.71 4.95 Favored Glycine 0 C--N 1.288 -2.103 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 173.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.513 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 26.3 mm -84.58 105.49 13.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 121.407 0.622 . . . . 0.0 110.337 -177.09 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -99.25 162.98 12.74 Favored 'General case' 0 C--N 1.279 -2.46 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 177.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.89 128.01 38.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.407 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.472 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -91.74 -39.07 12.02 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.303 0.573 . . . . 0.0 110.455 -177.049 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.7 m -159.65 161.0 34.9 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 17.5 t -117.62 167.73 10.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.216 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.9 t -68.86 -179.25 1.4 Allowed 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 123.044 0.538 . . . . 0.0 109.965 178.566 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -50.93 -64.29 0.86 Allowed 'General case' 0 C--O 1.225 -0.219 0 C-N-CA 124.112 0.965 . . . . 0.0 112.021 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 169.25 52.31 0.03 OUTLIER Glycine 0 N--CA 1.414 -2.802 0 C-N-CA 118.244 -1.931 . . . . 0.0 113.621 179.628 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.73 -149.01 15.95 Favored Glycine 0 N--CA 1.408 -3.215 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 170.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.401 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -58.44 -14.17 7.14 Favored 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 -172.241 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.55 -62.56 1.65 Allowed 'General case' 0 C--O 1.214 -0.807 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.4 mt-30 -72.73 -13.73 61.4 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.783 0.661 . . . . 0.0 112.783 176.208 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.401 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 27.4 mmt180 -81.17 -26.33 36.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 172.299 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -54.94 -57.55 11.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 123.743 0.652 . . . . 0.0 111.368 177.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.73 -13.15 56.48 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.225 -0.988 . . . . 0.0 114.352 175.322 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.568 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -93.74 -59.93 1.88 Allowed 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 118.082 0.941 . . . . 0.0 108.573 176.878 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.568 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 15.3 tt -64.29 143.67 15.47 Favored 'Isoleucine or valine' 0 C--O 1.246 0.893 0 O-C-N 123.707 0.63 . . . . 0.0 110.672 -175.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -142.52 172.76 12.26 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.029 0.442 . . . . 0.0 111.617 -178.377 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.7 p -76.68 -9.52 12.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.653 0 CA-C-O 121.889 0.852 . . . . 0.0 110.503 -177.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -92.22 -2.75 56.32 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.592 0.711 . . . . 0.0 110.288 -176.087 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 -82.29 174.94 10.68 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 121.988 0.899 . . . . 0.0 112.328 -176.173 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.513 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.3 tt0 -128.6 125.48 38.27 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.497 178.309 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 48.8 mm -77.16 104.74 5.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -178.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.773 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 86.1 t -87.13 -48.07 15.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.844 0.831 . . . . 0.0 110.82 -176.469 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.484 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 33.1 tt0 -151.66 125.95 9.35 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 t -115.64 128.05 73.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 175.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.1 t70 72.97 -9.15 1.16 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 125.23 1.412 . . . . 0.0 112.671 173.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.93 11.56 36.94 Favored Glycine 0 C--N 1.29 -2.011 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.763 -174.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.0 tt -70.95 -21.21 22.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-O 120.728 0.299 . . . . 0.0 111.36 -177.614 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 57.7 p 51.01 88.52 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.036 1.334 . . . . 0.0 112.192 -177.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.48 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.4 pp -100.29 17.9 20.22 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 122.29 1.043 . . . . 0.0 109.931 -175.595 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.464 ' HA ' HD21 ' A' ' 35' ' ' LEU . 39.2 t -60.69 98.49 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.297 178.234 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 112.75 9.67 18.34 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.609 177.538 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.48 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.7 m -95.56 174.21 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.485 -179.408 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 p -95.02 175.45 6.63 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.54 177.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.551 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.23 -34.35 72.1 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.628 -179.385 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.7 -36.87 73.48 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.439 -177.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.447 ' O ' HG22 ' A' ' 79' ' ' VAL . 35.4 t80 -70.68 -49.1 50.76 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.808 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.19 -45.07 94.38 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.399 -178.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -54.91 -43.29 73.14 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 122.716 0.406 . . . . 0.0 110.307 178.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 90.3 m -61.35 -41.78 97.61 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.981 177.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.447 HG22 ' O ' ' A' ' 75' ' ' PHE . 47.4 t -62.98 -51.82 67.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 178.022 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.401 HD12 ' CD1' ' A' ' 17' ' ' LEU . 3.5 mm? -68.26 -5.36 17.99 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-O 121.342 0.591 . . . . 0.0 111.63 179.525 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -102.47 -22.44 14.05 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.901 0.881 . . . . 0.0 110.891 176.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -90.44 0.85 57.13 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 121.253 0.549 . . . . 0.0 111.628 178.295 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 15.6 p -61.83 155.38 23.33 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.172 -0.922 . . . . 0.0 112.739 178.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.49 -157.55 0.8 Allowed 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.626 -1.17 . . . . 0.0 108.241 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 12' ' ' LYS . . . -51.61 -82.04 0.05 OUTLIER Glycine 0 CA--C 1.531 1.033 0 N-CA-C 114.601 0.6 . . . . 0.0 114.601 177.489 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -77.12 102.13 6.42 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.122 0.486 . . . . 0.0 111.419 -176.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 41.8 t -115.52 119.42 61.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.16 -178.323 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.34 104.49 15.22 Favored 'General case' 0 CA--C 1.487 -1.447 0 C-N-CA 120.282 -0.567 . . . . 0.0 109.963 173.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -93.33 101.33 13.57 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 174.445 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.773 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.9 t -91.53 85.77 2.3 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 N-CA-C 105.337 -2.098 . . . . 0.0 105.337 176.553 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 78.0 mt -102.68 155.37 5.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 CA-C-N 113.765 -1.561 . . . . 0.0 108.85 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -128.85 155.59 20.72 Favored Glycine 0 N--CA 1.4 -3.748 0 C-N-CA 119.747 -1.215 . . . . 0.0 110.479 177.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -132.15 152.17 51.41 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 121.551 0.691 . . . . 0.0 112.864 -178.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 . . . . . 0 C--N 1.299 -1.606 0 C-N-CA 127.231 2.212 . . . . 0.0 105.505 174.381 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.502 -0.722 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -70.43 102.28 2.15 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 26.1 ttt 71.47 118.86 0.04 OUTLIER 'General case' 0 C--N 1.342 0.281 0 C-N-CA 124.389 1.076 . . . . 0.0 111.19 -178.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -85.26 106.47 16.7 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -178.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -85.54 130.98 34.45 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -138.79 142.41 33.83 Favored Pre-proline 0 C--N 1.288 -2.065 0 CA-C-O 121.214 0.531 . . . . 0.0 111.802 -179.176 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -83.87 123.48 3.23 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.667 2.244 . . . . 0.0 112.732 177.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.2 t -114.65 105.38 18.55 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 174.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.527 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 27.6 tt0 -93.7 97.54 10.52 Favored 'General case' 0 N--CA 1.417 -2.121 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 -179.384 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -87.67 158.36 18.86 Favored 'General case' 0 N--CA 1.397 -3.105 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -174.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -124.04 98.93 6.01 Favored 'General case' 0 C--N 1.274 -2.681 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.229 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.458 ' O ' ' HA2' ' A' ' 85' ' ' GLY . 2.3 mmmp? -100.73 -170.0 1.79 Allowed 'General case' 0 N--CA 1.409 -2.512 0 CA-C-N 114.518 -1.219 . . . . 0.0 112.696 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.56 157.12 36.02 Favored 'General case' 0 N--CA 1.413 -2.312 0 CA-C-N 113.03 -1.896 . . . . 0.0 106.534 174.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -72.48 -8.95 57.75 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 121.438 0.637 . . . . 0.0 110.253 176.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -72.22 -38.47 68.97 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 175.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.59 -145.14 16.74 Favored Glycine 0 N--CA 1.42 -2.411 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.624 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.401 ' CD1' HD12 ' A' ' 80' ' ' LEU . 18.3 mt -104.53 -46.47 4.35 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.85 29.7 37.82 Favored Glycine 0 N--CA 1.422 -2.242 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.874 -175.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.2 pt -102.42 -174.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 120.059 -0.656 . . . . 0.0 112.357 -177.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 21.8 m -135.66 153.04 51.75 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.551 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -126.63 164.99 25.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 123.393 0.677 . . . . 0.0 109.336 -177.539 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.9 tt -135.41 130.02 50.17 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-O 120.811 0.338 . . . . 0.0 110.487 175.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.433 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.33 107.28 3.32 Favored Glycine 0 N--CA 1.428 -1.861 0 C-N-CA 121.085 -0.578 . . . . 0.0 112.029 -178.292 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.412 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.2 mmm -121.94 174.53 6.84 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.58 99.36 0.59 Allowed Glycine 0 C--N 1.29 -1.989 0 C-N-CA 119.418 -1.372 . . . . 0.0 112.171 179.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.0 p -96.63 91.9 2.89 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-O 122.723 1.249 . . . . 0.0 110.4 176.583 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.445 ' HA2' ' HA ' ' A' ' 33' ' ' GLU . . . -105.21 -116.81 4.26 Favored Glycine 0 N--CA 1.423 -2.213 0 CA-C-N 114.804 -1.089 . . . . 0.0 114.58 -174.194 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.97 -23.59 62.24 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 113.377 0.88 . . . . 0.0 113.377 -171.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -66.11 -28.14 68.58 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.476 0.655 . . . . 0.0 111.227 -177.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.2 -22.14 13.44 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.159 177.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.29 27.7 17.29 Favored Glycine 0 CA--C 1.494 -1.223 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.43 ' HB3' ' HG2' ' A' ' 34' ' ' LYS . 31.1 mt -109.75 -64.78 1.21 Allowed 'General case' 0 N--CA 1.423 -1.798 0 C-N-CA 120.051 -0.659 . . . . 0.0 111.541 -174.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.445 ' HA ' ' HA2' ' A' ' 27' ' ' GLY . 47.4 mt-10 65.93 35.21 6.65 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 122.414 1.102 . . . . 0.0 111.689 -178.485 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.43 ' HG2' ' HB3' ' A' ' 32' ' ' LEU . 2.5 ptpp? -111.48 -162.64 0.81 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-N 114.672 -1.149 . . . . 0.0 107.905 174.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.464 HD21 ' HA ' ' A' ' 69' ' ' VAL . 2.0 pp -57.56 145.67 32.8 Favored 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 123.904 0.882 . . . . 0.0 109.906 177.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -116.8 33.71 4.95 Favored Glycine 0 C--N 1.288 -2.103 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 173.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.513 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 26.3 mm -84.58 105.49 13.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 121.407 0.622 . . . . 0.0 110.337 -177.09 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -99.25 162.98 12.74 Favored 'General case' 0 C--N 1.279 -2.46 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 177.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.89 128.01 38.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.472 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -91.74 -39.07 12.02 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.303 0.573 . . . . 0.0 110.455 -177.049 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.7 m -159.65 161.0 34.9 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 17.5 t -117.62 167.73 10.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.9 t -68.86 -179.25 1.4 Allowed 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 123.044 0.538 . . . . 0.0 109.965 178.566 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -50.93 -64.29 0.86 Allowed 'General case' 0 C--O 1.225 -0.219 0 C-N-CA 124.112 0.965 . . . . 0.0 112.021 -178.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 169.25 52.31 0.03 OUTLIER Glycine 0 N--CA 1.414 -2.802 0 C-N-CA 118.244 -1.931 . . . . 0.0 113.621 179.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.73 -149.01 15.95 Favored Glycine 0 N--CA 1.408 -3.215 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 170.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.401 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -58.44 -14.17 7.14 Favored 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 -172.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.55 -62.56 1.65 Allowed 'General case' 0 C--O 1.214 -0.807 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.4 mt-30 -72.73 -13.73 61.4 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.783 0.661 . . . . 0.0 112.783 176.208 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.401 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 27.4 mmt180 -81.17 -26.33 36.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 172.299 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -54.94 -57.55 11.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 123.743 0.652 . . . . 0.0 111.368 177.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.73 -13.15 56.48 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.225 -0.988 . . . . 0.0 114.352 175.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.568 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -93.74 -59.93 1.88 Allowed 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 118.082 0.941 . . . . 0.0 108.573 176.878 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.568 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 15.3 tt -64.29 143.67 15.47 Favored 'Isoleucine or valine' 0 C--O 1.246 0.893 0 O-C-N 123.707 0.63 . . . . 0.0 110.672 -175.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -142.52 172.76 12.26 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.029 0.442 . . . . 0.0 111.617 -178.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.7 p -76.68 -9.52 12.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.653 0 CA-C-O 121.889 0.852 . . . . 0.0 110.503 -177.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -92.22 -2.75 56.32 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.592 0.711 . . . . 0.0 110.288 -176.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 -82.29 174.94 10.68 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 121.988 0.899 . . . . 0.0 112.328 -176.173 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.513 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.3 tt0 -128.6 125.48 38.27 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.497 178.309 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 48.8 mm -77.16 104.74 5.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -178.582 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.773 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 86.1 t -87.13 -48.07 15.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.844 0.831 . . . . 0.0 110.82 -176.469 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.484 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 33.1 tt0 -151.66 125.95 9.35 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 t -115.64 128.05 73.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 175.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.1 t70 72.97 -9.15 1.16 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 125.23 1.412 . . . . 0.0 112.671 173.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.93 11.56 36.94 Favored Glycine 0 C--N 1.29 -2.011 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.763 -174.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.0 tt -70.95 -21.21 22.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-O 120.728 0.299 . . . . 0.0 111.36 -177.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 57.7 p 51.01 88.52 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.036 1.334 . . . . 0.0 112.192 -177.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.48 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.4 pp -100.29 17.9 20.22 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 122.29 1.043 . . . . 0.0 109.931 -175.595 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.464 ' HA ' HD21 ' A' ' 35' ' ' LEU . 39.2 t -60.69 98.49 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.297 178.234 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 112.75 9.67 18.34 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.609 177.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.48 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.7 m -95.56 174.21 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.485 -179.408 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 p -95.02 175.45 6.63 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.54 177.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.551 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.23 -34.35 72.1 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.628 -179.385 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.7 -36.87 73.48 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.439 -177.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.447 ' O ' HG22 ' A' ' 79' ' ' VAL . 35.4 t80 -70.68 -49.1 50.76 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.808 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.19 -45.07 94.38 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.399 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -54.91 -43.29 73.14 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 122.716 0.406 . . . . 0.0 110.307 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 90.3 m -61.35 -41.78 97.61 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.981 177.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.447 HG22 ' O ' ' A' ' 75' ' ' PHE . 47.4 t -62.98 -51.82 67.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 178.022 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.401 HD12 ' CD1' ' A' ' 17' ' ' LEU . 3.5 mm? -68.26 -5.36 17.99 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-O 121.342 0.591 . . . . 0.0 111.63 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -102.47 -22.44 14.05 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.901 0.881 . . . . 0.0 110.891 176.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -90.44 0.85 57.13 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 121.253 0.549 . . . . 0.0 111.628 178.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 15.6 p -61.83 155.38 23.33 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.172 -0.922 . . . . 0.0 112.739 178.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.49 -157.55 0.8 Allowed 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.626 -1.17 . . . . 0.0 108.241 179.377 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 12' ' ' LYS . . . -51.61 -82.04 0.05 OUTLIER Glycine 0 CA--C 1.531 1.033 0 N-CA-C 114.601 0.6 . . . . 0.0 114.601 177.489 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -77.12 102.13 6.42 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.122 0.486 . . . . 0.0 111.419 -176.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 41.8 t -115.52 119.42 61.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.16 -178.323 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.34 104.49 15.22 Favored 'General case' 0 CA--C 1.487 -1.447 0 C-N-CA 120.282 -0.567 . . . . 0.0 109.963 173.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -93.33 101.33 13.57 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 174.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.773 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.9 t -91.53 85.77 2.3 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 N-CA-C 105.337 -2.098 . . . . 0.0 105.337 176.553 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 78.0 mt -102.68 155.37 5.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 CA-C-N 113.765 -1.561 . . . . 0.0 108.85 179.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -128.85 155.59 20.72 Favored Glycine 0 N--CA 1.4 -3.748 0 C-N-CA 119.747 -1.215 . . . . 0.0 110.479 177.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -132.15 152.17 51.41 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 121.551 0.691 . . . . 0.0 112.864 -178.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 . . . . . 0 C--N 1.299 -1.606 0 C-N-CA 127.231 2.212 . . . . 0.0 105.505 174.381 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.949 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 41.7 m80 -88.24 124.84 34.26 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.186 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 47.5 tpp -150.87 143.43 24.38 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 -176.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.401 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 40.9 tt0 -105.03 107.54 18.58 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 175.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -86.82 128.74 35.05 Favored 'General case' 0 C--N 1.313 -0.994 0 O-C-N 123.648 0.592 . . . . 0.0 110.007 -176.755 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 33.3 p90 -142.91 141.86 20.84 Favored Pre-proline 0 N--CA 1.423 -1.782 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -178.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -81.18 122.58 4.23 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.826 2.351 . . . . 0.0 112.107 176.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.486 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 47.2 t -103.03 100.35 10.23 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.98 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 174.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 35.9 tt0 -81.58 102.03 10.37 Favored 'General case' 0 N--CA 1.427 -1.587 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 174.174 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.539 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -104.04 134.49 47.22 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 -175.449 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -102.78 97.59 7.73 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 175.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.0 mmmp? -84.42 177.53 8.09 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 115.115 1.524 . . . . 0.0 115.115 -177.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -80.66 -174.47 4.73 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 112.759 -2.019 . . . . 0.0 110.457 -175.041 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -71.79 -26.62 62.49 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.742 176.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -59.11 -41.99 89.48 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.504 178.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 120.2 -114.12 2.61 Favored Glycine 0 N--CA 1.413 -2.888 0 N-CA-C 108.044 -2.023 . . . . 0.0 108.044 -175.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.427 ' HG ' HG21 ' A' ' 19' ' ' ILE . 10.5 tp -113.63 -64.41 1.31 Allowed 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -178.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 79.75 28.64 50.46 Favored Glycine 0 N--CA 1.437 -1.259 0 O-C-N 124.183 0.927 . . . . 0.0 113.014 177.021 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.427 HG21 ' HG ' ' A' ' 17' ' ' LEU . 18.0 pt -104.99 172.11 1.66 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.826 0 C-N-CA 119.543 -0.863 . . . . 0.0 111.278 179.649 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.1 m -123.81 147.4 47.61 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.854 -179.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.528 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -117.66 162.2 15.87 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -178.248 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.451 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.9 tt -128.96 132.83 67.05 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.116 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 174.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.413 ' HA2' HD12 ' A' ' 37' ' ' ILE . . . -93.22 106.69 3.45 Favored Glycine 0 N--CA 1.42 -2.405 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.029 -177.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.422 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.7 mmm -115.82 156.2 26.5 Favored 'General case' 0 C--N 1.289 -2.052 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 177.414 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.92 76.31 0.23 Allowed Glycine 0 C--N 1.286 -2.195 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 176.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.6 p -84.8 95.58 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 122.628 1.204 . . . . 0.0 112.031 -176.511 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -94.03 -126.19 4.42 Favored Glycine 0 N--CA 1.424 -2.137 0 CA-C-N 114.48 -1.236 . . . . 0.0 110.575 179.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -93.02 99.68 12.26 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.77 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -140.93 -57.16 0.51 Allowed 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.54 -40.51 7.39 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.913 174.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.22 28.78 0.15 Allowed Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.842 178.69 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -95.12 -59.54 1.88 Allowed 'General case' 0 C--N 1.313 -0.991 0 O-C-N 122.483 -0.422 . . . . 0.0 111.835 -177.181 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 54.3 70.48 0.61 Allowed 'General case' 0 C--O 1.248 1.013 0 C-N-CA 123.505 0.722 . . . . 0.0 111.732 178.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 13.6 ptmt -165.54 -165.25 0.82 Allowed 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -176.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.423 ' O ' ' HG ' ' A' ' 35' ' ' LEU . 1.0 OUTLIER -56.44 154.04 9.04 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 175.14 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -117.91 34.59 4.42 Favored Glycine 0 N--CA 1.416 -2.655 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.922 173.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.451 ' HA ' ' O ' ' A' ' 22' ' ' ILE . 29.3 mm -87.15 99.04 7.88 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 119.83 -0.748 . . . . 0.0 109.868 179.491 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -97.09 159.34 14.97 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 115.13 -0.941 . . . . 0.0 109.724 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.7 t -77.17 115.41 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.544 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 176.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -87.15 -51.4 6.01 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.858 -175.229 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -143.43 157.16 44.68 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 -179.006 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 50.0 t -126.85 151.01 33.14 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 N-CA-C 105.984 -1.858 . . . . 0.0 105.984 175.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.4 t -64.29 144.08 57.42 Favored 'General case' 0 N--CA 1.433 -1.325 0 CA-C-O 121.869 0.842 . . . . 0.0 109.942 178.253 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -80.24 -27.8 38.64 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 114.533 -1.212 . . . . 0.0 108.393 179.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -123.45 66.18 0.51 Allowed Glycine 0 CA--C 1.453 -3.791 0 CA-C-N 115.019 -0.991 . . . . 0.0 111.59 -173.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -154.63 155.17 26.03 Favored Glycine 1 N--CA 1.349 -7.159 0 N-CA-C 107.799 -2.121 . . . . 0.0 107.799 175.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.461 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -61.32 -0.76 0.4 Allowed 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -179.356 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.06 -53.69 9.43 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -76.66 -6.31 51.56 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.743 175.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.461 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 1.8 mmp_? -86.95 -38.27 16.81 Favored 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 172.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.537 ' OD1' ' HB2' ' A' ' 53' ' ' ARG . 11.4 t70 -66.13 -46.0 79.06 Favored 'General case' 0 C--O 1.217 -0.631 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 176.523 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.86 -17.44 11.33 Favored Glycine 0 N--CA 1.469 0.841 0 N-CA-C 114.54 0.576 . . . . 0.0 114.54 173.096 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.537 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 6.7 ttm180 -64.05 -40.37 96.14 Favored 'General case' 0 C--N 1.316 -0.85 0 C-N-CA 124.285 1.034 . . . . 0.0 110.238 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.8 tt -83.04 162.54 3.19 Favored 'Isoleucine or valine' 0 C--O 1.257 1.451 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 -178.465 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -125.74 -171.74 2.45 Favored 'General case' 0 N--CA 1.423 -1.805 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.308 -178.309 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.9 p -123.51 16.46 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.042 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 173.312 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 34.9 p30 -134.4 16.23 3.72 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 122.591 1.186 . . . . 0.0 109.923 -174.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -112.89 -169.89 1.57 Allowed 'General case' 0 C--N 1.27 -2.865 0 CA-C-N 113.69 -1.596 . . . . 0.0 109.943 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.444 ' O ' HG23 ' A' ' 91' ' ' ILE . 62.7 tt0 -132.39 132.35 42.74 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 116.72 -0.218 . . . . 0.0 110.595 -173.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.425 ' HA ' HG12 ' A' ' 91' ' ' ILE . 50.5 mm -74.38 104.83 3.15 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.961 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.013 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.701 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 94.1 t -86.33 -49.22 15.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 121.292 0.568 . . . . 0.0 110.139 -176.622 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.429 ' OE1' ' HB3' ' A' ' 67' ' ' SER . 34.8 tt0 -154.39 116.67 4.29 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.254 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.2 t -108.83 129.98 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.209 0 N-CA-C 111.765 0.283 . . . . 0.0 111.765 177.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 15.6 t70 62.09 17.06 8.79 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 124.922 1.289 . . . . 0.0 111.441 174.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.9 10.98 85.69 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 115.65 -0.705 . . . . 0.0 112.422 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.0 tt -73.83 -14.81 16.54 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 O-C-N 122.528 -0.395 . . . . 0.0 111.171 -176.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.429 ' HB3' ' OE1' ' A' ' 62' ' ' GLU . 8.9 p 42.95 79.59 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 124.801 1.24 . . . . 0.0 113.357 -176.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.47 ' O ' HG23 ' A' ' 71' ' ' VAL . 1.5 pp -90.84 14.14 14.46 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.739 -174.435 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.411 ' HA ' HD22 ' A' ' 35' ' ' LEU . 48.7 t -58.84 98.0 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 114.736 -1.12 . . . . 0.0 109.586 173.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 112.96 18.24 7.44 Favored Glycine 0 N--CA 1.435 -1.42 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.781 177.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 68' ' ' LEU . 15.6 m -105.33 175.72 1.13 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.518 0 CA-C-N 117.205 0.502 . . . . 0.0 110.578 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.6 p -94.65 179.37 5.28 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-O 121.633 0.73 . . . . 0.0 110.012 178.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.528 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -65.87 -35.29 80.23 Favored 'General case' 0 N--CA 1.419 -1.975 0 CA-C-N 114.803 -1.089 . . . . 0.0 111.055 -179.619 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -70.17 -27.68 64.72 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.492 -177.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 36.6 t80 -75.47 -51.8 12.18 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 175.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.2 -44.06 92.25 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.448 -0.797 . . . . 0.0 112.218 -178.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.46 -10.66 36.08 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.335 0.654 . . . . 0.0 111.59 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.417 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 98.3 m -93.01 -49.18 6.15 Favored 'General case' 0 N--CA 1.412 -2.355 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.668 175.224 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.526 ' O ' HG23 ' A' ' 83' ' ' THR . 38.5 t -59.64 -52.07 65.34 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.649 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.404 HD23 HG23 ' A' ' 60' ' ' ILE . 3.6 mm? -68.62 3.39 1.88 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.611 0.764 . . . . 0.0 112.228 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.417 ' HB3' ' O ' ' A' ' 78' ' ' THR . 11.7 ttm180 -109.91 -41.02 4.6 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 121.99 0.9 . . . . 0.0 109.109 176.334 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -80.31 -4.83 54.92 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 114.496 -1.229 . . . . 0.0 112.182 -174.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.526 HG23 ' O ' ' A' ' 79' ' ' VAL . 7.5 p -60.7 147.68 41.3 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 123.759 0.824 . . . . 0.0 112.194 177.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.85 -172.88 2.17 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.852 177.157 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -38.93 -73.74 0.15 Allowed Glycine 0 C--O 1.217 -0.94 0 O-C-N 124.484 1.115 . . . . 0.0 115.067 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.539 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 36.3 m-80 -83.05 105.11 13.76 Favored 'General case' 0 CA--C 1.497 -1.062 0 CA-C-N 118.0 0.9 . . . . 0.0 110.956 -179.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -104.24 143.38 16.0 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 CA-C-N 115.44 -0.8 . . . . 0.0 108.927 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 60.3 mtp180 -107.27 97.28 7.06 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 173.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.486 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 81.6 m-85 -94.67 104.76 16.68 Favored 'General case' 0 CA--C 1.483 -1.6 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 177.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.701 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 62.5 t -87.65 94.74 4.71 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.609 0 N-CA-C 105.108 -2.182 . . . . 0.0 105.108 173.198 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.444 HG23 ' O ' ' A' ' 59' ' ' GLN . 93.9 mt -114.49 153.76 15.95 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.671 0 CA-C-N 114.894 -1.048 . . . . 0.0 108.245 177.515 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -118.02 157.88 14.96 Favored Glycine 1 N--CA 1.393 -4.221 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.534 177.459 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.424 HH21 ' HG2' ' A' ' 94' ' ' GLU . 8.1 tpm_? -129.48 123.66 32.09 Favored 'General case' 0 C--N 1.29 -2.005 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.569 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.424 ' HG2' HH21 ' A' ' 93' ' ' ARG . 16.5 pt-20 . . . . . 0 N--CA 1.428 -1.567 0 N-CA-C 105.886 -1.894 . . . . 0.0 105.886 171.014 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.501 -0.826 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 41.5 m80 -113.74 18.23 17.58 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.975 0.387 . . . . 0.0 110.639 -178.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 25.4 ttt 71.76 117.25 0.05 OUTLIER 'General case' 0 CA--C 1.509 -0.613 0 C-N-CA 125.333 1.453 . . . . 0.0 109.606 -173.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.427 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 39.1 tt0 -87.4 107.81 18.71 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -177.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -89.93 120.33 31.06 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 177.346 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -131.63 143.64 50.01 Favored Pre-proline 0 C--N 1.29 -1.987 0 CA-C-O 121.322 0.582 . . . . 0.0 112.356 -174.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -84.01 127.45 4.1 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.914 2.409 . . . . 0.0 112.273 175.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 23.6 t -117.52 104.63 16.68 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.271 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 174.381 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.427 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 36.4 tt0 -91.48 102.41 15.08 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.741 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.505 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -91.23 144.51 25.54 Favored 'General case' 0 N--CA 1.422 -1.866 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 -173.983 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -113.12 84.54 2.01 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 170.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.447 ' HE2' ' H ' ' A' ' 48' ' ' ALA . 5.1 mmtt -71.89 165.5 24.04 Favored 'General case' 0 N--CA 1.417 -2.077 0 N-CA-C 114.071 1.137 . . . . 0.0 114.071 -179.243 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -84.38 -175.18 5.67 Favored 'General case' 0 N--CA 1.433 -1.308 0 CA-C-N 113.613 -1.631 . . . . 0.0 111.123 -176.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -78.21 -9.27 59.13 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 -172.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -77.72 -45.47 24.67 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 121.746 0.784 . . . . 0.0 108.889 176.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.85 -160.28 21.75 Favored Glycine 0 N--CA 1.422 -2.271 0 N-CA-C 108.551 -1.82 . . . . 0.0 108.551 -176.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.8 mt -75.52 -50.8 14.57 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 118.011 0.905 . . . . 0.0 109.599 -176.346 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 68.1 27.97 73.52 Favored Glycine 0 N--CA 1.433 -1.56 0 CA-C-N 114.695 -1.139 . . . . 0.0 110.453 -176.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 18.1 pt -99.57 171.02 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.832 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.165 -178.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.1 m -133.35 148.34 51.86 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -177.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -115.41 161.59 14.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.424 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 15.3 tt -129.14 131.84 67.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 C-N-CA 120.611 -0.436 . . . . 0.0 109.895 174.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.434 ' HA2' HD12 ' A' ' 37' ' ' ILE . . . -90.65 97.08 2.28 Favored Glycine 0 CA--C 1.494 -1.238 0 C-N-CA 120.974 -0.631 . . . . 0.0 112.138 -177.719 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.437 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 95.1 mmm -111.73 -175.72 2.76 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.01 86.45 0.2 Allowed Glycine 0 C--N 1.282 -2.43 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 174.107 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.2 p -89.67 120.32 38.23 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-O 121.727 0.775 . . . . 0.0 111.809 -175.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.4 ' HA2' ' HB1' ' A' ' 30' ' ' ALA . . . 70.36 20.55 76.91 Favored Glycine 0 N--CA 1.432 -1.574 0 CA-C-N 114.766 -1.106 . . . . 0.0 113.928 175.522 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.65 -39.57 94.67 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.453 0.644 . . . . 0.0 110.545 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.5 m-20 -114.08 12.15 17.82 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.003 -179.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.4 ' HB1' ' HA2' ' A' ' 27' ' ' GLY . . . -109.0 7.51 25.88 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.019 -0.537 . . . . 0.0 112.341 -176.625 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.01 11.55 42.61 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 119.881 -1.152 . . . . 0.0 114.168 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.7 mp -107.41 -62.91 1.36 Allowed 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 117.384 0.592 . . . . 0.0 110.968 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 57.32 84.8 0.09 Allowed 'General case' 0 C--O 1.245 0.862 0 C-N-CA 124.134 0.974 . . . . 0.0 111.9 -172.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.3 ptmt -143.93 174.45 10.82 Favored 'General case' 0 N--CA 1.413 -2.324 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 178.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.467 HD21 HG23 ' A' ' 69' ' ' VAL . 2.2 pt? -56.57 145.34 28.56 Favored 'General case' 0 C--N 1.289 -2.06 0 O-C-N 124.205 0.941 . . . . 0.0 110.933 176.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -110.49 19.07 26.92 Favored Glycine 0 N--CA 1.417 -2.592 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 175.152 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.605 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 35.9 mm -85.73 104.04 13.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-O 121.498 0.666 . . . . 0.0 110.457 -177.551 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.422 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 96.6 m-85 -101.65 163.31 12.33 Favored 'General case' 0 C--N 1.281 -2.4 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.484 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 47.0 t -77.35 116.29 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 N-CA-C 106.935 -1.505 . . . . 0.0 106.935 175.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.47 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.2 OUTLIER -83.44 -39.03 21.11 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 -177.621 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -157.56 158.23 35.23 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 4.3 p -137.52 97.81 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 CA-C-O 121.456 0.646 . . . . 0.0 111.557 178.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.8 t 51.94 168.36 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.478 0 C-N-CA 127.221 2.208 . . . . 0.0 113.933 178.307 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -73.35 -28.79 62.24 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 173.693 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 143.4 38.03 0.07 OUTLIER Glycine 0 N--CA 1.415 -2.716 0 CA-C-N 114.105 -1.407 . . . . 0.0 111.172 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -84.82 -151.36 13.88 Favored Glycine 0 N--CA 1.41 -3.096 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 174.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.408 ' HB2' ' HA ' ' A' ' 12' ' ' LYS . . . -61.67 -10.57 8.79 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 115.178 1.547 . . . . 0.0 115.178 -172.518 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.447 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -80.48 -58.01 3.32 Favored 'General case' 0 C--O 1.214 -0.796 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 43.0 mt-30 -63.27 -29.83 71.09 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.948 173.421 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 31.0 mmm180 -66.78 -34.37 77.68 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.863 176.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 48' ' ' ALA . 11.6 t70 -56.3 -52.15 65.57 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.719 176.607 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.19 -7.14 72.83 Favored Glycine 0 C--N 1.313 -0.737 0 N-CA-C 114.944 0.737 . . . . 0.0 114.944 173.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -86.57 -43.69 12.5 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.3 tt -78.54 152.12 5.11 Favored 'Isoleucine or valine' 0 C--O 1.243 0.736 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 177.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . 0.538 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 19.5 mt-30 -140.69 171.06 14.63 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 121.02 0.438 . . . . 0.0 110.019 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.7 p -83.24 -11.91 11.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.419 1.104 . . . . 0.0 108.587 175.288 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -88.65 3.24 51.33 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.786 -172.152 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.538 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 13.0 m-20 -109.6 -165.99 1.06 Allowed 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -174.254 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.605 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 18.9 tt0 -136.41 129.19 30.82 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 123.683 0.793 . . . . 0.0 111.261 -176.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.499 ' HA ' HG12 ' A' ' 91' ' ' ILE . 46.9 mm -73.88 108.33 5.25 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.877 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -179.331 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.765 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 97.3 t -92.41 -49.87 12.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 CA-C-O 121.854 0.835 . . . . 0.0 110.403 -178.349 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.543 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.2 tt0 -146.13 127.89 15.3 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.442 ' C ' ' H ' ' A' ' 65' ' ' GLY . 2.7 t -117.78 126.39 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.917 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.612 175.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.4 t70 72.51 -13.67 0.62 Allowed 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 125.391 1.476 . . . . 0.0 112.97 173.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.442 ' H ' ' C ' ' A' ' 63' ' ' VAL . . . 111.0 11.41 18.68 Favored Glycine 0 C--N 1.288 -2.099 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.003 -176.177 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.5 tt -75.33 -18.35 15.96 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.733 0 CA-C-O 120.777 0.323 . . . . 0.0 110.617 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.451 ' HA ' ' HG3' ' A' ' 62' ' ' GLU . 25.7 m 49.19 87.15 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.257 1.423 . . . . 0.0 111.54 -176.262 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.455 ' O ' HG23 ' A' ' 71' ' ' VAL . 2.1 pp -103.93 15.58 28.29 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-O 122.246 1.022 . . . . 0.0 109.484 -176.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.467 HG23 HD21 ' A' ' 35' ' ' LEU . 6.3 p -62.66 79.62 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 114.001 -1.454 . . . . 0.0 111.324 175.819 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 118.17 49.35 0.37 Allowed Glycine 0 N--CA 1.433 -1.505 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.048 -178.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 68' ' ' LEU . 32.4 m -127.02 178.08 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.242 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 13.3 p -91.08 174.66 7.29 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 120.933 0.397 . . . . 0.0 111.27 179.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.26 -35.35 80.76 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.026 -179.301 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -70.36 -31.14 68.28 Favored 'General case' 0 CA--C 1.511 -0.519 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.695 -177.604 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -71.52 -54.22 11.27 Favored 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.44 -48.25 79.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.419 -0.809 . . . . 0.0 112.022 -178.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.05 -25.75 65.59 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 -179.149 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 71.4 m -76.22 -44.14 39.01 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.485 176.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.407 ' O ' HG22 ' A' ' 83' ' ' THR . 33.5 t -61.75 -51.74 69.08 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.621 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -68.12 -3.82 11.67 Favored 'General case' 0 CA--C 1.556 1.188 0 CA-C-O 121.341 0.591 . . . . 0.0 112.448 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 36.4 ttt180 -95.64 -40.79 9.23 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 175.642 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 23.1 m-80 -89.01 8.06 31.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 114.241 -1.345 . . . . 0.0 113.88 -171.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.407 HG22 ' O ' ' A' ' 79' ' ' VAL . 1.3 p -75.9 154.38 36.05 Favored 'General case' 0 C--N 1.28 -2.431 0 C-N-CA 123.596 0.758 . . . . 0.0 112.332 178.689 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.29 -170.38 1.63 Allowed 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.984 176.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -50.41 -62.87 4.79 Favored Glycine 0 N--CA 1.473 1.116 0 N-CA-C 115.341 0.896 . . . . 0.0 115.341 -176.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.505 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 20.7 m120 -81.49 104.6 12.04 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 117.436 0.618 . . . . 0.0 110.992 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.427 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.3 t -113.75 128.76 70.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.195 -176.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.14 104.23 16.26 Favored 'General case' 0 C--N 1.293 -1.872 0 C-N-CA 119.979 -0.689 . . . . 0.0 109.474 170.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.423 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 93.2 m-85 -94.8 100.66 12.51 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 174.53 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.765 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 27.2 t -93.62 83.82 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.434 0 N-CA-C 105.288 -2.116 . . . . 0.0 105.288 177.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.514 HG23 ' O ' ' A' ' 59' ' ' GLN . 64.7 mt -97.61 158.36 3.31 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.588 0 CA-C-N 113.335 -1.757 . . . . 0.0 109.563 -178.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -133.3 147.83 19.13 Favored Glycine 1 N--CA 1.393 -4.187 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.607 176.836 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 24.8 tpt180 -115.73 119.2 35.27 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 . . . . . 0 N--CA 1.413 -2.315 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 173.717 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.501 -0.799 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -80.93 113.51 19.19 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.082 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 50.0 ttm -76.74 114.09 15.11 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-O 120.965 0.412 . . . . 0.0 110.896 -177.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -83.58 110.5 18.29 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.332 -0.849 . . . . 0.0 108.894 178.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -85.32 130.37 34.61 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.245 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 24.8 p90 -139.37 139.85 24.0 Favored Pre-proline 0 N--CA 1.426 -1.667 0 CA-C-O 121.454 0.645 . . . . 0.0 112.157 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -82.77 121.94 3.37 Favored 'Trans proline' 0 N--CA 1.446 -1.273 0 C-N-CA 122.765 2.31 . . . . 0.0 112.844 177.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.0 t -111.28 105.08 18.11 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 176.24 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.621 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.1 tt0 -85.39 105.28 15.91 Favored 'General case' 0 N--CA 1.42 -1.956 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 174.674 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.553 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 15.9 tp -95.76 151.35 19.45 Favored 'General case' 0 N--CA 1.41 -2.471 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 -176.719 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -115.27 92.59 3.97 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 177.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.401 ' HA ' ' HB1' ' A' ' 47' ' ' ALA . 2.6 mmmp? -84.24 177.61 8.12 Favored 'General case' 0 C--N 1.289 -2.032 0 CA-C-O 122.498 1.142 . . . . 0.0 113.675 178.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.401 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.0 p-10 -88.86 172.06 9.46 Favored 'General case' 0 C--N 1.286 -2.178 0 CA-C-N 112.835 -1.984 . . . . 0.0 109.536 179.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -64.32 -18.22 64.42 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -174.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.401 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 23.3 t70 -68.61 -32.98 73.24 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.778 0.799 . . . . 0.0 110.209 178.652 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.97 -124.44 5.94 Favored Glycine 0 CA--C 1.477 -2.285 0 N-CA-C 108.706 -1.758 . . . . 0.0 108.706 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.42 HD22 HG22 ' A' ' 87' ' ' VAL . 25.7 mt -104.27 -52.58 2.89 Favored 'General case' 0 CA--C 1.462 -2.407 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.45 178.499 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.2 24.55 76.53 Favored Glycine 0 N--CA 1.426 -2.003 0 O-C-N 124.678 1.236 . . . . 0.0 110.911 -175.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 28.0 pt -101.27 176.48 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.482 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 23.7 m -132.65 148.59 52.35 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -176.489 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -119.82 167.11 13.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.439 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.2 tt -133.36 132.26 57.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.668 177.391 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.428 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.1 102.07 2.79 Favored Glycine 0 N--CA 1.435 -1.43 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.607 -177.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 95.5 mmm -115.68 173.41 6.56 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.04 85.21 0.37 Allowed Glycine 0 C--N 1.295 -1.702 0 C-N-CA 120.121 -1.038 . . . . 0.0 112.469 179.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.421 HG12 ' HA2' ' A' ' 36' ' ' GLY . 13.2 p -122.47 154.74 27.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.391 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.46 -37.62 3.09 Favored Glycine 0 N--CA 1.421 -2.354 0 C-N-CA 120.18 -1.01 . . . . 0.0 111.425 177.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.08 -30.46 60.96 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -67.62 -40.02 84.68 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.47 175.174 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.93 -24.55 62.47 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 124.402 1.081 . . . . 0.0 111.945 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.15 6.54 68.92 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.399 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -101.46 -27.66 13.01 Favored 'General case' 0 C--N 1.314 -0.972 0 O-C-N 122.545 -0.385 . . . . 0.0 110.387 179.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 55.7 89.65 0.04 OUTLIER 'General case' 0 CA--C 1.514 -0.406 0 C-N-CA 124.557 1.143 . . . . 0.0 112.022 -176.292 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 21.9 ptmt -129.34 -173.05 2.9 Favored 'General case' 0 N--CA 1.411 -2.377 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.46 HD21 ' HA ' ' A' ' 69' ' ' VAL . 2.5 pp -72.23 149.63 44.39 Favored 'General case' 0 C--N 1.282 -2.337 0 O-C-N 123.956 0.785 . . . . 0.0 109.283 178.042 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.421 ' HA2' HG12 ' A' ' 26' ' ' VAL . . . -110.47 27.48 11.39 Favored Glycine 0 N--CA 1.423 -2.213 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 172.777 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.439 ' HA ' ' O ' ' A' ' 22' ' ' ILE . 35.3 mm -83.67 102.84 10.18 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 CA-C-O 121.47 0.652 . . . . 0.0 110.068 -178.626 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -96.83 169.2 10.02 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 177.232 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.0 t -83.43 129.33 37.67 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 175.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 55.6 tptt -93.64 -46.37 7.3 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.248 -177.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.8 m -151.72 161.45 42.64 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 -179.258 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 40.6 t -137.58 141.4 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.115 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 177.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 14.1 t -83.25 149.24 26.91 Favored 'General case' 0 C--N 1.29 -1.98 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.115 -178.036 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -93.27 -19.72 21.11 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 174.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.75 25.69 2.47 Favored Glycine 0 C--N 1.31 -0.895 0 CA-C-N 114.04 -1.436 . . . . 0.0 113.262 179.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -156.42 159.62 29.59 Favored Glycine 1 N--CA 1.359 -6.492 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 178.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.495 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -67.36 30.14 0.02 OUTLIER 'General case' 0 C--N 1.28 -2.436 0 C-N-CA 125.844 1.658 . . . . 0.0 114.179 -177.283 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -98.23 -62.99 1.17 Allowed 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -179.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -75.87 -28.9 58.33 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.679 0.752 . . . . 0.0 109.312 176.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.495 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 19.1 mmm180 -63.35 -32.65 74.13 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.473 -1.239 . . . . 0.0 109.63 172.595 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -70.4 -63.21 1.13 Allowed 'General case' 0 C--O 1.241 0.64 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 173.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.26 -17.28 40.82 Favored Glycine 0 N--CA 1.436 -1.356 0 N-CA-C 115.435 0.934 . . . . 0.0 115.435 175.049 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.501 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.3 OUTLIER -79.21 -25.69 42.66 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 118.816 1.308 . . . . 0.0 109.341 -177.914 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.9 tt -94.44 150.76 3.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . 0.591 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 23.6 mt-30 -136.64 166.11 24.3 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 121.232 0.539 . . . . 0.0 111.598 -176.327 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -86.88 -12.44 10.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.392 178.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -92.99 3.42 55.79 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 122.214 1.007 . . . . 0.0 110.647 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.591 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 24.9 m-20 -101.98 -174.54 2.61 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.268 -177.48 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.443 ' O ' HG23 ' A' ' 91' ' ' ILE . 61.5 tt0 -129.26 131.97 47.12 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.813 -176.017 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 49.1 mm -75.43 106.56 5.31 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.783 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.686 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 98.5 t -87.87 -44.65 15.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 120.967 0.413 . . . . 0.0 111.344 -177.09 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.46 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 37.6 tt0 -156.85 120.96 4.34 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 120.67 0.271 . . . . 0.0 110.544 178.281 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.3 t -112.62 129.04 68.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 111.575 0.213 . . . . 0.0 111.575 176.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.3 t70 66.95 7.52 5.41 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 125.737 1.615 . . . . 0.0 111.294 174.54 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.65 20.7 61.23 Favored Glycine 0 N--CA 1.434 -1.472 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.296 -175.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.4 tt -79.44 -22.68 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 CA-C-O 121.197 0.522 . . . . 0.0 110.267 -179.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.453 ' HB3' ' OE2' ' A' ' 62' ' ' GLU . 63.8 p 48.68 81.95 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.356 1.462 . . . . 0.0 111.935 -176.003 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.457 ' O ' HG23 ' A' ' 71' ' ' VAL . 0.0 OUTLIER -87.33 30.71 0.77 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 122.515 1.15 . . . . 0.0 111.283 -175.997 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.46 ' HA ' HD21 ' A' ' 35' ' ' LEU . 42.4 t -74.71 103.87 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.585 -179.424 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.08 26.83 6.84 Favored Glycine 0 N--CA 1.434 -1.436 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.784 179.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.457 HG23 ' O ' ' A' ' 68' ' ' LEU . 11.0 m -112.63 170.4 4.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 C-N-CA 120.391 -0.524 . . . . 0.0 110.071 177.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.9 p -93.6 172.2 8.41 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.323 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.494 ' N ' HE21 ' A' ' 73' ' ' GLN . 0.0 OUTLIER -60.98 -28.43 69.01 Favored 'General case' 0 C--O 1.205 -1.269 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.751 -179.141 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -73.44 -36.03 65.87 Favored 'General case' 0 CA--C 1.522 -0.122 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.557 -178.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 30.1 t80 -70.43 -49.8 45.05 Favored 'General case' 0 CA--C 1.506 -0.712 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 178.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.29 -46.73 87.76 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.934 -178.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.48 -34.19 72.26 Favored 'General case' 0 C--O 1.209 -1.036 0 CA-C-O 120.472 0.177 . . . . 0.0 110.554 179.391 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 77.6 m -65.91 -44.45 85.16 Favored 'General case' 0 N--CA 1.435 -1.217 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.755 177.219 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.413 ' O ' HG22 ' A' ' 83' ' ' THR . 39.3 t -61.89 -53.08 52.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 178.553 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -67.98 -2.23 7.19 Favored 'General case' 0 CA--C 1.564 1.509 0 CA-C-O 121.393 0.616 . . . . 0.0 112.183 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.23 -34.02 10.51 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 123.556 0.743 . . . . 0.0 109.714 175.132 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -82.0 -13.68 57.06 Favored 'General case' 0 CA--C 1.498 -1.019 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -175.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.413 HG22 ' O ' ' A' ' 79' ' ' VAL . 5.4 p -60.54 146.67 44.19 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.647 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.89 -161.28 0.75 Allowed 'General case' 0 C--N 1.297 -1.709 0 CA-C-N 114.88 -1.055 . . . . 0.0 109.238 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -51.21 -74.93 0.24 Allowed Glycine 0 CA--C 1.536 1.379 0 N-CA-C 115.399 0.92 . . . . 0.0 115.399 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.553 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 15.9 m120 -81.65 99.99 9.2 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 117.872 0.836 . . . . 0.0 112.18 -177.534 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.621 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.8 t -108.54 135.49 47.17 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.044 -175.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -94.05 101.49 13.52 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 172.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.49 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 98.8 m-85 -94.8 103.92 15.82 Favored 'General case' 0 CA--C 1.48 -1.741 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.206 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.686 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 60.8 t -88.81 93.31 4.26 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.89 0 N-CA-C 105.416 -2.068 . . . . 0.0 105.416 174.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.443 HG23 ' O ' ' A' ' 59' ' ' GLN . 88.7 mt -107.43 155.51 8.14 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.265 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.21 175.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -129.83 149.39 18.77 Favored Glycine 0 N--CA 1.406 -3.331 0 C-N-CA 119.376 -1.393 . . . . 0.0 111.673 -178.771 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 22.9 tpt180 -123.85 116.23 22.61 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 -178.313 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 . . . . . 0 N--CA 1.441 -0.92 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 173.879 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.507 -0.407 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 52.4 t60 -89.53 111.5 22.43 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.123 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 23.5 ttt -83.59 113.53 20.89 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.427 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 82.9 tt0 -92.59 111.49 23.11 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 -178.207 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -87.31 125.78 34.43 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -178.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -140.48 145.66 41.78 Favored Pre-proline 0 C--N 1.294 -1.845 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -176.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -82.64 125.48 4.35 Favored 'Trans proline' 0 N--CA 1.442 -1.511 0 C-N-CA 122.62 2.213 . . . . 0.0 112.202 175.635 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 23.7 t -111.14 102.77 14.44 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.58 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 175.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.498 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 28.7 tt0 -82.22 108.83 15.98 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 174.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.473 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -103.79 135.97 44.34 Favored 'General case' 0 C--N 1.279 -2.469 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 -177.772 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -106.99 97.73 7.48 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.521 -1.289 . . . . 0.0 107.521 171.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.415 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 2.7 mmmp? -83.71 173.78 11.04 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-O 122.406 1.098 . . . . 0.0 113.839 -177.329 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -88.15 172.68 9.32 Favored 'General case' 0 N--CA 1.423 -1.803 0 CA-C-N 112.818 -1.992 . . . . 0.0 110.026 -178.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -67.75 -9.29 42.64 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 114.197 1.184 . . . . 0.0 114.197 -173.188 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -73.49 -34.05 65.13 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.95 -127.14 6.98 Favored Glycine 0 CA--C 1.475 -2.452 0 N-CA-C 107.533 -2.227 . . . . 0.0 107.533 -177.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 18.2 mt -99.65 -48.92 4.56 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 175.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 73.94 31.03 60.48 Favored Glycine 0 N--CA 1.418 -2.524 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 -177.038 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 22.2 pt -110.84 178.35 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.3 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.641 -178.44 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 34.8 m -140.09 154.65 47.1 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -178.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -125.84 166.58 21.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -177.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 14.0 tt -140.23 134.6 35.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 C-N-CA 120.58 -0.448 . . . . 0.0 110.681 177.251 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.445 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -92.96 107.58 3.55 Favored Glycine 0 N--CA 1.425 -2.079 0 C-N-CA 120.965 -0.635 . . . . 0.0 111.794 -179.239 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.653 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 93.0 mmm -122.58 97.88 5.66 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.82 101.13 0.56 Allowed Glycine 0 C--N 1.308 -1.015 0 C-N-CA 120.98 -0.629 . . . . 0.0 113.428 -175.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.4 p -120.88 29.31 2.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-O 123.739 1.733 . . . . 0.0 106.525 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.616 ' O ' ' HA ' ' A' ' 33' ' ' GLU . . . -92.22 -19.26 39.62 Favored Glycine 0 N--CA 1.435 -1.373 0 CA-C-N 112.657 -2.065 . . . . 0.0 116.687 -168.565 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -130.86 -75.99 0.53 Allowed 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 119.328 1.564 . . . . 0.0 113.45 -175.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -61.51 -31.26 71.25 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.294 0.638 . . . . 0.0 111.954 -175.204 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.93 -26.54 68.86 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.428 -0.806 . . . . 0.0 112.424 -179.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.43 -3.61 79.32 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.551 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.9 mp -84.38 -38.02 20.8 Favored 'General case' 0 C--N 1.31 -1.135 0 O-C-N 122.478 -0.424 . . . . 0.0 110.617 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.616 ' HA ' ' O ' ' A' ' 27' ' ' GLY . 45.9 mt-10 53.89 76.72 0.21 Allowed 'General case' 0 C--O 1.244 0.772 0 O-C-N 124.56 1.163 . . . . 0.0 112.819 179.404 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.498 ' HE2' ' OE1' ' A' ' 59' ' ' GLN . 18.2 ptmt -162.03 168.65 22.38 Favored 'General case' 0 N--CA 1.42 -1.961 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 -178.54 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.5 pp -59.47 150.32 27.08 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 123.736 0.647 . . . . 0.0 109.262 172.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.653 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -115.12 32.85 5.58 Favored Glycine 0 N--CA 1.424 -2.16 0 C-N-CA 118.919 -1.61 . . . . 0.0 111.797 178.14 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.518 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 25.6 mm -91.04 98.73 8.71 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.779 0 CA-C-O 122.018 0.913 . . . . 0.0 110.117 -178.764 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -93.11 162.44 14.03 Favored 'General case' 0 C--N 1.277 -2.559 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.395 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 46.7 t -79.44 126.83 39.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 175.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 58.3 tptt -88.64 -50.45 6.25 Favored 'General case' 0 C--N 1.294 -1.811 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.806 -177.087 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -150.87 162.62 40.43 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 -177.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 61.4 t -128.02 159.55 38.93 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.134 0 N-CA-C 105.959 -1.867 . . . . 0.0 105.959 175.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 6.6 t -57.3 162.49 2.71 Favored 'General case' 0 CA--C 1.544 0.714 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 171.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -55.32 -34.67 64.39 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.116 0.484 . . . . 0.0 110.796 -176.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . 0.45 ' HA2' ' HB2' ' A' ' 49' ' ' GLN . . . -162.89 -58.13 0.02 OUTLIER Glycine 0 N--CA 1.428 -1.847 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 176.313 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 47.06 -101.64 0.04 OUTLIER Glycine 0 CA--C 1.485 -1.823 0 C-N-CA 126.352 1.929 . . . . 0.0 111.084 -173.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.415 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . -139.73 2.77 2.01 Favored 'General case' 0 C--N 1.26 -3.317 0 CA-C-N 113.278 -1.461 . . . . 0.0 108.915 173.495 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.472 ' O ' ' HB3' ' A' ' 51' ' ' ASP . . . -87.55 -55.06 3.95 Favored 'General case' 0 CA--C 1.486 -1.483 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -175.82 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.45 ' HB2' ' HA2' ' A' ' 45' ' ' GLY . 41.2 mt-30 -76.46 -22.3 54.76 Favored 'General case' 0 N--CA 1.433 -1.319 0 C-N-CA 118.586 -1.246 . . . . 0.0 110.87 176.706 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 25.7 mmm180 -69.0 -23.59 64.12 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.192 171.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.472 ' HB3' ' O ' ' A' ' 48' ' ' ALA . 12.1 t70 -71.39 -64.92 0.82 Allowed 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.099 -1.075 . . . . 0.0 108.099 170.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.71 -5.54 84.63 Favored Glycine 0 C--O 1.245 0.794 0 C-N-CA 121.24 -0.505 . . . . 0.0 113.792 174.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.62 -32.85 21.82 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 178.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.6 tt -93.52 143.46 11.49 Favored 'Isoleucine or valine' 0 C--O 1.251 1.148 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 170.164 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 62.0 mt-30 -139.05 178.42 7.18 Favored 'General case' 0 C--N 1.308 -1.225 0 O-C-N 122.183 -0.323 . . . . 0.0 111.412 -179.513 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.2 p -84.64 -14.96 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-O 121.66 0.743 . . . . 0.0 110.838 -176.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -91.24 7.9 38.51 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-O 122.107 0.956 . . . . 0.0 109.502 -176.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -88.47 -175.4 4.96 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.8 -176.063 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.518 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 30.9 tt0 -141.53 129.14 21.48 Favored 'General case' 0 N--CA 1.423 -1.795 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.007 -179.03 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 46.8 mm -77.2 105.31 5.96 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.786 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -178.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.755 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 94.2 t -85.07 -48.96 16.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-O 121.957 0.884 . . . . 0.0 109.357 -177.665 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.515 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 28.8 tt0 -150.87 135.1 16.89 Favored 'General case' 0 N--CA 1.419 -2.015 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.078 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 t -121.52 128.71 75.9 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 173.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 37.0 t70 71.23 -11.49 0.68 Allowed 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 125.3 1.44 . . . . 0.0 113.261 176.603 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.11 15.4 28.33 Favored Glycine 0 C--N 1.277 -2.729 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -174.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 9.3 tt -72.7 -21.02 19.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 CA-C-O 121.452 0.644 . . . . 0.0 110.046 -179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.409 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 62.9 p 49.25 88.2 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 125.399 1.48 . . . . 0.0 111.89 -175.407 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.404 ' O ' HG23 ' A' ' 71' ' ' VAL . 1.3 pp -98.11 20.1 12.94 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-O 122.429 1.109 . . . . 0.0 109.573 -176.775 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 50.4 t -57.6 94.26 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-N 114.025 -1.443 . . . . 0.0 110.944 175.549 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 107.77 27.35 5.21 Favored Glycine 0 N--CA 1.441 -1.003 0 CA-C-N 115.408 -0.815 . . . . 0.0 112.603 175.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.404 HG23 ' O ' ' A' ' 68' ' ' LEU . 20.2 m -105.73 176.15 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.885 -179.439 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 12.4 p -93.0 172.76 8.11 Favored 'General case' 0 C--O 1.254 1.327 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.546 179.08 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.97 -30.81 71.43 Favored 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.666 -178.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -73.73 -26.37 60.65 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.686 -177.5 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 40.3 t80 -75.27 -53.13 9.29 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.62 -48.8 78.42 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.054 -177.177 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -55.76 -36.96 67.89 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.642 0.258 . . . . 0.0 110.624 179.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 89.0 m -65.62 -44.64 85.85 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.854 177.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 34.7 t -61.93 -51.2 75.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -64.01 -20.2 65.73 Favored 'General case' 0 C--O 1.214 -0.794 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.423 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.82 -25.63 24.47 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 122.934 0.494 . . . . 0.0 110.927 177.177 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -89.02 3.62 51.06 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 112.747 0.647 . . . . 0.0 112.747 -178.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 38.9 p -73.49 -178.33 3.01 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.78 0.8 . . . . 0.0 111.846 177.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.23 -165.9 1.56 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 125.534 1.533 . . . . 0.0 107.045 -179.186 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -39.51 -78.27 0.06 OUTLIER Glycine 0 C--O 1.22 -0.719 0 O-C-N 124.504 1.128 . . . . 0.0 115.204 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.473 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 20.9 m120 -81.57 114.97 20.63 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 118.075 0.938 . . . . 0.0 111.272 -177.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.4 t -124.37 140.48 47.54 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.458 -179.112 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 20.2 mtp85 -100.41 100.7 11.51 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 120.907 0.384 . . . . 0.0 110.831 171.35 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.432 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 95.4 m-85 -93.09 105.02 17.17 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 176.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.755 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 41.0 t -95.86 86.19 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.274 -2.686 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 178.369 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 94.0 mt -104.92 160.82 5.06 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.49 0 CA-C-N 113.841 -1.527 . . . . 0.0 109.252 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -122.47 152.88 16.86 Favored Glycine 0 N--CA 1.409 -3.134 0 C-N-CA 119.666 -1.254 . . . . 0.0 110.613 177.015 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 14.8 tpp180 -95.55 123.15 38.96 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -176.255 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 . . . . . 0 C--N 1.303 -1.449 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 172.354 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.505 -0.571 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -102.82 138.11 40.15 Favored 'General case' 0 CA--C 1.493 -1.215 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 175.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 18.8 ttt -118.49 117.56 29.36 Favored 'General case' 0 C--N 1.29 -2.021 0 C-N-CA 119.939 -0.704 . . . . 0.0 109.452 -176.455 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -91.19 109.15 20.4 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -85.87 123.52 31.31 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-O 120.877 0.37 . . . . 0.0 110.468 -177.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -133.5 143.71 49.11 Favored Pre-proline 0 C--N 1.29 -1.979 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.72 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.43 126.08 5.96 Favored 'Trans proline' 0 N--CA 1.437 -1.817 0 C-N-CA 122.148 1.899 . . . . 0.0 112.4 177.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.439 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 61.1 t -107.0 98.87 7.49 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.677 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 173.527 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.5 tt0 -88.72 103.38 15.9 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -99.36 137.74 37.44 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -173.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -100.28 103.98 15.43 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 171.286 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.497 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.9 mmmp? -98.35 173.57 6.91 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -175.413 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -63.05 167.2 5.07 Favored 'General case' 0 C--N 1.313 -0.996 0 C-N-CA 126.917 2.087 . . . . 0.0 109.069 178.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -64.47 -24.48 67.63 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.646 0.736 . . . . 0.0 109.719 176.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -58.78 -45.96 88.6 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 114.501 -1.227 . . . . 0.0 110.333 177.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.74 -118.24 3.28 Favored Glycine 0 N--CA 1.413 -2.864 0 N-CA-C 107.834 -2.107 . . . . 0.0 107.834 -176.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 18.6 mt -105.76 -50.89 3.09 Favored 'General case' 0 CA--C 1.475 -1.911 0 CA-C-N 118.153 0.976 . . . . 0.0 110.305 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 71.27 30.49 67.15 Favored Glycine 0 N--CA 1.422 -2.291 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 -174.392 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 21.5 pt -107.32 172.04 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 119.708 -0.797 . . . . 0.0 110.195 179.166 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.3 m -124.67 150.53 46.0 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -177.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -124.92 160.68 29.83 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 -177.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.3 tt -133.55 126.13 51.21 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 177.023 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.444 ' HA2' HD11 ' A' ' 37' ' ' ILE . . . -89.26 96.53 2.22 Favored Glycine 0 N--CA 1.429 -1.786 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.504 -176.184 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.466 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 79.1 mmm -115.13 76.75 1.02 Allowed 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -49.01 108.63 0.44 Allowed Glycine 0 CA--C 1.504 -0.619 0 O-C-N 124.407 1.067 . . . . 0.0 113.093 -176.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -113.6 140.53 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.618 0 N-CA-C 107.969 -1.122 . . . . 0.0 107.969 179.723 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -100.2 -104.47 2.63 Favored Glycine 0 N--CA 1.428 -1.865 0 N-CA-C 110.109 -1.197 . . . . 0.0 110.109 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -102.71 7.94 39.63 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.279 0.561 . . . . 0.0 110.163 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -59.1 -32.21 69.61 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.49 -172.299 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.14 2.08 31.49 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.184 0.516 . . . . 0.0 111.262 -177.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 86.56 -20.85 20.91 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 115.046 0.779 . . . . 0.0 115.046 176.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -85.04 -37.06 20.8 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 112.975 0.732 . . . . 0.0 112.975 -176.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 64.79 91.68 0.08 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.063 0.945 . . . . 0.0 111.898 -178.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 7.3 ptpp? -161.29 -165.18 1.27 Allowed 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.622 HD13 ' O ' ' A' ' 60' ' ' ILE . 0.5 OUTLIER -58.2 158.75 6.68 Favored 'General case' 0 C--N 1.315 -0.899 0 O-C-N 124.192 0.932 . . . . 0.0 109.927 174.942 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.466 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -110.56 30.52 8.1 Favored Glycine 0 C--N 1.298 -1.569 0 C-N-CA 119.837 -1.173 . . . . 0.0 111.578 176.206 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.444 HD11 ' HA2' ' A' ' 23' ' ' GLY . 20.5 mm -90.56 112.03 24.35 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.125 0 CA-C-O 121.509 0.671 . . . . 0.0 110.628 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -104.92 159.88 15.46 Favored 'General case' 0 C--N 1.282 -2.341 0 CA-C-N 115.153 -0.93 . . . . 0.0 109.805 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 44.8 t -75.0 122.05 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 176.08 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 84.6 tttt -86.5 -47.8 8.94 Favored 'General case' 0 C--N 1.286 -2.178 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.623 -177.196 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -152.98 162.34 41.44 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 -179.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 47.8 t -130.02 151.84 36.48 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.052 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.2 t -61.29 151.23 32.47 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 176.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -48.36 -60.88 2.32 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 124.424 1.09 . . . . 0.0 113.14 -170.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 172.32 58.68 0.04 OUTLIER Glycine 0 C--N 1.29 -2.007 0 C-N-CA 118.428 -1.844 . . . . 0.0 114.1 179.416 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.47 -32.27 12.03 Favored Glycine 0 C--N 1.303 -1.298 0 C-N-CA 119.522 -1.323 . . . . 0.0 110.915 174.013 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.497 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . -161.95 -41.74 0.04 OUTLIER 'General case' 0 C--O 1.209 -1.055 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -178.58 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.402 ' HB1' ' CE ' ' A' ' 12' ' ' LYS . . . -65.56 -59.59 3.81 Favored 'General case' 0 N--CA 1.504 2.274 0 CA-C-N 118.719 0.691 . . . . 0.0 110.423 -175.799 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.1 mt-30 -78.02 6.8 7.12 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.349 177.437 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 26.0 mmm180 -95.59 -27.72 15.2 Favored 'General case' 0 N--CA 1.428 -1.568 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 171.697 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -66.65 -37.22 84.36 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 173.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.58 -31.74 4.13 Favored Glycine 0 N--CA 1.458 0.119 0 CA-C-N 115.471 -0.786 . . . . 0.0 113.985 172.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 2.7 ttm180 -61.55 -54.79 38.52 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 124.975 1.31 . . . . 0.0 111.401 -176.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.5 tt -84.82 141.55 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 CA-C-N 115.033 -0.985 . . . . 0.0 108.832 -176.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.7 mt-30 -143.0 -179.83 6.6 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 119.991 -0.684 . . . . 0.0 111.875 178.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.2 t -62.81 -30.69 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.701 178.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 35.3 m-80 -83.53 18.55 1.83 Allowed 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 113.252 0.834 . . . . 0.0 113.252 -175.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -104.57 175.43 5.49 Favored 'General case' 0 C--O 1.252 1.187 0 CA-C-O 121.491 0.662 . . . . 0.0 111.715 177.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.41 ' O ' HG21 ' A' ' 91' ' ' ILE . 62.3 tt0 -127.46 136.27 51.57 Favored 'General case' 0 N--CA 1.422 -1.827 0 CA-C-N 114.848 -1.069 . . . . 0.0 108.453 177.268 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.622 ' O ' HD13 ' A' ' 35' ' ' LEU . 49.0 mm -75.62 139.84 18.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 178.473 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.703 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 90.5 t -119.26 -53.71 3.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 CA-C-O 121.545 0.688 . . . . 0.0 109.805 177.57 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.494 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 32.0 tt0 -151.7 102.91 2.9 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 -177.617 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.8 t -96.41 127.61 48.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.762 -0.586 . . . . 0.0 111.38 179.185 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 35.2 t70 61.51 19.51 10.4 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 124.847 1.259 . . . . 0.0 111.17 173.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.17 20.24 79.69 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 114.891 -1.05 . . . . 0.0 112.505 -178.575 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.9 tt -81.33 -14.42 12.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 O-C-N 122.418 -0.46 . . . . 0.0 110.282 -179.269 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 17.8 m 45.33 81.23 0.04 OUTLIER 'General case' 0 C--N 1.351 0.642 0 C-N-CA 125.479 1.512 . . . . 0.0 112.172 -178.004 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.425 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.5 OUTLIER -91.4 18.31 7.36 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 121.88 0.848 . . . . 0.0 111.409 -174.901 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 57.2 t -57.95 104.67 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.941 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.264 173.426 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.47 29.27 6.36 Favored Glycine 0 N--CA 1.437 -1.261 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.633 179.028 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 68' ' ' LEU . 15.7 m -113.88 176.1 2.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 C-N-CA 120.166 -0.614 . . . . 0.0 110.735 176.704 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -104.06 173.27 6.38 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.734 178.008 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.28 -33.48 71.12 Favored 'General case' 0 C--O 1.204 -1.314 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.035 -176.616 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -66.09 -32.65 74.23 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 123.695 0.798 . . . . 0.0 111.967 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 51.3 t80 -78.92 -49.33 13.01 Favored 'General case' 0 N--CA 1.444 -0.752 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 177.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.42 -43.41 96.79 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.243 -177.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.437 ' O ' ' HB2' ' A' ' 81' ' ' ARG . . . -63.38 -22.59 66.97 Favored 'General case' 0 C--O 1.218 -0.592 0 CA-C-O 121.028 0.442 . . . . 0.0 110.798 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 52.9 m -80.96 -45.44 16.66 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.827 177.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.529 ' O ' HG21 ' A' ' 83' ' ' THR . 40.0 t -62.45 -52.71 56.63 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.571 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 178.338 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -70.13 6.82 1.14 Allowed 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 123.968 0.907 . . . . 0.0 112.213 -178.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.437 ' HB2' ' O ' ' A' ' 77' ' ' ALA . 41.5 ttt180 -109.12 -47.61 3.4 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 174.169 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -79.76 -10.76 59.83 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 113.99 -1.459 . . . . 0.0 114.021 -172.121 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.529 HG21 ' O ' ' A' ' 79' ' ' VAL . 12.5 p -63.14 138.43 58.55 Favored 'General case' 0 C--O 1.248 1.014 0 CA-C-O 120.418 0.151 . . . . 0.0 110.838 177.419 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.8 mmtt -131.17 132.38 44.69 Favored 'General case' 0 CA--C 1.487 -1.453 0 N-CA-C 113.516 0.932 . . . . 0.0 113.516 -175.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.46 -73.17 0.0 OUTLIER Glycine 0 CA--C 1.479 -2.179 0 C-N-CA 127.895 2.664 . . . . 0.0 115.079 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 19.2 m120 -102.53 100.19 10.27 Favored 'General case' 0 C--N 1.253 -3.63 0 CA-C-O 121.376 0.607 . . . . 0.0 109.417 -172.366 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.514 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 5.6 t -114.5 127.67 71.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.058 -172.388 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 37.7 mtm-85 -99.99 97.78 8.61 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-O 121.026 0.441 . . . . 0.0 109.942 175.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.439 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 80.8 m-85 -87.56 100.75 13.02 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.703 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.4 t -85.66 94.25 4.02 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.634 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 175.745 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.41 HG21 ' O ' ' A' ' 59' ' ' GLN . 90.3 mt -112.84 158.58 13.17 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.257 0 CA-C-N 114.05 -1.432 . . . . 0.0 107.749 176.807 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.47 167.34 14.29 Favored Glycine 0 N--CA 1.405 -3.405 0 C-N-CA 118.903 -1.617 . . . . 0.0 112.276 -178.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 2.6 tmt_? -113.59 128.55 56.48 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 176.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 . . . . . 0 C--N 1.302 -1.477 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 178.236 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.496 -1.113 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 8.9 p80 -161.21 173.6 14.84 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -178.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 25.0 ttt -117.71 117.36 29.14 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 178.179 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.45 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 35.3 tt0 -91.22 114.12 26.56 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.578 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -87.85 117.34 26.63 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -132.38 140.67 38.66 Favored Pre-proline 0 C--N 1.294 -1.816 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -177.167 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -77.78 125.0 7.16 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.525 2.15 . . . . 0.0 111.855 176.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 26.3 t -111.73 97.19 5.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -80.0 104.29 10.47 Favored 'General case' 0 N--CA 1.425 -1.691 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -98.4 141.22 31.55 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 -177.374 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -112.88 85.29 2.14 Favored 'General case' 0 N--CA 1.416 -2.133 0 C-N-CA 119.077 -1.049 . . . . 0.0 108.924 172.078 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.532 ' HA ' ' HB2' ' A' ' 47' ' ' ALA . 4.3 mmtt -68.69 168.67 12.72 Favored 'General case' 0 N--CA 1.409 -2.511 0 CA-C-N 114.402 -1.272 . . . . 0.0 114.398 -179.374 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -67.04 164.94 16.73 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 113.721 -1.582 . . . . 0.0 107.506 -178.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -70.25 -12.82 61.86 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.41 0.624 . . . . 0.0 111.712 -177.03 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -68.21 -43.87 77.06 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.186 174.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.462 ' O ' ' HD2' ' A' ' 12' ' ' LYS . . . 132.64 -152.48 20.29 Favored Glycine 0 N--CA 1.426 -1.98 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -176.292 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.585 ' O ' ' HB ' ' A' ' 43' ' ' THR . 22.8 mt -89.14 -49.49 6.72 Favored 'General case' 0 CA--C 1.489 -1.398 0 CA-C-N 117.678 0.739 . . . . 0.0 109.967 -177.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 73.11 23.82 76.93 Favored Glycine 0 N--CA 1.425 -2.054 0 CA-C-N 114.752 -1.113 . . . . 0.0 111.062 -174.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.408 HG21 ' HA ' ' A' ' 42' ' ' VAL . 19.5 pt -101.17 178.95 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.747 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.7 m -145.58 156.49 43.72 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.522 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -116.71 162.1 14.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 C-N-CA 122.83 0.452 . . . . 0.0 110.556 -176.065 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.4 tt -132.6 125.36 52.96 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.821 0 CA-C-O 120.965 0.412 . . . . 0.0 110.107 174.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.483 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.55 101.18 2.71 Favored Glycine 0 N--CA 1.417 -2.595 0 CA-C-N 115.743 -0.662 . . . . 0.0 112.013 -178.488 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 94.9 mmm -107.1 165.32 11.45 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 177.483 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.62 94.61 0.57 Allowed Glycine 0 C--N 1.287 -2.166 0 C-N-CA 119.207 -1.473 . . . . 0.0 111.414 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -93.93 113.09 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 CA-C-O 121.342 0.592 . . . . 0.0 109.65 178.5 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.03 -82.5 1.05 Allowed Glycine 0 N--CA 1.433 -1.551 0 CA-C-N 115.197 -0.911 . . . . 0.0 111.201 179.251 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.537 ' HA ' ' HG3' ' A' ' 33' ' ' GLU . . . -148.71 105.11 3.53 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -173.65 -42.71 0.01 OUTLIER 'General case' 0 CA--C 1.514 -0.423 0 O-C-N 123.885 0.741 . . . . 0.0 111.671 -177.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.32 -21.31 24.47 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 -170.088 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.01 -8.04 53.45 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -176.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -86.34 -48.47 8.45 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 114.58 -0.81 . . . . 0.0 109.434 179.493 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.537 ' HG3' ' HA ' ' A' ' 28' ' ' ALA . 1.0 OUTLIER 41.3 50.78 3.52 Favored 'General case' 0 C--O 1.243 0.76 0 N-CA-C 114.527 1.306 . . . . 0.0 114.527 176.522 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 6.9 ptpp? -150.57 -155.19 0.6 Allowed 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.504 ' CD2' ' HA ' ' A' ' 69' ' ' VAL . 1.6 pp -48.35 144.93 3.65 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 110.867 175.019 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -106.52 30.19 9.88 Favored Glycine 0 N--CA 1.431 -1.662 0 C-N-CA 120.009 -1.091 . . . . 0.0 111.229 177.038 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.554 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 24.8 mm -82.83 100.68 6.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 121.537 0.684 . . . . 0.0 110.038 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -99.28 167.35 10.72 Favored 'General case' 0 C--N 1.277 -2.545 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.482 179.306 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.1 t -83.21 113.62 22.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 56.6 tptt -76.74 -45.73 28.05 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.897 -176.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.4 m -152.37 162.92 40.49 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -175.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.408 ' HA ' HG21 ' A' ' 19' ' ' ILE . 59.6 t -134.27 158.08 41.88 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.066 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.309 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.585 ' HB ' ' O ' ' A' ' 17' ' ' LEU . 10.1 t -49.63 145.67 4.87 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 171.025 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -58.86 -39.14 80.43 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 123.178 0.591 . . . . 0.0 112.507 -174.649 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -175.55 44.56 0.12 Allowed Glycine 0 CA--C 1.471 -2.699 0 C-N-CA 119.784 -1.198 . . . . 0.0 112.567 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -89.05 -166.71 42.39 Favored Glycine 1 N--CA 1.381 -5.018 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 174.116 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.532 ' HB2' ' HA ' ' A' ' 12' ' ' LYS . . . -55.17 -17.98 5.1 Favored 'General case' 0 C--N 1.274 -2.711 0 N-CA-C 115.254 1.575 . . . . 0.0 115.254 -172.6 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.504 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -74.05 -58.99 2.93 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.217 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -69.84 -24.4 63.45 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 119.83 -0.748 . . . . 0.0 112.133 175.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.477 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 13.1 mmt180 -66.37 -36.77 83.72 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 174.017 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -57.23 -59.66 4.78 Favored 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.607 0.567 . . . . 0.0 109.728 177.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.06 -20.75 35.14 Favored Glycine 0 N--CA 1.437 -1.244 0 C-N-CA 120.222 -0.989 . . . . 0.0 114.442 174.37 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.543 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -77.11 -60.95 2.15 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.814 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.543 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 17.5 tt -69.08 140.75 18.33 Favored 'Isoleucine or valine' 0 C--O 1.245 0.831 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.428 -175.518 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 16.4 mm-40 -137.18 173.36 11.76 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-O 121.641 0.734 . . . . 0.0 111.669 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.6 p -81.77 23.75 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.227 0 CA-C-O 122.309 1.052 . . . . 0.0 110.362 -178.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -134.79 13.43 3.68 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 122.432 1.111 . . . . 0.0 108.816 -178.324 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -92.47 -177.4 4.6 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.151 -0.932 . . . . 0.0 110.806 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.554 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 32.3 tt0 -134.31 125.02 26.81 Favored 'General case' 0 N--CA 1.434 -1.229 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.303 179.156 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 45.1 mm -77.63 113.8 17.29 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.908 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -177.143 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.655 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 84.9 t -97.17 -49.14 12.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-O 121.65 0.738 . . . . 0.0 111.093 -177.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.551 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 28.6 tt0 -149.39 115.77 5.82 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.9 t -108.9 125.95 65.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.688 176.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 21.1 t70 69.98 1.62 3.56 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 124.807 1.243 . . . . 0.0 112.162 173.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.54 16.84 38.31 Favored Glycine 0 N--CA 1.427 -1.908 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.608 -176.185 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.8 tt -74.24 -32.85 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.786 0 O-C-N 122.343 -0.504 . . . . 0.0 110.357 179.109 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.407 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 20.8 t 58.0 93.45 0.03 OUTLIER 'General case' 0 C--N 1.344 0.327 0 C-N-CA 125.015 1.326 . . . . 0.0 110.038 -176.207 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.469 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.6 OUTLIER -105.27 21.0 17.91 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 121.747 0.784 . . . . 0.0 109.883 -174.954 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.504 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 21.4 t -56.31 96.22 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.287 -2.129 0 CA-C-N 114.532 -1.213 . . . . 0.0 112.046 179.091 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 108.49 6.86 30.77 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.859 175.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.469 HG22 ' O ' ' A' ' 68' ' ' LEU . 21.3 m -82.7 -177.26 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 117.245 0.522 . . . . 0.0 112.005 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 p -97.89 173.77 6.91 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.003 176.489 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.522 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -61.3 -35.11 76.47 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.437 -1.256 . . . . 0.0 111.706 179.044 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -71.33 -32.15 68.23 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 121.059 -0.257 . . . . 0.0 111.364 -178.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -70.75 -47.12 61.34 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 176.434 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.416 ' O ' HD21 ' A' ' 80' ' ' LEU . . . -61.14 -42.88 99.35 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.915 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.405 ' O ' ' HB3' ' A' ' 81' ' ' ARG . . . -59.26 -38.08 79.18 Favored 'General case' 0 C--O 1.212 -0.911 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 176.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 88.1 m -65.15 -50.95 64.01 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.099 178.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.403 ' O ' HG23 ' A' ' 83' ' ' THR . 5.6 p -63.65 -45.2 98.15 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.577 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 178.731 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.416 HD21 ' O ' ' A' ' 76' ' ' ALA . 4.0 mm? -67.29 -25.47 66.06 Favored 'General case' 0 C--O 1.216 -0.709 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.405 ' HB3' ' O ' ' A' ' 77' ' ' ALA . 0.4 OUTLIER -86.38 -23.54 26.11 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-O 120.857 0.36 . . . . 0.0 111.657 177.544 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -86.49 5.29 36.03 Favored 'General case' 0 N--CA 1.483 1.211 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 179.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.403 HG23 ' O ' ' A' ' 79' ' ' VAL . 31.2 p -70.08 178.05 2.94 Favored 'General case' 0 C--N 1.291 -1.965 0 CA-C-O 121.711 0.767 . . . . 0.0 112.348 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.77 -159.04 0.97 Allowed 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 125.01 1.324 . . . . 0.0 108.045 -179.014 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.12 -76.01 0.22 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 114.467 0.547 . . . . 0.0 114.467 -179.223 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -78.75 112.14 15.58 Favored 'General case' 0 CA--C 1.497 -1.076 0 O-C-N 122.654 -0.321 . . . . 0.0 110.427 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 83.0 t -132.36 128.05 57.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.153 -178.374 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.68 108.38 19.78 Favored 'General case' 0 CA--C 1.496 -1.098 0 C-N-CA 119.715 -0.794 . . . . 0.0 109.903 172.133 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -93.63 98.92 11.46 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 174.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.655 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.7 t -84.55 96.39 4.58 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.06 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 176.062 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.444 HG23 ' O ' ' A' ' 59' ' ' GLN . 95.0 mt -112.91 153.75 14.44 Favored 'Isoleucine or valine' 0 C--N 1.262 -3.202 0 CA-C-N 113.796 -1.547 . . . . 0.0 108.608 177.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.45 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -119.76 153.65 16.71 Favored Glycine 0 N--CA 1.403 -3.554 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 177.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.5 ' NH1' ' HG3' ' A' ' 94' ' ' GLU . 4.3 tmt_? -135.19 152.39 51.54 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -176.835 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.5 ' HG3' ' NH1' ' A' ' 93' ' ' ARG . 7.2 pt-20 . . . . . 0 C--N 1.321 -0.641 0 O-C-N 124.247 0.967 . . . . 0.0 110.771 177.306 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.601 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 48.4 tt0 . . . . . 0 N--CA 1.425 -1.706 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -90.79 108.39 19.8 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.822 -1.548 . . . . 0.0 106.822 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -123.13 140.71 34.17 Favored Pre-proline 0 C--N 1.293 -1.881 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -171.506 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -86.7 131.71 3.37 Favored 'Trans proline' 0 C--N 1.314 -1.267 0 C-N-CA 123.05 2.5 . . . . 0.0 111.928 174.308 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.3 t -124.32 105.79 15.85 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.302 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 175.004 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.58 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.1 tt0 -91.32 103.33 16.0 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 175.667 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.489 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.2 OUTLIER -91.85 143.7 26.24 Favored 'General case' 0 N--CA 1.421 -1.884 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 -174.556 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -112.05 87.92 2.68 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.79 0.805 . . . . 0.0 109.684 175.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.474 ' HG2' HD12 ' A' ' 10' ' ' LEU . 2.1 mmtp -84.87 -178.95 6.98 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -178.222 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.402 ' CG ' ' H ' ' A' ' 14' ' ' GLU . 18.9 t70 -76.08 -176.7 3.61 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 113.568 -1.651 . . . . 0.0 109.845 -178.577 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.402 ' H ' ' CG ' ' A' ' 13' ' ' ASP . 12.0 pt-20 -82.02 -19.86 39.57 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.809 -1.087 . . . . 0.0 109.936 -176.288 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -69.26 -47.46 64.59 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.68 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.73 -128.31 4.4 Favored Glycine 0 N--CA 1.425 -2.039 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.078 -177.308 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.468 HD21 HG21 ' A' ' 87' ' ' VAL . 9.6 mt -103.81 -49.49 3.64 Favored 'General case' 0 CA--C 1.495 -1.139 0 O-C-N 122.351 -0.499 . . . . 0.0 110.151 -174.817 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 71.74 31.91 64.55 Favored Glycine 0 N--CA 1.428 -1.858 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -175.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.412 HG22 ' HA ' ' A' ' 42' ' ' VAL . 18.5 pt -111.01 167.82 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 C-N-CA 120.151 -0.62 . . . . 0.0 110.399 -179.077 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.4 m -131.47 154.38 48.78 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.303 -177.09 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.428 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -123.34 170.04 14.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 C-N-CA 123.334 0.654 . . . . 0.0 109.352 -178.658 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.421 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.1 tt -136.37 131.41 48.38 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 C-N-CA 120.569 -0.452 . . . . 0.0 110.208 176.298 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.631 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.63 104.24 3.08 Favored Glycine 0 CA--C 1.477 -2.305 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.428 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 19.4 ptm -145.75 98.17 3.08 Favored 'General case' 0 C--N 1.29 -1.992 0 CA-C-N 115.389 -0.406 . . . . 0.0 110.699 -179.049 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.036 0 O-C-N 124.36 1.038 . . . . 0.0 111.32 -178.162 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.415 HD12 ' H ' ' A' ' 37' ' ' ILE . 3.4 pp . . . . . 0 N--CA 1.434 -1.251 0 CA-C-O 120.957 0.408 . . . . 0.0 110.018 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -109.8 32.59 6.62 Favored Glycine 0 C--N 1.281 -2.509 0 C-N-CA 120.19 -1.005 . . . . 0.0 111.329 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.631 HD13 ' HA2' ' A' ' 23' ' ' GLY . 28.4 mm -93.06 100.4 11.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-O 121.732 0.777 . . . . 0.0 110.064 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -97.24 166.65 11.46 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.336 178.171 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.0 t -80.95 131.37 34.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 175.598 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.445 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -93.27 -49.61 5.88 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.477 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.3 m -150.69 161.03 43.4 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 -176.123 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.534 HG11 ' HG3' ' A' ' 49' ' ' GLN . 57.7 t -132.66 160.39 42.6 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.662 0 N-CA-C 104.9 -2.259 . . . . 0.0 104.9 175.663 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.1 t . . . . . 0 N--CA 1.433 -1.287 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 173.412 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.485 ' O ' ' HB2' ' A' ' 51' ' ' ASP . . . . . . . . 0 C--O 1.187 -2.204 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -95.95 -57.07 2.45 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -176.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.534 ' HG3' HG11 ' A' ' 42' ' ' VAL . 25.6 mt-30 -80.92 -12.99 59.31 Favored 'General case' 0 CA--C 1.502 -0.874 0 C-N-CA 119.349 -0.94 . . . . 0.0 109.853 177.86 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.48 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 5.8 mmp_? -92.17 -9.83 40.95 Favored 'General case' 0 N--CA 1.427 -1.599 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.891 173.062 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.485 ' HB2' ' O ' ' A' ' 47' ' ' ALA . 13.2 t70 -70.54 -64.74 0.84 Allowed 'General case' 0 N--CA 1.481 1.12 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 171.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 115.54 -25.66 9.55 Favored Glycine 0 N--CA 1.431 -1.655 0 C-N-CA 120.383 -0.913 . . . . 0.0 114.297 175.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -80.48 -36.0 34.04 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 117.903 0.851 . . . . 0.0 109.149 -177.581 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.4 tt -92.97 149.55 4.18 Favored 'Isoleucine or valine' 0 C--O 1.254 1.303 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -130.8 167.43 18.91 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.156 0.503 . . . . 0.0 111.031 179.03 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.98 -8.81 11.48 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.165 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.641 178.482 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -106.38 12.62 29.59 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-O 121.423 0.63 . . . . 0.0 110.764 -177.001 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -91.28 -174.4 3.93 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.613 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.56 ' O ' HG23 ' A' ' 91' ' ' ILE . 30.6 tt0 -135.09 126.13 27.78 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.765 -176.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.542 HG22 HD11 ' A' ' 68' ' ' LEU . 47.0 mm -73.65 114.45 13.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.014 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.704 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 74.0 t -93.26 -49.95 12.5 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-O 121.675 0.75 . . . . 0.0 109.928 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.527 ' HG3' ' H ' ' A' ' 67' ' ' SER . 26.1 tt0 -151.27 126.73 10.06 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.464 178.681 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 5.0 t -118.43 130.65 72.96 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.048 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 174.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 16.6 t70 62.69 16.71 9.16 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 124.205 1.002 . . . . 0.0 111.623 174.558 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.89 15.81 78.37 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.209 -179.22 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.525 HD13 HG22 ' A' ' 79' ' ' VAL . 4.4 tt -79.86 -16.83 12.93 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.115 0 O-C-N 122.347 -0.502 . . . . 0.0 112.064 -175.657 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.527 ' H ' ' HG3' ' A' ' 62' ' ' GLU 0.282 0.8 OUTLIER 39.34 80.97 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 114.728 1.381 . . . . 0.0 114.728 -175.553 . . . . . . . . 4 4 . 1 . 001 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.62 ' H ' HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -92.24 36.78 0.99 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.859 -176.73 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.66 91.41 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.713 -177.821 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 107.4 33.17 3.21 Favored Glycine 0 C--N 1.303 -1.276 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.79 176.402 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.463 HG21 ' HB2' ' A' ' 68' ' ' LEU . 24.9 m -103.97 175.96 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 120.249 -0.58 . . . . 0.0 111.152 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 40.3 p -91.89 176.0 6.68 Favored 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 178.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.428 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 1.5 pm0 -68.35 -25.18 64.96 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.404 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 -65.32 -48.16 74.04 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.488 ' O ' HG23 ' A' ' 79' ' ' VAL . 29.5 t80 -64.44 -51.85 61.07 Favored 'General case' 0 N--CA 1.432 -1.331 0 CA-C-N 114.577 -1.192 . . . . 0.0 109.124 -178.208 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.77 -44.99 96.05 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.558 -177.288 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.5 -34.1 73.58 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.039 0.447 . . . . 0.0 110.066 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.467 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 76.8 m -65.75 -45.06 84.01 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.525 176.477 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.525 HG22 HD13 ' A' ' 66' ' ' ILE . 41.1 t -60.62 -52.33 62.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 C-N-CA 122.229 0.212 . . . . 0.0 110.527 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -70.7 0.07 7.78 Favored 'General case' 0 CA--C 1.552 1.049 0 CA-C-O 121.406 0.622 . . . . 0.0 112.154 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.467 ' HB3' ' O ' ' A' ' 78' ' ' THR . 25.9 ttm180 -100.14 -38.18 8.63 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 124.024 0.93 . . . . 0.0 108.986 174.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -75.17 -10.26 59.3 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.122 -175.758 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.3 p -71.58 161.23 31.34 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 113.183 0.808 . . . . 0.0 113.183 -178.141 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -118.9 -161.24 0.84 Allowed 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.23 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.59 -63.42 5.3 Favored Glycine 0 N--CA 1.439 -1.12 0 O-C-N 123.544 0.528 . . . . 0.0 113.323 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.489 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 17.9 m120 -82.14 108.82 15.91 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.58 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.8 t -119.7 136.66 56.1 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.677 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.721 -176.433 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 84.2 mtt180 -102.63 97.38 7.58 Favored 'General case' 0 C--N 1.288 -2.103 0 CA-C-O 121.4 0.619 . . . . 0.0 109.993 173.439 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.458 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 92.8 m-85 -89.36 106.16 18.27 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.735 177.504 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.704 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.4 t -95.65 88.77 2.13 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.743 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 175.9 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.56 HG23 ' O ' ' A' ' 59' ' ' GLN . 82.2 mt -101.09 149.68 6.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.678 0 CA-C-N 114.613 -1.176 . . . . 0.0 108.566 179.094 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.601 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -138.05 128.73 4.32 Favored Glycine 1 N--CA 1.393 -4.196 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 -178.638 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 15.7 ttp180 -157.9 162.1 38.28 Favored 'General case' 0 N--CA 1.414 -2.24 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 -175.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.409 ' H ' ' CD ' ' A' ' 94' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--N 1.285 -2.212 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 175.367 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.426 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 32.0 tt0 . . . . . 0 CA--C 1.479 -1.751 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.476 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.5 mm? -86.43 134.28 33.71 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 123.752 0.658 . . . . 0.0 109.884 -177.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 10.7 p90 -141.57 144.36 33.11 Favored Pre-proline 0 C--N 1.293 -1.865 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.802 -178.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -84.61 130.17 4.36 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 C-N-CA 122.57 2.18 . . . . 0.0 113.168 179.636 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.487 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 26.1 t -115.65 107.65 23.23 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.228 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 174.034 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -88.42 107.02 18.64 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 177.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.428 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -100.48 139.27 36.4 Favored 'General case' 0 N--CA 1.423 -1.802 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -176.157 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -109.76 81.77 1.49 Allowed 'General case' 0 N--CA 1.426 -1.641 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 173.359 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.558 ' HE2' ' H ' ' A' ' 48' ' ' ALA . 2.0 mmtt -77.9 171.72 14.56 Favored 'General case' 0 N--CA 1.409 -2.52 0 CA-C-N 115.05 -0.977 . . . . 0.0 113.426 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -72.96 167.98 19.93 Favored 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 126.06 1.744 . . . . 0.0 108.617 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -68.58 -21.41 64.53 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-O 121.412 0.625 . . . . 0.0 110.289 179.279 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -64.14 -32.43 74.0 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.418 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.23 -158.8 14.05 Favored Glycine 0 N--CA 1.434 -1.472 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -178.501 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.455 HD11 HG21 ' A' ' 83' ' ' THR . 17.6 mt -83.64 -48.78 9.84 Favored 'General case' 0 CA--C 1.49 -1.352 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -177.519 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.32 32.01 71.85 Favored Glycine 0 N--CA 1.431 -1.67 0 O-C-N 124.515 1.134 . . . . 0.0 110.677 -175.093 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.414 HG23 ' HB3' ' A' ' 17' ' ' LEU . 26.8 pt -98.91 -177.79 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.567 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.403 -178.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.8 m -138.13 149.09 45.58 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 122.766 0.426 . . . . 0.0 110.011 -178.01 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.446 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.5 pp -119.04 161.39 18.15 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 C-N-CA 123.324 0.65 . . . . 0.0 109.73 -177.51 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.6 tt -128.94 128.72 67.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 174.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.588 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.71 96.39 2.07 Favored Glycine 0 N--CA 1.432 -1.61 0 C-N-CA 120.468 -0.872 . . . . 0.0 112.77 -175.526 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 91.9 mmm -104.15 164.52 11.66 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -2.35 0 C-N-CA 119.969 -1.11 . . . . 0.0 110.653 177.36 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.484 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.6 pt? . . . . . 0 N--CA 1.436 -1.136 0 CA-C-O 121.738 0.78 . . . . 0.0 111.054 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -114.26 19.99 16.78 Favored Glycine 0 N--CA 1.412 -2.964 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 174.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.588 HD13 ' HA2' ' A' ' 23' ' ' GLY . 30.5 mm -77.7 116.53 21.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 177.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -114.92 165.88 12.39 Favored 'General case' 0 C--N 1.269 -2.924 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.7 t -77.96 132.37 32.66 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 176.437 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.518 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -95.89 -44.0 7.58 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 121.396 0.617 . . . . 0.0 110.049 -178.715 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.8 m -155.66 160.13 40.15 Favored 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 -178.566 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.41 ' HA ' HG22 ' A' ' 19' ' ' ILE . 64.0 t -129.11 148.8 33.29 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.621 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.3 t . . . . . 0 C--O 1.254 1.292 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 176.61 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 CA--C 1.563 1.463 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.558 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -77.88 -57.34 3.85 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -75.16 -12.61 60.34 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 119.764 -0.774 . . . . 0.0 112.085 175.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.568 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 20.5 mmm180 -73.4 -40.99 63.88 Favored 'General case' 0 CA--C 1.507 -0.689 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.564 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -62.36 -57.69 10.39 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.965 0.79 . . . . 0.0 109.603 176.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 83.25 -5.74 75.49 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 115.539 0.976 . . . . 0.0 115.539 173.009 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -78.36 -30.99 48.29 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.351 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 19.7 tt -89.11 152.6 3.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 175.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -133.03 -177.57 4.57 Favored 'General case' 0 N--CA 1.42 -1.962 0 CA-C-O 121.508 0.67 . . . . 0.0 111.019 -179.297 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.9 p -97.9 -5.06 9.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 121.822 0.82 . . . . 0.0 109.548 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -117.2 16.96 14.88 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.433 -174.16 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.426 ' OD1' HD13 ' A' ' 91' ' ' ILE . 3.0 p30 -100.66 -168.37 1.56 Allowed 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.167 177.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.476 ' O ' HG23 ' A' ' 91' ' ' ILE . 11.8 tt0 -131.39 117.6 19.11 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.374 -176.302 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.504 ' HA ' HG12 ' A' ' 91' ' ' ILE . 46.0 mm -68.83 106.85 1.24 Allowed 'Isoleucine or valine' 0 C--O 1.21 -1.024 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.778 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 89.3 t -87.76 -50.87 13.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-O 121.607 0.718 . . . . 0.0 110.326 -177.769 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.503 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.9 tt0 -145.62 133.32 21.04 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.31 129.56 71.98 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 176.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 31.3 t70 64.2 16.95 10.41 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 124.739 1.274 . . . . 0.0 111.143 172.058 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 72.2 26.03 73.16 Favored Glycine 0 N--CA 1.433 -1.525 0 CA-C-N 114.825 -1.08 . . . . 0.0 112.483 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.499 HD13 HG22 ' A' ' 79' ' ' VAL . 7.5 tt -85.09 -15.1 10.9 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 CA-C-O 121.417 0.627 . . . . 0.0 109.389 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.482 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 23.2 p 49.01 83.84 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 124.951 1.3 . . . . 0.0 112.704 -175.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.442 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.9 pp -97.88 14.02 28.6 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 122.22 1.01 . . . . 0.0 109.313 -177.682 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 22.4 t -56.13 93.43 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-N 113.836 -1.529 . . . . 0.0 110.356 176.587 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.484 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 106.74 14.52 19.24 Favored Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 116.032 -0.531 . . . . 0.0 113.3 176.571 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.442 HG22 ' O ' ' A' ' 68' ' ' LEU . 21.0 m -88.16 176.14 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 O-C-N 122.335 -0.509 . . . . 0.0 111.836 -179.426 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.6 p -92.16 176.72 6.39 Favored 'General case' 0 N--CA 1.428 -1.545 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.185 177.627 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.446 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 3.6 pm0 -66.98 -23.87 65.98 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 19.6 m-80 -63.53 -50.92 67.68 Favored 'General case' 0 CA--C 1.484 -1.581 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.429 ' O ' HG23 ' A' ' 79' ' ' VAL . 38.8 t80 -68.5 -50.56 51.31 Favored 'General case' 0 N--CA 1.415 -2.182 0 CA-C-N 114.067 -1.424 . . . . 0.0 110.093 -175.748 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.5 -44.45 95.96 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.29 -16.48 64.07 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-O 121.232 0.539 . . . . 0.0 111.063 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.407 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 60.2 m -85.04 -42.22 15.06 Favored 'General case' 0 N--CA 1.417 -2.107 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.944 176.678 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.499 HG22 HD13 ' A' ' 66' ' ' ILE . 38.7 t -62.85 -53.14 50.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 122.211 0.204 . . . . 0.0 110.588 178.811 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.434 HD21 HG21 ' A' ' 60' ' ' ILE . 3.4 mm? -68.59 -1.93 7.86 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-O 121.571 0.701 . . . . 0.0 112.434 -179.367 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.407 ' HB3' ' O ' ' A' ' 78' ' ' THR . 33.4 ttm180 -97.34 -43.41 7.32 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-O 121.922 0.868 . . . . 0.0 108.93 174.495 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 11.5 m-80 -83.78 8.59 14.22 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 114.338 -1.301 . . . . 0.0 112.794 -174.103 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.455 HG21 HD11 ' A' ' 17' ' ' LEU . 2.2 p -65.6 176.99 1.31 Allowed 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 123.86 0.864 . . . . 0.0 112.679 177.785 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -139.25 -155.57 0.6 Allowed 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.31 -175.075 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -71.77 -68.77 1.53 Allowed Glycine 0 N--CA 1.444 -0.786 0 O-C-N 123.66 0.6 . . . . 0.0 111.834 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.428 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 43.8 m-80 -87.28 104.12 16.1 Favored 'General case' 0 CA--C 1.498 -1.044 0 CA-C-O 121.638 0.732 . . . . 0.0 110.079 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.42 ' HB ' ' CE1' ' A' ' 89' ' ' PHE . 3.0 t -116.74 133.17 64.25 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 CA-C-N 115.261 -0.881 . . . . 0.0 109.76 -175.454 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 70.0 mtp180 -97.79 101.97 13.6 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 173.372 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.487 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 91.1 m-85 -92.74 107.36 19.16 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 176.416 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.778 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 42.8 t -96.05 86.26 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.268 -2.951 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.504 HG12 ' HA ' ' A' ' 60' ' ' ILE . 88.8 mt -96.08 158.73 3.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.25 0 C-N-CA 125.314 1.445 . . . . 0.0 108.689 -179.323 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.476 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -136.53 149.32 20.11 Favored Glycine 0 N--CA 1.398 -3.884 0 C-N-CA 119.565 -1.303 . . . . 0.0 111.267 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.23 135.18 54.44 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.078 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.291 -1.972 0 C-N-CA 124.335 1.054 . . . . 0.0 112.893 -175.76 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 . . . . . 0 N--CA 1.429 -1.485 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.54 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -87.31 128.6 35.17 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -140.43 144.08 35.49 Favored Pre-proline 0 C--N 1.307 -1.269 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -178.276 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -83.01 126.23 4.34 Favored 'Trans proline' 0 C--N 1.327 -0.594 0 C-N-CA 123.092 2.528 . . . . 0.0 113.393 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 41.4 t -118.05 99.94 9.08 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.018 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 175.762 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.489 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 34.0 tt0 -85.2 109.67 18.47 Favored 'General case' 0 N--CA 1.432 -1.372 0 C-N-CA 119.544 -0.863 . . . . 0.0 108.72 176.731 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.409 HD11 ' O ' ' A' ' 47' ' ' ALA . 0.1 OUTLIER -99.83 145.37 27.82 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -177.694 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -111.24 90.26 3.28 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 173.56 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.655 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 3.3 mtpm? -80.56 -176.63 5.84 Favored 'General case' 0 N--CA 1.423 -1.777 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -178.799 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -72.83 173.02 9.75 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 112.338 -2.21 . . . . 0.0 111.679 -173.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -61.29 -26.66 67.93 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.303 -0.862 . . . . 0.0 112.42 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -67.52 -45.52 75.51 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-O 121.494 0.664 . . . . 0.0 109.879 176.523 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.36 -114.3 2.34 Favored Glycine 0 N--CA 1.426 -2.025 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.73 -176.069 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.519 ' HG ' HG23 ' A' ' 19' ' ' ILE . 9.9 tp -108.1 -62.77 1.4 Allowed 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 117.349 0.575 . . . . 0.0 111.656 -173.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.87 36.25 92.87 Favored Glycine 0 N--CA 1.44 -1.034 0 O-C-N 123.889 0.743 . . . . 0.0 113.139 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.519 HG23 ' HG ' ' A' ' 17' ' ' LEU . 20.9 pt -102.17 178.48 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.519 177.546 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.8 m -130.79 148.79 52.61 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.53 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -118.66 162.86 16.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.453 -177.335 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.4 ' CG2' ' HB2' ' A' ' 38' ' ' PHE . 15.6 tt -126.9 125.55 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.938 0 C-N-CA 120.269 -0.573 . . . . 0.0 110.435 174.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.472 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -86.96 105.63 3.06 Favored Glycine 0 N--CA 1.431 -1.66 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.753 -178.417 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.462 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 9.0 ptp -137.03 176.96 8.24 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 122.668 0.387 . . . . 0.0 111.891 176.239 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.277 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.804 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.419 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.6 pt? . . . . . 0 N--CA 1.446 -0.627 0 CA-C-O 121.405 0.621 . . . . 0.0 111.438 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.462 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -124.41 33.0 3.94 Favored Glycine 0 N--CA 1.412 -2.909 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 174.525 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.542 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 32.8 mm -89.5 107.76 18.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 176.87 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.4 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 91.0 m-85 -104.21 168.66 8.96 Favored 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.9 t -78.72 121.63 32.16 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 176.014 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.524 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.1 OUTLIER -86.73 -49.19 7.65 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.503 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.09 157.65 43.68 Favored 'General case' 0 N--CA 1.417 -2.11 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.416 ' HA ' HG22 ' A' ' 19' ' ' ILE . 2.6 p -133.72 151.07 32.43 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.952 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 176.086 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.406 HG21 ' HE3' ' A' ' 12' ' ' LYS . 9.6 t . . . . . 0 N--CA 1.444 -0.726 0 CA-C-O 121.583 0.706 . . . . 0.0 112.132 -173.524 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.655 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . . . . . . 0 CA--C 1.55 0.943 0 N-CA-C 115.301 1.593 . . . . 0.0 115.301 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.29 -63.13 1.47 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 -70.6 -21.9 62.61 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 120.616 -0.434 . . . . 0.0 112.125 176.671 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.424 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 40.2 mmt180 -68.54 -33.71 74.58 Favored 'General case' 0 CA--C 1.522 -0.103 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -70.48 -64.98 0.79 Allowed 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.353 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.62 -10.97 57.84 Favored Glycine 0 N--CA 1.437 -1.278 0 C-N-CA 120.549 -0.834 . . . . 0.0 115.115 175.443 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.657 ' O ' ' HD3' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -76.72 -33.63 58.16 Favored 'General case' 0 C--O 1.239 0.507 0 CA-C-N 118.65 1.225 . . . . 0.0 108.448 178.404 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.3 tt -90.82 154.47 3.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 178.092 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -134.96 -163.43 1.38 Allowed 'General case' 0 N--CA 1.428 -1.57 0 C-N-CA 119.772 -0.771 . . . . 0.0 110.972 -174.446 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.9 p -115.16 11.43 7.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-O 122.81 1.29 . . . . 0.0 107.564 176.25 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -121.94 -7.34 8.95 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.435 -1.257 . . . . 0.0 110.655 -174.614 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.511 ' OD1' HD13 ' A' ' 91' ' ' ILE . 3.9 p30 -86.92 -165.29 1.25 Allowed 'General case' 0 C--O 1.255 1.358 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.425 -177.39 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.542 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 62.9 tt0 -142.04 121.55 13.27 Favored 'General case' 0 N--CA 1.416 -2.14 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.38 -175.065 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.461 ' HA ' HG12 ' A' ' 91' ' ' ILE . 42.3 mm -70.16 107.0 1.71 Allowed 'Isoleucine or valine' 0 C--O 1.212 -0.872 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 179.149 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.698 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 93.5 t -88.28 -52.26 11.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 CA-C-O 121.649 0.738 . . . . 0.0 110.724 -177.178 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.585 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 29.4 tt0 -146.15 110.53 5.07 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.75 -178.199 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 t -105.15 131.0 55.44 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.919 0 O-C-N 122.033 -0.417 . . . . 0.0 111.455 176.575 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 33.5 t70 61.65 16.75 8.02 Favored 'General case' 0 N--CA 1.484 1.273 0 O-C-N 124.722 1.264 . . . . 0.0 111.242 174.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.37 19.01 75.05 Favored Glycine 0 N--CA 1.443 -0.898 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.232 -179.263 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.4 tt -80.18 -30.23 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 O-C-N 122.36 -0.494 . . . . 0.0 110.971 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.473 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 19.4 t 54.59 95.24 0.02 OUTLIER 'General case' 0 C--N 1.345 0.392 0 C-N-CA 125.035 1.334 . . . . 0.0 110.5 -175.634 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.466 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.7 OUTLIER -101.65 20.35 16.35 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 122.204 1.002 . . . . 0.0 109.734 -176.144 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 39.0 t -61.84 93.56 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-N 114.496 -1.229 . . . . 0.0 111.343 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.419 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 117.07 5.77 14.68 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.697 176.641 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.466 HG22 ' O ' ' A' ' 68' ' ' LEU . 16.3 m -87.72 179.51 0.49 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.57 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -177.7 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 14.9 p -94.21 176.18 6.41 Favored 'General case' 0 C--O 1.255 1.376 0 CA-C-O 121.463 0.649 . . . . 0.0 109.9 177.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.53 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -62.81 -38.37 90.44 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 114.713 -1.131 . . . . 0.0 111.246 178.071 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -68.65 -32.76 72.84 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 111.768 0.284 . . . . 0.0 111.768 -177.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -68.28 -51.83 40.59 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 176.697 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.418 ' CB ' HG21 ' A' ' 37' ' ' ILE . . . -59.84 -44.64 93.98 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.463 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.58 -18.48 63.93 Favored 'General case' 0 C--O 1.22 -0.467 0 C-N-CA 122.995 0.518 . . . . 0.0 111.266 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 78.3 m -83.67 -49.66 8.94 Favored 'General case' 0 N--CA 1.416 -2.125 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 175.487 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.441 ' O ' HG23 ' A' ' 83' ' ' THR . 38.4 t -59.57 -54.82 29.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 CA-C-O 120.462 0.172 . . . . 0.0 110.831 -178.694 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -67.95 -2.77 8.12 Favored 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 123.331 0.652 . . . . 0.0 112.033 -179.492 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 38.5 ttt180 -98.8 -43.46 6.76 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 174.221 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -73.08 -11.73 60.65 Favored 'General case' 0 C--O 1.24 0.588 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.142 -174.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.441 HG23 ' O ' ' A' ' 79' ' ' VAL . 15.9 p -75.14 140.18 43.2 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-O 121.588 0.709 . . . . 0.0 112.464 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.464 ' O ' HG22 ' A' ' 87' ' ' VAL . 71.0 mmtt -107.07 -167.5 1.28 Allowed 'General case' 0 C--N 1.292 -1.908 0 CA-C-N 114.432 -1.258 . . . . 0.0 109.044 176.875 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -40.14 -58.57 2.33 Favored Glycine 0 C--O 1.216 -0.971 0 O-C-N 124.631 1.207 . . . . 0.0 115.761 -176.298 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -87.62 100.32 12.72 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 117.747 0.773 . . . . 0.0 111.399 -174.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.565 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 1.6 t -119.43 128.7 75.86 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.36 -175.658 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 42.3 mtp180 -92.31 99.46 12.23 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 173.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.565 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 97.1 m-85 -92.06 101.09 13.63 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 177.589 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.698 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.8 t -91.08 92.44 3.94 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 105.963 -1.865 . . . . 0.0 105.963 175.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.511 HD13 ' OD1' ' A' ' 58' ' ' ASP . 97.2 mt -110.56 153.39 12.35 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.777 0 CA-C-N 114.293 -1.321 . . . . 0.0 107.968 179.336 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.54 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -124.42 150.5 17.08 Favored Glycine 0 N--CA 1.401 -3.662 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.938 179.053 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 4.3 tmm_? -113.9 134.95 54.49 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 -177.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 . . . . . 0 C--N 1.309 -1.165 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.436 179.721 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 . . . . . 0 N--CA 1.436 -1.155 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.474 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.1 mm? -90.45 120.39 31.52 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -135.1 146.64 59.21 Favored Pre-proline 0 C--N 1.304 -1.398 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -175.647 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -80.28 126.89 6.42 Favored 'Trans proline' 0 N--CA 1.444 -1.431 0 C-N-CA 122.244 1.963 . . . . 0.0 112.488 175.703 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 48.8 t -108.45 103.26 15.21 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.076 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 173.779 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.455 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.1 tt0 -88.17 103.57 15.89 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.49 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -98.28 145.71 26.38 Favored 'General case' 0 N--CA 1.426 -1.625 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 -175.819 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -116.48 95.85 5.25 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-O 121.66 0.743 . . . . 0.0 109.188 175.18 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.478 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 1.9 mmmp? -92.49 -169.96 2.35 Favored 'General case' 0 N--CA 1.419 -1.991 0 CA-C-N 114.911 -1.041 . . . . 0.0 112.564 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -78.49 167.19 21.66 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 113.864 -1.516 . . . . 0.0 107.805 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -67.88 -20.11 65.09 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.325 0.584 . . . . 0.0 109.807 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -65.69 -31.77 72.96 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 114.697 -1.138 . . . . 0.0 109.707 177.482 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.73 -130.4 9.06 Favored Glycine 0 N--CA 1.413 -2.838 0 CA-C-N 114.841 -1.072 . . . . 0.0 111.613 177.086 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.6 ' HB3' HG23 ' A' ' 19' ' ' ILE . 20.7 mt -108.49 -63.68 1.31 Allowed 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.836 -174.587 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.62 23.27 36.87 Favored Glycine 0 N--CA 1.424 -2.1 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -172.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.6 HG23 ' HB3' ' A' ' 17' ' ' LEU . 22.7 pt -89.23 178.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.349 0.547 0 C-N-CA 120.446 -0.502 . . . . 0.0 110.908 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.1 m -139.17 147.59 42.05 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.431 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -126.8 162.4 31.44 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 C-N-CA 122.814 0.446 . . . . 0.0 110.108 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.441 ' HB ' ' HG2' ' A' ' 40' ' ' LYS . 13.5 tt -130.96 135.0 60.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.473 174.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.576 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.18 102.48 2.86 Favored Glycine 0 N--CA 1.427 -1.945 0 C-N-CA 120.722 -0.751 . . . . 0.0 111.792 -178.017 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.641 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 93.8 mmm -116.87 93.48 4.21 Favored 'General case' 0 C--N 1.291 -1.96 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -179.254 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.915 0 O-C-N 123.839 0.712 . . . . 0.0 111.743 -179.002 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.465 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.5 pp . . . . . 0 N--CA 1.43 -1.45 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.641 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -129.59 34.37 2.79 Favored Glycine 0 C--N 1.283 -2.38 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 172.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.576 HD13 ' HA2' ' A' ' 23' ' ' GLY . 26.8 mm -86.72 100.19 9.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.828 0 CA-C-O 121.556 0.693 . . . . 0.0 110.992 -175.405 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -93.16 160.3 14.91 Favored 'General case' 0 C--N 1.287 -2.134 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.211 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 49.3 t -83.63 130.52 35.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.821 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.441 ' HG2' ' HB ' ' A' ' 22' ' ' ILE . 20.3 mmmt -87.77 -53.09 4.95 Favored 'General case' 0 CA--C 1.491 -1.3 0 CA-C-O 121.661 0.743 . . . . 0.0 110.266 178.184 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -144.28 160.26 41.3 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 -176.107 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 60.9 t -131.53 86.95 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.473 -1.995 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -178.297 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.526 ' H ' ' HA ' ' A' ' 19' ' ' ILE 0.257 95.9 m . . . . . 0 CA--C 1.583 2.248 0 O-C-N 124.542 1.151 . . . . 0.0 110.182 179.381 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.478 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.201 -1.494 0 N-CA-C 115.114 1.524 . . . . 0.0 115.114 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.35 -60.42 2.25 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 179.075 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 44.1 mt-30 -70.64 -24.3 62.69 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.065 -0.516 . . . . 0.0 112.333 176.582 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.437 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 40.0 mmt180 -69.72 -37.46 76.54 Favored 'General case' 0 CA--C 1.504 -0.806 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.589 174.771 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -59.81 -48.73 80.52 Favored 'General case' 0 C--N 1.352 0.691 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.305 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.61 -10.61 36.94 Favored Glycine 0 N--CA 1.439 -1.116 0 N-CA-C 115.286 0.874 . . . . 0.0 115.286 172.253 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.464 ' O ' ' HD3' ' A' ' 53' ' ' ARG . 0.1 OUTLIER -75.46 -27.77 59.01 Favored 'General case' 0 C--O 1.221 -0.426 0 CA-C-N 118.57 1.185 . . . . 0.0 108.401 -179.782 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.0 tt -97.81 149.29 5.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 177.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 48.2 mt-30 -132.71 170.34 15.38 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-O 121.839 0.828 . . . . 0.0 112.499 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.4 p -83.26 -3.61 7.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.763 -179.356 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -103.85 15.98 27.42 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 122.6 1.191 . . . . 0.0 108.332 -178.184 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.512 ' HB3' HG21 ' A' ' 91' ' ' ILE . 68.5 m-20 -93.23 177.9 5.9 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.223 -0.899 . . . . 0.0 112.335 -178.628 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -136.7 122.46 19.89 Favored 'General case' 0 N--CA 1.416 -2.174 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.46 HG21 HD21 ' A' ' 80' ' ' LEU . 47.5 mm -74.11 111.95 10.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 -175.661 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.712 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 99.4 t -92.12 -51.22 11.77 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-O 121.771 0.796 . . . . 0.0 110.28 -177.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.527 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.4 tt0 -152.04 110.09 3.69 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.33 0.586 . . . . 0.0 111.066 -178.338 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.411 HG23 HG23 ' A' ' 60' ' ' ILE . 4.7 t -102.01 129.08 53.9 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 O-C-N 122.005 -0.434 . . . . 0.0 110.983 177.299 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 18.2 t70 65.11 10.52 6.42 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 124.764 1.226 . . . . 0.0 111.772 174.177 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.32 19.9 68.11 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.421 -177.428 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.517 HD13 HG22 ' A' ' 79' ' ' VAL . 9.7 tt -76.33 -18.96 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 CA-C-O 121.058 0.456 . . . . 0.0 110.357 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.518 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 31.4 p 48.2 84.96 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 124.875 1.27 . . . . 0.0 112.004 -175.189 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.447 HD21 HG22 ' A' ' 60' ' ' ILE . 1.5 pp -97.12 16.92 18.31 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.669 0.747 . . . . 0.0 110.084 -175.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.465 ' HA ' HD23 ' A' ' 35' ' ' LEU . 45.6 t -58.16 97.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.171 174.771 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.22 53.55 1.0 Allowed Glycine 0 N--CA 1.431 -1.652 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.551 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.6 m -134.32 173.87 13.91 Favored 'Isoleucine or valine' 0 C--O 1.244 0.796 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 176.191 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 14.5 p -92.45 175.53 6.8 Favored 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 122.873 0.469 . . . . 0.0 110.965 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.431 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 2.1 pm0 -66.38 -31.17 71.77 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.276 -179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -69.56 -36.94 76.77 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 120.783 -0.367 . . . . 0.0 111.166 -179.166 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.416 ' O ' HG23 ' A' ' 79' ' ' VAL . 44.1 t80 -68.02 -51.15 50.3 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.21 -47.14 86.45 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.036 -0.983 . . . . 0.0 111.693 -177.659 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.22 -37.07 74.12 Favored 'General case' 0 C--O 1.212 -0.9 0 O-C-N 122.94 0.15 . . . . 0.0 110.641 179.076 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 65.3 m -64.75 -42.75 94.93 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.088 176.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.517 HG22 HD13 ' A' ' 66' ' ' ILE . 47.8 t -61.12 -51.56 71.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 177.327 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.46 HD21 HG21 ' A' ' 60' ' ' ILE . 3.6 mm? -69.73 -2.34 11.63 Favored 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.448 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 3.4 tmt_? -99.51 -30.09 12.35 Favored 'General case' 0 C--N 1.312 -1.061 0 C-N-CA 123.667 0.787 . . . . 0.0 109.329 175.388 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -86.81 0.19 55.28 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 123.344 0.658 . . . . 0.0 112.004 -177.736 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.3 p -65.96 148.83 51.18 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.596 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.71 -157.48 0.72 Allowed 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 124.79 1.236 . . . . 0.0 108.587 178.76 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.27 -76.97 0.17 Allowed Glycine 0 C--N 1.315 -0.613 0 O-C-N 123.542 0.527 . . . . 0.0 113.963 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.49 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.3 m-80 -78.79 109.83 13.41 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.329 0.585 . . . . 0.0 111.537 -179.309 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.465 HG21 HD21 ' A' ' 17' ' ' LEU . 7.2 t -121.73 131.12 73.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.457 -178.46 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -98.58 98.71 9.84 Favored 'General case' 0 C--N 1.284 -2.271 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 174.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.442 ' CE1' ' HB ' ' A' ' 87' ' ' VAL . 89.8 m-85 -89.42 103.06 15.73 Favored 'General case' 0 CA--C 1.486 -1.481 0 CA-C-N 114.643 -1.162 . . . . 0.0 107.942 177.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.712 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.7 t -89.03 95.39 5.37 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.987 0 N-CA-C 106.6 -1.629 . . . . 0.0 106.6 177.633 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.512 HG21 ' HB3' ' A' ' 58' ' ' ASP . 96.7 mt -112.4 154.02 13.93 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.682 0 CA-C-N 114.143 -1.39 . . . . 0.0 108.248 176.768 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.474 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -120.91 149.72 17.38 Favored Glycine 0 N--CA 1.416 -2.657 0 C-N-CA 118.946 -1.597 . . . . 0.0 111.507 179.139 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 25.2 tpt180 -121.22 136.8 54.91 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 120.959 0.409 . . . . 0.0 110.859 179.238 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 . . . . . 0 N--CA 1.424 -1.755 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.171 176.611 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.527 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 42.1 tt0 . . . . . 0 CA--C 1.489 -1.373 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -87.09 116.21 25.0 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 174.333 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -132.07 137.19 29.57 Favored Pre-proline 0 N--CA 1.417 -2.113 0 CA-C-O 121.896 0.855 . . . . 0.0 113.237 -173.182 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -82.31 128.47 5.57 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.972 2.448 . . . . 0.0 112.144 175.659 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.449 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 38.4 t -118.95 112.92 39.81 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.491 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 174.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.461 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.2 tt0 -96.11 105.2 17.22 Favored 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 176.764 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.429 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -92.93 143.46 26.23 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -175.02 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -108.34 90.73 3.38 Favored 'General case' 0 C--N 1.291 -1.941 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 174.387 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.8 mmmp? -87.05 -175.46 5.35 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 113.966 1.099 . . . . 0.0 113.966 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.439 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.2 p-10 -89.32 -172.39 3.61 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 126.285 1.834 . . . . 0.0 111.179 -178.248 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -82.1 -6.44 59.18 Favored 'General case' 0 N--CA 1.465 0.286 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -175.571 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.439 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 11.3 t70 -82.16 -34.09 29.24 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 122.005 0.907 . . . . 0.0 108.757 176.001 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 121.37 -109.95 1.59 Allowed Glycine 0 N--CA 1.415 -2.735 0 CA-C-N 114.146 -1.388 . . . . 0.0 110.118 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.763 ' HG ' HG23 ' A' ' 19' ' ' ILE . 14.1 tp -117.31 -62.75 1.53 Allowed 'General case' 0 C--N 1.291 -1.939 0 O-C-N 122.341 -0.505 . . . . 0.0 109.878 -177.216 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.56 33.55 55.75 Favored Glycine 0 N--CA 1.434 -1.496 0 O-C-N 124.175 0.922 . . . . 0.0 113.157 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.763 HG23 ' HG ' ' A' ' 17' ' ' LEU . 27.5 pt -101.02 172.6 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 C-N-CA 119.892 -0.723 . . . . 0.0 110.279 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 34.8 m -119.33 145.98 45.69 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -179.016 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.417 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -122.71 164.38 20.09 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -178.112 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.6 tt -132.53 132.78 60.09 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 174.361 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.629 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.58 105.73 3.29 Favored Glycine 0 N--CA 1.428 -1.9 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.926 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.469 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 16.7 ptm -143.65 85.22 1.82 Allowed 'General case' 0 C--N 1.291 -1.948 0 CA-C-O 121.585 0.707 . . . . 0.0 110.8 179.264 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.519 0 CA-C-N 114.013 -1.449 . . . . 0.0 113.845 -176.248 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.478 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.0 OUTLIER . . . . . 0 N--CA 1.414 -2.253 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -131.67 35.48 2.39 Favored Glycine 0 N--CA 1.414 -2.781 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.039 176.255 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.629 HD13 ' HA2' ' A' ' 23' ' ' GLY . 26.7 mm -94.81 105.72 17.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 C-N-CA 119.405 -0.918 . . . . 0.0 109.547 -179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -102.17 161.54 13.61 Favored 'General case' 0 C--N 1.276 -2.604 0 CA-C-N 114.721 -1.127 . . . . 0.0 110.191 -179.171 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 29.0 t -77.5 117.81 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.087 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 176.58 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 56.3 tptt -84.64 -51.33 6.92 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -178.176 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -149.51 160.69 43.26 Favored 'General case' 0 N--CA 1.427 -1.61 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 -179.777 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.443 ' HB ' ' OE1' ' A' ' 49' ' ' GLN . 16.8 t -122.75 162.36 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.151 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 178.031 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.485 ' H ' HG22 ' A' ' 19' ' ' ILE . 9.1 t . . . . . 0 N--CA 1.422 -1.83 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.332 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 C--O 1.201 -1.473 0 N-CA-C 115.424 1.638 . . . . 0.0 115.424 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.89 -53.25 10.58 Favored 'General case' 0 N--CA 1.465 0.275 0 O-C-N 121.46 -0.775 . . . . 0.0 109.952 -178.203 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.443 ' OE1' ' HB ' ' A' ' 42' ' ' VAL . 27.8 mt-30 -78.46 -13.89 59.63 Favored 'General case' 0 CA--C 1.508 -0.66 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.739 176.647 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.478 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 13.5 mmm180 -74.45 -41.06 61.46 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 174.614 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.45 ' OD1' ' HB2' ' A' ' 53' ' ' ARG . 12.2 t70 -60.29 -59.03 6.06 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.461 177.065 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.4 -9.35 77.79 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 115.03 0.772 . . . . 0.0 115.03 174.642 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.45 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -69.35 -37.27 77.56 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.545 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.9 tt -81.93 152.33 4.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -178.705 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 30.3 mt-30 -127.88 161.6 28.69 Favored 'General case' 0 C--N 1.312 -1.061 0 C-N-CA 120.031 -0.668 . . . . 0.0 109.303 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.9 p -89.64 16.82 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 CA-C-O 121.747 0.784 . . . . 0.0 110.531 -177.687 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -137.59 20.38 2.9 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 122.236 1.017 . . . . 0.0 110.11 -177.021 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -103.72 -175.19 2.73 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.234 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.447 ' O ' HG23 ' A' ' 91' ' ' ILE . 33.6 tt0 -120.68 132.65 55.2 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.132 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.517 HG22 HD11 ' A' ' 68' ' ' LEU . 47.2 mm -76.73 101.45 2.91 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.128 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.699 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.722 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 81.2 t -80.8 -48.06 19.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 CA-C-O 121.233 0.539 . . . . 0.0 110.571 -175.32 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.481 ' HG3' ' H ' ' A' ' 67' ' ' SER . 39.5 tt0 -156.64 112.91 3.02 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-O 121.015 0.436 . . . . 0.0 110.639 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.435 ' C ' ' H ' ' A' ' 65' ' ' GLY . 4.8 t -102.26 131.08 51.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.566 175.636 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.3 t70 73.03 -22.56 0.23 Allowed 'General case' 0 N--CA 1.503 2.22 0 C-N-CA 125.747 1.619 . . . . 0.0 112.975 176.667 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 63' ' ' VAL . . . 110.36 12.41 17.4 Favored Glycine 0 C--N 1.274 -2.911 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -173.323 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.438 HD13 HG22 ' A' ' 79' ' ' VAL . 7.3 tt -70.02 -19.51 22.56 Favored 'Isoleucine or valine' 0 C--N 1.344 0.326 0 C-N-CA 122.885 0.474 . . . . 0.0 110.903 -178.119 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.481 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 12.3 p 49.03 81.57 0.05 Allowed 'General case' 0 C--O 1.233 0.19 0 C-N-CA 124.26 1.024 . . . . 0.0 112.88 -176.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.517 HD11 HG22 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -95.58 30.22 2.36 Favored 'General case' 0 N--CA 1.423 -1.778 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.381 -178.625 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 47.9 t -73.45 97.04 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-N 114.974 -1.012 . . . . 0.0 109.585 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.478 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 108.26 33.07 3.05 Favored Glycine 0 C--N 1.294 -1.799 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 176.423 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.471 HG21 ' HB2' ' A' ' 68' ' ' LEU . 19.7 m -109.39 174.53 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 119.917 -0.713 . . . . 0.0 111.461 -178.746 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 22.2 p -91.29 172.82 8.27 Favored 'General case' 0 N--CA 1.418 -2.049 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.794 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.417 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 2.5 pm0 -66.97 -32.01 72.96 Favored 'General case' 0 C--O 1.204 -1.293 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.018 -179.682 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -71.44 -31.6 67.39 Favored 'General case' 0 CA--C 1.516 -0.362 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.82 -178.321 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -70.38 -51.67 28.03 Favored 'General case' 0 N--CA 1.443 -0.819 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 177.453 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.41 ' CB ' HG21 ' A' ' 37' ' ' ILE . . . -62.56 -42.16 99.37 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.031 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.09 -11.4 48.52 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 121.23 0.538 . . . . 0.0 111.102 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 58.0 m -89.75 -47.13 8.12 Favored 'General case' 0 N--CA 1.415 -2.204 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.862 174.618 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.494 ' O ' HG23 ' A' ' 83' ' ' THR . 31.4 t -61.86 -54.27 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.43 HD21 HG21 ' A' ' 60' ' ' ILE . 3.3 mm? -68.41 0.42 3.96 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.617 0.767 . . . . 0.0 112.716 -178.835 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -104.07 -45.95 4.59 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 174.494 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 -80.83 7.36 10.64 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 114.405 -1.27 . . . . 0.0 113.142 -173.598 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.494 HG23 ' O ' ' A' ' 79' ' ' VAL . 1.7 p -60.45 154.22 21.18 Favored 'General case' 0 C--N 1.29 -2.013 0 C-N-CA 124.854 1.261 . . . . 0.0 111.405 175.047 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.439 ' HD3' ' HA ' ' A' ' 84' ' ' LYS . 31.8 mmtp -111.51 -164.91 0.95 Allowed 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.061 178.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.32 -67.59 2.12 Favored Glycine 0 N--CA 1.439 -1.152 0 O-C-N 123.657 0.598 . . . . 0.0 112.886 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.429 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 15.6 m120 -82.52 117.07 22.25 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.461 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.2 t -125.04 127.79 72.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.453 -177.326 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -91.68 104.33 16.8 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-O 120.877 0.37 . . . . 0.0 110.169 172.465 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.449 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.7 m-85 -95.6 103.99 15.88 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 175.234 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.722 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 47.7 t -92.85 91.48 3.37 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.921 0 N-CA-C 104.781 -2.303 . . . . 0.0 104.781 174.687 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.492 HG12 ' HA ' ' A' ' 60' ' ' ILE . 74.8 mt -108.0 157.05 8.33 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.09 178.605 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -131.78 143.66 15.22 Favored Glycine 0 N--CA 1.397 -3.913 0 C-N-CA 119.404 -1.379 . . . . 0.0 111.093 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.42 ' HD2' ' C ' ' A' ' 93' ' ' ARG . 5.2 tmm_? -108.22 128.47 54.75 Favored 'General case' 0 C--N 1.291 -1.97 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -178.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 . . . . . 0 C--N 1.311 -1.095 0 O-C-N 123.353 0.408 . . . . 0.0 110.459 178.961 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.429 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 32.2 tt0 . . . . . 0 CA--C 1.498 -1.031 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -91.72 127.87 37.34 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.761 -1.199 . . . . 0.0 107.761 173.73 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.494 ' O ' ' HA ' ' A' ' 90' ' ' VAL . 20.9 p90 -133.21 137.59 29.67 Favored Pre-proline 0 C--N 1.283 -2.295 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -175.465 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -84.21 121.67 2.75 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 123.472 2.781 . . . . 0.0 112.146 176.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 35.8 t -112.17 98.47 7.07 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.048 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 175.886 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.608 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 31.6 tt0 -83.8 101.54 11.69 Favored 'General case' 0 N--CA 1.421 -1.899 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 176.793 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.472 HD11 ' HA ' ' A' ' 48' ' ' ALA . 0.1 OUTLIER -93.23 133.67 36.21 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 -175.948 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -101.15 92.98 5.23 Favored 'General case' 0 N--CA 1.419 -2.016 0 CA-C-O 121.995 0.903 . . . . 0.0 109.282 175.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.572 ' CD ' ' HB3' ' A' ' 47' ' ' ALA . 2.0 mmmp? -92.95 -175.45 3.89 Favored 'General case' 0 N--CA 1.421 -1.921 0 CA-C-N 114.302 -1.317 . . . . 0.0 113.218 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.467 ' OD1' ' HB3' ' A' ' 15' ' ' ASP . 1.7 p30 -77.31 176.62 8.63 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-N 112.784 -2.007 . . . . 0.0 110.743 178.063 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -82.94 -6.65 59.56 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.612 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.467 ' HB3' ' OD1' ' A' ' 13' ' ' ASP . 9.6 t70 -81.77 -41.94 20.45 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 175.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.32 -123.26 2.6 Favored Glycine 0 N--CA 1.42 -2.381 0 C-N-CA 120.136 -1.031 . . . . 0.0 112.909 175.501 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.444 HD21 HG21 ' A' ' 87' ' ' VAL . 13.0 mt -108.36 -45.1 3.97 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 122.211 -0.582 . . . . 0.0 110.569 -172.796 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.67 28.45 70.89 Favored Glycine 0 N--CA 1.426 -2.014 0 O-C-N 124.336 1.023 . . . . 0.0 110.663 -174.345 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 20.4 pt -106.38 -176.95 0.58 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.293 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.797 -178.083 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.3 m -144.22 151.86 40.05 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.496 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.6 pp -125.0 162.67 26.84 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -178.762 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 12.1 tt -134.59 130.42 53.3 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.833 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 176.703 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.623 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -98.01 104.92 3.05 Favored Glycine 0 CA--C 1.481 -2.034 0 C-N-CA 120.357 -0.925 . . . . 0.0 111.744 -178.876 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.492 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 18.4 ptm -147.16 96.41 2.72 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 120.643 0.258 . . . . 0.0 111.562 -179.469 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.704 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.315 -178.914 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.507 HD22 HG23 ' A' ' 69' ' ' VAL . 1.8 pt? . . . . . 0 N--CA 1.448 -0.561 0 CA-C-O 122.254 1.026 . . . . 0.0 111.985 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.492 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -131.66 32.04 2.99 Favored Glycine 0 N--CA 1.41 -3.076 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.873 175.777 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.623 HD13 ' HA2' ' A' ' 23' ' ' GLY . 23.8 mm -90.1 98.61 8.41 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 119.778 -0.769 . . . . 0.0 109.098 178.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -96.98 162.5 13.37 Favored 'General case' 0 C--N 1.273 -2.744 0 CA-C-N 115.047 -0.979 . . . . 0.0 108.914 -178.489 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 40.9 t -79.71 122.71 35.44 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.537 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -81.15 -49.92 10.24 Favored 'General case' 0 C--N 1.293 -1.86 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.331 -177.379 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -154.31 161.23 41.89 Favored 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 -178.121 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 51.0 t -136.25 147.54 27.88 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 N-CA-C 105.415 -2.068 . . . . 0.0 105.415 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.2 t . . . . . 0 C--O 1.257 1.465 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 173.967 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.572 ' HB3' ' CD ' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.197 -1.704 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.472 ' HA ' HD11 ' A' ' 10' ' ' LEU . . . -64.42 -54.74 27.94 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.239 0.542 . . . . 0.0 110.662 -176.515 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 42.8 mt-30 -76.45 -7.79 55.81 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.772 178.674 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.415 ' HD3' ' HA ' ' A' ' 50' ' ' ARG . 23.4 mmt180 -90.44 -23.29 21.06 Favored 'General case' 0 N--CA 1.437 -1.085 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.12 176.56 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -61.01 -54.9 39.17 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 170.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 105.3 -26.55 21.46 Favored Glycine 0 N--CA 1.432 -1.576 0 CA-C-N 115.164 -0.925 . . . . 0.0 114.746 174.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -72.93 -31.5 64.66 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 118.446 1.123 . . . . 0.0 109.666 -176.545 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.9 tt -97.09 146.96 6.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -179.193 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLN . . . . . 0.424 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 97.0 mt-30 -136.57 162.52 32.9 Favored 'General case' 0 N--CA 1.436 -1.13 0 CA-C-O 121.331 0.586 . . . . 0.0 110.945 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.4 p -75.71 -15.34 15.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 C-N-CA 124.085 0.954 . . . . 0.0 111.298 -178.709 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -95.06 9.84 38.01 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.455 0.645 . . . . 0.0 111.557 -175.812 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.424 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 39.9 m-20 -97.84 -172.68 2.43 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.691 -177.157 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.564 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.6 tt0 -134.91 133.21 39.38 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.836 -177.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.461 ' HA ' HG12 ' A' ' 91' ' ' ILE . 44.1 mm -78.4 115.15 20.04 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.001 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 -177.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.657 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.2 t -94.49 -51.8 10.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-O 121.679 0.752 . . . . 0.0 110.552 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.609 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 21.4 tt0 -147.55 110.01 4.62 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.92 -177.427 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.5 t -103.39 126.54 57.78 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 O-C-N 122.018 -0.427 . . . . 0.0 110.204 175.132 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.5 t70 62.19 17.52 9.29 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 124.452 1.101 . . . . 0.0 112.215 174.455 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 83.09 8.75 85.15 Favored Glycine 0 N--CA 1.442 -0.915 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.975 -179.214 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.512 HD13 HG22 ' A' ' 79' ' ' VAL . 5.7 tt -75.25 -16.62 15.91 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 O-C-N 122.571 -0.37 . . . . 0.0 110.845 -176.642 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.43 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 31.3 m 49.09 79.71 0.07 Allowed 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 124.876 1.27 . . . . 0.0 112.706 -177.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.495 ' O ' HG22 ' A' ' 71' ' ' VAL . 2.3 pp -96.16 11.73 33.32 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 122.322 1.058 . . . . 0.0 110.074 -175.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.507 HG23 HD22 ' A' ' 35' ' ' LEU . 5.2 p -58.11 92.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.294 -1.841 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.497 173.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.489 ' N ' ' HB3' ' A' ' 35' ' ' LEU . . . 113.79 21.42 5.71 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.829 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.495 HG22 ' O ' ' A' ' 68' ' ' LEU . 20.4 m -103.48 176.97 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 O-C-N 121.978 -0.719 . . . . 0.0 110.965 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.3 p -93.7 171.71 8.71 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.026 177.034 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.496 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 1.8 pm0 -64.78 -28.83 69.84 Favored 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.775 -176.337 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.82 -30.49 66.94 Favored 'General case' 0 CA--C 1.512 -0.492 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.358 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.451 ' O ' HG23 ' A' ' 79' ' ' VAL . 31.2 t80 -77.32 -52.01 9.91 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 177.686 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -56.25 -50.12 72.23 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.274 -0.876 . . . . 0.0 112.364 -177.359 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.15 -36.41 75.21 Favored 'General case' 0 C--O 1.214 -0.786 0 CA-C-O 120.505 0.193 . . . . 0.0 110.796 -179.199 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 84.0 m -62.88 -42.75 99.88 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.301 177.044 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.512 HG22 HD13 ' A' ' 66' ' ' ILE . 31.6 t -64.27 -51.78 64.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 178.483 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -63.58 -18.28 63.72 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.841 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.13 -26.44 23.62 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 123.276 0.631 . . . . 0.0 110.32 174.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -88.67 6.17 39.68 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-O 121.48 0.657 . . . . 0.0 112.251 -178.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 36.4 p -74.89 -178.2 3.64 Favored 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.043 177.658 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.18 -163.0 1.52 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.166 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -49.25 -73.3 0.37 Allowed Glycine 0 CA--C 1.531 1.036 0 O-C-N 123.884 0.74 . . . . 0.0 114.49 178.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.463 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 19.0 m120 -82.99 104.74 13.42 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 117.667 0.734 . . . . 0.0 111.628 -178.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.608 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -114.71 137.51 47.89 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.503 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 90.6 mtt180 -99.64 99.04 9.83 Favored 'General case' 0 C--N 1.283 -2.304 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.507 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 91.9 m-85 -92.2 101.45 13.96 Favored 'General case' 0 CA--C 1.489 -1.386 0 CA-C-N 114.895 -1.048 . . . . 0.0 108.555 177.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.657 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 60.8 t -92.32 94.76 4.96 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.89 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.498 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.47 HG23 ' O ' ' A' ' 59' ' ' GLN . 90.6 mt -106.3 163.19 4.92 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.929 0 CA-C-N 114.104 -1.407 . . . . 0.0 108.543 178.532 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -139.07 161.23 25.94 Favored Glycine 0 N--CA 1.412 -2.912 0 C-N-CA 119.489 -1.338 . . . . 0.0 112.162 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 37.0 ttp-105 -142.58 144.17 32.76 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.552 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 . . . . . 0 C--N 1.302 -1.485 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 176.291 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 . . . . . 0 N--CA 1.43 -1.473 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -93.1 127.55 38.68 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 175.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 19.6 p90 -137.25 141.34 33.79 Favored Pre-proline 0 C--N 1.297 -1.684 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -175.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -82.24 123.9 4.1 Favored 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 122.76 2.307 . . . . 0.0 112.21 177.467 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.415 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 38.9 t -109.44 95.99 4.29 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.688 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 174.385 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 29.7 tt0 -83.37 102.72 12.21 Favored 'General case' 0 N--CA 1.423 -1.825 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -98.44 140.43 32.7 Favored 'General case' 0 N--CA 1.411 -2.386 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 -175.025 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -108.86 95.74 5.85 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 173.425 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.539 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 1.9 mmmp? -84.72 174.21 10.09 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 114.381 1.252 . . . . 0.0 114.381 -178.573 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -92.12 179.91 5.45 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 112.714 -2.039 . . . . 0.0 111.032 -176.656 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -68.81 -15.51 63.52 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -173.366 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -77.3 -28.03 53.17 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 121.572 0.701 . . . . 0.0 109.411 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.12 -125.62 6.61 Favored Glycine 0 CA--C 1.482 -1.997 0 N-CA-C 108.513 -1.835 . . . . 0.0 108.513 -179.275 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt -103.79 -50.24 3.46 Favored 'General case' 0 CA--C 1.483 -1.609 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 176.489 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.94 27.33 64.77 Favored Glycine 0 N--CA 1.434 -1.491 0 O-C-N 124.642 1.214 . . . . 0.0 110.773 -176.776 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.499 HG22 ' HA ' ' A' ' 42' ' ' VAL . 21.6 pt -102.54 -179.51 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.817 -177.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.3 t -138.72 153.23 48.49 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -178.371 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.51 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.6 pp -125.75 163.43 27.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -177.304 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.615 ' HB ' ' HG2' ' A' ' 40' ' ' LYS . 11.3 tt -130.96 132.69 63.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-O 120.536 0.208 . . . . 0.0 110.686 174.503 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.519 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.15 103.83 3.1 Favored Glycine 0 N--CA 1.426 -1.978 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.5 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.42 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 16.5 ptm -143.94 91.3 2.21 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 178.755 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.34 0.799 0 CA-C-N 114.184 -1.371 . . . . 0.0 113.018 -177.421 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.416 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 2.6 pp . . . . . 0 N--CA 1.428 -1.568 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -118.79 30.88 5.74 Favored Glycine 0 N--CA 1.417 -2.583 0 C-N-CA 119.684 -1.246 . . . . 0.0 110.303 176.782 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.519 HD13 ' HA2' ' A' ' 23' ' ' GLY . 30.3 mm -91.95 100.97 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.868 0 CA-C-O 121.553 0.692 . . . . 0.0 110.998 -176.515 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.419 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 96.2 m-85 -96.98 165.0 12.29 Favored 'General case' 0 C--N 1.285 -2.209 0 CA-C-N 115.075 -0.966 . . . . 0.0 108.532 177.567 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 47.1 t -81.41 128.17 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.14 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.53 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.615 ' HG2' ' HB ' ' A' ' 22' ' ' ILE . 15.9 mmmt -85.36 -57.34 3.11 Favored 'General case' 0 CA--C 1.473 -2.015 0 CA-C-O 121.567 0.698 . . . . 0.0 109.332 177.666 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.48 163.6 34.19 Favored 'General case' 0 C--N 1.291 -1.978 0 CA-C-N 114.241 -1.345 . . . . 0.0 107.789 -176.875 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.499 ' HA ' HG22 ' A' ' 19' ' ' ILE . 86.6 t -129.68 157.26 42.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.23 0 N-CA-C 104.9 -2.259 . . . . 0.0 104.9 174.582 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 14.9 t . . . . . 0 N--CA 1.435 -1.193 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 175.939 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.539 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . . . . . . 0 N--CA 1.423 -1.799 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -95.1 -55.8 2.95 Favored 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 115.795 -0.638 . . . . 0.0 109.608 -175.478 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -79.08 -16.19 57.1 Favored 'General case' 0 N--CA 1.438 -1.044 0 C-N-CA 119.301 -0.96 . . . . 0.0 110.037 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 36.0 mmt180 -78.43 -25.32 45.95 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.55 171.338 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -70.91 -61.0 1.92 Allowed 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 172.601 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.77 2.07 84.67 Favored Glycine 0 N--CA 1.437 -1.247 0 N-CA-C 115.055 0.782 . . . . 0.0 115.055 173.023 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -85.23 -36.37 20.99 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 176.142 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.6 tt -88.04 146.71 5.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 87.0 mm-40 -128.71 177.56 6.97 Favored 'General case' 0 N--CA 1.431 -1.377 0 C-N-CA 120.163 -0.615 . . . . 0.0 111.406 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 5.2 t -90.47 -9.99 10.29 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.774 0 CA-C-O 121.936 0.874 . . . . 0.0 109.46 -175.524 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -103.56 7.56 37.67 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.699 -176.615 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -83.25 -177.93 6.91 Favored 'General case' 0 C--O 1.247 0.954 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.537 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.426 ' O ' HG23 ' A' ' 91' ' ' ILE . 63.9 tt0 -133.32 128.3 35.41 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-N 115.112 -0.949 . . . . 0.0 108.746 -177.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.508 HG23 HG23 ' A' ' 63' ' ' VAL . 49.4 mm -76.83 109.99 11.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -176.165 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.677 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 88.1 t -92.64 -47.66 13.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 CA-C-O 121.242 0.544 . . . . 0.0 111.137 -176.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.532 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 38.7 tt0 -155.2 102.17 2.28 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-O 121.623 0.725 . . . . 0.0 110.541 -178.456 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.508 HG23 HG23 ' A' ' 60' ' ' ILE . 4.8 t -94.61 129.3 45.02 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 O-C-N 121.921 -0.487 . . . . 0.0 111.089 177.095 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 38.5 t70 65.32 11.72 7.52 Favored 'General case' 0 N--CA 1.487 1.394 0 CA-C-O 122.234 1.016 . . . . 0.0 111.55 172.369 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.35 15.47 78.31 Favored Glycine 0 N--CA 1.441 -1.026 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.084 -178.509 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.5 HD13 HG22 ' A' ' 79' ' ' VAL . 6.2 tt -76.41 -20.53 15.07 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.798 0 CA-C-O 121.215 0.531 . . . . 0.0 110.683 -177.694 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.529 ' H ' ' HG3' ' A' ' 62' ' ' GLU 0.267 13.1 p 47.97 76.48 0.11 Allowed 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 124.708 1.203 . . . . 0.0 113.879 -177.048 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.502 ' H ' HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -88.9 32.2 0.82 Allowed 'General case' 0 N--CA 1.432 -1.367 0 CA-C-N 114.432 -1.258 . . . . 0.0 111.287 -177.063 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 46.3 t -69.69 95.81 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 CA-C-N 114.799 -1.092 . . . . 0.0 110.385 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.416 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 105.44 19.74 10.24 Favored Glycine 0 C--N 1.31 -0.901 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.574 176.174 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.455 HG21 ' HB2' ' A' ' 68' ' ' LEU . 23.9 m -93.1 179.21 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 177.496 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.9 p -94.54 171.0 9.07 Favored 'General case' 0 N--CA 1.416 -2.163 0 CA-C-O 121.221 0.534 . . . . 0.0 110.349 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.51 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.17 -34.64 70.53 Favored 'General case' 0 C--N 1.294 -1.814 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.916 178.126 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.27 -36.97 74.75 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.332 -178.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.491 ' O ' HG23 ' A' ' 79' ' ' VAL . 45.9 t80 -66.99 -49.42 65.41 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.178 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.48 -45.58 93.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.758 -179.434 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -64.11 -16.84 62.67 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 120.915 0.388 . . . . 0.0 111.425 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 66.3 m -85.93 -44.81 12.08 Favored 'General case' 0 N--CA 1.426 -1.631 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.625 174.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.5 HG22 HD13 ' A' ' 66' ' ' ILE . 47.1 t -58.11 -51.5 70.15 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.627 0 N-CA-C 110.091 -0.336 . . . . 0.0 110.091 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -70.24 3.21 3.01 Favored 'General case' 0 CA--C 1.556 1.194 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.769 179.08 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 1.3 tmt_? -114.95 -17.76 11.43 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 123.373 0.669 . . . . 0.0 109.682 177.186 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -92.0 -7.46 48.83 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.279 0.632 . . . . 0.0 110.319 177.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.448 HG23 ' O ' ' A' ' 79' ' ' VAL . 2.5 p -64.5 161.48 17.21 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 115.061 -0.972 . . . . 0.0 113.444 -177.58 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 43.5 mmtm -113.42 -163.41 0.86 Allowed 'General case' 0 C--N 1.293 -1.875 0 CA-C-N 114.434 -1.257 . . . . 0.0 109.282 -178.066 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.87 -60.4 6.14 Favored Glycine 0 N--CA 1.424 -2.113 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 171.499 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -76.39 106.93 8.31 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-O 121.2 0.524 . . . . 0.0 110.168 177.057 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.0 t -121.87 132.36 71.05 Favored 'Isoleucine or valine' 0 CA--C 1.484 -1.571 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 -178.005 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 79.5 mtt180 -102.42 96.77 7.15 Favored 'General case' 0 C--N 1.283 -2.314 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 173.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.415 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 90.5 m-85 -87.35 102.53 14.61 Favored 'General case' 0 CA--C 1.491 -1.312 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 177.788 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.677 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.1 t -90.99 90.87 3.42 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.625 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 177.875 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.426 HG23 ' O ' ' A' ' 59' ' ' GLN . 86.2 mt -104.12 156.49 5.64 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.689 0 CA-C-N 114.248 -1.342 . . . . 0.0 108.189 179.094 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.65 166.81 22.89 Favored Glycine 0 N--CA 1.406 -3.344 0 C-N-CA 119.42 -1.371 . . . . 0.0 110.926 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 46.1 ttp180 -142.59 141.32 31.95 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 . . . . . 0 N--CA 1.431 -1.414 0 N-CA-C 106.087 -1.82 . . . . 0.0 106.087 170.204 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 . . . . . 0 C--O 1.212 -0.909 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.49 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.2 mm? -90.11 136.12 33.24 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.481 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 20.8 p90 -145.99 140.63 15.76 Favored Pre-proline 0 C--N 1.303 -1.421 0 CA-C-O 121.079 0.466 . . . . 0.0 112.141 -178.648 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -81.4 126.58 5.51 Favored 'Trans proline' 0 C--O 1.248 1.022 0 C-N-CA 123.29 2.66 . . . . 0.0 113.081 177.463 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.405 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 26.2 t -120.83 102.87 13.01 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 175.686 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 37.4 tt0 -84.24 105.98 15.5 Favored 'General case' 0 N--CA 1.427 -1.592 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.763 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.634 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 12.9 tp -89.91 155.08 19.37 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 -174.518 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -120.29 93.05 3.92 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 175.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.553 ' HG2' HD23 ' A' ' 10' ' ' LEU . 2.5 mmmp? -89.65 176.16 6.97 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 115.278 1.584 . . . . 0.0 115.278 -179.304 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -77.25 168.33 20.23 Favored 'General case' 0 N--CA 1.428 -1.547 0 CA-C-N 111.934 -2.393 . . . . 0.0 107.435 -179.275 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -74.01 -10.48 59.68 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-O 121.217 0.532 . . . . 0.0 110.967 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -63.55 -33.16 74.97 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 172.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.4 -130.87 9.08 Favored Glycine 0 N--CA 1.413 -2.897 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.009 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.509 ' HG ' HG23 ' A' ' 19' ' ' ILE . 13.7 tp -103.5 -61.51 1.41 Allowed 'General case' 0 C--N 1.285 -2.219 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 -177.8 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.462 ' O ' ' HB ' ' A' ' 43' ' ' THR . . . 71.32 37.85 62.88 Favored Glycine 0 N--CA 1.429 -1.786 0 O-C-N 124.284 0.99 . . . . 0.0 112.854 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.509 HG23 ' HG ' ' A' ' 17' ' ' LEU . 15.5 pt -107.95 167.51 3.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 118.949 -1.101 . . . . 0.0 111.435 176.382 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.3 m -117.08 148.54 41.43 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 -177.32 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -125.41 166.34 21.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -177.207 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 11.9 tt -130.35 132.15 65.03 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.877 0 C-N-CA 120.701 -0.4 . . . . 0.0 110.575 175.706 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.513 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.61 95.77 2.13 Favored Glycine 0 N--CA 1.424 -2.14 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.589 -178.58 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 95.1 mmm -109.3 173.72 6.19 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 176.676 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.292 -1.916 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 177.743 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.436 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.0 OUTLIER . . . . . 0 N--CA 1.428 -1.535 0 CA-C-O 120.806 0.336 . . . . 0.0 110.153 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -124.07 25.13 6.15 Favored Glycine 0 N--CA 1.414 -2.771 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 174.135 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.513 HD13 ' HA2' ' A' ' 23' ' ' GLY . 33.4 mm -85.02 100.71 8.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 121.525 0.679 . . . . 0.0 109.524 -179.809 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -97.43 164.39 12.47 Favored 'General case' 0 C--N 1.278 -2.502 0 CA-C-N 115.252 -0.885 . . . . 0.0 108.917 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.565 ' HB ' ' O ' ' A' ' 56' ' ' VAL . 39.7 t -78.83 127.98 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.19 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 176.2 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 55.6 tptt -89.13 -44.13 10.55 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -178.429 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -161.18 162.82 31.42 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 89.1 t -127.35 152.52 35.49 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.167 0 N-CA-C 106.223 -1.769 . . . . 0.0 106.223 178.373 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.462 ' HB ' ' O ' ' A' ' 18' ' ' GLY . 10.6 t . . . . . 0 N--CA 1.428 -1.557 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.648 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.458 ' HA ' ' CG ' ' A' ' 50' ' ' ARG . . . . . . . . 0 CA--C 1.557 1.235 0 N-CA-C 115.542 1.682 . . . . 0.0 115.542 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.97 -50.38 16.86 Favored 'General case' 0 C--O 1.215 -0.728 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -80.54 -3.59 50.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 120.285 -0.566 . . . . 0.0 111.101 176.5 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.458 ' CG ' ' HA ' ' A' ' 47' ' ' ALA . 36.1 mmt180 -82.65 -39.09 22.56 Favored 'General case' 0 CA--C 1.507 -0.691 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 171.283 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -53.83 -60.42 3.35 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 114.856 -1.065 . . . . 0.0 112.088 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.48 -17.56 56.55 Favored Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 120.316 -0.945 . . . . 0.0 114.353 175.057 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.432 ' HE ' ' C ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -88.69 -46.77 8.75 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.68 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.0 tt -73.67 145.13 11.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.171 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLN . . . . . 0.419 ' HB2' ' OD1' ' A' ' 58' ' ' ASP . 35.6 mt-30 -138.79 -172.66 3.36 Favored 'General case' 0 C--N 1.316 -0.868 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.843 -176.26 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.565 ' O ' ' HB ' ' A' ' 39' ' ' VAL . 49.0 t -93.22 -34.55 5.94 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.104 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.413 -178.258 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -92.24 20.67 5.79 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -174.118 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.419 ' OD1' ' HB2' ' A' ' 55' ' ' GLN . 4.2 m-20 -101.75 -172.9 2.23 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.967 177.326 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.467 ' O ' HG23 ' A' ' 91' ' ' ILE . 63.7 tt0 -128.54 126.51 40.52 Favored 'General case' 0 C--N 1.313 -0.995 0 O-C-N 122.089 -0.382 . . . . 0.0 111.328 -175.137 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.526 ' HA ' HG12 ' A' ' 91' ' ' ILE . 48.2 mm -74.93 104.36 3.27 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.016 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.749 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.2 t -91.41 -50.15 12.85 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-O 121.694 0.759 . . . . 0.0 111.315 -175.166 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.528 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 32.1 tt0 -149.0 105.74 3.56 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.398 0.618 . . . . 0.0 110.226 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.433 HG23 HG23 ' A' ' 60' ' ' ILE . 3.0 t -98.02 126.98 50.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.146 177.398 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 26.9 t70 71.42 -9.96 0.86 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 125.599 1.56 . . . . 0.0 112.702 173.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 103.61 12.96 29.21 Favored Glycine 0 N--CA 1.424 -2.151 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.126 -175.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.569 HD13 HG22 ' A' ' 79' ' ' VAL . 11.0 tt -72.98 -18.07 18.24 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-O 121.077 0.465 . . . . 0.0 111.198 -178.56 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.511 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 29.6 p 50.87 81.41 0.07 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.985 1.314 . . . . 0.0 112.92 -175.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.489 HD21 HG22 ' A' ' 60' ' ' ILE . 1.8 pp -96.12 14.91 22.33 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-O 122.092 0.948 . . . . 0.0 109.94 -176.114 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 61.2 t -57.62 98.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.427 174.253 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.436 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 103.51 35.03 3.68 Favored Glycine 0 N--CA 1.438 -1.223 0 CA-C-N 115.54 -0.754 . . . . 0.0 112.457 176.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.438 HG22 ' O ' ' A' ' 68' ' ' LEU . 20.6 m -115.02 177.55 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 117.14 0.47 . . . . 0.0 111.221 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 12.9 p -91.31 172.56 8.45 Favored 'General case' 0 N--CA 1.433 -1.318 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.605 178.609 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.445 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 2.4 pm0 -65.37 -32.04 73.47 Favored 'General case' 0 C--O 1.205 -1.24 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.232 -178.638 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -71.58 -35.4 70.53 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 120.861 -0.336 . . . . 0.0 110.985 -178.192 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.493 ' O ' HG23 ' A' ' 79' ' ' VAL . 29.7 t80 -65.86 -52.19 52.39 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 176.472 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.83 -46.27 89.79 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.135 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.04 -33.96 69.56 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.795 0.331 . . . . 0.0 110.73 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 97.8 m -68.07 -45.57 73.46 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.069 176.29 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.569 HG22 HD13 ' A' ' 66' ' ' ILE . 32.7 t -61.56 -51.85 67.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 C-N-CA 122.632 0.373 . . . . 0.0 110.902 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.408 HD21 HG21 ' A' ' 60' ' ' ILE . 3.4 mm? -68.52 -4.57 15.59 Favored 'General case' 0 CA--C 1.542 0.65 0 CA-C-O 121.237 0.541 . . . . 0.0 112.364 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.403 ' HD3' ' C ' ' A' ' 81' ' ' ARG . 0.7 OUTLIER -99.73 -32.52 11.0 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.218 0.533 . . . . 0.0 109.796 172.868 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 8.7 m-80 -80.13 6.68 10.99 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 121.794 0.807 . . . . 0.0 111.856 -178.09 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.0 p -70.61 170.21 12.69 Favored 'General case' 0 N--CA 1.408 -2.551 0 CA-C-N 114.536 -1.211 . . . . 0.0 111.562 175.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.436 ' HE3' ' O ' ' A' ' 86' ' ' ASN . 0.0 OUTLIER -147.81 -161.3 1.31 Allowed 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 124.898 1.279 . . . . 0.0 107.831 -175.036 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -55.88 -75.15 0.26 Allowed Glycine 0 CA--C 1.525 0.696 0 O-C-N 123.524 0.515 . . . . 0.0 114.016 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.634 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.5 m120 -88.79 105.93 18.03 Favored 'General case' 0 CA--C 1.497 -1.061 0 CA-C-N 117.637 0.718 . . . . 0.0 111.482 -177.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.513 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.9 t -116.22 136.29 53.68 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.09 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.994 -175.628 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 46.8 mtp180 -92.89 99.97 12.52 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 175.379 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.503 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 97.3 m-85 -92.38 103.26 15.72 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 176.597 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.749 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 40.3 t -92.45 86.52 2.28 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.858 0 N-CA-C 104.984 -2.228 . . . . 0.0 104.984 175.402 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.526 HG12 ' HA ' ' A' ' 60' ' ' ILE . 64.1 mt -101.25 159.11 4.05 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 CA-C-N 113.989 -1.46 . . . . 0.0 109.174 -179.2 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.49 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -130.61 158.04 22.36 Favored Glycine 1 N--CA 1.385 -4.724 0 C-N-CA 119.85 -1.167 . . . . 0.0 110.329 176.83 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 4.9 tpp180 -133.31 138.79 46.54 Favored 'General case' 0 C--N 1.286 -2.154 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 . . . . . 0 N--CA 1.416 -2.167 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.051 174.098 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.431 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 32.0 tt0 . . . . . 0 C--O 1.214 -0.783 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.567 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -88.14 126.99 35.41 Favored 'General case' 0 C--O 1.249 1.052 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -138.97 142.73 34.45 Favored Pre-proline 0 C--N 1.306 -1.316 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -176.407 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -79.27 125.85 6.62 Favored 'Trans proline' 0 C--O 1.25 1.122 0 C-N-CA 122.929 2.419 . . . . 0.0 113.357 177.344 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.44 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 46.5 t -118.71 105.2 17.23 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 174.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -88.71 102.45 15.0 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.77 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.536 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 15.3 tp -90.94 153.13 20.4 Favored 'General case' 0 N--CA 1.422 -1.827 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 -176.107 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -125.39 78.41 1.72 Allowed 'General case' 0 C--N 1.289 -2.049 0 CA-C-O 122.062 0.934 . . . . 0.0 108.757 177.014 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.674 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 5.5 mmtt -68.92 -169.72 0.19 Allowed 'General case' 0 N--CA 1.402 -2.842 0 CA-C-N 113.56 -1.654 . . . . 0.0 113.047 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.478 ' H ' ' HD2' ' A' ' 12' ' ' LYS . 9.1 m-20 -91.79 176.37 6.55 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 124.619 1.168 . . . . 0.0 108.346 -174.231 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -63.61 -22.46 66.91 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -176.339 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -72.0 -32.53 67.29 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.62 0.724 . . . . 0.0 110.151 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.404 ' O ' ' HD2' ' A' ' 12' ' ' LYS . . . 108.82 -140.07 15.45 Favored Glycine 0 N--CA 1.414 -2.831 0 N-CA-C 107.49 -2.244 . . . . 0.0 107.49 -173.21 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.51 ' HB3' HG23 ' A' ' 19' ' ' ILE . 14.7 mt -91.18 -60.9 1.78 Allowed 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.208 179.292 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.58 33.92 60.45 Favored Glycine 0 N--CA 1.424 -2.117 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -173.844 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.51 HG23 ' HB3' ' A' ' 17' ' ' LEU . 30.6 pt -96.56 177.78 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 C-N-CA 120.369 -0.532 . . . . 0.0 111.018 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.4 m -120.4 150.11 41.3 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 115.252 -0.885 . . . . 0.0 109.092 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.465 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -125.84 162.98 28.17 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 -179.038 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.8 tt -136.13 126.31 41.1 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.256 176.335 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.578 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -85.37 104.95 2.86 Favored Glycine 0 N--CA 1.435 -1.38 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.657 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.583 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 89.6 mmm -120.98 88.92 3.03 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.314 -0.689 0 O-C-N 123.918 0.761 . . . . 0.0 112.528 -177.622 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.49 HD12 ' HB ' ' A' ' 37' ' ' ILE . 1.1 pt? . . . . . 0 N--CA 1.44 -0.959 0 CA-C-O 121.406 0.622 . . . . 0.0 111.122 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.583 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -122.07 26.6 6.39 Favored Glycine 0 N--CA 1.417 -2.609 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 173.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.578 HD13 ' HA2' ' A' ' 23' ' ' GLY . 17.9 mm -85.36 101.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 121.547 0.689 . . . . 0.0 109.981 -178.743 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -95.12 161.93 13.92 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.315 179.26 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -77.6 122.85 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.202 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -85.54 -49.79 7.76 Favored 'General case' 0 C--N 1.291 -1.96 0 CA-C-O 121.333 0.587 . . . . 0.0 110.501 -177.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.434 ' O ' ' HB ' ' A' ' 19' ' ' ILE . 0.7 OUTLIER -150.84 156.49 41.34 Favored 'General case' 0 N--CA 1.421 -1.876 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.59 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 64.8 t -125.88 145.96 32.45 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.431 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 176.233 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 8.4 t . . . . . 0 C--O 1.253 1.289 0 O-C-N 123.556 0.535 . . . . 0.0 109.773 176.019 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.674 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . . . . . . 0 CA--C 1.552 1.052 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.403 ' HA ' HD21 ' A' ' 10' ' ' LEU . . . -116.56 -65.56 1.17 Allowed 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 174.727 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -74.09 -26.06 60.15 Favored 'General case' 0 N--CA 1.464 0.239 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.111 175.516 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.561 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 2.0 mmp_? -69.09 -26.94 65.18 Favored 'General case' 0 CA--C 1.503 -0.828 0 CA-C-O 121.053 0.454 . . . . 0.0 110.058 173.128 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -73.74 -57.18 4.16 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 178.347 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.09 -20.73 48.79 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.505 -0.855 . . . . 0.0 114.262 174.68 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.52 ' O ' ' HD3' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -73.66 -22.86 59.83 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-O 121.648 0.737 . . . . 0.0 109.114 -177.757 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.8 tt -104.85 148.98 8.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.709 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 26.7 mm-40 -129.54 165.98 20.6 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-O 121.168 0.509 . . . . 0.0 111.906 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -83.45 -8.94 11.49 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.892 0 CA-C-O 122.166 0.984 . . . . 0.0 108.621 176.195 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -102.43 16.85 25.1 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 122.286 1.041 . . . . 0.0 109.443 -175.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -102.05 -179.62 4.05 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.009 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.493 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 33.4 tt0 -128.72 124.96 36.93 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.477 HG22 HD11 ' A' ' 68' ' ' LEU . 46.1 mm -76.36 95.39 1.24 Allowed 'Isoleucine or valine' 0 C--O 1.206 -1.192 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 -176.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.697 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 60.6 t -79.42 -42.09 22.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 CA-C-O 121.59 0.71 . . . . 0.0 111.159 -175.158 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.562 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 36.8 tt0 -151.07 131.14 13.44 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.401 HG23 ' CG2' ' A' ' 60' ' ' ILE . 4.0 t -123.51 126.05 72.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 172.889 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 24.3 t70 69.47 5.47 5.18 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-O 122.356 1.074 . . . . 0.0 111.804 172.569 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.99 13.3 62.44 Favored Glycine 0 N--CA 1.434 -1.493 0 CA-C-N 115.362 -0.836 . . . . 0.0 111.624 -176.53 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.405 HD13 HG22 ' A' ' 79' ' ' VAL . 7.2 tt -77.34 -16.73 14.41 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.774 0 O-C-N 122.793 -0.239 . . . . 0.0 110.44 -178.837 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.467 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 8.6 m 39.74 80.67 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.985 1.714 . . . . 0.0 112.7 -176.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.498 ' CD1' ' H ' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -89.53 31.82 0.9 Allowed 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 122.216 1.007 . . . . 0.0 111.959 -175.606 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 47.8 t -70.52 106.16 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.075 0 CA-C-N 115.199 -0.91 . . . . 0.0 109.288 178.635 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.93 15.89 20.81 Favored Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.913 176.679 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.444 HG22 ' O ' ' A' ' 68' ' ' LEU . 19.1 m -96.63 175.83 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.973 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.711 178.434 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 8.4 p -91.54 172.86 8.22 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.99 178.119 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.465 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 3.2 pm0 -61.24 -33.65 73.86 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.509 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -73.09 -33.05 65.38 Favored 'General case' 0 CA--C 1.512 -0.507 0 C-N-CA 121.072 -0.251 . . . . 0.0 111.568 -176.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 33.4 t80 -69.94 -49.71 49.14 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -58.1 -49.22 77.7 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.516 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -55.87 -36.7 67.89 Favored 'General case' 0 C--O 1.216 -0.682 0 C-N-CA 122.467 0.307 . . . . 0.0 110.957 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 86.9 m -63.39 -45.51 90.75 Favored 'General case' 0 CA--C 1.55 0.957 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.086 176.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.405 HG22 HD13 ' A' ' 66' ' ' ILE . 31.0 t -65.1 -49.92 76.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.663 0.268 . . . . 0.0 110.788 178.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -69.77 -4.87 21.83 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.224 0.61 . . . . 0.0 111.993 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.41 ' HB3' ' O ' ' A' ' 78' ' ' THR . 59.5 ttt180 -92.15 -46.62 7.67 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 124.055 0.942 . . . . 0.0 108.541 174.708 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -77.41 5.68 8.33 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.326 -1.306 . . . . 0.0 113.366 -174.322 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.476 ' OG1' ' HG ' ' A' ' 17' ' ' LEU . 16.8 p -63.45 154.19 32.97 Favored 'General case' 0 C--N 1.294 -1.806 0 C-N-CA 123.832 0.853 . . . . 0.0 112.711 176.543 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.0 mmtt -120.24 -161.92 0.91 Allowed 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 114.567 -1.197 . . . . 0.0 108.501 176.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.05 -68.03 1.89 Allowed Glycine 0 N--CA 1.444 -0.824 0 O-C-N 123.818 0.699 . . . . 0.0 111.901 176.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.536 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.7 m120 -83.06 118.57 23.63 Favored 'General case' 0 C--N 1.307 -1.268 0 O-C-N 122.244 -0.562 . . . . 0.0 110.635 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.442 HG21 HD21 ' A' ' 17' ' ' LEU . 4.4 t -130.75 130.0 64.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.504 -176.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 22.1 mtp180 -94.33 100.59 12.6 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-O 121.186 0.517 . . . . 0.0 110.917 174.689 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.496 ' HB3' HG13 ' A' ' 91' ' ' ILE . 89.0 m-85 -95.12 112.0 23.76 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 176.101 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.697 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 10.7 t -100.48 65.54 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.496 HG13 ' HB3' ' A' ' 89' ' ' PHE . 76.4 mt -77.14 153.8 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.516 0 CA-C-N 112.796 -2.002 . . . . 0.0 109.909 -177.683 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.567 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -131.07 149.3 19.15 Favored Glycine 1 N--CA 1.385 -4.709 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 177.386 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -111.25 133.0 53.92 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 -178.626 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 . . . . . 0 C--N 1.309 -1.185 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 177.968 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 . . . . . 0 N--CA 1.437 -1.094 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.527 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -87.86 125.17 34.33 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -132.02 140.66 38.81 Favored Pre-proline 0 C--N 1.287 -2.112 0 CA-C-O 121.461 0.648 . . . . 0.0 112.061 -176.286 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -83.11 125.85 4.18 Favored 'Trans proline' 0 C--N 1.301 -1.927 0 C-N-CA 122.535 2.157 . . . . 0.0 112.188 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.472 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 36.9 t -109.04 109.05 26.89 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.593 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 172.828 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.47 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 45.3 tt0 -92.89 103.23 15.58 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.51 HD21 ' HB2' ' A' ' 51' ' ' ASP . 0.5 OUTLIER -103.38 154.21 19.65 Favored 'General case' 0 N--CA 1.395 -3.182 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 -175.669 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.45 ' H ' HD23 ' A' ' 10' ' ' LEU . 42.2 tt0 -123.06 100.56 6.94 Favored 'General case' 0 N--CA 1.409 -2.483 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 177.651 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.65 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.3 mmmp? -92.48 178.92 5.67 Favored 'General case' 0 C--N 1.284 -2.282 0 CA-C-N 114.524 -1.217 . . . . 0.0 109.486 176.254 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.547 ' OD2' ' HG2' ' A' ' 14' ' ' GLU . 19.6 t70 -101.41 -160.01 0.77 Allowed 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -176.814 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.547 ' HG2' ' OD2' ' A' ' 13' ' ' ASP . 11.0 pt-20 -75.77 -13.08 60.29 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -171.305 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -71.07 -43.9 66.84 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.213 0.53 . . . . 0.0 110.254 177.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 125.1 -131.02 7.57 Favored Glycine 0 CA--C 1.481 -2.066 0 N-CA-C 108.28 -1.928 . . . . 0.0 108.28 -177.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 14.3 mt -100.7 -60.94 1.43 Allowed 'General case' 0 CA--C 1.476 -1.902 0 C-N-CA 119.012 -1.075 . . . . 0.0 109.462 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.12 29.94 39.65 Favored Glycine 0 N--CA 1.419 -2.472 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -174.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.435 HD11 HD12 ' A' ' 80' ' ' LEU . 24.5 pt -104.54 176.87 0.94 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.987 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.4 m -135.42 150.08 49.78 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 -177.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.588 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -120.16 166.02 15.0 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 C-N-CA 123.303 0.641 . . . . 0.0 110.098 -177.242 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 11.9 tt -140.94 127.93 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.014 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 174.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.51 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.57 109.48 3.81 Favored Glycine 0 CA--C 1.484 -1.869 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -177.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.626 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 88.7 mmm -125.99 92.92 3.69 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.397 0 N-CA-C 114.77 0.668 . . . . 0.0 114.77 -175.523 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.489 HD12 ' H ' ' A' ' 37' ' ' ILE . 2.3 pp . . . . . 0 N--CA 1.44 -0.927 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.626 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -121.98 30.62 5.21 Favored Glycine 0 N--CA 1.422 -2.281 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.75 178.505 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.51 HD13 ' HA2' ' A' ' 23' ' ' GLY . 23.5 mm -82.25 103.65 9.74 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 CA-C-O 121.847 0.832 . . . . 0.0 110.537 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -99.32 164.33 12.16 Favored 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.0 t -82.6 131.04 34.69 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.484 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 177.701 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.556 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.4 OUTLIER -91.7 -45.39 8.47 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.137 0.494 . . . . 0.0 109.832 -178.692 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.0 m -154.66 162.24 41.21 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -127.11 160.98 35.13 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.15 0 N-CA-C 105.363 -2.088 . . . . 0.0 105.363 178.454 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.6 t . . . . . 0 C--N 1.293 -1.883 0 CA-C-O 121.908 0.861 . . . . 0.0 111.007 -178.599 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.65 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.211 -0.942 0 N-CA-C 115.685 1.735 . . . . 0.0 115.685 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.455 ' HB2' ' CE ' ' A' ' 12' ' ' LYS . . . -82.38 -56.79 3.68 Favored 'General case' 0 N--CA 1.488 1.461 0 CA-C-N 118.974 0.806 . . . . 0.0 110.91 -176.515 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -73.9 -16.99 61.09 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.561 0.696 . . . . 0.0 110.45 177.055 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.508 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 3.9 mmp_? -83.14 -17.03 44.42 Favored 'General case' 0 N--CA 1.432 -1.353 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.092 174.073 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.51 ' HB2' HD21 ' A' ' 10' ' ' LEU . 11.7 t70 -61.43 -61.75 2.32 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.964 0.411 . . . . 0.0 109.987 173.584 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.92 -9.86 74.75 Favored Glycine 0 N--CA 1.44 -1.073 0 C-N-CA 120.575 -0.821 . . . . 0.0 114.849 173.408 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -89.35 -45.35 9.55 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 178.856 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.7 tt -74.9 150.51 6.96 Favored 'Isoleucine or valine' 0 C--O 1.252 1.225 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 176.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -134.87 160.35 38.51 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.162 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.7 p -73.27 -17.0 17.7 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.139 0 CA-C-O 121.79 0.805 . . . . 0.0 109.743 176.492 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -90.32 -6.37 55.16 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.389 -173.327 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -95.07 -176.12 3.73 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 113.249 0.833 . . . . 0.0 113.249 -174.231 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.503 ' O ' HG23 ' A' ' 91' ' ' ILE . 32.4 tt0 -116.99 127.43 54.18 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.102 -174.365 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.521 HG23 HG23 ' A' ' 63' ' ' VAL . 50.4 mm -73.4 105.57 2.87 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.627 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.644 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 97.9 t -90.04 -49.46 13.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 CA-C-O 121.664 0.745 . . . . 0.0 111.008 -176.006 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.516 ' HG3' ' H ' ' A' ' 67' ' ' SER . 37.4 tt0 -151.99 104.15 2.96 Favored 'General case' 0 C--N 1.296 -1.751 0 CA-C-O 121.518 0.675 . . . . 0.0 109.834 -178.181 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.521 HG23 HG23 ' A' ' 60' ' ' ILE . 3.8 t -91.75 123.04 43.73 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.061 0 CA-C-O 121.322 0.582 . . . . 0.0 111.717 176.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 24.5 t70 65.86 4.66 3.05 Favored 'General case' 0 C--N 1.311 -1.067 0 C-N-CA 126.813 2.045 . . . . 0.0 112.769 174.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.98 12.34 57.84 Favored Glycine 0 N--CA 1.429 -1.771 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.613 -177.285 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.469 HD13 HG22 ' A' ' 79' ' ' VAL . 9.6 tt -73.01 -17.8 18.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-O 121.185 0.517 . . . . 0.0 110.408 -179.294 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.516 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 9.7 p 49.69 82.83 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 124.826 1.25 . . . . 0.0 113.259 -176.531 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.536 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.8 pp -93.03 14.43 17.78 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.572 -177.42 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.41 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 58.6 t -57.75 102.5 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.5 176.315 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.467 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 113.62 -5.25 24.54 Favored Glycine 0 N--CA 1.442 -0.941 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.433 176.198 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.536 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.5 m -83.98 178.15 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.247 0.925 0 CA-C-O 121.245 0.545 . . . . 0.0 111.69 -175.849 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.4 p -101.12 170.53 8.2 Favored 'General case' 0 N--CA 1.415 -2.18 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.116 176.778 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.588 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -56.13 -33.5 65.21 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-N 114.51 -1.223 . . . . 0.0 112.256 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -74.4 -22.36 59.2 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 111.744 0.275 . . . . 0.0 111.744 -177.664 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.426 ' O ' ' HB ' ' A' ' 78' ' ' THR . 38.6 t80 -80.85 -50.14 10.17 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 174.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.64 -47.99 80.71 Favored 'General case' 0 C--O 1.22 -0.459 0 CA-C-N 114.719 -1.128 . . . . 0.0 112.12 -178.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -56.74 -33.22 66.34 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 120.89 0.376 . . . . 0.0 110.687 179.024 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.426 ' HB ' ' O ' ' A' ' 75' ' ' PHE . 53.0 m -68.62 -47.15 67.4 Favored 'General case' 0 N--CA 1.435 -1.205 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.904 176.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.469 HG22 HD13 ' A' ' 66' ' ' ILE . 44.3 t -58.82 -50.27 79.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 110.097 -0.335 . . . . 0.0 110.097 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.435 HD12 HD11 ' A' ' 19' ' ' ILE . 3.6 mm? -67.67 -10.62 53.93 Favored 'General case' 0 CA--C 1.551 1.014 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.681 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 81' ' ' ARG . 0.8 OUTLIER -97.7 -23.05 16.11 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.256 0.551 . . . . 0.0 110.43 176.082 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -83.84 -23.18 31.47 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.092 179.447 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.4 p -63.99 156.62 27.42 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 113.646 0.98 . . . . 0.0 113.646 -178.427 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.75 -145.97 0.36 Allowed 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 114.685 -1.143 . . . . 0.0 109.764 -176.424 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.8 -67.64 1.91 Allowed Glycine 0 C--N 1.295 -1.719 0 O-C-N 123.671 0.607 . . . . 0.0 112.603 -177.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -77.25 109.73 11.37 Favored 'General case' 0 CA--C 1.497 -1.079 0 C-N-CA 119.937 -0.705 . . . . 0.0 110.118 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -124.09 144.53 33.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.82 98.26 7.78 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 173.396 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.472 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 86.5 m-85 -90.42 98.4 11.75 Favored 'General case' 0 C--N 1.279 -2.498 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 178.134 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.644 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 58.9 t -89.3 91.8 3.77 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.433 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 178.168 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.503 HG23 ' O ' ' A' ' 59' ' ' GLN . 81.6 mt -106.52 156.67 7.04 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.073 0 CA-C-N 114.0 -1.454 . . . . 0.0 108.096 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.527 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -134.25 164.47 24.53 Favored Glycine 1 N--CA 1.393 -4.182 0 C-N-CA 119.566 -1.302 . . . . 0.0 109.931 178.595 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -149.46 131.06 14.91 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . 0.26 0.0 OUTLIER . . . . . 0 N--CA 1.411 -2.377 0 CA-C-O 118.436 -0.792 . . . . 0.0 110.671 175.218 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 . . . . . 0 N--CA 1.438 -1.026 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.42 HD12 HG21 ' A' ' 61' ' ' VAL . 1.8 mm? -81.73 130.55 35.1 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 178.628 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -137.11 141.53 34.84 Favored Pre-proline 0 C--N 1.284 -2.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.324 -179.16 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -77.89 128.71 9.4 Favored 'Trans proline' 0 N--CA 1.443 -1.474 0 C-N-CA 122.368 2.046 . . . . 0.0 112.418 178.839 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.416 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 21.7 t -119.11 94.99 3.34 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.258 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 174.508 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.512 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 40.7 tt0 -78.33 112.44 15.34 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 175.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -97.43 123.07 41.15 Favored 'General case' 0 N--CA 1.405 -2.701 0 N-CA-C 105.444 -2.058 . . . . 0.0 105.444 178.617 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.456 ' HG3' ' OD1' ' A' ' 86' ' ' ASN . 30.9 tt0 -94.44 90.45 6.23 Favored 'General case' 0 C--N 1.281 -2.373 0 CA-C-O 121.839 0.828 . . . . 0.0 109.005 179.786 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 2.8 mmmp? -93.82 -175.4 3.72 Favored 'General case' 0 N--CA 1.428 -1.563 0 CA-C-N 114.263 -1.335 . . . . 0.0 111.778 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.57 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.5 p-10 -88.27 -172.42 3.78 Favored 'General case' 0 C--N 1.28 -2.452 0 C-N-CA 126.8 2.04 . . . . 0.0 112.384 -177.386 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -77.45 -20.21 54.82 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 114.705 -1.134 . . . . 0.0 111.577 -179.458 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.57 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 18.8 t70 -73.95 -35.64 64.55 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 118.25 -124.58 6.11 Favored Glycine 0 CA--C 1.486 -1.747 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.661 172.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.525 ' HB3' HG23 ' A' ' 19' ' ' ILE . 31.7 mt -112.76 -54.54 2.61 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.1 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.55 27.51 69.32 Favored Glycine 0 N--CA 1.425 -2.062 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.818 -173.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.525 HG23 ' HB3' ' A' ' 17' ' ' LEU . 27.0 pt -94.67 176.32 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.26 -178.845 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 49.0 m -132.33 150.31 52.18 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.882 -178.702 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -120.05 159.89 20.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 15.4 tt -124.13 132.01 72.01 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 C-N-CA 120.063 -0.655 . . . . 0.0 110.045 175.741 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.539 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.82 92.45 1.78 Allowed Glycine 0 N--CA 1.427 -1.94 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.852 -177.503 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 91.8 mmm -108.26 -179.07 3.78 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.284 -2.354 0 C-N-CA 120.087 -1.054 . . . . 0.0 112.333 179.913 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.653 HD23 ' HA ' ' A' ' 69' ' ' VAL . 3.2 pp . . . . . 0 N--CA 1.44 -0.969 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -116.47 32.54 5.51 Favored Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 175.172 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.539 HD13 ' HA2' ' A' ' 23' ' ' GLY . 29.7 mm -81.31 103.87 9.01 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.867 0 CA-C-O 121.624 0.726 . . . . 0.0 110.14 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -102.21 160.16 14.76 Favored 'General case' 0 C--N 1.275 -2.645 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.296 176.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 40.5 t -74.32 123.97 30.84 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 175.293 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.405 ' HB2' ' HB ' ' A' ' 22' ' ' ILE . 53.5 tptt -89.29 -48.61 7.25 Favored 'General case' 0 C--N 1.293 -1.871 0 CA-C-O 121.118 0.485 . . . . 0.0 110.28 -176.762 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -150.25 159.15 44.65 Favored 'General case' 0 N--CA 1.422 -1.874 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -177.401 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.517 HG11 ' HG3' ' A' ' 49' ' ' GLN . 23.3 t -121.24 174.16 6.17 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.522 0 N-CA-C 104.894 -2.261 . . . . 0.0 104.894 175.296 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.413 ' N ' HG12 ' A' ' 42' ' ' VAL . 3.2 t . . . . . 0 CA--C 1.561 1.377 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 173.831 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.434 ' O ' ' HB2' ' A' ' 51' ' ' ASP . . . . . . . . 0 C--O 1.193 -1.921 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.57 -60.11 2.44 Favored 'General case' 0 C--N 1.35 0.59 0 C-N-CA 123.551 0.74 . . . . 0.0 110.059 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.517 ' HG3' HG11 ' A' ' 42' ' ' VAL . 26.5 mt-30 -70.5 -27.46 64.22 Favored 'General case' 0 CA--C 1.511 -0.536 0 C-N-CA 120.14 -0.624 . . . . 0.0 111.029 178.087 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -78.45 -19.5 53.01 Favored 'General case' 0 N--CA 1.44 -0.975 0 C-N-CA 120.04 -0.664 . . . . 0.0 111.778 175.822 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.434 ' HB2' ' O ' ' A' ' 47' ' ' ALA . 11.1 t70 -66.7 -64.01 0.94 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 172.058 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.89 -10.11 70.4 Favored Glycine 0 N--CA 1.44 -1.092 0 C-N-CA 120.557 -0.83 . . . . 0.0 115.13 173.561 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.08 -21.56 43.2 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -179.817 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.6 tt -105.05 164.59 3.91 Favored 'Isoleucine or valine' 0 C--O 1.254 1.305 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 175.164 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 63.1 mt-30 -136.17 -156.72 0.73 Allowed 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 119.033 0.833 . . . . 0.0 110.923 -177.552 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.2 p -123.94 18.21 4.77 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 174.343 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -132.91 -8.43 3.09 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.758 0.789 . . . . 0.0 111.206 -174.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.564 ' OD2' HD13 ' A' ' 91' ' ' ILE . 7.1 p-10 -83.18 179.24 7.78 Favored 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 124.571 1.148 . . . . 0.0 110.919 -177.357 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.46 ' O ' HG23 ' A' ' 91' ' ' ILE . 31.1 tt0 -119.76 126.08 50.18 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.087 -176.054 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.538 HG21 HD21 ' A' ' 80' ' ' LEU . 50.8 mm -74.36 114.71 14.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.089 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.701 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 84.7 t -98.37 -48.92 11.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.85 0.834 . . . . 0.0 111.022 -178.164 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.576 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 26.9 tt0 -150.28 114.88 5.23 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -178.614 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.48 HG23 HG23 ' A' ' 60' ' ' ILE . 3.4 t -110.1 128.13 66.51 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.821 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.589 178.905 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.7 t70 72.58 -8.84 1.15 Allowed 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 125.265 1.426 . . . . 0.0 112.348 175.376 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.83 13.43 31.98 Favored Glycine 0 C--N 1.286 -2.203 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.686 -174.546 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.4 tt -74.97 -17.44 16.2 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.498 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 17.4 m 45.83 84.56 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 125.659 1.584 . . . . 0.0 111.585 -176.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.535 HD21 HG22 ' A' ' 60' ' ' ILE . 0.7 OUTLIER -93.06 20.98 6.19 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.659 0.742 . . . . 0.0 110.671 -175.317 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.653 ' HA ' HD23 ' A' ' 35' ' ' LEU . 59.1 t -52.77 100.63 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 CA-C-N 114.691 -1.141 . . . . 0.0 111.77 177.474 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 94.59 21.7 25.89 Favored Glycine 0 N--CA 1.443 -0.844 0 CA-C-N 115.47 -0.786 . . . . 0.0 114.131 174.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.418 ' CG2' ' HB2' ' A' ' 68' ' ' LEU . 20.5 m -93.43 -178.66 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 117.497 0.649 . . . . 0.0 111.173 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.9 p -98.37 178.97 4.87 Favored 'General case' 0 C--O 1.251 1.146 0 CA-C-O 121.037 0.446 . . . . 0.0 110.377 177.591 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -66.92 -25.31 66.3 Favored 'General case' 0 C--O 1.204 -1.337 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.337 179.638 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 25.6 m-80 -63.02 -48.57 78.22 Favored 'General case' 0 CA--C 1.483 -1.603 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.183 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -68.61 -47.79 65.78 Favored 'General case' 0 N--CA 1.426 -1.633 0 CA-C-N 114.76 -1.109 . . . . 0.0 109.698 -175.89 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.438 ' HA ' HG12 ' A' ' 79' ' ' VAL . . . -62.94 -40.29 97.21 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.167 -178.738 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -69.08 -18.19 63.97 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.229 0.537 . . . . 0.0 110.426 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 83.3 m -84.01 -47.5 10.91 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.457 176.763 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.542 HG13 HD22 ' A' ' 80' ' ' LEU . 3.9 p -62.78 -48.6 87.36 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 N-CA-C 112.943 0.72 . . . . 0.0 112.943 177.323 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.542 HD22 HG13 ' A' ' 79' ' ' VAL . 3.9 mm? -67.2 -12.22 59.48 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.531 0.682 . . . . 0.0 112.056 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -84.47 -46.05 12.04 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 176.249 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -79.56 -11.09 59.89 Favored 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 114.388 1.255 . . . . 0.0 114.388 -171.188 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.434 HG23 ' O ' ' A' ' 79' ' ' VAL . 12.0 p -68.45 140.7 55.76 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -135.93 141.75 44.54 Favored 'General case' 0 CA--C 1.482 -1.659 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.096 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 47.67 -88.13 0.01 OUTLIER Glycine 0 CA--C 1.474 -2.508 0 O-C-N 126.039 2.087 . . . . 0.0 113.696 178.081 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.456 ' OD1' ' HG3' ' A' ' 11' ' ' GLU . 3.0 m-20 -97.94 102.0 13.63 Favored 'General case' 0 C--N 1.247 -3.849 0 CA-C-N 113.804 -1.198 . . . . 0.0 110.52 -173.283 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 40.2 t -113.15 124.82 70.16 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 CA-C-N 115.021 -0.991 . . . . 0.0 111.611 -173.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.59 104.18 16.61 Favored 'General case' 0 CA--C 1.49 -1.364 0 C-N-CA 120.204 -0.598 . . . . 0.0 109.944 174.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.416 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 90.9 m-85 -93.49 100.19 12.52 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 175.697 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.701 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.8 t -89.5 92.99 4.13 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.82 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 177.282 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.564 HD13 ' OD2' ' A' ' 58' ' ' ASP . 96.5 mt -108.62 163.84 5.79 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.375 0 C-N-CA 125.485 1.514 . . . . 0.0 107.494 179.486 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -133.75 159.82 23.83 Favored Glycine 0 N--CA 1.411 -2.97 0 C-N-CA 118.557 -1.782 . . . . 0.0 113.301 -177.146 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 35.5 ttt180 -114.32 137.41 51.84 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 123.321 0.648 . . . . 0.0 109.533 177.16 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? . . . . . 0 C--N 1.294 -1.834 0 CA-C-O 119.395 -0.336 . . . . 0.0 110.976 -178.445 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.473 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 35.2 tt0 . . . . . 0 N--CA 1.44 -0.961 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -84.14 131.89 34.74 Favored 'General case' 0 CA--C 1.5 -0.963 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -140.58 138.5 18.73 Favored Pre-proline 0 N--CA 1.42 -1.971 0 CA-C-O 121.507 0.67 . . . . 0.0 112.012 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -81.47 124.27 4.64 Favored 'Trans proline' 0 C--N 1.314 -1.263 0 C-N-CA 122.856 2.37 . . . . 0.0 112.781 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.445 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 25.0 t -113.61 106.14 20.13 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 175.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.492 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 30.8 tt0 -89.64 109.13 20.11 Favored 'General case' 0 N--CA 1.416 -2.132 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 177.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -100.91 149.34 23.99 Favored 'General case' 0 C--N 1.289 -2.063 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 -176.689 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -120.44 93.03 3.91 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 171.726 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.491 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.0 mmmp? -82.73 172.86 12.43 Favored 'General case' 0 N--CA 1.421 -1.92 0 CA-C-O 122.63 1.205 . . . . 0.0 114.177 -179.046 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -72.78 171.23 13.03 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 112.077 -2.329 . . . . 0.0 108.564 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -68.83 -16.93 63.92 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.345 0.593 . . . . 0.0 110.373 178.521 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.05 -33.02 72.65 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 122.023 0.916 . . . . 0.0 109.986 174.462 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.59 -138.38 14.93 Favored Glycine 0 N--CA 1.41 -3.095 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.414 HD21 HG21 ' A' ' 87' ' ' VAL . 16.8 mt -89.46 -43.91 10.52 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 119.734 -0.786 . . . . 0.0 109.735 -179.445 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 66.64 28.0 73.52 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 124.547 1.155 . . . . 0.0 111.013 -174.23 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.475 HD11 HD12 ' A' ' 80' ' ' LEU . 20.7 pt -109.0 177.07 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.452 -178.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.0 m -138.64 153.81 48.61 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -177.427 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.411 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -122.39 166.72 16.76 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 -178.204 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 13.7 tt -135.08 133.57 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.79 0 C-N-CA 120.026 -0.67 . . . . 0.0 111.435 176.649 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.537 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -92.93 103.44 3.05 Favored Glycine 0 N--CA 1.413 -2.886 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.912 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 18.1 ptm -140.85 86.94 2.08 Favored 'General case' 0 C--N 1.288 -2.079 0 CA-C-O 121.584 0.707 . . . . 0.0 109.77 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.44 -1.09 0 CA-C-N 114.066 -1.425 . . . . 0.0 112.966 -176.058 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.437 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 0.8 OUTLIER . . . . . 0 C--O 1.24 0.597 0 CA-C-O 121.664 0.745 . . . . 0.0 112.6 . . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -120.02 47.43 1.03 Allowed Glycine 0 N--CA 1.413 -2.877 0 N-CA-C 109.961 -1.255 . . . . 0.0 109.961 175.423 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.584 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 28.9 mm -109.12 111.43 36.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 177.659 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -110.49 170.41 8.1 Favored 'General case' 0 C--N 1.269 -2.909 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.385 -178.406 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 38.9 t -83.47 128.21 39.0 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.076 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.748 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.574 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -92.92 -47.12 7.17 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 120.944 0.402 . . . . 0.0 110.165 -176.884 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.1 m -150.36 163.46 38.3 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 -178.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 61.0 t -136.38 148.4 27.29 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 N-CA-C 105.007 -2.22 . . . . 0.0 105.007 178.347 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.6 t . . . . . 0 C--O 1.251 1.176 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 175.277 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.543 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 CA--C 1.56 1.342 0 N-CA-C 114.825 1.417 . . . . 0.0 114.825 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.43 -59.33 2.82 Favored 'General case' 0 C--O 1.219 -0.535 0 O-C-N 121.745 -0.597 . . . . 0.0 109.993 -176.588 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -74.34 -15.12 60.96 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.387 175.626 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.543 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 24.2 mmm180 -73.12 -34.02 65.88 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 172.219 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -59.53 -58.63 7.75 Favored 'General case' 0 N--CA 1.473 0.681 0 O-C-N 123.565 0.54 . . . . 0.0 109.813 173.254 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.82 -12.81 67.68 Favored Glycine 0 C--N 1.312 -0.782 0 C-N-CA 120.319 -0.943 . . . . 0.0 114.879 173.458 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 63.5 ttt180 -80.18 -40.77 26.59 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.09 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.4 tt -86.23 143.73 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.99 0 CA-C-N 114.335 -1.302 . . . . 0.0 107.857 179.031 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -138.5 175.85 9.21 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-O 121.258 0.551 . . . . 0.0 110.665 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.7 p -81.38 -3.25 6.57 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.49 -177.05 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -105.38 6.89 32.97 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.638 0.732 . . . . 0.0 110.545 -174.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -93.01 -173.66 3.34 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 115.186 -0.916 . . . . 0.0 111.08 -176.71 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.584 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 27.5 tt0 -131.86 127.45 36.56 Favored 'General case' 0 C--N 1.322 -0.608 0 C-N-CA 123.488 0.715 . . . . 0.0 111.001 -177.494 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.549 HG22 HD21 ' A' ' 68' ' ' LEU . 48.9 mm -77.21 106.45 7.29 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.852 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.45 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.72 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.1 t -89.18 -49.5 13.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-O 122.219 1.009 . . . . 0.0 110.116 -176.779 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.558 ' HG3' ' H ' ' A' ' 67' ' ' SER . 23.8 tt0 -148.64 126.84 12.13 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.496 179.225 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.431 HG23 HG23 ' A' ' 60' ' ' ILE . 2.7 t -118.37 127.69 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.641 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.118 176.216 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.9 t70 63.94 15.15 8.95 Favored 'General case' 0 N--CA 1.477 0.886 0 O-C-N 124.744 1.277 . . . . 0.0 111.081 173.558 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.93 17.32 67.83 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.855 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.437 HG21 HG21 ' A' ' 79' ' ' VAL . 6.1 tt -77.23 -18.68 14.34 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.156 0 CA-C-N 117.166 0.483 . . . . 0.0 111.283 -179.098 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.558 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 16.8 p 49.56 83.88 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.419 1.488 . . . . 0.0 113.126 -174.628 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.549 HD21 HG22 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.87 17.36 18.34 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.582 0.706 . . . . 0.0 110.805 -175.894 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 44.6 t -57.06 94.13 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.134 174.441 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.437 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 102.96 52.74 0.93 Allowed Glycine 0 N--CA 1.436 -1.355 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.866 178.29 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 23.5 m -130.05 178.71 4.93 Favored 'Isoleucine or valine' 0 C--O 1.243 0.723 0 CA-C-O 120.97 0.414 . . . . 0.0 111.107 178.519 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 15.5 p -98.31 174.61 6.41 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.425 178.336 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.411 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 1.4 pm0 -67.45 -27.38 66.99 Favored 'General case' 0 C--O 1.2 -1.541 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.395 -178.61 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -71.81 -30.87 65.96 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.064 -179.383 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -74.64 -48.39 26.57 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 176.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.429 ' HA ' HG12 ' A' ' 79' ' ' VAL . . . -61.72 -42.15 98.57 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.733 -179.115 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.1 -33.22 71.8 Favored 'General case' 0 C--O 1.204 -1.32 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 177.512 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 92.0 m -71.67 -48.7 45.8 Favored 'General case' 0 N--CA 1.434 -1.25 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.185 178.658 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.591 HG13 HD22 ' A' ' 80' ' ' LEU . 3.4 p -62.23 -45.59 98.4 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 178.713 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.591 HD22 HG13 ' A' ' 79' ' ' VAL . 3.8 mm? -70.68 -7.82 47.4 Favored 'General case' 0 CA--C 1.549 0.918 0 CA-C-O 121.053 0.454 . . . . 0.0 111.597 178.283 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.9 tmt_? -97.44 -28.12 14.14 Favored 'General case' 0 C--O 1.214 -0.799 0 C-N-CA 122.73 0.412 . . . . 0.0 110.773 176.747 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -84.92 -2.52 57.96 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -177.397 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.0 p -76.82 159.85 29.74 Favored 'General case' 0 C--N 1.288 -2.072 0 CA-C-O 121.655 0.741 . . . . 0.0 112.866 -177.424 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 33.2 mmtp -118.39 -162.51 0.89 Allowed 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 114.931 -1.031 . . . . 0.0 108.639 177.89 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -53.04 -62.71 5.69 Favored Glycine 0 C--O 1.217 -0.953 0 O-C-N 123.846 0.716 . . . . 0.0 113.228 174.258 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -79.16 115.2 18.67 Favored 'General case' 0 C--O 1.245 0.867 0 CA-C-N 117.597 0.699 . . . . 0.0 110.014 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.0 t -132.24 136.43 56.44 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.907 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.213 -177.712 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 65.2 mtp180 -99.2 99.71 10.72 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 171.843 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.445 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 95.9 m-85 -90.31 102.78 15.51 Favored 'General case' 0 CA--C 1.486 -1.493 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 175.34 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.72 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 47.5 t -93.65 87.28 2.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.694 0 N-CA-C 105.326 -2.102 . . . . 0.0 105.326 178.164 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.473 HG23 ' O ' ' A' ' 59' ' ' GLN . 76.9 mt -104.11 153.22 6.24 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.785 0 CA-C-N 113.684 -1.598 . . . . 0.0 109.223 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -126.08 155.74 19.37 Favored Glycine 1 N--CA 1.384 -4.778 0 N-CA-C 108.405 -1.878 . . . . 0.0 108.405 177.135 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 64.7 ttt-85 -141.03 137.48 32.98 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 119.169 -1.012 . . . . 0.0 112.83 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 . . . . . 0 C--N 1.311 -1.102 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 173.585 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.446 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 45.5 tt0 . . . . . 0 CA--C 1.498 -1.029 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.462 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.7 mm? -85.54 130.98 34.45 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 176.844 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -138.79 142.41 33.83 Favored Pre-proline 0 C--N 1.288 -2.065 0 CA-C-O 121.214 0.531 . . . . 0.0 111.802 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -83.87 123.48 3.23 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.667 2.244 . . . . 0.0 112.732 177.21 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.4 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 40.2 t -114.65 105.38 18.55 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 174.316 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.487 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 27.6 tt0 -93.7 97.54 10.52 Favored 'General case' 0 N--CA 1.417 -2.121 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 -179.384 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.496 HD21 ' HB2' ' A' ' 51' ' ' ASP . 0.5 OUTLIER -87.67 158.36 18.86 Favored 'General case' 0 N--CA 1.397 -3.105 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -174.778 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.421 ' H ' HD23 ' A' ' 10' ' ' LEU . 48.1 tt0 -124.04 98.93 6.01 Favored 'General case' 0 C--N 1.274 -2.681 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.229 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 85' ' ' GLY . 2.3 mmmp? -100.73 -170.0 1.79 Allowed 'General case' 0 N--CA 1.409 -2.512 0 CA-C-N 114.518 -1.219 . . . . 0.0 112.696 -179.791 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.56 157.12 36.02 Favored 'General case' 0 N--CA 1.413 -2.312 0 CA-C-N 113.03 -1.896 . . . . 0.0 106.534 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -72.48 -8.95 57.75 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 121.438 0.637 . . . . 0.0 110.253 176.704 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -72.22 -38.47 68.97 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 175.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.59 -145.14 16.74 Favored Glycine 0 N--CA 1.42 -2.411 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.624 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.404 HD11 HG21 ' A' ' 83' ' ' THR . 18.3 mt -104.53 -46.47 4.35 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.44 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.85 29.7 37.82 Favored Glycine 0 N--CA 1.422 -2.242 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.874 -175.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.2 pt -102.42 -174.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 120.059 -0.656 . . . . 0.0 112.357 -177.293 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 21.8 m -135.66 153.04 51.75 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.589 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -126.63 164.99 25.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 123.393 0.677 . . . . 0.0 109.336 -177.539 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.9 tt -135.41 130.02 50.17 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-O 120.811 0.338 . . . . 0.0 110.487 175.062 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.505 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.33 107.28 3.32 Favored Glycine 0 N--CA 1.428 -1.861 0 C-N-CA 121.085 -0.578 . . . . 0.0 112.029 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.405 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.2 mmm -121.94 174.53 6.84 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.645 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.29 -1.989 0 C-N-CA 119.418 -1.372 . . . . 0.0 112.171 179.616 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.507 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.0 pp . . . . . 0 N--CA 1.437 -1.084 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -116.8 33.71 4.95 Favored Glycine 0 C--N 1.288 -2.103 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 173.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.522 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 26.3 mm -84.58 105.49 13.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 121.407 0.622 . . . . 0.0 110.337 -177.09 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -99.25 162.98 12.74 Favored 'General case' 0 C--N 1.279 -2.46 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 177.7 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.89 128.01 38.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.407 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.542 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -91.74 -39.07 12.02 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.303 0.573 . . . . 0.0 110.455 -177.049 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.7 m -159.65 161.0 34.9 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.441 HG11 ' HG3' ' A' ' 49' ' ' GLN . 17.5 t -117.62 167.73 10.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.216 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.9 t . . . . . 0 C--N 1.305 -1.364 0 C-N-CA 123.044 0.538 . . . . 0.0 109.965 178.566 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.462 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 C--O 1.203 -1.392 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.55 -62.56 1.65 Allowed 'General case' 0 C--O 1.214 -0.807 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.441 ' HG3' HG11 ' A' ' 42' ' ' VAL . 27.4 mt-30 -72.73 -13.73 61.4 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.783 0.661 . . . . 0.0 112.783 176.208 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.462 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 27.4 mmt180 -81.17 -26.33 36.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 172.299 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.496 ' HB2' HD21 ' A' ' 10' ' ' LEU . 24.6 t70 -54.94 -57.55 11.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 123.743 0.652 . . . . 0.0 111.368 177.655 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.73 -13.15 56.48 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.225 -0.988 . . . . 0.0 114.352 175.322 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.579 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -93.74 -59.93 1.88 Allowed 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 118.082 0.941 . . . . 0.0 108.573 176.878 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.579 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 15.3 tt -64.29 143.67 15.47 Favored 'Isoleucine or valine' 0 C--O 1.246 0.893 0 O-C-N 123.707 0.63 . . . . 0.0 110.672 -175.743 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -142.52 172.76 12.26 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.029 0.442 . . . . 0.0 111.617 -178.377 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.7 p -76.68 -9.52 12.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.653 0 CA-C-O 121.889 0.852 . . . . 0.0 110.503 -177.768 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -92.22 -2.75 56.32 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.592 0.711 . . . . 0.0 110.288 -176.087 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.487 ' HB3' HG21 ' A' ' 91' ' ' ILE . 76.9 m-20 -82.29 174.94 10.68 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 121.988 0.899 . . . . 0.0 112.328 -176.173 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.522 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.3 tt0 -128.6 125.48 38.27 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.497 178.309 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.508 HG22 HD21 ' A' ' 68' ' ' LEU . 48.8 mm -77.16 104.74 5.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -178.582 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.779 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 86.1 t -87.13 -48.07 15.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.844 0.831 . . . . 0.0 110.82 -176.469 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.517 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 33.1 tt0 -151.66 125.95 9.35 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.782 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.442 HG23 HG23 ' A' ' 60' ' ' ILE . 3.0 t -115.64 128.05 73.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 175.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.1 t70 72.97 -9.15 1.16 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 125.23 1.412 . . . . 0.0 112.671 173.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.93 11.56 36.94 Favored Glycine 0 C--N 1.29 -2.011 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.763 -174.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.558 HD13 HG22 ' A' ' 79' ' ' VAL . 7.0 tt -70.95 -21.21 22.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-O 120.728 0.299 . . . . 0.0 111.36 -177.614 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.499 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 57.7 p 51.01 88.52 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.036 1.334 . . . . 0.0 112.192 -177.31 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.508 HD21 HG22 ' A' ' 60' ' ' ILE . 1.4 pp -100.29 17.9 20.22 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 122.29 1.043 . . . . 0.0 109.931 -175.595 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.507 ' HA ' HD23 ' A' ' 35' ' ' LEU . 39.2 t -60.69 98.49 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.297 178.234 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.411 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 112.75 9.67 18.34 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.609 177.538 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.7 m -95.56 174.21 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.485 -179.408 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 p -95.02 175.45 6.63 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.54 177.617 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.589 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.23 -34.35 72.1 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.628 -179.385 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.7 -36.87 73.48 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.439 -177.44 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.467 ' O ' HG23 ' A' ' 79' ' ' VAL . 35.4 t80 -70.68 -49.1 50.76 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.808 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.19 -45.07 94.38 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.399 -178.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -54.91 -43.29 73.14 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 122.716 0.406 . . . . 0.0 110.307 178.204 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 90.3 m -61.35 -41.78 97.61 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.981 177.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.558 HG22 HD13 ' A' ' 66' ' ' ILE . 47.4 t -62.98 -51.82 67.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 178.022 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.429 HD21 HG21 ' A' ' 60' ' ' ILE . 3.5 mm? -68.26 -5.36 17.99 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-O 121.342 0.591 . . . . 0.0 111.63 179.525 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -102.47 -22.44 14.05 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.901 0.881 . . . . 0.0 110.891 176.35 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -90.44 0.85 57.13 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 121.253 0.549 . . . . 0.0 111.628 178.295 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.404 HG21 HD11 ' A' ' 17' ' ' LEU . 15.6 p -61.83 155.38 23.33 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.172 -0.922 . . . . 0.0 112.739 178.578 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.49 -157.55 0.8 Allowed 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.626 -1.17 . . . . 0.0 108.241 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 12' ' ' LYS . . . -51.61 -82.04 0.05 OUTLIER Glycine 0 CA--C 1.531 1.033 0 N-CA-C 114.601 0.6 . . . . 0.0 114.601 177.489 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -77.12 102.13 6.42 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.122 0.486 . . . . 0.0 111.419 -176.543 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 41.8 t -115.52 119.42 61.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.16 -178.323 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.34 104.49 15.22 Favored 'General case' 0 CA--C 1.487 -1.447 0 C-N-CA 120.282 -0.567 . . . . 0.0 109.963 173.881 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.4 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.4 m-85 -93.33 101.33 13.57 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 174.445 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.779 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.9 t -91.53 85.77 2.3 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 N-CA-C 105.337 -2.098 . . . . 0.0 105.337 176.553 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.487 HG21 ' HB3' ' A' ' 58' ' ' ASP . 78.0 mt -102.68 155.37 5.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 CA-C-N 113.765 -1.561 . . . . 0.0 108.85 179.641 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.462 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -128.85 155.59 20.72 Favored Glycine 0 N--CA 1.4 -3.748 0 C-N-CA 119.747 -1.215 . . . . 0.0 110.479 177.9 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -132.15 152.17 51.41 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 121.551 0.691 . . . . 0.0 112.864 -178.599 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 . . . . . 0 C--N 1.299 -1.606 0 C-N-CA 127.231 2.212 . . . . 0.0 105.505 174.381 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.446 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 45.5 tt0 . . . . . 0 CA--C 1.498 -1.029 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.462 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.7 mm? -85.54 130.98 34.45 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 176.844 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -138.79 142.41 33.83 Favored Pre-proline 0 C--N 1.288 -2.065 0 CA-C-O 121.214 0.531 . . . . 0.0 111.802 -179.176 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -83.87 123.48 3.23 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.667 2.244 . . . . 0.0 112.732 177.21 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.4 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 40.2 t -114.65 105.38 18.55 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 174.316 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.487 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 27.6 tt0 -93.7 97.54 10.52 Favored 'General case' 0 N--CA 1.417 -2.121 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 -179.384 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.496 HD21 ' HB2' ' A' ' 51' ' ' ASP . 0.5 OUTLIER -87.67 158.36 18.86 Favored 'General case' 0 N--CA 1.397 -3.105 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -174.778 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.421 ' H ' HD23 ' A' ' 10' ' ' LEU . 48.1 tt0 -124.04 98.93 6.01 Favored 'General case' 0 C--N 1.274 -2.681 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.229 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 85' ' ' GLY . 2.3 mmmp? -100.73 -170.0 1.79 Allowed 'General case' 0 N--CA 1.409 -2.512 0 CA-C-N 114.518 -1.219 . . . . 0.0 112.696 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.56 157.12 36.02 Favored 'General case' 0 N--CA 1.413 -2.312 0 CA-C-N 113.03 -1.896 . . . . 0.0 106.534 174.724 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -72.48 -8.95 57.75 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 121.438 0.637 . . . . 0.0 110.253 176.704 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -72.22 -38.47 68.97 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 175.895 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.59 -145.14 16.74 Favored Glycine 0 N--CA 1.42 -2.411 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.624 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.404 HD11 HG21 ' A' ' 83' ' ' THR . 18.3 mt -104.53 -46.47 4.35 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.44 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.85 29.7 37.82 Favored Glycine 0 N--CA 1.422 -2.242 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.874 -175.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.2 pt -102.42 -174.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 120.059 -0.656 . . . . 0.0 112.357 -177.293 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 21.8 m -135.66 153.04 51.75 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.589 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -126.63 164.99 25.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 123.393 0.677 . . . . 0.0 109.336 -177.539 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.9 tt -135.41 130.02 50.17 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-O 120.811 0.338 . . . . 0.0 110.487 175.062 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.505 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.33 107.28 3.32 Favored Glycine 0 N--CA 1.428 -1.861 0 C-N-CA 121.085 -0.578 . . . . 0.0 112.029 -178.292 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.405 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.2 mmm -121.94 174.53 6.84 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.645 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.29 -1.989 0 C-N-CA 119.418 -1.372 . . . . 0.0 112.171 179.616 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.507 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.0 pp . . . . . 0 N--CA 1.437 -1.084 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -116.8 33.71 4.95 Favored Glycine 0 C--N 1.288 -2.103 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 173.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.522 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 26.3 mm -84.58 105.49 13.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 121.407 0.622 . . . . 0.0 110.337 -177.09 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -99.25 162.98 12.74 Favored 'General case' 0 C--N 1.279 -2.46 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 177.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.89 128.01 38.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.407 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.542 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -91.74 -39.07 12.02 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.303 0.573 . . . . 0.0 110.455 -177.049 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.7 m -159.65 161.0 34.9 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.441 HG11 ' HG3' ' A' ' 49' ' ' GLN . 17.5 t -117.62 167.73 10.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.216 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.9 t . . . . . 0 C--N 1.305 -1.364 0 C-N-CA 123.044 0.538 . . . . 0.0 109.965 178.566 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.462 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 C--O 1.203 -1.392 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.55 -62.56 1.65 Allowed 'General case' 0 C--O 1.214 -0.807 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.441 ' HG3' HG11 ' A' ' 42' ' ' VAL . 27.4 mt-30 -72.73 -13.73 61.4 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.783 0.661 . . . . 0.0 112.783 176.208 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.462 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 27.4 mmt180 -81.17 -26.33 36.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 172.299 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.496 ' HB2' HD21 ' A' ' 10' ' ' LEU . 24.6 t70 -54.94 -57.55 11.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 123.743 0.652 . . . . 0.0 111.368 177.655 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.73 -13.15 56.48 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.225 -0.988 . . . . 0.0 114.352 175.322 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.579 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -93.74 -59.93 1.88 Allowed 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 118.082 0.941 . . . . 0.0 108.573 176.878 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.579 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 15.3 tt -64.29 143.67 15.47 Favored 'Isoleucine or valine' 0 C--O 1.246 0.893 0 O-C-N 123.707 0.63 . . . . 0.0 110.672 -175.743 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -142.52 172.76 12.26 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.029 0.442 . . . . 0.0 111.617 -178.377 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.7 p -76.68 -9.52 12.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.653 0 CA-C-O 121.889 0.852 . . . . 0.0 110.503 -177.768 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -92.22 -2.75 56.32 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.592 0.711 . . . . 0.0 110.288 -176.087 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.487 ' HB3' HG21 ' A' ' 91' ' ' ILE . 76.9 m-20 -82.29 174.94 10.68 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 121.988 0.899 . . . . 0.0 112.328 -176.173 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.522 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.3 tt0 -128.6 125.48 38.27 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.497 178.309 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.508 HG22 HD21 ' A' ' 68' ' ' LEU . 48.8 mm -77.16 104.74 5.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -178.582 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.779 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 86.1 t -87.13 -48.07 15.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.844 0.831 . . . . 0.0 110.82 -176.469 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.517 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 33.1 tt0 -151.66 125.95 9.35 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.782 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.442 HG23 HG23 ' A' ' 60' ' ' ILE . 3.0 t -115.64 128.05 73.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 175.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.1 t70 72.97 -9.15 1.16 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 125.23 1.412 . . . . 0.0 112.671 173.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.93 11.56 36.94 Favored Glycine 0 C--N 1.29 -2.011 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.763 -174.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.558 HD13 HG22 ' A' ' 79' ' ' VAL . 7.0 tt -70.95 -21.21 22.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-O 120.728 0.299 . . . . 0.0 111.36 -177.614 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.499 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 57.7 p 51.01 88.52 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.036 1.334 . . . . 0.0 112.192 -177.31 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.508 HD21 HG22 ' A' ' 60' ' ' ILE . 1.4 pp -100.29 17.9 20.22 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 122.29 1.043 . . . . 0.0 109.931 -175.595 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.507 ' HA ' HD23 ' A' ' 35' ' ' LEU . 39.2 t -60.69 98.49 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.297 178.234 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.411 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 112.75 9.67 18.34 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.609 177.538 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.7 m -95.56 174.21 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.485 -179.408 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 p -95.02 175.45 6.63 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.54 177.617 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.589 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.23 -34.35 72.1 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.628 -179.385 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.7 -36.87 73.48 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.439 -177.44 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.467 ' O ' HG23 ' A' ' 79' ' ' VAL . 35.4 t80 -70.68 -49.1 50.76 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.808 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.19 -45.07 94.38 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.399 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -54.91 -43.29 73.14 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 122.716 0.406 . . . . 0.0 110.307 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 90.3 m -61.35 -41.78 97.61 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.981 177.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.558 HG22 HD13 ' A' ' 66' ' ' ILE . 47.4 t -62.98 -51.82 67.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 178.022 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.429 HD21 HG21 ' A' ' 60' ' ' ILE . 3.5 mm? -68.26 -5.36 17.99 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-O 121.342 0.591 . . . . 0.0 111.63 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -102.47 -22.44 14.05 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.901 0.881 . . . . 0.0 110.891 176.35 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -90.44 0.85 57.13 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 121.253 0.549 . . . . 0.0 111.628 178.295 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.404 HG21 HD11 ' A' ' 17' ' ' LEU . 15.6 p -61.83 155.38 23.33 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.172 -0.922 . . . . 0.0 112.739 178.578 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.49 -157.55 0.8 Allowed 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.626 -1.17 . . . . 0.0 108.241 179.377 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 12' ' ' LYS . . . -51.61 -82.04 0.05 OUTLIER Glycine 0 CA--C 1.531 1.033 0 N-CA-C 114.601 0.6 . . . . 0.0 114.601 177.489 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -77.12 102.13 6.42 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.122 0.486 . . . . 0.0 111.419 -176.543 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 41.8 t -115.52 119.42 61.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.16 -178.323 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.34 104.49 15.22 Favored 'General case' 0 CA--C 1.487 -1.447 0 C-N-CA 120.282 -0.567 . . . . 0.0 109.963 173.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.4 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.4 m-85 -93.33 101.33 13.57 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 174.445 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.779 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.9 t -91.53 85.77 2.3 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 N-CA-C 105.337 -2.098 . . . . 0.0 105.337 176.553 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.487 HG21 ' HB3' ' A' ' 58' ' ' ASP . 78.0 mt -102.68 155.37 5.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 CA-C-N 113.765 -1.561 . . . . 0.0 108.85 179.641 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.462 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -128.85 155.59 20.72 Favored Glycine 0 N--CA 1.4 -3.748 0 C-N-CA 119.747 -1.215 . . . . 0.0 110.479 177.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -132.15 152.17 51.41 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 121.551 0.691 . . . . 0.0 112.864 -178.599 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 . . . . . 0 C--N 1.299 -1.606 0 C-N-CA 127.231 2.212 . . . . 0.0 105.505 174.381 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.468 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 40.9 tt0 . . . . . 0 CA--C 1.496 -1.12 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -86.82 128.74 35.05 Favored 'General case' 0 C--N 1.313 -0.994 0 O-C-N 123.648 0.592 . . . . 0.0 110.007 -176.755 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 33.3 p90 -142.91 141.86 20.84 Favored Pre-proline 0 N--CA 1.423 -1.782 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -178.648 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -81.18 122.58 4.23 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.826 2.351 . . . . 0.0 112.107 176.044 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.524 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 47.2 t -103.03 100.35 10.23 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.98 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 174.91 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.485 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 35.9 tt0 -81.58 102.03 10.37 Favored 'General case' 0 N--CA 1.427 -1.587 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 174.174 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.522 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -104.04 134.49 47.22 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 -175.449 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -102.78 97.59 7.73 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 175.243 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.459 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.0 mmmp? -84.42 177.53 8.09 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 115.115 1.524 . . . . 0.0 115.115 -177.196 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -80.66 -174.47 4.73 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 112.759 -2.019 . . . . 0.0 110.457 -175.041 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -71.79 -26.62 62.49 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.742 176.876 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -59.11 -41.99 89.48 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.504 178.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 120.2 -114.12 2.61 Favored Glycine 0 N--CA 1.413 -2.888 0 N-CA-C 108.044 -2.023 . . . . 0.0 108.044 -175.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.515 ' HG ' HG23 ' A' ' 19' ' ' ILE . 10.5 tp -113.63 -64.41 1.31 Allowed 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -178.869 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 79.75 28.64 50.46 Favored Glycine 0 N--CA 1.437 -1.259 0 O-C-N 124.183 0.927 . . . . 0.0 113.014 177.021 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.515 HG23 ' HG ' ' A' ' 17' ' ' LEU . 18.0 pt -104.99 172.11 1.66 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.826 0 C-N-CA 119.543 -0.863 . . . . 0.0 111.278 179.649 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.1 m -123.81 147.4 47.61 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.854 -179.114 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.565 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -117.66 162.2 15.87 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -178.248 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.438 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.9 tt -128.96 132.83 67.05 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.116 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 174.314 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.482 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.22 106.69 3.45 Favored Glycine 0 N--CA 1.42 -2.405 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.029 -177.891 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.419 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.7 mmm -115.82 156.2 26.5 Favored 'General case' 0 C--N 1.289 -2.052 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 177.414 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.286 -2.195 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 176.498 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.52 HD22 ' HA ' ' A' ' 69' ' ' VAL . 1.0 OUTLIER . . . . . 0 N--CA 1.447 -0.617 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 . . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.419 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -117.91 34.59 4.42 Favored Glycine 0 N--CA 1.416 -2.655 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.922 173.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.482 HD13 ' HA2' ' A' ' 23' ' ' GLY . 29.3 mm -87.15 99.04 7.88 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 119.83 -0.748 . . . . 0.0 109.868 179.491 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -97.09 159.34 14.97 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 115.13 -0.941 . . . . 0.0 109.724 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.7 t -77.17 115.41 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.544 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 176.563 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -87.15 -51.4 6.01 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.858 -175.229 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -143.43 157.16 44.68 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 -179.006 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.409 ' HA ' HG22 ' A' ' 19' ' ' ILE . 50.0 t -126.85 151.01 33.14 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 N-CA-C 105.984 -1.858 . . . . 0.0 105.984 175.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.4 t . . . . . 0 N--CA 1.433 -1.325 0 CA-C-O 121.869 0.842 . . . . 0.0 109.942 178.253 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.531 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 C--O 1.195 -1.768 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.06 -53.69 9.43 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -76.66 -6.31 51.56 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.743 175.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.531 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 1.8 mmp_? -86.95 -38.27 16.81 Favored 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 172.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.56 ' OD1' ' HB2' ' A' ' 53' ' ' ARG . 11.4 t70 -66.13 -46.0 79.06 Favored 'General case' 0 C--O 1.217 -0.631 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 176.523 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.86 -17.44 11.33 Favored Glycine 0 N--CA 1.469 0.841 0 N-CA-C 114.54 0.576 . . . . 0.0 114.54 173.096 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.56 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 6.7 ttm180 -64.05 -40.37 96.14 Favored 'General case' 0 C--N 1.316 -0.85 0 C-N-CA 124.285 1.034 . . . . 0.0 110.238 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.8 tt -83.04 162.54 3.19 Favored 'Isoleucine or valine' 0 C--O 1.257 1.451 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 -178.465 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -125.74 -171.74 2.45 Favored 'General case' 0 N--CA 1.423 -1.805 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.308 -178.309 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.9 p -123.51 16.46 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.042 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 173.312 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 34.9 p30 -134.4 16.23 3.72 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 122.591 1.186 . . . . 0.0 109.923 -174.64 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -112.89 -169.89 1.57 Allowed 'General case' 0 C--N 1.27 -2.865 0 CA-C-N 113.69 -1.596 . . . . 0.0 109.943 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.45 ' O ' HG23 ' A' ' 91' ' ' ILE . 62.7 tt0 -132.39 132.35 42.74 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 116.72 -0.218 . . . . 0.0 110.595 -173.503 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.49 HG21 HD21 ' A' ' 80' ' ' LEU . 50.5 mm -74.38 104.83 3.15 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.961 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.013 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.712 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 94.1 t -86.33 -49.22 15.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 121.292 0.568 . . . . 0.0 110.139 -176.622 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.506 ' HG3' ' H ' ' A' ' 67' ' ' SER . 34.8 tt0 -154.39 116.67 4.29 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.254 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.405 HG23 HG23 ' A' ' 60' ' ' ILE . 4.2 t -108.83 129.98 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.209 0 N-CA-C 111.765 0.283 . . . . 0.0 111.765 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 15.6 t70 62.09 17.06 8.79 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 124.922 1.289 . . . . 0.0 111.441 174.826 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.9 10.98 85.69 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 115.65 -0.705 . . . . 0.0 112.422 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.0 tt -73.83 -14.81 16.54 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 O-C-N 122.528 -0.395 . . . . 0.0 111.171 -176.079 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.506 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 8.9 p 42.95 79.59 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 124.801 1.24 . . . . 0.0 113.357 -176.915 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.464 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.5 pp -90.84 14.14 14.46 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.739 -174.435 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.52 ' HA ' HD22 ' A' ' 35' ' ' LEU . 48.7 t -58.84 98.0 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 114.736 -1.12 . . . . 0.0 109.586 173.848 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.439 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 112.96 18.24 7.44 Favored Glycine 0 N--CA 1.435 -1.42 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.781 177.271 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.464 HG22 ' O ' ' A' ' 68' ' ' LEU . 15.6 m -105.33 175.72 1.13 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.518 0 CA-C-N 117.205 0.502 . . . . 0.0 110.578 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.6 p -94.65 179.37 5.28 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-O 121.633 0.73 . . . . 0.0 110.012 178.75 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.565 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -65.87 -35.29 80.23 Favored 'General case' 0 N--CA 1.419 -1.975 0 CA-C-N 114.803 -1.089 . . . . 0.0 111.055 -179.619 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -70.17 -27.68 64.72 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.492 -177.584 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 36.6 t80 -75.47 -51.8 12.18 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 175.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.2 -44.06 92.25 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.448 -0.797 . . . . 0.0 112.218 -178.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.46 -10.66 36.08 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.335 0.654 . . . . 0.0 111.59 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.423 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 98.3 m -93.01 -49.18 6.15 Favored 'General case' 0 N--CA 1.412 -2.355 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.668 175.224 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.535 ' O ' HG23 ' A' ' 83' ' ' THR . 38.5 t -59.64 -52.07 65.34 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.649 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.49 HD21 HG21 ' A' ' 60' ' ' ILE . 3.6 mm? -68.62 3.39 1.88 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.611 0.764 . . . . 0.0 112.228 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.423 ' HB3' ' O ' ' A' ' 78' ' ' THR . 11.7 ttm180 -109.91 -41.02 4.6 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 121.99 0.9 . . . . 0.0 109.109 176.334 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -80.31 -4.83 54.92 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 114.496 -1.229 . . . . 0.0 112.182 -174.668 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 79' ' ' VAL . 7.5 p -60.7 147.68 41.3 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 123.759 0.824 . . . . 0.0 112.194 177.503 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.85 -172.88 2.17 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.852 177.157 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -38.93 -73.74 0.15 Allowed Glycine 0 C--O 1.217 -0.94 0 O-C-N 124.484 1.115 . . . . 0.0 115.067 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.522 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 36.3 m-80 -83.05 105.11 13.76 Favored 'General case' 0 CA--C 1.497 -1.062 0 CA-C-N 118.0 0.9 . . . . 0.0 110.956 -179.536 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.493 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 2.5 t -104.24 143.38 16.0 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 CA-C-N 115.44 -0.8 . . . . 0.0 108.927 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 60.3 mtp180 -107.27 97.28 7.06 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 173.681 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.524 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 81.6 m-85 -94.67 104.76 16.68 Favored 'General case' 0 CA--C 1.483 -1.6 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 177.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.712 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 62.5 t -87.65 94.74 4.71 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.609 0 N-CA-C 105.108 -2.182 . . . . 0.0 105.108 173.198 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.456 HG12 ' HA ' ' A' ' 60' ' ' ILE . 93.9 mt -114.49 153.76 15.95 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.671 0 CA-C-N 114.894 -1.048 . . . . 0.0 108.245 177.515 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -118.02 157.88 14.96 Favored Glycine 1 N--CA 1.393 -4.221 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.534 177.459 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.485 HH21 ' HG2' ' A' ' 94' ' ' GLU . 8.1 tpm_? -129.48 123.66 32.09 Favored 'General case' 0 C--N 1.29 -2.005 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.569 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.485 ' HG2' HH21 ' A' ' 93' ' ' ARG . 16.5 pt-20 . . . . . 0 N--CA 1.428 -1.567 0 N-CA-C 105.886 -1.894 . . . . 0.0 105.886 171.014 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.481 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 39.1 tt0 . . . . . 0 N--CA 1.439 -0.99 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.437 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.7 mm? -89.93 120.33 31.06 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 177.346 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -131.63 143.64 50.01 Favored Pre-proline 0 C--N 1.29 -1.987 0 CA-C-O 121.322 0.582 . . . . 0.0 112.356 -174.459 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -84.01 127.45 4.1 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.914 2.409 . . . . 0.0 112.273 175.398 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.415 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 23.6 t -117.52 104.63 16.68 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.271 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 174.381 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.415 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 36.4 tt0 -91.48 102.41 15.08 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.741 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.497 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -91.23 144.51 25.54 Favored 'General case' 0 N--CA 1.422 -1.866 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 -173.983 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -113.12 84.54 2.01 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 170.928 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.538 ' HE2' ' H ' ' A' ' 48' ' ' ALA . 5.1 mmtt -71.89 165.5 24.04 Favored 'General case' 0 N--CA 1.417 -2.077 0 N-CA-C 114.071 1.137 . . . . 0.0 114.071 -179.243 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -84.38 -175.18 5.67 Favored 'General case' 0 N--CA 1.433 -1.308 0 CA-C-N 113.613 -1.631 . . . . 0.0 111.123 -176.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -78.21 -9.27 59.13 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 -172.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -77.72 -45.47 24.67 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 121.746 0.784 . . . . 0.0 108.889 176.344 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.85 -160.28 21.75 Favored Glycine 0 N--CA 1.422 -2.271 0 N-CA-C 108.551 -1.82 . . . . 0.0 108.551 -176.928 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.8 mt -75.52 -50.8 14.57 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 118.011 0.905 . . . . 0.0 109.599 -176.346 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 68.1 27.97 73.52 Favored Glycine 0 N--CA 1.433 -1.56 0 CA-C-N 114.695 -1.139 . . . . 0.0 110.453 -176.261 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.54 HD11 HD12 ' A' ' 80' ' ' LEU . 18.1 pt -99.57 171.02 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.832 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.165 -178.804 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.1 m -133.35 148.34 51.86 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -177.398 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -115.41 161.59 14.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.429 ' CG2' ' HB2' ' A' ' 38' ' ' PHE . 15.3 tt -129.14 131.84 67.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 C-N-CA 120.611 -0.436 . . . . 0.0 109.895 174.882 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.496 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -90.65 97.08 2.28 Favored Glycine 0 CA--C 1.494 -1.238 0 C-N-CA 120.974 -0.631 . . . . 0.0 112.138 -177.719 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.434 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 95.1 mmm -111.73 -175.72 2.76 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.282 -2.43 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 174.107 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.678 HD22 HG23 ' A' ' 69' ' ' VAL . 2.2 pt? . . . . . 0 N--CA 1.436 -1.132 0 CA-C-O 121.377 0.608 . . . . 0.0 110.933 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -110.49 19.07 26.92 Favored Glycine 0 N--CA 1.417 -2.592 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 175.152 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.611 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 35.9 mm -85.73 104.04 13.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-O 121.498 0.666 . . . . 0.0 110.457 -177.551 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.429 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 96.6 m-85 -101.65 163.31 12.33 Favored 'General case' 0 C--N 1.281 -2.4 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.484 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 47.0 t -77.35 116.29 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 N-CA-C 106.935 -1.505 . . . . 0.0 106.935 175.647 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.532 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.2 OUTLIER -83.44 -39.03 21.11 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 -177.621 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -157.56 158.23 35.23 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.44 HG12 ' HB ' ' A' ' 56' ' ' VAL . 4.3 p -137.52 97.81 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 CA-C-O 121.456 0.646 . . . . 0.0 111.557 178.114 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.8 t . . . . . 0 CA--C 1.563 1.478 0 C-N-CA 127.221 2.208 . . . . 0.0 113.933 178.307 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.449 ' HB3' ' HD3' ' A' ' 12' ' ' LYS . . . . . . . . 0 CA--C 1.548 0.894 0 N-CA-C 115.178 1.547 . . . . 0.0 115.178 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.538 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -80.48 -58.01 3.32 Favored 'General case' 0 C--O 1.214 -0.796 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 43.0 mt-30 -63.27 -29.83 71.09 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.948 173.421 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 31.0 mmm180 -66.78 -34.37 77.68 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.863 176.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.412 ' HB3' ' O ' ' A' ' 48' ' ' ALA . 11.6 t70 -56.3 -52.15 65.57 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.719 176.607 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.19 -7.14 72.83 Favored Glycine 0 C--N 1.313 -0.737 0 N-CA-C 114.944 0.737 . . . . 0.0 114.944 173.609 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -86.57 -43.69 12.5 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.3 tt -78.54 152.12 5.11 Favored 'Isoleucine or valine' 0 C--O 1.243 0.736 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 177.6 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLN . . . . . 0.541 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 19.5 mt-30 -140.69 171.06 14.63 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 121.02 0.438 . . . . 0.0 110.019 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.44 ' HB ' HG12 ' A' ' 42' ' ' VAL . 10.7 p -83.24 -11.91 11.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.419 1.104 . . . . 0.0 108.587 175.288 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -88.65 3.24 51.33 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.786 -172.152 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.541 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 13.0 m-20 -109.6 -165.99 1.06 Allowed 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -174.254 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.611 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 18.9 tt0 -136.41 129.19 30.82 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 123.683 0.793 . . . . 0.0 111.261 -176.383 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.541 ' HA ' HG12 ' A' ' 91' ' ' ILE . 46.9 mm -73.88 108.33 5.25 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.877 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -179.331 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.777 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 97.3 t -92.41 -49.87 12.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 CA-C-O 121.854 0.835 . . . . 0.0 110.403 -178.349 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.576 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.2 tt0 -146.13 127.89 15.3 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.457 HG21 HD11 ' A' ' 80' ' ' LEU . 2.7 t -117.78 126.39 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.917 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.612 175.05 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.4 t70 72.51 -13.67 0.62 Allowed 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 125.391 1.476 . . . . 0.0 112.97 173.839 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 111.0 11.41 18.68 Favored Glycine 0 C--N 1.288 -2.099 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.003 -176.177 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.417 HD13 HG22 ' A' ' 79' ' ' VAL . 7.5 tt -75.33 -18.35 15.96 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.733 0 CA-C-O 120.777 0.323 . . . . 0.0 110.617 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.57 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 25.7 m 49.19 87.15 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.257 1.423 . . . . 0.0 111.54 -176.262 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.445 ' O ' HG22 ' A' ' 71' ' ' VAL . 2.1 pp -103.93 15.58 28.29 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-O 122.246 1.022 . . . . 0.0 109.484 -176.009 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.678 HG23 HD22 ' A' ' 35' ' ' LEU . 6.3 p -62.66 79.62 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 114.001 -1.454 . . . . 0.0 111.324 175.819 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 118.17 49.35 0.37 Allowed Glycine 0 N--CA 1.433 -1.505 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.048 -178.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.445 HG22 ' O ' ' A' ' 68' ' ' LEU . 32.4 m -127.02 178.08 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.242 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 13.3 p -91.08 174.66 7.29 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 120.933 0.397 . . . . 0.0 111.27 179.673 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.42 ' HB3' ' HA3' ' A' ' 23' ' ' GLY . 2.5 pm0 -65.26 -35.35 80.76 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.026 -179.301 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -70.36 -31.14 68.28 Favored 'General case' 0 CA--C 1.511 -0.519 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.695 -177.604 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -71.52 -54.22 11.27 Favored 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.807 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.44 -48.25 79.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.419 -0.809 . . . . 0.0 112.022 -178.188 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.05 -25.75 65.59 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 -179.149 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 71.4 m -76.22 -44.14 39.01 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.485 176.761 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.417 HG22 HD13 ' A' ' 66' ' ' ILE . 33.5 t -61.75 -51.74 69.08 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.621 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.54 HD12 HD11 ' A' ' 19' ' ' ILE . 3.5 mm? -68.12 -3.82 11.67 Favored 'General case' 0 CA--C 1.556 1.188 0 CA-C-O 121.341 0.591 . . . . 0.0 112.448 -179.114 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 36.4 ttt180 -95.64 -40.79 9.23 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 175.642 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 23.1 m-80 -89.01 8.06 31.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 114.241 -1.345 . . . . 0.0 113.88 -171.702 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.415 HG23 ' O ' ' A' ' 79' ' ' VAL . 1.3 p -75.9 154.38 36.05 Favored 'General case' 0 C--N 1.28 -2.431 0 C-N-CA 123.596 0.758 . . . . 0.0 112.332 178.689 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.29 -170.38 1.63 Allowed 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.984 176.9 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -50.41 -62.87 4.79 Favored Glycine 0 N--CA 1.473 1.116 0 N-CA-C 115.341 0.896 . . . . 0.0 115.341 -176.628 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.497 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 20.7 m120 -81.49 104.6 12.04 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 117.436 0.618 . . . . 0.0 110.992 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.441 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 2.3 t -113.75 128.76 70.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.195 -176.542 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.14 104.23 16.26 Favored 'General case' 0 C--N 1.293 -1.872 0 C-N-CA 119.979 -0.689 . . . . 0.0 109.474 170.832 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.441 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 93.2 m-85 -94.8 100.66 12.51 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 174.53 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.777 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 27.2 t -93.62 83.82 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.434 0 N-CA-C 105.288 -2.116 . . . . 0.0 105.288 177.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.541 HG12 ' HA ' ' A' ' 60' ' ' ILE . 64.7 mt -97.61 158.36 3.31 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.588 0 CA-C-N 113.335 -1.757 . . . . 0.0 109.563 -178.904 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.481 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -133.3 147.83 19.13 Favored Glycine 1 N--CA 1.393 -4.187 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.607 176.836 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 24.8 tpt180 -115.73 119.2 35.27 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 . . . . . 0 N--CA 1.413 -2.315 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 173.717 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.423 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 41.2 tt0 . . . . . 0 N--CA 1.434 -1.259 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.442 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -85.32 130.37 34.61 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.245 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 24.8 p90 -139.37 139.85 24.0 Favored Pre-proline 0 N--CA 1.426 -1.667 0 CA-C-O 121.454 0.645 . . . . 0.0 112.157 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -82.77 121.94 3.37 Favored 'Trans proline' 0 N--CA 1.446 -1.273 0 C-N-CA 122.765 2.31 . . . . 0.0 112.844 177.466 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.0 t -111.28 105.08 18.11 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 176.24 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.602 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.1 tt0 -85.39 105.28 15.91 Favored 'General case' 0 N--CA 1.42 -1.956 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 174.674 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.551 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 15.9 tp -95.76 151.35 19.45 Favored 'General case' 0 N--CA 1.41 -2.471 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 -176.719 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -115.27 92.59 3.97 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 177.513 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.466 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 2.6 mmmp? -84.24 177.61 8.12 Favored 'General case' 0 C--N 1.289 -2.032 0 CA-C-O 122.498 1.142 . . . . 0.0 113.675 178.837 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.418 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.0 p-10 -88.86 172.06 9.46 Favored 'General case' 0 C--N 1.286 -2.178 0 CA-C-N 112.835 -1.984 . . . . 0.0 109.536 179.598 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -64.32 -18.22 64.42 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -174.532 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.418 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 23.3 t70 -68.61 -32.98 73.24 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.778 0.799 . . . . 0.0 110.209 178.652 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.97 -124.44 5.94 Favored Glycine 0 CA--C 1.477 -2.285 0 N-CA-C 108.706 -1.758 . . . . 0.0 108.706 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.488 HD21 HG21 ' A' ' 87' ' ' VAL . 25.7 mt -104.27 -52.58 2.89 Favored 'General case' 0 CA--C 1.462 -2.407 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.45 178.499 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.2 24.55 76.53 Favored Glycine 0 N--CA 1.426 -2.003 0 O-C-N 124.678 1.236 . . . . 0.0 110.911 -175.163 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 28.0 pt -101.27 176.48 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.482 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 23.7 m -132.65 148.59 52.35 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -176.489 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -119.82 167.11 13.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.2 tt -133.36 132.26 57.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.668 177.391 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.508 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.1 102.07 2.79 Favored Glycine 0 N--CA 1.435 -1.43 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.607 -177.788 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 95.5 mmm -115.68 173.41 6.56 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.471 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.295 -1.702 0 C-N-CA 120.121 -1.038 . . . . 0.0 112.469 179.162 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.625 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.5 pp . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -110.47 27.48 11.39 Favored Glycine 0 N--CA 1.423 -2.213 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 172.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.508 HD13 ' HA2' ' A' ' 23' ' ' GLY . 35.3 mm -83.67 102.84 10.18 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 CA-C-O 121.47 0.652 . . . . 0.0 110.068 -178.626 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -96.83 169.2 10.02 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 177.232 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.0 t -83.43 129.33 37.67 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 175.407 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 55.6 tptt -93.64 -46.37 7.3 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.248 -177.384 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.8 m -151.72 161.45 42.64 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 -179.258 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 40.6 t -137.58 141.4 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.115 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 177.839 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 14.1 t . . . . . 0 C--N 1.29 -1.98 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.115 -178.036 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.604 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 CA--C 1.555 1.173 0 N-CA-C 114.179 1.177 . . . . 0.0 114.179 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.437 ' HA ' HD21 ' A' ' 10' ' ' LEU . . . -98.23 -62.99 1.17 Allowed 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -75.87 -28.9 58.33 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.679 0.752 . . . . 0.0 109.312 176.543 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.604 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 19.1 mmm180 -63.35 -32.65 74.13 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.473 -1.239 . . . . 0.0 109.63 172.595 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -70.4 -63.21 1.13 Allowed 'General case' 0 C--O 1.241 0.64 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 173.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.26 -17.28 40.82 Favored Glycine 0 N--CA 1.436 -1.356 0 N-CA-C 115.435 0.934 . . . . 0.0 115.435 175.049 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.512 ' O ' ' HD3' ' A' ' 53' ' ' ARG . 0.3 OUTLIER -79.21 -25.69 42.66 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 118.816 1.308 . . . . 0.0 109.341 -177.914 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.9 tt -94.44 150.76 3.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLN . . . . . 0.596 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 23.6 mt-30 -136.64 166.11 24.3 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 121.232 0.539 . . . . 0.0 111.598 -176.327 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -86.88 -12.44 10.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.392 178.803 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -92.99 3.42 55.79 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 122.214 1.007 . . . . 0.0 110.647 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.596 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 24.9 m-20 -101.98 -174.54 2.61 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.268 -177.48 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.442 ' O ' HG23 ' A' ' 91' ' ' ILE . 61.5 tt0 -129.26 131.97 47.12 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.813 -176.017 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.456 HG22 HD11 ' A' ' 68' ' ' LEU . 49.1 mm -75.43 106.56 5.31 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.783 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 179.697 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.692 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 98.5 t -87.87 -44.65 15.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 120.967 0.413 . . . . 0.0 111.344 -177.09 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.557 ' HG3' ' H ' ' A' ' 67' ' ' SER . 37.6 tt0 -156.85 120.96 4.34 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 120.67 0.271 . . . . 0.0 110.544 178.281 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.3 t -112.62 129.04 68.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 111.575 0.213 . . . . 0.0 111.575 176.892 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.3 t70 66.95 7.52 5.41 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 125.737 1.615 . . . . 0.0 111.294 174.54 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.65 20.7 61.23 Favored Glycine 0 N--CA 1.434 -1.472 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.296 -175.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.437 HD13 HG22 ' A' ' 79' ' ' VAL . 6.4 tt -79.44 -22.68 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 CA-C-O 121.197 0.522 . . . . 0.0 110.267 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.557 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 63.8 p 48.68 81.95 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.356 1.462 . . . . 0.0 111.935 -176.003 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.456 HD11 HG22 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -87.33 30.71 0.77 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 122.515 1.15 . . . . 0.0 111.283 -175.997 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.625 ' HA ' HD23 ' A' ' 35' ' ' LEU . 42.4 t -74.71 103.87 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.585 -179.424 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.08 26.83 6.84 Favored Glycine 0 N--CA 1.434 -1.436 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.784 179.403 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.451 HG21 ' HB2' ' A' ' 68' ' ' LEU . 11.0 m -112.63 170.4 4.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 C-N-CA 120.391 -0.524 . . . . 0.0 110.071 177.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.9 p -93.6 172.2 8.41 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.323 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -60.98 -28.43 69.01 Favored 'General case' 0 C--O 1.205 -1.269 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.751 -179.141 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -73.44 -36.03 65.87 Favored 'General case' 0 CA--C 1.522 -0.122 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.557 -178.425 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.401 ' O ' HG23 ' A' ' 79' ' ' VAL . 30.1 t80 -70.43 -49.8 45.05 Favored 'General case' 0 CA--C 1.506 -0.712 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 178.189 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.29 -46.73 87.76 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.934 -178.088 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.48 -34.19 72.26 Favored 'General case' 0 C--O 1.209 -1.036 0 CA-C-O 120.472 0.177 . . . . 0.0 110.554 179.391 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 77.6 m -65.91 -44.45 85.16 Favored 'General case' 0 N--CA 1.435 -1.217 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.755 177.219 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.437 HG22 HD13 ' A' ' 66' ' ' ILE . 39.3 t -61.89 -53.08 52.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 178.553 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -67.98 -2.23 7.19 Favored 'General case' 0 CA--C 1.564 1.509 0 CA-C-O 121.393 0.616 . . . . 0.0 112.183 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.23 -34.02 10.51 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 123.556 0.743 . . . . 0.0 109.714 175.132 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -82.0 -13.68 57.06 Favored 'General case' 0 CA--C 1.498 -1.019 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -175.918 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.435 ' OG1' ' HG ' ' A' ' 17' ' ' LEU . 5.4 p -60.54 146.67 44.19 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.647 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.89 -161.28 0.75 Allowed 'General case' 0 C--N 1.297 -1.709 0 CA-C-N 114.88 -1.055 . . . . 0.0 109.238 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -51.21 -74.93 0.24 Allowed Glycine 0 CA--C 1.536 1.379 0 N-CA-C 115.399 0.92 . . . . 0.0 115.399 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.551 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 15.9 m120 -81.65 99.99 9.2 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 117.872 0.836 . . . . 0.0 112.18 -177.534 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.602 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.8 t -108.54 135.49 47.17 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.044 -175.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -94.05 101.49 13.52 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 172.384 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.513 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 98.8 m-85 -94.8 103.92 15.82 Favored 'General case' 0 CA--C 1.48 -1.741 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.206 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.692 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 60.8 t -88.81 93.31 4.26 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.89 0 N-CA-C 105.416 -2.068 . . . . 0.0 105.416 174.744 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.442 HG23 ' O ' ' A' ' 59' ' ' GLN . 88.7 mt -107.43 155.51 8.14 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.265 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.21 175.844 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.442 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -129.83 149.39 18.77 Favored Glycine 0 N--CA 1.406 -3.331 0 C-N-CA 119.376 -1.393 . . . . 0.0 111.673 -178.771 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 22.9 tpt180 -123.85 116.23 22.61 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 -178.313 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 . . . . . 0 N--CA 1.441 -0.92 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 173.879 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.49 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 82.9 tt0 . . . . . 0 N--CA 1.431 -1.404 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.413 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.0 mm? -87.31 125.78 34.43 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -178.637 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -140.48 145.66 41.78 Favored Pre-proline 0 C--N 1.294 -1.845 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -176.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -82.64 125.48 4.35 Favored 'Trans proline' 0 N--CA 1.442 -1.511 0 C-N-CA 122.62 2.213 . . . . 0.0 112.202 175.635 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.422 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 23.7 t -111.14 102.77 14.44 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.58 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 175.297 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 28.7 tt0 -82.22 108.83 15.98 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 174.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -103.79 135.97 44.34 Favored 'General case' 0 C--N 1.279 -2.469 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 -177.772 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -106.99 97.73 7.48 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.521 -1.289 . . . . 0.0 107.521 171.819 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.619 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 2.7 mmmp? -83.71 173.78 11.04 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-O 122.406 1.098 . . . . 0.0 113.839 -177.329 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -88.15 172.68 9.32 Favored 'General case' 0 N--CA 1.423 -1.803 0 CA-C-N 112.818 -1.992 . . . . 0.0 110.026 -178.855 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -67.75 -9.29 42.64 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 114.197 1.184 . . . . 0.0 114.197 -173.188 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -73.49 -34.05 65.13 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.323 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.95 -127.14 6.98 Favored Glycine 0 CA--C 1.475 -2.452 0 N-CA-C 107.533 -2.227 . . . . 0.0 107.533 -177.554 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 18.2 mt -99.65 -48.92 4.56 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 175.042 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 73.94 31.03 60.48 Favored Glycine 0 N--CA 1.418 -2.524 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 -177.038 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 22.2 pt -110.84 178.35 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.3 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.641 -178.44 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 34.8 m -140.09 154.65 47.1 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -178.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -125.84 166.58 21.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -177.825 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 14.0 tt -140.23 134.6 35.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 C-N-CA 120.58 -0.448 . . . . 0.0 110.681 177.251 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.515 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -92.96 107.58 3.55 Favored Glycine 0 N--CA 1.425 -2.079 0 C-N-CA 120.965 -0.635 . . . . 0.0 111.794 -179.239 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.663 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 93.0 mmm -122.58 97.88 5.66 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.308 -1.015 0 C-N-CA 120.98 -0.629 . . . . 0.0 113.428 -175.651 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.458 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.5 pp . . . . . 0 N--CA 1.436 -1.136 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.663 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -115.12 32.85 5.58 Favored Glycine 0 N--CA 1.424 -2.16 0 C-N-CA 118.919 -1.61 . . . . 0.0 111.797 178.14 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.531 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 25.6 mm -91.04 98.73 8.71 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.779 0 CA-C-O 122.018 0.913 . . . . 0.0 110.117 -178.764 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -93.11 162.44 14.03 Favored 'General case' 0 C--N 1.277 -2.559 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.395 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 46.7 t -79.44 126.83 39.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 175.136 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 58.3 tptt -88.64 -50.45 6.25 Favored 'General case' 0 C--N 1.294 -1.811 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.806 -177.087 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -150.87 162.62 40.43 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 -177.338 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.422 HG11 ' HG3' ' A' ' 49' ' ' GLN . 61.4 t -128.02 159.55 38.93 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.134 0 N-CA-C 105.959 -1.867 . . . . 0.0 105.959 175.239 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 6.6 t . . . . . 0 CA--C 1.544 0.714 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 171.659 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.619 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.204 -1.333 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.478 ' O ' ' HB3' ' A' ' 51' ' ' ASP . . . -87.55 -55.06 3.95 Favored 'General case' 0 CA--C 1.486 -1.483 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -175.82 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.422 ' HG3' HG11 ' A' ' 42' ' ' VAL . 41.2 mt-30 -76.46 -22.3 54.76 Favored 'General case' 0 N--CA 1.433 -1.319 0 C-N-CA 118.586 -1.246 . . . . 0.0 110.87 176.706 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 25.7 mmm180 -69.0 -23.59 64.12 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.192 171.697 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.478 ' HB3' ' O ' ' A' ' 48' ' ' ALA . 12.1 t70 -71.39 -64.92 0.82 Allowed 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.099 -1.075 . . . . 0.0 108.099 170.464 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.71 -5.54 84.63 Favored Glycine 0 C--O 1.245 0.794 0 C-N-CA 121.24 -0.505 . . . . 0.0 113.792 174.699 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.62 -32.85 21.82 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 178.707 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.6 tt -93.52 143.46 11.49 Favored 'Isoleucine or valine' 0 C--O 1.251 1.148 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 170.164 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 62.0 mt-30 -139.05 178.42 7.18 Favored 'General case' 0 C--N 1.308 -1.225 0 O-C-N 122.183 -0.323 . . . . 0.0 111.412 -179.513 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.2 p -84.64 -14.96 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-O 121.66 0.743 . . . . 0.0 110.838 -176.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -91.24 7.9 38.51 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-O 122.107 0.956 . . . . 0.0 109.502 -176.718 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.402 ' HB3' HG21 ' A' ' 91' ' ' ILE . 6.6 m-20 -88.47 -175.4 4.96 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.8 -176.063 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.531 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 30.9 tt0 -141.53 129.14 21.48 Favored 'General case' 0 N--CA 1.423 -1.795 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.007 -179.03 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.434 HG22 HD21 ' A' ' 68' ' ' LEU . 46.8 mm -77.2 105.31 5.96 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.786 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -178.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.766 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 94.2 t -85.07 -48.96 16.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-O 121.957 0.884 . . . . 0.0 109.357 -177.665 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.565 ' HG3' ' H ' ' A' ' 67' ' ' SER . 28.8 tt0 -150.87 135.1 16.89 Favored 'General case' 0 N--CA 1.419 -2.015 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.078 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 t -121.52 128.71 75.9 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 173.489 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 37.0 t70 71.23 -11.49 0.68 Allowed 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 125.3 1.44 . . . . 0.0 113.261 176.603 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.11 15.4 28.33 Favored Glycine 0 C--N 1.277 -2.729 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -174.27 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.425 HD13 HG22 ' A' ' 79' ' ' VAL . 9.3 tt -72.7 -21.02 19.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 CA-C-O 121.452 0.644 . . . . 0.0 110.046 -179.671 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.565 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 62.9 p 49.25 88.2 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 125.399 1.48 . . . . 0.0 111.89 -175.407 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.434 HD21 HG22 ' A' ' 60' ' ' ILE . 1.3 pp -98.11 20.1 12.94 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-O 122.429 1.109 . . . . 0.0 109.573 -176.775 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 50.4 t -57.6 94.26 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-N 114.025 -1.443 . . . . 0.0 110.944 175.549 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.458 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 107.77 27.35 5.21 Favored Glycine 0 N--CA 1.441 -1.003 0 CA-C-N 115.408 -0.815 . . . . 0.0 112.603 175.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.403 HG22 ' O ' ' A' ' 68' ' ' LEU . 20.2 m -105.73 176.15 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.885 -179.439 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 12.4 p -93.0 172.76 8.11 Favored 'General case' 0 C--O 1.254 1.327 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.546 179.08 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.3 pm0 -65.97 -30.81 71.43 Favored 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.666 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -73.73 -26.37 60.65 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.686 -177.5 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 40.3 t80 -75.27 -53.13 9.29 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.775 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.62 -48.8 78.42 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.054 -177.177 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -55.76 -36.96 67.89 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.642 0.258 . . . . 0.0 110.624 179.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 89.0 m -65.62 -44.64 85.85 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.854 177.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.425 HG22 HD13 ' A' ' 66' ' ' ILE . 34.7 t -61.93 -51.2 75.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 178.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -64.01 -20.2 65.73 Favored 'General case' 0 C--O 1.214 -0.794 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.423 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.82 -25.63 24.47 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 122.934 0.494 . . . . 0.0 110.927 177.177 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -89.02 3.62 51.06 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 112.747 0.647 . . . . 0.0 112.747 -178.367 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 38.9 p -73.49 -178.33 3.01 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.78 0.8 . . . . 0.0 111.846 177.67 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.23 -165.9 1.56 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 125.534 1.533 . . . . 0.0 107.045 -179.186 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -39.51 -78.27 0.06 OUTLIER Glycine 0 C--O 1.22 -0.719 0 O-C-N 124.504 1.128 . . . . 0.0 115.204 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.467 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 20.9 m120 -81.57 114.97 20.63 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 118.075 0.938 . . . . 0.0 111.272 -177.917 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.4 t -124.37 140.48 47.54 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.458 -179.112 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 20.2 mtp85 -100.41 100.7 11.51 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 120.907 0.384 . . . . 0.0 110.831 171.35 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.456 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 95.4 m-85 -93.09 105.02 17.17 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 176.338 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.766 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 41.0 t -95.86 86.19 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.274 -2.686 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 178.369 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.402 HG21 ' HB3' ' A' ' 58' ' ' ASP . 94.0 mt -104.92 160.82 5.06 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.49 0 CA-C-N 113.841 -1.527 . . . . 0.0 109.252 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.49 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -122.47 152.88 16.86 Favored Glycine 0 N--CA 1.409 -3.134 0 C-N-CA 119.666 -1.254 . . . . 0.0 110.613 177.015 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 14.8 tpp180 -95.55 123.15 38.96 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -176.255 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 . . . . . 0 C--N 1.303 -1.449 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 172.354 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 . . . . . 0 N--CA 1.442 -0.869 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -85.87 123.52 31.31 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-O 120.877 0.37 . . . . 0.0 110.468 -177.891 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -133.5 143.71 49.11 Favored Pre-proline 0 C--N 1.29 -1.979 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.72 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.43 126.08 5.96 Favored 'Trans proline' 0 N--CA 1.437 -1.817 0 C-N-CA 122.148 1.899 . . . . 0.0 112.4 177.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.467 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 61.1 t -107.0 98.87 7.49 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.677 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 173.527 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.5 tt0 -88.72 103.38 15.9 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -99.36 137.74 37.44 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -173.738 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -100.28 103.98 15.43 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 171.286 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.754 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.9 mmmp? -98.35 173.57 6.91 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -175.413 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -63.05 167.2 5.07 Favored 'General case' 0 C--N 1.313 -0.996 0 C-N-CA 126.917 2.087 . . . . 0.0 109.069 178.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -64.47 -24.48 67.63 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.646 0.736 . . . . 0.0 109.719 176.724 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -58.78 -45.96 88.6 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 114.501 -1.227 . . . . 0.0 110.333 177.734 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.4 ' O ' ' HB3' ' A' ' 12' ' ' LYS . . . 124.74 -118.24 3.28 Favored Glycine 0 N--CA 1.413 -2.864 0 N-CA-C 107.834 -2.107 . . . . 0.0 107.834 -176.234 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.445 HD21 HG21 ' A' ' 87' ' ' VAL . 18.6 mt -105.76 -50.89 3.09 Favored 'General case' 0 CA--C 1.475 -1.911 0 CA-C-N 118.153 0.976 . . . . 0.0 110.305 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 71.27 30.49 67.15 Favored Glycine 0 N--CA 1.422 -2.291 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 -174.392 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.45 HD11 HD12 ' A' ' 80' ' ' LEU . 21.5 pt -107.32 172.04 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 119.708 -0.797 . . . . 0.0 110.195 179.166 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.3 m -124.67 150.53 46.0 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -177.409 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -124.92 160.68 29.83 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 -177.803 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.3 tt -133.55 126.13 51.21 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 177.023 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.631 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.26 96.53 2.22 Favored Glycine 0 N--CA 1.429 -1.786 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.504 -176.184 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.473 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 79.1 mmm -115.13 76.75 1.02 Allowed 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.619 0 O-C-N 124.407 1.067 . . . . 0.0 113.093 -176.464 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.636 HD11 ' O ' ' A' ' 60' ' ' ILE . 0.5 OUTLIER . . . . . 0 N--CA 1.451 -0.408 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.473 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -110.56 30.52 8.1 Favored Glycine 0 C--N 1.298 -1.569 0 C-N-CA 119.837 -1.173 . . . . 0.0 111.578 176.206 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.631 HD13 ' HA2' ' A' ' 23' ' ' GLY . 20.5 mm -90.56 112.03 24.35 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.125 0 CA-C-O 121.509 0.671 . . . . 0.0 110.628 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -104.92 159.88 15.46 Favored 'General case' 0 C--N 1.282 -2.341 0 CA-C-N 115.153 -0.93 . . . . 0.0 109.805 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 44.8 t -75.0 122.05 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 176.08 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 84.6 tttt -86.5 -47.8 8.94 Favored 'General case' 0 C--N 1.286 -2.178 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.623 -177.196 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -152.98 162.34 41.44 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 -179.268 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.431 HG11 ' HG3' ' A' ' 49' ' ' GLN . 47.8 t -130.02 151.84 36.48 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.052 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.2 t . . . . . 0 C--N 1.314 -0.966 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 176.629 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.754 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.209 -1.055 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.438 ' HB2' ' CE ' ' A' ' 12' ' ' LYS . . . -65.56 -59.59 3.81 Favored 'General case' 0 N--CA 1.504 2.274 0 CA-C-N 118.719 0.691 . . . . 0.0 110.423 -175.799 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.431 ' HG3' HG11 ' A' ' 42' ' ' VAL . 26.1 mt-30 -78.02 6.8 7.12 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.349 177.437 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 26.0 mmm180 -95.59 -27.72 15.2 Favored 'General case' 0 N--CA 1.428 -1.568 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 171.697 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -66.65 -37.22 84.36 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 173.768 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.58 -31.74 4.13 Favored Glycine 0 N--CA 1.458 0.119 0 CA-C-N 115.471 -0.786 . . . . 0.0 113.985 172.568 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 2.7 ttm180 -61.55 -54.79 38.52 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 124.975 1.31 . . . . 0.0 111.401 -176.78 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.5 tt -84.82 141.55 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 CA-C-N 115.033 -0.985 . . . . 0.0 108.832 -176.689 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.7 mt-30 -143.0 -179.83 6.6 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 119.991 -0.684 . . . . 0.0 111.875 178.816 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.2 t -62.81 -30.69 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.701 178.469 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 35.3 m-80 -83.53 18.55 1.83 Allowed 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 113.252 0.834 . . . . 0.0 113.252 -175.409 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -104.57 175.43 5.49 Favored 'General case' 0 C--O 1.252 1.187 0 CA-C-O 121.491 0.662 . . . . 0.0 111.715 177.573 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.414 ' O ' HG23 ' A' ' 91' ' ' ILE . 62.3 tt0 -127.46 136.27 51.57 Favored 'General case' 0 N--CA 1.422 -1.827 0 CA-C-N 114.848 -1.069 . . . . 0.0 108.453 177.268 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.636 ' O ' HD11 ' A' ' 35' ' ' LEU . 49.0 mm -75.62 139.84 18.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 178.473 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.712 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 90.5 t -119.26 -53.71 3.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 CA-C-O 121.545 0.688 . . . . 0.0 109.805 177.57 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.563 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 32.0 tt0 -151.7 102.91 2.9 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 -177.617 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.449 HG23 HG23 ' A' ' 60' ' ' ILE . 7.8 t -96.41 127.61 48.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.762 -0.586 . . . . 0.0 111.38 179.185 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 35.2 t70 61.51 19.51 10.4 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 124.847 1.259 . . . . 0.0 111.17 173.786 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.17 20.24 79.69 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 114.891 -1.05 . . . . 0.0 112.505 -178.575 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.455 HD13 HG22 ' A' ' 79' ' ' VAL . 6.9 tt -81.33 -14.42 12.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 O-C-N 122.418 -0.46 . . . . 0.0 110.282 -179.269 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.42 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 17.8 m 45.33 81.23 0.04 OUTLIER 'General case' 0 C--N 1.351 0.642 0 C-N-CA 125.479 1.512 . . . . 0.0 112.172 -178.004 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.421 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.5 OUTLIER -91.4 18.31 7.36 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 121.88 0.848 . . . . 0.0 111.409 -174.901 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.409 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 57.2 t -57.95 104.67 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.941 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.264 173.426 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.47 29.27 6.36 Favored Glycine 0 N--CA 1.437 -1.261 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.633 179.028 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 68' ' ' LEU . 15.7 m -113.88 176.1 2.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 C-N-CA 120.166 -0.614 . . . . 0.0 110.735 176.704 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -104.06 173.27 6.38 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.734 178.008 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -59.28 -33.48 71.12 Favored 'General case' 0 C--O 1.204 -1.314 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.035 -176.616 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -66.09 -32.65 74.23 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 123.695 0.798 . . . . 0.0 111.967 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 51.3 t80 -78.92 -49.33 13.01 Favored 'General case' 0 N--CA 1.444 -0.752 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 177.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.42 -43.41 96.79 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.243 -177.892 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.446 ' O ' ' HB2' ' A' ' 81' ' ' ARG . . . -63.38 -22.59 66.97 Favored 'General case' 0 C--O 1.218 -0.592 0 CA-C-O 121.028 0.442 . . . . 0.0 110.798 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 52.9 m -80.96 -45.44 16.66 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.827 177.32 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.539 ' O ' HG23 ' A' ' 83' ' ' THR . 40.0 t -62.45 -52.71 56.63 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.571 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 178.338 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.45 HD12 HD11 ' A' ' 19' ' ' ILE . 3.7 mm? -70.13 6.82 1.14 Allowed 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 123.968 0.907 . . . . 0.0 112.213 -178.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.446 ' HB2' ' O ' ' A' ' 77' ' ' ALA . 41.5 ttt180 -109.12 -47.61 3.4 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 174.169 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -79.76 -10.76 59.83 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 113.99 -1.459 . . . . 0.0 114.021 -172.121 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.539 HG23 ' O ' ' A' ' 79' ' ' VAL . 12.5 p -63.14 138.43 58.55 Favored 'General case' 0 C--O 1.248 1.014 0 CA-C-O 120.418 0.151 . . . . 0.0 110.838 177.419 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.8 mmtt -131.17 132.38 44.69 Favored 'General case' 0 CA--C 1.487 -1.453 0 N-CA-C 113.516 0.932 . . . . 0.0 113.516 -175.714 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.46 -73.17 0.0 OUTLIER Glycine 0 CA--C 1.479 -2.179 0 C-N-CA 127.895 2.664 . . . . 0.0 115.079 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 19.2 m120 -102.53 100.19 10.27 Favored 'General case' 0 C--N 1.253 -3.63 0 CA-C-O 121.376 0.607 . . . . 0.0 109.417 -172.366 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.514 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 5.6 t -114.5 127.67 71.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.058 -172.388 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 37.7 mtm-85 -99.99 97.78 8.61 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-O 121.026 0.441 . . . . 0.0 109.942 175.811 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' PHE . . . . . 0.467 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 80.8 m-85 -87.56 100.75 13.02 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.494 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.712 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.4 t -85.66 94.25 4.02 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.634 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 175.745 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.414 HG23 ' O ' ' A' ' 59' ' ' GLN . 90.3 mt -112.84 158.58 13.17 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.257 0 CA-C-N 114.05 -1.432 . . . . 0.0 107.749 176.807 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.47 167.34 14.29 Favored Glycine 0 N--CA 1.405 -3.405 0 C-N-CA 118.903 -1.617 . . . . 0.0 112.276 -178.608 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 2.6 tmt_? -113.59 128.55 56.48 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 176.811 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 . . . . . 0 C--N 1.302 -1.477 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 178.236 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.507 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 35.3 tt0 . . . . . 0 CA--C 1.499 -0.988 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.451 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.0 mm? -87.85 117.34 26.63 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.409 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -132.38 140.67 38.66 Favored Pre-proline 0 C--N 1.294 -1.816 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -177.167 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.401 ' HA ' ' HA ' ' A' ' 90' ' ' VAL . 55.6 Cg_endo -77.78 125.0 7.16 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.525 2.15 . . . . 0.0 111.855 176.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 26.3 t -111.73 97.19 5.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.513 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -80.0 104.29 10.47 Favored 'General case' 0 N--CA 1.425 -1.691 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.676 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -98.4 141.22 31.55 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 -177.374 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -112.88 85.29 2.14 Favored 'General case' 0 N--CA 1.416 -2.133 0 C-N-CA 119.077 -1.049 . . . . 0.0 108.924 172.078 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.631 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 4.3 mmtt -68.69 168.67 12.72 Favored 'General case' 0 N--CA 1.409 -2.511 0 CA-C-N 114.402 -1.272 . . . . 0.0 114.398 -179.374 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.4 ' H ' ' CD ' ' A' ' 12' ' ' LYS . 6.3 m-20 -67.04 164.94 16.73 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 113.721 -1.582 . . . . 0.0 107.506 -178.632 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -70.25 -12.82 61.86 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.41 0.624 . . . . 0.0 111.712 -177.03 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -68.21 -43.87 77.06 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.186 174.48 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.464 ' O ' ' HD2' ' A' ' 12' ' ' LYS . . . 132.64 -152.48 20.29 Favored Glycine 0 N--CA 1.426 -1.98 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -176.292 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.574 ' O ' ' HB ' ' A' ' 43' ' ' THR . 22.8 mt -89.14 -49.49 6.72 Favored 'General case' 0 CA--C 1.489 -1.398 0 CA-C-N 117.678 0.739 . . . . 0.0 109.967 -177.475 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 73.11 23.82 76.93 Favored Glycine 0 N--CA 1.425 -2.054 0 CA-C-N 114.752 -1.113 . . . . 0.0 111.062 -174.728 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.469 HG22 ' HA ' ' A' ' 42' ' ' VAL . 19.5 pt -101.17 178.95 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.747 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.7 m -145.58 156.49 43.72 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.56 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -116.71 162.1 14.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 C-N-CA 122.83 0.452 . . . . 0.0 110.556 -176.065 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.4 tt -132.6 125.36 52.96 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.821 0 CA-C-O 120.965 0.412 . . . . 0.0 110.107 174.272 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.574 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.55 101.18 2.71 Favored Glycine 0 N--CA 1.417 -2.595 0 CA-C-N 115.743 -0.662 . . . . 0.0 112.013 -178.488 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 94.9 mmm -107.1 165.32 11.45 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 177.483 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.287 -2.166 0 C-N-CA 119.207 -1.473 . . . . 0.0 111.414 -179.852 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.516 ' CD2' ' HA ' ' A' ' 69' ' ' VAL . 1.6 pp . . . . . 0 N--CA 1.451 -0.411 0 CA-C-O 120.63 0.252 . . . . 0.0 110.867 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -106.52 30.19 9.88 Favored Glycine 0 N--CA 1.431 -1.662 0 C-N-CA 120.009 -1.091 . . . . 0.0 111.229 177.038 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.574 HD13 ' HA2' ' A' ' 23' ' ' GLY . 24.8 mm -82.83 100.68 6.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 121.537 0.684 . . . . 0.0 110.038 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -99.28 167.35 10.72 Favored 'General case' 0 C--N 1.277 -2.545 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.482 179.306 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.1 t -83.21 113.62 22.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.689 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 56.6 tptt -76.74 -45.73 28.05 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.897 -176.643 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.4 m -152.37 162.92 40.49 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -175.846 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.469 ' HA ' HG22 ' A' ' 19' ' ' ILE . 59.6 t -134.27 158.08 41.88 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.066 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.309 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.574 ' HB ' ' O ' ' A' ' 17' ' ' LEU . 10.1 t . . . . . 0 CA--C 1.546 0.792 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 171.025 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.631 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.201 -1.457 0 N-CA-C 115.254 1.575 . . . . 0.0 115.254 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.605 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -74.05 -58.99 2.93 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.217 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -69.84 -24.4 63.45 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 119.83 -0.748 . . . . 0.0 112.133 175.076 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.544 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 13.1 mmt180 -66.37 -36.77 83.72 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 174.017 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -57.23 -59.66 4.78 Favored 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.607 0.567 . . . . 0.0 109.728 177.866 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.06 -20.75 35.14 Favored Glycine 0 N--CA 1.437 -1.244 0 C-N-CA 120.222 -0.989 . . . . 0.0 114.442 174.37 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.553 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -77.11 -60.95 2.15 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.814 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.553 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 17.5 tt -69.08 140.75 18.33 Favored 'Isoleucine or valine' 0 C--O 1.245 0.831 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.428 -175.518 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 16.4 mm-40 -137.18 173.36 11.76 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-O 121.641 0.734 . . . . 0.0 111.669 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.6 p -81.77 23.75 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.227 0 CA-C-O 122.309 1.052 . . . . 0.0 110.362 -178.687 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -134.79 13.43 3.68 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 122.432 1.111 . . . . 0.0 108.816 -178.324 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.472 ' HB3' HG21 ' A' ' 91' ' ' ILE . 64.9 m-20 -92.47 -177.4 4.6 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.151 -0.932 . . . . 0.0 110.806 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.563 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 32.3 tt0 -134.31 125.02 26.81 Favored 'General case' 0 N--CA 1.434 -1.229 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.303 179.156 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.578 HG21 HD21 ' A' ' 80' ' ' LEU . 45.1 mm -77.63 113.8 17.29 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.908 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -177.143 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.668 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 84.9 t -97.17 -49.14 12.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-O 121.65 0.738 . . . . 0.0 111.093 -177.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.636 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 28.6 tt0 -149.39 115.77 5.82 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.9 t -108.9 125.95 65.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.688 176.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 21.1 t70 69.98 1.62 3.56 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 124.807 1.243 . . . . 0.0 112.162 173.723 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.54 16.84 38.31 Favored Glycine 0 N--CA 1.427 -1.908 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.608 -176.185 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.467 HG21 HG21 ' A' ' 79' ' ' VAL . 7.8 tt -74.24 -32.85 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.786 0 O-C-N 122.343 -0.504 . . . . 0.0 110.357 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.548 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 20.8 t 58.0 93.45 0.03 OUTLIER 'General case' 0 C--N 1.344 0.327 0 C-N-CA 125.015 1.326 . . . . 0.0 110.038 -176.207 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.54 HD21 HG22 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -105.27 21.0 17.91 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 121.747 0.784 . . . . 0.0 109.883 -174.954 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.516 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 21.4 t -56.31 96.22 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.287 -2.129 0 CA-C-N 114.532 -1.213 . . . . 0.0 112.046 179.091 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.49 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 108.49 6.86 30.77 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.859 175.863 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.463 HG22 ' O ' ' A' ' 68' ' ' LEU . 21.3 m -82.7 -177.26 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 117.245 0.522 . . . . 0.0 112.005 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 p -97.89 173.77 6.91 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.003 176.489 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.56 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -61.3 -35.11 76.47 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.437 -1.256 . . . . 0.0 111.706 179.044 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -71.33 -32.15 68.23 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 121.059 -0.257 . . . . 0.0 111.364 -178.547 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -70.75 -47.12 61.34 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 176.434 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.413 ' HA ' HG12 ' A' ' 79' ' ' VAL . . . -61.14 -42.88 99.35 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.915 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.411 ' O ' ' HB3' ' A' ' 81' ' ' ARG . . . -59.26 -38.08 79.18 Favored 'General case' 0 C--O 1.212 -0.911 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 176.773 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 88.1 m -65.15 -50.95 64.01 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.099 178.3 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.535 HG13 HD22 ' A' ' 80' ' ' LEU . 5.6 p -63.65 -45.2 98.15 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.577 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 178.731 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.578 HD21 HG21 ' A' ' 60' ' ' ILE . 4.0 mm? -67.29 -25.47 66.06 Favored 'General case' 0 C--O 1.216 -0.709 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.411 ' HB3' ' O ' ' A' ' 77' ' ' ALA . 0.4 OUTLIER -86.38 -23.54 26.11 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-O 120.857 0.36 . . . . 0.0 111.657 177.544 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -86.49 5.29 36.03 Favored 'General case' 0 N--CA 1.483 1.211 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 179.062 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.451 HG21 HD11 ' A' ' 17' ' ' LEU . 31.2 p -70.08 178.05 2.94 Favored 'General case' 0 C--N 1.291 -1.965 0 CA-C-O 121.711 0.767 . . . . 0.0 112.348 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.77 -159.04 0.97 Allowed 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 125.01 1.324 . . . . 0.0 108.045 -179.014 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.12 -76.01 0.22 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 114.467 0.547 . . . . 0.0 114.467 -179.223 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -78.75 112.14 15.58 Favored 'General case' 0 CA--C 1.497 -1.076 0 O-C-N 122.654 -0.321 . . . . 0.0 110.427 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 83.0 t -132.36 128.05 57.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.153 -178.374 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.68 108.38 19.78 Favored 'General case' 0 CA--C 1.496 -1.098 0 C-N-CA 119.715 -0.794 . . . . 0.0 109.903 172.133 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -93.63 98.92 11.46 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 174.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.668 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.7 t -84.55 96.39 4.58 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.06 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 176.062 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.472 HG21 ' HB3' ' A' ' 58' ' ' ASP . 95.0 mt -112.91 153.75 14.44 Favored 'Isoleucine or valine' 0 C--N 1.262 -3.202 0 CA-C-N 113.796 -1.547 . . . . 0.0 108.608 177.462 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -119.76 153.65 16.71 Favored Glycine 0 N--CA 1.403 -3.554 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 177.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.513 ' NH1' ' HG3' ' A' ' 94' ' ' GLU . 4.3 tmt_? -135.19 152.39 51.54 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -176.835 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.513 ' HG3' ' NH1' ' A' ' 93' ' ' ARG . 7.2 pt-20 . . . . . 0 C--N 1.321 -0.641 0 O-C-N 124.247 0.967 . . . . 0.0 110.771 177.306 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.19 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 17.8 p80 -146.15 142.05 28.1 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 54.7 ttp -77.99 109.44 12.06 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 121.295 0.569 . . . . 0.0 109.602 179.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.601 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 48.4 tt0 -87.9 114.47 24.55 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.904 -1.044 . . . . 0.0 108.737 -178.507 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -90.79 108.39 19.8 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.822 -1.548 . . . . 0.0 106.822 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -123.13 140.71 34.17 Favored Pre-proline 0 C--N 1.293 -1.881 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -171.506 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -86.7 131.71 3.37 Favored 'Trans proline' 0 C--N 1.314 -1.267 0 C-N-CA 123.05 2.5 . . . . 0.0 111.928 174.308 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.3 t -124.32 105.79 15.85 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.302 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 175.004 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.58 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.1 tt0 -91.32 103.33 16.0 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 175.667 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.489 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.2 OUTLIER -91.85 143.7 26.24 Favored 'General case' 0 N--CA 1.421 -1.884 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 -174.556 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -112.05 87.92 2.68 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.79 0.805 . . . . 0.0 109.684 175.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.474 ' HG2' HD12 ' A' ' 10' ' ' LEU . 2.1 mmtp -84.87 -178.95 6.98 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -178.222 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.402 ' CG ' ' H ' ' A' ' 14' ' ' GLU . 18.9 t70 -76.08 -176.7 3.61 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 113.568 -1.651 . . . . 0.0 109.845 -178.577 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.402 ' H ' ' CG ' ' A' ' 13' ' ' ASP . 12.0 pt-20 -82.02 -19.86 39.57 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.809 -1.087 . . . . 0.0 109.936 -176.288 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -69.26 -47.46 64.59 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.68 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.73 -128.31 4.4 Favored Glycine 0 N--CA 1.425 -2.039 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.078 -177.308 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.468 HD21 HG21 ' A' ' 87' ' ' VAL . 9.6 mt -103.81 -49.49 3.64 Favored 'General case' 0 CA--C 1.495 -1.139 0 O-C-N 122.351 -0.499 . . . . 0.0 110.151 -174.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 71.74 31.91 64.55 Favored Glycine 0 N--CA 1.428 -1.858 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -175.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.412 HG22 ' HA ' ' A' ' 42' ' ' VAL . 18.5 pt -111.01 167.82 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 C-N-CA 120.151 -0.62 . . . . 0.0 110.399 -179.077 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.4 m -131.47 154.38 48.78 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.303 -177.09 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.428 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -123.34 170.04 14.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 C-N-CA 123.334 0.654 . . . . 0.0 109.352 -178.658 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.421 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.1 tt -136.37 131.41 48.38 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 C-N-CA 120.569 -0.452 . . . . 0.0 110.208 176.298 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.631 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.63 104.24 3.08 Favored Glycine 0 CA--C 1.477 -2.305 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.428 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 19.4 ptm -145.75 98.17 3.08 Favored 'General case' 0 C--N 1.29 -1.992 0 CA-C-N 115.389 -0.406 . . . . 0.0 110.699 -179.049 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.7 111.36 1.2 Allowed Glycine 0 CA--C 1.497 -1.036 0 O-C-N 124.36 1.038 . . . . 0.0 111.32 -178.162 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -75.6 116.5 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.682 0 CA-C-O 121.779 0.8 . . . . 0.0 112.482 -174.343 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.73 75.07 2.05 Favored Glycine 0 N--CA 1.433 -1.538 0 N-CA-C 108.516 -1.834 . . . . 0.0 108.516 173.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.435 ' H ' ' HG2' ' A' ' 33' ' ' GLU . . . -58.13 -20.76 42.89 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 124.575 1.15 . . . . 0.0 113.554 -175.188 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.2 t70 76.13 -32.07 0.2 Allowed 'General case' 0 N--CA 1.495 1.825 0 C-N-CA 124.879 1.271 . . . . 0.0 111.681 176.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.419 ' H ' ' C ' ' A' ' 28' ' ' ALA . . . -60.76 -33.05 72.37 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 125.046 1.338 . . . . 0.0 111.596 178.556 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 123.71 -28.47 5.45 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 119.806 -1.188 . . . . 0.0 112.696 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.0 mp -71.94 -60.93 1.98 Allowed 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -177.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.435 ' HG2' ' H ' ' A' ' 28' ' ' ALA . 41.4 mt-10 60.03 75.79 0.39 Allowed 'General case' 0 CA--C 1.505 -0.753 0 CA-C-O 122.452 1.12 . . . . 0.0 110.31 176.236 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -72.06 -171.04 0.67 Allowed 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 113.161 -1.836 . . . . 0.0 111.175 -176.133 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.415 HD12 ' H ' ' A' ' 37' ' ' ILE . 3.4 pp -50.82 143.3 10.13 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.018 174.203 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -109.8 32.59 6.62 Favored Glycine 0 C--N 1.281 -2.509 0 C-N-CA 120.19 -1.005 . . . . 0.0 111.329 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.631 HD13 ' HA2' ' A' ' 23' ' ' GLY . 28.4 mm -93.06 100.4 11.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-O 121.732 0.777 . . . . 0.0 110.064 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -97.24 166.65 11.46 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.336 178.171 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.0 t -80.95 131.37 34.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 175.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.445 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -93.27 -49.61 5.88 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.477 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.3 m -150.69 161.03 43.4 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 -176.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.534 HG11 ' HG3' ' A' ' 49' ' ' GLN . 57.7 t -132.66 160.39 42.6 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.662 0 N-CA-C 104.9 -2.259 . . . . 0.0 104.9 175.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.1 t -59.31 155.6 14.2 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 173.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -48.54 -31.4 6.44 Favored 'General case' 0 C--O 1.241 0.613 0 C-N-CA 124.384 1.074 . . . . 0.0 112.826 -176.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -163.53 -62.53 0.02 OUTLIER Glycine 0 N--CA 1.417 -2.591 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.755 175.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 43.56 -112.12 0.51 Allowed Glycine 0 N--CA 1.421 -2.308 0 C-N-CA 125.28 1.419 . . . . 0.0 110.891 -170.536 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.485 ' O ' ' HB2' ' A' ' 51' ' ' ASP . . . -129.6 7.92 5.33 Favored 'General case' 0 C--N 1.258 -3.398 0 CA-C-N 112.853 -1.673 . . . . 0.0 108.938 175.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -95.95 -57.07 2.45 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -176.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.534 ' HG3' HG11 ' A' ' 42' ' ' VAL . 25.6 mt-30 -80.92 -12.99 59.31 Favored 'General case' 0 CA--C 1.502 -0.874 0 C-N-CA 119.349 -0.94 . . . . 0.0 109.853 177.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.48 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 5.8 mmp_? -92.17 -9.83 40.95 Favored 'General case' 0 N--CA 1.427 -1.599 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.891 173.062 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.485 ' HB2' ' O ' ' A' ' 47' ' ' ALA . 13.2 t70 -70.54 -64.74 0.84 Allowed 'General case' 0 N--CA 1.481 1.12 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 171.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 115.54 -25.66 9.55 Favored Glycine 0 N--CA 1.431 -1.655 0 C-N-CA 120.383 -0.913 . . . . 0.0 114.297 175.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -80.48 -36.0 34.04 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 117.903 0.851 . . . . 0.0 109.149 -177.581 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.4 tt -92.97 149.55 4.18 Favored 'Isoleucine or valine' 0 C--O 1.254 1.303 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -130.8 167.43 18.91 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.156 0.503 . . . . 0.0 111.031 179.03 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.98 -8.81 11.48 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.165 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.641 178.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -106.38 12.62 29.59 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-O 121.423 0.63 . . . . 0.0 110.764 -177.001 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -91.28 -174.4 3.93 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.613 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.56 ' O ' HG23 ' A' ' 91' ' ' ILE . 30.6 tt0 -135.09 126.13 27.78 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.765 -176.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.542 HG22 HD11 ' A' ' 68' ' ' LEU . 47.0 mm -73.65 114.45 13.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.014 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.704 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 74.0 t -93.26 -49.95 12.5 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-O 121.675 0.75 . . . . 0.0 109.928 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.527 ' HG3' ' H ' ' A' ' 67' ' ' SER . 26.1 tt0 -151.27 126.73 10.06 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.464 178.681 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 5.0 t -118.43 130.65 72.96 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.048 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 174.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 16.6 t70 62.69 16.71 9.16 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 124.205 1.002 . . . . 0.0 111.623 174.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.89 15.81 78.37 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.209 -179.22 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.525 HD13 HG22 ' A' ' 79' ' ' VAL . 4.4 tt -79.86 -16.83 12.93 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.115 0 O-C-N 122.347 -0.502 . . . . 0.0 112.064 -175.657 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.527 ' H ' ' HG3' ' A' ' 62' ' ' GLU 0.282 0.8 OUTLIER 39.34 80.97 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 114.728 1.381 . . . . 0.0 114.728 -175.553 . . . . . . . . 4 4 . 1 . 001 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.62 ' H ' HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -92.24 36.78 0.99 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.859 -176.73 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.66 91.41 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.713 -177.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 107.4 33.17 3.21 Favored Glycine 0 C--N 1.303 -1.276 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.79 176.402 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.463 HG21 ' HB2' ' A' ' 68' ' ' LEU . 24.9 m -103.97 175.96 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 120.249 -0.58 . . . . 0.0 111.152 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 40.3 p -91.89 176.0 6.68 Favored 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 178.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.428 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 1.5 pm0 -68.35 -25.18 64.96 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.404 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 -65.32 -48.16 74.04 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.488 ' O ' HG23 ' A' ' 79' ' ' VAL . 29.5 t80 -64.44 -51.85 61.07 Favored 'General case' 0 N--CA 1.432 -1.331 0 CA-C-N 114.577 -1.192 . . . . 0.0 109.124 -178.208 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.77 -44.99 96.05 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.558 -177.288 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.5 -34.1 73.58 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.039 0.447 . . . . 0.0 110.066 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.467 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 76.8 m -65.75 -45.06 84.01 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.525 176.477 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.525 HG22 HD13 ' A' ' 66' ' ' ILE . 41.1 t -60.62 -52.33 62.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 C-N-CA 122.229 0.212 . . . . 0.0 110.527 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -70.7 0.07 7.78 Favored 'General case' 0 CA--C 1.552 1.049 0 CA-C-O 121.406 0.622 . . . . 0.0 112.154 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.467 ' HB3' ' O ' ' A' ' 78' ' ' THR . 25.9 ttm180 -100.14 -38.18 8.63 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 124.024 0.93 . . . . 0.0 108.986 174.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -75.17 -10.26 59.3 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.122 -175.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.3 p -71.58 161.23 31.34 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 113.183 0.808 . . . . 0.0 113.183 -178.141 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -118.9 -161.24 0.84 Allowed 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.23 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.59 -63.42 5.3 Favored Glycine 0 N--CA 1.439 -1.12 0 O-C-N 123.544 0.528 . . . . 0.0 113.323 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.489 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 17.9 m120 -82.14 108.82 15.91 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.58 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.8 t -119.7 136.66 56.1 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.677 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.721 -176.433 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 84.2 mtt180 -102.63 97.38 7.58 Favored 'General case' 0 C--N 1.288 -2.103 0 CA-C-O 121.4 0.619 . . . . 0.0 109.993 173.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.458 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 92.8 m-85 -89.36 106.16 18.27 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.735 177.504 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.704 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.4 t -95.65 88.77 2.13 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.743 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 175.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.56 HG23 ' O ' ' A' ' 59' ' ' GLN . 82.2 mt -101.09 149.68 6.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.678 0 CA-C-N 114.613 -1.176 . . . . 0.0 108.566 179.094 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.601 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -138.05 128.73 4.32 Favored Glycine 1 N--CA 1.393 -4.196 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 -178.638 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 15.7 ttp180 -157.9 162.1 38.28 Favored 'General case' 0 N--CA 1.414 -2.24 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 -175.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.409 ' H ' ' CD ' ' A' ' 94' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--N 1.285 -2.212 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 175.367 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.496 -1.129 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 54.3 m80 55.42 63.41 2.09 Favored 'General case' 0 CA--C 1.508 -0.666 0 CA-C-O 121.73 0.776 . . . . 0.0 111.093 -177.459 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' MET . . . . . 0.498 ' HA ' ' O ' ' A' ' 93' ' ' ARG 0.273 43.7 ttm 69.38 93.81 0.08 Allowed 'General case' 0 N--CA 1.432 -1.336 0 CA-C-N 113.736 -1.574 . . . . 0.0 113.236 -178.317 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.426 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 32.0 tt0 -85.25 115.46 23.03 Favored 'General case' 0 C--N 1.288 -2.09 0 CA-C-N 112.901 -1.954 . . . . 0.0 108.117 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.476 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.5 mm? -86.43 134.28 33.71 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 123.752 0.658 . . . . 0.0 109.884 -177.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 10.7 p90 -141.57 144.36 33.11 Favored Pre-proline 0 C--N 1.293 -1.865 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.802 -178.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -84.61 130.17 4.36 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 C-N-CA 122.57 2.18 . . . . 0.0 113.168 179.636 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.487 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 26.1 t -115.65 107.65 23.23 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.228 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 174.034 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -88.42 107.02 18.64 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 177.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.428 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -100.48 139.27 36.4 Favored 'General case' 0 N--CA 1.423 -1.802 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -176.157 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -109.76 81.77 1.49 Allowed 'General case' 0 N--CA 1.426 -1.641 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 173.359 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.632 ' HZ1' HG21 ' A' ' 43' ' ' THR . 2.0 mmtt -77.9 171.72 14.56 Favored 'General case' 0 N--CA 1.409 -2.52 0 CA-C-N 115.05 -0.977 . . . . 0.0 113.426 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -72.96 167.98 19.93 Favored 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 126.06 1.744 . . . . 0.0 108.617 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -68.58 -21.41 64.53 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-O 121.412 0.625 . . . . 0.0 110.289 179.279 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -64.14 -32.43 74.0 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.418 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.23 -158.8 14.05 Favored Glycine 0 N--CA 1.434 -1.472 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -178.501 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.455 HD11 HG21 ' A' ' 83' ' ' THR . 17.6 mt -83.64 -48.78 9.84 Favored 'General case' 0 CA--C 1.49 -1.352 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -177.519 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.32 32.01 71.85 Favored Glycine 0 N--CA 1.431 -1.67 0 O-C-N 124.515 1.134 . . . . 0.0 110.677 -175.093 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.414 HG23 ' HB3' ' A' ' 17' ' ' LEU . 26.8 pt -98.91 -177.79 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.567 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.403 -178.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.8 m -138.13 149.09 45.58 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 122.766 0.426 . . . . 0.0 110.011 -178.01 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.446 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.5 pp -119.04 161.39 18.15 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 C-N-CA 123.324 0.65 . . . . 0.0 109.73 -177.51 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.6 tt -128.94 128.72 67.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 174.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.588 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.71 96.39 2.07 Favored Glycine 0 N--CA 1.432 -1.61 0 C-N-CA 120.468 -0.872 . . . . 0.0 112.77 -175.526 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 91.9 mmm -104.15 164.52 11.66 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.8 73.97 0.36 Allowed Glycine 0 N--CA 1.421 -2.35 0 C-N-CA 119.969 -1.11 . . . . 0.0 110.653 177.36 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.4 p -101.33 94.77 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.405 0 CA-C-O 122.473 1.13 . . . . 0.0 108.939 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.487 ' CA ' ' HA ' ' A' ' 33' ' ' GLU . . . -148.13 -75.49 0.02 OUTLIER Glycine 0 N--CA 1.424 -2.154 0 C-N-CA 119.671 -1.252 . . . . 0.0 112.715 -173.779 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.32 -33.91 77.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.806 0.812 . . . . 0.0 109.81 -179.24 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -71.67 -19.22 62.12 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 114.225 -1.352 . . . . 0.0 111.481 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.99 -33.88 11.98 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 121.608 0.718 . . . . 0.0 109.241 177.53 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.14 -32.14 7.66 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.759 179.165 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.6 mp -78.83 -36.57 42.3 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.865 0.364 . . . . 0.0 110.991 -177.368 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.487 ' HA ' ' CA ' ' A' ' 27' ' ' GLY . 44.5 mt-10 64.22 97.15 0.04 OUTLIER 'General case' 0 CA--C 1.509 -0.605 0 C-N-CA 124.436 1.094 . . . . 0.0 113.393 -175.573 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -142.95 -179.42 6.34 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 172.726 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.484 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.6 pt? -57.71 151.56 17.2 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-O 121.738 0.78 . . . . 0.0 111.054 176.199 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -114.26 19.99 16.78 Favored Glycine 0 N--CA 1.412 -2.964 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 174.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.588 HD13 ' HA2' ' A' ' 23' ' ' GLY . 30.5 mm -77.7 116.53 21.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 177.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -114.92 165.88 12.39 Favored 'General case' 0 C--N 1.269 -2.924 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.7 t -77.96 132.37 32.66 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 176.437 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.518 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -95.89 -44.0 7.58 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 121.396 0.617 . . . . 0.0 110.049 -178.715 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.8 m -155.66 160.13 40.15 Favored 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 -178.566 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.41 ' HA ' HG22 ' A' ' 19' ' ' ILE . 64.0 t -129.11 148.8 33.29 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.621 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.632 HG21 ' HZ1' ' A' ' 12' ' ' LYS . 15.3 t -54.44 140.04 35.38 Favored 'General case' 0 C--O 1.254 1.292 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 176.61 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -68.89 -35.39 76.81 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -171.617 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -152.32 77.81 0.21 Allowed Glycine 0 CA--C 1.46 -3.373 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.289 -178.176 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -137.69 174.09 22.0 Favored Glycine 1 N--CA 1.366 -5.979 0 N-CA-C 103.422 -3.871 . . . . 0.0 103.422 173.761 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -61.73 -1.2 0.56 Allowed 'General case' 0 C--N 1.273 -2.74 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 -174.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.558 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -77.88 -57.34 3.85 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -75.16 -12.61 60.34 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 119.764 -0.774 . . . . 0.0 112.085 175.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.568 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 20.5 mmm180 -73.4 -40.99 63.88 Favored 'General case' 0 CA--C 1.507 -0.689 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.564 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -62.36 -57.69 10.39 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.965 0.79 . . . . 0.0 109.603 176.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 83.25 -5.74 75.49 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 115.539 0.976 . . . . 0.0 115.539 173.009 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -78.36 -30.99 48.29 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 19.7 tt -89.11 152.6 3.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 175.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -133.03 -177.57 4.57 Favored 'General case' 0 N--CA 1.42 -1.962 0 CA-C-O 121.508 0.67 . . . . 0.0 111.019 -179.297 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.9 p -97.9 -5.06 9.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 121.822 0.82 . . . . 0.0 109.548 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -117.2 16.96 14.88 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.433 -174.16 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.426 ' OD1' HD13 ' A' ' 91' ' ' ILE . 3.0 p30 -100.66 -168.37 1.56 Allowed 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.167 177.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.476 ' O ' HG23 ' A' ' 91' ' ' ILE . 11.8 tt0 -131.39 117.6 19.11 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.374 -176.302 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.504 ' HA ' HG12 ' A' ' 91' ' ' ILE . 46.0 mm -68.83 106.85 1.24 Allowed 'Isoleucine or valine' 0 C--O 1.21 -1.024 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.778 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 89.3 t -87.76 -50.87 13.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-O 121.607 0.718 . . . . 0.0 110.326 -177.769 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.503 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.9 tt0 -145.62 133.32 21.04 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.31 129.56 71.98 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 176.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 31.3 t70 64.2 16.95 10.41 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 124.739 1.274 . . . . 0.0 111.143 172.058 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 72.2 26.03 73.16 Favored Glycine 0 N--CA 1.433 -1.525 0 CA-C-N 114.825 -1.08 . . . . 0.0 112.483 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.499 HD13 HG22 ' A' ' 79' ' ' VAL . 7.5 tt -85.09 -15.1 10.9 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 CA-C-O 121.417 0.627 . . . . 0.0 109.389 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.482 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 23.2 p 49.01 83.84 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 124.951 1.3 . . . . 0.0 112.704 -175.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.442 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.9 pp -97.88 14.02 28.6 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 122.22 1.01 . . . . 0.0 109.313 -177.682 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 22.4 t -56.13 93.43 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-N 113.836 -1.529 . . . . 0.0 110.356 176.587 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.484 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 106.74 14.52 19.24 Favored Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 116.032 -0.531 . . . . 0.0 113.3 176.571 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.442 HG22 ' O ' ' A' ' 68' ' ' LEU . 21.0 m -88.16 176.14 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 O-C-N 122.335 -0.509 . . . . 0.0 111.836 -179.426 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.6 p -92.16 176.72 6.39 Favored 'General case' 0 N--CA 1.428 -1.545 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.185 177.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.446 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 3.6 pm0 -66.98 -23.87 65.98 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 19.6 m-80 -63.53 -50.92 67.68 Favored 'General case' 0 CA--C 1.484 -1.581 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.429 ' O ' HG23 ' A' ' 79' ' ' VAL . 38.8 t80 -68.5 -50.56 51.31 Favored 'General case' 0 N--CA 1.415 -2.182 0 CA-C-N 114.067 -1.424 . . . . 0.0 110.093 -175.748 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.5 -44.45 95.96 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.29 -16.48 64.07 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-O 121.232 0.539 . . . . 0.0 111.063 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.407 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 60.2 m -85.04 -42.22 15.06 Favored 'General case' 0 N--CA 1.417 -2.107 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.944 176.678 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.499 HG22 HD13 ' A' ' 66' ' ' ILE . 38.7 t -62.85 -53.14 50.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 122.211 0.204 . . . . 0.0 110.588 178.811 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.434 HD21 HG21 ' A' ' 60' ' ' ILE . 3.4 mm? -68.59 -1.93 7.86 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-O 121.571 0.701 . . . . 0.0 112.434 -179.367 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.407 ' HB3' ' O ' ' A' ' 78' ' ' THR . 33.4 ttm180 -97.34 -43.41 7.32 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-O 121.922 0.868 . . . . 0.0 108.93 174.495 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 11.5 m-80 -83.78 8.59 14.22 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 114.338 -1.301 . . . . 0.0 112.794 -174.103 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.455 HG21 HD11 ' A' ' 17' ' ' LEU . 2.2 p -65.6 176.99 1.31 Allowed 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 123.86 0.864 . . . . 0.0 112.679 177.785 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -139.25 -155.57 0.6 Allowed 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.31 -175.075 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -71.77 -68.77 1.53 Allowed Glycine 0 N--CA 1.444 -0.786 0 O-C-N 123.66 0.6 . . . . 0.0 111.834 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.428 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 43.8 m-80 -87.28 104.12 16.1 Favored 'General case' 0 CA--C 1.498 -1.044 0 CA-C-O 121.638 0.732 . . . . 0.0 110.079 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.42 ' HB ' ' CE1' ' A' ' 89' ' ' PHE . 3.0 t -116.74 133.17 64.25 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 CA-C-N 115.261 -0.881 . . . . 0.0 109.76 -175.454 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 70.0 mtp180 -97.79 101.97 13.6 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 173.372 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.487 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 91.1 m-85 -92.74 107.36 19.16 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 176.416 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.778 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 42.8 t -96.05 86.26 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.268 -2.951 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.504 HG12 ' HA ' ' A' ' 60' ' ' ILE . 88.8 mt -96.08 158.73 3.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.25 0 C-N-CA 125.314 1.445 . . . . 0.0 108.689 -179.323 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.476 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -136.53 149.32 20.11 Favored Glycine 0 N--CA 1.398 -3.884 0 C-N-CA 119.565 -1.303 . . . . 0.0 111.267 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.498 ' O ' ' HA ' ' A' ' 3' ' ' MET . 0.0 OUTLIER -115.23 135.18 54.44 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.078 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.291 -1.972 0 C-N-CA 124.335 1.054 . . . . 0.0 112.893 -175.76 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.28 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 31.2 t60 -154.19 139.73 17.84 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -178.074 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 49.7 ttm -160.41 112.09 1.94 Allowed 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 174.079 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -99.48 114.91 28.15 Favored 'General case' 0 C--N 1.285 -2.197 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.479 -178.219 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.54 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -87.31 128.6 35.17 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -140.43 144.08 35.49 Favored Pre-proline 0 C--N 1.307 -1.269 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -178.276 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -83.01 126.23 4.34 Favored 'Trans proline' 0 C--N 1.327 -0.594 0 C-N-CA 123.092 2.528 . . . . 0.0 113.393 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 41.4 t -118.05 99.94 9.08 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.018 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 175.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.489 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 34.0 tt0 -85.2 109.67 18.47 Favored 'General case' 0 N--CA 1.432 -1.372 0 C-N-CA 119.544 -0.863 . . . . 0.0 108.72 176.731 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.409 HD11 ' O ' ' A' ' 47' ' ' ALA . 0.1 OUTLIER -99.83 145.37 27.82 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -177.694 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -111.24 90.26 3.28 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 173.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.655 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 3.3 mtpm? -80.56 -176.63 5.84 Favored 'General case' 0 N--CA 1.423 -1.777 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -178.799 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -72.83 173.02 9.75 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 112.338 -2.21 . . . . 0.0 111.679 -173.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -61.29 -26.66 67.93 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.303 -0.862 . . . . 0.0 112.42 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -67.52 -45.52 75.51 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-O 121.494 0.664 . . . . 0.0 109.879 176.523 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.36 -114.3 2.34 Favored Glycine 0 N--CA 1.426 -2.025 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.73 -176.069 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.519 ' HG ' HG23 ' A' ' 19' ' ' ILE . 9.9 tp -108.1 -62.77 1.4 Allowed 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 117.349 0.575 . . . . 0.0 111.656 -173.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.87 36.25 92.87 Favored Glycine 0 N--CA 1.44 -1.034 0 O-C-N 123.889 0.743 . . . . 0.0 113.139 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.519 HG23 ' HG ' ' A' ' 17' ' ' LEU . 20.9 pt -102.17 178.48 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.519 177.546 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.8 m -130.79 148.79 52.61 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.53 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -118.66 162.86 16.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.453 -177.335 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.4 ' CG2' ' HB2' ' A' ' 38' ' ' PHE . 15.6 tt -126.9 125.55 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.938 0 C-N-CA 120.269 -0.573 . . . . 0.0 110.435 174.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.472 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -86.96 105.63 3.06 Favored Glycine 0 N--CA 1.431 -1.66 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.753 -178.417 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.462 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 9.0 ptp -137.03 176.96 8.24 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 122.668 0.387 . . . . 0.0 111.891 176.239 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.43 94.96 0.49 Allowed Glycine 0 C--N 1.303 -1.277 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.468 HG12 ' HA2' ' A' ' 36' ' ' GLY . 7.2 p -87.56 94.12 4.43 Favored 'Isoleucine or valine' 0 C--O 1.257 1.483 0 CA-C-O 122.238 1.018 . . . . 0.0 113.433 -176.031 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.4 76.31 0.59 Allowed Glycine 0 N--CA 1.435 -1.399 0 CA-C-N 114.182 -1.372 . . . . 0.0 115.724 173.235 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.76 -18.78 34.03 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 172.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -100.92 9.73 41.96 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.346 -1.297 . . . . 0.0 109.512 177.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.09 13.38 34.29 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 112.977 0.732 . . . . 0.0 112.977 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.09 -50.91 3.42 Favored Glycine 0 C--N 1.306 -1.099 0 C-N-CA 119.948 -1.12 . . . . 0.0 114.821 174.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 26.8 mt -71.78 -44.92 63.17 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-O 120.623 0.249 . . . . 0.0 111.067 -173.227 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 54.64 77.32 0.21 Allowed 'General case' 0 CA--C 1.511 -0.52 0 O-C-N 124.301 1.0 . . . . 0.0 111.544 178.254 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.57 ' HD3' ' H ' ' A' ' 34' ' ' LYS . 0.0 OUTLIER -128.21 179.24 5.72 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.685 -178.786 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.419 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.6 pt? -53.73 155.71 3.07 Favored 'General case' 0 C--N 1.321 -0.638 0 O-C-N 124.413 1.071 . . . . 0.0 111.438 -179.191 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.468 ' HA2' HG12 ' A' ' 26' ' ' VAL . . . -124.41 33.0 3.94 Favored Glycine 0 N--CA 1.412 -2.909 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 174.525 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.542 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 32.8 mm -89.5 107.76 18.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 176.87 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.4 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 91.0 m-85 -104.21 168.66 8.96 Favored 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.9 t -78.72 121.63 32.16 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 176.014 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.524 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.1 OUTLIER -86.73 -49.19 7.65 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.503 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.09 157.65 43.68 Favored 'General case' 0 N--CA 1.417 -2.11 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.416 ' HA ' HG22 ' A' ' 19' ' ' ILE . 2.6 p -133.72 151.07 32.43 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.952 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 176.086 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.406 HG21 ' HE3' ' A' ' 12' ' ' LYS . 9.6 t -53.58 140.16 29.53 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-O 121.583 0.706 . . . . 0.0 112.132 -173.524 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -53.35 -44.12 68.28 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 126.184 1.793 . . . . 0.0 113.794 -174.091 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -159.76 36.66 0.47 Allowed Glycine 0 CA--C 1.458 -3.517 0 C-N-CA 118.541 -1.79 . . . . 0.0 113.997 -179.498 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -86.48 179.27 49.19 Favored Glycine 1 N--CA 1.365 -6.097 0 N-CA-C 106.497 -2.641 . . . . 0.0 106.497 170.366 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.655 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . -56.61 -8.12 0.52 Allowed 'General case' 0 C--N 1.259 -3.344 0 N-CA-C 115.301 1.593 . . . . 0.0 115.301 -174.265 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.29 -63.13 1.47 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 -70.6 -21.9 62.61 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 120.616 -0.434 . . . . 0.0 112.125 176.671 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.424 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 40.2 mmt180 -68.54 -33.71 74.58 Favored 'General case' 0 CA--C 1.522 -0.103 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -70.48 -64.98 0.79 Allowed 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.353 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.62 -10.97 57.84 Favored Glycine 0 N--CA 1.437 -1.278 0 C-N-CA 120.549 -0.834 . . . . 0.0 115.115 175.443 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.657 ' O ' ' HD3' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -76.72 -33.63 58.16 Favored 'General case' 0 C--O 1.239 0.507 0 CA-C-N 118.65 1.225 . . . . 0.0 108.448 178.404 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.3 tt -90.82 154.47 3.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 178.092 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -134.96 -163.43 1.38 Allowed 'General case' 0 N--CA 1.428 -1.57 0 C-N-CA 119.772 -0.771 . . . . 0.0 110.972 -174.446 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.9 p -115.16 11.43 7.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-O 122.81 1.29 . . . . 0.0 107.564 176.25 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -121.94 -7.34 8.95 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.435 -1.257 . . . . 0.0 110.655 -174.614 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.511 ' OD1' HD13 ' A' ' 91' ' ' ILE . 3.9 p30 -86.92 -165.29 1.25 Allowed 'General case' 0 C--O 1.255 1.358 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.425 -177.39 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.542 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 62.9 tt0 -142.04 121.55 13.27 Favored 'General case' 0 N--CA 1.416 -2.14 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.38 -175.065 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.461 ' HA ' HG12 ' A' ' 91' ' ' ILE . 42.3 mm -70.16 107.0 1.71 Allowed 'Isoleucine or valine' 0 C--O 1.212 -0.872 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 179.149 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.698 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 93.5 t -88.28 -52.26 11.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 CA-C-O 121.649 0.738 . . . . 0.0 110.724 -177.178 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.585 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 29.4 tt0 -146.15 110.53 5.07 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.75 -178.199 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 t -105.15 131.0 55.44 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.919 0 O-C-N 122.033 -0.417 . . . . 0.0 111.455 176.575 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 33.5 t70 61.65 16.75 8.02 Favored 'General case' 0 N--CA 1.484 1.273 0 O-C-N 124.722 1.264 . . . . 0.0 111.242 174.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.37 19.01 75.05 Favored Glycine 0 N--CA 1.443 -0.898 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.232 -179.263 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.4 tt -80.18 -30.23 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 O-C-N 122.36 -0.494 . . . . 0.0 110.971 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.473 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 19.4 t 54.59 95.24 0.02 OUTLIER 'General case' 0 C--N 1.345 0.392 0 C-N-CA 125.035 1.334 . . . . 0.0 110.5 -175.634 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.466 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.7 OUTLIER -101.65 20.35 16.35 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 122.204 1.002 . . . . 0.0 109.734 -176.144 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 39.0 t -61.84 93.56 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-N 114.496 -1.229 . . . . 0.0 111.343 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.419 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 117.07 5.77 14.68 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.697 176.641 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.466 HG22 ' O ' ' A' ' 68' ' ' LEU . 16.3 m -87.72 179.51 0.49 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.57 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -177.7 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 14.9 p -94.21 176.18 6.41 Favored 'General case' 0 C--O 1.255 1.376 0 CA-C-O 121.463 0.649 . . . . 0.0 109.9 177.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.53 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -62.81 -38.37 90.44 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 114.713 -1.131 . . . . 0.0 111.246 178.071 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -68.65 -32.76 72.84 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 111.768 0.284 . . . . 0.0 111.768 -177.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -68.28 -51.83 40.59 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 176.697 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.418 ' CB ' HG21 ' A' ' 37' ' ' ILE . . . -59.84 -44.64 93.98 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.463 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.58 -18.48 63.93 Favored 'General case' 0 C--O 1.22 -0.467 0 C-N-CA 122.995 0.518 . . . . 0.0 111.266 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 78.3 m -83.67 -49.66 8.94 Favored 'General case' 0 N--CA 1.416 -2.125 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 175.487 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.441 ' O ' HG23 ' A' ' 83' ' ' THR . 38.4 t -59.57 -54.82 29.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 CA-C-O 120.462 0.172 . . . . 0.0 110.831 -178.694 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -67.95 -2.77 8.12 Favored 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 123.331 0.652 . . . . 0.0 112.033 -179.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 38.5 ttt180 -98.8 -43.46 6.76 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 174.221 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -73.08 -11.73 60.65 Favored 'General case' 0 C--O 1.24 0.588 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.142 -174.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.441 HG23 ' O ' ' A' ' 79' ' ' VAL . 15.9 p -75.14 140.18 43.2 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-O 121.588 0.709 . . . . 0.0 112.464 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.464 ' O ' HG22 ' A' ' 87' ' ' VAL . 71.0 mmtt -107.07 -167.5 1.28 Allowed 'General case' 0 C--N 1.292 -1.908 0 CA-C-N 114.432 -1.258 . . . . 0.0 109.044 176.875 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -40.14 -58.57 2.33 Favored Glycine 0 C--O 1.216 -0.971 0 O-C-N 124.631 1.207 . . . . 0.0 115.761 -176.298 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -87.62 100.32 12.72 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 117.747 0.773 . . . . 0.0 111.399 -174.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.565 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 1.6 t -119.43 128.7 75.86 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.36 -175.658 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 42.3 mtp180 -92.31 99.46 12.23 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 173.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.565 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 97.1 m-85 -92.06 101.09 13.63 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 177.589 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.698 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.8 t -91.08 92.44 3.94 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 105.963 -1.865 . . . . 0.0 105.963 175.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.511 HD13 ' OD1' ' A' ' 58' ' ' ASP . 97.2 mt -110.56 153.39 12.35 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.777 0 CA-C-N 114.293 -1.321 . . . . 0.0 107.968 179.336 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.54 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -124.42 150.5 17.08 Favored Glycine 0 N--CA 1.401 -3.662 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.938 179.053 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 4.3 tmm_? -113.9 134.95 54.49 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 -177.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 . . . . . 0 C--N 1.309 -1.165 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.436 179.721 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.507 -0.457 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' HIS . . . . . 0.421 ' O ' ' HA ' ' A' ' 94' ' ' GLU . 59.9 m80 -68.78 131.87 45.87 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 177.356 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 45.0 ttp -137.59 132.89 33.75 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-O 121.089 0.471 . . . . 0.0 112.248 -174.187 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -102.14 120.0 39.73 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.474 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.1 mm? -90.45 120.39 31.52 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -135.1 146.64 59.21 Favored Pre-proline 0 C--N 1.304 -1.398 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -175.647 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -80.28 126.89 6.42 Favored 'Trans proline' 0 N--CA 1.444 -1.431 0 C-N-CA 122.244 1.963 . . . . 0.0 112.488 175.703 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 48.8 t -108.45 103.26 15.21 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.076 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 173.779 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.455 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.1 tt0 -88.17 103.57 15.89 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.49 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -98.28 145.71 26.38 Favored 'General case' 0 N--CA 1.426 -1.625 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 -175.819 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -116.48 95.85 5.25 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-O 121.66 0.743 . . . . 0.0 109.188 175.18 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.478 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 1.9 mmmp? -92.49 -169.96 2.35 Favored 'General case' 0 N--CA 1.419 -1.991 0 CA-C-N 114.911 -1.041 . . . . 0.0 112.564 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -78.49 167.19 21.66 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 113.864 -1.516 . . . . 0.0 107.805 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -67.88 -20.11 65.09 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.325 0.584 . . . . 0.0 109.807 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -65.69 -31.77 72.96 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 114.697 -1.138 . . . . 0.0 109.707 177.482 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.73 -130.4 9.06 Favored Glycine 0 N--CA 1.413 -2.838 0 CA-C-N 114.841 -1.072 . . . . 0.0 111.613 177.086 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.6 ' HB3' HG23 ' A' ' 19' ' ' ILE . 20.7 mt -108.49 -63.68 1.31 Allowed 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.836 -174.587 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.62 23.27 36.87 Favored Glycine 0 N--CA 1.424 -2.1 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -172.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.6 HG23 ' HB3' ' A' ' 17' ' ' LEU . 22.7 pt -89.23 178.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.349 0.547 0 C-N-CA 120.446 -0.502 . . . . 0.0 110.908 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.1 m -139.17 147.59 42.05 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.431 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -126.8 162.4 31.44 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 C-N-CA 122.814 0.446 . . . . 0.0 110.108 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.441 ' HB ' ' HG2' ' A' ' 40' ' ' LYS . 13.5 tt -130.96 135.0 60.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.473 174.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.576 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.18 102.48 2.86 Favored Glycine 0 N--CA 1.427 -1.945 0 C-N-CA 120.722 -0.751 . . . . 0.0 111.792 -178.017 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.641 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 93.8 mmm -116.87 93.48 4.21 Favored 'General case' 0 C--N 1.291 -1.96 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -179.254 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.93 107.07 0.56 Allowed Glycine 0 C--O 1.247 0.915 0 O-C-N 123.839 0.712 . . . . 0.0 111.743 -179.002 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.5 p -137.58 163.19 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -177.246 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 114.71 -9.49 21.61 Favored Glycine 0 N--CA 1.419 -2.471 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.7 177.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.92 -41.68 61.73 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -71.73 -30.96 66.19 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.921 0.867 . . . . 0.0 108.949 178.46 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.54 -29.28 66.83 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.403 175.785 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.53 24.43 28.46 Favored Glycine 0 N--CA 1.442 -0.934 0 C-N-CA 121.219 -0.515 . . . . 0.0 112.638 178.608 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -117.32 -38.94 3.25 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 122.546 -0.385 . . . . 0.0 111.013 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 54.45 82.88 0.09 Allowed 'General case' 0 C--O 1.238 0.495 0 CA-C-O 122.104 0.954 . . . . 0.0 110.377 -172.182 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -126.63 -155.6 0.7 Allowed 'General case' 0 C--N 1.297 -1.695 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.958 -175.099 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.465 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.5 pp -73.57 150.72 41.25 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 178.105 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.641 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -129.59 34.37 2.79 Favored Glycine 0 C--N 1.283 -2.38 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 172.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.576 HD13 ' HA2' ' A' ' 23' ' ' GLY . 26.8 mm -86.72 100.19 9.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.828 0 CA-C-O 121.556 0.693 . . . . 0.0 110.992 -175.405 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -93.16 160.3 14.91 Favored 'General case' 0 C--N 1.287 -2.134 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.211 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 49.3 t -83.63 130.52 35.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.441 ' HG2' ' HB ' ' A' ' 22' ' ' ILE . 20.3 mmmt -87.77 -53.09 4.95 Favored 'General case' 0 CA--C 1.491 -1.3 0 CA-C-O 121.661 0.743 . . . . 0.0 110.266 178.184 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -144.28 160.26 41.3 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 -176.107 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 60.9 t -131.53 86.95 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.473 -1.995 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -178.297 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.526 ' H ' ' HA ' ' A' ' 19' ' ' ILE 0.257 95.9 m 53.91 -170.5 0.05 Allowed 'General case' 0 CA--C 1.583 2.248 0 O-C-N 124.542 1.151 . . . . 0.0 110.182 179.381 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.486 ' N ' HG22 ' A' ' 43' ' ' THR . 11.8 pt-20 -81.84 -153.37 0.11 Allowed 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 104.887 -2.264 . . . . 0.0 104.887 161.436 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -93.78 57.41 2.22 Favored Glycine 0 C--N 1.287 -2.176 0 C-N-CA 118.796 -1.668 . . . . 0.0 111.047 177.265 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.449 ' O ' ' HG2' ' A' ' 50' ' ' ARG . . . -94.33 -160.38 34.41 Favored Glycine 1 N--CA 1.393 -4.215 0 N-CA-C 108.722 -1.751 . . . . 0.0 108.722 173.942 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.478 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . -58.67 -17.78 25.37 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 115.114 1.524 . . . . 0.0 115.114 -171.544 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.35 -60.42 2.25 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 179.075 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 44.1 mt-30 -70.64 -24.3 62.69 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.065 -0.516 . . . . 0.0 112.333 176.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.449 ' HG2' ' O ' ' A' ' 46' ' ' GLY . 40.0 mmt180 -69.72 -37.46 76.54 Favored 'General case' 0 CA--C 1.504 -0.806 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.589 174.771 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -59.81 -48.73 80.52 Favored 'General case' 0 C--N 1.352 0.691 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.305 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.61 -10.61 36.94 Favored Glycine 0 N--CA 1.439 -1.116 0 N-CA-C 115.286 0.874 . . . . 0.0 115.286 172.253 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.464 ' O ' ' HD3' ' A' ' 53' ' ' ARG . 0.1 OUTLIER -75.46 -27.77 59.01 Favored 'General case' 0 C--O 1.221 -0.426 0 CA-C-N 118.57 1.185 . . . . 0.0 108.401 -179.782 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.0 tt -97.81 149.29 5.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 177.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 48.2 mt-30 -132.71 170.34 15.38 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-O 121.839 0.828 . . . . 0.0 112.499 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.4 p -83.26 -3.61 7.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.763 -179.356 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -103.85 15.98 27.42 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 122.6 1.191 . . . . 0.0 108.332 -178.184 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.512 ' HB3' HG21 ' A' ' 91' ' ' ILE . 68.5 m-20 -93.23 177.9 5.9 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.223 -0.899 . . . . 0.0 112.335 -178.628 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -136.7 122.46 19.89 Favored 'General case' 0 N--CA 1.416 -2.174 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.46 HG21 HD21 ' A' ' 80' ' ' LEU . 47.5 mm -74.11 111.95 10.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 -175.661 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.712 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 99.4 t -92.12 -51.22 11.77 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-O 121.771 0.796 . . . . 0.0 110.28 -177.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.527 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.4 tt0 -152.04 110.09 3.69 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.33 0.586 . . . . 0.0 111.066 -178.338 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.411 HG23 HG23 ' A' ' 60' ' ' ILE . 4.7 t -102.01 129.08 53.9 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 O-C-N 122.005 -0.434 . . . . 0.0 110.983 177.299 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 18.2 t70 65.11 10.52 6.42 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 124.764 1.226 . . . . 0.0 111.772 174.177 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.32 19.9 68.11 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.421 -177.428 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.517 HD13 HG22 ' A' ' 79' ' ' VAL . 9.7 tt -76.33 -18.96 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 CA-C-O 121.058 0.456 . . . . 0.0 110.357 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.518 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 31.4 p 48.2 84.96 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 124.875 1.27 . . . . 0.0 112.004 -175.189 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.447 HD21 HG22 ' A' ' 60' ' ' ILE . 1.5 pp -97.12 16.92 18.31 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.669 0.747 . . . . 0.0 110.084 -175.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.465 ' HA ' HD23 ' A' ' 35' ' ' LEU . 45.6 t -58.16 97.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.171 174.771 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.22 53.55 1.0 Allowed Glycine 0 N--CA 1.431 -1.652 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.551 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.6 m -134.32 173.87 13.91 Favored 'Isoleucine or valine' 0 C--O 1.244 0.796 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 176.191 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 14.5 p -92.45 175.53 6.8 Favored 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 122.873 0.469 . . . . 0.0 110.965 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.431 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 2.1 pm0 -66.38 -31.17 71.77 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.276 -179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -69.56 -36.94 76.77 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 120.783 -0.367 . . . . 0.0 111.166 -179.166 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.416 ' O ' HG23 ' A' ' 79' ' ' VAL . 44.1 t80 -68.02 -51.15 50.3 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.21 -47.14 86.45 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.036 -0.983 . . . . 0.0 111.693 -177.659 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.22 -37.07 74.12 Favored 'General case' 0 C--O 1.212 -0.9 0 O-C-N 122.94 0.15 . . . . 0.0 110.641 179.076 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 65.3 m -64.75 -42.75 94.93 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.088 176.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.517 HG22 HD13 ' A' ' 66' ' ' ILE . 47.8 t -61.12 -51.56 71.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 177.327 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.46 HD21 HG21 ' A' ' 60' ' ' ILE . 3.6 mm? -69.73 -2.34 11.63 Favored 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.448 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 3.4 tmt_? -99.51 -30.09 12.35 Favored 'General case' 0 C--N 1.312 -1.061 0 C-N-CA 123.667 0.787 . . . . 0.0 109.329 175.388 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -86.81 0.19 55.28 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 123.344 0.658 . . . . 0.0 112.004 -177.736 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.3 p -65.96 148.83 51.18 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.596 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.71 -157.48 0.72 Allowed 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 124.79 1.236 . . . . 0.0 108.587 178.76 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.27 -76.97 0.17 Allowed Glycine 0 C--N 1.315 -0.613 0 O-C-N 123.542 0.527 . . . . 0.0 113.963 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.49 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.3 m-80 -78.79 109.83 13.41 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.329 0.585 . . . . 0.0 111.537 -179.309 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.465 HG21 HD21 ' A' ' 17' ' ' LEU . 7.2 t -121.73 131.12 73.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.457 -178.46 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -98.58 98.71 9.84 Favored 'General case' 0 C--N 1.284 -2.271 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 174.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.442 ' CE1' ' HB ' ' A' ' 87' ' ' VAL . 89.8 m-85 -89.42 103.06 15.73 Favored 'General case' 0 CA--C 1.486 -1.481 0 CA-C-N 114.643 -1.162 . . . . 0.0 107.942 177.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.712 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.7 t -89.03 95.39 5.37 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.987 0 N-CA-C 106.6 -1.629 . . . . 0.0 106.6 177.633 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.512 HG21 ' HB3' ' A' ' 58' ' ' ASP . 96.7 mt -112.4 154.02 13.93 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.682 0 CA-C-N 114.143 -1.39 . . . . 0.0 108.248 176.768 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.474 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -120.91 149.72 17.38 Favored Glycine 0 N--CA 1.416 -2.657 0 C-N-CA 118.946 -1.597 . . . . 0.0 111.507 179.139 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 25.2 tpt180 -121.22 136.8 54.91 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 120.959 0.409 . . . . 0.0 110.859 179.238 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.421 ' HA ' ' O ' ' A' ' 2' ' ' HIS . 7.1 pt-20 . . . . . 0 N--CA 1.424 -1.755 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.171 176.611 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.503 -0.676 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 17.5 t-80 -92.61 10.02 32.27 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 122.858 1.314 . . . . 0.0 108.361 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 25.7 ttt -152.32 120.21 6.16 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 105.028 -2.212 . . . . 0.0 105.028 174.166 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.527 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 42.1 tt0 -88.22 104.4 16.68 Favored 'General case' 0 C--N 1.289 -2.054 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 -178.324 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -87.09 116.21 25.0 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 174.333 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -132.07 137.19 29.57 Favored Pre-proline 0 N--CA 1.417 -2.113 0 CA-C-O 121.896 0.855 . . . . 0.0 113.237 -173.182 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -82.31 128.47 5.57 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.972 2.448 . . . . 0.0 112.144 175.659 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.449 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 38.4 t -118.95 112.92 39.81 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.491 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 174.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.461 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.2 tt0 -96.11 105.2 17.22 Favored 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 176.764 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.429 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -92.93 143.46 26.23 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -175.02 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -108.34 90.73 3.38 Favored 'General case' 0 C--N 1.291 -1.941 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 174.387 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.8 mmmp? -87.05 -175.46 5.35 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 113.966 1.099 . . . . 0.0 113.966 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.439 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.2 p-10 -89.32 -172.39 3.61 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 126.285 1.834 . . . . 0.0 111.179 -178.248 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -82.1 -6.44 59.18 Favored 'General case' 0 N--CA 1.465 0.286 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -175.571 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.439 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 11.3 t70 -82.16 -34.09 29.24 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 122.005 0.907 . . . . 0.0 108.757 176.001 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 121.37 -109.95 1.59 Allowed Glycine 0 N--CA 1.415 -2.735 0 CA-C-N 114.146 -1.388 . . . . 0.0 110.118 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.763 ' HG ' HG23 ' A' ' 19' ' ' ILE . 14.1 tp -117.31 -62.75 1.53 Allowed 'General case' 0 C--N 1.291 -1.939 0 O-C-N 122.341 -0.505 . . . . 0.0 109.878 -177.216 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.56 33.55 55.75 Favored Glycine 0 N--CA 1.434 -1.496 0 O-C-N 124.175 0.922 . . . . 0.0 113.157 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.763 HG23 ' HG ' ' A' ' 17' ' ' LEU . 27.5 pt -101.02 172.6 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 C-N-CA 119.892 -0.723 . . . . 0.0 110.279 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 34.8 m -119.33 145.98 45.69 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -179.016 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.417 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -122.71 164.38 20.09 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -178.112 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.6 tt -132.53 132.78 60.09 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 174.361 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.629 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.58 105.73 3.29 Favored Glycine 0 N--CA 1.428 -1.9 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.926 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.469 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 16.7 ptm -143.65 85.22 1.82 Allowed 'General case' 0 C--N 1.291 -1.948 0 CA-C-O 121.585 0.707 . . . . 0.0 110.8 179.264 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.21 112.99 2.58 Favored Glycine 0 C--O 1.24 0.519 0 CA-C-N 114.013 -1.449 . . . . 0.0 113.845 -176.248 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.3 p -129.17 166.93 25.55 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 105.39 -18.49 41.64 Favored Glycine 0 N--CA 1.435 -1.411 0 C-N-CA 121.165 -0.54 . . . . 0.0 111.916 176.04 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.45 -39.84 74.08 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 120.649 0.261 . . . . 0.0 110.547 -177.459 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -65.91 -37.08 85.15 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.249 177.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.74 -26.73 66.28 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.998 178.79 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.78 -8.12 42.68 Favored Glycine 0 N--CA 1.443 -0.871 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.457 179.027 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.7 mp -84.89 -32.64 23.05 Favored 'General case' 0 C--N 1.312 -1.029 0 O-C-N 122.938 -0.154 . . . . 0.0 111.062 -178.188 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 57.77 78.46 0.24 Allowed 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 122.146 0.975 . . . . 0.0 110.01 -175.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.0 tptt -100.59 176.63 5.26 Favored 'General case' 0 N--CA 1.405 -2.7 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -175.243 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.478 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.0 OUTLIER -77.39 170.63 16.22 Favored 'General case' 0 N--CA 1.414 -2.253 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 170.197 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -131.67 35.48 2.39 Favored Glycine 0 N--CA 1.414 -2.781 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.039 176.255 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.629 HD13 ' HA2' ' A' ' 23' ' ' GLY . 26.7 mm -94.81 105.72 17.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 C-N-CA 119.405 -0.918 . . . . 0.0 109.547 -179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -102.17 161.54 13.61 Favored 'General case' 0 C--N 1.276 -2.604 0 CA-C-N 114.721 -1.127 . . . . 0.0 110.191 -179.171 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 29.0 t -77.5 117.81 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.087 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 176.58 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 56.3 tptt -84.64 -51.33 6.92 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -178.176 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -149.51 160.69 43.26 Favored 'General case' 0 N--CA 1.427 -1.61 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 -179.777 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.59 ' HB ' ' NE2' ' A' ' 49' ' ' GLN . 16.8 t -122.75 162.36 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.151 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 178.031 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.485 ' H ' HG22 ' A' ' 19' ' ' ILE . 9.1 t -74.48 141.36 44.94 Favored 'General case' 0 N--CA 1.422 -1.83 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -95.91 -31.08 13.29 Favored 'General case' 0 C--N 1.27 -2.864 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -175.247 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -106.09 49.3 0.89 Allowed Glycine 0 CA--C 1.478 -2.273 0 CA-C-N 114.288 -1.324 . . . . 0.0 111.757 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -152.83 150.87 22.73 Favored Glycine 1 N--CA 1.368 -5.863 0 N-CA-C 107.309 -2.317 . . . . 0.0 107.309 178.722 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -58.59 0.59 0.07 Allowed 'General case' 0 C--N 1.279 -2.467 0 N-CA-C 115.424 1.638 . . . . 0.0 115.424 -176.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.89 -53.25 10.58 Favored 'General case' 0 N--CA 1.465 0.275 0 O-C-N 121.46 -0.775 . . . . 0.0 109.952 -178.203 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.59 ' NE2' ' HB ' ' A' ' 42' ' ' VAL . 96.1 mt-30 -78.46 -13.89 59.63 Favored 'General case' 0 CA--C 1.508 -0.66 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.739 176.647 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.478 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 13.5 mmm180 -74.45 -41.06 61.46 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 174.614 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.45 ' OD1' ' HB2' ' A' ' 53' ' ' ARG . 12.2 t70 -60.29 -59.03 6.06 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.461 177.065 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.4 -9.35 77.79 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 115.03 0.772 . . . . 0.0 115.03 174.642 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.45 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -69.35 -37.27 77.56 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.545 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.9 tt -81.93 152.33 4.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -178.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 30.3 mt-30 -127.88 161.6 28.69 Favored 'General case' 0 C--N 1.312 -1.061 0 C-N-CA 120.031 -0.668 . . . . 0.0 109.303 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.9 p -89.64 16.82 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 CA-C-O 121.747 0.784 . . . . 0.0 110.531 -177.687 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -137.59 20.38 2.9 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 122.236 1.017 . . . . 0.0 110.11 -177.021 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -103.72 -175.19 2.73 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.234 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.447 ' O ' HG23 ' A' ' 91' ' ' ILE . 33.6 tt0 -120.68 132.65 55.2 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.132 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.517 HG22 HD11 ' A' ' 68' ' ' LEU . 47.2 mm -76.73 101.45 2.91 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.128 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.699 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.722 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 81.2 t -80.8 -48.06 19.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 CA-C-O 121.233 0.539 . . . . 0.0 110.571 -175.32 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.481 ' HG3' ' H ' ' A' ' 67' ' ' SER . 39.5 tt0 -156.64 112.91 3.02 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-O 121.015 0.436 . . . . 0.0 110.639 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.435 ' C ' ' H ' ' A' ' 65' ' ' GLY . 4.8 t -102.26 131.08 51.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.566 175.636 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.3 t70 73.03 -22.56 0.23 Allowed 'General case' 0 N--CA 1.503 2.22 0 C-N-CA 125.747 1.619 . . . . 0.0 112.975 176.667 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 63' ' ' VAL . . . 110.36 12.41 17.4 Favored Glycine 0 C--N 1.274 -2.911 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -173.323 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.438 HD13 HG22 ' A' ' 79' ' ' VAL . 7.3 tt -70.02 -19.51 22.56 Favored 'Isoleucine or valine' 0 C--N 1.344 0.326 0 C-N-CA 122.885 0.474 . . . . 0.0 110.903 -178.119 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.481 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 12.3 p 49.03 81.57 0.05 Allowed 'General case' 0 C--O 1.233 0.19 0 C-N-CA 124.26 1.024 . . . . 0.0 112.88 -176.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.517 HD11 HG22 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -95.58 30.22 2.36 Favored 'General case' 0 N--CA 1.423 -1.778 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.381 -178.625 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 47.9 t -73.45 97.04 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-N 114.974 -1.012 . . . . 0.0 109.585 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.478 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 108.26 33.07 3.05 Favored Glycine 0 C--N 1.294 -1.799 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 176.423 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.471 HG21 ' HB2' ' A' ' 68' ' ' LEU . 19.7 m -109.39 174.53 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 119.917 -0.713 . . . . 0.0 111.461 -178.746 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 22.2 p -91.29 172.82 8.27 Favored 'General case' 0 N--CA 1.418 -2.049 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.794 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.417 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 2.5 pm0 -66.97 -32.01 72.96 Favored 'General case' 0 C--O 1.204 -1.293 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.018 -179.682 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -71.44 -31.6 67.39 Favored 'General case' 0 CA--C 1.516 -0.362 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.82 -178.321 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -70.38 -51.67 28.03 Favored 'General case' 0 N--CA 1.443 -0.819 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 177.453 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.41 ' CB ' HG21 ' A' ' 37' ' ' ILE . . . -62.56 -42.16 99.37 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.031 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.09 -11.4 48.52 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 121.23 0.538 . . . . 0.0 111.102 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 58.0 m -89.75 -47.13 8.12 Favored 'General case' 0 N--CA 1.415 -2.204 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.862 174.618 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.494 ' O ' HG23 ' A' ' 83' ' ' THR . 31.4 t -61.86 -54.27 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.43 HD21 HG21 ' A' ' 60' ' ' ILE . 3.3 mm? -68.41 0.42 3.96 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.617 0.767 . . . . 0.0 112.716 -178.835 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -104.07 -45.95 4.59 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 174.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 -80.83 7.36 10.64 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 114.405 -1.27 . . . . 0.0 113.142 -173.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.494 HG23 ' O ' ' A' ' 79' ' ' VAL . 1.7 p -60.45 154.22 21.18 Favored 'General case' 0 C--N 1.29 -2.013 0 C-N-CA 124.854 1.261 . . . . 0.0 111.405 175.047 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.439 ' HD3' ' HA ' ' A' ' 84' ' ' LYS . 31.8 mmtp -111.51 -164.91 0.95 Allowed 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.061 178.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.32 -67.59 2.12 Favored Glycine 0 N--CA 1.439 -1.152 0 O-C-N 123.657 0.598 . . . . 0.0 112.886 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.429 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 15.6 m120 -82.52 117.07 22.25 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.461 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.2 t -125.04 127.79 72.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.453 -177.326 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -91.68 104.33 16.8 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-O 120.877 0.37 . . . . 0.0 110.169 172.465 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.449 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.7 m-85 -95.6 103.99 15.88 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 175.234 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.722 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 47.7 t -92.85 91.48 3.37 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.921 0 N-CA-C 104.781 -2.303 . . . . 0.0 104.781 174.687 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.492 HG12 ' HA ' ' A' ' 60' ' ' ILE . 74.8 mt -108.0 157.05 8.33 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.09 178.605 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -131.78 143.66 15.22 Favored Glycine 0 N--CA 1.397 -3.913 0 C-N-CA 119.404 -1.379 . . . . 0.0 111.093 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.42 ' HD2' ' C ' ' A' ' 93' ' ' ARG . 5.2 tmm_? -108.22 128.47 54.75 Favored 'General case' 0 C--N 1.291 -1.97 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -178.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 . . . . . 0 C--N 1.311 -1.095 0 O-C-N 123.353 0.408 . . . . 0.0 110.459 178.961 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.576 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 53.1 t-80 -128.91 127.22 41.35 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 117.351 0.576 . . . . 0.0 110.365 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 44.0 ttp -91.6 128.66 37.52 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.012 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.429 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 32.2 tt0 -88.3 109.43 19.95 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -179.168 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -91.72 127.87 37.34 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.761 -1.199 . . . . 0.0 107.761 173.73 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.494 ' O ' ' HA ' ' A' ' 90' ' ' VAL . 20.9 p90 -133.21 137.59 29.67 Favored Pre-proline 0 C--N 1.283 -2.295 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -175.465 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -84.21 121.67 2.75 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 123.472 2.781 . . . . 0.0 112.146 176.363 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 35.8 t -112.17 98.47 7.07 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.048 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 175.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.608 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 31.6 tt0 -83.8 101.54 11.69 Favored 'General case' 0 N--CA 1.421 -1.899 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 176.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.472 HD11 ' HA ' ' A' ' 48' ' ' ALA . 0.1 OUTLIER -93.23 133.67 36.21 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 -175.948 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -101.15 92.98 5.23 Favored 'General case' 0 N--CA 1.419 -2.016 0 CA-C-O 121.995 0.903 . . . . 0.0 109.282 175.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.572 ' CD ' ' HB3' ' A' ' 47' ' ' ALA . 2.0 mmmp? -92.95 -175.45 3.89 Favored 'General case' 0 N--CA 1.421 -1.921 0 CA-C-N 114.302 -1.317 . . . . 0.0 113.218 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.467 ' OD1' ' HB3' ' A' ' 15' ' ' ASP . 1.7 p30 -77.31 176.62 8.63 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-N 112.784 -2.007 . . . . 0.0 110.743 178.063 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -82.94 -6.65 59.56 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.612 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.467 ' HB3' ' OD1' ' A' ' 13' ' ' ASP . 9.6 t70 -81.77 -41.94 20.45 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 175.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.32 -123.26 2.6 Favored Glycine 0 N--CA 1.42 -2.381 0 C-N-CA 120.136 -1.031 . . . . 0.0 112.909 175.501 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.444 HD21 HG21 ' A' ' 87' ' ' VAL . 13.0 mt -108.36 -45.1 3.97 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 122.211 -0.582 . . . . 0.0 110.569 -172.796 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.67 28.45 70.89 Favored Glycine 0 N--CA 1.426 -2.014 0 O-C-N 124.336 1.023 . . . . 0.0 110.663 -174.345 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 20.4 pt -106.38 -176.95 0.58 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.293 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.797 -178.083 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.3 m -144.22 151.86 40.05 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.496 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.6 pp -125.0 162.67 26.84 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -178.762 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 12.1 tt -134.59 130.42 53.3 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.833 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 176.703 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.623 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -98.01 104.92 3.05 Favored Glycine 0 CA--C 1.481 -2.034 0 C-N-CA 120.357 -0.925 . . . . 0.0 111.744 -178.876 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.492 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 18.4 ptm -147.16 96.41 2.72 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 120.643 0.258 . . . . 0.0 111.562 -179.469 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.36 107.69 0.55 Allowed Glycine 0 C--O 1.243 0.704 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.315 -178.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -74.69 88.44 0.63 Allowed 'Isoleucine or valine' 0 C--O 1.252 1.201 0 N-CA-C 114.039 1.126 . . . . 0.0 114.039 -174.23 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 74.54 -71.96 1.53 Allowed Glycine 0 N--CA 1.439 -1.136 0 CA-C-N 114.376 -1.284 . . . . 0.0 115.926 171.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . 64.06 26.23 13.97 Favored 'General case' 0 C--N 1.35 0.597 0 CA-C-O 122.651 1.215 . . . . 0.0 107.979 -171.515 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -104.16 -42.45 5.52 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 113.775 -1.557 . . . . 0.0 111.594 -173.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.32 -29.7 70.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.897 -177.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.57 -20.29 10.25 Favored Glycine 0 CA--C 1.498 -1.011 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.78 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.2 mp -67.81 -47.14 69.88 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 53.66 72.84 0.41 Allowed 'General case' 0 C--O 1.247 0.955 0 C-N-CA 124.379 1.072 . . . . 0.0 112.081 174.771 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.2 ptpt -109.84 177.65 4.66 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 178.524 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.507 HD22 HG23 ' A' ' 69' ' ' VAL . 1.8 pt? -56.0 170.9 0.28 Allowed 'General case' 0 C--N 1.305 -1.346 0 CA-C-O 122.254 1.026 . . . . 0.0 111.985 173.652 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.492 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -131.66 32.04 2.99 Favored Glycine 0 N--CA 1.41 -3.076 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.873 175.777 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.623 HD13 ' HA2' ' A' ' 23' ' ' GLY . 23.8 mm -90.1 98.61 8.41 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 119.778 -0.769 . . . . 0.0 109.098 178.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -96.98 162.5 13.37 Favored 'General case' 0 C--N 1.273 -2.744 0 CA-C-N 115.047 -0.979 . . . . 0.0 108.914 -178.489 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 40.9 t -79.71 122.71 35.44 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.537 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -81.15 -49.92 10.24 Favored 'General case' 0 C--N 1.293 -1.86 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.331 -177.379 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -154.31 161.23 41.89 Favored 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 -178.121 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 51.0 t -136.25 147.54 27.88 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 N-CA-C 105.415 -2.068 . . . . 0.0 105.415 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.2 t -54.48 132.88 45.5 Favored 'General case' 0 C--O 1.257 1.465 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 173.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 16.5 tp10 -55.4 -58.34 8.15 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 124.759 1.223 . . . . 0.0 111.218 -172.639 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -144.36 39.36 1.24 Allowed Glycine 0 N--CA 1.421 -2.315 0 C-N-CA 120.094 -1.051 . . . . 0.0 112.744 179.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -63.39 -48.21 80.64 Favored Glycine 0 C--O 1.221 -0.667 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 175.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.572 ' HB3' ' CD ' ' A' ' 12' ' ' LYS . . . 170.44 -25.61 0.0 OUTLIER 'General case' 0 C--O 1.197 -1.704 0 C-N-CA 124.999 1.32 . . . . 0.0 109.797 177.765 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.472 ' HA ' HD11 ' A' ' 10' ' ' LEU . . . -64.42 -54.74 27.94 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.239 0.542 . . . . 0.0 110.662 -176.515 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 42.8 mt-30 -76.45 -7.79 55.81 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.772 178.674 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.415 ' HD3' ' HA ' ' A' ' 50' ' ' ARG . 23.4 mmt180 -90.44 -23.29 21.06 Favored 'General case' 0 N--CA 1.437 -1.085 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.12 176.56 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -61.01 -54.9 39.17 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 170.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 105.3 -26.55 21.46 Favored Glycine 0 N--CA 1.432 -1.576 0 CA-C-N 115.164 -0.925 . . . . 0.0 114.746 174.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -72.93 -31.5 64.66 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 118.446 1.123 . . . . 0.0 109.666 -176.545 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.9 tt -97.09 146.96 6.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -179.193 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLN . . . . . 0.424 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 97.0 mt-30 -136.57 162.52 32.9 Favored 'General case' 0 N--CA 1.436 -1.13 0 CA-C-O 121.331 0.586 . . . . 0.0 110.945 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.4 p -75.71 -15.34 15.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 C-N-CA 124.085 0.954 . . . . 0.0 111.298 -178.709 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -95.06 9.84 38.01 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.455 0.645 . . . . 0.0 111.557 -175.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.424 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 39.9 m-20 -97.84 -172.68 2.43 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.691 -177.157 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.564 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.6 tt0 -134.91 133.21 39.38 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.836 -177.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.461 ' HA ' HG12 ' A' ' 91' ' ' ILE . 44.1 mm -78.4 115.15 20.04 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.001 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 -177.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.657 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.2 t -94.49 -51.8 10.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-O 121.679 0.752 . . . . 0.0 110.552 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.609 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 21.4 tt0 -147.55 110.01 4.62 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.92 -177.427 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.5 t -103.39 126.54 57.78 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 O-C-N 122.018 -0.427 . . . . 0.0 110.204 175.132 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.5 t70 62.19 17.52 9.29 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 124.452 1.101 . . . . 0.0 112.215 174.455 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 83.09 8.75 85.15 Favored Glycine 0 N--CA 1.442 -0.915 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.975 -179.214 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.512 HD13 HG22 ' A' ' 79' ' ' VAL . 5.7 tt -75.25 -16.62 15.91 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 O-C-N 122.571 -0.37 . . . . 0.0 110.845 -176.642 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.43 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 31.3 m 49.09 79.71 0.07 Allowed 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 124.876 1.27 . . . . 0.0 112.706 -177.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.495 ' O ' HG22 ' A' ' 71' ' ' VAL . 2.3 pp -96.16 11.73 33.32 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 122.322 1.058 . . . . 0.0 110.074 -175.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.507 HG23 HD22 ' A' ' 35' ' ' LEU . 5.2 p -58.11 92.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.294 -1.841 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.497 173.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.489 ' N ' ' HB3' ' A' ' 35' ' ' LEU . . . 113.79 21.42 5.71 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.829 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.495 HG22 ' O ' ' A' ' 68' ' ' LEU . 20.4 m -103.48 176.97 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 O-C-N 121.978 -0.719 . . . . 0.0 110.965 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.3 p -93.7 171.71 8.71 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.026 177.034 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.496 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 1.8 pm0 -64.78 -28.83 69.84 Favored 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.775 -176.337 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.82 -30.49 66.94 Favored 'General case' 0 CA--C 1.512 -0.492 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.358 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.451 ' O ' HG23 ' A' ' 79' ' ' VAL . 31.2 t80 -77.32 -52.01 9.91 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 177.686 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -56.25 -50.12 72.23 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.274 -0.876 . . . . 0.0 112.364 -177.359 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.15 -36.41 75.21 Favored 'General case' 0 C--O 1.214 -0.786 0 CA-C-O 120.505 0.193 . . . . 0.0 110.796 -179.199 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 84.0 m -62.88 -42.75 99.88 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.301 177.044 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.512 HG22 HD13 ' A' ' 66' ' ' ILE . 31.6 t -64.27 -51.78 64.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 178.483 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -63.58 -18.28 63.72 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.841 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.13 -26.44 23.62 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 123.276 0.631 . . . . 0.0 110.32 174.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -88.67 6.17 39.68 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-O 121.48 0.657 . . . . 0.0 112.251 -178.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 36.4 p -74.89 -178.2 3.64 Favored 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.043 177.658 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.18 -163.0 1.52 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.166 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -49.25 -73.3 0.37 Allowed Glycine 0 CA--C 1.531 1.036 0 O-C-N 123.884 0.74 . . . . 0.0 114.49 178.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.463 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 19.0 m120 -82.99 104.74 13.42 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 117.667 0.734 . . . . 0.0 111.628 -178.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.608 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -114.71 137.51 47.89 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.503 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 90.6 mtt180 -99.64 99.04 9.83 Favored 'General case' 0 C--N 1.283 -2.304 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.507 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 91.9 m-85 -92.2 101.45 13.96 Favored 'General case' 0 CA--C 1.489 -1.386 0 CA-C-N 114.895 -1.048 . . . . 0.0 108.555 177.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.657 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 60.8 t -92.32 94.76 4.96 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.89 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.498 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.47 HG23 ' O ' ' A' ' 59' ' ' GLN . 90.6 mt -106.3 163.19 4.92 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.929 0 CA-C-N 114.104 -1.407 . . . . 0.0 108.543 178.532 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -139.07 161.23 25.94 Favored Glycine 0 N--CA 1.412 -2.912 0 C-N-CA 119.489 -1.338 . . . . 0.0 112.162 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 37.0 ttp-105 -142.58 144.17 32.76 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.552 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 . . . . . 0 C--N 1.302 -1.485 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 176.291 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.5 -0.902 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 58.2 m80 -93.99 94.83 8.67 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 26.6 ttt -84.05 111.82 19.64 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 119.003 -1.079 . . . . 0.0 108.964 176.159 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -95.66 117.38 30.38 Favored 'General case' 0 C--N 1.287 -2.115 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 -179.148 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -93.1 127.55 38.68 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 175.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 19.6 p90 -137.25 141.34 33.79 Favored Pre-proline 0 C--N 1.297 -1.684 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -175.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -82.24 123.9 4.1 Favored 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 122.76 2.307 . . . . 0.0 112.21 177.467 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.415 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 38.9 t -109.44 95.99 4.29 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.688 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 174.385 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 29.7 tt0 -83.37 102.72 12.21 Favored 'General case' 0 N--CA 1.423 -1.825 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -98.44 140.43 32.7 Favored 'General case' 0 N--CA 1.411 -2.386 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 -175.025 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -108.86 95.74 5.85 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 173.425 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.539 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 1.9 mmmp? -84.72 174.21 10.09 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 114.381 1.252 . . . . 0.0 114.381 -178.573 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -92.12 179.91 5.45 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 112.714 -2.039 . . . . 0.0 111.032 -176.656 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -68.81 -15.51 63.52 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -173.366 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -77.3 -28.03 53.17 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 121.572 0.701 . . . . 0.0 109.411 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.12 -125.62 6.61 Favored Glycine 0 CA--C 1.482 -1.997 0 N-CA-C 108.513 -1.835 . . . . 0.0 108.513 -179.275 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt -103.79 -50.24 3.46 Favored 'General case' 0 CA--C 1.483 -1.609 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 176.489 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.94 27.33 64.77 Favored Glycine 0 N--CA 1.434 -1.491 0 O-C-N 124.642 1.214 . . . . 0.0 110.773 -176.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.499 HG22 ' HA ' ' A' ' 42' ' ' VAL . 21.6 pt -102.54 -179.51 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.817 -177.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.3 t -138.72 153.23 48.49 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -178.371 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.51 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.6 pp -125.75 163.43 27.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -177.304 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.615 ' HB ' ' HG2' ' A' ' 40' ' ' LYS . 11.3 tt -130.96 132.69 63.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-O 120.536 0.208 . . . . 0.0 110.686 174.503 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.519 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.15 103.83 3.1 Favored Glycine 0 N--CA 1.426 -1.978 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.5 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.42 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 16.5 ptm -143.94 91.3 2.21 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 178.755 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -51.82 109.98 0.98 Allowed Glycine 0 C--N 1.34 0.799 0 CA-C-N 114.184 -1.371 . . . . 0.0 113.018 -177.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -135.3 164.12 34.06 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.922 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -175.155 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 81.17 59.51 2.41 Favored Glycine 0 N--CA 1.432 -1.58 0 C-N-CA 121.22 -0.514 . . . . 0.0 113.381 173.51 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -109.04 -1.74 18.68 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 174.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -59.71 -41.2 90.26 Favored 'General case' 0 C--N 1.312 -1.023 0 C-N-CA 126.151 1.78 . . . . 0.0 111.909 -172.199 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.64 3.7 55.08 Favored 'General case' 0 C--N 1.31 -1.141 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.402 -178.564 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 89.83 8.79 66.91 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.831 -0.7 . . . . 0.0 114.02 177.025 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -90.77 -44.22 9.59 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 117.791 0.795 . . . . 0.0 113.057 -178.271 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 61.55 84.35 0.14 Allowed 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -171.14 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -96.38 -173.91 2.91 Favored 'General case' 0 N--CA 1.422 -1.865 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.266 -171.438 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.416 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 2.6 pp -64.95 146.35 55.1 Favored 'General case' 0 C--N 1.296 -1.735 0 CA-C-N 114.996 -1.002 . . . . 0.0 109.054 176.011 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -118.79 30.88 5.74 Favored Glycine 0 N--CA 1.417 -2.583 0 C-N-CA 119.684 -1.246 . . . . 0.0 110.303 176.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.519 HD13 ' HA2' ' A' ' 23' ' ' GLY . 30.3 mm -91.95 100.97 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.868 0 CA-C-O 121.553 0.692 . . . . 0.0 110.998 -176.515 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.419 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 96.2 m-85 -96.98 165.0 12.29 Favored 'General case' 0 C--N 1.285 -2.209 0 CA-C-N 115.075 -0.966 . . . . 0.0 108.532 177.567 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 47.1 t -81.41 128.17 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.14 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.53 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.615 ' HG2' ' HB ' ' A' ' 22' ' ' ILE . 15.9 mmmt -85.36 -57.34 3.11 Favored 'General case' 0 CA--C 1.473 -2.015 0 CA-C-O 121.567 0.698 . . . . 0.0 109.332 177.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.48 163.6 34.19 Favored 'General case' 0 C--N 1.291 -1.978 0 CA-C-N 114.241 -1.345 . . . . 0.0 107.789 -176.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.499 ' HA ' HG22 ' A' ' 19' ' ' ILE . 86.6 t -129.68 157.26 42.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.23 0 N-CA-C 104.9 -2.259 . . . . 0.0 104.9 174.582 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 14.9 t -61.54 150.9 34.59 Favored 'General case' 0 N--CA 1.435 -1.193 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 175.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -54.44 -30.99 54.4 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -172.06 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -149.74 -62.08 0.01 OUTLIER Glycine 0 N--CA 1.417 -2.573 0 C-N-CA 119.653 -1.26 . . . . 0.0 111.769 174.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 43.24 -103.99 0.05 OUTLIER Glycine 0 CA--C 1.477 -2.324 0 C-N-CA 125.325 1.441 . . . . 0.0 110.095 -170.096 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.539 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . -141.1 6.35 1.96 Allowed 'General case' 0 C--N 1.257 -3.419 0 CA-C-N 113.083 -1.559 . . . . 0.0 108.646 173.761 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -95.1 -55.8 2.95 Favored 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 115.795 -0.638 . . . . 0.0 109.608 -175.478 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -79.08 -16.19 57.1 Favored 'General case' 0 N--CA 1.438 -1.044 0 C-N-CA 119.301 -0.96 . . . . 0.0 110.037 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 36.0 mmt180 -78.43 -25.32 45.95 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.55 171.338 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -70.91 -61.0 1.92 Allowed 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 172.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.77 2.07 84.67 Favored Glycine 0 N--CA 1.437 -1.247 0 N-CA-C 115.055 0.782 . . . . 0.0 115.055 173.023 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -85.23 -36.37 20.99 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 176.142 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.6 tt -88.04 146.71 5.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 87.0 mm-40 -128.71 177.56 6.97 Favored 'General case' 0 N--CA 1.431 -1.377 0 C-N-CA 120.163 -0.615 . . . . 0.0 111.406 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 5.2 t -90.47 -9.99 10.29 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.774 0 CA-C-O 121.936 0.874 . . . . 0.0 109.46 -175.524 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -103.56 7.56 37.67 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.699 -176.615 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -83.25 -177.93 6.91 Favored 'General case' 0 C--O 1.247 0.954 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.537 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.426 ' O ' HG23 ' A' ' 91' ' ' ILE . 63.9 tt0 -133.32 128.3 35.41 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-N 115.112 -0.949 . . . . 0.0 108.746 -177.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.508 HG23 HG23 ' A' ' 63' ' ' VAL . 49.4 mm -76.83 109.99 11.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -176.165 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.677 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 88.1 t -92.64 -47.66 13.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 CA-C-O 121.242 0.544 . . . . 0.0 111.137 -176.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.532 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 38.7 tt0 -155.2 102.17 2.28 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-O 121.623 0.725 . . . . 0.0 110.541 -178.456 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.508 HG23 HG23 ' A' ' 60' ' ' ILE . 4.8 t -94.61 129.3 45.02 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 O-C-N 121.921 -0.487 . . . . 0.0 111.089 177.095 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 38.5 t70 65.32 11.72 7.52 Favored 'General case' 0 N--CA 1.487 1.394 0 CA-C-O 122.234 1.016 . . . . 0.0 111.55 172.369 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.35 15.47 78.31 Favored Glycine 0 N--CA 1.441 -1.026 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.084 -178.509 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.5 HD13 HG22 ' A' ' 79' ' ' VAL . 6.2 tt -76.41 -20.53 15.07 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.798 0 CA-C-O 121.215 0.531 . . . . 0.0 110.683 -177.694 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.529 ' H ' ' HG3' ' A' ' 62' ' ' GLU 0.267 13.1 p 47.97 76.48 0.11 Allowed 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 124.708 1.203 . . . . 0.0 113.879 -177.048 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.502 ' H ' HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -88.9 32.2 0.82 Allowed 'General case' 0 N--CA 1.432 -1.367 0 CA-C-N 114.432 -1.258 . . . . 0.0 111.287 -177.063 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 46.3 t -69.69 95.81 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 CA-C-N 114.799 -1.092 . . . . 0.0 110.385 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.416 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 105.44 19.74 10.24 Favored Glycine 0 C--N 1.31 -0.901 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.574 176.174 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.455 HG21 ' HB2' ' A' ' 68' ' ' LEU . 23.9 m -93.1 179.21 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 177.496 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.9 p -94.54 171.0 9.07 Favored 'General case' 0 N--CA 1.416 -2.163 0 CA-C-O 121.221 0.534 . . . . 0.0 110.349 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.51 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.17 -34.64 70.53 Favored 'General case' 0 C--N 1.294 -1.814 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.916 178.126 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.27 -36.97 74.75 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.332 -178.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.491 ' O ' HG23 ' A' ' 79' ' ' VAL . 45.9 t80 -66.99 -49.42 65.41 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.178 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.48 -45.58 93.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.758 -179.434 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -64.11 -16.84 62.67 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 120.915 0.388 . . . . 0.0 111.425 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 66.3 m -85.93 -44.81 12.08 Favored 'General case' 0 N--CA 1.426 -1.631 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.625 174.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.5 HG22 HD13 ' A' ' 66' ' ' ILE . 47.1 t -58.11 -51.5 70.15 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.627 0 N-CA-C 110.091 -0.336 . . . . 0.0 110.091 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -70.24 3.21 3.01 Favored 'General case' 0 CA--C 1.556 1.194 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.769 179.08 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 1.3 tmt_? -114.95 -17.76 11.43 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 123.373 0.669 . . . . 0.0 109.682 177.186 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -92.0 -7.46 48.83 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.279 0.632 . . . . 0.0 110.319 177.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.448 HG23 ' O ' ' A' ' 79' ' ' VAL . 2.5 p -64.5 161.48 17.21 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 115.061 -0.972 . . . . 0.0 113.444 -177.58 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 43.5 mmtm -113.42 -163.41 0.86 Allowed 'General case' 0 C--N 1.293 -1.875 0 CA-C-N 114.434 -1.257 . . . . 0.0 109.282 -178.066 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.87 -60.4 6.14 Favored Glycine 0 N--CA 1.424 -2.113 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 171.499 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -76.39 106.93 8.31 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-O 121.2 0.524 . . . . 0.0 110.168 177.057 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.0 t -121.87 132.36 71.05 Favored 'Isoleucine or valine' 0 CA--C 1.484 -1.571 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 -178.005 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 79.5 mtt180 -102.42 96.77 7.15 Favored 'General case' 0 C--N 1.283 -2.314 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 173.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.415 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 90.5 m-85 -87.35 102.53 14.61 Favored 'General case' 0 CA--C 1.491 -1.312 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 177.788 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.677 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.1 t -90.99 90.87 3.42 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.625 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 177.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.426 HG23 ' O ' ' A' ' 59' ' ' GLN . 86.2 mt -104.12 156.49 5.64 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.689 0 CA-C-N 114.248 -1.342 . . . . 0.0 108.189 179.094 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.65 166.81 22.89 Favored Glycine 0 N--CA 1.406 -3.344 0 C-N-CA 119.42 -1.371 . . . . 0.0 110.926 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 46.1 ttp180 -142.59 141.32 31.95 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 . . . . . 0 N--CA 1.431 -1.414 0 N-CA-C 106.087 -1.82 . . . . 0.0 106.087 170.204 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.503 -0.718 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 72.3 m-70 -103.54 104.16 14.19 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 117.228 0.514 . . . . 0.0 110.761 179.655 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 57.3 tpp -119.91 134.13 55.34 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -104.71 111.43 24.14 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.49 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.2 mm? -90.11 136.12 33.24 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.481 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 20.8 p90 -145.99 140.63 15.76 Favored Pre-proline 0 C--N 1.303 -1.421 0 CA-C-O 121.079 0.466 . . . . 0.0 112.141 -178.648 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -81.4 126.58 5.51 Favored 'Trans proline' 0 C--O 1.248 1.022 0 C-N-CA 123.29 2.66 . . . . 0.0 113.081 177.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.405 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 26.2 t -120.83 102.87 13.01 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 175.686 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 37.4 tt0 -84.24 105.98 15.5 Favored 'General case' 0 N--CA 1.427 -1.592 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.763 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.634 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 12.9 tp -89.91 155.08 19.37 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 -174.518 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -120.29 93.05 3.92 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 175.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.553 ' HG2' HD23 ' A' ' 10' ' ' LEU . 2.5 mmmp? -89.65 176.16 6.97 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 115.278 1.584 . . . . 0.0 115.278 -179.304 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -77.25 168.33 20.23 Favored 'General case' 0 N--CA 1.428 -1.547 0 CA-C-N 111.934 -2.393 . . . . 0.0 107.435 -179.275 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -74.01 -10.48 59.68 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-O 121.217 0.532 . . . . 0.0 110.967 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -63.55 -33.16 74.97 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 172.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.4 -130.87 9.08 Favored Glycine 0 N--CA 1.413 -2.897 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.009 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.509 ' HG ' HG23 ' A' ' 19' ' ' ILE . 13.7 tp -103.5 -61.51 1.41 Allowed 'General case' 0 C--N 1.285 -2.219 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 -177.8 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.462 ' O ' ' HB ' ' A' ' 43' ' ' THR . . . 71.32 37.85 62.88 Favored Glycine 0 N--CA 1.429 -1.786 0 O-C-N 124.284 0.99 . . . . 0.0 112.854 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.509 HG23 ' HG ' ' A' ' 17' ' ' LEU . 15.5 pt -107.95 167.51 3.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 118.949 -1.101 . . . . 0.0 111.435 176.382 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.3 m -117.08 148.54 41.43 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 -177.32 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -125.41 166.34 21.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -177.207 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 11.9 tt -130.35 132.15 65.03 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.877 0 C-N-CA 120.701 -0.4 . . . . 0.0 110.575 175.706 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.513 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.61 95.77 2.13 Favored Glycine 0 N--CA 1.424 -2.14 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.589 -178.58 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 95.1 mmm -109.3 173.72 6.19 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 176.676 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -130.31 61.74 0.66 Allowed Glycine 0 C--N 1.292 -1.916 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 177.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.43 HG12 ' HA2' ' A' ' 36' ' ' GLY . 10.7 p -69.17 133.4 31.93 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.394 0.616 . . . . 0.0 110.246 -177.523 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 78.06 0.45 76.35 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 115.848 -0.615 . . . . 0.0 113.277 178.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.49 -58.64 3.22 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 117.733 0.766 . . . . 0.0 110.517 -178.262 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -66.46 -29.96 70.2 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.515 178.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.64 -31.41 72.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.471 178.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 119.26 5.57 11.4 Favored Glycine 0 C--O 1.239 0.431 0 C-N-CA 119.389 -1.386 . . . . 0.0 114.851 176.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 4.4 mp -92.51 -47.82 6.94 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 117.386 0.593 . . . . 0.0 109.949 -178.662 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 60.01 82.86 0.15 Allowed 'General case' 0 C--O 1.248 1.001 0 C-N-CA 124.446 1.098 . . . . 0.0 111.081 -172.738 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 26.2 ttmt -128.41 176.26 7.86 Favored 'General case' 0 N--CA 1.385 -3.71 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 178.085 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.436 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.0 OUTLIER -68.74 147.65 51.5 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 120.806 0.336 . . . . 0.0 110.153 -178.718 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.43 ' HA2' HG12 ' A' ' 26' ' ' VAL . . . -124.07 25.13 6.15 Favored Glycine 0 N--CA 1.414 -2.771 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 174.135 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.513 HD13 ' HA2' ' A' ' 23' ' ' GLY . 33.4 mm -85.02 100.71 8.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 121.525 0.679 . . . . 0.0 109.524 -179.809 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -97.43 164.39 12.47 Favored 'General case' 0 C--N 1.278 -2.502 0 CA-C-N 115.252 -0.885 . . . . 0.0 108.917 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.565 ' HB ' ' O ' ' A' ' 56' ' ' VAL . 39.7 t -78.83 127.98 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.19 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 176.2 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 55.6 tptt -89.13 -44.13 10.55 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -178.429 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -161.18 162.82 31.42 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 89.1 t -127.35 152.52 35.49 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.167 0 N-CA-C 106.223 -1.769 . . . . 0.0 106.223 178.373 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.462 ' HB ' ' O ' ' A' ' 18' ' ' GLY . 10.6 t -63.6 143.63 57.67 Favored 'General case' 0 N--CA 1.428 -1.557 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.648 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.451 ' HA ' ' OE1' ' A' ' 49' ' ' GLN . 34.7 tt0 -79.54 -52.44 8.01 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -176.269 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -104.29 64.61 0.34 Allowed Glycine 0 CA--C 1.455 -3.707 0 CA-C-N 114.556 -1.202 . . . . 0.0 110.889 -178.155 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -145.33 148.51 20.3 Favored Glycine 1 N--CA 1.366 -6.002 0 N-CA-C 105.569 -3.012 . . . . 0.0 105.569 172.589 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.458 ' HA ' ' CG ' ' A' ' 50' ' ' ARG . . . -58.73 0.87 0.07 Allowed 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 115.542 1.682 . . . . 0.0 115.542 -175.63 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.97 -50.38 16.86 Favored 'General case' 0 C--O 1.215 -0.728 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.451 ' OE1' ' HA ' ' A' ' 44' ' ' GLU . 96.3 mt-30 -80.54 -3.59 50.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 120.285 -0.566 . . . . 0.0 111.101 176.5 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.458 ' CG ' ' HA ' ' A' ' 47' ' ' ALA . 36.1 mmt180 -82.65 -39.09 22.56 Favored 'General case' 0 CA--C 1.507 -0.691 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 171.283 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -53.83 -60.42 3.35 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 114.856 -1.065 . . . . 0.0 112.088 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.48 -17.56 56.55 Favored Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 120.316 -0.945 . . . . 0.0 114.353 175.057 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.432 ' HE ' ' C ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -88.69 -46.77 8.75 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.68 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.0 tt -73.67 145.13 11.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.171 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLN . . . . . 0.419 ' HB2' ' OD1' ' A' ' 58' ' ' ASP . 35.6 mt-30 -138.79 -172.66 3.36 Favored 'General case' 0 C--N 1.316 -0.868 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.843 -176.26 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.565 ' O ' ' HB ' ' A' ' 39' ' ' VAL . 49.0 t -93.22 -34.55 5.94 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.104 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.413 -178.258 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -92.24 20.67 5.79 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -174.118 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.419 ' OD1' ' HB2' ' A' ' 55' ' ' GLN . 4.2 m-20 -101.75 -172.9 2.23 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.967 177.326 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.467 ' O ' HG23 ' A' ' 91' ' ' ILE . 63.7 tt0 -128.54 126.51 40.52 Favored 'General case' 0 C--N 1.313 -0.995 0 O-C-N 122.089 -0.382 . . . . 0.0 111.328 -175.137 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.526 ' HA ' HG12 ' A' ' 91' ' ' ILE . 48.2 mm -74.93 104.36 3.27 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.016 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.749 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.2 t -91.41 -50.15 12.85 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-O 121.694 0.759 . . . . 0.0 111.315 -175.166 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.528 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 32.1 tt0 -149.0 105.74 3.56 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.398 0.618 . . . . 0.0 110.226 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.433 HG23 HG23 ' A' ' 60' ' ' ILE . 3.0 t -98.02 126.98 50.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.146 177.398 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 26.9 t70 71.42 -9.96 0.86 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 125.599 1.56 . . . . 0.0 112.702 173.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 103.61 12.96 29.21 Favored Glycine 0 N--CA 1.424 -2.151 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.126 -175.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.569 HD13 HG22 ' A' ' 79' ' ' VAL . 11.0 tt -72.98 -18.07 18.24 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-O 121.077 0.465 . . . . 0.0 111.198 -178.56 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.511 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 29.6 p 50.87 81.41 0.07 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.985 1.314 . . . . 0.0 112.92 -175.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.489 HD21 HG22 ' A' ' 60' ' ' ILE . 1.8 pp -96.12 14.91 22.33 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-O 122.092 0.948 . . . . 0.0 109.94 -176.114 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 61.2 t -57.62 98.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.427 174.253 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.436 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 103.51 35.03 3.68 Favored Glycine 0 N--CA 1.438 -1.223 0 CA-C-N 115.54 -0.754 . . . . 0.0 112.457 176.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.438 HG22 ' O ' ' A' ' 68' ' ' LEU . 20.6 m -115.02 177.55 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 117.14 0.47 . . . . 0.0 111.221 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 12.9 p -91.31 172.56 8.45 Favored 'General case' 0 N--CA 1.433 -1.318 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.605 178.609 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.445 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 2.4 pm0 -65.37 -32.04 73.47 Favored 'General case' 0 C--O 1.205 -1.24 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.232 -178.638 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -71.58 -35.4 70.53 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 120.861 -0.336 . . . . 0.0 110.985 -178.192 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.493 ' O ' HG23 ' A' ' 79' ' ' VAL . 29.7 t80 -65.86 -52.19 52.39 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 176.472 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.83 -46.27 89.79 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.135 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.04 -33.96 69.56 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.795 0.331 . . . . 0.0 110.73 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 97.8 m -68.07 -45.57 73.46 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.069 176.29 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.569 HG22 HD13 ' A' ' 66' ' ' ILE . 32.7 t -61.56 -51.85 67.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 C-N-CA 122.632 0.373 . . . . 0.0 110.902 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.408 HD21 HG21 ' A' ' 60' ' ' ILE . 3.4 mm? -68.52 -4.57 15.59 Favored 'General case' 0 CA--C 1.542 0.65 0 CA-C-O 121.237 0.541 . . . . 0.0 112.364 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.403 ' HD3' ' C ' ' A' ' 81' ' ' ARG . 0.7 OUTLIER -99.73 -32.52 11.0 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.218 0.533 . . . . 0.0 109.796 172.868 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 8.7 m-80 -80.13 6.68 10.99 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 121.794 0.807 . . . . 0.0 111.856 -178.09 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.0 p -70.61 170.21 12.69 Favored 'General case' 0 N--CA 1.408 -2.551 0 CA-C-N 114.536 -1.211 . . . . 0.0 111.562 175.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.436 ' HE3' ' O ' ' A' ' 86' ' ' ASN . 0.0 OUTLIER -147.81 -161.3 1.31 Allowed 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 124.898 1.279 . . . . 0.0 107.831 -175.036 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -55.88 -75.15 0.26 Allowed Glycine 0 CA--C 1.525 0.696 0 O-C-N 123.524 0.515 . . . . 0.0 114.016 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.634 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.5 m120 -88.79 105.93 18.03 Favored 'General case' 0 CA--C 1.497 -1.061 0 CA-C-N 117.637 0.718 . . . . 0.0 111.482 -177.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.513 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.9 t -116.22 136.29 53.68 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.09 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.994 -175.628 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 46.8 mtp180 -92.89 99.97 12.52 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 175.379 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.503 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 97.3 m-85 -92.38 103.26 15.72 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 176.597 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.749 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 40.3 t -92.45 86.52 2.28 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.858 0 N-CA-C 104.984 -2.228 . . . . 0.0 104.984 175.402 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.526 HG12 ' HA ' ' A' ' 60' ' ' ILE . 64.1 mt -101.25 159.11 4.05 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 CA-C-N 113.989 -1.46 . . . . 0.0 109.174 -179.2 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.49 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -130.61 158.04 22.36 Favored Glycine 1 N--CA 1.385 -4.724 0 C-N-CA 119.85 -1.167 . . . . 0.0 110.329 176.83 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 4.9 tpp180 -133.31 138.79 46.54 Favored 'General case' 0 C--N 1.286 -2.154 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 . . . . . 0 N--CA 1.416 -2.167 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.051 174.098 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.289 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 39.6 m-70 69.53 102.64 0.06 Allowed 'General case' 0 CA--C 1.503 -0.844 0 C-N-CA 124.373 1.069 . . . . 0.0 113.354 -178.069 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 25.3 ttt 68.92 115.45 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 O-C-N 124.614 1.196 . . . . 0.0 112.361 176.317 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.431 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 32.0 tt0 -92.45 108.72 20.18 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.567 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -88.14 126.99 35.41 Favored 'General case' 0 C--O 1.249 1.052 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -138.97 142.73 34.45 Favored Pre-proline 0 C--N 1.306 -1.316 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -176.407 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -79.27 125.85 6.62 Favored 'Trans proline' 0 C--O 1.25 1.122 0 C-N-CA 122.929 2.419 . . . . 0.0 113.357 177.344 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.44 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 46.5 t -118.71 105.2 17.23 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 174.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -88.71 102.45 15.0 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.536 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 15.3 tp -90.94 153.13 20.4 Favored 'General case' 0 N--CA 1.422 -1.827 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 -176.107 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -125.39 78.41 1.72 Allowed 'General case' 0 C--N 1.289 -2.049 0 CA-C-O 122.062 0.934 . . . . 0.0 108.757 177.014 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.674 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 5.5 mmtt -68.92 -169.72 0.19 Allowed 'General case' 0 N--CA 1.402 -2.842 0 CA-C-N 113.56 -1.654 . . . . 0.0 113.047 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.478 ' H ' ' HD2' ' A' ' 12' ' ' LYS . 9.1 m-20 -91.79 176.37 6.55 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 124.619 1.168 . . . . 0.0 108.346 -174.231 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -63.61 -22.46 66.91 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -176.339 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -72.0 -32.53 67.29 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.62 0.724 . . . . 0.0 110.151 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.404 ' O ' ' HD2' ' A' ' 12' ' ' LYS . . . 108.82 -140.07 15.45 Favored Glycine 0 N--CA 1.414 -2.831 0 N-CA-C 107.49 -2.244 . . . . 0.0 107.49 -173.21 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.51 ' HB3' HG23 ' A' ' 19' ' ' ILE . 14.7 mt -91.18 -60.9 1.78 Allowed 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.208 179.292 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.58 33.92 60.45 Favored Glycine 0 N--CA 1.424 -2.117 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -173.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.51 HG23 ' HB3' ' A' ' 17' ' ' LEU . 30.6 pt -96.56 177.78 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 C-N-CA 120.369 -0.532 . . . . 0.0 111.018 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.4 m -120.4 150.11 41.3 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 115.252 -0.885 . . . . 0.0 109.092 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.465 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -125.84 162.98 28.17 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 -179.038 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.8 tt -136.13 126.31 41.1 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.256 176.335 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.578 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -85.37 104.95 2.86 Favored Glycine 0 N--CA 1.435 -1.38 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.657 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.583 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 89.6 mmm -120.98 88.92 3.03 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -56.11 112.09 3.0 Favored Glycine 0 C--N 1.314 -0.689 0 O-C-N 123.918 0.761 . . . . 0.0 112.528 -177.622 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.8 p -111.76 38.09 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 CA-C-O 123.284 1.516 . . . . 0.0 108.239 -178.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -62.09 130.87 45.07 Favored Glycine 0 N--CA 1.442 -0.922 0 CA-C-N 113.612 -1.631 . . . . 0.0 112.313 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.417 ' HA ' ' HG2' ' A' ' 33' ' ' GLU . . . 71.64 -47.2 0.66 Allowed 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 126.104 1.761 . . . . 0.0 113.679 179.831 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -73.13 5.57 3.36 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -176.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.31 -12.37 21.6 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 173.52 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 81.77 -53.24 4.69 Favored Glycine 0 C--N 1.335 0.481 0 CA-C-O 121.952 0.751 . . . . 0.0 111.342 -177.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.2 mp -78.2 -25.5 47.1 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 114.512 -0.844 . . . . 0.0 110.399 -179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.417 ' HG2' ' HA ' ' A' ' 28' ' ' ALA . 39.8 mt-10 55.85 92.12 0.03 OUTLIER 'General case' 0 C--N 1.349 0.567 0 C-N-CA 123.989 0.916 . . . . 0.0 111.261 -170.485 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.471 ' HD3' ' H ' ' A' ' 34' ' ' LYS . 0.1 OUTLIER -134.06 -176.02 4.05 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 177.855 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.49 HD12 ' HB ' ' A' ' 37' ' ' ILE . 1.1 pt? -58.97 161.01 5.34 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 124.136 0.897 . . . . 0.0 111.122 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.583 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -122.07 26.6 6.39 Favored Glycine 0 N--CA 1.417 -2.609 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 173.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.578 HD13 ' HA2' ' A' ' 23' ' ' GLY . 17.9 mm -85.36 101.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 121.547 0.689 . . . . 0.0 109.981 -178.743 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -95.12 161.93 13.92 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.315 179.26 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -77.6 122.85 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.202 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -85.54 -49.79 7.76 Favored 'General case' 0 C--N 1.291 -1.96 0 CA-C-O 121.333 0.587 . . . . 0.0 110.501 -177.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.434 ' O ' ' HB ' ' A' ' 19' ' ' ILE . 0.7 OUTLIER -150.84 156.49 41.34 Favored 'General case' 0 N--CA 1.421 -1.876 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.59 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 64.8 t -125.88 145.96 32.45 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.431 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 176.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 8.4 t -56.84 147.99 21.92 Favored 'General case' 0 C--O 1.253 1.289 0 O-C-N 123.556 0.535 . . . . 0.0 109.773 176.019 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -43.83 -68.62 0.18 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 126.73 2.012 . . . . 0.0 115.126 -169.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -154.35 53.17 0.45 Allowed Glycine 0 CA--C 1.471 -2.701 0 C-N-CA 118.828 -1.653 . . . . 0.0 113.756 -174.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -94.83 -165.26 35.66 Favored Glycine 1 N--CA 1.386 -4.664 0 N-CA-C 107.298 -2.321 . . . . 0.0 107.298 169.661 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.674 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . -74.82 33.54 0.1 Allowed 'General case' 0 C--N 1.27 -2.849 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -173.122 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.403 ' HA ' HD21 ' A' ' 10' ' ' LEU . . . -116.56 -65.56 1.17 Allowed 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 174.727 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -74.09 -26.06 60.15 Favored 'General case' 0 N--CA 1.464 0.239 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.111 175.516 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.561 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 2.0 mmp_? -69.09 -26.94 65.18 Favored 'General case' 0 CA--C 1.503 -0.828 0 CA-C-O 121.053 0.454 . . . . 0.0 110.058 173.128 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -73.74 -57.18 4.16 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 178.347 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.09 -20.73 48.79 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.505 -0.855 . . . . 0.0 114.262 174.68 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.52 ' O ' ' HD3' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -73.66 -22.86 59.83 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-O 121.648 0.737 . . . . 0.0 109.114 -177.757 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.8 tt -104.85 148.98 8.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.709 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 26.7 mm-40 -129.54 165.98 20.6 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-O 121.168 0.509 . . . . 0.0 111.906 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -83.45 -8.94 11.49 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.892 0 CA-C-O 122.166 0.984 . . . . 0.0 108.621 176.195 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -102.43 16.85 25.1 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 122.286 1.041 . . . . 0.0 109.443 -175.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -102.05 -179.62 4.05 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.009 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.493 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 33.4 tt0 -128.72 124.96 36.93 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.477 HG22 HD11 ' A' ' 68' ' ' LEU . 46.1 mm -76.36 95.39 1.24 Allowed 'Isoleucine or valine' 0 C--O 1.206 -1.192 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 -176.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.697 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 60.6 t -79.42 -42.09 22.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 CA-C-O 121.59 0.71 . . . . 0.0 111.159 -175.158 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.562 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 36.8 tt0 -151.07 131.14 13.44 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.401 HG23 ' CG2' ' A' ' 60' ' ' ILE . 4.0 t -123.51 126.05 72.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 172.889 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 24.3 t70 69.47 5.47 5.18 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-O 122.356 1.074 . . . . 0.0 111.804 172.569 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.99 13.3 62.44 Favored Glycine 0 N--CA 1.434 -1.493 0 CA-C-N 115.362 -0.836 . . . . 0.0 111.624 -176.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.405 HD13 HG22 ' A' ' 79' ' ' VAL . 7.2 tt -77.34 -16.73 14.41 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.774 0 O-C-N 122.793 -0.239 . . . . 0.0 110.44 -178.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.467 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 8.6 m 39.74 80.67 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.985 1.714 . . . . 0.0 112.7 -176.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.498 ' CD1' ' H ' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -89.53 31.82 0.9 Allowed 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 122.216 1.007 . . . . 0.0 111.959 -175.606 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 47.8 t -70.52 106.16 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.075 0 CA-C-N 115.199 -0.91 . . . . 0.0 109.288 178.635 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.93 15.89 20.81 Favored Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.913 176.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.444 HG22 ' O ' ' A' ' 68' ' ' LEU . 19.1 m -96.63 175.83 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.973 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.711 178.434 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 8.4 p -91.54 172.86 8.22 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.99 178.119 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.465 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 3.2 pm0 -61.24 -33.65 73.86 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.509 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -73.09 -33.05 65.38 Favored 'General case' 0 CA--C 1.512 -0.507 0 C-N-CA 121.072 -0.251 . . . . 0.0 111.568 -176.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 33.4 t80 -69.94 -49.71 49.14 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -58.1 -49.22 77.7 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.516 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -55.87 -36.7 67.89 Favored 'General case' 0 C--O 1.216 -0.682 0 C-N-CA 122.467 0.307 . . . . 0.0 110.957 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 86.9 m -63.39 -45.51 90.75 Favored 'General case' 0 CA--C 1.55 0.957 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.086 176.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.405 HG22 HD13 ' A' ' 66' ' ' ILE . 31.0 t -65.1 -49.92 76.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.663 0.268 . . . . 0.0 110.788 178.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -69.77 -4.87 21.83 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.224 0.61 . . . . 0.0 111.993 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.41 ' HB3' ' O ' ' A' ' 78' ' ' THR . 59.5 ttt180 -92.15 -46.62 7.67 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 124.055 0.942 . . . . 0.0 108.541 174.708 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -77.41 5.68 8.33 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.326 -1.306 . . . . 0.0 113.366 -174.322 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.476 ' OG1' ' HG ' ' A' ' 17' ' ' LEU . 16.8 p -63.45 154.19 32.97 Favored 'General case' 0 C--N 1.294 -1.806 0 C-N-CA 123.832 0.853 . . . . 0.0 112.711 176.543 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.0 mmtt -120.24 -161.92 0.91 Allowed 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 114.567 -1.197 . . . . 0.0 108.501 176.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.05 -68.03 1.89 Allowed Glycine 0 N--CA 1.444 -0.824 0 O-C-N 123.818 0.699 . . . . 0.0 111.901 176.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.536 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.7 m120 -83.06 118.57 23.63 Favored 'General case' 0 C--N 1.307 -1.268 0 O-C-N 122.244 -0.562 . . . . 0.0 110.635 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.442 HG21 HD21 ' A' ' 17' ' ' LEU . 4.4 t -130.75 130.0 64.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.504 -176.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 22.1 mtp180 -94.33 100.59 12.6 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-O 121.186 0.517 . . . . 0.0 110.917 174.689 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.496 ' HB3' HG13 ' A' ' 91' ' ' ILE . 89.0 m-85 -95.12 112.0 23.76 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 176.101 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.697 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 10.7 t -100.48 65.54 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.496 HG13 ' HB3' ' A' ' 89' ' ' PHE . 76.4 mt -77.14 153.8 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.516 0 CA-C-N 112.796 -2.002 . . . . 0.0 109.909 -177.683 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.567 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -131.07 149.3 19.15 Favored Glycine 1 N--CA 1.385 -4.709 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 177.386 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -111.25 133.0 53.92 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 -178.626 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 . . . . . 0 C--N 1.309 -1.185 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 177.968 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.498 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -92.7 161.67 14.46 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 175.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' MET . . . . . 0.408 ' O ' HD22 ' A' ' 5' ' ' LEU . 22.5 ttt -164.65 138.99 5.28 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 177.575 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -90.9 101.37 14.13 Favored 'General case' 0 C--N 1.294 -1.828 0 C-N-CA 119.396 -0.922 . . . . 0.0 108.898 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.527 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -87.86 125.17 34.33 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -132.02 140.66 38.81 Favored Pre-proline 0 C--N 1.287 -2.112 0 CA-C-O 121.461 0.648 . . . . 0.0 112.061 -176.286 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -83.11 125.85 4.18 Favored 'Trans proline' 0 C--N 1.301 -1.927 0 C-N-CA 122.535 2.157 . . . . 0.0 112.188 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.472 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 36.9 t -109.04 109.05 26.89 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.593 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 172.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.47 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 45.3 tt0 -92.89 103.23 15.58 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.51 HD21 ' HB2' ' A' ' 51' ' ' ASP . 0.5 OUTLIER -103.38 154.21 19.65 Favored 'General case' 0 N--CA 1.395 -3.182 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 -175.669 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.45 ' H ' HD23 ' A' ' 10' ' ' LEU . 42.2 tt0 -123.06 100.56 6.94 Favored 'General case' 0 N--CA 1.409 -2.483 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 177.651 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.65 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.3 mmmp? -92.48 178.92 5.67 Favored 'General case' 0 C--N 1.284 -2.282 0 CA-C-N 114.524 -1.217 . . . . 0.0 109.486 176.254 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.547 ' OD2' ' HG2' ' A' ' 14' ' ' GLU . 19.6 t70 -101.41 -160.01 0.77 Allowed 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -176.814 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.547 ' HG2' ' OD2' ' A' ' 13' ' ' ASP . 11.0 pt-20 -75.77 -13.08 60.29 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -171.305 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -71.07 -43.9 66.84 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.213 0.53 . . . . 0.0 110.254 177.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 125.1 -131.02 7.57 Favored Glycine 0 CA--C 1.481 -2.066 0 N-CA-C 108.28 -1.928 . . . . 0.0 108.28 -177.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 14.3 mt -100.7 -60.94 1.43 Allowed 'General case' 0 CA--C 1.476 -1.902 0 C-N-CA 119.012 -1.075 . . . . 0.0 109.462 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.12 29.94 39.65 Favored Glycine 0 N--CA 1.419 -2.472 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -174.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.435 HD11 HD12 ' A' ' 80' ' ' LEU . 24.5 pt -104.54 176.87 0.94 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.987 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.4 m -135.42 150.08 49.78 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 -177.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.588 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -120.16 166.02 15.0 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 C-N-CA 123.303 0.641 . . . . 0.0 110.098 -177.242 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 11.9 tt -140.94 127.93 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.014 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 174.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.51 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.57 109.48 3.81 Favored Glycine 0 CA--C 1.484 -1.869 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -177.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.626 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 88.7 mmm -125.99 92.92 3.69 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -56.74 97.9 0.06 OUTLIER Glycine 0 CA--C 1.52 0.397 0 N-CA-C 114.77 0.668 . . . . 0.0 114.77 -175.523 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.6 p -91.11 41.48 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 CA-C-O 123.18 1.467 . . . . 0.0 108.732 178.024 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.35 105.39 2.9 Favored Glycine 0 N--CA 1.432 -1.625 0 CA-C-N 114.367 -1.288 . . . . 0.0 110.904 -179.202 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.599 ' H ' ' HG3' ' A' ' 33' ' ' GLU . . . 68.44 66.09 0.32 Allowed 'General case' 0 CA--C 1.493 -1.232 0 C-N-CA 125.016 1.326 . . . . 0.0 109.766 -178.847 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -134.81 -64.63 0.66 Allowed 'General case' 0 N--CA 1.428 -1.538 0 CA-C-N 114.578 -1.192 . . . . 0.0 111.47 -174.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.36 9.94 7.3 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 -171.147 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.27 -7.93 48.07 Favored Glycine 0 CA--C 1.502 -0.721 0 C-N-CA 119.194 -1.479 . . . . 0.0 112.505 178.326 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.4 mp -80.61 -46.34 15.84 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.599 ' HG3' ' H ' ' A' ' 28' ' ' ALA . 0.4 OUTLIER 40.27 70.63 0.23 Allowed 'General case' 0 C--N 1.348 0.517 0 C-N-CA 124.871 1.268 . . . . 0.0 113.616 178.05 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 17.8 ptmt -160.02 -163.42 1.13 Allowed 'General case' 0 N--CA 1.424 -1.751 0 CA-C-N 115.158 -0.928 . . . . 0.0 108.94 -174.238 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.489 HD12 ' H ' ' A' ' 37' ' ' ILE . 2.3 pp -56.95 150.54 16.53 Favored 'General case' 0 N--CA 1.44 -0.927 0 O-C-N 124.175 0.922 . . . . 0.0 109.183 174.406 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.626 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -121.98 30.62 5.21 Favored Glycine 0 N--CA 1.422 -2.281 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.75 178.505 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.51 HD13 ' HA2' ' A' ' 23' ' ' GLY . 23.5 mm -82.25 103.65 9.74 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 CA-C-O 121.847 0.832 . . . . 0.0 110.537 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -99.32 164.33 12.16 Favored 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.0 t -82.6 131.04 34.69 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.484 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 177.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.556 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.4 OUTLIER -91.7 -45.39 8.47 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.137 0.494 . . . . 0.0 109.832 -178.692 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.0 m -154.66 162.24 41.21 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -127.11 160.98 35.13 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.15 0 N-CA-C 105.363 -2.088 . . . . 0.0 105.363 178.454 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.6 t -72.51 146.21 46.96 Favored 'General case' 0 C--N 1.293 -1.883 0 CA-C-O 121.908 0.861 . . . . 0.0 111.007 -178.599 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -102.78 -0.33 31.64 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-O 123.742 1.734 . . . . 0.0 107.305 176.388 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -70.28 -30.27 69.54 Favored Glycine 0 C--N 1.294 -1.776 0 CA-C-N 112.541 -2.118 . . . . 0.0 114.467 -177.486 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 142.81 150.63 5.34 Favored Glycine 0 N--CA 1.426 -2.031 0 C-N-CA 119.351 -1.404 . . . . 0.0 113.217 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.65 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . 73.92 -34.86 0.29 Allowed 'General case' 0 C--N 1.311 -1.088 0 C-N-CA 126.822 2.049 . . . . 0.0 115.685 171.345 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.455 ' HB2' ' CE ' ' A' ' 12' ' ' LYS . . . -82.38 -56.79 3.68 Favored 'General case' 0 N--CA 1.488 1.461 0 CA-C-N 118.974 0.806 . . . . 0.0 110.91 -176.515 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -73.9 -16.99 61.09 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.561 0.696 . . . . 0.0 110.45 177.055 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.508 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 3.9 mmp_? -83.14 -17.03 44.42 Favored 'General case' 0 N--CA 1.432 -1.353 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.092 174.073 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.51 ' HB2' HD21 ' A' ' 10' ' ' LEU . 11.7 t70 -61.43 -61.75 2.32 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.964 0.411 . . . . 0.0 109.987 173.584 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.92 -9.86 74.75 Favored Glycine 0 N--CA 1.44 -1.073 0 C-N-CA 120.575 -0.821 . . . . 0.0 114.849 173.408 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -89.35 -45.35 9.55 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 178.856 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.7 tt -74.9 150.51 6.96 Favored 'Isoleucine or valine' 0 C--O 1.252 1.225 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 176.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -134.87 160.35 38.51 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.162 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.7 p -73.27 -17.0 17.7 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.139 0 CA-C-O 121.79 0.805 . . . . 0.0 109.743 176.492 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -90.32 -6.37 55.16 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.389 -173.327 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -95.07 -176.12 3.73 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 113.249 0.833 . . . . 0.0 113.249 -174.231 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.503 ' O ' HG23 ' A' ' 91' ' ' ILE . 32.4 tt0 -116.99 127.43 54.18 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.102 -174.365 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.521 HG23 HG23 ' A' ' 63' ' ' VAL . 50.4 mm -73.4 105.57 2.87 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.627 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.644 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 97.9 t -90.04 -49.46 13.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 CA-C-O 121.664 0.745 . . . . 0.0 111.008 -176.006 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.516 ' HG3' ' H ' ' A' ' 67' ' ' SER . 37.4 tt0 -151.99 104.15 2.96 Favored 'General case' 0 C--N 1.296 -1.751 0 CA-C-O 121.518 0.675 . . . . 0.0 109.834 -178.181 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.521 HG23 HG23 ' A' ' 60' ' ' ILE . 3.8 t -91.75 123.04 43.73 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.061 0 CA-C-O 121.322 0.582 . . . . 0.0 111.717 176.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 24.5 t70 65.86 4.66 3.05 Favored 'General case' 0 C--N 1.311 -1.067 0 C-N-CA 126.813 2.045 . . . . 0.0 112.769 174.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.98 12.34 57.84 Favored Glycine 0 N--CA 1.429 -1.771 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.613 -177.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.469 HD13 HG22 ' A' ' 79' ' ' VAL . 9.6 tt -73.01 -17.8 18.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-O 121.185 0.517 . . . . 0.0 110.408 -179.294 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.516 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 9.7 p 49.69 82.83 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 124.826 1.25 . . . . 0.0 113.259 -176.531 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.536 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.8 pp -93.03 14.43 17.78 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.572 -177.42 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.41 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 58.6 t -57.75 102.5 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.5 176.315 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.467 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 113.62 -5.25 24.54 Favored Glycine 0 N--CA 1.442 -0.941 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.433 176.198 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.536 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.5 m -83.98 178.15 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.247 0.925 0 CA-C-O 121.245 0.545 . . . . 0.0 111.69 -175.849 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.4 p -101.12 170.53 8.2 Favored 'General case' 0 N--CA 1.415 -2.18 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.116 176.778 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.588 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -56.13 -33.5 65.21 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-N 114.51 -1.223 . . . . 0.0 112.256 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -74.4 -22.36 59.2 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 111.744 0.275 . . . . 0.0 111.744 -177.664 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.426 ' O ' ' HB ' ' A' ' 78' ' ' THR . 38.6 t80 -80.85 -50.14 10.17 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 174.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.64 -47.99 80.71 Favored 'General case' 0 C--O 1.22 -0.459 0 CA-C-N 114.719 -1.128 . . . . 0.0 112.12 -178.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -56.74 -33.22 66.34 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 120.89 0.376 . . . . 0.0 110.687 179.024 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.426 ' HB ' ' O ' ' A' ' 75' ' ' PHE . 53.0 m -68.62 -47.15 67.4 Favored 'General case' 0 N--CA 1.435 -1.205 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.904 176.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.469 HG22 HD13 ' A' ' 66' ' ' ILE . 44.3 t -58.82 -50.27 79.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 110.097 -0.335 . . . . 0.0 110.097 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.435 HD12 HD11 ' A' ' 19' ' ' ILE . 3.6 mm? -67.67 -10.62 53.93 Favored 'General case' 0 CA--C 1.551 1.014 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.681 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 81' ' ' ARG . 0.8 OUTLIER -97.7 -23.05 16.11 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.256 0.551 . . . . 0.0 110.43 176.082 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -83.84 -23.18 31.47 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.092 179.447 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.4 p -63.99 156.62 27.42 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 113.646 0.98 . . . . 0.0 113.646 -178.427 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.75 -145.97 0.36 Allowed 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 114.685 -1.143 . . . . 0.0 109.764 -176.424 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.8 -67.64 1.91 Allowed Glycine 0 C--N 1.295 -1.719 0 O-C-N 123.671 0.607 . . . . 0.0 112.603 -177.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -77.25 109.73 11.37 Favored 'General case' 0 CA--C 1.497 -1.079 0 C-N-CA 119.937 -0.705 . . . . 0.0 110.118 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -124.09 144.53 33.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.82 98.26 7.78 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 173.396 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.472 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 86.5 m-85 -90.42 98.4 11.75 Favored 'General case' 0 C--N 1.279 -2.498 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 178.134 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.644 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 58.9 t -89.3 91.8 3.77 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.433 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 178.168 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.503 HG23 ' O ' ' A' ' 59' ' ' GLN . 81.6 mt -106.52 156.67 7.04 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.073 0 CA-C-N 114.0 -1.454 . . . . 0.0 108.096 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.527 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -134.25 164.47 24.53 Favored Glycine 1 N--CA 1.393 -4.182 0 C-N-CA 119.566 -1.302 . . . . 0.0 109.931 178.595 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -149.46 131.06 14.91 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . 0.26 0.0 OUTLIER . . . . . 0 N--CA 1.411 -2.377 0 CA-C-O 118.436 -0.792 . . . . 0.0 110.671 175.218 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.428 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 36.6 t60 68.59 138.73 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.682 1.193 . . . . 0.0 109.827 -175.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' MET . . . . . 0.419 ' O ' HD22 ' A' ' 5' ' ' LEU . 24.8 ttt -84.75 103.79 14.15 Favored 'General case' 0 N--CA 1.427 -1.595 0 C-N-CA 119.142 -1.023 . . . . 0.0 109.472 -179.319 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -79.86 104.56 10.52 Favored 'General case' 0 C--N 1.295 -1.801 0 CA-C-N 114.792 -1.094 . . . . 0.0 108.597 -179.211 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.42 HD12 HG21 ' A' ' 61' ' ' VAL . 1.8 mm? -81.73 130.55 35.1 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 178.628 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -137.11 141.53 34.84 Favored Pre-proline 0 C--N 1.284 -2.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.324 -179.16 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -77.89 128.71 9.4 Favored 'Trans proline' 0 N--CA 1.443 -1.474 0 C-N-CA 122.368 2.046 . . . . 0.0 112.418 178.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.416 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 21.7 t -119.11 94.99 3.34 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.258 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 174.508 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.512 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 40.7 tt0 -78.33 112.44 15.34 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 175.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -97.43 123.07 41.15 Favored 'General case' 0 N--CA 1.405 -2.701 0 N-CA-C 105.444 -2.058 . . . . 0.0 105.444 178.617 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.456 ' HG3' ' OD1' ' A' ' 86' ' ' ASN . 30.9 tt0 -94.44 90.45 6.23 Favored 'General case' 0 C--N 1.281 -2.373 0 CA-C-O 121.839 0.828 . . . . 0.0 109.005 179.786 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 2.8 mmmp? -93.82 -175.4 3.72 Favored 'General case' 0 N--CA 1.428 -1.563 0 CA-C-N 114.263 -1.335 . . . . 0.0 111.778 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.57 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.5 p-10 -88.27 -172.42 3.78 Favored 'General case' 0 C--N 1.28 -2.452 0 C-N-CA 126.8 2.04 . . . . 0.0 112.384 -177.386 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -77.45 -20.21 54.82 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 114.705 -1.134 . . . . 0.0 111.577 -179.458 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.57 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 18.8 t70 -73.95 -35.64 64.55 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 118.25 -124.58 6.11 Favored Glycine 0 CA--C 1.486 -1.747 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.661 172.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.525 ' HB3' HG23 ' A' ' 19' ' ' ILE . 31.7 mt -112.76 -54.54 2.61 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.1 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.55 27.51 69.32 Favored Glycine 0 N--CA 1.425 -2.062 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.818 -173.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.525 HG23 ' HB3' ' A' ' 17' ' ' LEU . 27.0 pt -94.67 176.32 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.26 -178.845 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 49.0 m -132.33 150.31 52.18 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.882 -178.702 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -120.05 159.89 20.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 15.4 tt -124.13 132.01 72.01 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 C-N-CA 120.063 -0.655 . . . . 0.0 110.045 175.741 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.539 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.82 92.45 1.78 Allowed Glycine 0 N--CA 1.427 -1.94 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.852 -177.503 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 91.8 mmm -108.26 -179.07 3.78 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -133.59 93.16 0.26 Allowed Glycine 0 C--N 1.284 -2.354 0 C-N-CA 120.087 -1.054 . . . . 0.0 112.333 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.433 HG12 ' HA2' ' A' ' 36' ' ' GLY . 11.1 p -97.68 75.21 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 123.601 1.667 . . . . 0.0 110.08 174.809 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.34 -164.52 15.53 Favored Glycine 0 N--CA 1.41 -3.058 0 CA-C-N 113.746 -1.57 . . . . 0.0 110.394 -178.429 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.52 ' H ' ' HG2' ' A' ' 33' ' ' GLU . . . 62.17 -83.57 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 125.125 1.37 . . . . 0.0 112.299 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -93.72 -12.5 29.08 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-O 122.409 1.1 . . . . 0.0 109.405 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.419 ' C ' ' H ' ' A' ' 32' ' ' LEU . . . -95.65 99.86 11.66 Favored 'General case' 0 N--CA 1.399 -2.98 0 N-CA-C 104.265 -2.495 . . . . 0.0 104.265 174.712 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -45.59 20.34 0.0 OUTLIER Glycine 0 N--CA 1.497 2.755 0 C-N-CA 128.608 3.004 . . . . 0.0 118.972 -175.519 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' A' ' 30' ' ' ALA . 19.8 mt -106.13 -37.56 6.56 Favored 'General case' 0 C--N 1.278 -2.515 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.097 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.52 ' HG2' ' H ' ' A' ' 28' ' ' ALA . 44.2 mt-10 49.5 73.88 0.22 Allowed 'General case' 0 C--O 1.247 0.97 0 CA-C-N 115.128 -0.942 . . . . 0.0 113.508 -179.076 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 17.7 ptmt -154.52 -172.03 4.06 Favored 'General case' 0 N--CA 1.406 -2.662 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 -179.211 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.653 HD23 ' HA ' ' A' ' 69' ' ' VAL . 3.2 pp -63.02 152.35 37.17 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 124.31 1.006 . . . . 0.0 110.066 179.066 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.433 ' HA2' HG12 ' A' ' 26' ' ' VAL . . . -116.47 32.54 5.51 Favored Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 175.172 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.539 HD13 ' HA2' ' A' ' 23' ' ' GLY . 29.7 mm -81.31 103.87 9.01 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.867 0 CA-C-O 121.624 0.726 . . . . 0.0 110.14 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -102.21 160.16 14.76 Favored 'General case' 0 C--N 1.275 -2.645 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.296 176.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 40.5 t -74.32 123.97 30.84 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 175.293 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.405 ' HB2' ' HB ' ' A' ' 22' ' ' ILE . 53.5 tptt -89.29 -48.61 7.25 Favored 'General case' 0 C--N 1.293 -1.871 0 CA-C-O 121.118 0.485 . . . . 0.0 110.28 -176.762 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -150.25 159.15 44.65 Favored 'General case' 0 N--CA 1.422 -1.874 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -177.401 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.517 HG11 ' HG3' ' A' ' 49' ' ' GLN . 23.3 t -121.24 174.16 6.17 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.522 0 N-CA-C 104.894 -2.261 . . . . 0.0 104.894 175.296 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.413 ' N ' HG12 ' A' ' 42' ' ' VAL . 3.2 t -61.07 178.23 0.27 Allowed 'General case' 0 CA--C 1.561 1.377 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 173.831 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -56.01 -31.09 62.77 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 124.065 0.946 . . . . 0.0 110.251 176.771 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -169.64 -73.87 0.04 OUTLIER Glycine 0 N--CA 1.402 -3.627 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.752 178.303 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 55.13 -177.51 0.42 Allowed Glycine 1 N--CA 1.382 -4.931 0 CA-C-O 123.398 1.554 . . . . 0.0 113.003 -173.163 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.434 ' O ' ' HB2' ' A' ' 51' ' ' ASP . . . -71.26 -4.93 28.5 Favored 'General case' 1 C--N 1.237 -4.291 0 CA-C-N 113.398 -1.401 . . . . 0.0 109.977 172.445 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.57 -60.11 2.44 Favored 'General case' 0 C--N 1.35 0.59 0 C-N-CA 123.551 0.74 . . . . 0.0 110.059 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.517 ' HG3' HG11 ' A' ' 42' ' ' VAL . 87.3 mt-30 -70.5 -27.46 64.22 Favored 'General case' 0 CA--C 1.511 -0.536 0 C-N-CA 120.14 -0.624 . . . . 0.0 111.029 178.087 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -78.45 -19.5 53.01 Favored 'General case' 0 N--CA 1.44 -0.975 0 C-N-CA 120.04 -0.664 . . . . 0.0 111.778 175.822 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.434 ' HB2' ' O ' ' A' ' 47' ' ' ALA . 11.1 t70 -66.7 -64.01 0.94 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 172.058 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.89 -10.11 70.4 Favored Glycine 0 N--CA 1.44 -1.092 0 C-N-CA 120.557 -0.83 . . . . 0.0 115.13 173.561 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.08 -21.56 43.2 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -179.817 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.6 tt -105.05 164.59 3.91 Favored 'Isoleucine or valine' 0 C--O 1.254 1.305 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 175.164 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 63.1 mt-30 -136.17 -156.72 0.73 Allowed 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 119.033 0.833 . . . . 0.0 110.923 -177.552 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.2 p -123.94 18.21 4.77 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 174.343 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -132.91 -8.43 3.09 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.758 0.789 . . . . 0.0 111.206 -174.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.564 ' OD2' HD13 ' A' ' 91' ' ' ILE . 7.1 p-10 -83.18 179.24 7.78 Favored 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 124.571 1.148 . . . . 0.0 110.919 -177.357 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.46 ' O ' HG23 ' A' ' 91' ' ' ILE . 31.1 tt0 -119.76 126.08 50.18 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.087 -176.054 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.538 HG21 HD21 ' A' ' 80' ' ' LEU . 50.8 mm -74.36 114.71 14.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.089 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.701 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 84.7 t -98.37 -48.92 11.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.85 0.834 . . . . 0.0 111.022 -178.164 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.576 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 26.9 tt0 -150.28 114.88 5.23 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -178.614 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.48 HG23 HG23 ' A' ' 60' ' ' ILE . 3.4 t -110.1 128.13 66.51 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.821 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.589 178.905 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.7 t70 72.58 -8.84 1.15 Allowed 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 125.265 1.426 . . . . 0.0 112.348 175.376 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.83 13.43 31.98 Favored Glycine 0 C--N 1.286 -2.203 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.686 -174.546 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.4 tt -74.97 -17.44 16.2 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.498 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 17.4 m 45.83 84.56 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 125.659 1.584 . . . . 0.0 111.585 -176.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.535 HD21 HG22 ' A' ' 60' ' ' ILE . 0.7 OUTLIER -93.06 20.98 6.19 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.659 0.742 . . . . 0.0 110.671 -175.317 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.653 ' HA ' HD23 ' A' ' 35' ' ' LEU . 59.1 t -52.77 100.63 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 CA-C-N 114.691 -1.141 . . . . 0.0 111.77 177.474 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 94.59 21.7 25.89 Favored Glycine 0 N--CA 1.443 -0.844 0 CA-C-N 115.47 -0.786 . . . . 0.0 114.131 174.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.418 ' CG2' ' HB2' ' A' ' 68' ' ' LEU . 20.5 m -93.43 -178.66 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 117.497 0.649 . . . . 0.0 111.173 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.9 p -98.37 178.97 4.87 Favored 'General case' 0 C--O 1.251 1.146 0 CA-C-O 121.037 0.446 . . . . 0.0 110.377 177.591 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -66.92 -25.31 66.3 Favored 'General case' 0 C--O 1.204 -1.337 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.337 179.638 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 25.6 m-80 -63.02 -48.57 78.22 Favored 'General case' 0 CA--C 1.483 -1.603 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.183 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -68.61 -47.79 65.78 Favored 'General case' 0 N--CA 1.426 -1.633 0 CA-C-N 114.76 -1.109 . . . . 0.0 109.698 -175.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.438 ' HA ' HG12 ' A' ' 79' ' ' VAL . . . -62.94 -40.29 97.21 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.167 -178.738 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -69.08 -18.19 63.97 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.229 0.537 . . . . 0.0 110.426 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 83.3 m -84.01 -47.5 10.91 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.457 176.763 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.542 HG13 HD22 ' A' ' 80' ' ' LEU . 3.9 p -62.78 -48.6 87.36 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 N-CA-C 112.943 0.72 . . . . 0.0 112.943 177.323 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.542 HD22 HG13 ' A' ' 79' ' ' VAL . 3.9 mm? -67.2 -12.22 59.48 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.531 0.682 . . . . 0.0 112.056 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -84.47 -46.05 12.04 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 176.249 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -79.56 -11.09 59.89 Favored 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 114.388 1.255 . . . . 0.0 114.388 -171.188 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.434 HG23 ' O ' ' A' ' 79' ' ' VAL . 12.0 p -68.45 140.7 55.76 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -135.93 141.75 44.54 Favored 'General case' 0 CA--C 1.482 -1.659 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.096 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 47.67 -88.13 0.01 OUTLIER Glycine 0 CA--C 1.474 -2.508 0 O-C-N 126.039 2.087 . . . . 0.0 113.696 178.081 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.456 ' OD1' ' HG3' ' A' ' 11' ' ' GLU . 3.0 m-20 -97.94 102.0 13.63 Favored 'General case' 0 C--N 1.247 -3.849 0 CA-C-N 113.804 -1.198 . . . . 0.0 110.52 -173.283 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 40.2 t -113.15 124.82 70.16 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 CA-C-N 115.021 -0.991 . . . . 0.0 111.611 -173.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.59 104.18 16.61 Favored 'General case' 0 CA--C 1.49 -1.364 0 C-N-CA 120.204 -0.598 . . . . 0.0 109.944 174.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.416 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 90.9 m-85 -93.49 100.19 12.52 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 175.697 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.701 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.8 t -89.5 92.99 4.13 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.82 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 177.282 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.564 HD13 ' OD2' ' A' ' 58' ' ' ASP . 96.5 mt -108.62 163.84 5.79 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.375 0 C-N-CA 125.485 1.514 . . . . 0.0 107.494 179.486 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -133.75 159.82 23.83 Favored Glycine 0 N--CA 1.411 -2.97 0 C-N-CA 118.557 -1.782 . . . . 0.0 113.301 -177.146 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 35.5 ttt180 -114.32 137.41 51.84 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 123.321 0.648 . . . . 0.0 109.533 177.16 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? . . . . . 0 C--N 1.294 -1.834 0 CA-C-O 119.395 -0.336 . . . . 0.0 110.976 -178.445 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.359 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 32.4 m-70 -83.68 103.33 12.9 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-O 121.066 0.46 . . . . 0.0 110.732 176.469 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' MET . . . . . 0.537 ' SD ' ' HG3' ' A' ' 94' ' ' GLU . 57.3 tpp -70.42 127.47 32.84 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 177.221 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.473 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 35.2 tt0 -85.61 102.52 13.63 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 177.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -84.14 131.89 34.74 Favored 'General case' 0 CA--C 1.5 -0.963 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -140.58 138.5 18.73 Favored Pre-proline 0 N--CA 1.42 -1.971 0 CA-C-O 121.507 0.67 . . . . 0.0 112.012 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -81.47 124.27 4.64 Favored 'Trans proline' 0 C--N 1.314 -1.263 0 C-N-CA 122.856 2.37 . . . . 0.0 112.781 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.445 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 25.0 t -113.61 106.14 20.13 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 175.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.492 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 30.8 tt0 -89.64 109.13 20.11 Favored 'General case' 0 N--CA 1.416 -2.132 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 177.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -100.91 149.34 23.99 Favored 'General case' 0 C--N 1.289 -2.063 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 -176.689 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -120.44 93.03 3.91 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 171.726 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.491 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.0 mmmp? -82.73 172.86 12.43 Favored 'General case' 0 N--CA 1.421 -1.92 0 CA-C-O 122.63 1.205 . . . . 0.0 114.177 -179.046 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -72.78 171.23 13.03 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 112.077 -2.329 . . . . 0.0 108.564 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -68.83 -16.93 63.92 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.345 0.593 . . . . 0.0 110.373 178.521 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.05 -33.02 72.65 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 122.023 0.916 . . . . 0.0 109.986 174.462 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.59 -138.38 14.93 Favored Glycine 0 N--CA 1.41 -3.095 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.414 HD21 HG21 ' A' ' 87' ' ' VAL . 16.8 mt -89.46 -43.91 10.52 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 119.734 -0.786 . . . . 0.0 109.735 -179.445 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 66.64 28.0 73.52 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 124.547 1.155 . . . . 0.0 111.013 -174.23 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.475 HD11 HD12 ' A' ' 80' ' ' LEU . 20.7 pt -109.0 177.07 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.452 -178.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.0 m -138.64 153.81 48.61 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -177.427 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.411 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -122.39 166.72 16.76 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 -178.204 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 13.7 tt -135.08 133.57 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.79 0 C-N-CA 120.026 -0.67 . . . . 0.0 111.435 176.649 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.537 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -92.93 103.44 3.05 Favored Glycine 0 N--CA 1.413 -2.886 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 18.1 ptm -140.85 86.94 2.08 Favored 'General case' 0 C--N 1.288 -2.079 0 CA-C-O 121.584 0.707 . . . . 0.0 109.77 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -57.98 110.08 2.22 Favored Glycine 0 N--CA 1.44 -1.09 0 CA-C-N 114.066 -1.425 . . . . 0.0 112.966 -176.058 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.1 p -97.23 146.66 7.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -100.71 -151.9 25.65 Favored Glycine 0 N--CA 1.422 -2.291 0 C-N-CA 120.269 -0.967 . . . . 0.0 113.618 -177.748 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.431 ' CB ' ' HG2' ' A' ' 33' ' ' GLU . . . -90.7 -17.32 26.97 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.438 -0.881 . . . . 0.0 111.39 -177.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -66.44 -33.02 74.76 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 121.713 0.768 . . . . 0.0 110.171 -174.203 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -84.38 -5.1 59.24 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.403 -179.434 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 87.94 11.21 68.08 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.103 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.488 ' O ' ' HE3' ' A' ' 34' ' ' LYS . 4.0 mm? -88.81 -59.22 2.29 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 120.858 -0.337 . . . . 0.0 111.452 -179.208 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.431 ' HG2' ' CB ' ' A' ' 28' ' ' ALA . 40.1 mt-10 62.32 33.22 16.62 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.254 0.622 . . . . 0.0 111.669 177.05 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.488 ' HE3' ' O ' ' A' ' 32' ' ' LEU . 15.0 ptpt -155.02 -164.41 1.79 Allowed 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.814 -175.622 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.437 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 0.8 OUTLIER -48.8 150.02 1.6 Allowed 'General case' 0 C--O 1.24 0.597 0 C-N-CA 124.984 1.314 . . . . 0.0 112.6 179.457 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -120.02 47.43 1.03 Allowed Glycine 0 N--CA 1.413 -2.877 0 N-CA-C 109.961 -1.255 . . . . 0.0 109.961 175.423 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.584 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 28.9 mm -109.12 111.43 36.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 177.659 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -110.49 170.41 8.1 Favored 'General case' 0 C--N 1.269 -2.909 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.385 -178.406 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 38.9 t -83.47 128.21 39.0 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.076 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.748 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.574 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -92.92 -47.12 7.17 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 120.944 0.402 . . . . 0.0 110.165 -176.884 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.1 m -150.36 163.46 38.3 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 -178.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 61.0 t -136.38 148.4 27.29 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 N-CA-C 105.007 -2.22 . . . . 0.0 105.007 178.347 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.6 t -59.34 142.04 53.06 Favored 'General case' 0 C--O 1.251 1.176 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 175.277 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.542 ' HA ' ' NE2' ' A' ' 49' ' ' GLN . 12.0 pt-20 -82.77 -27.51 30.97 Favored 'General case' 0 C--N 1.277 -2.568 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.261 -175.65 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -137.42 70.8 0.48 Allowed Glycine 0 CA--C 1.471 -2.696 0 CA-C-O 122.1 0.833 . . . . 0.0 112.402 -175.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -150.42 170.21 30.34 Favored Glycine 1 N--CA 1.372 -5.583 0 N-CA-C 105.032 -3.227 . . . . 0.0 105.032 174.77 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.543 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -59.59 -3.66 0.51 Allowed 'General case' 0 C--N 1.277 -2.557 0 N-CA-C 114.825 1.417 . . . . 0.0 114.825 -176.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.43 -59.33 2.82 Favored 'General case' 0 C--O 1.219 -0.535 0 O-C-N 121.745 -0.597 . . . . 0.0 109.993 -176.588 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.542 ' NE2' ' HA ' ' A' ' 44' ' ' GLU . 41.2 mt-30 -74.34 -15.12 60.96 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.387 175.626 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.543 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 24.2 mmm180 -73.12 -34.02 65.88 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 172.219 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -59.53 -58.63 7.75 Favored 'General case' 0 N--CA 1.473 0.681 0 O-C-N 123.565 0.54 . . . . 0.0 109.813 173.254 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.82 -12.81 67.68 Favored Glycine 0 C--N 1.312 -0.782 0 C-N-CA 120.319 -0.943 . . . . 0.0 114.879 173.458 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 63.5 ttt180 -80.18 -40.77 26.59 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.09 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.4 tt -86.23 143.73 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.99 0 CA-C-N 114.335 -1.302 . . . . 0.0 107.857 179.031 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -138.5 175.85 9.21 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-O 121.258 0.551 . . . . 0.0 110.665 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.7 p -81.38 -3.25 6.57 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.49 -177.05 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -105.38 6.89 32.97 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.638 0.732 . . . . 0.0 110.545 -174.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -93.01 -173.66 3.34 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 115.186 -0.916 . . . . 0.0 111.08 -176.71 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.584 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 27.5 tt0 -131.86 127.45 36.56 Favored 'General case' 0 C--N 1.322 -0.608 0 C-N-CA 123.488 0.715 . . . . 0.0 111.001 -177.494 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.549 HG22 HD21 ' A' ' 68' ' ' LEU . 48.9 mm -77.21 106.45 7.29 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.852 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.45 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.72 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.1 t -89.18 -49.5 13.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-O 122.219 1.009 . . . . 0.0 110.116 -176.779 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.558 ' HG3' ' H ' ' A' ' 67' ' ' SER . 23.8 tt0 -148.64 126.84 12.13 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.496 179.225 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.431 HG23 HG23 ' A' ' 60' ' ' ILE . 2.7 t -118.37 127.69 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.641 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.118 176.216 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.9 t70 63.94 15.15 8.95 Favored 'General case' 0 N--CA 1.477 0.886 0 O-C-N 124.744 1.277 . . . . 0.0 111.081 173.558 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.93 17.32 67.83 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.855 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.437 HG21 HG21 ' A' ' 79' ' ' VAL . 6.1 tt -77.23 -18.68 14.34 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.156 0 CA-C-N 117.166 0.483 . . . . 0.0 111.283 -179.098 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.558 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 16.8 p 49.56 83.88 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.419 1.488 . . . . 0.0 113.126 -174.628 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.549 HD21 HG22 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.87 17.36 18.34 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.582 0.706 . . . . 0.0 110.805 -175.894 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 44.6 t -57.06 94.13 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.134 174.441 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.437 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 102.96 52.74 0.93 Allowed Glycine 0 N--CA 1.436 -1.355 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.866 178.29 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 23.5 m -130.05 178.71 4.93 Favored 'Isoleucine or valine' 0 C--O 1.243 0.723 0 CA-C-O 120.97 0.414 . . . . 0.0 111.107 178.519 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 15.5 p -98.31 174.61 6.41 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.425 178.336 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.411 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 1.4 pm0 -67.45 -27.38 66.99 Favored 'General case' 0 C--O 1.2 -1.541 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.395 -178.61 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -71.81 -30.87 65.96 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.064 -179.383 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -74.64 -48.39 26.57 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 176.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.429 ' HA ' HG12 ' A' ' 79' ' ' VAL . . . -61.72 -42.15 98.57 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.733 -179.115 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.1 -33.22 71.8 Favored 'General case' 0 C--O 1.204 -1.32 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 177.512 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 92.0 m -71.67 -48.7 45.8 Favored 'General case' 0 N--CA 1.434 -1.25 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.185 178.658 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.591 HG13 HD22 ' A' ' 80' ' ' LEU . 3.4 p -62.23 -45.59 98.4 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 178.713 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.591 HD22 HG13 ' A' ' 79' ' ' VAL . 3.8 mm? -70.68 -7.82 47.4 Favored 'General case' 0 CA--C 1.549 0.918 0 CA-C-O 121.053 0.454 . . . . 0.0 111.597 178.283 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.9 tmt_? -97.44 -28.12 14.14 Favored 'General case' 0 C--O 1.214 -0.799 0 C-N-CA 122.73 0.412 . . . . 0.0 110.773 176.747 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -84.92 -2.52 57.96 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -177.397 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.0 p -76.82 159.85 29.74 Favored 'General case' 0 C--N 1.288 -2.072 0 CA-C-O 121.655 0.741 . . . . 0.0 112.866 -177.424 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 33.2 mmtp -118.39 -162.51 0.89 Allowed 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 114.931 -1.031 . . . . 0.0 108.639 177.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -53.04 -62.71 5.69 Favored Glycine 0 C--O 1.217 -0.953 0 O-C-N 123.846 0.716 . . . . 0.0 113.228 174.258 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -79.16 115.2 18.67 Favored 'General case' 0 C--O 1.245 0.867 0 CA-C-N 117.597 0.699 . . . . 0.0 110.014 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.0 t -132.24 136.43 56.44 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.907 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.213 -177.712 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 65.2 mtp180 -99.2 99.71 10.72 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 171.843 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.445 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 95.9 m-85 -90.31 102.78 15.51 Favored 'General case' 0 CA--C 1.486 -1.493 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 175.34 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.72 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 47.5 t -93.65 87.28 2.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.694 0 N-CA-C 105.326 -2.102 . . . . 0.0 105.326 178.164 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.473 HG23 ' O ' ' A' ' 59' ' ' GLN . 76.9 mt -104.11 153.22 6.24 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.785 0 CA-C-N 113.684 -1.598 . . . . 0.0 109.223 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -126.08 155.74 19.37 Favored Glycine 1 N--CA 1.384 -4.778 0 N-CA-C 108.405 -1.878 . . . . 0.0 108.405 177.135 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 64.7 ttt-85 -141.03 137.48 32.98 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 119.169 -1.012 . . . . 0.0 112.83 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.537 ' HG3' ' SD ' ' A' ' 3' ' ' MET . 39.6 mt-10 . . . . . 0 C--N 1.311 -1.102 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 173.585 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.502 -0.722 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -70.43 102.28 2.15 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 26.1 ttt 71.47 118.86 0.04 OUTLIER 'General case' 0 C--N 1.342 0.281 0 C-N-CA 124.389 1.076 . . . . 0.0 111.19 -178.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.446 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 45.5 tt0 -85.26 106.47 16.7 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -178.511 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.462 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.7 mm? -85.54 130.98 34.45 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 176.844 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -138.79 142.41 33.83 Favored Pre-proline 0 C--N 1.288 -2.065 0 CA-C-O 121.214 0.531 . . . . 0.0 111.802 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -83.87 123.48 3.23 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.667 2.244 . . . . 0.0 112.732 177.21 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.4 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 40.2 t -114.65 105.38 18.55 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 174.316 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.487 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 27.6 tt0 -93.7 97.54 10.52 Favored 'General case' 0 N--CA 1.417 -2.121 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 -179.384 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.496 HD21 ' HB2' ' A' ' 51' ' ' ASP . 0.5 OUTLIER -87.67 158.36 18.86 Favored 'General case' 0 N--CA 1.397 -3.105 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -174.778 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.421 ' H ' HD23 ' A' ' 10' ' ' LEU . 48.1 tt0 -124.04 98.93 6.01 Favored 'General case' 0 C--N 1.274 -2.681 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.229 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 85' ' ' GLY . 2.3 mmmp? -100.73 -170.0 1.79 Allowed 'General case' 0 N--CA 1.409 -2.512 0 CA-C-N 114.518 -1.219 . . . . 0.0 112.696 -179.791 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.56 157.12 36.02 Favored 'General case' 0 N--CA 1.413 -2.312 0 CA-C-N 113.03 -1.896 . . . . 0.0 106.534 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -72.48 -8.95 57.75 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 121.438 0.637 . . . . 0.0 110.253 176.704 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -72.22 -38.47 68.97 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 175.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.59 -145.14 16.74 Favored Glycine 0 N--CA 1.42 -2.411 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.624 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.404 HD11 HG21 ' A' ' 83' ' ' THR . 18.3 mt -104.53 -46.47 4.35 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.44 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.85 29.7 37.82 Favored Glycine 0 N--CA 1.422 -2.242 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.874 -175.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.2 pt -102.42 -174.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 120.059 -0.656 . . . . 0.0 112.357 -177.293 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 21.8 m -135.66 153.04 51.75 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.589 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -126.63 164.99 25.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 123.393 0.677 . . . . 0.0 109.336 -177.539 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.9 tt -135.41 130.02 50.17 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-O 120.811 0.338 . . . . 0.0 110.487 175.062 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.505 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.33 107.28 3.32 Favored Glycine 0 N--CA 1.428 -1.861 0 C-N-CA 121.085 -0.578 . . . . 0.0 112.029 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.405 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.2 mmm -121.94 174.53 6.84 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.645 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.58 99.36 0.59 Allowed Glycine 0 C--N 1.29 -1.989 0 C-N-CA 119.418 -1.372 . . . . 0.0 112.171 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.0 p -96.63 91.9 2.89 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-O 122.723 1.249 . . . . 0.0 110.4 176.583 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.484 ' HA2' ' HA ' ' A' ' 33' ' ' GLU . . . -105.21 -116.81 4.26 Favored Glycine 0 N--CA 1.423 -2.213 0 CA-C-N 114.804 -1.089 . . . . 0.0 114.58 -174.194 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.97 -23.59 62.24 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 113.377 0.88 . . . . 0.0 113.377 -171.559 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -66.11 -28.14 68.58 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.476 0.655 . . . . 0.0 111.227 -177.757 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.2 -22.14 13.44 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.159 177.135 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.29 27.7 17.29 Favored Glycine 0 CA--C 1.494 -1.223 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -178.784 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.454 ' HB3' ' HG2' ' A' ' 34' ' ' LYS . 31.1 mt -109.75 -64.78 1.21 Allowed 'General case' 0 N--CA 1.423 -1.798 0 C-N-CA 120.051 -0.659 . . . . 0.0 111.541 -174.226 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.484 ' HA ' ' HA2' ' A' ' 27' ' ' GLY . 47.4 mt-10 65.93 35.21 6.65 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 122.414 1.102 . . . . 0.0 111.689 -178.485 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.454 ' HG2' ' HB3' ' A' ' 32' ' ' LEU . 2.5 ptpp? -111.48 -162.64 0.81 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-N 114.672 -1.149 . . . . 0.0 107.905 174.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.507 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.0 pp -57.56 145.67 32.8 Favored 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 123.904 0.882 . . . . 0.0 109.906 177.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -116.8 33.71 4.95 Favored Glycine 0 C--N 1.288 -2.103 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 173.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.522 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 26.3 mm -84.58 105.49 13.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 121.407 0.622 . . . . 0.0 110.337 -177.09 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -99.25 162.98 12.74 Favored 'General case' 0 C--N 1.279 -2.46 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 177.7 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.89 128.01 38.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.407 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.542 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -91.74 -39.07 12.02 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.303 0.573 . . . . 0.0 110.455 -177.049 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.7 m -159.65 161.0 34.9 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.441 HG11 ' HG3' ' A' ' 49' ' ' GLN . 17.5 t -117.62 167.73 10.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.216 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.9 t -68.86 -179.25 1.4 Allowed 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 123.044 0.538 . . . . 0.0 109.965 178.566 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -50.93 -64.29 0.86 Allowed 'General case' 0 C--O 1.225 -0.219 0 C-N-CA 124.112 0.965 . . . . 0.0 112.021 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.436 ' HA2' ' HB2' ' A' ' 49' ' ' GLN . . . 169.25 52.31 0.03 OUTLIER Glycine 0 N--CA 1.414 -2.802 0 C-N-CA 118.244 -1.931 . . . . 0.0 113.621 179.628 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.73 -149.01 15.95 Favored Glycine 0 N--CA 1.408 -3.215 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 170.699 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.462 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -58.44 -14.17 7.14 Favored 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 -172.241 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.55 -62.56 1.65 Allowed 'General case' 0 C--O 1.214 -0.807 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.441 ' HG3' HG11 ' A' ' 42' ' ' VAL . 27.4 mt-30 -72.73 -13.73 61.4 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.783 0.661 . . . . 0.0 112.783 176.208 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.462 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 27.4 mmt180 -81.17 -26.33 36.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 172.299 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.496 ' HB2' HD21 ' A' ' 10' ' ' LEU . 24.6 t70 -54.94 -57.55 11.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 123.743 0.652 . . . . 0.0 111.368 177.655 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.73 -13.15 56.48 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.225 -0.988 . . . . 0.0 114.352 175.322 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.579 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -93.74 -59.93 1.88 Allowed 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 118.082 0.941 . . . . 0.0 108.573 176.878 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.579 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 15.3 tt -64.29 143.67 15.47 Favored 'Isoleucine or valine' 0 C--O 1.246 0.893 0 O-C-N 123.707 0.63 . . . . 0.0 110.672 -175.743 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -142.52 172.76 12.26 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.029 0.442 . . . . 0.0 111.617 -178.377 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.7 p -76.68 -9.52 12.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.653 0 CA-C-O 121.889 0.852 . . . . 0.0 110.503 -177.768 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -92.22 -2.75 56.32 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.592 0.711 . . . . 0.0 110.288 -176.087 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.487 ' HB3' HG21 ' A' ' 91' ' ' ILE . 76.9 m-20 -82.29 174.94 10.68 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 121.988 0.899 . . . . 0.0 112.328 -176.173 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.522 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.3 tt0 -128.6 125.48 38.27 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.497 178.309 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.508 HG22 HD21 ' A' ' 68' ' ' LEU . 48.8 mm -77.16 104.74 5.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -178.582 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.779 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 86.1 t -87.13 -48.07 15.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.844 0.831 . . . . 0.0 110.82 -176.469 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.517 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 33.1 tt0 -151.66 125.95 9.35 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.782 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.442 HG23 HG23 ' A' ' 60' ' ' ILE . 3.0 t -115.64 128.05 73.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 175.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.1 t70 72.97 -9.15 1.16 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 125.23 1.412 . . . . 0.0 112.671 173.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.93 11.56 36.94 Favored Glycine 0 C--N 1.29 -2.011 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.763 -174.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.558 HD13 HG22 ' A' ' 79' ' ' VAL . 7.0 tt -70.95 -21.21 22.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-O 120.728 0.299 . . . . 0.0 111.36 -177.614 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.499 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 57.7 p 51.01 88.52 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.036 1.334 . . . . 0.0 112.192 -177.31 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.508 HD21 HG22 ' A' ' 60' ' ' ILE . 1.4 pp -100.29 17.9 20.22 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 122.29 1.043 . . . . 0.0 109.931 -175.595 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.507 ' HA ' HD23 ' A' ' 35' ' ' LEU . 39.2 t -60.69 98.49 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.297 178.234 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.411 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 112.75 9.67 18.34 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.609 177.538 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.7 m -95.56 174.21 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.485 -179.408 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 p -95.02 175.45 6.63 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.54 177.617 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.589 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.23 -34.35 72.1 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.628 -179.385 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.7 -36.87 73.48 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.439 -177.44 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.467 ' O ' HG23 ' A' ' 79' ' ' VAL . 35.4 t80 -70.68 -49.1 50.76 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.808 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.19 -45.07 94.38 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.399 -178.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -54.91 -43.29 73.14 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 122.716 0.406 . . . . 0.0 110.307 178.204 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 90.3 m -61.35 -41.78 97.61 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.981 177.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.558 HG22 HD13 ' A' ' 66' ' ' ILE . 47.4 t -62.98 -51.82 67.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 178.022 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.429 HD21 HG21 ' A' ' 60' ' ' ILE . 3.5 mm? -68.26 -5.36 17.99 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-O 121.342 0.591 . . . . 0.0 111.63 179.525 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -102.47 -22.44 14.05 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.901 0.881 . . . . 0.0 110.891 176.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -90.44 0.85 57.13 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 121.253 0.549 . . . . 0.0 111.628 178.295 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.404 HG21 HD11 ' A' ' 17' ' ' LEU . 15.6 p -61.83 155.38 23.33 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.172 -0.922 . . . . 0.0 112.739 178.578 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.49 -157.55 0.8 Allowed 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.626 -1.17 . . . . 0.0 108.241 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 12' ' ' LYS . . . -51.61 -82.04 0.05 OUTLIER Glycine 0 CA--C 1.531 1.033 0 N-CA-C 114.601 0.6 . . . . 0.0 114.601 177.489 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -77.12 102.13 6.42 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.122 0.486 . . . . 0.0 111.419 -176.543 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 41.8 t -115.52 119.42 61.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.16 -178.323 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.34 104.49 15.22 Favored 'General case' 0 CA--C 1.487 -1.447 0 C-N-CA 120.282 -0.567 . . . . 0.0 109.963 173.881 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.4 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.4 m-85 -93.33 101.33 13.57 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 174.445 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.779 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.9 t -91.53 85.77 2.3 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 N-CA-C 105.337 -2.098 . . . . 0.0 105.337 176.553 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.487 HG21 ' HB3' ' A' ' 58' ' ' ASP . 78.0 mt -102.68 155.37 5.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 CA-C-N 113.765 -1.561 . . . . 0.0 108.85 179.641 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.462 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -128.85 155.59 20.72 Favored Glycine 0 N--CA 1.4 -3.748 0 C-N-CA 119.747 -1.215 . . . . 0.0 110.479 177.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -132.15 152.17 51.41 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 121.551 0.691 . . . . 0.0 112.864 -178.599 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 . . . . . 0 C--N 1.299 -1.606 0 C-N-CA 127.231 2.212 . . . . 0.0 105.505 174.381 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.502 -0.722 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -70.43 102.28 2.15 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 26.1 ttt 71.47 118.86 0.04 OUTLIER 'General case' 0 C--N 1.342 0.281 0 C-N-CA 124.389 1.076 . . . . 0.0 111.19 -178.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.446 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 45.5 tt0 -85.26 106.47 16.7 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -178.511 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.462 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.7 mm? -85.54 130.98 34.45 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 176.844 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -138.79 142.41 33.83 Favored Pre-proline 0 C--N 1.288 -2.065 0 CA-C-O 121.214 0.531 . . . . 0.0 111.802 -179.176 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -83.87 123.48 3.23 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.667 2.244 . . . . 0.0 112.732 177.21 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.4 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 40.2 t -114.65 105.38 18.55 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 174.316 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.487 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 27.6 tt0 -93.7 97.54 10.52 Favored 'General case' 0 N--CA 1.417 -2.121 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 -179.384 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.496 HD21 ' HB2' ' A' ' 51' ' ' ASP . 0.5 OUTLIER -87.67 158.36 18.86 Favored 'General case' 0 N--CA 1.397 -3.105 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -174.778 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.421 ' H ' HD23 ' A' ' 10' ' ' LEU . 48.1 tt0 -124.04 98.93 6.01 Favored 'General case' 0 C--N 1.274 -2.681 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.229 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 85' ' ' GLY . 2.3 mmmp? -100.73 -170.0 1.79 Allowed 'General case' 0 N--CA 1.409 -2.512 0 CA-C-N 114.518 -1.219 . . . . 0.0 112.696 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.56 157.12 36.02 Favored 'General case' 0 N--CA 1.413 -2.312 0 CA-C-N 113.03 -1.896 . . . . 0.0 106.534 174.724 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -72.48 -8.95 57.75 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 121.438 0.637 . . . . 0.0 110.253 176.704 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -72.22 -38.47 68.97 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 175.895 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.59 -145.14 16.74 Favored Glycine 0 N--CA 1.42 -2.411 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.624 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.404 HD11 HG21 ' A' ' 83' ' ' THR . 18.3 mt -104.53 -46.47 4.35 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.44 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.85 29.7 37.82 Favored Glycine 0 N--CA 1.422 -2.242 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.874 -175.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.2 pt -102.42 -174.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 120.059 -0.656 . . . . 0.0 112.357 -177.293 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 21.8 m -135.66 153.04 51.75 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.589 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -126.63 164.99 25.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 123.393 0.677 . . . . 0.0 109.336 -177.539 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.9 tt -135.41 130.02 50.17 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-O 120.811 0.338 . . . . 0.0 110.487 175.062 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.505 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.33 107.28 3.32 Favored Glycine 0 N--CA 1.428 -1.861 0 C-N-CA 121.085 -0.578 . . . . 0.0 112.029 -178.292 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.405 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.2 mmm -121.94 174.53 6.84 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.645 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.58 99.36 0.59 Allowed Glycine 0 C--N 1.29 -1.989 0 C-N-CA 119.418 -1.372 . . . . 0.0 112.171 179.616 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.0 p -96.63 91.9 2.89 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-O 122.723 1.249 . . . . 0.0 110.4 176.583 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.484 ' HA2' ' HA ' ' A' ' 33' ' ' GLU . . . -105.21 -116.81 4.26 Favored Glycine 0 N--CA 1.423 -2.213 0 CA-C-N 114.804 -1.089 . . . . 0.0 114.58 -174.194 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.97 -23.59 62.24 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 113.377 0.88 . . . . 0.0 113.377 -171.559 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -66.11 -28.14 68.58 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.476 0.655 . . . . 0.0 111.227 -177.757 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.2 -22.14 13.44 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.159 177.135 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.29 27.7 17.29 Favored Glycine 0 CA--C 1.494 -1.223 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.454 ' HB3' ' HG2' ' A' ' 34' ' ' LYS . 31.1 mt -109.75 -64.78 1.21 Allowed 'General case' 0 N--CA 1.423 -1.798 0 C-N-CA 120.051 -0.659 . . . . 0.0 111.541 -174.226 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.484 ' HA ' ' HA2' ' A' ' 27' ' ' GLY . 47.4 mt-10 65.93 35.21 6.65 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 122.414 1.102 . . . . 0.0 111.689 -178.485 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.454 ' HG2' ' HB3' ' A' ' 32' ' ' LEU . 2.5 ptpp? -111.48 -162.64 0.81 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-N 114.672 -1.149 . . . . 0.0 107.905 174.928 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.507 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.0 pp -57.56 145.67 32.8 Favored 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 123.904 0.882 . . . . 0.0 109.906 177.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -116.8 33.71 4.95 Favored Glycine 0 C--N 1.288 -2.103 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 173.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.522 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 26.3 mm -84.58 105.49 13.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 121.407 0.622 . . . . 0.0 110.337 -177.09 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -99.25 162.98 12.74 Favored 'General case' 0 C--N 1.279 -2.46 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 177.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.89 128.01 38.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.407 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.542 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -91.74 -39.07 12.02 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.303 0.573 . . . . 0.0 110.455 -177.049 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.7 m -159.65 161.0 34.9 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.441 HG11 ' HG3' ' A' ' 49' ' ' GLN . 17.5 t -117.62 167.73 10.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.216 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.9 t -68.86 -179.25 1.4 Allowed 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 123.044 0.538 . . . . 0.0 109.965 178.566 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -50.93 -64.29 0.86 Allowed 'General case' 0 C--O 1.225 -0.219 0 C-N-CA 124.112 0.965 . . . . 0.0 112.021 -178.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.436 ' HA2' ' HB2' ' A' ' 49' ' ' GLN . . . 169.25 52.31 0.03 OUTLIER Glycine 0 N--CA 1.414 -2.802 0 C-N-CA 118.244 -1.931 . . . . 0.0 113.621 179.628 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.73 -149.01 15.95 Favored Glycine 0 N--CA 1.408 -3.215 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 170.699 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.462 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -58.44 -14.17 7.14 Favored 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 -172.241 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.55 -62.56 1.65 Allowed 'General case' 0 C--O 1.214 -0.807 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.441 ' HG3' HG11 ' A' ' 42' ' ' VAL . 27.4 mt-30 -72.73 -13.73 61.4 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.783 0.661 . . . . 0.0 112.783 176.208 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.462 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 27.4 mmt180 -81.17 -26.33 36.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 172.299 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.496 ' HB2' HD21 ' A' ' 10' ' ' LEU . 24.6 t70 -54.94 -57.55 11.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 123.743 0.652 . . . . 0.0 111.368 177.655 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.73 -13.15 56.48 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.225 -0.988 . . . . 0.0 114.352 175.322 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.579 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -93.74 -59.93 1.88 Allowed 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 118.082 0.941 . . . . 0.0 108.573 176.878 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.579 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 15.3 tt -64.29 143.67 15.47 Favored 'Isoleucine or valine' 0 C--O 1.246 0.893 0 O-C-N 123.707 0.63 . . . . 0.0 110.672 -175.743 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -142.52 172.76 12.26 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.029 0.442 . . . . 0.0 111.617 -178.377 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.7 p -76.68 -9.52 12.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.653 0 CA-C-O 121.889 0.852 . . . . 0.0 110.503 -177.768 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -92.22 -2.75 56.32 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.592 0.711 . . . . 0.0 110.288 -176.087 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.487 ' HB3' HG21 ' A' ' 91' ' ' ILE . 76.9 m-20 -82.29 174.94 10.68 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 121.988 0.899 . . . . 0.0 112.328 -176.173 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.522 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.3 tt0 -128.6 125.48 38.27 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.497 178.309 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.508 HG22 HD21 ' A' ' 68' ' ' LEU . 48.8 mm -77.16 104.74 5.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -178.582 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.779 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 86.1 t -87.13 -48.07 15.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.844 0.831 . . . . 0.0 110.82 -176.469 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.517 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 33.1 tt0 -151.66 125.95 9.35 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.782 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.442 HG23 HG23 ' A' ' 60' ' ' ILE . 3.0 t -115.64 128.05 73.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 175.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.1 t70 72.97 -9.15 1.16 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 125.23 1.412 . . . . 0.0 112.671 173.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.93 11.56 36.94 Favored Glycine 0 C--N 1.29 -2.011 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.763 -174.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.558 HD13 HG22 ' A' ' 79' ' ' VAL . 7.0 tt -70.95 -21.21 22.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-O 120.728 0.299 . . . . 0.0 111.36 -177.614 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.499 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 57.7 p 51.01 88.52 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.036 1.334 . . . . 0.0 112.192 -177.31 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.508 HD21 HG22 ' A' ' 60' ' ' ILE . 1.4 pp -100.29 17.9 20.22 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 122.29 1.043 . . . . 0.0 109.931 -175.595 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.507 ' HA ' HD23 ' A' ' 35' ' ' LEU . 39.2 t -60.69 98.49 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.297 178.234 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.411 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 112.75 9.67 18.34 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.609 177.538 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.7 m -95.56 174.21 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.485 -179.408 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 p -95.02 175.45 6.63 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.54 177.617 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.589 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.23 -34.35 72.1 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.628 -179.385 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.7 -36.87 73.48 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.439 -177.44 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.467 ' O ' HG23 ' A' ' 79' ' ' VAL . 35.4 t80 -70.68 -49.1 50.76 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.808 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.19 -45.07 94.38 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.399 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -54.91 -43.29 73.14 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 122.716 0.406 . . . . 0.0 110.307 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 90.3 m -61.35 -41.78 97.61 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.981 177.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.558 HG22 HD13 ' A' ' 66' ' ' ILE . 47.4 t -62.98 -51.82 67.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 178.022 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.429 HD21 HG21 ' A' ' 60' ' ' ILE . 3.5 mm? -68.26 -5.36 17.99 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-O 121.342 0.591 . . . . 0.0 111.63 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -102.47 -22.44 14.05 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.901 0.881 . . . . 0.0 110.891 176.35 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -90.44 0.85 57.13 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 121.253 0.549 . . . . 0.0 111.628 178.295 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.404 HG21 HD11 ' A' ' 17' ' ' LEU . 15.6 p -61.83 155.38 23.33 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.172 -0.922 . . . . 0.0 112.739 178.578 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.49 -157.55 0.8 Allowed 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.626 -1.17 . . . . 0.0 108.241 179.377 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 12' ' ' LYS . . . -51.61 -82.04 0.05 OUTLIER Glycine 0 CA--C 1.531 1.033 0 N-CA-C 114.601 0.6 . . . . 0.0 114.601 177.489 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -77.12 102.13 6.42 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.122 0.486 . . . . 0.0 111.419 -176.543 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 41.8 t -115.52 119.42 61.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.16 -178.323 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.34 104.49 15.22 Favored 'General case' 0 CA--C 1.487 -1.447 0 C-N-CA 120.282 -0.567 . . . . 0.0 109.963 173.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.4 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.4 m-85 -93.33 101.33 13.57 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 174.445 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.779 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.9 t -91.53 85.77 2.3 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 N-CA-C 105.337 -2.098 . . . . 0.0 105.337 176.553 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.487 HG21 ' HB3' ' A' ' 58' ' ' ASP . 78.0 mt -102.68 155.37 5.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 CA-C-N 113.765 -1.561 . . . . 0.0 108.85 179.641 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.462 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -128.85 155.59 20.72 Favored Glycine 0 N--CA 1.4 -3.748 0 C-N-CA 119.747 -1.215 . . . . 0.0 110.479 177.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -132.15 152.17 51.41 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 121.551 0.691 . . . . 0.0 112.864 -178.599 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 . . . . . 0 C--N 1.299 -1.606 0 C-N-CA 127.231 2.212 . . . . 0.0 105.505 174.381 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.949 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 41.7 m80 -88.24 124.84 34.26 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.186 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 47.5 tpp -150.87 143.43 24.38 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 -176.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.468 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 40.9 tt0 -105.03 107.54 18.58 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 175.788 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -86.82 128.74 35.05 Favored 'General case' 0 C--N 1.313 -0.994 0 O-C-N 123.648 0.592 . . . . 0.0 110.007 -176.755 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 33.3 p90 -142.91 141.86 20.84 Favored Pre-proline 0 N--CA 1.423 -1.782 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -178.648 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -81.18 122.58 4.23 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.826 2.351 . . . . 0.0 112.107 176.044 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.524 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 47.2 t -103.03 100.35 10.23 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.98 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 174.91 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.485 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 35.9 tt0 -81.58 102.03 10.37 Favored 'General case' 0 N--CA 1.427 -1.587 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 174.174 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.522 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -104.04 134.49 47.22 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 -175.449 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -102.78 97.59 7.73 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 175.243 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.459 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.0 mmmp? -84.42 177.53 8.09 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 115.115 1.524 . . . . 0.0 115.115 -177.196 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -80.66 -174.47 4.73 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 112.759 -2.019 . . . . 0.0 110.457 -175.041 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -71.79 -26.62 62.49 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.742 176.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -59.11 -41.99 89.48 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.504 178.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 120.2 -114.12 2.61 Favored Glycine 0 N--CA 1.413 -2.888 0 N-CA-C 108.044 -2.023 . . . . 0.0 108.044 -175.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.515 ' HG ' HG23 ' A' ' 19' ' ' ILE . 10.5 tp -113.63 -64.41 1.31 Allowed 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -178.869 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 79.75 28.64 50.46 Favored Glycine 0 N--CA 1.437 -1.259 0 O-C-N 124.183 0.927 . . . . 0.0 113.014 177.021 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.515 HG23 ' HG ' ' A' ' 17' ' ' LEU . 18.0 pt -104.99 172.11 1.66 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.826 0 C-N-CA 119.543 -0.863 . . . . 0.0 111.278 179.649 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.1 m -123.81 147.4 47.61 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.854 -179.114 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.565 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -117.66 162.2 15.87 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -178.248 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.438 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.9 tt -128.96 132.83 67.05 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.116 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 174.314 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.482 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.22 106.69 3.45 Favored Glycine 0 N--CA 1.42 -2.405 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.029 -177.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.419 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.7 mmm -115.82 156.2 26.5 Favored 'General case' 0 C--N 1.289 -2.052 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 177.414 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.92 76.31 0.23 Allowed Glycine 0 C--N 1.286 -2.195 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 176.498 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.6 p -84.8 95.58 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 122.628 1.204 . . . . 0.0 112.031 -176.511 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -94.03 -126.19 4.42 Favored Glycine 0 N--CA 1.424 -2.137 0 CA-C-N 114.48 -1.236 . . . . 0.0 110.575 179.807 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -93.02 99.68 12.26 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.77 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -140.93 -57.16 0.51 Allowed 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.54 -40.51 7.39 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.913 174.679 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.22 28.78 0.15 Allowed Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.842 178.69 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -95.12 -59.54 1.88 Allowed 'General case' 0 C--N 1.313 -0.991 0 O-C-N 122.483 -0.422 . . . . 0.0 111.835 -177.181 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 54.3 70.48 0.61 Allowed 'General case' 0 C--O 1.248 1.013 0 C-N-CA 123.505 0.722 . . . . 0.0 111.732 178.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 13.6 ptmt -165.54 -165.25 0.82 Allowed 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -176.657 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.52 HD22 ' HA ' ' A' ' 69' ' ' VAL . 1.0 OUTLIER -56.44 154.04 9.04 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 175.14 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.419 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -117.91 34.59 4.42 Favored Glycine 0 N--CA 1.416 -2.655 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.922 173.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.482 HD13 ' HA2' ' A' ' 23' ' ' GLY . 29.3 mm -87.15 99.04 7.88 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 119.83 -0.748 . . . . 0.0 109.868 179.491 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -97.09 159.34 14.97 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 115.13 -0.941 . . . . 0.0 109.724 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.7 t -77.17 115.41 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.544 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 176.563 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -87.15 -51.4 6.01 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.858 -175.229 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -143.43 157.16 44.68 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 -179.006 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.409 ' HA ' HG22 ' A' ' 19' ' ' ILE . 50.0 t -126.85 151.01 33.14 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 N-CA-C 105.984 -1.858 . . . . 0.0 105.984 175.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.4 t -64.29 144.08 57.42 Favored 'General case' 0 N--CA 1.433 -1.325 0 CA-C-O 121.869 0.842 . . . . 0.0 109.942 178.253 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -80.24 -27.8 38.64 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 114.533 -1.212 . . . . 0.0 108.393 179.377 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -123.45 66.18 0.51 Allowed Glycine 0 CA--C 1.453 -3.791 0 CA-C-N 115.019 -0.991 . . . . 0.0 111.59 -173.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -154.63 155.17 26.03 Favored Glycine 1 N--CA 1.349 -7.159 0 N-CA-C 107.799 -2.121 . . . . 0.0 107.799 175.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.531 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -61.32 -0.76 0.4 Allowed 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -179.356 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.06 -53.69 9.43 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -76.66 -6.31 51.56 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.743 175.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.531 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 1.8 mmp_? -86.95 -38.27 16.81 Favored 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 172.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.56 ' OD1' ' HB2' ' A' ' 53' ' ' ARG . 11.4 t70 -66.13 -46.0 79.06 Favored 'General case' 0 C--O 1.217 -0.631 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 176.523 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.86 -17.44 11.33 Favored Glycine 0 N--CA 1.469 0.841 0 N-CA-C 114.54 0.576 . . . . 0.0 114.54 173.096 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.56 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 6.7 ttm180 -64.05 -40.37 96.14 Favored 'General case' 0 C--N 1.316 -0.85 0 C-N-CA 124.285 1.034 . . . . 0.0 110.238 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.8 tt -83.04 162.54 3.19 Favored 'Isoleucine or valine' 0 C--O 1.257 1.451 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 -178.465 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -125.74 -171.74 2.45 Favored 'General case' 0 N--CA 1.423 -1.805 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.308 -178.309 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.9 p -123.51 16.46 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.042 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 173.312 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 34.9 p30 -134.4 16.23 3.72 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 122.591 1.186 . . . . 0.0 109.923 -174.64 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -112.89 -169.89 1.57 Allowed 'General case' 0 C--N 1.27 -2.865 0 CA-C-N 113.69 -1.596 . . . . 0.0 109.943 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.45 ' O ' HG23 ' A' ' 91' ' ' ILE . 62.7 tt0 -132.39 132.35 42.74 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 116.72 -0.218 . . . . 0.0 110.595 -173.503 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.49 HG21 HD21 ' A' ' 80' ' ' LEU . 50.5 mm -74.38 104.83 3.15 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.961 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.013 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.712 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 94.1 t -86.33 -49.22 15.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 121.292 0.568 . . . . 0.0 110.139 -176.622 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.506 ' HG3' ' H ' ' A' ' 67' ' ' SER . 34.8 tt0 -154.39 116.67 4.29 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.254 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.405 HG23 HG23 ' A' ' 60' ' ' ILE . 4.2 t -108.83 129.98 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.209 0 N-CA-C 111.765 0.283 . . . . 0.0 111.765 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 15.6 t70 62.09 17.06 8.79 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 124.922 1.289 . . . . 0.0 111.441 174.826 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.9 10.98 85.69 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 115.65 -0.705 . . . . 0.0 112.422 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.0 tt -73.83 -14.81 16.54 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 O-C-N 122.528 -0.395 . . . . 0.0 111.171 -176.079 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.506 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 8.9 p 42.95 79.59 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 124.801 1.24 . . . . 0.0 113.357 -176.915 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.464 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.5 pp -90.84 14.14 14.46 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.739 -174.435 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.52 ' HA ' HD22 ' A' ' 35' ' ' LEU . 48.7 t -58.84 98.0 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 114.736 -1.12 . . . . 0.0 109.586 173.848 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.439 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 112.96 18.24 7.44 Favored Glycine 0 N--CA 1.435 -1.42 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.781 177.271 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.464 HG22 ' O ' ' A' ' 68' ' ' LEU . 15.6 m -105.33 175.72 1.13 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.518 0 CA-C-N 117.205 0.502 . . . . 0.0 110.578 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.6 p -94.65 179.37 5.28 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-O 121.633 0.73 . . . . 0.0 110.012 178.75 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.565 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -65.87 -35.29 80.23 Favored 'General case' 0 N--CA 1.419 -1.975 0 CA-C-N 114.803 -1.089 . . . . 0.0 111.055 -179.619 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -70.17 -27.68 64.72 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.492 -177.584 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 36.6 t80 -75.47 -51.8 12.18 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 175.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.2 -44.06 92.25 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.448 -0.797 . . . . 0.0 112.218 -178.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.46 -10.66 36.08 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.335 0.654 . . . . 0.0 111.59 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.423 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 98.3 m -93.01 -49.18 6.15 Favored 'General case' 0 N--CA 1.412 -2.355 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.668 175.224 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.535 ' O ' HG23 ' A' ' 83' ' ' THR . 38.5 t -59.64 -52.07 65.34 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.649 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.49 HD21 HG21 ' A' ' 60' ' ' ILE . 3.6 mm? -68.62 3.39 1.88 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.611 0.764 . . . . 0.0 112.228 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.423 ' HB3' ' O ' ' A' ' 78' ' ' THR . 11.7 ttm180 -109.91 -41.02 4.6 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 121.99 0.9 . . . . 0.0 109.109 176.334 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -80.31 -4.83 54.92 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 114.496 -1.229 . . . . 0.0 112.182 -174.668 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 79' ' ' VAL . 7.5 p -60.7 147.68 41.3 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 123.759 0.824 . . . . 0.0 112.194 177.503 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.85 -172.88 2.17 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.852 177.157 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -38.93 -73.74 0.15 Allowed Glycine 0 C--O 1.217 -0.94 0 O-C-N 124.484 1.115 . . . . 0.0 115.067 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.522 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 36.3 m-80 -83.05 105.11 13.76 Favored 'General case' 0 CA--C 1.497 -1.062 0 CA-C-N 118.0 0.9 . . . . 0.0 110.956 -179.536 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.493 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 2.5 t -104.24 143.38 16.0 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 CA-C-N 115.44 -0.8 . . . . 0.0 108.927 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 60.3 mtp180 -107.27 97.28 7.06 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 173.681 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.524 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 81.6 m-85 -94.67 104.76 16.68 Favored 'General case' 0 CA--C 1.483 -1.6 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 177.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.712 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 62.5 t -87.65 94.74 4.71 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.609 0 N-CA-C 105.108 -2.182 . . . . 0.0 105.108 173.198 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.456 HG12 ' HA ' ' A' ' 60' ' ' ILE . 93.9 mt -114.49 153.76 15.95 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.671 0 CA-C-N 114.894 -1.048 . . . . 0.0 108.245 177.515 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -118.02 157.88 14.96 Favored Glycine 1 N--CA 1.393 -4.221 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.534 177.459 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.485 HH21 ' HG2' ' A' ' 94' ' ' GLU . 8.1 tpm_? -129.48 123.66 32.09 Favored 'General case' 0 C--N 1.29 -2.005 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.569 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.485 ' HG2' HH21 ' A' ' 93' ' ' ARG . 16.5 pt-20 . . . . . 0 N--CA 1.428 -1.567 0 N-CA-C 105.886 -1.894 . . . . 0.0 105.886 171.014 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.501 -0.826 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 41.5 m80 -113.74 18.23 17.58 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.975 0.387 . . . . 0.0 110.639 -178.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 25.4 ttt 71.76 117.25 0.05 OUTLIER 'General case' 0 CA--C 1.509 -0.613 0 C-N-CA 125.333 1.453 . . . . 0.0 109.606 -173.396 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.481 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 39.1 tt0 -87.4 107.81 18.71 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -177.896 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.437 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.7 mm? -89.93 120.33 31.06 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 177.346 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -131.63 143.64 50.01 Favored Pre-proline 0 C--N 1.29 -1.987 0 CA-C-O 121.322 0.582 . . . . 0.0 112.356 -174.459 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -84.01 127.45 4.1 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.914 2.409 . . . . 0.0 112.273 175.398 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.415 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 23.6 t -117.52 104.63 16.68 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.271 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 174.381 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.415 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 36.4 tt0 -91.48 102.41 15.08 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.741 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.497 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -91.23 144.51 25.54 Favored 'General case' 0 N--CA 1.422 -1.866 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 -173.983 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -113.12 84.54 2.01 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 170.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.538 ' HE2' ' H ' ' A' ' 48' ' ' ALA . 5.1 mmtt -71.89 165.5 24.04 Favored 'General case' 0 N--CA 1.417 -2.077 0 N-CA-C 114.071 1.137 . . . . 0.0 114.071 -179.243 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -84.38 -175.18 5.67 Favored 'General case' 0 N--CA 1.433 -1.308 0 CA-C-N 113.613 -1.631 . . . . 0.0 111.123 -176.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -78.21 -9.27 59.13 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 -172.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -77.72 -45.47 24.67 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 121.746 0.784 . . . . 0.0 108.889 176.344 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.85 -160.28 21.75 Favored Glycine 0 N--CA 1.422 -2.271 0 N-CA-C 108.551 -1.82 . . . . 0.0 108.551 -176.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.8 mt -75.52 -50.8 14.57 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 118.011 0.905 . . . . 0.0 109.599 -176.346 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 68.1 27.97 73.52 Favored Glycine 0 N--CA 1.433 -1.56 0 CA-C-N 114.695 -1.139 . . . . 0.0 110.453 -176.261 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.54 HD11 HD12 ' A' ' 80' ' ' LEU . 18.1 pt -99.57 171.02 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.832 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.165 -178.804 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.1 m -133.35 148.34 51.86 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -177.398 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -115.41 161.59 14.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.429 ' CG2' ' HB2' ' A' ' 38' ' ' PHE . 15.3 tt -129.14 131.84 67.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 C-N-CA 120.611 -0.436 . . . . 0.0 109.895 174.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.496 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -90.65 97.08 2.28 Favored Glycine 0 CA--C 1.494 -1.238 0 C-N-CA 120.974 -0.631 . . . . 0.0 112.138 -177.719 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.434 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 95.1 mmm -111.73 -175.72 2.76 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.01 86.45 0.2 Allowed Glycine 0 C--N 1.282 -2.43 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 174.107 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.2 p -89.67 120.32 38.23 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-O 121.727 0.775 . . . . 0.0 111.809 -175.298 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.572 ' HA2' ' HB3' ' A' ' 30' ' ' ALA . . . 70.36 20.55 76.91 Favored Glycine 0 N--CA 1.432 -1.574 0 CA-C-N 114.766 -1.106 . . . . 0.0 113.928 175.522 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.65 -39.57 94.67 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.453 0.644 . . . . 0.0 110.545 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.5 m-20 -114.08 12.15 17.82 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.003 -179.513 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.572 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . . . -109.0 7.51 25.88 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.019 -0.537 . . . . 0.0 112.341 -176.625 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.01 11.55 42.61 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 119.881 -1.152 . . . . 0.0 114.168 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.7 mp -107.41 -62.91 1.36 Allowed 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 117.384 0.592 . . . . 0.0 110.968 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 57.32 84.8 0.09 Allowed 'General case' 0 C--O 1.245 0.862 0 C-N-CA 124.134 0.974 . . . . 0.0 111.9 -172.595 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.3 ptmt -143.93 174.45 10.82 Favored 'General case' 0 N--CA 1.413 -2.324 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 178.419 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.678 HD22 HG23 ' A' ' 69' ' ' VAL . 2.2 pt? -56.57 145.34 28.56 Favored 'General case' 0 C--N 1.289 -2.06 0 O-C-N 124.205 0.941 . . . . 0.0 110.933 176.852 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -110.49 19.07 26.92 Favored Glycine 0 N--CA 1.417 -2.592 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 175.152 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.611 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 35.9 mm -85.73 104.04 13.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-O 121.498 0.666 . . . . 0.0 110.457 -177.551 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.429 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 96.6 m-85 -101.65 163.31 12.33 Favored 'General case' 0 C--N 1.281 -2.4 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.484 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 47.0 t -77.35 116.29 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 N-CA-C 106.935 -1.505 . . . . 0.0 106.935 175.647 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.532 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.2 OUTLIER -83.44 -39.03 21.11 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 -177.621 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -157.56 158.23 35.23 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.44 HG12 ' HB ' ' A' ' 56' ' ' VAL . 4.3 p -137.52 97.81 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 CA-C-O 121.456 0.646 . . . . 0.0 111.557 178.114 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.8 t 51.94 168.36 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.478 0 C-N-CA 127.221 2.208 . . . . 0.0 113.933 178.307 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -73.35 -28.79 62.24 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 173.693 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 143.4 38.03 0.07 OUTLIER Glycine 0 N--CA 1.415 -2.716 0 CA-C-N 114.105 -1.407 . . . . 0.0 111.172 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -84.82 -151.36 13.88 Favored Glycine 0 N--CA 1.41 -3.096 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 174.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.449 ' HB3' ' HD3' ' A' ' 12' ' ' LYS . . . -61.67 -10.57 8.79 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 115.178 1.547 . . . . 0.0 115.178 -172.518 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.538 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -80.48 -58.01 3.32 Favored 'General case' 0 C--O 1.214 -0.796 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 43.0 mt-30 -63.27 -29.83 71.09 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.948 173.421 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 31.0 mmm180 -66.78 -34.37 77.68 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.863 176.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.412 ' HB3' ' O ' ' A' ' 48' ' ' ALA . 11.6 t70 -56.3 -52.15 65.57 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.719 176.607 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.19 -7.14 72.83 Favored Glycine 0 C--N 1.313 -0.737 0 N-CA-C 114.944 0.737 . . . . 0.0 114.944 173.609 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -86.57 -43.69 12.5 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.3 tt -78.54 152.12 5.11 Favored 'Isoleucine or valine' 0 C--O 1.243 0.736 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 177.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLN . . . . . 0.541 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 19.5 mt-30 -140.69 171.06 14.63 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 121.02 0.438 . . . . 0.0 110.019 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.44 ' HB ' HG12 ' A' ' 42' ' ' VAL . 10.7 p -83.24 -11.91 11.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.419 1.104 . . . . 0.0 108.587 175.288 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -88.65 3.24 51.33 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.786 -172.152 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.541 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 13.0 m-20 -109.6 -165.99 1.06 Allowed 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -174.254 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.611 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 18.9 tt0 -136.41 129.19 30.82 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 123.683 0.793 . . . . 0.0 111.261 -176.383 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.541 ' HA ' HG12 ' A' ' 91' ' ' ILE . 46.9 mm -73.88 108.33 5.25 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.877 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -179.331 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.777 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 97.3 t -92.41 -49.87 12.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 CA-C-O 121.854 0.835 . . . . 0.0 110.403 -178.349 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.576 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.2 tt0 -146.13 127.89 15.3 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.457 HG21 HD11 ' A' ' 80' ' ' LEU . 2.7 t -117.78 126.39 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.917 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.612 175.05 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.4 t70 72.51 -13.67 0.62 Allowed 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 125.391 1.476 . . . . 0.0 112.97 173.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 111.0 11.41 18.68 Favored Glycine 0 C--N 1.288 -2.099 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.003 -176.177 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.417 HD13 HG22 ' A' ' 79' ' ' VAL . 7.5 tt -75.33 -18.35 15.96 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.733 0 CA-C-O 120.777 0.323 . . . . 0.0 110.617 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.57 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 25.7 m 49.19 87.15 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.257 1.423 . . . . 0.0 111.54 -176.262 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.445 ' O ' HG22 ' A' ' 71' ' ' VAL . 2.1 pp -103.93 15.58 28.29 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-O 122.246 1.022 . . . . 0.0 109.484 -176.009 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.678 HG23 HD22 ' A' ' 35' ' ' LEU . 6.3 p -62.66 79.62 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 114.001 -1.454 . . . . 0.0 111.324 175.819 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 118.17 49.35 0.37 Allowed Glycine 0 N--CA 1.433 -1.505 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.048 -178.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.445 HG22 ' O ' ' A' ' 68' ' ' LEU . 32.4 m -127.02 178.08 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.242 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 13.3 p -91.08 174.66 7.29 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 120.933 0.397 . . . . 0.0 111.27 179.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.42 ' HB3' ' HA3' ' A' ' 23' ' ' GLY . 2.5 pm0 -65.26 -35.35 80.76 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.026 -179.301 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -70.36 -31.14 68.28 Favored 'General case' 0 CA--C 1.511 -0.519 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.695 -177.604 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -71.52 -54.22 11.27 Favored 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.44 -48.25 79.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.419 -0.809 . . . . 0.0 112.022 -178.188 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.05 -25.75 65.59 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 -179.149 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 71.4 m -76.22 -44.14 39.01 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.485 176.761 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.417 HG22 HD13 ' A' ' 66' ' ' ILE . 33.5 t -61.75 -51.74 69.08 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.621 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.54 HD12 HD11 ' A' ' 19' ' ' ILE . 3.5 mm? -68.12 -3.82 11.67 Favored 'General case' 0 CA--C 1.556 1.188 0 CA-C-O 121.341 0.591 . . . . 0.0 112.448 -179.114 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 36.4 ttt180 -95.64 -40.79 9.23 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 175.642 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 23.1 m-80 -89.01 8.06 31.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 114.241 -1.345 . . . . 0.0 113.88 -171.702 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.415 HG23 ' O ' ' A' ' 79' ' ' VAL . 1.3 p -75.9 154.38 36.05 Favored 'General case' 0 C--N 1.28 -2.431 0 C-N-CA 123.596 0.758 . . . . 0.0 112.332 178.689 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.29 -170.38 1.63 Allowed 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.984 176.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -50.41 -62.87 4.79 Favored Glycine 0 N--CA 1.473 1.116 0 N-CA-C 115.341 0.896 . . . . 0.0 115.341 -176.628 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.497 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 20.7 m120 -81.49 104.6 12.04 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 117.436 0.618 . . . . 0.0 110.992 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.441 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 2.3 t -113.75 128.76 70.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.195 -176.542 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.14 104.23 16.26 Favored 'General case' 0 C--N 1.293 -1.872 0 C-N-CA 119.979 -0.689 . . . . 0.0 109.474 170.832 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.441 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 93.2 m-85 -94.8 100.66 12.51 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 174.53 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.777 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 27.2 t -93.62 83.82 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.434 0 N-CA-C 105.288 -2.116 . . . . 0.0 105.288 177.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.541 HG12 ' HA ' ' A' ' 60' ' ' ILE . 64.7 mt -97.61 158.36 3.31 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.588 0 CA-C-N 113.335 -1.757 . . . . 0.0 109.563 -178.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.481 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -133.3 147.83 19.13 Favored Glycine 1 N--CA 1.393 -4.187 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.607 176.836 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 24.8 tpt180 -115.73 119.2 35.27 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 . . . . . 0 N--CA 1.413 -2.315 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 173.717 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.501 -0.799 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -80.93 113.51 19.19 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.082 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 50.0 ttm -76.74 114.09 15.11 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-O 120.965 0.412 . . . . 0.0 110.896 -177.41 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.423 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 41.2 tt0 -83.58 110.5 18.29 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.332 -0.849 . . . . 0.0 108.894 178.475 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.442 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -85.32 130.37 34.61 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.245 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 24.8 p90 -139.37 139.85 24.0 Favored Pre-proline 0 N--CA 1.426 -1.667 0 CA-C-O 121.454 0.645 . . . . 0.0 112.157 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -82.77 121.94 3.37 Favored 'Trans proline' 0 N--CA 1.446 -1.273 0 C-N-CA 122.765 2.31 . . . . 0.0 112.844 177.466 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.0 t -111.28 105.08 18.11 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 176.24 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.602 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.1 tt0 -85.39 105.28 15.91 Favored 'General case' 0 N--CA 1.42 -1.956 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 174.674 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.551 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 15.9 tp -95.76 151.35 19.45 Favored 'General case' 0 N--CA 1.41 -2.471 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 -176.719 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -115.27 92.59 3.97 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 177.513 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.466 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 2.6 mmmp? -84.24 177.61 8.12 Favored 'General case' 0 C--N 1.289 -2.032 0 CA-C-O 122.498 1.142 . . . . 0.0 113.675 178.837 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.418 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.0 p-10 -88.86 172.06 9.46 Favored 'General case' 0 C--N 1.286 -2.178 0 CA-C-N 112.835 -1.984 . . . . 0.0 109.536 179.598 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -64.32 -18.22 64.42 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -174.532 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.418 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 23.3 t70 -68.61 -32.98 73.24 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.778 0.799 . . . . 0.0 110.209 178.652 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.97 -124.44 5.94 Favored Glycine 0 CA--C 1.477 -2.285 0 N-CA-C 108.706 -1.758 . . . . 0.0 108.706 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.488 HD21 HG21 ' A' ' 87' ' ' VAL . 25.7 mt -104.27 -52.58 2.89 Favored 'General case' 0 CA--C 1.462 -2.407 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.45 178.499 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.2 24.55 76.53 Favored Glycine 0 N--CA 1.426 -2.003 0 O-C-N 124.678 1.236 . . . . 0.0 110.911 -175.163 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 28.0 pt -101.27 176.48 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.482 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 23.7 m -132.65 148.59 52.35 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -176.489 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -119.82 167.11 13.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.2 tt -133.36 132.26 57.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.668 177.391 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.508 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.1 102.07 2.79 Favored Glycine 0 N--CA 1.435 -1.43 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.607 -177.788 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 95.5 mmm -115.68 173.41 6.56 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.471 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.04 85.21 0.37 Allowed Glycine 0 C--N 1.295 -1.702 0 C-N-CA 120.121 -1.038 . . . . 0.0 112.469 179.162 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.53 HG12 ' HA2' ' A' ' 36' ' ' GLY . 13.2 p -122.47 154.74 27.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.391 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.46 -37.62 3.09 Favored Glycine 0 N--CA 1.421 -2.354 0 C-N-CA 120.18 -1.01 . . . . 0.0 111.425 177.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.08 -30.46 60.96 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.759 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -67.62 -40.02 84.68 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.47 175.174 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.93 -24.55 62.47 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 124.402 1.081 . . . . 0.0 111.945 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.15 6.54 68.92 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.399 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -101.46 -27.66 13.01 Favored 'General case' 0 C--N 1.314 -0.972 0 O-C-N 122.545 -0.385 . . . . 0.0 110.387 179.483 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 55.7 89.65 0.04 OUTLIER 'General case' 0 CA--C 1.514 -0.406 0 C-N-CA 124.557 1.143 . . . . 0.0 112.022 -176.292 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 21.9 ptmt -129.34 -173.05 2.9 Favored 'General case' 0 N--CA 1.411 -2.377 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.625 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.5 pp -72.23 149.63 44.39 Favored 'General case' 0 C--N 1.282 -2.337 0 O-C-N 123.956 0.785 . . . . 0.0 109.283 178.042 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.53 ' HA2' HG12 ' A' ' 26' ' ' VAL . . . -110.47 27.48 11.39 Favored Glycine 0 N--CA 1.423 -2.213 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 172.777 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.508 HD13 ' HA2' ' A' ' 23' ' ' GLY . 35.3 mm -83.67 102.84 10.18 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 CA-C-O 121.47 0.652 . . . . 0.0 110.068 -178.626 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -96.83 169.2 10.02 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 177.232 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.0 t -83.43 129.33 37.67 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 175.407 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 55.6 tptt -93.64 -46.37 7.3 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.248 -177.384 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.8 m -151.72 161.45 42.64 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 -179.258 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 40.6 t -137.58 141.4 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.115 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 177.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 14.1 t -83.25 149.24 26.91 Favored 'General case' 0 C--N 1.29 -1.98 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.115 -178.036 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -93.27 -19.72 21.11 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 174.279 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.75 25.69 2.47 Favored Glycine 0 C--N 1.31 -0.895 0 CA-C-N 114.04 -1.436 . . . . 0.0 113.262 179.363 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -156.42 159.62 29.59 Favored Glycine 1 N--CA 1.359 -6.492 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 178.787 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.604 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -67.36 30.14 0.02 OUTLIER 'General case' 0 C--N 1.28 -2.436 0 C-N-CA 125.844 1.658 . . . . 0.0 114.179 -177.283 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.437 ' HA ' HD21 ' A' ' 10' ' ' LEU . . . -98.23 -62.99 1.17 Allowed 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -75.87 -28.9 58.33 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.679 0.752 . . . . 0.0 109.312 176.543 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.604 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 19.1 mmm180 -63.35 -32.65 74.13 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.473 -1.239 . . . . 0.0 109.63 172.595 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -70.4 -63.21 1.13 Allowed 'General case' 0 C--O 1.241 0.64 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 173.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.26 -17.28 40.82 Favored Glycine 0 N--CA 1.436 -1.356 0 N-CA-C 115.435 0.934 . . . . 0.0 115.435 175.049 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.512 ' O ' ' HD3' ' A' ' 53' ' ' ARG . 0.3 OUTLIER -79.21 -25.69 42.66 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 118.816 1.308 . . . . 0.0 109.341 -177.914 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.9 tt -94.44 150.76 3.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLN . . . . . 0.596 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 23.6 mt-30 -136.64 166.11 24.3 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 121.232 0.539 . . . . 0.0 111.598 -176.327 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -86.88 -12.44 10.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.392 178.803 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -92.99 3.42 55.79 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 122.214 1.007 . . . . 0.0 110.647 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.596 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 24.9 m-20 -101.98 -174.54 2.61 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.268 -177.48 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.442 ' O ' HG23 ' A' ' 91' ' ' ILE . 61.5 tt0 -129.26 131.97 47.12 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.813 -176.017 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.456 HG22 HD11 ' A' ' 68' ' ' LEU . 49.1 mm -75.43 106.56 5.31 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.783 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 179.697 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.692 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 98.5 t -87.87 -44.65 15.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 120.967 0.413 . . . . 0.0 111.344 -177.09 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.557 ' HG3' ' H ' ' A' ' 67' ' ' SER . 37.6 tt0 -156.85 120.96 4.34 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 120.67 0.271 . . . . 0.0 110.544 178.281 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.3 t -112.62 129.04 68.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 111.575 0.213 . . . . 0.0 111.575 176.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.3 t70 66.95 7.52 5.41 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 125.737 1.615 . . . . 0.0 111.294 174.54 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.65 20.7 61.23 Favored Glycine 0 N--CA 1.434 -1.472 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.296 -175.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.437 HD13 HG22 ' A' ' 79' ' ' VAL . 6.4 tt -79.44 -22.68 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 CA-C-O 121.197 0.522 . . . . 0.0 110.267 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.557 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 63.8 p 48.68 81.95 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.356 1.462 . . . . 0.0 111.935 -176.003 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.456 HD11 HG22 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -87.33 30.71 0.77 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 122.515 1.15 . . . . 0.0 111.283 -175.997 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.625 ' HA ' HD23 ' A' ' 35' ' ' LEU . 42.4 t -74.71 103.87 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.585 -179.424 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.08 26.83 6.84 Favored Glycine 0 N--CA 1.434 -1.436 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.784 179.403 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.451 HG21 ' HB2' ' A' ' 68' ' ' LEU . 11.0 m -112.63 170.4 4.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 C-N-CA 120.391 -0.524 . . . . 0.0 110.071 177.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.9 p -93.6 172.2 8.41 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.323 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -60.98 -28.43 69.01 Favored 'General case' 0 C--O 1.205 -1.269 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.751 -179.141 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -73.44 -36.03 65.87 Favored 'General case' 0 CA--C 1.522 -0.122 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.557 -178.425 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.401 ' O ' HG23 ' A' ' 79' ' ' VAL . 30.1 t80 -70.43 -49.8 45.05 Favored 'General case' 0 CA--C 1.506 -0.712 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 178.189 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.29 -46.73 87.76 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.934 -178.088 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.48 -34.19 72.26 Favored 'General case' 0 C--O 1.209 -1.036 0 CA-C-O 120.472 0.177 . . . . 0.0 110.554 179.391 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 77.6 m -65.91 -44.45 85.16 Favored 'General case' 0 N--CA 1.435 -1.217 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.755 177.219 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.437 HG22 HD13 ' A' ' 66' ' ' ILE . 39.3 t -61.89 -53.08 52.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 178.553 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -67.98 -2.23 7.19 Favored 'General case' 0 CA--C 1.564 1.509 0 CA-C-O 121.393 0.616 . . . . 0.0 112.183 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.23 -34.02 10.51 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 123.556 0.743 . . . . 0.0 109.714 175.132 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -82.0 -13.68 57.06 Favored 'General case' 0 CA--C 1.498 -1.019 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -175.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.435 ' OG1' ' HG ' ' A' ' 17' ' ' LEU . 5.4 p -60.54 146.67 44.19 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.647 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.89 -161.28 0.75 Allowed 'General case' 0 C--N 1.297 -1.709 0 CA-C-N 114.88 -1.055 . . . . 0.0 109.238 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -51.21 -74.93 0.24 Allowed Glycine 0 CA--C 1.536 1.379 0 N-CA-C 115.399 0.92 . . . . 0.0 115.399 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.551 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 15.9 m120 -81.65 99.99 9.2 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 117.872 0.836 . . . . 0.0 112.18 -177.534 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.602 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.8 t -108.54 135.49 47.17 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.044 -175.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -94.05 101.49 13.52 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 172.384 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.513 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 98.8 m-85 -94.8 103.92 15.82 Favored 'General case' 0 CA--C 1.48 -1.741 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.206 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.692 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 60.8 t -88.81 93.31 4.26 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.89 0 N-CA-C 105.416 -2.068 . . . . 0.0 105.416 174.744 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.442 HG23 ' O ' ' A' ' 59' ' ' GLN . 88.7 mt -107.43 155.51 8.14 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.265 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.21 175.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.442 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -129.83 149.39 18.77 Favored Glycine 0 N--CA 1.406 -3.331 0 C-N-CA 119.376 -1.393 . . . . 0.0 111.673 -178.771 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 22.9 tpt180 -123.85 116.23 22.61 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 -178.313 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 . . . . . 0 N--CA 1.441 -0.92 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 173.879 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.507 -0.407 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 52.4 t60 -89.53 111.5 22.43 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.123 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 23.5 ttt -83.59 113.53 20.89 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.424 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.49 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 82.9 tt0 -92.59 111.49 23.11 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 -178.207 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.413 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.0 mm? -87.31 125.78 34.43 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -178.637 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -140.48 145.66 41.78 Favored Pre-proline 0 C--N 1.294 -1.845 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -176.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -82.64 125.48 4.35 Favored 'Trans proline' 0 N--CA 1.442 -1.511 0 C-N-CA 122.62 2.213 . . . . 0.0 112.202 175.635 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.422 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 23.7 t -111.14 102.77 14.44 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.58 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 175.297 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 28.7 tt0 -82.22 108.83 15.98 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 174.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -103.79 135.97 44.34 Favored 'General case' 0 C--N 1.279 -2.469 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 -177.772 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -106.99 97.73 7.48 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.521 -1.289 . . . . 0.0 107.521 171.819 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.619 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 2.7 mmmp? -83.71 173.78 11.04 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-O 122.406 1.098 . . . . 0.0 113.839 -177.329 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -88.15 172.68 9.32 Favored 'General case' 0 N--CA 1.423 -1.803 0 CA-C-N 112.818 -1.992 . . . . 0.0 110.026 -178.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -67.75 -9.29 42.64 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 114.197 1.184 . . . . 0.0 114.197 -173.188 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -73.49 -34.05 65.13 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.323 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.95 -127.14 6.98 Favored Glycine 0 CA--C 1.475 -2.452 0 N-CA-C 107.533 -2.227 . . . . 0.0 107.533 -177.554 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 18.2 mt -99.65 -48.92 4.56 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 175.042 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 73.94 31.03 60.48 Favored Glycine 0 N--CA 1.418 -2.524 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 -177.038 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 22.2 pt -110.84 178.35 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.3 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.641 -178.44 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 34.8 m -140.09 154.65 47.1 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -178.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -125.84 166.58 21.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -177.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 14.0 tt -140.23 134.6 35.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 C-N-CA 120.58 -0.448 . . . . 0.0 110.681 177.251 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.515 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -92.96 107.58 3.55 Favored Glycine 0 N--CA 1.425 -2.079 0 C-N-CA 120.965 -0.635 . . . . 0.0 111.794 -179.239 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.663 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 93.0 mmm -122.58 97.88 5.66 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.82 101.13 0.56 Allowed Glycine 0 C--N 1.308 -1.015 0 C-N-CA 120.98 -0.629 . . . . 0.0 113.428 -175.651 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.4 p -120.88 29.31 2.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-O 123.739 1.733 . . . . 0.0 106.525 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.633 ' O ' ' HA ' ' A' ' 33' ' ' GLU . . . -92.22 -19.26 39.62 Favored Glycine 0 N--CA 1.435 -1.373 0 CA-C-N 112.657 -2.065 . . . . 0.0 116.687 -168.565 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -130.86 -75.99 0.53 Allowed 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 119.328 1.564 . . . . 0.0 113.45 -175.652 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -61.51 -31.26 71.25 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.294 0.638 . . . . 0.0 111.954 -175.204 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.93 -26.54 68.86 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.428 -0.806 . . . . 0.0 112.424 -179.408 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.43 -3.61 79.32 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.551 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.9 mp -84.38 -38.02 20.8 Favored 'General case' 0 C--N 1.31 -1.135 0 O-C-N 122.478 -0.424 . . . . 0.0 110.617 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.633 ' HA ' ' O ' ' A' ' 27' ' ' GLY . 45.9 mt-10 53.89 76.72 0.21 Allowed 'General case' 0 C--O 1.244 0.772 0 O-C-N 124.56 1.163 . . . . 0.0 112.819 179.404 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.51 ' HE2' ' OE1' ' A' ' 59' ' ' GLN . 18.2 ptmt -162.03 168.65 22.38 Favored 'General case' 0 N--CA 1.42 -1.961 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 -178.54 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.458 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.5 pp -59.47 150.32 27.08 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 123.736 0.647 . . . . 0.0 109.262 172.617 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.663 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -115.12 32.85 5.58 Favored Glycine 0 N--CA 1.424 -2.16 0 C-N-CA 118.919 -1.61 . . . . 0.0 111.797 178.14 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.531 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 25.6 mm -91.04 98.73 8.71 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.779 0 CA-C-O 122.018 0.913 . . . . 0.0 110.117 -178.764 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -93.11 162.44 14.03 Favored 'General case' 0 C--N 1.277 -2.559 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.395 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 46.7 t -79.44 126.83 39.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 175.136 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 58.3 tptt -88.64 -50.45 6.25 Favored 'General case' 0 C--N 1.294 -1.811 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.806 -177.087 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -150.87 162.62 40.43 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 -177.338 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.422 HG11 ' HG3' ' A' ' 49' ' ' GLN . 61.4 t -128.02 159.55 38.93 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.134 0 N-CA-C 105.959 -1.867 . . . . 0.0 105.959 175.239 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 6.6 t -57.3 162.49 2.71 Favored 'General case' 0 CA--C 1.544 0.714 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 171.659 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -55.32 -34.67 64.39 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.116 0.484 . . . . 0.0 110.796 -176.661 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.489 ' HA2' ' HB2' ' A' ' 49' ' ' GLN . . . -162.89 -58.13 0.02 OUTLIER Glycine 0 N--CA 1.428 -1.847 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 176.313 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 47.06 -101.64 0.04 OUTLIER Glycine 0 CA--C 1.485 -1.823 0 C-N-CA 126.352 1.929 . . . . 0.0 111.084 -173.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.619 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . -139.73 2.77 2.01 Favored 'General case' 0 C--N 1.26 -3.317 0 CA-C-N 113.278 -1.461 . . . . 0.0 108.915 173.495 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.478 ' O ' ' HB3' ' A' ' 51' ' ' ASP . . . -87.55 -55.06 3.95 Favored 'General case' 0 CA--C 1.486 -1.483 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -175.82 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.489 ' HB2' ' HA2' ' A' ' 45' ' ' GLY . 41.2 mt-30 -76.46 -22.3 54.76 Favored 'General case' 0 N--CA 1.433 -1.319 0 C-N-CA 118.586 -1.246 . . . . 0.0 110.87 176.706 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 25.7 mmm180 -69.0 -23.59 64.12 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.192 171.697 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.478 ' HB3' ' O ' ' A' ' 48' ' ' ALA . 12.1 t70 -71.39 -64.92 0.82 Allowed 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.099 -1.075 . . . . 0.0 108.099 170.464 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.71 -5.54 84.63 Favored Glycine 0 C--O 1.245 0.794 0 C-N-CA 121.24 -0.505 . . . . 0.0 113.792 174.699 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.62 -32.85 21.82 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 178.707 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.6 tt -93.52 143.46 11.49 Favored 'Isoleucine or valine' 0 C--O 1.251 1.148 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 170.164 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 62.0 mt-30 -139.05 178.42 7.18 Favored 'General case' 0 C--N 1.308 -1.225 0 O-C-N 122.183 -0.323 . . . . 0.0 111.412 -179.513 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.2 p -84.64 -14.96 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-O 121.66 0.743 . . . . 0.0 110.838 -176.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -91.24 7.9 38.51 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-O 122.107 0.956 . . . . 0.0 109.502 -176.718 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.402 ' HB3' HG21 ' A' ' 91' ' ' ILE . 6.6 m-20 -88.47 -175.4 4.96 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.8 -176.063 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.531 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 30.9 tt0 -141.53 129.14 21.48 Favored 'General case' 0 N--CA 1.423 -1.795 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.007 -179.03 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.434 HG22 HD21 ' A' ' 68' ' ' LEU . 46.8 mm -77.2 105.31 5.96 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.786 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -178.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.766 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 94.2 t -85.07 -48.96 16.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-O 121.957 0.884 . . . . 0.0 109.357 -177.665 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.565 ' HG3' ' H ' ' A' ' 67' ' ' SER . 28.8 tt0 -150.87 135.1 16.89 Favored 'General case' 0 N--CA 1.419 -2.015 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.078 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 t -121.52 128.71 75.9 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 173.489 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 37.0 t70 71.23 -11.49 0.68 Allowed 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 125.3 1.44 . . . . 0.0 113.261 176.603 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.11 15.4 28.33 Favored Glycine 0 C--N 1.277 -2.729 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -174.27 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.425 HD13 HG22 ' A' ' 79' ' ' VAL . 9.3 tt -72.7 -21.02 19.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 CA-C-O 121.452 0.644 . . . . 0.0 110.046 -179.671 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.565 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 62.9 p 49.25 88.2 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 125.399 1.48 . . . . 0.0 111.89 -175.407 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.434 HD21 HG22 ' A' ' 60' ' ' ILE . 1.3 pp -98.11 20.1 12.94 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-O 122.429 1.109 . . . . 0.0 109.573 -176.775 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 50.4 t -57.6 94.26 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-N 114.025 -1.443 . . . . 0.0 110.944 175.549 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.458 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 107.77 27.35 5.21 Favored Glycine 0 N--CA 1.441 -1.003 0 CA-C-N 115.408 -0.815 . . . . 0.0 112.603 175.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.403 HG22 ' O ' ' A' ' 68' ' ' LEU . 20.2 m -105.73 176.15 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.885 -179.439 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 12.4 p -93.0 172.76 8.11 Favored 'General case' 0 C--O 1.254 1.327 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.546 179.08 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.3 pm0 -65.97 -30.81 71.43 Favored 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.666 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -73.73 -26.37 60.65 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.686 -177.5 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 40.3 t80 -75.27 -53.13 9.29 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.62 -48.8 78.42 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.054 -177.177 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -55.76 -36.96 67.89 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.642 0.258 . . . . 0.0 110.624 179.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 89.0 m -65.62 -44.64 85.85 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.854 177.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.425 HG22 HD13 ' A' ' 66' ' ' ILE . 34.7 t -61.93 -51.2 75.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 178.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -64.01 -20.2 65.73 Favored 'General case' 0 C--O 1.214 -0.794 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.423 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.82 -25.63 24.47 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 122.934 0.494 . . . . 0.0 110.927 177.177 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -89.02 3.62 51.06 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 112.747 0.647 . . . . 0.0 112.747 -178.367 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 38.9 p -73.49 -178.33 3.01 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.78 0.8 . . . . 0.0 111.846 177.67 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.23 -165.9 1.56 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 125.534 1.533 . . . . 0.0 107.045 -179.186 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -39.51 -78.27 0.06 OUTLIER Glycine 0 C--O 1.22 -0.719 0 O-C-N 124.504 1.128 . . . . 0.0 115.204 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.467 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 20.9 m120 -81.57 114.97 20.63 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 118.075 0.938 . . . . 0.0 111.272 -177.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.4 t -124.37 140.48 47.54 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.458 -179.112 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 20.2 mtp85 -100.41 100.7 11.51 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 120.907 0.384 . . . . 0.0 110.831 171.35 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.456 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 95.4 m-85 -93.09 105.02 17.17 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 176.338 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.766 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 41.0 t -95.86 86.19 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.274 -2.686 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 178.369 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.402 HG21 ' HB3' ' A' ' 58' ' ' ASP . 94.0 mt -104.92 160.82 5.06 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.49 0 CA-C-N 113.841 -1.527 . . . . 0.0 109.252 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.49 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -122.47 152.88 16.86 Favored Glycine 0 N--CA 1.409 -3.134 0 C-N-CA 119.666 -1.254 . . . . 0.0 110.613 177.015 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 14.8 tpp180 -95.55 123.15 38.96 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -176.255 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 . . . . . 0 C--N 1.303 -1.449 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 172.354 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.505 -0.571 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -102.82 138.11 40.15 Favored 'General case' 0 CA--C 1.493 -1.215 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 175.407 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 18.8 ttt -118.49 117.56 29.36 Favored 'General case' 0 C--N 1.29 -2.021 0 C-N-CA 119.939 -0.704 . . . . 0.0 109.452 -176.455 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -91.19 109.15 20.4 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.233 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -85.87 123.52 31.31 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-O 120.877 0.37 . . . . 0.0 110.468 -177.891 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -133.5 143.71 49.11 Favored Pre-proline 0 C--N 1.29 -1.979 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.72 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.43 126.08 5.96 Favored 'Trans proline' 0 N--CA 1.437 -1.817 0 C-N-CA 122.148 1.899 . . . . 0.0 112.4 177.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.467 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 61.1 t -107.0 98.87 7.49 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.677 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 173.527 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.5 tt0 -88.72 103.38 15.9 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -99.36 137.74 37.44 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -173.738 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -100.28 103.98 15.43 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 171.286 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.754 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.9 mmmp? -98.35 173.57 6.91 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -175.413 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -63.05 167.2 5.07 Favored 'General case' 0 C--N 1.313 -0.996 0 C-N-CA 126.917 2.087 . . . . 0.0 109.069 178.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -64.47 -24.48 67.63 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.646 0.736 . . . . 0.0 109.719 176.724 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -58.78 -45.96 88.6 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 114.501 -1.227 . . . . 0.0 110.333 177.734 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.4 ' O ' ' HB3' ' A' ' 12' ' ' LYS . . . 124.74 -118.24 3.28 Favored Glycine 0 N--CA 1.413 -2.864 0 N-CA-C 107.834 -2.107 . . . . 0.0 107.834 -176.234 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.445 HD21 HG21 ' A' ' 87' ' ' VAL . 18.6 mt -105.76 -50.89 3.09 Favored 'General case' 0 CA--C 1.475 -1.911 0 CA-C-N 118.153 0.976 . . . . 0.0 110.305 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 71.27 30.49 67.15 Favored Glycine 0 N--CA 1.422 -2.291 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 -174.392 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.45 HD11 HD12 ' A' ' 80' ' ' LEU . 21.5 pt -107.32 172.04 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 119.708 -0.797 . . . . 0.0 110.195 179.166 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.3 m -124.67 150.53 46.0 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -177.409 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -124.92 160.68 29.83 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 -177.803 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.3 tt -133.55 126.13 51.21 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 177.023 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.631 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.26 96.53 2.22 Favored Glycine 0 N--CA 1.429 -1.786 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.504 -176.184 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.473 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 79.1 mmm -115.13 76.75 1.02 Allowed 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -49.01 108.63 0.44 Allowed Glycine 0 CA--C 1.504 -0.619 0 O-C-N 124.407 1.067 . . . . 0.0 113.093 -176.464 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -113.6 140.53 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.618 0 N-CA-C 107.969 -1.122 . . . . 0.0 107.969 179.723 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.401 ' O ' ' HA ' ' A' ' 33' ' ' GLU . . . -100.2 -104.47 2.63 Favored Glycine 0 N--CA 1.428 -1.865 0 N-CA-C 110.109 -1.197 . . . . 0.0 110.109 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.408 ' HA ' ' HG2' ' A' ' 33' ' ' GLU . . . -102.71 7.94 39.63 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.279 0.561 . . . . 0.0 110.163 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -59.1 -32.21 69.61 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.49 -172.299 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.14 2.08 31.49 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.184 0.516 . . . . 0.0 111.262 -177.623 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 86.56 -20.85 20.91 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 115.046 0.779 . . . . 0.0 115.046 176.714 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -85.04 -37.06 20.8 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 112.975 0.732 . . . . 0.0 112.975 -176.592 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.408 ' HG2' ' HA ' ' A' ' 28' ' ' ALA . 47.5 mt-10 64.79 91.68 0.08 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.063 0.945 . . . . 0.0 111.898 -178.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 7.3 ptpp? -161.29 -165.18 1.27 Allowed 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.636 HD11 ' O ' ' A' ' 60' ' ' ILE . 0.5 OUTLIER -58.2 158.75 6.68 Favored 'General case' 0 C--N 1.315 -0.899 0 O-C-N 124.192 0.932 . . . . 0.0 109.927 174.942 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.473 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -110.56 30.52 8.1 Favored Glycine 0 C--N 1.298 -1.569 0 C-N-CA 119.837 -1.173 . . . . 0.0 111.578 176.206 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.631 HD13 ' HA2' ' A' ' 23' ' ' GLY . 20.5 mm -90.56 112.03 24.35 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.125 0 CA-C-O 121.509 0.671 . . . . 0.0 110.628 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -104.92 159.88 15.46 Favored 'General case' 0 C--N 1.282 -2.341 0 CA-C-N 115.153 -0.93 . . . . 0.0 109.805 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 44.8 t -75.0 122.05 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 176.08 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 84.6 tttt -86.5 -47.8 8.94 Favored 'General case' 0 C--N 1.286 -2.178 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.623 -177.196 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -152.98 162.34 41.44 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 -179.268 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.431 HG11 ' HG3' ' A' ' 49' ' ' GLN . 47.8 t -130.02 151.84 36.48 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.052 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.2 t -61.29 151.23 32.47 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 176.629 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -48.36 -60.88 2.32 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 124.424 1.09 . . . . 0.0 113.14 -170.683 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 172.32 58.68 0.04 OUTLIER Glycine 0 C--N 1.29 -2.007 0 C-N-CA 118.428 -1.844 . . . . 0.0 114.1 179.416 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.47 -32.27 12.03 Favored Glycine 0 C--N 1.303 -1.298 0 C-N-CA 119.522 -1.323 . . . . 0.0 110.915 174.013 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.754 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . -161.95 -41.74 0.04 OUTLIER 'General case' 0 C--O 1.209 -1.055 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -178.58 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.438 ' HB2' ' CE ' ' A' ' 12' ' ' LYS . . . -65.56 -59.59 3.81 Favored 'General case' 0 N--CA 1.504 2.274 0 CA-C-N 118.719 0.691 . . . . 0.0 110.423 -175.799 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.431 ' HG3' HG11 ' A' ' 42' ' ' VAL . 26.1 mt-30 -78.02 6.8 7.12 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.349 177.437 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 26.0 mmm180 -95.59 -27.72 15.2 Favored 'General case' 0 N--CA 1.428 -1.568 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 171.697 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -66.65 -37.22 84.36 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 173.768 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.58 -31.74 4.13 Favored Glycine 0 N--CA 1.458 0.119 0 CA-C-N 115.471 -0.786 . . . . 0.0 113.985 172.568 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 2.7 ttm180 -61.55 -54.79 38.52 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 124.975 1.31 . . . . 0.0 111.401 -176.78 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.5 tt -84.82 141.55 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 CA-C-N 115.033 -0.985 . . . . 0.0 108.832 -176.689 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.7 mt-30 -143.0 -179.83 6.6 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 119.991 -0.684 . . . . 0.0 111.875 178.816 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.2 t -62.81 -30.69 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.701 178.469 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 35.3 m-80 -83.53 18.55 1.83 Allowed 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 113.252 0.834 . . . . 0.0 113.252 -175.409 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -104.57 175.43 5.49 Favored 'General case' 0 C--O 1.252 1.187 0 CA-C-O 121.491 0.662 . . . . 0.0 111.715 177.573 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.414 ' O ' HG23 ' A' ' 91' ' ' ILE . 62.3 tt0 -127.46 136.27 51.57 Favored 'General case' 0 N--CA 1.422 -1.827 0 CA-C-N 114.848 -1.069 . . . . 0.0 108.453 177.268 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.636 ' O ' HD11 ' A' ' 35' ' ' LEU . 49.0 mm -75.62 139.84 18.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 178.473 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.712 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 90.5 t -119.26 -53.71 3.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 CA-C-O 121.545 0.688 . . . . 0.0 109.805 177.57 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.563 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 32.0 tt0 -151.7 102.91 2.9 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 -177.617 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.449 HG23 HG23 ' A' ' 60' ' ' ILE . 7.8 t -96.41 127.61 48.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.762 -0.586 . . . . 0.0 111.38 179.185 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 35.2 t70 61.51 19.51 10.4 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 124.847 1.259 . . . . 0.0 111.17 173.786 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.17 20.24 79.69 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 114.891 -1.05 . . . . 0.0 112.505 -178.575 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.455 HD13 HG22 ' A' ' 79' ' ' VAL . 6.9 tt -81.33 -14.42 12.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 O-C-N 122.418 -0.46 . . . . 0.0 110.282 -179.269 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.42 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 17.8 m 45.33 81.23 0.04 OUTLIER 'General case' 0 C--N 1.351 0.642 0 C-N-CA 125.479 1.512 . . . . 0.0 112.172 -178.004 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.421 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.5 OUTLIER -91.4 18.31 7.36 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 121.88 0.848 . . . . 0.0 111.409 -174.901 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.409 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 57.2 t -57.95 104.67 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.941 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.264 173.426 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.47 29.27 6.36 Favored Glycine 0 N--CA 1.437 -1.261 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.633 179.028 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 68' ' ' LEU . 15.7 m -113.88 176.1 2.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 C-N-CA 120.166 -0.614 . . . . 0.0 110.735 176.704 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -104.06 173.27 6.38 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.734 178.008 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -59.28 -33.48 71.12 Favored 'General case' 0 C--O 1.204 -1.314 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.035 -176.616 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -66.09 -32.65 74.23 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 123.695 0.798 . . . . 0.0 111.967 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 51.3 t80 -78.92 -49.33 13.01 Favored 'General case' 0 N--CA 1.444 -0.752 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 177.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.42 -43.41 96.79 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.243 -177.892 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.446 ' O ' ' HB2' ' A' ' 81' ' ' ARG . . . -63.38 -22.59 66.97 Favored 'General case' 0 C--O 1.218 -0.592 0 CA-C-O 121.028 0.442 . . . . 0.0 110.798 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 52.9 m -80.96 -45.44 16.66 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.827 177.32 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.539 ' O ' HG23 ' A' ' 83' ' ' THR . 40.0 t -62.45 -52.71 56.63 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.571 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 178.338 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.45 HD12 HD11 ' A' ' 19' ' ' ILE . 3.7 mm? -70.13 6.82 1.14 Allowed 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 123.968 0.907 . . . . 0.0 112.213 -178.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.446 ' HB2' ' O ' ' A' ' 77' ' ' ALA . 41.5 ttt180 -109.12 -47.61 3.4 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 174.169 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -79.76 -10.76 59.83 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 113.99 -1.459 . . . . 0.0 114.021 -172.121 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.539 HG23 ' O ' ' A' ' 79' ' ' VAL . 12.5 p -63.14 138.43 58.55 Favored 'General case' 0 C--O 1.248 1.014 0 CA-C-O 120.418 0.151 . . . . 0.0 110.838 177.419 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.8 mmtt -131.17 132.38 44.69 Favored 'General case' 0 CA--C 1.487 -1.453 0 N-CA-C 113.516 0.932 . . . . 0.0 113.516 -175.714 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.46 -73.17 0.0 OUTLIER Glycine 0 CA--C 1.479 -2.179 0 C-N-CA 127.895 2.664 . . . . 0.0 115.079 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 19.2 m120 -102.53 100.19 10.27 Favored 'General case' 0 C--N 1.253 -3.63 0 CA-C-O 121.376 0.607 . . . . 0.0 109.417 -172.366 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.514 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 5.6 t -114.5 127.67 71.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.058 -172.388 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 37.7 mtm-85 -99.99 97.78 8.61 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-O 121.026 0.441 . . . . 0.0 109.942 175.811 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.467 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 80.8 m-85 -87.56 100.75 13.02 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.494 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.712 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.4 t -85.66 94.25 4.02 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.634 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 175.745 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.414 HG23 ' O ' ' A' ' 59' ' ' GLN . 90.3 mt -112.84 158.58 13.17 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.257 0 CA-C-N 114.05 -1.432 . . . . 0.0 107.749 176.807 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.47 167.34 14.29 Favored Glycine 0 N--CA 1.405 -3.405 0 C-N-CA 118.903 -1.617 . . . . 0.0 112.276 -178.608 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 2.6 tmt_? -113.59 128.55 56.48 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 176.811 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 . . . . . 0 C--N 1.302 -1.477 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 178.236 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.496 -1.113 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 8.9 p80 -161.21 173.6 14.84 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -178.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 25.0 ttt -117.71 117.36 29.14 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 178.179 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.507 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 35.3 tt0 -91.22 114.12 26.56 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.578 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.451 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.0 mm? -87.85 117.34 26.63 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.409 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -132.38 140.67 38.66 Favored Pre-proline 0 C--N 1.294 -1.816 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -177.167 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.401 ' HA ' ' HA ' ' A' ' 90' ' ' VAL . 55.6 Cg_endo -77.78 125.0 7.16 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.525 2.15 . . . . 0.0 111.855 176.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 26.3 t -111.73 97.19 5.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.513 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -80.0 104.29 10.47 Favored 'General case' 0 N--CA 1.425 -1.691 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.676 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -98.4 141.22 31.55 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 -177.374 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -112.88 85.29 2.14 Favored 'General case' 0 N--CA 1.416 -2.133 0 C-N-CA 119.077 -1.049 . . . . 0.0 108.924 172.078 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.631 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 4.3 mmtt -68.69 168.67 12.72 Favored 'General case' 0 N--CA 1.409 -2.511 0 CA-C-N 114.402 -1.272 . . . . 0.0 114.398 -179.374 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.4 ' H ' ' CD ' ' A' ' 12' ' ' LYS . 6.3 m-20 -67.04 164.94 16.73 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 113.721 -1.582 . . . . 0.0 107.506 -178.632 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -70.25 -12.82 61.86 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.41 0.624 . . . . 0.0 111.712 -177.03 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -68.21 -43.87 77.06 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.186 174.48 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.464 ' O ' ' HD2' ' A' ' 12' ' ' LYS . . . 132.64 -152.48 20.29 Favored Glycine 0 N--CA 1.426 -1.98 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -176.292 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.574 ' O ' ' HB ' ' A' ' 43' ' ' THR . 22.8 mt -89.14 -49.49 6.72 Favored 'General case' 0 CA--C 1.489 -1.398 0 CA-C-N 117.678 0.739 . . . . 0.0 109.967 -177.475 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 73.11 23.82 76.93 Favored Glycine 0 N--CA 1.425 -2.054 0 CA-C-N 114.752 -1.113 . . . . 0.0 111.062 -174.728 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.469 HG22 ' HA ' ' A' ' 42' ' ' VAL . 19.5 pt -101.17 178.95 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.747 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.7 m -145.58 156.49 43.72 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.56 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -116.71 162.1 14.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 C-N-CA 122.83 0.452 . . . . 0.0 110.556 -176.065 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.4 tt -132.6 125.36 52.96 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.821 0 CA-C-O 120.965 0.412 . . . . 0.0 110.107 174.272 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.574 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.55 101.18 2.71 Favored Glycine 0 N--CA 1.417 -2.595 0 CA-C-N 115.743 -0.662 . . . . 0.0 112.013 -178.488 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 94.9 mmm -107.1 165.32 11.45 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 177.483 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.62 94.61 0.57 Allowed Glycine 0 C--N 1.287 -2.166 0 C-N-CA 119.207 -1.473 . . . . 0.0 111.414 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -93.93 113.09 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 CA-C-O 121.342 0.592 . . . . 0.0 109.65 178.5 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.03 -82.5 1.05 Allowed Glycine 0 N--CA 1.433 -1.551 0 CA-C-N 115.197 -0.911 . . . . 0.0 111.201 179.251 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.631 ' HA ' ' HG3' ' A' ' 33' ' ' GLU . . . -148.71 105.11 3.53 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.401 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -173.65 -42.71 0.01 OUTLIER 'General case' 0 CA--C 1.514 -0.423 0 O-C-N 123.885 0.741 . . . . 0.0 111.671 -177.537 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.32 -21.31 24.47 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 -170.088 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.01 -8.04 53.45 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -176.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -86.34 -48.47 8.45 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 114.58 -0.81 . . . . 0.0 109.434 179.493 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.631 ' HG3' ' HA ' ' A' ' 28' ' ' ALA . 1.0 OUTLIER 41.3 50.78 3.52 Favored 'General case' 0 C--O 1.243 0.76 0 N-CA-C 114.527 1.306 . . . . 0.0 114.527 176.522 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 6.9 ptpp? -150.57 -155.19 0.6 Allowed 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.516 ' CD2' ' HA ' ' A' ' 69' ' ' VAL . 1.6 pp -48.35 144.93 3.65 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 110.867 175.019 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -106.52 30.19 9.88 Favored Glycine 0 N--CA 1.431 -1.662 0 C-N-CA 120.009 -1.091 . . . . 0.0 111.229 177.038 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.574 HD13 ' HA2' ' A' ' 23' ' ' GLY . 24.8 mm -82.83 100.68 6.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 121.537 0.684 . . . . 0.0 110.038 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -99.28 167.35 10.72 Favored 'General case' 0 C--N 1.277 -2.545 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.482 179.306 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.1 t -83.21 113.62 22.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.689 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 56.6 tptt -76.74 -45.73 28.05 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.897 -176.643 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.4 m -152.37 162.92 40.49 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -175.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.469 ' HA ' HG22 ' A' ' 19' ' ' ILE . 59.6 t -134.27 158.08 41.88 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.066 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.309 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.574 ' HB ' ' O ' ' A' ' 17' ' ' LEU . 10.1 t -49.63 145.67 4.87 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 171.025 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -58.86 -39.14 80.43 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 123.178 0.591 . . . . 0.0 112.507 -174.649 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -175.55 44.56 0.12 Allowed Glycine 0 CA--C 1.471 -2.699 0 C-N-CA 119.784 -1.198 . . . . 0.0 112.567 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -89.05 -166.71 42.39 Favored Glycine 1 N--CA 1.381 -5.018 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 174.116 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.631 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . -55.17 -17.98 5.1 Favored 'General case' 0 C--N 1.274 -2.711 0 N-CA-C 115.254 1.575 . . . . 0.0 115.254 -172.6 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.605 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -74.05 -58.99 2.93 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.217 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -69.84 -24.4 63.45 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 119.83 -0.748 . . . . 0.0 112.133 175.076 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.544 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 13.1 mmt180 -66.37 -36.77 83.72 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 174.017 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -57.23 -59.66 4.78 Favored 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.607 0.567 . . . . 0.0 109.728 177.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.06 -20.75 35.14 Favored Glycine 0 N--CA 1.437 -1.244 0 C-N-CA 120.222 -0.989 . . . . 0.0 114.442 174.37 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.553 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -77.11 -60.95 2.15 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.814 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.553 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 17.5 tt -69.08 140.75 18.33 Favored 'Isoleucine or valine' 0 C--O 1.245 0.831 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.428 -175.518 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 16.4 mm-40 -137.18 173.36 11.76 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-O 121.641 0.734 . . . . 0.0 111.669 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.6 p -81.77 23.75 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.227 0 CA-C-O 122.309 1.052 . . . . 0.0 110.362 -178.687 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -134.79 13.43 3.68 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 122.432 1.111 . . . . 0.0 108.816 -178.324 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.472 ' HB3' HG21 ' A' ' 91' ' ' ILE . 64.9 m-20 -92.47 -177.4 4.6 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.151 -0.932 . . . . 0.0 110.806 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.563 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 32.3 tt0 -134.31 125.02 26.81 Favored 'General case' 0 N--CA 1.434 -1.229 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.303 179.156 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.578 HG21 HD21 ' A' ' 80' ' ' LEU . 45.1 mm -77.63 113.8 17.29 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.908 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -177.143 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.668 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 84.9 t -97.17 -49.14 12.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-O 121.65 0.738 . . . . 0.0 111.093 -177.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.636 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 28.6 tt0 -149.39 115.77 5.82 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.9 t -108.9 125.95 65.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.688 176.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 21.1 t70 69.98 1.62 3.56 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 124.807 1.243 . . . . 0.0 112.162 173.723 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.54 16.84 38.31 Favored Glycine 0 N--CA 1.427 -1.908 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.608 -176.185 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.467 HG21 HG21 ' A' ' 79' ' ' VAL . 7.8 tt -74.24 -32.85 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.786 0 O-C-N 122.343 -0.504 . . . . 0.0 110.357 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.548 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 20.8 t 58.0 93.45 0.03 OUTLIER 'General case' 0 C--N 1.344 0.327 0 C-N-CA 125.015 1.326 . . . . 0.0 110.038 -176.207 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.54 HD21 HG22 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -105.27 21.0 17.91 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 121.747 0.784 . . . . 0.0 109.883 -174.954 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.516 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 21.4 t -56.31 96.22 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.287 -2.129 0 CA-C-N 114.532 -1.213 . . . . 0.0 112.046 179.091 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.49 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 108.49 6.86 30.77 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.859 175.863 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.463 HG22 ' O ' ' A' ' 68' ' ' LEU . 21.3 m -82.7 -177.26 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 117.245 0.522 . . . . 0.0 112.005 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 p -97.89 173.77 6.91 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.003 176.489 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.56 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -61.3 -35.11 76.47 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.437 -1.256 . . . . 0.0 111.706 179.044 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -71.33 -32.15 68.23 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 121.059 -0.257 . . . . 0.0 111.364 -178.547 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -70.75 -47.12 61.34 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 176.434 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.413 ' HA ' HG12 ' A' ' 79' ' ' VAL . . . -61.14 -42.88 99.35 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.915 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.411 ' O ' ' HB3' ' A' ' 81' ' ' ARG . . . -59.26 -38.08 79.18 Favored 'General case' 0 C--O 1.212 -0.911 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 176.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 88.1 m -65.15 -50.95 64.01 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.099 178.3 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.535 HG13 HD22 ' A' ' 80' ' ' LEU . 5.6 p -63.65 -45.2 98.15 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.577 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 178.731 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.578 HD21 HG21 ' A' ' 60' ' ' ILE . 4.0 mm? -67.29 -25.47 66.06 Favored 'General case' 0 C--O 1.216 -0.709 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.411 ' HB3' ' O ' ' A' ' 77' ' ' ALA . 0.4 OUTLIER -86.38 -23.54 26.11 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-O 120.857 0.36 . . . . 0.0 111.657 177.544 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -86.49 5.29 36.03 Favored 'General case' 0 N--CA 1.483 1.211 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 179.062 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.451 HG21 HD11 ' A' ' 17' ' ' LEU . 31.2 p -70.08 178.05 2.94 Favored 'General case' 0 C--N 1.291 -1.965 0 CA-C-O 121.711 0.767 . . . . 0.0 112.348 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.77 -159.04 0.97 Allowed 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 125.01 1.324 . . . . 0.0 108.045 -179.014 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.12 -76.01 0.22 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 114.467 0.547 . . . . 0.0 114.467 -179.223 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -78.75 112.14 15.58 Favored 'General case' 0 CA--C 1.497 -1.076 0 O-C-N 122.654 -0.321 . . . . 0.0 110.427 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 83.0 t -132.36 128.05 57.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.153 -178.374 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.68 108.38 19.78 Favored 'General case' 0 CA--C 1.496 -1.098 0 C-N-CA 119.715 -0.794 . . . . 0.0 109.903 172.133 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -93.63 98.92 11.46 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 174.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.668 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.7 t -84.55 96.39 4.58 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.06 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 176.062 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.472 HG21 ' HB3' ' A' ' 58' ' ' ASP . 95.0 mt -112.91 153.75 14.44 Favored 'Isoleucine or valine' 0 C--N 1.262 -3.202 0 CA-C-N 113.796 -1.547 . . . . 0.0 108.608 177.462 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -119.76 153.65 16.71 Favored Glycine 0 N--CA 1.403 -3.554 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 177.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.513 ' NH1' ' HG3' ' A' ' 94' ' ' GLU . 4.3 tmt_? -135.19 152.39 51.54 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -176.835 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.513 ' HG3' ' NH1' ' A' ' 93' ' ' ARG . 7.2 pt-20 . . . . . 0 C--N 1.321 -0.641 0 O-C-N 124.247 0.967 . . . . 0.0 110.771 177.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.601 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 48.4 tt0 . . . . . 0 N--CA 1.425 -1.706 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -90.79 108.39 19.8 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.822 -1.548 . . . . 0.0 106.822 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -123.13 140.71 34.17 Favored Pre-proline 0 C--N 1.293 -1.881 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -171.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -86.7 131.71 3.37 Favored 'Trans proline' 0 C--N 1.314 -1.267 0 C-N-CA 123.05 2.5 . . . . 0.0 111.928 174.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.3 t -124.32 105.79 15.85 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.302 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 175.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.58 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.1 tt0 -91.32 103.33 16.0 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 175.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.489 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.2 OUTLIER -91.85 143.7 26.24 Favored 'General case' 0 N--CA 1.421 -1.884 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 -174.556 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -112.05 87.92 2.68 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.79 0.805 . . . . 0.0 109.684 175.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.474 ' HG2' HD12 ' A' ' 10' ' ' LEU . 2.1 mmtp -84.87 -178.95 6.98 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -178.222 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.402 ' CG ' ' H ' ' A' ' 14' ' ' GLU . 18.9 t70 -76.08 -176.7 3.61 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 113.568 -1.651 . . . . 0.0 109.845 -178.577 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.402 ' H ' ' CG ' ' A' ' 13' ' ' ASP . 12.0 pt-20 -82.02 -19.86 39.57 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.809 -1.087 . . . . 0.0 109.936 -176.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -69.26 -47.46 64.59 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.73 -128.31 4.4 Favored Glycine 0 N--CA 1.425 -2.039 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.078 -177.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.468 HD21 HG21 ' A' ' 87' ' ' VAL . 9.6 mt -103.81 -49.49 3.64 Favored 'General case' 0 CA--C 1.495 -1.139 0 O-C-N 122.351 -0.499 . . . . 0.0 110.151 -174.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 71.74 31.91 64.55 Favored Glycine 0 N--CA 1.428 -1.858 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -175.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.412 HG22 ' HA ' ' A' ' 42' ' ' VAL . 18.5 pt -111.01 167.82 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 C-N-CA 120.151 -0.62 . . . . 0.0 110.399 -179.077 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.4 m -131.47 154.38 48.78 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.303 -177.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.428 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -123.34 170.04 14.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 C-N-CA 123.334 0.654 . . . . 0.0 109.352 -178.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.421 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.1 tt -136.37 131.41 48.38 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 C-N-CA 120.569 -0.452 . . . . 0.0 110.208 176.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.631 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.63 104.24 3.08 Favored Glycine 0 CA--C 1.477 -2.305 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.428 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 19.4 ptm -145.75 98.17 3.08 Favored 'General case' 0 C--N 1.29 -1.992 0 CA-C-N 115.389 -0.406 . . . . 0.0 110.699 -179.049 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.036 0 O-C-N 124.36 1.038 . . . . 0.0 111.32 -178.162 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.415 HD12 ' H ' ' A' ' 37' ' ' ILE . 3.4 pp . . . . . 0 N--CA 1.434 -1.251 0 CA-C-O 120.957 0.408 . . . . 0.0 110.018 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -109.8 32.59 6.62 Favored Glycine 0 C--N 1.281 -2.509 0 C-N-CA 120.19 -1.005 . . . . 0.0 111.329 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.631 HD13 ' HA2' ' A' ' 23' ' ' GLY . 28.4 mm -93.06 100.4 11.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-O 121.732 0.777 . . . . 0.0 110.064 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -97.24 166.65 11.46 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.336 178.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.0 t -80.95 131.37 34.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 175.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.445 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -93.27 -49.61 5.88 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.477 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.3 m -150.69 161.03 43.4 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 -176.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.534 HG11 ' HG3' ' A' ' 49' ' ' GLN . 57.7 t -132.66 160.39 42.6 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.662 0 N-CA-C 104.9 -2.259 . . . . 0.0 104.9 175.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.1 t . . . . . 0 N--CA 1.433 -1.287 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 173.412 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.485 ' O ' ' HB2' ' A' ' 51' ' ' ASP . . . . . . . . 0 C--O 1.187 -2.204 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -95.95 -57.07 2.45 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -176.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.534 ' HG3' HG11 ' A' ' 42' ' ' VAL . 25.6 mt-30 -80.92 -12.99 59.31 Favored 'General case' 0 CA--C 1.502 -0.874 0 C-N-CA 119.349 -0.94 . . . . 0.0 109.853 177.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.48 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 5.8 mmp_? -92.17 -9.83 40.95 Favored 'General case' 0 N--CA 1.427 -1.599 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.891 173.062 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.485 ' HB2' ' O ' ' A' ' 47' ' ' ALA . 13.2 t70 -70.54 -64.74 0.84 Allowed 'General case' 0 N--CA 1.481 1.12 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 171.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 115.54 -25.66 9.55 Favored Glycine 0 N--CA 1.431 -1.655 0 C-N-CA 120.383 -0.913 . . . . 0.0 114.297 175.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -80.48 -36.0 34.04 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 117.903 0.851 . . . . 0.0 109.149 -177.581 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.4 tt -92.97 149.55 4.18 Favored 'Isoleucine or valine' 0 C--O 1.254 1.303 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 23.5 mt-30 -130.8 167.43 18.91 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.156 0.503 . . . . 0.0 111.031 179.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.98 -8.81 11.48 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.165 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.641 178.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 10.3 p30 -106.38 12.62 29.59 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-O 121.423 0.63 . . . . 0.0 110.764 -177.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -91.28 -174.4 3.93 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.613 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.56 ' O ' HG23 ' A' ' 91' ' ' ILE . 30.6 tt0 -135.09 126.13 27.78 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.765 -176.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.542 HG22 HD11 ' A' ' 68' ' ' LEU . 47.0 mm -73.65 114.45 13.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.704 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 74.0 t -93.26 -49.95 12.5 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-O 121.675 0.75 . . . . 0.0 109.928 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.527 ' HG3' ' H ' ' A' ' 67' ' ' SER . 26.1 tt0 -151.27 126.73 10.06 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.464 178.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 5.0 t -118.43 130.65 72.96 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.048 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 174.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 16.6 t70 62.69 16.71 9.16 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 124.205 1.002 . . . . 0.0 111.623 174.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.89 15.81 78.37 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.209 -179.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.525 HD13 HG22 ' A' ' 79' ' ' VAL . 4.4 tt -79.86 -16.83 12.93 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.115 0 O-C-N 122.347 -0.502 . . . . 0.0 112.064 -175.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.527 ' H ' ' HG3' ' A' ' 62' ' ' GLU 0.282 0.8 OUTLIER 39.34 80.97 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 114.728 1.381 . . . . 0.0 114.728 -175.553 . . . . . . . . 4 4 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.62 ' H ' HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -92.24 36.78 0.99 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.859 -176.73 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.66 91.41 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.713 -177.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 107.4 33.17 3.21 Favored Glycine 0 C--N 1.303 -1.276 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.79 176.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.463 HG21 ' HB2' ' A' ' 68' ' ' LEU . 24.9 m -103.97 175.96 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 120.249 -0.58 . . . . 0.0 111.152 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 40.3 p -91.89 176.0 6.68 Favored 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 178.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.428 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -68.35 -25.18 64.96 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.404 179.86 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 -65.32 -48.16 74.04 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.488 ' O ' HG23 ' A' ' 79' ' ' VAL . 29.5 t80 -64.44 -51.85 61.07 Favored 'General case' 0 N--CA 1.432 -1.331 0 CA-C-N 114.577 -1.192 . . . . 0.0 109.124 -178.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.77 -44.99 96.05 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.558 -177.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.5 -34.1 73.58 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.039 0.447 . . . . 0.0 110.066 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.467 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 76.8 m -65.75 -45.06 84.01 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.525 176.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.525 HG22 HD13 ' A' ' 66' ' ' ILE . 41.1 t -60.62 -52.33 62.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 C-N-CA 122.229 0.212 . . . . 0.0 110.527 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -70.7 0.07 7.78 Favored 'General case' 0 CA--C 1.552 1.049 0 CA-C-O 121.406 0.622 . . . . 0.0 112.154 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.467 ' HB3' ' O ' ' A' ' 78' ' ' THR . 25.9 ttm180 -100.14 -38.18 8.63 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 124.024 0.93 . . . . 0.0 108.986 174.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.17 -10.26 59.3 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.122 -175.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.3 p -71.58 161.23 31.34 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 113.183 0.808 . . . . 0.0 113.183 -178.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -118.9 -161.24 0.84 Allowed 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.23 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.59 -63.42 5.3 Favored Glycine 0 N--CA 1.439 -1.12 0 O-C-N 123.544 0.528 . . . . 0.0 113.323 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.489 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 17.9 m120 -82.14 108.82 15.91 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.58 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.8 t -119.7 136.66 56.1 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.677 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.721 -176.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 84.2 mtt180 -102.63 97.38 7.58 Favored 'General case' 0 C--N 1.288 -2.103 0 CA-C-O 121.4 0.619 . . . . 0.0 109.993 173.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.458 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 92.8 m-85 -89.36 106.16 18.27 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.735 177.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.704 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.4 t -95.65 88.77 2.13 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.743 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 175.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.56 HG23 ' O ' ' A' ' 59' ' ' GLN . 82.2 mt -101.09 149.68 6.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.678 0 CA-C-N 114.613 -1.176 . . . . 0.0 108.566 179.094 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.601 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -138.05 128.73 4.32 Favored Glycine 1 N--CA 1.393 -4.196 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 -178.638 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 15.7 ttp180 -157.9 162.1 38.28 Favored 'General case' 0 N--CA 1.414 -2.24 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 -175.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.409 ' H ' ' CD ' ' A' ' 94' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--N 1.285 -2.212 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 175.367 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.426 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 32.0 tt0 . . . . . 0 CA--C 1.479 -1.751 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.476 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.5 mm? -86.43 134.28 33.71 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 123.752 0.658 . . . . 0.0 109.884 -177.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 10.7 p90 -141.57 144.36 33.11 Favored Pre-proline 0 C--N 1.293 -1.865 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.802 -178.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -84.61 130.17 4.36 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 C-N-CA 122.57 2.18 . . . . 0.0 113.168 179.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.487 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 26.1 t -115.65 107.65 23.23 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.228 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 174.034 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -88.42 107.02 18.64 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 177.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.428 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -100.48 139.27 36.4 Favored 'General case' 0 N--CA 1.423 -1.802 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -176.157 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -109.76 81.77 1.49 Allowed 'General case' 0 N--CA 1.426 -1.641 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 173.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.558 ' HE2' ' H ' ' A' ' 48' ' ' ALA . 2.0 mmtt -77.9 171.72 14.56 Favored 'General case' 0 N--CA 1.409 -2.52 0 CA-C-N 115.05 -0.977 . . . . 0.0 113.426 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -72.96 167.98 19.93 Favored 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 126.06 1.744 . . . . 0.0 108.617 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -68.58 -21.41 64.53 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-O 121.412 0.625 . . . . 0.0 110.289 179.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -64.14 -32.43 74.0 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.418 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.23 -158.8 14.05 Favored Glycine 0 N--CA 1.434 -1.472 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -178.501 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.455 HD11 HG21 ' A' ' 83' ' ' THR . 17.6 mt -83.64 -48.78 9.84 Favored 'General case' 0 CA--C 1.49 -1.352 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -177.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.32 32.01 71.85 Favored Glycine 0 N--CA 1.431 -1.67 0 O-C-N 124.515 1.134 . . . . 0.0 110.677 -175.093 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.414 HG23 ' HB3' ' A' ' 17' ' ' LEU . 26.8 pt -98.91 -177.79 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.567 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.403 -178.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.8 m -138.13 149.09 45.58 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 122.766 0.426 . . . . 0.0 110.011 -178.01 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.446 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.5 pp -119.04 161.39 18.15 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 C-N-CA 123.324 0.65 . . . . 0.0 109.73 -177.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.6 tt -128.94 128.72 67.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 174.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.588 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.71 96.39 2.07 Favored Glycine 0 N--CA 1.432 -1.61 0 C-N-CA 120.468 -0.872 . . . . 0.0 112.77 -175.526 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 91.9 mmm -104.15 164.52 11.66 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -2.35 0 C-N-CA 119.969 -1.11 . . . . 0.0 110.653 177.36 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.484 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.6 pt? . . . . . 0 N--CA 1.436 -1.136 0 CA-C-O 121.738 0.78 . . . . 0.0 111.054 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -114.26 19.99 16.78 Favored Glycine 0 N--CA 1.412 -2.964 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 174.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.588 HD13 ' HA2' ' A' ' 23' ' ' GLY . 30.5 mm -77.7 116.53 21.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 177.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -114.92 165.88 12.39 Favored 'General case' 0 C--N 1.269 -2.924 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.7 t -77.96 132.37 32.66 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 176.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.518 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -95.89 -44.0 7.58 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 121.396 0.617 . . . . 0.0 110.049 -178.715 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.8 m -155.66 160.13 40.15 Favored 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 -178.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.41 ' HA ' HG22 ' A' ' 19' ' ' ILE . 64.0 t -129.11 148.8 33.29 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.621 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.3 t . . . . . 0 C--O 1.254 1.292 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 176.61 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 CA--C 1.563 1.463 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.558 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -77.88 -57.34 3.85 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -75.16 -12.61 60.34 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 119.764 -0.774 . . . . 0.0 112.085 175.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.568 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 20.5 mmm180 -73.4 -40.99 63.88 Favored 'General case' 0 CA--C 1.507 -0.689 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -62.36 -57.69 10.39 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.965 0.79 . . . . 0.0 109.603 176.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 83.25 -5.74 75.49 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 115.539 0.976 . . . . 0.0 115.539 173.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -78.36 -30.99 48.29 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 19.7 tt -89.11 152.6 3.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 175.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -133.03 -177.57 4.57 Favored 'General case' 0 N--CA 1.42 -1.962 0 CA-C-O 121.508 0.67 . . . . 0.0 111.019 -179.297 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.9 p -97.9 -5.06 9.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 121.822 0.82 . . . . 0.0 109.548 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.402 HD22 ' HA ' ' A' ' 57' ' ' ASN . 2.1 t-20 -117.2 16.96 14.88 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.433 -174.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.426 ' OD1' HD13 ' A' ' 91' ' ' ILE . 3.0 p30 -100.66 -168.37 1.56 Allowed 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.167 177.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.476 ' O ' HG23 ' A' ' 91' ' ' ILE . 11.8 tt0 -131.39 117.6 19.11 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.374 -176.302 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.504 ' HA ' HG12 ' A' ' 91' ' ' ILE . 46.0 mm -68.83 106.85 1.24 Allowed 'Isoleucine or valine' 0 C--O 1.21 -1.024 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.778 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 89.3 t -87.76 -50.87 13.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-O 121.607 0.718 . . . . 0.0 110.326 -177.769 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.503 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.9 tt0 -145.62 133.32 21.04 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.31 129.56 71.98 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 176.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 31.3 t70 64.2 16.95 10.41 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 124.739 1.274 . . . . 0.0 111.143 172.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 72.2 26.03 73.16 Favored Glycine 0 N--CA 1.433 -1.525 0 CA-C-N 114.825 -1.08 . . . . 0.0 112.483 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.499 HD13 HG22 ' A' ' 79' ' ' VAL . 7.5 tt -85.09 -15.1 10.9 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 CA-C-O 121.417 0.627 . . . . 0.0 109.389 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.482 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 23.2 p 49.01 83.84 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 124.951 1.3 . . . . 0.0 112.704 -175.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.442 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.9 pp -97.88 14.02 28.6 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 122.22 1.01 . . . . 0.0 109.313 -177.682 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 22.4 t -56.13 93.43 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-N 113.836 -1.529 . . . . 0.0 110.356 176.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.484 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 106.74 14.52 19.24 Favored Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 116.032 -0.531 . . . . 0.0 113.3 176.571 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.442 HG22 ' O ' ' A' ' 68' ' ' LEU . 21.0 m -88.16 176.14 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 O-C-N 122.335 -0.509 . . . . 0.0 111.836 -179.426 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.6 p -92.16 176.72 6.39 Favored 'General case' 0 N--CA 1.428 -1.545 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.185 177.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.446 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -66.98 -23.87 65.98 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.07 179.895 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 19.6 m-80 -63.53 -50.92 67.68 Favored 'General case' 0 CA--C 1.484 -1.581 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.429 ' O ' HG23 ' A' ' 79' ' ' VAL . 38.8 t80 -68.5 -50.56 51.31 Favored 'General case' 0 N--CA 1.415 -2.182 0 CA-C-N 114.067 -1.424 . . . . 0.0 110.093 -175.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.5 -44.45 95.96 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.29 -16.48 64.07 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-O 121.232 0.539 . . . . 0.0 111.063 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.407 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 60.2 m -85.04 -42.22 15.06 Favored 'General case' 0 N--CA 1.417 -2.107 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.944 176.678 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.499 HG22 HD13 ' A' ' 66' ' ' ILE . 38.7 t -62.85 -53.14 50.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 122.211 0.204 . . . . 0.0 110.588 178.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.434 HD21 HG21 ' A' ' 60' ' ' ILE . 3.4 mm? -68.59 -1.93 7.86 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-O 121.571 0.701 . . . . 0.0 112.434 -179.367 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.407 ' HB3' ' O ' ' A' ' 78' ' ' THR . 33.4 ttm180 -97.34 -43.41 7.32 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-O 121.922 0.868 . . . . 0.0 108.93 174.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 11.5 m-80 -83.78 8.59 14.22 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 114.338 -1.301 . . . . 0.0 112.794 -174.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.455 HG21 HD11 ' A' ' 17' ' ' LEU . 2.2 p -65.6 176.99 1.31 Allowed 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 123.86 0.864 . . . . 0.0 112.679 177.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -139.25 -155.57 0.6 Allowed 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.31 -175.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -71.77 -68.77 1.53 Allowed Glycine 0 N--CA 1.444 -0.786 0 O-C-N 123.66 0.6 . . . . 0.0 111.834 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.428 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 43.8 m-80 -87.28 104.12 16.1 Favored 'General case' 0 CA--C 1.498 -1.044 0 CA-C-O 121.638 0.732 . . . . 0.0 110.079 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.42 ' HB ' ' CE1' ' A' ' 89' ' ' PHE . 3.0 t -116.74 133.17 64.25 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 CA-C-N 115.261 -0.881 . . . . 0.0 109.76 -175.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 70.0 mtp180 -97.79 101.97 13.6 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 173.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.487 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 91.1 m-85 -92.74 107.36 19.16 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 176.416 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.778 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 42.8 t -96.05 86.26 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.268 -2.951 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.504 HG12 ' HA ' ' A' ' 60' ' ' ILE . 88.8 mt -96.08 158.73 3.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.25 0 C-N-CA 125.314 1.445 . . . . 0.0 108.689 -179.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.476 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -136.53 149.32 20.11 Favored Glycine 0 N--CA 1.398 -3.884 0 C-N-CA 119.565 -1.303 . . . . 0.0 111.267 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.23 135.18 54.44 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.078 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.291 -1.972 0 C-N-CA 124.335 1.054 . . . . 0.0 112.893 -175.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 . . . . . 0 N--CA 1.429 -1.485 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.54 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -87.31 128.6 35.17 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -140.43 144.08 35.49 Favored Pre-proline 0 C--N 1.307 -1.269 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -178.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -83.01 126.23 4.34 Favored 'Trans proline' 0 C--N 1.327 -0.594 0 C-N-CA 123.092 2.528 . . . . 0.0 113.393 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 41.4 t -118.05 99.94 9.08 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.018 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 175.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.489 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 34.0 tt0 -85.2 109.67 18.47 Favored 'General case' 0 N--CA 1.432 -1.372 0 C-N-CA 119.544 -0.863 . . . . 0.0 108.72 176.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.409 HD11 ' O ' ' A' ' 47' ' ' ALA . 0.1 OUTLIER -99.83 145.37 27.82 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -177.694 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -111.24 90.26 3.28 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 173.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.655 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 3.3 mtpm? -80.56 -176.63 5.84 Favored 'General case' 0 N--CA 1.423 -1.777 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -178.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -72.83 173.02 9.75 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 112.338 -2.21 . . . . 0.0 111.679 -173.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -61.29 -26.66 67.93 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.303 -0.862 . . . . 0.0 112.42 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -67.52 -45.52 75.51 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-O 121.494 0.664 . . . . 0.0 109.879 176.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.36 -114.3 2.34 Favored Glycine 0 N--CA 1.426 -2.025 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.73 -176.069 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.519 ' HG ' HG23 ' A' ' 19' ' ' ILE . 9.9 tp -108.1 -62.77 1.4 Allowed 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 117.349 0.575 . . . . 0.0 111.656 -173.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.87 36.25 92.87 Favored Glycine 0 N--CA 1.44 -1.034 0 O-C-N 123.889 0.743 . . . . 0.0 113.139 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.519 HG23 ' HG ' ' A' ' 17' ' ' LEU . 20.9 pt -102.17 178.48 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.519 177.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.8 m -130.79 148.79 52.61 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.53 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -118.66 162.86 16.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.453 -177.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.4 ' CG2' ' HB2' ' A' ' 38' ' ' PHE . 15.6 tt -126.9 125.55 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.938 0 C-N-CA 120.269 -0.573 . . . . 0.0 110.435 174.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.472 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -86.96 105.63 3.06 Favored Glycine 0 N--CA 1.431 -1.66 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.753 -178.417 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.462 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 9.0 ptp -137.03 176.96 8.24 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 122.668 0.387 . . . . 0.0 111.891 176.239 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.277 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.804 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.419 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.6 pt? . . . . . 0 N--CA 1.446 -0.627 0 CA-C-O 121.405 0.621 . . . . 0.0 111.438 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.462 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -124.41 33.0 3.94 Favored Glycine 0 N--CA 1.412 -2.909 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 174.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.542 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 32.8 mm -89.5 107.76 18.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 176.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.4 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 91.0 m-85 -104.21 168.66 8.96 Favored 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.9 t -78.72 121.63 32.16 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 176.014 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.524 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.1 OUTLIER -86.73 -49.19 7.65 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.503 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.09 157.65 43.68 Favored 'General case' 0 N--CA 1.417 -2.11 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.416 ' HA ' HG22 ' A' ' 19' ' ' ILE . 2.6 p -133.72 151.07 32.43 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.952 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 176.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.406 HG21 ' HE3' ' A' ' 12' ' ' LYS . 9.6 t . . . . . 0 N--CA 1.444 -0.726 0 CA-C-O 121.583 0.706 . . . . 0.0 112.132 -173.524 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.655 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . . . . . . 0 CA--C 1.55 0.943 0 N-CA-C 115.301 1.593 . . . . 0.0 115.301 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.29 -63.13 1.47 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 -70.6 -21.9 62.61 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 120.616 -0.434 . . . . 0.0 112.125 176.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.424 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 40.2 mmt180 -68.54 -33.71 74.58 Favored 'General case' 0 CA--C 1.522 -0.103 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -70.48 -64.98 0.79 Allowed 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.353 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.62 -10.97 57.84 Favored Glycine 0 N--CA 1.437 -1.278 0 C-N-CA 120.549 -0.834 . . . . 0.0 115.115 175.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.657 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -76.72 -33.63 58.16 Favored 'General case' 0 C--O 1.239 0.507 0 CA-C-N 118.65 1.225 . . . . 0.0 108.448 178.404 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.3 tt -90.82 154.47 3.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 178.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -134.96 -163.43 1.38 Allowed 'General case' 0 N--CA 1.428 -1.57 0 C-N-CA 119.772 -0.771 . . . . 0.0 110.972 -174.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.9 p -115.16 11.43 7.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-O 122.81 1.29 . . . . 0.0 107.564 176.25 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -121.94 -7.34 8.95 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.435 -1.257 . . . . 0.0 110.655 -174.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.511 ' OD1' HD13 ' A' ' 91' ' ' ILE . 3.9 p30 -86.92 -165.29 1.25 Allowed 'General case' 0 C--O 1.255 1.358 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.425 -177.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.542 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 62.9 tt0 -142.04 121.55 13.27 Favored 'General case' 0 N--CA 1.416 -2.14 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.38 -175.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.461 ' HA ' HG12 ' A' ' 91' ' ' ILE . 42.3 mm -70.16 107.0 1.71 Allowed 'Isoleucine or valine' 0 C--O 1.212 -0.872 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 179.149 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.698 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 93.5 t -88.28 -52.26 11.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 CA-C-O 121.649 0.738 . . . . 0.0 110.724 -177.178 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.585 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 29.4 tt0 -146.15 110.53 5.07 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.75 -178.199 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 t -105.15 131.0 55.44 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.919 0 O-C-N 122.033 -0.417 . . . . 0.0 111.455 176.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 33.5 t70 61.65 16.75 8.02 Favored 'General case' 0 N--CA 1.484 1.273 0 O-C-N 124.722 1.264 . . . . 0.0 111.242 174.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.37 19.01 75.05 Favored Glycine 0 N--CA 1.443 -0.898 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.232 -179.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.4 tt -80.18 -30.23 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 O-C-N 122.36 -0.494 . . . . 0.0 110.971 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.473 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 19.4 t 54.59 95.24 0.02 OUTLIER 'General case' 0 C--N 1.345 0.392 0 C-N-CA 125.035 1.334 . . . . 0.0 110.5 -175.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.466 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.7 OUTLIER -101.65 20.35 16.35 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 122.204 1.002 . . . . 0.0 109.734 -176.144 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 39.0 t -61.84 93.56 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-N 114.496 -1.229 . . . . 0.0 111.343 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.419 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 117.07 5.77 14.68 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.697 176.641 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.466 HG22 ' O ' ' A' ' 68' ' ' LEU . 16.3 m -87.72 179.51 0.49 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.57 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -177.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 14.9 p -94.21 176.18 6.41 Favored 'General case' 0 C--O 1.255 1.376 0 CA-C-O 121.463 0.649 . . . . 0.0 109.9 177.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.53 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -62.81 -38.37 90.44 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 114.713 -1.131 . . . . 0.0 111.246 178.071 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -68.65 -32.76 72.84 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 111.768 0.284 . . . . 0.0 111.768 -177.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -68.28 -51.83 40.59 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 176.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.418 ' CB ' HG21 ' A' ' 37' ' ' ILE . . . -59.84 -44.64 93.98 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.463 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.58 -18.48 63.93 Favored 'General case' 0 C--O 1.22 -0.467 0 C-N-CA 122.995 0.518 . . . . 0.0 111.266 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 78.3 m -83.67 -49.66 8.94 Favored 'General case' 0 N--CA 1.416 -2.125 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 175.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.441 ' O ' HG23 ' A' ' 83' ' ' THR . 38.4 t -59.57 -54.82 29.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 CA-C-O 120.462 0.172 . . . . 0.0 110.831 -178.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -67.95 -2.77 8.12 Favored 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 123.331 0.652 . . . . 0.0 112.033 -179.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 38.5 ttt180 -98.8 -43.46 6.76 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 174.221 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -73.08 -11.73 60.65 Favored 'General case' 0 C--O 1.24 0.588 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.142 -174.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.441 HG23 ' O ' ' A' ' 79' ' ' VAL . 15.9 p -75.14 140.18 43.2 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-O 121.588 0.709 . . . . 0.0 112.464 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.464 ' O ' HG22 ' A' ' 87' ' ' VAL . 71.0 mmtt -107.07 -167.5 1.28 Allowed 'General case' 0 C--N 1.292 -1.908 0 CA-C-N 114.432 -1.258 . . . . 0.0 109.044 176.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -40.14 -58.57 2.33 Favored Glycine 0 C--O 1.216 -0.971 0 O-C-N 124.631 1.207 . . . . 0.0 115.761 -176.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -87.62 100.32 12.72 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 117.747 0.773 . . . . 0.0 111.399 -174.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.565 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 1.6 t -119.43 128.7 75.86 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.36 -175.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 42.3 mtp180 -92.31 99.46 12.23 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 173.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.565 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 97.1 m-85 -92.06 101.09 13.63 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 177.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.698 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.8 t -91.08 92.44 3.94 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 105.963 -1.865 . . . . 0.0 105.963 175.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.511 HD13 ' OD1' ' A' ' 58' ' ' ASP . 97.2 mt -110.56 153.39 12.35 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.777 0 CA-C-N 114.293 -1.321 . . . . 0.0 107.968 179.336 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.54 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -124.42 150.5 17.08 Favored Glycine 0 N--CA 1.401 -3.662 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.938 179.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 4.3 tmm_? -113.9 134.95 54.49 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 -177.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 . . . . . 0 C--N 1.309 -1.165 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.436 179.721 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 . . . . . 0 N--CA 1.436 -1.155 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.474 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.1 mm? -90.45 120.39 31.52 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -135.1 146.64 59.21 Favored Pre-proline 0 C--N 1.304 -1.398 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -175.647 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -80.28 126.89 6.42 Favored 'Trans proline' 0 N--CA 1.444 -1.431 0 C-N-CA 122.244 1.963 . . . . 0.0 112.488 175.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 48.8 t -108.45 103.26 15.21 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.076 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 173.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.455 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.1 tt0 -88.17 103.57 15.89 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.49 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -98.28 145.71 26.38 Favored 'General case' 0 N--CA 1.426 -1.625 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 -175.819 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -116.48 95.85 5.25 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-O 121.66 0.743 . . . . 0.0 109.188 175.18 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.478 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 1.9 mmmp? -92.49 -169.96 2.35 Favored 'General case' 0 N--CA 1.419 -1.991 0 CA-C-N 114.911 -1.041 . . . . 0.0 112.564 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -78.49 167.19 21.66 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 113.864 -1.516 . . . . 0.0 107.805 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -67.88 -20.11 65.09 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.325 0.584 . . . . 0.0 109.807 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -65.69 -31.77 72.96 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 114.697 -1.138 . . . . 0.0 109.707 177.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.73 -130.4 9.06 Favored Glycine 0 N--CA 1.413 -2.838 0 CA-C-N 114.841 -1.072 . . . . 0.0 111.613 177.086 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.6 ' HB3' HG23 ' A' ' 19' ' ' ILE . 20.7 mt -108.49 -63.68 1.31 Allowed 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.836 -174.587 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.62 23.27 36.87 Favored Glycine 0 N--CA 1.424 -2.1 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -172.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.6 HG23 ' HB3' ' A' ' 17' ' ' LEU . 22.7 pt -89.23 178.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.349 0.547 0 C-N-CA 120.446 -0.502 . . . . 0.0 110.908 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.1 m -139.17 147.59 42.05 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.431 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -126.8 162.4 31.44 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 C-N-CA 122.814 0.446 . . . . 0.0 110.108 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.441 ' HB ' ' HG2' ' A' ' 40' ' ' LYS . 13.5 tt -130.96 135.0 60.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.473 174.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.576 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.18 102.48 2.86 Favored Glycine 0 N--CA 1.427 -1.945 0 C-N-CA 120.722 -0.751 . . . . 0.0 111.792 -178.017 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.641 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 93.8 mmm -116.87 93.48 4.21 Favored 'General case' 0 C--N 1.291 -1.96 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -179.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.915 0 O-C-N 123.839 0.712 . . . . 0.0 111.743 -179.002 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.465 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.5 pp . . . . . 0 N--CA 1.43 -1.45 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.641 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -129.59 34.37 2.79 Favored Glycine 0 C--N 1.283 -2.38 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 172.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.576 HD13 ' HA2' ' A' ' 23' ' ' GLY . 26.8 mm -86.72 100.19 9.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.828 0 CA-C-O 121.556 0.693 . . . . 0.0 110.992 -175.405 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -93.16 160.3 14.91 Favored 'General case' 0 C--N 1.287 -2.134 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.211 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 49.3 t -83.63 130.52 35.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.441 ' HG2' ' HB ' ' A' ' 22' ' ' ILE . 20.3 mmmt -87.77 -53.09 4.95 Favored 'General case' 0 CA--C 1.491 -1.3 0 CA-C-O 121.661 0.743 . . . . 0.0 110.266 178.184 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -144.28 160.26 41.3 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 -176.107 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 60.9 t -131.53 86.95 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.473 -1.995 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -178.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.526 ' H ' ' HA ' ' A' ' 19' ' ' ILE 0.257 95.9 m . . . . . 0 CA--C 1.583 2.248 0 O-C-N 124.542 1.151 . . . . 0.0 110.182 179.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.478 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.201 -1.494 0 N-CA-C 115.114 1.524 . . . . 0.0 115.114 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.35 -60.42 2.25 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 179.075 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 44.1 mt-30 -70.64 -24.3 62.69 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.065 -0.516 . . . . 0.0 112.333 176.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.437 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 40.0 mmt180 -69.72 -37.46 76.54 Favored 'General case' 0 CA--C 1.504 -0.806 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.589 174.771 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -59.81 -48.73 80.52 Favored 'General case' 0 C--N 1.352 0.691 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.61 -10.61 36.94 Favored Glycine 0 N--CA 1.439 -1.116 0 N-CA-C 115.286 0.874 . . . . 0.0 115.286 172.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.464 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.1 OUTLIER -75.46 -27.77 59.01 Favored 'General case' 0 C--O 1.221 -0.426 0 CA-C-N 118.57 1.185 . . . . 0.0 108.401 -179.782 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.0 tt -97.81 149.29 5.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 177.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 48.2 mt-30 -132.71 170.34 15.38 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-O 121.839 0.828 . . . . 0.0 112.499 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.4 p -83.26 -3.61 7.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.763 -179.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -103.85 15.98 27.42 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 122.6 1.191 . . . . 0.0 108.332 -178.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.512 ' HB3' HG21 ' A' ' 91' ' ' ILE . 68.5 m-20 -93.23 177.9 5.9 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.223 -0.899 . . . . 0.0 112.335 -178.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -136.7 122.46 19.89 Favored 'General case' 0 N--CA 1.416 -2.174 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.46 HG21 HD21 ' A' ' 80' ' ' LEU . 47.5 mm -74.11 111.95 10.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 -175.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.712 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 99.4 t -92.12 -51.22 11.77 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-O 121.771 0.796 . . . . 0.0 110.28 -177.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.527 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.4 tt0 -152.04 110.09 3.69 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.33 0.586 . . . . 0.0 111.066 -178.338 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.411 HG23 HG23 ' A' ' 60' ' ' ILE . 4.7 t -102.01 129.08 53.9 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 O-C-N 122.005 -0.434 . . . . 0.0 110.983 177.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 18.2 t70 65.11 10.52 6.42 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 124.764 1.226 . . . . 0.0 111.772 174.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.32 19.9 68.11 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.421 -177.428 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.517 HD13 HG22 ' A' ' 79' ' ' VAL . 9.7 tt -76.33 -18.96 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 CA-C-O 121.058 0.456 . . . . 0.0 110.357 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.518 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 31.4 p 48.2 84.96 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 124.875 1.27 . . . . 0.0 112.004 -175.189 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.447 HD21 HG22 ' A' ' 60' ' ' ILE . 1.5 pp -97.12 16.92 18.31 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.669 0.747 . . . . 0.0 110.084 -175.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.465 ' HA ' HD23 ' A' ' 35' ' ' LEU . 45.6 t -58.16 97.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.171 174.771 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.22 53.55 1.0 Allowed Glycine 0 N--CA 1.431 -1.652 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.551 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.6 m -134.32 173.87 13.91 Favored 'Isoleucine or valine' 0 C--O 1.244 0.796 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 176.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 14.5 p -92.45 175.53 6.8 Favored 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 122.873 0.469 . . . . 0.0 110.965 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.431 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -66.38 -31.17 71.77 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.276 -179.36 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -69.56 -36.94 76.77 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 120.783 -0.367 . . . . 0.0 111.166 -179.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.416 ' O ' HG23 ' A' ' 79' ' ' VAL . 44.1 t80 -68.02 -51.15 50.3 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.21 -47.14 86.45 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.036 -0.983 . . . . 0.0 111.693 -177.659 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.22 -37.07 74.12 Favored 'General case' 0 C--O 1.212 -0.9 0 O-C-N 122.94 0.15 . . . . 0.0 110.641 179.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 65.3 m -64.75 -42.75 94.93 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.088 176.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.517 HG22 HD13 ' A' ' 66' ' ' ILE . 47.8 t -61.12 -51.56 71.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 177.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.46 HD21 HG21 ' A' ' 60' ' ' ILE . 3.6 mm? -69.73 -2.34 11.63 Favored 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.448 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 3.4 tmt_? -99.51 -30.09 12.35 Favored 'General case' 0 C--N 1.312 -1.061 0 C-N-CA 123.667 0.787 . . . . 0.0 109.329 175.388 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -86.81 0.19 55.28 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 123.344 0.658 . . . . 0.0 112.004 -177.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.3 p -65.96 148.83 51.18 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.596 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.71 -157.48 0.72 Allowed 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 124.79 1.236 . . . . 0.0 108.587 178.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.27 -76.97 0.17 Allowed Glycine 0 C--N 1.315 -0.613 0 O-C-N 123.542 0.527 . . . . 0.0 113.963 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.49 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.3 m-80 -78.79 109.83 13.41 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.329 0.585 . . . . 0.0 111.537 -179.309 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.465 HG21 HD21 ' A' ' 17' ' ' LEU . 7.2 t -121.73 131.12 73.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.457 -178.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -98.58 98.71 9.84 Favored 'General case' 0 C--N 1.284 -2.271 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 174.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.442 ' CE1' ' HB ' ' A' ' 87' ' ' VAL . 89.8 m-85 -89.42 103.06 15.73 Favored 'General case' 0 CA--C 1.486 -1.481 0 CA-C-N 114.643 -1.162 . . . . 0.0 107.942 177.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.712 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.7 t -89.03 95.39 5.37 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.987 0 N-CA-C 106.6 -1.629 . . . . 0.0 106.6 177.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.512 HG21 ' HB3' ' A' ' 58' ' ' ASP . 96.7 mt -112.4 154.02 13.93 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.682 0 CA-C-N 114.143 -1.39 . . . . 0.0 108.248 176.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.474 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -120.91 149.72 17.38 Favored Glycine 0 N--CA 1.416 -2.657 0 C-N-CA 118.946 -1.597 . . . . 0.0 111.507 179.139 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 25.2 tpt180 -121.22 136.8 54.91 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 120.959 0.409 . . . . 0.0 110.859 179.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 . . . . . 0 N--CA 1.424 -1.755 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.171 176.611 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.527 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 42.1 tt0 . . . . . 0 CA--C 1.489 -1.373 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -87.09 116.21 25.0 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 174.333 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -132.07 137.19 29.57 Favored Pre-proline 0 N--CA 1.417 -2.113 0 CA-C-O 121.896 0.855 . . . . 0.0 113.237 -173.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -82.31 128.47 5.57 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.972 2.448 . . . . 0.0 112.144 175.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.449 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 38.4 t -118.95 112.92 39.81 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.491 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 174.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.461 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.2 tt0 -96.11 105.2 17.22 Favored 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 176.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.429 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -92.93 143.46 26.23 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -175.02 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -108.34 90.73 3.38 Favored 'General case' 0 C--N 1.291 -1.941 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 174.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.8 mmmp? -87.05 -175.46 5.35 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 113.966 1.099 . . . . 0.0 113.966 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.439 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.2 p-10 -89.32 -172.39 3.61 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 126.285 1.834 . . . . 0.0 111.179 -178.248 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -82.1 -6.44 59.18 Favored 'General case' 0 N--CA 1.465 0.286 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -175.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.439 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 11.3 t70 -82.16 -34.09 29.24 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 122.005 0.907 . . . . 0.0 108.757 176.001 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 121.37 -109.95 1.59 Allowed Glycine 0 N--CA 1.415 -2.735 0 CA-C-N 114.146 -1.388 . . . . 0.0 110.118 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.763 ' HG ' HG23 ' A' ' 19' ' ' ILE . 14.1 tp -117.31 -62.75 1.53 Allowed 'General case' 0 C--N 1.291 -1.939 0 O-C-N 122.341 -0.505 . . . . 0.0 109.878 -177.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.56 33.55 55.75 Favored Glycine 0 N--CA 1.434 -1.496 0 O-C-N 124.175 0.922 . . . . 0.0 113.157 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.763 HG23 ' HG ' ' A' ' 17' ' ' LEU . 27.5 pt -101.02 172.6 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 C-N-CA 119.892 -0.723 . . . . 0.0 110.279 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 34.8 m -119.33 145.98 45.69 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -179.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.417 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -122.71 164.38 20.09 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -178.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.6 tt -132.53 132.78 60.09 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 174.361 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.629 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.58 105.73 3.29 Favored Glycine 0 N--CA 1.428 -1.9 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.926 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.469 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 16.7 ptm -143.65 85.22 1.82 Allowed 'General case' 0 C--N 1.291 -1.948 0 CA-C-O 121.585 0.707 . . . . 0.0 110.8 179.264 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.519 0 CA-C-N 114.013 -1.449 . . . . 0.0 113.845 -176.248 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.478 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.0 OUTLIER . . . . . 0 N--CA 1.414 -2.253 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -131.67 35.48 2.39 Favored Glycine 0 N--CA 1.414 -2.781 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.039 176.255 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.629 HD13 ' HA2' ' A' ' 23' ' ' GLY . 26.7 mm -94.81 105.72 17.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 C-N-CA 119.405 -0.918 . . . . 0.0 109.547 -179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -102.17 161.54 13.61 Favored 'General case' 0 C--N 1.276 -2.604 0 CA-C-N 114.721 -1.127 . . . . 0.0 110.191 -179.171 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 29.0 t -77.5 117.81 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.087 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 176.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 56.3 tptt -84.64 -51.33 6.92 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -178.176 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -149.51 160.69 43.26 Favored 'General case' 0 N--CA 1.427 -1.61 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 -179.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.443 ' HB ' ' OE1' ' A' ' 49' ' ' GLN . 16.8 t -122.75 162.36 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.151 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 178.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.485 ' H ' HG22 ' A' ' 19' ' ' ILE . 9.1 t . . . . . 0 N--CA 1.422 -1.83 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 C--O 1.201 -1.473 0 N-CA-C 115.424 1.638 . . . . 0.0 115.424 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.89 -53.25 10.58 Favored 'General case' 0 N--CA 1.465 0.275 0 O-C-N 121.46 -0.775 . . . . 0.0 109.952 -178.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.443 ' OE1' ' HB ' ' A' ' 42' ' ' VAL . 27.8 mt-30 -78.46 -13.89 59.63 Favored 'General case' 0 CA--C 1.508 -0.66 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.739 176.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.478 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 13.5 mmm180 -74.45 -41.06 61.46 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 174.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.45 ' OD1' ' HB2' ' A' ' 53' ' ' ARG . 12.2 t70 -60.29 -59.03 6.06 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.461 177.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.4 -9.35 77.79 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 115.03 0.772 . . . . 0.0 115.03 174.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.45 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -69.35 -37.27 77.56 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.545 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.9 tt -81.93 152.33 4.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -178.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 30.3 mt-30 -127.88 161.6 28.69 Favored 'General case' 0 C--N 1.312 -1.061 0 C-N-CA 120.031 -0.668 . . . . 0.0 109.303 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.9 p -89.64 16.82 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 CA-C-O 121.747 0.784 . . . . 0.0 110.531 -177.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -137.59 20.38 2.9 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 122.236 1.017 . . . . 0.0 110.11 -177.021 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -103.72 -175.19 2.73 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.234 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.447 ' O ' HG23 ' A' ' 91' ' ' ILE . 33.6 tt0 -120.68 132.65 55.2 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.132 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.517 HG22 HD11 ' A' ' 68' ' ' LEU . 47.2 mm -76.73 101.45 2.91 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.128 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.722 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 81.2 t -80.8 -48.06 19.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 CA-C-O 121.233 0.539 . . . . 0.0 110.571 -175.32 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.481 ' HG3' ' H ' ' A' ' 67' ' ' SER . 39.5 tt0 -156.64 112.91 3.02 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-O 121.015 0.436 . . . . 0.0 110.639 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.435 ' C ' ' H ' ' A' ' 65' ' ' GLY . 4.8 t -102.26 131.08 51.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.566 175.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.3 t70 73.03 -22.56 0.23 Allowed 'General case' 0 N--CA 1.503 2.22 0 C-N-CA 125.747 1.619 . . . . 0.0 112.975 176.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 63' ' ' VAL . . . 110.36 12.41 17.4 Favored Glycine 0 C--N 1.274 -2.911 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -173.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.438 HD13 HG22 ' A' ' 79' ' ' VAL . 7.3 tt -70.02 -19.51 22.56 Favored 'Isoleucine or valine' 0 C--N 1.344 0.326 0 C-N-CA 122.885 0.474 . . . . 0.0 110.903 -178.119 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.481 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 12.3 p 49.03 81.57 0.05 Allowed 'General case' 0 C--O 1.233 0.19 0 C-N-CA 124.26 1.024 . . . . 0.0 112.88 -176.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.517 HD11 HG22 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -95.58 30.22 2.36 Favored 'General case' 0 N--CA 1.423 -1.778 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.381 -178.625 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 47.9 t -73.45 97.04 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-N 114.974 -1.012 . . . . 0.0 109.585 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.478 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 108.26 33.07 3.05 Favored Glycine 0 C--N 1.294 -1.799 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 176.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.471 HG21 ' HB2' ' A' ' 68' ' ' LEU . 19.7 m -109.39 174.53 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 119.917 -0.713 . . . . 0.0 111.461 -178.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 22.2 p -91.29 172.82 8.27 Favored 'General case' 0 N--CA 1.418 -2.049 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.794 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.417 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -66.97 -32.01 72.96 Favored 'General case' 0 C--O 1.204 -1.293 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.018 -179.682 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -71.44 -31.6 67.39 Favored 'General case' 0 CA--C 1.516 -0.362 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.82 -178.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -70.38 -51.67 28.03 Favored 'General case' 0 N--CA 1.443 -0.819 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 177.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.41 ' CB ' HG21 ' A' ' 37' ' ' ILE . . . -62.56 -42.16 99.37 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.031 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.09 -11.4 48.52 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 121.23 0.538 . . . . 0.0 111.102 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 58.0 m -89.75 -47.13 8.12 Favored 'General case' 0 N--CA 1.415 -2.204 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.862 174.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.494 ' O ' HG23 ' A' ' 83' ' ' THR . 31.4 t -61.86 -54.27 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.43 HD21 HG21 ' A' ' 60' ' ' ILE . 3.3 mm? -68.41 0.42 3.96 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.617 0.767 . . . . 0.0 112.716 -178.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -104.07 -45.95 4.59 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 174.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 -80.83 7.36 10.64 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 114.405 -1.27 . . . . 0.0 113.142 -173.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.494 HG23 ' O ' ' A' ' 79' ' ' VAL . 1.7 p -60.45 154.22 21.18 Favored 'General case' 0 C--N 1.29 -2.013 0 C-N-CA 124.854 1.261 . . . . 0.0 111.405 175.047 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.439 ' HD3' ' HA ' ' A' ' 84' ' ' LYS . 31.8 mmtp -111.51 -164.91 0.95 Allowed 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.061 178.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.32 -67.59 2.12 Favored Glycine 0 N--CA 1.439 -1.152 0 O-C-N 123.657 0.598 . . . . 0.0 112.886 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.429 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 15.6 m120 -82.52 117.07 22.25 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.461 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.2 t -125.04 127.79 72.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.453 -177.326 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -91.68 104.33 16.8 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-O 120.877 0.37 . . . . 0.0 110.169 172.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.449 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.7 m-85 -95.6 103.99 15.88 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 175.234 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.722 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 47.7 t -92.85 91.48 3.37 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.921 0 N-CA-C 104.781 -2.303 . . . . 0.0 104.781 174.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.492 HG12 ' HA ' ' A' ' 60' ' ' ILE . 74.8 mt -108.0 157.05 8.33 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.09 178.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -131.78 143.66 15.22 Favored Glycine 0 N--CA 1.397 -3.913 0 C-N-CA 119.404 -1.379 . . . . 0.0 111.093 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.42 ' C ' ' HD2' ' A' ' 93' ' ' ARG . 5.2 tmm_? -108.22 128.47 54.75 Favored 'General case' 0 C--N 1.291 -1.97 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -178.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 . . . . . 0 C--N 1.311 -1.095 0 O-C-N 123.353 0.408 . . . . 0.0 110.459 178.961 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.429 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 32.2 tt0 . . . . . 0 CA--C 1.498 -1.031 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -91.72 127.87 37.34 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.761 -1.199 . . . . 0.0 107.761 173.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.494 ' O ' ' HA ' ' A' ' 90' ' ' VAL . 20.9 p90 -133.21 137.59 29.67 Favored Pre-proline 0 C--N 1.283 -2.295 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -175.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -84.21 121.67 2.75 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 123.472 2.781 . . . . 0.0 112.146 176.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 35.8 t -112.17 98.47 7.07 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.048 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 175.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.608 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 31.6 tt0 -83.8 101.54 11.69 Favored 'General case' 0 N--CA 1.421 -1.899 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 176.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.472 HD11 ' HA ' ' A' ' 48' ' ' ALA . 0.1 OUTLIER -93.23 133.67 36.21 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 -175.948 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -101.15 92.98 5.23 Favored 'General case' 0 N--CA 1.419 -2.016 0 CA-C-O 121.995 0.903 . . . . 0.0 109.282 175.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.572 ' CD ' ' HB3' ' A' ' 47' ' ' ALA . 2.0 mmmp? -92.95 -175.45 3.89 Favored 'General case' 0 N--CA 1.421 -1.921 0 CA-C-N 114.302 -1.317 . . . . 0.0 113.218 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.467 ' OD1' ' HB3' ' A' ' 15' ' ' ASP . 1.7 p30 -77.31 176.62 8.63 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-N 112.784 -2.007 . . . . 0.0 110.743 178.063 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -82.94 -6.65 59.56 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.612 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.467 ' HB3' ' OD1' ' A' ' 13' ' ' ASP . 9.6 t70 -81.77 -41.94 20.45 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 175.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.32 -123.26 2.6 Favored Glycine 0 N--CA 1.42 -2.381 0 C-N-CA 120.136 -1.031 . . . . 0.0 112.909 175.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.444 HD21 HG21 ' A' ' 87' ' ' VAL . 13.0 mt -108.36 -45.1 3.97 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 122.211 -0.582 . . . . 0.0 110.569 -172.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.67 28.45 70.89 Favored Glycine 0 N--CA 1.426 -2.014 0 O-C-N 124.336 1.023 . . . . 0.0 110.663 -174.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 20.4 pt -106.38 -176.95 0.58 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.293 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.797 -178.083 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.3 m -144.22 151.86 40.05 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.496 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.6 pp -125.0 162.67 26.84 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -178.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 12.1 tt -134.59 130.42 53.3 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.833 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 176.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.623 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -98.01 104.92 3.05 Favored Glycine 0 CA--C 1.481 -2.034 0 C-N-CA 120.357 -0.925 . . . . 0.0 111.744 -178.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.492 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 18.4 ptm -147.16 96.41 2.72 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 120.643 0.258 . . . . 0.0 111.562 -179.469 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.704 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.315 -178.914 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.507 HD22 HG23 ' A' ' 69' ' ' VAL . 1.8 pt? . . . . . 0 N--CA 1.448 -0.561 0 CA-C-O 122.254 1.026 . . . . 0.0 111.985 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.492 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -131.66 32.04 2.99 Favored Glycine 0 N--CA 1.41 -3.076 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.873 175.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.623 HD13 ' HA2' ' A' ' 23' ' ' GLY . 23.8 mm -90.1 98.61 8.41 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 119.778 -0.769 . . . . 0.0 109.098 178.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -96.98 162.5 13.37 Favored 'General case' 0 C--N 1.273 -2.744 0 CA-C-N 115.047 -0.979 . . . . 0.0 108.914 -178.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 40.9 t -79.71 122.71 35.44 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.537 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -81.15 -49.92 10.24 Favored 'General case' 0 C--N 1.293 -1.86 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.331 -177.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -154.31 161.23 41.89 Favored 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 -178.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 51.0 t -136.25 147.54 27.88 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 N-CA-C 105.415 -2.068 . . . . 0.0 105.415 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.2 t . . . . . 0 C--O 1.257 1.465 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 173.967 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.572 ' HB3' ' CD ' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.197 -1.704 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.472 ' HA ' HD11 ' A' ' 10' ' ' LEU . . . -64.42 -54.74 27.94 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.239 0.542 . . . . 0.0 110.662 -176.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 42.8 mt-30 -76.45 -7.79 55.81 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.772 178.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.415 ' HD3' ' HA ' ' A' ' 50' ' ' ARG . 23.4 mmt180 -90.44 -23.29 21.06 Favored 'General case' 0 N--CA 1.437 -1.085 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.12 176.56 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -61.01 -54.9 39.17 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 170.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 105.3 -26.55 21.46 Favored Glycine 0 N--CA 1.432 -1.576 0 CA-C-N 115.164 -0.925 . . . . 0.0 114.746 174.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -72.93 -31.5 64.66 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 118.446 1.123 . . . . 0.0 109.666 -176.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.9 tt -97.09 146.96 6.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -179.193 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . 0.424 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 97.0 mt-30 -136.57 162.52 32.9 Favored 'General case' 0 N--CA 1.436 -1.13 0 CA-C-O 121.331 0.586 . . . . 0.0 110.945 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.4 p -75.71 -15.34 15.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 C-N-CA 124.085 0.954 . . . . 0.0 111.298 -178.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -95.06 9.84 38.01 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.455 0.645 . . . . 0.0 111.557 -175.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.424 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 39.9 m-20 -97.84 -172.68 2.43 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.691 -177.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.564 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.6 tt0 -134.91 133.21 39.38 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.836 -177.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.461 ' HA ' HG12 ' A' ' 91' ' ' ILE . 44.1 mm -78.4 115.15 20.04 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.001 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 -177.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.657 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.2 t -94.49 -51.8 10.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-O 121.679 0.752 . . . . 0.0 110.552 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.609 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 21.4 tt0 -147.55 110.01 4.62 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.92 -177.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.5 t -103.39 126.54 57.78 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 O-C-N 122.018 -0.427 . . . . 0.0 110.204 175.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.5 t70 62.19 17.52 9.29 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 124.452 1.101 . . . . 0.0 112.215 174.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 83.09 8.75 85.15 Favored Glycine 0 N--CA 1.442 -0.915 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.975 -179.214 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.512 HD13 HG22 ' A' ' 79' ' ' VAL . 5.7 tt -75.25 -16.62 15.91 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 O-C-N 122.571 -0.37 . . . . 0.0 110.845 -176.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.43 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 31.3 m 49.09 79.71 0.07 Allowed 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 124.876 1.27 . . . . 0.0 112.706 -177.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.495 ' O ' HG22 ' A' ' 71' ' ' VAL . 2.3 pp -96.16 11.73 33.32 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 122.322 1.058 . . . . 0.0 110.074 -175.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.507 HG23 HD22 ' A' ' 35' ' ' LEU . 5.2 p -58.11 92.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.294 -1.841 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.497 173.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.489 ' N ' ' HB3' ' A' ' 35' ' ' LEU . . . 113.79 21.42 5.71 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.829 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.495 HG22 ' O ' ' A' ' 68' ' ' LEU . 20.4 m -103.48 176.97 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 O-C-N 121.978 -0.719 . . . . 0.0 110.965 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.3 p -93.7 171.71 8.71 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.026 177.034 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.496 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -64.78 -28.83 69.84 Favored 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.775 -176.337 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.82 -30.49 66.94 Favored 'General case' 0 CA--C 1.512 -0.492 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.358 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.451 ' O ' HG23 ' A' ' 79' ' ' VAL . 31.2 t80 -77.32 -52.01 9.91 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 177.686 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -56.25 -50.12 72.23 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.274 -0.876 . . . . 0.0 112.364 -177.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.15 -36.41 75.21 Favored 'General case' 0 C--O 1.214 -0.786 0 CA-C-O 120.505 0.193 . . . . 0.0 110.796 -179.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 84.0 m -62.88 -42.75 99.88 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.301 177.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.512 HG22 HD13 ' A' ' 66' ' ' ILE . 31.6 t -64.27 -51.78 64.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 178.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -63.58 -18.28 63.72 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.841 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.13 -26.44 23.62 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 123.276 0.631 . . . . 0.0 110.32 174.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -88.67 6.17 39.68 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-O 121.48 0.657 . . . . 0.0 112.251 -178.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 36.4 p -74.89 -178.2 3.64 Favored 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.043 177.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.18 -163.0 1.52 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.166 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -49.25 -73.3 0.37 Allowed Glycine 0 CA--C 1.531 1.036 0 O-C-N 123.884 0.74 . . . . 0.0 114.49 178.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.463 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 19.0 m120 -82.99 104.74 13.42 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 117.667 0.734 . . . . 0.0 111.628 -178.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.608 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -114.71 137.51 47.89 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.503 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 90.6 mtt180 -99.64 99.04 9.83 Favored 'General case' 0 C--N 1.283 -2.304 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.507 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 91.9 m-85 -92.2 101.45 13.96 Favored 'General case' 0 CA--C 1.489 -1.386 0 CA-C-N 114.895 -1.048 . . . . 0.0 108.555 177.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.657 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 60.8 t -92.32 94.76 4.96 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.89 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.47 HG23 ' O ' ' A' ' 59' ' ' GLN . 90.6 mt -106.3 163.19 4.92 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.929 0 CA-C-N 114.104 -1.407 . . . . 0.0 108.543 178.532 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -139.07 161.23 25.94 Favored Glycine 0 N--CA 1.412 -2.912 0 C-N-CA 119.489 -1.338 . . . . 0.0 112.162 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 37.0 ttp-105 -142.58 144.17 32.76 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 . . . . . 0 C--N 1.302 -1.485 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 176.291 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 . . . . . 0 N--CA 1.43 -1.473 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -93.1 127.55 38.68 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 175.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 19.6 p90 -137.25 141.34 33.79 Favored Pre-proline 0 C--N 1.297 -1.684 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -175.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -82.24 123.9 4.1 Favored 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 122.76 2.307 . . . . 0.0 112.21 177.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.415 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 38.9 t -109.44 95.99 4.29 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.688 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 174.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 29.7 tt0 -83.37 102.72 12.21 Favored 'General case' 0 N--CA 1.423 -1.825 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -98.44 140.43 32.7 Favored 'General case' 0 N--CA 1.411 -2.386 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 -175.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -108.86 95.74 5.85 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 173.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.539 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 1.9 mmmp? -84.72 174.21 10.09 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 114.381 1.252 . . . . 0.0 114.381 -178.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -92.12 179.91 5.45 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 112.714 -2.039 . . . . 0.0 111.032 -176.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -68.81 -15.51 63.52 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -173.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -77.3 -28.03 53.17 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 121.572 0.701 . . . . 0.0 109.411 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.12 -125.62 6.61 Favored Glycine 0 CA--C 1.482 -1.997 0 N-CA-C 108.513 -1.835 . . . . 0.0 108.513 -179.275 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt -103.79 -50.24 3.46 Favored 'General case' 0 CA--C 1.483 -1.609 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 176.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.94 27.33 64.77 Favored Glycine 0 N--CA 1.434 -1.491 0 O-C-N 124.642 1.214 . . . . 0.0 110.773 -176.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.499 HG22 ' HA ' ' A' ' 42' ' ' VAL . 21.6 pt -102.54 -179.51 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.817 -177.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.3 t -138.72 153.23 48.49 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -178.371 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.51 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.6 pp -125.75 163.43 27.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -177.304 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.615 ' HB ' ' HG2' ' A' ' 40' ' ' LYS . 11.3 tt -130.96 132.69 63.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-O 120.536 0.208 . . . . 0.0 110.686 174.503 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.519 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.15 103.83 3.1 Favored Glycine 0 N--CA 1.426 -1.978 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.5 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.42 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 16.5 ptm -143.94 91.3 2.21 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 178.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.34 0.799 0 CA-C-N 114.184 -1.371 . . . . 0.0 113.018 -177.421 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.416 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 2.6 pp . . . . . 0 N--CA 1.428 -1.568 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -118.79 30.88 5.74 Favored Glycine 0 N--CA 1.417 -2.583 0 C-N-CA 119.684 -1.246 . . . . 0.0 110.303 176.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.519 HD13 ' HA2' ' A' ' 23' ' ' GLY . 30.3 mm -91.95 100.97 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.868 0 CA-C-O 121.553 0.692 . . . . 0.0 110.998 -176.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.419 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 96.2 m-85 -96.98 165.0 12.29 Favored 'General case' 0 C--N 1.285 -2.209 0 CA-C-N 115.075 -0.966 . . . . 0.0 108.532 177.567 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 47.1 t -81.41 128.17 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.14 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.615 ' HG2' ' HB ' ' A' ' 22' ' ' ILE . 15.9 mmmt -85.36 -57.34 3.11 Favored 'General case' 0 CA--C 1.473 -2.015 0 CA-C-O 121.567 0.698 . . . . 0.0 109.332 177.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.48 163.6 34.19 Favored 'General case' 0 C--N 1.291 -1.978 0 CA-C-N 114.241 -1.345 . . . . 0.0 107.789 -176.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.499 ' HA ' HG22 ' A' ' 19' ' ' ILE . 86.6 t -129.68 157.26 42.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.23 0 N-CA-C 104.9 -2.259 . . . . 0.0 104.9 174.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 14.9 t . . . . . 0 N--CA 1.435 -1.193 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 175.939 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.539 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . . . . . . 0 N--CA 1.423 -1.799 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -95.1 -55.8 2.95 Favored 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 115.795 -0.638 . . . . 0.0 109.608 -175.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -79.08 -16.19 57.1 Favored 'General case' 0 N--CA 1.438 -1.044 0 C-N-CA 119.301 -0.96 . . . . 0.0 110.037 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 36.0 mmt180 -78.43 -25.32 45.95 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.55 171.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -70.91 -61.0 1.92 Allowed 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 172.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.77 2.07 84.67 Favored Glycine 0 N--CA 1.437 -1.247 0 N-CA-C 115.055 0.782 . . . . 0.0 115.055 173.023 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -85.23 -36.37 20.99 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 176.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.6 tt -88.04 146.71 5.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -128.71 177.56 6.97 Favored 'General case' 0 N--CA 1.431 -1.377 0 C-N-CA 120.163 -0.615 . . . . 0.0 111.406 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 5.2 t -90.47 -9.99 10.29 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.774 0 CA-C-O 121.936 0.874 . . . . 0.0 109.46 -175.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -103.56 7.56 37.67 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.699 -176.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -83.25 -177.93 6.91 Favored 'General case' 0 C--O 1.247 0.954 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.537 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.426 ' O ' HG23 ' A' ' 91' ' ' ILE . 63.9 tt0 -133.32 128.3 35.41 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-N 115.112 -0.949 . . . . 0.0 108.746 -177.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.508 HG23 HG23 ' A' ' 63' ' ' VAL . 49.4 mm -76.83 109.99 11.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -176.165 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.677 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 88.1 t -92.64 -47.66 13.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 CA-C-O 121.242 0.544 . . . . 0.0 111.137 -176.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.532 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 38.7 tt0 -155.2 102.17 2.28 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-O 121.623 0.725 . . . . 0.0 110.541 -178.456 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.508 HG23 HG23 ' A' ' 60' ' ' ILE . 4.8 t -94.61 129.3 45.02 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 O-C-N 121.921 -0.487 . . . . 0.0 111.089 177.095 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 38.5 t70 65.32 11.72 7.52 Favored 'General case' 0 N--CA 1.487 1.394 0 CA-C-O 122.234 1.016 . . . . 0.0 111.55 172.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.35 15.47 78.31 Favored Glycine 0 N--CA 1.441 -1.026 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.084 -178.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.5 HD13 HG22 ' A' ' 79' ' ' VAL . 6.2 tt -76.41 -20.53 15.07 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.798 0 CA-C-O 121.215 0.531 . . . . 0.0 110.683 -177.694 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.529 ' H ' ' HG3' ' A' ' 62' ' ' GLU 0.267 13.1 p 47.97 76.48 0.11 Allowed 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 124.708 1.203 . . . . 0.0 113.879 -177.048 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.502 ' H ' HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -88.9 32.2 0.82 Allowed 'General case' 0 N--CA 1.432 -1.367 0 CA-C-N 114.432 -1.258 . . . . 0.0 111.287 -177.063 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 46.3 t -69.69 95.81 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 CA-C-N 114.799 -1.092 . . . . 0.0 110.385 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.416 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 105.44 19.74 10.24 Favored Glycine 0 C--N 1.31 -0.901 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.574 176.174 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.455 HG21 ' HB2' ' A' ' 68' ' ' LEU . 23.9 m -93.1 179.21 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 177.496 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.9 p -94.54 171.0 9.07 Favored 'General case' 0 N--CA 1.416 -2.163 0 CA-C-O 121.221 0.534 . . . . 0.0 110.349 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.51 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.17 -34.64 70.53 Favored 'General case' 0 C--N 1.294 -1.814 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.916 178.126 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.27 -36.97 74.75 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.332 -178.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.491 ' O ' HG23 ' A' ' 79' ' ' VAL . 45.9 t80 -66.99 -49.42 65.41 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.178 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.48 -45.58 93.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.758 -179.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -64.11 -16.84 62.67 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 120.915 0.388 . . . . 0.0 111.425 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 66.3 m -85.93 -44.81 12.08 Favored 'General case' 0 N--CA 1.426 -1.631 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.625 174.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.5 HG22 HD13 ' A' ' 66' ' ' ILE . 47.1 t -58.11 -51.5 70.15 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.627 0 N-CA-C 110.091 -0.336 . . . . 0.0 110.091 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -70.24 3.21 3.01 Favored 'General case' 0 CA--C 1.556 1.194 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.769 179.08 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 1.3 tmt_? -114.95 -17.76 11.43 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 123.373 0.669 . . . . 0.0 109.682 177.186 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -92.0 -7.46 48.83 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.279 0.632 . . . . 0.0 110.319 177.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.448 HG23 ' O ' ' A' ' 79' ' ' VAL . 2.5 p -64.5 161.48 17.21 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 115.061 -0.972 . . . . 0.0 113.444 -177.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 43.5 mmtm -113.42 -163.41 0.86 Allowed 'General case' 0 C--N 1.293 -1.875 0 CA-C-N 114.434 -1.257 . . . . 0.0 109.282 -178.066 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.87 -60.4 6.14 Favored Glycine 0 N--CA 1.424 -2.113 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 171.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -76.39 106.93 8.31 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-O 121.2 0.524 . . . . 0.0 110.168 177.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.0 t -121.87 132.36 71.05 Favored 'Isoleucine or valine' 0 CA--C 1.484 -1.571 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 -178.005 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 79.5 mtt180 -102.42 96.77 7.15 Favored 'General case' 0 C--N 1.283 -2.314 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 173.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.415 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 90.5 m-85 -87.35 102.53 14.61 Favored 'General case' 0 CA--C 1.491 -1.312 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 177.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.677 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.1 t -90.99 90.87 3.42 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.625 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 177.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.426 HG23 ' O ' ' A' ' 59' ' ' GLN . 86.2 mt -104.12 156.49 5.64 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.689 0 CA-C-N 114.248 -1.342 . . . . 0.0 108.189 179.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.65 166.81 22.89 Favored Glycine 0 N--CA 1.406 -3.344 0 C-N-CA 119.42 -1.371 . . . . 0.0 110.926 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 46.1 ttp180 -142.59 141.32 31.95 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 . . . . . 0 N--CA 1.431 -1.414 0 N-CA-C 106.087 -1.82 . . . . 0.0 106.087 170.204 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 . . . . . 0 C--O 1.212 -0.909 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.49 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.2 mm? -90.11 136.12 33.24 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.481 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 20.8 p90 -145.99 140.63 15.76 Favored Pre-proline 0 C--N 1.303 -1.421 0 CA-C-O 121.079 0.466 . . . . 0.0 112.141 -178.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -81.4 126.58 5.51 Favored 'Trans proline' 0 C--O 1.248 1.022 0 C-N-CA 123.29 2.66 . . . . 0.0 113.081 177.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.405 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 26.2 t -120.83 102.87 13.01 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 175.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 37.4 tt0 -84.24 105.98 15.5 Favored 'General case' 0 N--CA 1.427 -1.592 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.634 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 12.9 tp -89.91 155.08 19.37 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 -174.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -120.29 93.05 3.92 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 175.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.553 ' HG2' HD23 ' A' ' 10' ' ' LEU . 2.5 mmmp? -89.65 176.16 6.97 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 115.278 1.584 . . . . 0.0 115.278 -179.304 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -77.25 168.33 20.23 Favored 'General case' 0 N--CA 1.428 -1.547 0 CA-C-N 111.934 -2.393 . . . . 0.0 107.435 -179.275 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -74.01 -10.48 59.68 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-O 121.217 0.532 . . . . 0.0 110.967 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -63.55 -33.16 74.97 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 172.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.4 -130.87 9.08 Favored Glycine 0 N--CA 1.413 -2.897 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.509 ' HG ' HG23 ' A' ' 19' ' ' ILE . 13.7 tp -103.5 -61.51 1.41 Allowed 'General case' 0 C--N 1.285 -2.219 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 -177.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.462 ' O ' ' HB ' ' A' ' 43' ' ' THR . . . 71.32 37.85 62.88 Favored Glycine 0 N--CA 1.429 -1.786 0 O-C-N 124.284 0.99 . . . . 0.0 112.854 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.509 HG23 ' HG ' ' A' ' 17' ' ' LEU . 15.5 pt -107.95 167.51 3.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 118.949 -1.101 . . . . 0.0 111.435 176.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.3 m -117.08 148.54 41.43 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 -177.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -125.41 166.34 21.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -177.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 11.9 tt -130.35 132.15 65.03 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.877 0 C-N-CA 120.701 -0.4 . . . . 0.0 110.575 175.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.513 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.61 95.77 2.13 Favored Glycine 0 N--CA 1.424 -2.14 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.589 -178.58 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 95.1 mmm -109.3 173.72 6.19 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 176.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.292 -1.916 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 177.743 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.436 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.0 OUTLIER . . . . . 0 N--CA 1.428 -1.535 0 CA-C-O 120.806 0.336 . . . . 0.0 110.153 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -124.07 25.13 6.15 Favored Glycine 0 N--CA 1.414 -2.771 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 174.135 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.513 HD13 ' HA2' ' A' ' 23' ' ' GLY . 33.4 mm -85.02 100.71 8.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 121.525 0.679 . . . . 0.0 109.524 -179.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -97.43 164.39 12.47 Favored 'General case' 0 C--N 1.278 -2.502 0 CA-C-N 115.252 -0.885 . . . . 0.0 108.917 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.565 ' HB ' ' O ' ' A' ' 56' ' ' VAL . 39.7 t -78.83 127.98 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.19 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 176.2 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 55.6 tptt -89.13 -44.13 10.55 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -178.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -161.18 162.82 31.42 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 89.1 t -127.35 152.52 35.49 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.167 0 N-CA-C 106.223 -1.769 . . . . 0.0 106.223 178.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.462 ' HB ' ' O ' ' A' ' 18' ' ' GLY . 10.6 t . . . . . 0 N--CA 1.428 -1.557 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.458 ' HA ' ' CG ' ' A' ' 50' ' ' ARG . . . . . . . . 0 CA--C 1.557 1.235 0 N-CA-C 115.542 1.682 . . . . 0.0 115.542 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.97 -50.38 16.86 Favored 'General case' 0 C--O 1.215 -0.728 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -80.54 -3.59 50.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 120.285 -0.566 . . . . 0.0 111.101 176.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.458 ' CG ' ' HA ' ' A' ' 47' ' ' ALA . 36.1 mmt180 -82.65 -39.09 22.56 Favored 'General case' 0 CA--C 1.507 -0.691 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 171.283 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -53.83 -60.42 3.35 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 114.856 -1.065 . . . . 0.0 112.088 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.48 -17.56 56.55 Favored Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 120.316 -0.945 . . . . 0.0 114.353 175.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.432 ' HE ' ' C ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -88.69 -46.77 8.75 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.68 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.0 tt -73.67 145.13 11.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . 0.419 ' HB2' ' OD1' ' A' ' 58' ' ' ASP . 35.6 mt-30 -138.79 -172.66 3.36 Favored 'General case' 0 C--N 1.316 -0.868 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.843 -176.26 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.565 ' O ' ' HB ' ' A' ' 39' ' ' VAL . 49.0 t -93.22 -34.55 5.94 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.104 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.413 -178.258 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -92.24 20.67 5.79 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -174.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.419 ' OD1' ' HB2' ' A' ' 55' ' ' GLN . 4.2 m-20 -101.75 -172.9 2.23 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.967 177.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.467 ' O ' HG23 ' A' ' 91' ' ' ILE . 63.7 tt0 -128.54 126.51 40.52 Favored 'General case' 0 C--N 1.313 -0.995 0 O-C-N 122.089 -0.382 . . . . 0.0 111.328 -175.137 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.526 ' HA ' HG12 ' A' ' 91' ' ' ILE . 48.2 mm -74.93 104.36 3.27 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.016 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.749 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.2 t -91.41 -50.15 12.85 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-O 121.694 0.759 . . . . 0.0 111.315 -175.166 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.528 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 32.1 tt0 -149.0 105.74 3.56 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.398 0.618 . . . . 0.0 110.226 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.433 HG23 HG23 ' A' ' 60' ' ' ILE . 3.0 t -98.02 126.98 50.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.146 177.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 26.9 t70 71.42 -9.96 0.86 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 125.599 1.56 . . . . 0.0 112.702 173.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 103.61 12.96 29.21 Favored Glycine 0 N--CA 1.424 -2.151 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.126 -175.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.569 HD13 HG22 ' A' ' 79' ' ' VAL . 11.0 tt -72.98 -18.07 18.24 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-O 121.077 0.465 . . . . 0.0 111.198 -178.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.511 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 29.6 p 50.87 81.41 0.07 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.985 1.314 . . . . 0.0 112.92 -175.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.489 HD21 HG22 ' A' ' 60' ' ' ILE . 1.8 pp -96.12 14.91 22.33 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-O 122.092 0.948 . . . . 0.0 109.94 -176.114 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 61.2 t -57.62 98.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.427 174.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.436 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 103.51 35.03 3.68 Favored Glycine 0 N--CA 1.438 -1.223 0 CA-C-N 115.54 -0.754 . . . . 0.0 112.457 176.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.438 HG22 ' O ' ' A' ' 68' ' ' LEU . 20.6 m -115.02 177.55 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 117.14 0.47 . . . . 0.0 111.221 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 12.9 p -91.31 172.56 8.45 Favored 'General case' 0 N--CA 1.433 -1.318 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.605 178.609 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.445 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -65.37 -32.04 73.47 Favored 'General case' 0 C--O 1.205 -1.24 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.232 -178.638 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -71.58 -35.4 70.53 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 120.861 -0.336 . . . . 0.0 110.985 -178.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.493 ' O ' HG23 ' A' ' 79' ' ' VAL . 29.7 t80 -65.86 -52.19 52.39 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 176.472 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.83 -46.27 89.79 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.135 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.04 -33.96 69.56 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.795 0.331 . . . . 0.0 110.73 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 97.8 m -68.07 -45.57 73.46 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.069 176.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.569 HG22 HD13 ' A' ' 66' ' ' ILE . 32.7 t -61.56 -51.85 67.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 C-N-CA 122.632 0.373 . . . . 0.0 110.902 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.408 HD21 HG21 ' A' ' 60' ' ' ILE . 3.4 mm? -68.52 -4.57 15.59 Favored 'General case' 0 CA--C 1.542 0.65 0 CA-C-O 121.237 0.541 . . . . 0.0 112.364 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.403 ' HD3' ' C ' ' A' ' 81' ' ' ARG . 0.7 OUTLIER -99.73 -32.52 11.0 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.218 0.533 . . . . 0.0 109.796 172.868 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 8.7 m-80 -80.13 6.68 10.99 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 121.794 0.807 . . . . 0.0 111.856 -178.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.0 p -70.61 170.21 12.69 Favored 'General case' 0 N--CA 1.408 -2.551 0 CA-C-N 114.536 -1.211 . . . . 0.0 111.562 175.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.436 ' HE3' ' O ' ' A' ' 86' ' ' ASN . 0.0 OUTLIER -147.81 -161.3 1.31 Allowed 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 124.898 1.279 . . . . 0.0 107.831 -175.036 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -55.88 -75.15 0.26 Allowed Glycine 0 CA--C 1.525 0.696 0 O-C-N 123.524 0.515 . . . . 0.0 114.016 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.634 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.5 m120 -88.79 105.93 18.03 Favored 'General case' 0 CA--C 1.497 -1.061 0 CA-C-N 117.637 0.718 . . . . 0.0 111.482 -177.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.513 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.9 t -116.22 136.29 53.68 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.09 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.994 -175.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 46.8 mtp180 -92.89 99.97 12.52 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 175.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.503 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 97.3 m-85 -92.38 103.26 15.72 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 176.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.749 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 40.3 t -92.45 86.52 2.28 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.858 0 N-CA-C 104.984 -2.228 . . . . 0.0 104.984 175.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.526 HG12 ' HA ' ' A' ' 60' ' ' ILE . 64.1 mt -101.25 159.11 4.05 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 CA-C-N 113.989 -1.46 . . . . 0.0 109.174 -179.2 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.49 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -130.61 158.04 22.36 Favored Glycine 1 N--CA 1.385 -4.724 0 C-N-CA 119.85 -1.167 . . . . 0.0 110.329 176.83 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 4.9 tpp180 -133.31 138.79 46.54 Favored 'General case' 0 C--N 1.286 -2.154 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 . . . . . 0 N--CA 1.416 -2.167 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.051 174.098 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.431 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 32.0 tt0 . . . . . 0 C--O 1.214 -0.783 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.567 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -88.14 126.99 35.41 Favored 'General case' 0 C--O 1.249 1.052 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -138.97 142.73 34.45 Favored Pre-proline 0 C--N 1.306 -1.316 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -176.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -79.27 125.85 6.62 Favored 'Trans proline' 0 C--O 1.25 1.122 0 C-N-CA 122.929 2.419 . . . . 0.0 113.357 177.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.44 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 46.5 t -118.71 105.2 17.23 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 174.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -88.71 102.45 15.0 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.536 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 15.3 tp -90.94 153.13 20.4 Favored 'General case' 0 N--CA 1.422 -1.827 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 -176.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -125.39 78.41 1.72 Allowed 'General case' 0 C--N 1.289 -2.049 0 CA-C-O 122.062 0.934 . . . . 0.0 108.757 177.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.674 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 5.5 mmtt -68.92 -169.72 0.19 Allowed 'General case' 0 N--CA 1.402 -2.842 0 CA-C-N 113.56 -1.654 . . . . 0.0 113.047 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.478 ' H ' ' HD2' ' A' ' 12' ' ' LYS . 9.1 m-20 -91.79 176.37 6.55 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 124.619 1.168 . . . . 0.0 108.346 -174.231 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -63.61 -22.46 66.91 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -176.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -72.0 -32.53 67.29 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.62 0.724 . . . . 0.0 110.151 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.404 ' O ' ' HD2' ' A' ' 12' ' ' LYS . . . 108.82 -140.07 15.45 Favored Glycine 0 N--CA 1.414 -2.831 0 N-CA-C 107.49 -2.244 . . . . 0.0 107.49 -173.21 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.51 ' HB3' HG23 ' A' ' 19' ' ' ILE . 14.7 mt -91.18 -60.9 1.78 Allowed 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.208 179.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.58 33.92 60.45 Favored Glycine 0 N--CA 1.424 -2.117 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -173.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.51 HG23 ' HB3' ' A' ' 17' ' ' LEU . 30.6 pt -96.56 177.78 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 C-N-CA 120.369 -0.532 . . . . 0.0 111.018 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.4 m -120.4 150.11 41.3 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 115.252 -0.885 . . . . 0.0 109.092 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.465 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -125.84 162.98 28.17 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 -179.038 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.8 tt -136.13 126.31 41.1 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.256 176.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.578 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -85.37 104.95 2.86 Favored Glycine 0 N--CA 1.435 -1.38 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.657 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.583 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 89.6 mmm -120.98 88.92 3.03 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.314 -0.689 0 O-C-N 123.918 0.761 . . . . 0.0 112.528 -177.622 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.49 HD12 ' HB ' ' A' ' 37' ' ' ILE . 1.1 pt? . . . . . 0 N--CA 1.44 -0.959 0 CA-C-O 121.406 0.622 . . . . 0.0 111.122 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.583 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -122.07 26.6 6.39 Favored Glycine 0 N--CA 1.417 -2.609 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 173.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.578 HD13 ' HA2' ' A' ' 23' ' ' GLY . 17.9 mm -85.36 101.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 121.547 0.689 . . . . 0.0 109.981 -178.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -95.12 161.93 13.92 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.315 179.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -77.6 122.85 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.202 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -85.54 -49.79 7.76 Favored 'General case' 0 C--N 1.291 -1.96 0 CA-C-O 121.333 0.587 . . . . 0.0 110.501 -177.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.434 ' O ' ' HB ' ' A' ' 19' ' ' ILE . 0.7 OUTLIER -150.84 156.49 41.34 Favored 'General case' 0 N--CA 1.421 -1.876 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.59 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 64.8 t -125.88 145.96 32.45 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.431 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 176.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 8.4 t . . . . . 0 C--O 1.253 1.289 0 O-C-N 123.556 0.535 . . . . 0.0 109.773 176.019 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.674 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . . . . . . 0 CA--C 1.552 1.052 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.403 ' HA ' HD21 ' A' ' 10' ' ' LEU . . . -116.56 -65.56 1.17 Allowed 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 174.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -74.09 -26.06 60.15 Favored 'General case' 0 N--CA 1.464 0.239 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.111 175.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.561 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 2.0 mmp_? -69.09 -26.94 65.18 Favored 'General case' 0 CA--C 1.503 -0.828 0 CA-C-O 121.053 0.454 . . . . 0.0 110.058 173.128 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -73.74 -57.18 4.16 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 178.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.09 -20.73 48.79 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.505 -0.855 . . . . 0.0 114.262 174.68 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.52 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -73.66 -22.86 59.83 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-O 121.648 0.737 . . . . 0.0 109.114 -177.757 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.8 tt -104.85 148.98 8.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 26.7 mm-40 -129.54 165.98 20.6 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-O 121.168 0.509 . . . . 0.0 111.906 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -83.45 -8.94 11.49 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.892 0 CA-C-O 122.166 0.984 . . . . 0.0 108.621 176.195 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -102.43 16.85 25.1 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 122.286 1.041 . . . . 0.0 109.443 -175.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -102.05 -179.62 4.05 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.009 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.493 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 33.4 tt0 -128.72 124.96 36.93 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.477 HG22 HD11 ' A' ' 68' ' ' LEU . 46.1 mm -76.36 95.39 1.24 Allowed 'Isoleucine or valine' 0 C--O 1.206 -1.192 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 -176.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.697 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 60.6 t -79.42 -42.09 22.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 CA-C-O 121.59 0.71 . . . . 0.0 111.159 -175.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.562 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 36.8 tt0 -151.07 131.14 13.44 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.401 HG23 ' CG2' ' A' ' 60' ' ' ILE . 4.0 t -123.51 126.05 72.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 172.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 24.3 t70 69.47 5.47 5.18 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-O 122.356 1.074 . . . . 0.0 111.804 172.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.99 13.3 62.44 Favored Glycine 0 N--CA 1.434 -1.493 0 CA-C-N 115.362 -0.836 . . . . 0.0 111.624 -176.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.405 HD13 HG22 ' A' ' 79' ' ' VAL . 7.2 tt -77.34 -16.73 14.41 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.774 0 O-C-N 122.793 -0.239 . . . . 0.0 110.44 -178.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.467 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 8.6 m 39.74 80.67 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.985 1.714 . . . . 0.0 112.7 -176.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.498 ' H ' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -89.53 31.82 0.9 Allowed 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 122.216 1.007 . . . . 0.0 111.959 -175.606 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 47.8 t -70.52 106.16 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.075 0 CA-C-N 115.199 -0.91 . . . . 0.0 109.288 178.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.93 15.89 20.81 Favored Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.913 176.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.444 HG22 ' O ' ' A' ' 68' ' ' LEU . 19.1 m -96.63 175.83 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.973 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.711 178.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 8.4 p -91.54 172.86 8.22 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.99 178.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.465 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -61.24 -33.65 73.86 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.509 -179.488 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -73.09 -33.05 65.38 Favored 'General case' 0 CA--C 1.512 -0.507 0 C-N-CA 121.072 -0.251 . . . . 0.0 111.568 -176.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 33.4 t80 -69.94 -49.71 49.14 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -58.1 -49.22 77.7 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.516 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -55.87 -36.7 67.89 Favored 'General case' 0 C--O 1.216 -0.682 0 C-N-CA 122.467 0.307 . . . . 0.0 110.957 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 86.9 m -63.39 -45.51 90.75 Favored 'General case' 0 CA--C 1.55 0.957 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.086 176.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.405 HG22 HD13 ' A' ' 66' ' ' ILE . 31.0 t -65.1 -49.92 76.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.663 0.268 . . . . 0.0 110.788 178.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -69.77 -4.87 21.83 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.224 0.61 . . . . 0.0 111.993 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.41 ' HB3' ' O ' ' A' ' 78' ' ' THR . 59.5 ttt180 -92.15 -46.62 7.67 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 124.055 0.942 . . . . 0.0 108.541 174.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -77.41 5.68 8.33 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.326 -1.306 . . . . 0.0 113.366 -174.322 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.476 ' OG1' ' HG ' ' A' ' 17' ' ' LEU . 16.8 p -63.45 154.19 32.97 Favored 'General case' 0 C--N 1.294 -1.806 0 C-N-CA 123.832 0.853 . . . . 0.0 112.711 176.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.0 mmtt -120.24 -161.92 0.91 Allowed 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 114.567 -1.197 . . . . 0.0 108.501 176.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.05 -68.03 1.89 Allowed Glycine 0 N--CA 1.444 -0.824 0 O-C-N 123.818 0.699 . . . . 0.0 111.901 176.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.536 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.7 m120 -83.06 118.57 23.63 Favored 'General case' 0 C--N 1.307 -1.268 0 O-C-N 122.244 -0.562 . . . . 0.0 110.635 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.442 HG21 HD21 ' A' ' 17' ' ' LEU . 4.4 t -130.75 130.0 64.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.504 -176.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 22.1 mtp180 -94.33 100.59 12.6 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-O 121.186 0.517 . . . . 0.0 110.917 174.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.496 ' HB3' HG13 ' A' ' 91' ' ' ILE . 89.0 m-85 -95.12 112.0 23.76 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 176.101 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.697 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 10.7 t -100.48 65.54 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.496 HG13 ' HB3' ' A' ' 89' ' ' PHE . 76.4 mt -77.14 153.8 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.516 0 CA-C-N 112.796 -2.002 . . . . 0.0 109.909 -177.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.567 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -131.07 149.3 19.15 Favored Glycine 1 N--CA 1.385 -4.709 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 177.386 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -111.25 133.0 53.92 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 -178.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 . . . . . 0 C--N 1.309 -1.185 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 177.968 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 . . . . . 0 N--CA 1.437 -1.094 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.527 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -87.86 125.17 34.33 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -132.02 140.66 38.81 Favored Pre-proline 0 C--N 1.287 -2.112 0 CA-C-O 121.461 0.648 . . . . 0.0 112.061 -176.286 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -83.11 125.85 4.18 Favored 'Trans proline' 0 C--N 1.301 -1.927 0 C-N-CA 122.535 2.157 . . . . 0.0 112.188 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.472 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 36.9 t -109.04 109.05 26.89 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.593 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 172.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.47 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 45.3 tt0 -92.89 103.23 15.58 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.51 HD21 ' HB2' ' A' ' 51' ' ' ASP . 0.5 OUTLIER -103.38 154.21 19.65 Favored 'General case' 0 N--CA 1.395 -3.182 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 -175.669 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.45 ' H ' HD23 ' A' ' 10' ' ' LEU . 42.2 tt0 -123.06 100.56 6.94 Favored 'General case' 0 N--CA 1.409 -2.483 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 177.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.65 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.3 mmmp? -92.48 178.92 5.67 Favored 'General case' 0 C--N 1.284 -2.282 0 CA-C-N 114.524 -1.217 . . . . 0.0 109.486 176.254 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.547 ' OD2' ' HG2' ' A' ' 14' ' ' GLU . 19.6 t70 -101.41 -160.01 0.77 Allowed 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -176.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.547 ' HG2' ' OD2' ' A' ' 13' ' ' ASP . 11.0 pt-20 -75.77 -13.08 60.29 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -171.305 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -71.07 -43.9 66.84 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.213 0.53 . . . . 0.0 110.254 177.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 125.1 -131.02 7.57 Favored Glycine 0 CA--C 1.481 -2.066 0 N-CA-C 108.28 -1.928 . . . . 0.0 108.28 -177.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 14.3 mt -100.7 -60.94 1.43 Allowed 'General case' 0 CA--C 1.476 -1.902 0 C-N-CA 119.012 -1.075 . . . . 0.0 109.462 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.12 29.94 39.65 Favored Glycine 0 N--CA 1.419 -2.472 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -174.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.435 HD11 HD12 ' A' ' 80' ' ' LEU . 24.5 pt -104.54 176.87 0.94 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.987 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.4 m -135.42 150.08 49.78 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 -177.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.588 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -120.16 166.02 15.0 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 C-N-CA 123.303 0.641 . . . . 0.0 110.098 -177.242 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 11.9 tt -140.94 127.93 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.014 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 174.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.51 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.57 109.48 3.81 Favored Glycine 0 CA--C 1.484 -1.869 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -177.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.626 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 88.7 mmm -125.99 92.92 3.69 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.397 0 N-CA-C 114.77 0.668 . . . . 0.0 114.77 -175.523 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.489 HD12 ' H ' ' A' ' 37' ' ' ILE . 2.3 pp . . . . . 0 N--CA 1.44 -0.927 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.626 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -121.98 30.62 5.21 Favored Glycine 0 N--CA 1.422 -2.281 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.75 178.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.51 HD13 ' HA2' ' A' ' 23' ' ' GLY . 23.5 mm -82.25 103.65 9.74 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 CA-C-O 121.847 0.832 . . . . 0.0 110.537 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -99.32 164.33 12.16 Favored 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.0 t -82.6 131.04 34.69 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.484 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 177.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.556 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.4 OUTLIER -91.7 -45.39 8.47 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.137 0.494 . . . . 0.0 109.832 -178.692 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.0 m -154.66 162.24 41.21 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -127.11 160.98 35.13 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.15 0 N-CA-C 105.363 -2.088 . . . . 0.0 105.363 178.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.6 t . . . . . 0 C--N 1.293 -1.883 0 CA-C-O 121.908 0.861 . . . . 0.0 111.007 -178.599 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.65 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.211 -0.942 0 N-CA-C 115.685 1.735 . . . . 0.0 115.685 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.455 ' HB2' ' CE ' ' A' ' 12' ' ' LYS . . . -82.38 -56.79 3.68 Favored 'General case' 0 N--CA 1.488 1.461 0 CA-C-N 118.974 0.806 . . . . 0.0 110.91 -176.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -73.9 -16.99 61.09 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.561 0.696 . . . . 0.0 110.45 177.055 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.508 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 3.9 mmp_? -83.14 -17.03 44.42 Favored 'General case' 0 N--CA 1.432 -1.353 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.092 174.073 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.51 ' HB2' HD21 ' A' ' 10' ' ' LEU . 11.7 t70 -61.43 -61.75 2.32 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.964 0.411 . . . . 0.0 109.987 173.584 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.92 -9.86 74.75 Favored Glycine 0 N--CA 1.44 -1.073 0 C-N-CA 120.575 -0.821 . . . . 0.0 114.849 173.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -89.35 -45.35 9.55 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 178.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.7 tt -74.9 150.51 6.96 Favored 'Isoleucine or valine' 0 C--O 1.252 1.225 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 176.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -134.87 160.35 38.51 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.7 p -73.27 -17.0 17.7 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.139 0 CA-C-O 121.79 0.805 . . . . 0.0 109.743 176.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -90.32 -6.37 55.16 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.389 -173.327 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -95.07 -176.12 3.73 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 113.249 0.833 . . . . 0.0 113.249 -174.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.503 ' O ' HG23 ' A' ' 91' ' ' ILE . 32.4 tt0 -116.99 127.43 54.18 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.102 -174.365 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.521 HG23 HG23 ' A' ' 63' ' ' VAL . 50.4 mm -73.4 105.57 2.87 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.627 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.644 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 97.9 t -90.04 -49.46 13.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 CA-C-O 121.664 0.745 . . . . 0.0 111.008 -176.006 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.516 ' HG3' ' H ' ' A' ' 67' ' ' SER . 37.4 tt0 -151.99 104.15 2.96 Favored 'General case' 0 C--N 1.296 -1.751 0 CA-C-O 121.518 0.675 . . . . 0.0 109.834 -178.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.521 HG23 HG23 ' A' ' 60' ' ' ILE . 3.8 t -91.75 123.04 43.73 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.061 0 CA-C-O 121.322 0.582 . . . . 0.0 111.717 176.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 24.5 t70 65.86 4.66 3.05 Favored 'General case' 0 C--N 1.311 -1.067 0 C-N-CA 126.813 2.045 . . . . 0.0 112.769 174.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.98 12.34 57.84 Favored Glycine 0 N--CA 1.429 -1.771 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.613 -177.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.469 HD13 HG22 ' A' ' 79' ' ' VAL . 9.6 tt -73.01 -17.8 18.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-O 121.185 0.517 . . . . 0.0 110.408 -179.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.516 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 9.7 p 49.69 82.83 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 124.826 1.25 . . . . 0.0 113.259 -176.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.536 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.8 pp -93.03 14.43 17.78 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.572 -177.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.41 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 58.6 t -57.75 102.5 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.5 176.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.467 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 113.62 -5.25 24.54 Favored Glycine 0 N--CA 1.442 -0.941 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.433 176.198 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.536 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.5 m -83.98 178.15 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.247 0.925 0 CA-C-O 121.245 0.545 . . . . 0.0 111.69 -175.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.4 p -101.12 170.53 8.2 Favored 'General case' 0 N--CA 1.415 -2.18 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.116 176.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.588 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -56.13 -33.5 65.21 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-N 114.51 -1.223 . . . . 0.0 112.256 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -74.4 -22.36 59.2 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 111.744 0.275 . . . . 0.0 111.744 -177.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.426 ' O ' ' HB ' ' A' ' 78' ' ' THR . 38.6 t80 -80.85 -50.14 10.17 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 174.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.64 -47.99 80.71 Favored 'General case' 0 C--O 1.22 -0.459 0 CA-C-N 114.719 -1.128 . . . . 0.0 112.12 -178.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -56.74 -33.22 66.34 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 120.89 0.376 . . . . 0.0 110.687 179.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.426 ' HB ' ' O ' ' A' ' 75' ' ' PHE . 53.0 m -68.62 -47.15 67.4 Favored 'General case' 0 N--CA 1.435 -1.205 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.904 176.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.469 HG22 HD13 ' A' ' 66' ' ' ILE . 44.3 t -58.82 -50.27 79.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 110.097 -0.335 . . . . 0.0 110.097 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.435 HD12 HD11 ' A' ' 19' ' ' ILE . 3.6 mm? -67.67 -10.62 53.93 Favored 'General case' 0 CA--C 1.551 1.014 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.681 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 81' ' ' ARG . 0.8 OUTLIER -97.7 -23.05 16.11 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.256 0.551 . . . . 0.0 110.43 176.082 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -83.84 -23.18 31.47 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.092 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.4 p -63.99 156.62 27.42 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 113.646 0.98 . . . . 0.0 113.646 -178.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.75 -145.97 0.36 Allowed 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 114.685 -1.143 . . . . 0.0 109.764 -176.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.8 -67.64 1.91 Allowed Glycine 0 C--N 1.295 -1.719 0 O-C-N 123.671 0.607 . . . . 0.0 112.603 -177.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -77.25 109.73 11.37 Favored 'General case' 0 CA--C 1.497 -1.079 0 C-N-CA 119.937 -0.705 . . . . 0.0 110.118 178.657 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -124.09 144.53 33.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.82 98.26 7.78 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 173.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.472 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 86.5 m-85 -90.42 98.4 11.75 Favored 'General case' 0 C--N 1.279 -2.498 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 178.134 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.644 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 58.9 t -89.3 91.8 3.77 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.433 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 178.168 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.503 HG23 ' O ' ' A' ' 59' ' ' GLN . 81.6 mt -106.52 156.67 7.04 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.073 0 CA-C-N 114.0 -1.454 . . . . 0.0 108.096 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.527 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -134.25 164.47 24.53 Favored Glycine 1 N--CA 1.393 -4.182 0 C-N-CA 119.566 -1.302 . . . . 0.0 109.931 178.595 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -149.46 131.06 14.91 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . 0.26 0.0 OUTLIER . . . . . 0 N--CA 1.411 -2.377 0 CA-C-O 118.436 -0.792 . . . . 0.0 110.671 175.218 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 . . . . . 0 N--CA 1.438 -1.026 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.42 HD12 HG21 ' A' ' 61' ' ' VAL . 1.8 mm? -81.73 130.55 35.1 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 178.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -137.11 141.53 34.84 Favored Pre-proline 0 C--N 1.284 -2.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.324 -179.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -77.89 128.71 9.4 Favored 'Trans proline' 0 N--CA 1.443 -1.474 0 C-N-CA 122.368 2.046 . . . . 0.0 112.418 178.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.416 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 21.7 t -119.11 94.99 3.34 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.258 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 174.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.512 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 40.7 tt0 -78.33 112.44 15.34 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 175.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -97.43 123.07 41.15 Favored 'General case' 0 N--CA 1.405 -2.701 0 N-CA-C 105.444 -2.058 . . . . 0.0 105.444 178.617 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.456 ' HG3' ' OD1' ' A' ' 86' ' ' ASN . 30.9 tt0 -94.44 90.45 6.23 Favored 'General case' 0 C--N 1.281 -2.373 0 CA-C-O 121.839 0.828 . . . . 0.0 109.005 179.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 2.8 mmmp? -93.82 -175.4 3.72 Favored 'General case' 0 N--CA 1.428 -1.563 0 CA-C-N 114.263 -1.335 . . . . 0.0 111.778 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.57 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.5 p-10 -88.27 -172.42 3.78 Favored 'General case' 0 C--N 1.28 -2.452 0 C-N-CA 126.8 2.04 . . . . 0.0 112.384 -177.386 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -77.45 -20.21 54.82 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 114.705 -1.134 . . . . 0.0 111.577 -179.458 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.57 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 18.8 t70 -73.95 -35.64 64.55 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 118.25 -124.58 6.11 Favored Glycine 0 CA--C 1.486 -1.747 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.661 172.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.525 ' HB3' HG23 ' A' ' 19' ' ' ILE . 31.7 mt -112.76 -54.54 2.61 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.1 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.55 27.51 69.32 Favored Glycine 0 N--CA 1.425 -2.062 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.818 -173.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.525 HG23 ' HB3' ' A' ' 17' ' ' LEU . 27.0 pt -94.67 176.32 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.26 -178.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 49.0 m -132.33 150.31 52.18 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.882 -178.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -120.05 159.89 20.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 15.4 tt -124.13 132.01 72.01 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 C-N-CA 120.063 -0.655 . . . . 0.0 110.045 175.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.539 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.82 92.45 1.78 Allowed Glycine 0 N--CA 1.427 -1.94 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.852 -177.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 91.8 mmm -108.26 -179.07 3.78 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.284 -2.354 0 C-N-CA 120.087 -1.054 . . . . 0.0 112.333 179.913 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.653 HD23 ' HA ' ' A' ' 69' ' ' VAL . 3.2 pp . . . . . 0 N--CA 1.44 -0.969 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -116.47 32.54 5.51 Favored Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 175.172 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.539 HD13 ' HA2' ' A' ' 23' ' ' GLY . 29.7 mm -81.31 103.87 9.01 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.867 0 CA-C-O 121.624 0.726 . . . . 0.0 110.14 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -102.21 160.16 14.76 Favored 'General case' 0 C--N 1.275 -2.645 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.296 176.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 40.5 t -74.32 123.97 30.84 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 175.293 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.405 ' HB2' ' HB ' ' A' ' 22' ' ' ILE . 53.5 tptt -89.29 -48.61 7.25 Favored 'General case' 0 C--N 1.293 -1.871 0 CA-C-O 121.118 0.485 . . . . 0.0 110.28 -176.762 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -150.25 159.15 44.65 Favored 'General case' 0 N--CA 1.422 -1.874 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -177.401 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.517 HG11 ' HG3' ' A' ' 49' ' ' GLN . 23.3 t -121.24 174.16 6.17 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.522 0 N-CA-C 104.894 -2.261 . . . . 0.0 104.894 175.296 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.413 ' N ' HG12 ' A' ' 42' ' ' VAL . 3.2 t . . . . . 0 CA--C 1.561 1.377 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 173.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.434 ' O ' ' HB2' ' A' ' 51' ' ' ASP . . . . . . . . 0 C--O 1.193 -1.921 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.57 -60.11 2.44 Favored 'General case' 0 C--N 1.35 0.59 0 C-N-CA 123.551 0.74 . . . . 0.0 110.059 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.517 ' HG3' HG11 ' A' ' 42' ' ' VAL . 26.5 mt-30 -70.5 -27.46 64.22 Favored 'General case' 0 CA--C 1.511 -0.536 0 C-N-CA 120.14 -0.624 . . . . 0.0 111.029 178.087 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -78.45 -19.5 53.01 Favored 'General case' 0 N--CA 1.44 -0.975 0 C-N-CA 120.04 -0.664 . . . . 0.0 111.778 175.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.434 ' HB2' ' O ' ' A' ' 47' ' ' ALA . 11.1 t70 -66.7 -64.01 0.94 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 172.058 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.89 -10.11 70.4 Favored Glycine 0 N--CA 1.44 -1.092 0 C-N-CA 120.557 -0.83 . . . . 0.0 115.13 173.561 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.08 -21.56 43.2 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -179.817 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.6 tt -105.05 164.59 3.91 Favored 'Isoleucine or valine' 0 C--O 1.254 1.305 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 175.164 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 63.1 mt-30 -136.17 -156.72 0.73 Allowed 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 119.033 0.833 . . . . 0.0 110.923 -177.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.2 p -123.94 18.21 4.77 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 174.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -132.91 -8.43 3.09 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.758 0.789 . . . . 0.0 111.206 -174.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.564 ' OD2' HD13 ' A' ' 91' ' ' ILE . 7.1 p-10 -83.18 179.24 7.78 Favored 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 124.571 1.148 . . . . 0.0 110.919 -177.357 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.46 ' O ' HG23 ' A' ' 91' ' ' ILE . 31.1 tt0 -119.76 126.08 50.18 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.087 -176.054 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.538 HG21 HD21 ' A' ' 80' ' ' LEU . 50.8 mm -74.36 114.71 14.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.089 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.701 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 84.7 t -98.37 -48.92 11.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.85 0.834 . . . . 0.0 111.022 -178.164 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.576 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 26.9 tt0 -150.28 114.88 5.23 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -178.614 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.48 HG23 HG23 ' A' ' 60' ' ' ILE . 3.4 t -110.1 128.13 66.51 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.821 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.589 178.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.7 t70 72.58 -8.84 1.15 Allowed 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 125.265 1.426 . . . . 0.0 112.348 175.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.83 13.43 31.98 Favored Glycine 0 C--N 1.286 -2.203 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.686 -174.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.4 tt -74.97 -17.44 16.2 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.498 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 17.4 m 45.83 84.56 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 125.659 1.584 . . . . 0.0 111.585 -176.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.535 HD21 HG22 ' A' ' 60' ' ' ILE . 0.7 OUTLIER -93.06 20.98 6.19 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.659 0.742 . . . . 0.0 110.671 -175.317 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.653 ' HA ' HD23 ' A' ' 35' ' ' LEU . 59.1 t -52.77 100.63 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 CA-C-N 114.691 -1.141 . . . . 0.0 111.77 177.474 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 94.59 21.7 25.89 Favored Glycine 0 N--CA 1.443 -0.844 0 CA-C-N 115.47 -0.786 . . . . 0.0 114.131 174.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.418 ' CG2' ' HB2' ' A' ' 68' ' ' LEU . 20.5 m -93.43 -178.66 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 117.497 0.649 . . . . 0.0 111.173 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.9 p -98.37 178.97 4.87 Favored 'General case' 0 C--O 1.251 1.146 0 CA-C-O 121.037 0.446 . . . . 0.0 110.377 177.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.92 -25.31 66.3 Favored 'General case' 0 C--O 1.204 -1.337 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.337 179.638 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 25.6 m-80 -63.02 -48.57 78.22 Favored 'General case' 0 CA--C 1.483 -1.603 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.183 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -68.61 -47.79 65.78 Favored 'General case' 0 N--CA 1.426 -1.633 0 CA-C-N 114.76 -1.109 . . . . 0.0 109.698 -175.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.438 ' HA ' HG12 ' A' ' 79' ' ' VAL . . . -62.94 -40.29 97.21 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.167 -178.738 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -69.08 -18.19 63.97 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.229 0.537 . . . . 0.0 110.426 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 83.3 m -84.01 -47.5 10.91 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.457 176.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.542 HG13 HD22 ' A' ' 80' ' ' LEU . 3.9 p -62.78 -48.6 87.36 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 N-CA-C 112.943 0.72 . . . . 0.0 112.943 177.323 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.542 HD22 HG13 ' A' ' 79' ' ' VAL . 3.9 mm? -67.2 -12.22 59.48 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.531 0.682 . . . . 0.0 112.056 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -84.47 -46.05 12.04 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 176.249 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -79.56 -11.09 59.89 Favored 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 114.388 1.255 . . . . 0.0 114.388 -171.188 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.434 HG23 ' O ' ' A' ' 79' ' ' VAL . 12.0 p -68.45 140.7 55.76 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -135.93 141.75 44.54 Favored 'General case' 0 CA--C 1.482 -1.659 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.096 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 47.67 -88.13 0.01 OUTLIER Glycine 0 CA--C 1.474 -2.508 0 O-C-N 126.039 2.087 . . . . 0.0 113.696 178.081 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.456 ' OD1' ' HG3' ' A' ' 11' ' ' GLU . 3.0 m-20 -97.94 102.0 13.63 Favored 'General case' 0 C--N 1.247 -3.849 0 CA-C-N 113.804 -1.198 . . . . 0.0 110.52 -173.283 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 40.2 t -113.15 124.82 70.16 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 CA-C-N 115.021 -0.991 . . . . 0.0 111.611 -173.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.59 104.18 16.61 Favored 'General case' 0 CA--C 1.49 -1.364 0 C-N-CA 120.204 -0.598 . . . . 0.0 109.944 174.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.416 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 90.9 m-85 -93.49 100.19 12.52 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 175.697 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.701 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.8 t -89.5 92.99 4.13 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.82 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 177.282 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.564 HD13 ' OD2' ' A' ' 58' ' ' ASP . 96.5 mt -108.62 163.84 5.79 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.375 0 C-N-CA 125.485 1.514 . . . . 0.0 107.494 179.486 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -133.75 159.82 23.83 Favored Glycine 0 N--CA 1.411 -2.97 0 C-N-CA 118.557 -1.782 . . . . 0.0 113.301 -177.146 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 35.5 ttt180 -114.32 137.41 51.84 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 123.321 0.648 . . . . 0.0 109.533 177.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? . . . . . 0 C--N 1.294 -1.834 0 CA-C-O 119.395 -0.336 . . . . 0.0 110.976 -178.445 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.473 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 35.2 tt0 . . . . . 0 N--CA 1.44 -0.961 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -84.14 131.89 34.74 Favored 'General case' 0 CA--C 1.5 -0.963 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -140.58 138.5 18.73 Favored Pre-proline 0 N--CA 1.42 -1.971 0 CA-C-O 121.507 0.67 . . . . 0.0 112.012 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -81.47 124.27 4.64 Favored 'Trans proline' 0 C--N 1.314 -1.263 0 C-N-CA 122.856 2.37 . . . . 0.0 112.781 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.445 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 25.0 t -113.61 106.14 20.13 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 175.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.492 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 30.8 tt0 -89.64 109.13 20.11 Favored 'General case' 0 N--CA 1.416 -2.132 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 177.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -100.91 149.34 23.99 Favored 'General case' 0 C--N 1.289 -2.063 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 -176.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -120.44 93.03 3.91 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 171.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.491 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.0 mmmp? -82.73 172.86 12.43 Favored 'General case' 0 N--CA 1.421 -1.92 0 CA-C-O 122.63 1.205 . . . . 0.0 114.177 -179.046 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -72.78 171.23 13.03 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 112.077 -2.329 . . . . 0.0 108.564 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -68.83 -16.93 63.92 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.345 0.593 . . . . 0.0 110.373 178.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.05 -33.02 72.65 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 122.023 0.916 . . . . 0.0 109.986 174.462 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.59 -138.38 14.93 Favored Glycine 0 N--CA 1.41 -3.095 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.414 HD21 HG21 ' A' ' 87' ' ' VAL . 16.8 mt -89.46 -43.91 10.52 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 119.734 -0.786 . . . . 0.0 109.735 -179.445 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 66.64 28.0 73.52 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 124.547 1.155 . . . . 0.0 111.013 -174.23 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.475 HD11 HD12 ' A' ' 80' ' ' LEU . 20.7 pt -109.0 177.07 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.452 -178.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.0 m -138.64 153.81 48.61 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -177.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.411 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -122.39 166.72 16.76 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 -178.204 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 13.7 tt -135.08 133.57 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.79 0 C-N-CA 120.026 -0.67 . . . . 0.0 111.435 176.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.537 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -92.93 103.44 3.05 Favored Glycine 0 N--CA 1.413 -2.886 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 18.1 ptm -140.85 86.94 2.08 Favored 'General case' 0 C--N 1.288 -2.079 0 CA-C-O 121.584 0.707 . . . . 0.0 109.77 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.44 -1.09 0 CA-C-N 114.066 -1.425 . . . . 0.0 112.966 -176.058 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.437 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 0.8 OUTLIER . . . . . 0 C--O 1.24 0.597 0 CA-C-O 121.664 0.745 . . . . 0.0 112.6 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -120.02 47.43 1.03 Allowed Glycine 0 N--CA 1.413 -2.877 0 N-CA-C 109.961 -1.255 . . . . 0.0 109.961 175.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.584 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 28.9 mm -109.12 111.43 36.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 177.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -110.49 170.41 8.1 Favored 'General case' 0 C--N 1.269 -2.909 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.385 -178.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 38.9 t -83.47 128.21 39.0 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.076 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.574 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -92.92 -47.12 7.17 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 120.944 0.402 . . . . 0.0 110.165 -176.884 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.1 m -150.36 163.46 38.3 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 -178.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 61.0 t -136.38 148.4 27.29 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 N-CA-C 105.007 -2.22 . . . . 0.0 105.007 178.347 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.6 t . . . . . 0 C--O 1.251 1.176 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 175.277 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.543 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 CA--C 1.56 1.342 0 N-CA-C 114.825 1.417 . . . . 0.0 114.825 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.43 -59.33 2.82 Favored 'General case' 0 C--O 1.219 -0.535 0 O-C-N 121.745 -0.597 . . . . 0.0 109.993 -176.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -74.34 -15.12 60.96 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.387 175.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.543 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 24.2 mmm180 -73.12 -34.02 65.88 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 172.219 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -59.53 -58.63 7.75 Favored 'General case' 0 N--CA 1.473 0.681 0 O-C-N 123.565 0.54 . . . . 0.0 109.813 173.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.82 -12.81 67.68 Favored Glycine 0 C--N 1.312 -0.782 0 C-N-CA 120.319 -0.943 . . . . 0.0 114.879 173.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 63.5 ttt180 -80.18 -40.77 26.59 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.09 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.4 tt -86.23 143.73 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.99 0 CA-C-N 114.335 -1.302 . . . . 0.0 107.857 179.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -138.5 175.85 9.21 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-O 121.258 0.551 . . . . 0.0 110.665 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.7 p -81.38 -3.25 6.57 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.49 -177.05 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -105.38 6.89 32.97 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.638 0.732 . . . . 0.0 110.545 -174.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -93.01 -173.66 3.34 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 115.186 -0.916 . . . . 0.0 111.08 -176.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.584 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 27.5 tt0 -131.86 127.45 36.56 Favored 'General case' 0 C--N 1.322 -0.608 0 C-N-CA 123.488 0.715 . . . . 0.0 111.001 -177.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.549 HG22 HD21 ' A' ' 68' ' ' LEU . 48.9 mm -77.21 106.45 7.29 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.852 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.45 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.72 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.1 t -89.18 -49.5 13.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-O 122.219 1.009 . . . . 0.0 110.116 -176.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.558 ' HG3' ' H ' ' A' ' 67' ' ' SER . 23.8 tt0 -148.64 126.84 12.13 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.496 179.225 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.431 HG23 HG23 ' A' ' 60' ' ' ILE . 2.7 t -118.37 127.69 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.641 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.118 176.216 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.9 t70 63.94 15.15 8.95 Favored 'General case' 0 N--CA 1.477 0.886 0 O-C-N 124.744 1.277 . . . . 0.0 111.081 173.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.93 17.32 67.83 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.855 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.437 HG21 HG21 ' A' ' 79' ' ' VAL . 6.1 tt -77.23 -18.68 14.34 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.156 0 CA-C-N 117.166 0.483 . . . . 0.0 111.283 -179.098 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.558 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 16.8 p 49.56 83.88 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.419 1.488 . . . . 0.0 113.126 -174.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.549 HD21 HG22 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.87 17.36 18.34 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.582 0.706 . . . . 0.0 110.805 -175.894 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 44.6 t -57.06 94.13 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.134 174.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.437 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 102.96 52.74 0.93 Allowed Glycine 0 N--CA 1.436 -1.355 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.866 178.29 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 23.5 m -130.05 178.71 4.93 Favored 'Isoleucine or valine' 0 C--O 1.243 0.723 0 CA-C-O 120.97 0.414 . . . . 0.0 111.107 178.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 15.5 p -98.31 174.61 6.41 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.425 178.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.411 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -67.45 -27.38 66.99 Favored 'General case' 0 C--O 1.2 -1.541 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.395 -178.61 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -71.81 -30.87 65.96 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.064 -179.383 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -74.64 -48.39 26.57 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 176.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.429 ' HA ' HG12 ' A' ' 79' ' ' VAL . . . -61.72 -42.15 98.57 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.733 -179.115 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.1 -33.22 71.8 Favored 'General case' 0 C--O 1.204 -1.32 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 177.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 92.0 m -71.67 -48.7 45.8 Favored 'General case' 0 N--CA 1.434 -1.25 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.185 178.658 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.591 HG13 HD22 ' A' ' 80' ' ' LEU . 3.4 p -62.23 -45.59 98.4 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 178.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.591 HD22 HG13 ' A' ' 79' ' ' VAL . 3.8 mm? -70.68 -7.82 47.4 Favored 'General case' 0 CA--C 1.549 0.918 0 CA-C-O 121.053 0.454 . . . . 0.0 111.597 178.283 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.9 tmt_? -97.44 -28.12 14.14 Favored 'General case' 0 C--O 1.214 -0.799 0 C-N-CA 122.73 0.412 . . . . 0.0 110.773 176.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -84.92 -2.52 57.96 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -177.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.0 p -76.82 159.85 29.74 Favored 'General case' 0 C--N 1.288 -2.072 0 CA-C-O 121.655 0.741 . . . . 0.0 112.866 -177.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 33.2 mmtp -118.39 -162.51 0.89 Allowed 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 114.931 -1.031 . . . . 0.0 108.639 177.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -53.04 -62.71 5.69 Favored Glycine 0 C--O 1.217 -0.953 0 O-C-N 123.846 0.716 . . . . 0.0 113.228 174.258 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.16 115.2 18.67 Favored 'General case' 0 C--O 1.245 0.867 0 CA-C-N 117.597 0.699 . . . . 0.0 110.014 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.0 t -132.24 136.43 56.44 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.907 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.213 -177.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 65.2 mtp180 -99.2 99.71 10.72 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 171.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.445 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 95.9 m-85 -90.31 102.78 15.51 Favored 'General case' 0 CA--C 1.486 -1.493 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 175.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.72 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 47.5 t -93.65 87.28 2.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.694 0 N-CA-C 105.326 -2.102 . . . . 0.0 105.326 178.164 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.473 HG23 ' O ' ' A' ' 59' ' ' GLN . 76.9 mt -104.11 153.22 6.24 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.785 0 CA-C-N 113.684 -1.598 . . . . 0.0 109.223 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -126.08 155.74 19.37 Favored Glycine 1 N--CA 1.384 -4.778 0 N-CA-C 108.405 -1.878 . . . . 0.0 108.405 177.135 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 64.7 ttt-85 -141.03 137.48 32.98 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 119.169 -1.012 . . . . 0.0 112.83 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 . . . . . 0 C--N 1.311 -1.102 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 173.585 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.446 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 45.5 tt0 . . . . . 0 CA--C 1.498 -1.029 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.462 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.7 mm? -85.54 130.98 34.45 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 176.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -138.79 142.41 33.83 Favored Pre-proline 0 C--N 1.288 -2.065 0 CA-C-O 121.214 0.531 . . . . 0.0 111.802 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -83.87 123.48 3.23 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.667 2.244 . . . . 0.0 112.732 177.21 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.4 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 40.2 t -114.65 105.38 18.55 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 174.316 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.487 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 27.6 tt0 -93.7 97.54 10.52 Favored 'General case' 0 N--CA 1.417 -2.121 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 -179.384 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.496 HD21 ' HB2' ' A' ' 51' ' ' ASP . 0.5 OUTLIER -87.67 158.36 18.86 Favored 'General case' 0 N--CA 1.397 -3.105 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -174.778 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.421 ' H ' HD23 ' A' ' 10' ' ' LEU . 48.1 tt0 -124.04 98.93 6.01 Favored 'General case' 0 C--N 1.274 -2.681 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.229 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 85' ' ' GLY . 2.3 mmmp? -100.73 -170.0 1.79 Allowed 'General case' 0 N--CA 1.409 -2.512 0 CA-C-N 114.518 -1.219 . . . . 0.0 112.696 -179.791 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.56 157.12 36.02 Favored 'General case' 0 N--CA 1.413 -2.312 0 CA-C-N 113.03 -1.896 . . . . 0.0 106.534 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -72.48 -8.95 57.75 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 121.438 0.637 . . . . 0.0 110.253 176.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -72.22 -38.47 68.97 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 175.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.59 -145.14 16.74 Favored Glycine 0 N--CA 1.42 -2.411 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.624 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.404 HD11 HG21 ' A' ' 83' ' ' THR . 18.3 mt -104.53 -46.47 4.35 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.44 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.85 29.7 37.82 Favored Glycine 0 N--CA 1.422 -2.242 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.874 -175.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.2 pt -102.42 -174.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 120.059 -0.656 . . . . 0.0 112.357 -177.293 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 21.8 m -135.66 153.04 51.75 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.589 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -126.63 164.99 25.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 123.393 0.677 . . . . 0.0 109.336 -177.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.9 tt -135.41 130.02 50.17 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-O 120.811 0.338 . . . . 0.0 110.487 175.062 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.505 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.33 107.28 3.32 Favored Glycine 0 N--CA 1.428 -1.861 0 C-N-CA 121.085 -0.578 . . . . 0.0 112.029 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.405 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.2 mmm -121.94 174.53 6.84 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.645 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.29 -1.989 0 C-N-CA 119.418 -1.372 . . . . 0.0 112.171 179.616 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.507 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.0 pp . . . . . 0 N--CA 1.437 -1.084 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -116.8 33.71 4.95 Favored Glycine 0 C--N 1.288 -2.103 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 173.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.522 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 26.3 mm -84.58 105.49 13.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 121.407 0.622 . . . . 0.0 110.337 -177.09 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -99.25 162.98 12.74 Favored 'General case' 0 C--N 1.279 -2.46 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 177.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.89 128.01 38.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.407 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.542 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -91.74 -39.07 12.02 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.303 0.573 . . . . 0.0 110.455 -177.049 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.7 m -159.65 161.0 34.9 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.441 HG11 ' HG3' ' A' ' 49' ' ' GLN . 17.5 t -117.62 167.73 10.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.216 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.9 t . . . . . 0 C--N 1.305 -1.364 0 C-N-CA 123.044 0.538 . . . . 0.0 109.965 178.566 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.462 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 C--O 1.203 -1.392 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.55 -62.56 1.65 Allowed 'General case' 0 C--O 1.214 -0.807 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.441 ' HG3' HG11 ' A' ' 42' ' ' VAL . 27.4 mt-30 -72.73 -13.73 61.4 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.783 0.661 . . . . 0.0 112.783 176.208 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.462 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 27.4 mmt180 -81.17 -26.33 36.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 172.299 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.496 ' HB2' HD21 ' A' ' 10' ' ' LEU . 24.6 t70 -54.94 -57.55 11.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 123.743 0.652 . . . . 0.0 111.368 177.655 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.73 -13.15 56.48 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.225 -0.988 . . . . 0.0 114.352 175.322 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.579 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -93.74 -59.93 1.88 Allowed 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 118.082 0.941 . . . . 0.0 108.573 176.878 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.579 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 15.3 tt -64.29 143.67 15.47 Favored 'Isoleucine or valine' 0 C--O 1.246 0.893 0 O-C-N 123.707 0.63 . . . . 0.0 110.672 -175.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -142.52 172.76 12.26 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.029 0.442 . . . . 0.0 111.617 -178.377 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.7 p -76.68 -9.52 12.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.653 0 CA-C-O 121.889 0.852 . . . . 0.0 110.503 -177.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -92.22 -2.75 56.32 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.592 0.711 . . . . 0.0 110.288 -176.087 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.487 ' HB3' HG21 ' A' ' 91' ' ' ILE . 76.9 m-20 -82.29 174.94 10.68 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 121.988 0.899 . . . . 0.0 112.328 -176.173 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.522 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.3 tt0 -128.6 125.48 38.27 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.497 178.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.508 HG22 HD21 ' A' ' 68' ' ' LEU . 48.8 mm -77.16 104.74 5.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -178.582 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.779 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 86.1 t -87.13 -48.07 15.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.844 0.831 . . . . 0.0 110.82 -176.469 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.517 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 33.1 tt0 -151.66 125.95 9.35 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.442 HG23 HG23 ' A' ' 60' ' ' ILE . 3.0 t -115.64 128.05 73.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 175.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.1 t70 72.97 -9.15 1.16 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 125.23 1.412 . . . . 0.0 112.671 173.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.93 11.56 36.94 Favored Glycine 0 C--N 1.29 -2.011 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.763 -174.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.558 HD13 HG22 ' A' ' 79' ' ' VAL . 7.0 tt -70.95 -21.21 22.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-O 120.728 0.299 . . . . 0.0 111.36 -177.614 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.499 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 57.7 p 51.01 88.52 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.036 1.334 . . . . 0.0 112.192 -177.31 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.508 HD21 HG22 ' A' ' 60' ' ' ILE . 1.4 pp -100.29 17.9 20.22 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 122.29 1.043 . . . . 0.0 109.931 -175.595 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.507 ' HA ' HD23 ' A' ' 35' ' ' LEU . 39.2 t -60.69 98.49 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.297 178.234 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.411 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 112.75 9.67 18.34 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.609 177.538 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.7 m -95.56 174.21 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.485 -179.408 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 p -95.02 175.45 6.63 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.54 177.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.589 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.23 -34.35 72.1 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.628 -179.385 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.7 -36.87 73.48 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.439 -177.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.467 ' O ' HG23 ' A' ' 79' ' ' VAL . 35.4 t80 -70.68 -49.1 50.76 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.19 -45.07 94.38 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.399 -178.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -54.91 -43.29 73.14 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 122.716 0.406 . . . . 0.0 110.307 178.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 90.3 m -61.35 -41.78 97.61 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.981 177.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.558 HG22 HD13 ' A' ' 66' ' ' ILE . 47.4 t -62.98 -51.82 67.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 178.022 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.429 HD21 HG21 ' A' ' 60' ' ' ILE . 3.5 mm? -68.26 -5.36 17.99 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-O 121.342 0.591 . . . . 0.0 111.63 179.525 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -102.47 -22.44 14.05 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.901 0.881 . . . . 0.0 110.891 176.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -90.44 0.85 57.13 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 121.253 0.549 . . . . 0.0 111.628 178.295 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.404 HG21 HD11 ' A' ' 17' ' ' LEU . 15.6 p -61.83 155.38 23.33 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.172 -0.922 . . . . 0.0 112.739 178.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.49 -157.55 0.8 Allowed 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.626 -1.17 . . . . 0.0 108.241 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 12' ' ' LYS . . . -51.61 -82.04 0.05 OUTLIER Glycine 0 CA--C 1.531 1.033 0 N-CA-C 114.601 0.6 . . . . 0.0 114.601 177.489 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -77.12 102.13 6.42 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.122 0.486 . . . . 0.0 111.419 -176.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 41.8 t -115.52 119.42 61.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.16 -178.323 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.34 104.49 15.22 Favored 'General case' 0 CA--C 1.487 -1.447 0 C-N-CA 120.282 -0.567 . . . . 0.0 109.963 173.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.4 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.4 m-85 -93.33 101.33 13.57 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 174.445 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.779 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.9 t -91.53 85.77 2.3 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 N-CA-C 105.337 -2.098 . . . . 0.0 105.337 176.553 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.487 HG21 ' HB3' ' A' ' 58' ' ' ASP . 78.0 mt -102.68 155.37 5.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 CA-C-N 113.765 -1.561 . . . . 0.0 108.85 179.641 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.462 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -128.85 155.59 20.72 Favored Glycine 0 N--CA 1.4 -3.748 0 C-N-CA 119.747 -1.215 . . . . 0.0 110.479 177.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -132.15 152.17 51.41 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 121.551 0.691 . . . . 0.0 112.864 -178.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 . . . . . 0 C--N 1.299 -1.606 0 C-N-CA 127.231 2.212 . . . . 0.0 105.505 174.381 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.446 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 45.5 tt0 . . . . . 0 CA--C 1.498 -1.029 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.462 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.7 mm? -85.54 130.98 34.45 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 176.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -138.79 142.41 33.83 Favored Pre-proline 0 C--N 1.288 -2.065 0 CA-C-O 121.214 0.531 . . . . 0.0 111.802 -179.176 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -83.87 123.48 3.23 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.667 2.244 . . . . 0.0 112.732 177.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.4 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 40.2 t -114.65 105.38 18.55 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 174.316 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.487 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 27.6 tt0 -93.7 97.54 10.52 Favored 'General case' 0 N--CA 1.417 -2.121 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 -179.384 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.496 HD21 ' HB2' ' A' ' 51' ' ' ASP . 0.5 OUTLIER -87.67 158.36 18.86 Favored 'General case' 0 N--CA 1.397 -3.105 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -174.778 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.421 ' H ' HD23 ' A' ' 10' ' ' LEU . 48.1 tt0 -124.04 98.93 6.01 Favored 'General case' 0 C--N 1.274 -2.681 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.229 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 85' ' ' GLY . 2.3 mmmp? -100.73 -170.0 1.79 Allowed 'General case' 0 N--CA 1.409 -2.512 0 CA-C-N 114.518 -1.219 . . . . 0.0 112.696 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.56 157.12 36.02 Favored 'General case' 0 N--CA 1.413 -2.312 0 CA-C-N 113.03 -1.896 . . . . 0.0 106.534 174.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -72.48 -8.95 57.75 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 121.438 0.637 . . . . 0.0 110.253 176.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -72.22 -38.47 68.97 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 175.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.59 -145.14 16.74 Favored Glycine 0 N--CA 1.42 -2.411 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.624 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.404 HD11 HG21 ' A' ' 83' ' ' THR . 18.3 mt -104.53 -46.47 4.35 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.85 29.7 37.82 Favored Glycine 0 N--CA 1.422 -2.242 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.874 -175.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.2 pt -102.42 -174.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 120.059 -0.656 . . . . 0.0 112.357 -177.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 21.8 m -135.66 153.04 51.75 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.589 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -126.63 164.99 25.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 123.393 0.677 . . . . 0.0 109.336 -177.539 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.9 tt -135.41 130.02 50.17 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-O 120.811 0.338 . . . . 0.0 110.487 175.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.505 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.33 107.28 3.32 Favored Glycine 0 N--CA 1.428 -1.861 0 C-N-CA 121.085 -0.578 . . . . 0.0 112.029 -178.292 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.405 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.2 mmm -121.94 174.53 6.84 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.29 -1.989 0 C-N-CA 119.418 -1.372 . . . . 0.0 112.171 179.616 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.507 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.0 pp . . . . . 0 N--CA 1.437 -1.084 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -116.8 33.71 4.95 Favored Glycine 0 C--N 1.288 -2.103 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 173.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.522 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 26.3 mm -84.58 105.49 13.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 121.407 0.622 . . . . 0.0 110.337 -177.09 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -99.25 162.98 12.74 Favored 'General case' 0 C--N 1.279 -2.46 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 177.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.89 128.01 38.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.542 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -91.74 -39.07 12.02 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.303 0.573 . . . . 0.0 110.455 -177.049 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.7 m -159.65 161.0 34.9 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.441 HG11 ' HG3' ' A' ' 49' ' ' GLN . 17.5 t -117.62 167.73 10.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.216 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.9 t . . . . . 0 C--N 1.305 -1.364 0 C-N-CA 123.044 0.538 . . . . 0.0 109.965 178.566 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.462 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 C--O 1.203 -1.392 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.55 -62.56 1.65 Allowed 'General case' 0 C--O 1.214 -0.807 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.441 ' HG3' HG11 ' A' ' 42' ' ' VAL . 27.4 mt-30 -72.73 -13.73 61.4 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.783 0.661 . . . . 0.0 112.783 176.208 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.462 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 27.4 mmt180 -81.17 -26.33 36.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 172.299 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.496 ' HB2' HD21 ' A' ' 10' ' ' LEU . 24.6 t70 -54.94 -57.55 11.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 123.743 0.652 . . . . 0.0 111.368 177.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.73 -13.15 56.48 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.225 -0.988 . . . . 0.0 114.352 175.322 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.579 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -93.74 -59.93 1.88 Allowed 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 118.082 0.941 . . . . 0.0 108.573 176.878 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.579 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 15.3 tt -64.29 143.67 15.47 Favored 'Isoleucine or valine' 0 C--O 1.246 0.893 0 O-C-N 123.707 0.63 . . . . 0.0 110.672 -175.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -142.52 172.76 12.26 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.029 0.442 . . . . 0.0 111.617 -178.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.7 p -76.68 -9.52 12.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.653 0 CA-C-O 121.889 0.852 . . . . 0.0 110.503 -177.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -92.22 -2.75 56.32 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.592 0.711 . . . . 0.0 110.288 -176.087 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.487 ' HB3' HG21 ' A' ' 91' ' ' ILE . 76.9 m-20 -82.29 174.94 10.68 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 121.988 0.899 . . . . 0.0 112.328 -176.173 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.522 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.3 tt0 -128.6 125.48 38.27 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.497 178.309 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.508 HG22 HD21 ' A' ' 68' ' ' LEU . 48.8 mm -77.16 104.74 5.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -178.582 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.779 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 86.1 t -87.13 -48.07 15.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.844 0.831 . . . . 0.0 110.82 -176.469 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.517 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 33.1 tt0 -151.66 125.95 9.35 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.782 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.442 HG23 HG23 ' A' ' 60' ' ' ILE . 3.0 t -115.64 128.05 73.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 175.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.1 t70 72.97 -9.15 1.16 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 125.23 1.412 . . . . 0.0 112.671 173.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.93 11.56 36.94 Favored Glycine 0 C--N 1.29 -2.011 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.763 -174.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.558 HD13 HG22 ' A' ' 79' ' ' VAL . 7.0 tt -70.95 -21.21 22.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-O 120.728 0.299 . . . . 0.0 111.36 -177.614 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.499 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 57.7 p 51.01 88.52 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.036 1.334 . . . . 0.0 112.192 -177.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.508 HD21 HG22 ' A' ' 60' ' ' ILE . 1.4 pp -100.29 17.9 20.22 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 122.29 1.043 . . . . 0.0 109.931 -175.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.507 ' HA ' HD23 ' A' ' 35' ' ' LEU . 39.2 t -60.69 98.49 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.297 178.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.411 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 112.75 9.67 18.34 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.609 177.538 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.7 m -95.56 174.21 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.485 -179.408 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 p -95.02 175.45 6.63 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.54 177.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.589 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.23 -34.35 72.1 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.628 -179.385 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.7 -36.87 73.48 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.439 -177.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.467 ' O ' HG23 ' A' ' 79' ' ' VAL . 35.4 t80 -70.68 -49.1 50.76 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.808 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.19 -45.07 94.38 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.399 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -54.91 -43.29 73.14 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 122.716 0.406 . . . . 0.0 110.307 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 90.3 m -61.35 -41.78 97.61 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.981 177.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.558 HG22 HD13 ' A' ' 66' ' ' ILE . 47.4 t -62.98 -51.82 67.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 178.022 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.429 HD21 HG21 ' A' ' 60' ' ' ILE . 3.5 mm? -68.26 -5.36 17.99 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-O 121.342 0.591 . . . . 0.0 111.63 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -102.47 -22.44 14.05 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.901 0.881 . . . . 0.0 110.891 176.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -90.44 0.85 57.13 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 121.253 0.549 . . . . 0.0 111.628 178.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.404 HG21 HD11 ' A' ' 17' ' ' LEU . 15.6 p -61.83 155.38 23.33 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.172 -0.922 . . . . 0.0 112.739 178.578 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.49 -157.55 0.8 Allowed 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.626 -1.17 . . . . 0.0 108.241 179.377 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 12' ' ' LYS . . . -51.61 -82.04 0.05 OUTLIER Glycine 0 CA--C 1.531 1.033 0 N-CA-C 114.601 0.6 . . . . 0.0 114.601 177.489 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -77.12 102.13 6.42 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.122 0.486 . . . . 0.0 111.419 -176.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 41.8 t -115.52 119.42 61.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.16 -178.323 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.34 104.49 15.22 Favored 'General case' 0 CA--C 1.487 -1.447 0 C-N-CA 120.282 -0.567 . . . . 0.0 109.963 173.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.4 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.4 m-85 -93.33 101.33 13.57 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 174.445 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.779 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.9 t -91.53 85.77 2.3 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 N-CA-C 105.337 -2.098 . . . . 0.0 105.337 176.553 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.487 HG21 ' HB3' ' A' ' 58' ' ' ASP . 78.0 mt -102.68 155.37 5.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 CA-C-N 113.765 -1.561 . . . . 0.0 108.85 179.641 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.462 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -128.85 155.59 20.72 Favored Glycine 0 N--CA 1.4 -3.748 0 C-N-CA 119.747 -1.215 . . . . 0.0 110.479 177.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -132.15 152.17 51.41 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 121.551 0.691 . . . . 0.0 112.864 -178.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 . . . . . 0 C--N 1.299 -1.606 0 C-N-CA 127.231 2.212 . . . . 0.0 105.505 174.381 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.468 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 40.9 tt0 . . . . . 0 CA--C 1.496 -1.12 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -86.82 128.74 35.05 Favored 'General case' 0 C--N 1.313 -0.994 0 O-C-N 123.648 0.592 . . . . 0.0 110.007 -176.755 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 33.3 p90 -142.91 141.86 20.84 Favored Pre-proline 0 N--CA 1.423 -1.782 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -178.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -81.18 122.58 4.23 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.826 2.351 . . . . 0.0 112.107 176.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.524 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 47.2 t -103.03 100.35 10.23 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.98 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 174.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.485 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 35.9 tt0 -81.58 102.03 10.37 Favored 'General case' 0 N--CA 1.427 -1.587 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 174.174 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.522 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -104.04 134.49 47.22 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 -175.449 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -102.78 97.59 7.73 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 175.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.459 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.0 mmmp? -84.42 177.53 8.09 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 115.115 1.524 . . . . 0.0 115.115 -177.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -80.66 -174.47 4.73 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 112.759 -2.019 . . . . 0.0 110.457 -175.041 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -71.79 -26.62 62.49 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.742 176.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -59.11 -41.99 89.48 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.504 178.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 120.2 -114.12 2.61 Favored Glycine 0 N--CA 1.413 -2.888 0 N-CA-C 108.044 -2.023 . . . . 0.0 108.044 -175.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.515 ' HG ' HG23 ' A' ' 19' ' ' ILE . 10.5 tp -113.63 -64.41 1.31 Allowed 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -178.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 79.75 28.64 50.46 Favored Glycine 0 N--CA 1.437 -1.259 0 O-C-N 124.183 0.927 . . . . 0.0 113.014 177.021 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.515 HG23 ' HG ' ' A' ' 17' ' ' LEU . 18.0 pt -104.99 172.11 1.66 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.826 0 C-N-CA 119.543 -0.863 . . . . 0.0 111.278 179.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.1 m -123.81 147.4 47.61 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.854 -179.114 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.565 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -117.66 162.2 15.87 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -178.248 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.438 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.9 tt -128.96 132.83 67.05 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.116 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 174.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.482 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.22 106.69 3.45 Favored Glycine 0 N--CA 1.42 -2.405 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.029 -177.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.419 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.7 mmm -115.82 156.2 26.5 Favored 'General case' 0 C--N 1.289 -2.052 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 177.414 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.286 -2.195 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 176.498 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.52 HD22 ' HA ' ' A' ' 69' ' ' VAL . 1.0 OUTLIER . . . . . 0 N--CA 1.447 -0.617 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.419 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -117.91 34.59 4.42 Favored Glycine 0 N--CA 1.416 -2.655 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.922 173.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.482 HD13 ' HA2' ' A' ' 23' ' ' GLY . 29.3 mm -87.15 99.04 7.88 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 119.83 -0.748 . . . . 0.0 109.868 179.491 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -97.09 159.34 14.97 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 115.13 -0.941 . . . . 0.0 109.724 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.7 t -77.17 115.41 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.544 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 176.563 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -87.15 -51.4 6.01 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.858 -175.229 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -143.43 157.16 44.68 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 -179.006 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.409 ' HA ' HG22 ' A' ' 19' ' ' ILE . 50.0 t -126.85 151.01 33.14 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 N-CA-C 105.984 -1.858 . . . . 0.0 105.984 175.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.4 t . . . . . 0 N--CA 1.433 -1.325 0 CA-C-O 121.869 0.842 . . . . 0.0 109.942 178.253 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.531 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 C--O 1.195 -1.768 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.06 -53.69 9.43 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -76.66 -6.31 51.56 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.743 175.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.531 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 1.8 mmp_? -86.95 -38.27 16.81 Favored 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 172.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.56 ' OD1' ' HB2' ' A' ' 53' ' ' ARG . 11.4 t70 -66.13 -46.0 79.06 Favored 'General case' 0 C--O 1.217 -0.631 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 176.523 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.86 -17.44 11.33 Favored Glycine 0 N--CA 1.469 0.841 0 N-CA-C 114.54 0.576 . . . . 0.0 114.54 173.096 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.56 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 6.7 ttm180 -64.05 -40.37 96.14 Favored 'General case' 0 C--N 1.316 -0.85 0 C-N-CA 124.285 1.034 . . . . 0.0 110.238 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.8 tt -83.04 162.54 3.19 Favored 'Isoleucine or valine' 0 C--O 1.257 1.451 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 -178.465 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -125.74 -171.74 2.45 Favored 'General case' 0 N--CA 1.423 -1.805 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.308 -178.309 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.9 p -123.51 16.46 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.042 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 173.312 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 34.9 p30 -134.4 16.23 3.72 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 122.591 1.186 . . . . 0.0 109.923 -174.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -112.89 -169.89 1.57 Allowed 'General case' 0 C--N 1.27 -2.865 0 CA-C-N 113.69 -1.596 . . . . 0.0 109.943 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.45 ' O ' HG23 ' A' ' 91' ' ' ILE . 62.7 tt0 -132.39 132.35 42.74 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 116.72 -0.218 . . . . 0.0 110.595 -173.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.49 HG21 HD21 ' A' ' 80' ' ' LEU . 50.5 mm -74.38 104.83 3.15 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.961 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.013 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.712 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 94.1 t -86.33 -49.22 15.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 121.292 0.568 . . . . 0.0 110.139 -176.622 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.506 ' HG3' ' H ' ' A' ' 67' ' ' SER . 34.8 tt0 -154.39 116.67 4.29 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.254 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.405 HG23 HG23 ' A' ' 60' ' ' ILE . 4.2 t -108.83 129.98 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.209 0 N-CA-C 111.765 0.283 . . . . 0.0 111.765 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 15.6 t70 62.09 17.06 8.79 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 124.922 1.289 . . . . 0.0 111.441 174.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.9 10.98 85.69 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 115.65 -0.705 . . . . 0.0 112.422 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.0 tt -73.83 -14.81 16.54 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 O-C-N 122.528 -0.395 . . . . 0.0 111.171 -176.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.506 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 8.9 p 42.95 79.59 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 124.801 1.24 . . . . 0.0 113.357 -176.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.464 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.5 pp -90.84 14.14 14.46 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.739 -174.435 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.52 ' HA ' HD22 ' A' ' 35' ' ' LEU . 48.7 t -58.84 98.0 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 114.736 -1.12 . . . . 0.0 109.586 173.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.439 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 112.96 18.24 7.44 Favored Glycine 0 N--CA 1.435 -1.42 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.781 177.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.464 HG22 ' O ' ' A' ' 68' ' ' LEU . 15.6 m -105.33 175.72 1.13 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.518 0 CA-C-N 117.205 0.502 . . . . 0.0 110.578 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.6 p -94.65 179.37 5.28 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-O 121.633 0.73 . . . . 0.0 110.012 178.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.565 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -65.87 -35.29 80.23 Favored 'General case' 0 N--CA 1.419 -1.975 0 CA-C-N 114.803 -1.089 . . . . 0.0 111.055 -179.619 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -70.17 -27.68 64.72 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.492 -177.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 36.6 t80 -75.47 -51.8 12.18 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 175.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.2 -44.06 92.25 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.448 -0.797 . . . . 0.0 112.218 -178.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.46 -10.66 36.08 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.335 0.654 . . . . 0.0 111.59 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.423 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 98.3 m -93.01 -49.18 6.15 Favored 'General case' 0 N--CA 1.412 -2.355 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.668 175.224 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.535 ' O ' HG23 ' A' ' 83' ' ' THR . 38.5 t -59.64 -52.07 65.34 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.649 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.49 HD21 HG21 ' A' ' 60' ' ' ILE . 3.6 mm? -68.62 3.39 1.88 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.611 0.764 . . . . 0.0 112.228 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.423 ' HB3' ' O ' ' A' ' 78' ' ' THR . 11.7 ttm180 -109.91 -41.02 4.6 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 121.99 0.9 . . . . 0.0 109.109 176.334 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -80.31 -4.83 54.92 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 114.496 -1.229 . . . . 0.0 112.182 -174.668 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 79' ' ' VAL . 7.5 p -60.7 147.68 41.3 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 123.759 0.824 . . . . 0.0 112.194 177.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.85 -172.88 2.17 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.852 177.157 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -38.93 -73.74 0.15 Allowed Glycine 0 C--O 1.217 -0.94 0 O-C-N 124.484 1.115 . . . . 0.0 115.067 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.522 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 36.3 m-80 -83.05 105.11 13.76 Favored 'General case' 0 CA--C 1.497 -1.062 0 CA-C-N 118.0 0.9 . . . . 0.0 110.956 -179.536 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.493 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 2.5 t -104.24 143.38 16.0 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 CA-C-N 115.44 -0.8 . . . . 0.0 108.927 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 60.3 mtp180 -107.27 97.28 7.06 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 173.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.524 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 81.6 m-85 -94.67 104.76 16.68 Favored 'General case' 0 CA--C 1.483 -1.6 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 177.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.712 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 62.5 t -87.65 94.74 4.71 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.609 0 N-CA-C 105.108 -2.182 . . . . 0.0 105.108 173.198 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.456 HG12 ' HA ' ' A' ' 60' ' ' ILE . 93.9 mt -114.49 153.76 15.95 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.671 0 CA-C-N 114.894 -1.048 . . . . 0.0 108.245 177.515 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -118.02 157.88 14.96 Favored Glycine 1 N--CA 1.393 -4.221 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.534 177.459 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.485 HH21 ' HG2' ' A' ' 94' ' ' GLU . 8.1 tpm_? -129.48 123.66 32.09 Favored 'General case' 0 C--N 1.29 -2.005 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.569 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.485 ' HG2' HH21 ' A' ' 93' ' ' ARG . 16.5 pt-20 . . . . . 0 N--CA 1.428 -1.567 0 N-CA-C 105.886 -1.894 . . . . 0.0 105.886 171.014 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.481 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 39.1 tt0 . . . . . 0 N--CA 1.439 -0.99 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.437 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.7 mm? -89.93 120.33 31.06 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 177.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -131.63 143.64 50.01 Favored Pre-proline 0 C--N 1.29 -1.987 0 CA-C-O 121.322 0.582 . . . . 0.0 112.356 -174.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -84.01 127.45 4.1 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.914 2.409 . . . . 0.0 112.273 175.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.415 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 23.6 t -117.52 104.63 16.68 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.271 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 174.381 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.415 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 36.4 tt0 -91.48 102.41 15.08 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.497 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -91.23 144.51 25.54 Favored 'General case' 0 N--CA 1.422 -1.866 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 -173.983 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -113.12 84.54 2.01 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 170.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.538 ' HE2' ' H ' ' A' ' 48' ' ' ALA . 5.1 mmtt -71.89 165.5 24.04 Favored 'General case' 0 N--CA 1.417 -2.077 0 N-CA-C 114.071 1.137 . . . . 0.0 114.071 -179.243 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -84.38 -175.18 5.67 Favored 'General case' 0 N--CA 1.433 -1.308 0 CA-C-N 113.613 -1.631 . . . . 0.0 111.123 -176.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -78.21 -9.27 59.13 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 -172.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -77.72 -45.47 24.67 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 121.746 0.784 . . . . 0.0 108.889 176.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.85 -160.28 21.75 Favored Glycine 0 N--CA 1.422 -2.271 0 N-CA-C 108.551 -1.82 . . . . 0.0 108.551 -176.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.8 mt -75.52 -50.8 14.57 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 118.011 0.905 . . . . 0.0 109.599 -176.346 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 68.1 27.97 73.52 Favored Glycine 0 N--CA 1.433 -1.56 0 CA-C-N 114.695 -1.139 . . . . 0.0 110.453 -176.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.54 HD11 HD12 ' A' ' 80' ' ' LEU . 18.1 pt -99.57 171.02 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.832 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.165 -178.804 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.1 m -133.35 148.34 51.86 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -177.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -115.41 161.59 14.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.429 ' CG2' ' HB2' ' A' ' 38' ' ' PHE . 15.3 tt -129.14 131.84 67.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 C-N-CA 120.611 -0.436 . . . . 0.0 109.895 174.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.496 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -90.65 97.08 2.28 Favored Glycine 0 CA--C 1.494 -1.238 0 C-N-CA 120.974 -0.631 . . . . 0.0 112.138 -177.719 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.434 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 95.1 mmm -111.73 -175.72 2.76 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.282 -2.43 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 174.107 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.678 HD22 HG23 ' A' ' 69' ' ' VAL . 2.2 pt? . . . . . 0 N--CA 1.436 -1.132 0 CA-C-O 121.377 0.608 . . . . 0.0 110.933 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -110.49 19.07 26.92 Favored Glycine 0 N--CA 1.417 -2.592 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 175.152 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.611 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 35.9 mm -85.73 104.04 13.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-O 121.498 0.666 . . . . 0.0 110.457 -177.551 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.429 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 96.6 m-85 -101.65 163.31 12.33 Favored 'General case' 0 C--N 1.281 -2.4 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.484 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 47.0 t -77.35 116.29 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 N-CA-C 106.935 -1.505 . . . . 0.0 106.935 175.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.532 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.2 OUTLIER -83.44 -39.03 21.11 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 -177.621 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -157.56 158.23 35.23 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.44 HG12 ' HB ' ' A' ' 56' ' ' VAL . 4.3 p -137.52 97.81 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 CA-C-O 121.456 0.646 . . . . 0.0 111.557 178.114 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.8 t . . . . . 0 CA--C 1.563 1.478 0 C-N-CA 127.221 2.208 . . . . 0.0 113.933 178.307 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.449 ' HB3' ' HD3' ' A' ' 12' ' ' LYS . . . . . . . . 0 CA--C 1.548 0.894 0 N-CA-C 115.178 1.547 . . . . 0.0 115.178 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.538 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -80.48 -58.01 3.32 Favored 'General case' 0 C--O 1.214 -0.796 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 43.0 mt-30 -63.27 -29.83 71.09 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.948 173.421 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 31.0 mmm180 -66.78 -34.37 77.68 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.863 176.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.412 ' HB3' ' O ' ' A' ' 48' ' ' ALA . 11.6 t70 -56.3 -52.15 65.57 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.719 176.607 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.19 -7.14 72.83 Favored Glycine 0 C--N 1.313 -0.737 0 N-CA-C 114.944 0.737 . . . . 0.0 114.944 173.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -86.57 -43.69 12.5 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.3 tt -78.54 152.12 5.11 Favored 'Isoleucine or valine' 0 C--O 1.243 0.736 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 177.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . 0.541 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 19.5 mt-30 -140.69 171.06 14.63 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 121.02 0.438 . . . . 0.0 110.019 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.44 ' HB ' HG12 ' A' ' 42' ' ' VAL . 10.7 p -83.24 -11.91 11.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.419 1.104 . . . . 0.0 108.587 175.288 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -88.65 3.24 51.33 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.786 -172.152 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.541 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 13.0 m-20 -109.6 -165.99 1.06 Allowed 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -174.254 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.611 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 18.9 tt0 -136.41 129.19 30.82 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 123.683 0.793 . . . . 0.0 111.261 -176.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.541 ' HA ' HG12 ' A' ' 91' ' ' ILE . 46.9 mm -73.88 108.33 5.25 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.877 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -179.331 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.777 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 97.3 t -92.41 -49.87 12.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 CA-C-O 121.854 0.835 . . . . 0.0 110.403 -178.349 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.576 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.2 tt0 -146.13 127.89 15.3 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.457 HG21 HD11 ' A' ' 80' ' ' LEU . 2.7 t -117.78 126.39 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.917 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.612 175.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.4 t70 72.51 -13.67 0.62 Allowed 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 125.391 1.476 . . . . 0.0 112.97 173.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 111.0 11.41 18.68 Favored Glycine 0 C--N 1.288 -2.099 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.003 -176.177 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.417 HD13 HG22 ' A' ' 79' ' ' VAL . 7.5 tt -75.33 -18.35 15.96 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.733 0 CA-C-O 120.777 0.323 . . . . 0.0 110.617 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.57 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 25.7 m 49.19 87.15 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.257 1.423 . . . . 0.0 111.54 -176.262 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.445 ' O ' HG22 ' A' ' 71' ' ' VAL . 2.1 pp -103.93 15.58 28.29 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-O 122.246 1.022 . . . . 0.0 109.484 -176.009 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.678 HG23 HD22 ' A' ' 35' ' ' LEU . 6.3 p -62.66 79.62 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 114.001 -1.454 . . . . 0.0 111.324 175.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 118.17 49.35 0.37 Allowed Glycine 0 N--CA 1.433 -1.505 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.048 -178.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.445 HG22 ' O ' ' A' ' 68' ' ' LEU . 32.4 m -127.02 178.08 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.242 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 13.3 p -91.08 174.66 7.29 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 120.933 0.397 . . . . 0.0 111.27 179.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.42 ' HB3' ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -65.26 -35.35 80.76 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.026 -179.301 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -70.36 -31.14 68.28 Favored 'General case' 0 CA--C 1.511 -0.519 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.695 -177.604 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -71.52 -54.22 11.27 Favored 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.44 -48.25 79.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.419 -0.809 . . . . 0.0 112.022 -178.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.05 -25.75 65.59 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 -179.149 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 71.4 m -76.22 -44.14 39.01 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.485 176.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.417 HG22 HD13 ' A' ' 66' ' ' ILE . 33.5 t -61.75 -51.74 69.08 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.621 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.54 HD12 HD11 ' A' ' 19' ' ' ILE . 3.5 mm? -68.12 -3.82 11.67 Favored 'General case' 0 CA--C 1.556 1.188 0 CA-C-O 121.341 0.591 . . . . 0.0 112.448 -179.114 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 36.4 ttt180 -95.64 -40.79 9.23 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 175.642 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 23.1 m-80 -89.01 8.06 31.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 114.241 -1.345 . . . . 0.0 113.88 -171.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.415 HG23 ' O ' ' A' ' 79' ' ' VAL . 1.3 p -75.9 154.38 36.05 Favored 'General case' 0 C--N 1.28 -2.431 0 C-N-CA 123.596 0.758 . . . . 0.0 112.332 178.689 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.29 -170.38 1.63 Allowed 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.984 176.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -50.41 -62.87 4.79 Favored Glycine 0 N--CA 1.473 1.116 0 N-CA-C 115.341 0.896 . . . . 0.0 115.341 -176.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.497 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 20.7 m120 -81.49 104.6 12.04 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 117.436 0.618 . . . . 0.0 110.992 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.441 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 2.3 t -113.75 128.76 70.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.195 -176.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.14 104.23 16.26 Favored 'General case' 0 C--N 1.293 -1.872 0 C-N-CA 119.979 -0.689 . . . . 0.0 109.474 170.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.441 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 93.2 m-85 -94.8 100.66 12.51 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 174.53 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.777 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 27.2 t -93.62 83.82 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.434 0 N-CA-C 105.288 -2.116 . . . . 0.0 105.288 177.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.541 HG12 ' HA ' ' A' ' 60' ' ' ILE . 64.7 mt -97.61 158.36 3.31 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.588 0 CA-C-N 113.335 -1.757 . . . . 0.0 109.563 -178.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.481 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -133.3 147.83 19.13 Favored Glycine 1 N--CA 1.393 -4.187 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.607 176.836 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 24.8 tpt180 -115.73 119.2 35.27 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 . . . . . 0 N--CA 1.413 -2.315 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 173.717 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.423 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 41.2 tt0 . . . . . 0 N--CA 1.434 -1.259 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.442 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -85.32 130.37 34.61 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.245 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 24.8 p90 -139.37 139.85 24.0 Favored Pre-proline 0 N--CA 1.426 -1.667 0 CA-C-O 121.454 0.645 . . . . 0.0 112.157 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -82.77 121.94 3.37 Favored 'Trans proline' 0 N--CA 1.446 -1.273 0 C-N-CA 122.765 2.31 . . . . 0.0 112.844 177.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.0 t -111.28 105.08 18.11 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 176.24 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.602 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.1 tt0 -85.39 105.28 15.91 Favored 'General case' 0 N--CA 1.42 -1.956 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 174.674 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.551 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 15.9 tp -95.76 151.35 19.45 Favored 'General case' 0 N--CA 1.41 -2.471 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 -176.719 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -115.27 92.59 3.97 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 177.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.466 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 2.6 mmmp? -84.24 177.61 8.12 Favored 'General case' 0 C--N 1.289 -2.032 0 CA-C-O 122.498 1.142 . . . . 0.0 113.675 178.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.418 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.0 p-10 -88.86 172.06 9.46 Favored 'General case' 0 C--N 1.286 -2.178 0 CA-C-N 112.835 -1.984 . . . . 0.0 109.536 179.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -64.32 -18.22 64.42 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -174.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.418 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 23.3 t70 -68.61 -32.98 73.24 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.778 0.799 . . . . 0.0 110.209 178.652 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.97 -124.44 5.94 Favored Glycine 0 CA--C 1.477 -2.285 0 N-CA-C 108.706 -1.758 . . . . 0.0 108.706 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.488 HD21 HG21 ' A' ' 87' ' ' VAL . 25.7 mt -104.27 -52.58 2.89 Favored 'General case' 0 CA--C 1.462 -2.407 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.45 178.499 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.2 24.55 76.53 Favored Glycine 0 N--CA 1.426 -2.003 0 O-C-N 124.678 1.236 . . . . 0.0 110.911 -175.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 28.0 pt -101.27 176.48 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.482 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 23.7 m -132.65 148.59 52.35 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -176.489 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -119.82 167.11 13.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.2 tt -133.36 132.26 57.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.668 177.391 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.508 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.1 102.07 2.79 Favored Glycine 0 N--CA 1.435 -1.43 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.607 -177.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 95.5 mmm -115.68 173.41 6.56 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.295 -1.702 0 C-N-CA 120.121 -1.038 . . . . 0.0 112.469 179.162 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.625 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.5 pp . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -110.47 27.48 11.39 Favored Glycine 0 N--CA 1.423 -2.213 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 172.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.508 HD13 ' HA2' ' A' ' 23' ' ' GLY . 35.3 mm -83.67 102.84 10.18 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 CA-C-O 121.47 0.652 . . . . 0.0 110.068 -178.626 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -96.83 169.2 10.02 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 177.232 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.0 t -83.43 129.33 37.67 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 175.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 55.6 tptt -93.64 -46.37 7.3 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.248 -177.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.8 m -151.72 161.45 42.64 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 -179.258 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 40.6 t -137.58 141.4 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.115 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 177.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 14.1 t . . . . . 0 C--N 1.29 -1.98 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.115 -178.036 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.604 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . . . . . . 0 CA--C 1.555 1.173 0 N-CA-C 114.179 1.177 . . . . 0.0 114.179 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.437 ' HA ' HD21 ' A' ' 10' ' ' LEU . . . -98.23 -62.99 1.17 Allowed 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -75.87 -28.9 58.33 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.679 0.752 . . . . 0.0 109.312 176.543 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.604 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 19.1 mmm180 -63.35 -32.65 74.13 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.473 -1.239 . . . . 0.0 109.63 172.595 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -70.4 -63.21 1.13 Allowed 'General case' 0 C--O 1.241 0.64 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 173.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.26 -17.28 40.82 Favored Glycine 0 N--CA 1.436 -1.356 0 N-CA-C 115.435 0.934 . . . . 0.0 115.435 175.049 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.512 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.3 OUTLIER -79.21 -25.69 42.66 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 118.816 1.308 . . . . 0.0 109.341 -177.914 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.9 tt -94.44 150.76 3.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . 0.596 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 23.6 mt-30 -136.64 166.11 24.3 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 121.232 0.539 . . . . 0.0 111.598 -176.327 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -86.88 -12.44 10.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.392 178.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -92.99 3.42 55.79 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 122.214 1.007 . . . . 0.0 110.647 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.596 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 24.9 m-20 -101.98 -174.54 2.61 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.268 -177.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.442 ' O ' HG23 ' A' ' 91' ' ' ILE . 61.5 tt0 -129.26 131.97 47.12 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.813 -176.017 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.456 HG22 HD11 ' A' ' 68' ' ' LEU . 49.1 mm -75.43 106.56 5.31 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.783 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 179.697 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.692 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 98.5 t -87.87 -44.65 15.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 120.967 0.413 . . . . 0.0 111.344 -177.09 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.557 ' HG3' ' H ' ' A' ' 67' ' ' SER . 37.6 tt0 -156.85 120.96 4.34 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 120.67 0.271 . . . . 0.0 110.544 178.281 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.3 t -112.62 129.04 68.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 111.575 0.213 . . . . 0.0 111.575 176.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.3 t70 66.95 7.52 5.41 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 125.737 1.615 . . . . 0.0 111.294 174.54 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.65 20.7 61.23 Favored Glycine 0 N--CA 1.434 -1.472 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.296 -175.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.437 HD13 HG22 ' A' ' 79' ' ' VAL . 6.4 tt -79.44 -22.68 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 CA-C-O 121.197 0.522 . . . . 0.0 110.267 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.557 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 63.8 p 48.68 81.95 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.356 1.462 . . . . 0.0 111.935 -176.003 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.456 HD11 HG22 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -87.33 30.71 0.77 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 122.515 1.15 . . . . 0.0 111.283 -175.997 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.625 ' HA ' HD23 ' A' ' 35' ' ' LEU . 42.4 t -74.71 103.87 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.585 -179.424 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.08 26.83 6.84 Favored Glycine 0 N--CA 1.434 -1.436 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.784 179.403 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.451 HG21 ' HB2' ' A' ' 68' ' ' LEU . 11.0 m -112.63 170.4 4.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 C-N-CA 120.391 -0.524 . . . . 0.0 110.071 177.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.9 p -93.6 172.2 8.41 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.323 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.535 ' N ' HE21 ' A' ' 73' ' ' GLN . 0.0 OUTLIER -60.98 -28.43 69.01 Favored 'General case' 0 C--O 1.205 -1.269 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.751 -179.141 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -73.44 -36.03 65.87 Favored 'General case' 0 CA--C 1.522 -0.122 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.557 -178.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.401 ' O ' HG23 ' A' ' 79' ' ' VAL . 30.1 t80 -70.43 -49.8 45.05 Favored 'General case' 0 CA--C 1.506 -0.712 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 178.189 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.29 -46.73 87.76 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.934 -178.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.48 -34.19 72.26 Favored 'General case' 0 C--O 1.209 -1.036 0 CA-C-O 120.472 0.177 . . . . 0.0 110.554 179.391 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 77.6 m -65.91 -44.45 85.16 Favored 'General case' 0 N--CA 1.435 -1.217 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.755 177.219 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.437 HG22 HD13 ' A' ' 66' ' ' ILE . 39.3 t -61.89 -53.08 52.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 178.553 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -67.98 -2.23 7.19 Favored 'General case' 0 CA--C 1.564 1.509 0 CA-C-O 121.393 0.616 . . . . 0.0 112.183 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.23 -34.02 10.51 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 123.556 0.743 . . . . 0.0 109.714 175.132 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -82.0 -13.68 57.06 Favored 'General case' 0 CA--C 1.498 -1.019 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -175.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.435 ' OG1' ' HG ' ' A' ' 17' ' ' LEU . 5.4 p -60.54 146.67 44.19 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.647 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.89 -161.28 0.75 Allowed 'General case' 0 C--N 1.297 -1.709 0 CA-C-N 114.88 -1.055 . . . . 0.0 109.238 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -51.21 -74.93 0.24 Allowed Glycine 0 CA--C 1.536 1.379 0 N-CA-C 115.399 0.92 . . . . 0.0 115.399 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.551 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 15.9 m120 -81.65 99.99 9.2 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 117.872 0.836 . . . . 0.0 112.18 -177.534 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.602 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.8 t -108.54 135.49 47.17 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.044 -175.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -94.05 101.49 13.52 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 172.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.513 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 98.8 m-85 -94.8 103.92 15.82 Favored 'General case' 0 CA--C 1.48 -1.741 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.206 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.692 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 60.8 t -88.81 93.31 4.26 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.89 0 N-CA-C 105.416 -2.068 . . . . 0.0 105.416 174.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.442 HG23 ' O ' ' A' ' 59' ' ' GLN . 88.7 mt -107.43 155.51 8.14 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.265 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.21 175.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.442 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -129.83 149.39 18.77 Favored Glycine 0 N--CA 1.406 -3.331 0 C-N-CA 119.376 -1.393 . . . . 0.0 111.673 -178.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 22.9 tpt180 -123.85 116.23 22.61 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 -178.313 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 . . . . . 0 N--CA 1.441 -0.92 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 173.879 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.49 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 82.9 tt0 . . . . . 0 N--CA 1.431 -1.404 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.413 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.0 mm? -87.31 125.78 34.43 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -178.637 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -140.48 145.66 41.78 Favored Pre-proline 0 C--N 1.294 -1.845 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -176.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -82.64 125.48 4.35 Favored 'Trans proline' 0 N--CA 1.442 -1.511 0 C-N-CA 122.62 2.213 . . . . 0.0 112.202 175.635 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.422 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 23.7 t -111.14 102.77 14.44 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.58 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 175.297 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 28.7 tt0 -82.22 108.83 15.98 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 174.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -103.79 135.97 44.34 Favored 'General case' 0 C--N 1.279 -2.469 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 -177.772 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -106.99 97.73 7.48 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.521 -1.289 . . . . 0.0 107.521 171.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.619 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 2.7 mmmp? -83.71 173.78 11.04 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-O 122.406 1.098 . . . . 0.0 113.839 -177.329 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -88.15 172.68 9.32 Favored 'General case' 0 N--CA 1.423 -1.803 0 CA-C-N 112.818 -1.992 . . . . 0.0 110.026 -178.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -67.75 -9.29 42.64 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 114.197 1.184 . . . . 0.0 114.197 -173.188 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -73.49 -34.05 65.13 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.95 -127.14 6.98 Favored Glycine 0 CA--C 1.475 -2.452 0 N-CA-C 107.533 -2.227 . . . . 0.0 107.533 -177.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 18.2 mt -99.65 -48.92 4.56 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 175.042 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 73.94 31.03 60.48 Favored Glycine 0 N--CA 1.418 -2.524 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 -177.038 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 22.2 pt -110.84 178.35 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.3 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.641 -178.44 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 34.8 m -140.09 154.65 47.1 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -178.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -125.84 166.58 21.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -177.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 14.0 tt -140.23 134.6 35.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 C-N-CA 120.58 -0.448 . . . . 0.0 110.681 177.251 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.515 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -92.96 107.58 3.55 Favored Glycine 0 N--CA 1.425 -2.079 0 C-N-CA 120.965 -0.635 . . . . 0.0 111.794 -179.239 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.663 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 93.0 mmm -122.58 97.88 5.66 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.308 -1.015 0 C-N-CA 120.98 -0.629 . . . . 0.0 113.428 -175.651 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.458 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.5 pp . . . . . 0 N--CA 1.436 -1.136 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.663 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -115.12 32.85 5.58 Favored Glycine 0 N--CA 1.424 -2.16 0 C-N-CA 118.919 -1.61 . . . . 0.0 111.797 178.14 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.531 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 25.6 mm -91.04 98.73 8.71 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.779 0 CA-C-O 122.018 0.913 . . . . 0.0 110.117 -178.764 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -93.11 162.44 14.03 Favored 'General case' 0 C--N 1.277 -2.559 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.395 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 46.7 t -79.44 126.83 39.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 175.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 58.3 tptt -88.64 -50.45 6.25 Favored 'General case' 0 C--N 1.294 -1.811 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.806 -177.087 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -150.87 162.62 40.43 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 -177.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.422 HG11 ' HG3' ' A' ' 49' ' ' GLN . 61.4 t -128.02 159.55 38.93 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.134 0 N-CA-C 105.959 -1.867 . . . . 0.0 105.959 175.239 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 6.6 t . . . . . 0 CA--C 1.544 0.714 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 171.659 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.619 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.204 -1.333 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.478 ' O ' ' HB3' ' A' ' 51' ' ' ASP . . . -87.55 -55.06 3.95 Favored 'General case' 0 CA--C 1.486 -1.483 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -175.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.422 ' HG3' HG11 ' A' ' 42' ' ' VAL . 41.2 mt-30 -76.46 -22.3 54.76 Favored 'General case' 0 N--CA 1.433 -1.319 0 C-N-CA 118.586 -1.246 . . . . 0.0 110.87 176.706 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 25.7 mmm180 -69.0 -23.59 64.12 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.192 171.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.478 ' HB3' ' O ' ' A' ' 48' ' ' ALA . 12.1 t70 -71.39 -64.92 0.82 Allowed 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.099 -1.075 . . . . 0.0 108.099 170.464 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.71 -5.54 84.63 Favored Glycine 0 C--O 1.245 0.794 0 C-N-CA 121.24 -0.505 . . . . 0.0 113.792 174.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.62 -32.85 21.82 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 178.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.6 tt -93.52 143.46 11.49 Favored 'Isoleucine or valine' 0 C--O 1.251 1.148 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 170.164 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 62.0 mt-30 -139.05 178.42 7.18 Favored 'General case' 0 C--N 1.308 -1.225 0 O-C-N 122.183 -0.323 . . . . 0.0 111.412 -179.513 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.2 p -84.64 -14.96 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-O 121.66 0.743 . . . . 0.0 110.838 -176.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -91.24 7.9 38.51 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-O 122.107 0.956 . . . . 0.0 109.502 -176.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.402 ' HB3' HG21 ' A' ' 91' ' ' ILE . 6.6 m-20 -88.47 -175.4 4.96 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.8 -176.063 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.531 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 30.9 tt0 -141.53 129.14 21.48 Favored 'General case' 0 N--CA 1.423 -1.795 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.007 -179.03 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.434 HG22 HD21 ' A' ' 68' ' ' LEU . 46.8 mm -77.2 105.31 5.96 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.786 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -178.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.766 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 94.2 t -85.07 -48.96 16.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-O 121.957 0.884 . . . . 0.0 109.357 -177.665 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.565 ' HG3' ' H ' ' A' ' 67' ' ' SER . 28.8 tt0 -150.87 135.1 16.89 Favored 'General case' 0 N--CA 1.419 -2.015 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.078 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 t -121.52 128.71 75.9 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 173.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 37.0 t70 71.23 -11.49 0.68 Allowed 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 125.3 1.44 . . . . 0.0 113.261 176.603 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.11 15.4 28.33 Favored Glycine 0 C--N 1.277 -2.729 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -174.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.425 HD13 HG22 ' A' ' 79' ' ' VAL . 9.3 tt -72.7 -21.02 19.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 CA-C-O 121.452 0.644 . . . . 0.0 110.046 -179.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.565 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 62.9 p 49.25 88.2 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 125.399 1.48 . . . . 0.0 111.89 -175.407 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.434 HD21 HG22 ' A' ' 60' ' ' ILE . 1.3 pp -98.11 20.1 12.94 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-O 122.429 1.109 . . . . 0.0 109.573 -176.775 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 50.4 t -57.6 94.26 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-N 114.025 -1.443 . . . . 0.0 110.944 175.549 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.458 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 107.77 27.35 5.21 Favored Glycine 0 N--CA 1.441 -1.003 0 CA-C-N 115.408 -0.815 . . . . 0.0 112.603 175.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.403 HG22 ' O ' ' A' ' 68' ' ' LEU . 20.2 m -105.73 176.15 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.885 -179.439 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 12.4 p -93.0 172.76 8.11 Favored 'General case' 0 C--O 1.254 1.327 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.546 179.08 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.97 -30.81 71.43 Favored 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.666 -178.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -73.73 -26.37 60.65 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.686 -177.5 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 40.3 t80 -75.27 -53.13 9.29 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.62 -48.8 78.42 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.054 -177.177 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -55.76 -36.96 67.89 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.642 0.258 . . . . 0.0 110.624 179.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 89.0 m -65.62 -44.64 85.85 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.854 177.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.425 HG22 HD13 ' A' ' 66' ' ' ILE . 34.7 t -61.93 -51.2 75.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 178.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -64.01 -20.2 65.73 Favored 'General case' 0 C--O 1.214 -0.794 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.423 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.82 -25.63 24.47 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 122.934 0.494 . . . . 0.0 110.927 177.177 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -89.02 3.62 51.06 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 112.747 0.647 . . . . 0.0 112.747 -178.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 38.9 p -73.49 -178.33 3.01 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.78 0.8 . . . . 0.0 111.846 177.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.23 -165.9 1.56 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 125.534 1.533 . . . . 0.0 107.045 -179.186 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -39.51 -78.27 0.06 OUTLIER Glycine 0 C--O 1.22 -0.719 0 O-C-N 124.504 1.128 . . . . 0.0 115.204 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.467 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 20.9 m120 -81.57 114.97 20.63 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 118.075 0.938 . . . . 0.0 111.272 -177.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.4 t -124.37 140.48 47.54 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.458 -179.112 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 20.2 mtp85 -100.41 100.7 11.51 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 120.907 0.384 . . . . 0.0 110.831 171.35 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.456 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 95.4 m-85 -93.09 105.02 17.17 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 176.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.766 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 41.0 t -95.86 86.19 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.274 -2.686 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 178.369 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.402 HG21 ' HB3' ' A' ' 58' ' ' ASP . 94.0 mt -104.92 160.82 5.06 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.49 0 CA-C-N 113.841 -1.527 . . . . 0.0 109.252 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.49 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -122.47 152.88 16.86 Favored Glycine 0 N--CA 1.409 -3.134 0 C-N-CA 119.666 -1.254 . . . . 0.0 110.613 177.015 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 14.8 tpp180 -95.55 123.15 38.96 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -176.255 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 . . . . . 0 C--N 1.303 -1.449 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 172.354 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 . . . . . 0 N--CA 1.442 -0.869 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -85.87 123.52 31.31 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-O 120.877 0.37 . . . . 0.0 110.468 -177.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -133.5 143.71 49.11 Favored Pre-proline 0 C--N 1.29 -1.979 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.72 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.43 126.08 5.96 Favored 'Trans proline' 0 N--CA 1.437 -1.817 0 C-N-CA 122.148 1.899 . . . . 0.0 112.4 177.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.467 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 61.1 t -107.0 98.87 7.49 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.677 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 173.527 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.5 tt0 -88.72 103.38 15.9 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -99.36 137.74 37.44 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -173.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -100.28 103.98 15.43 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 171.286 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.754 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.9 mmmp? -98.35 173.57 6.91 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -175.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -63.05 167.2 5.07 Favored 'General case' 0 C--N 1.313 -0.996 0 C-N-CA 126.917 2.087 . . . . 0.0 109.069 178.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -64.47 -24.48 67.63 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.646 0.736 . . . . 0.0 109.719 176.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -58.78 -45.96 88.6 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 114.501 -1.227 . . . . 0.0 110.333 177.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.4 ' O ' ' HB3' ' A' ' 12' ' ' LYS . . . 124.74 -118.24 3.28 Favored Glycine 0 N--CA 1.413 -2.864 0 N-CA-C 107.834 -2.107 . . . . 0.0 107.834 -176.234 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.445 HD21 HG21 ' A' ' 87' ' ' VAL . 18.6 mt -105.76 -50.89 3.09 Favored 'General case' 0 CA--C 1.475 -1.911 0 CA-C-N 118.153 0.976 . . . . 0.0 110.305 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 71.27 30.49 67.15 Favored Glycine 0 N--CA 1.422 -2.291 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 -174.392 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.45 HD11 HD12 ' A' ' 80' ' ' LEU . 21.5 pt -107.32 172.04 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 119.708 -0.797 . . . . 0.0 110.195 179.166 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.3 m -124.67 150.53 46.0 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -177.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -124.92 160.68 29.83 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 -177.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.3 tt -133.55 126.13 51.21 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 177.023 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.631 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.26 96.53 2.22 Favored Glycine 0 N--CA 1.429 -1.786 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.504 -176.184 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.473 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 79.1 mmm -115.13 76.75 1.02 Allowed 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.619 0 O-C-N 124.407 1.067 . . . . 0.0 113.093 -176.464 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.636 HD11 ' O ' ' A' ' 60' ' ' ILE . 0.5 OUTLIER . . . . . 0 N--CA 1.451 -0.408 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.473 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -110.56 30.52 8.1 Favored Glycine 0 C--N 1.298 -1.569 0 C-N-CA 119.837 -1.173 . . . . 0.0 111.578 176.206 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.631 HD13 ' HA2' ' A' ' 23' ' ' GLY . 20.5 mm -90.56 112.03 24.35 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.125 0 CA-C-O 121.509 0.671 . . . . 0.0 110.628 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -104.92 159.88 15.46 Favored 'General case' 0 C--N 1.282 -2.341 0 CA-C-N 115.153 -0.93 . . . . 0.0 109.805 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 44.8 t -75.0 122.05 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 176.08 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 84.6 tttt -86.5 -47.8 8.94 Favored 'General case' 0 C--N 1.286 -2.178 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.623 -177.196 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -152.98 162.34 41.44 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 -179.268 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.431 HG11 ' HG3' ' A' ' 49' ' ' GLN . 47.8 t -130.02 151.84 36.48 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.052 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.2 t . . . . . 0 C--N 1.314 -0.966 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 176.629 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.754 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.209 -1.055 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.438 ' HB2' ' CE ' ' A' ' 12' ' ' LYS . . . -65.56 -59.59 3.81 Favored 'General case' 0 N--CA 1.504 2.274 0 CA-C-N 118.719 0.691 . . . . 0.0 110.423 -175.799 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.431 ' HG3' HG11 ' A' ' 42' ' ' VAL . 26.1 mt-30 -78.02 6.8 7.12 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.349 177.437 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 26.0 mmm180 -95.59 -27.72 15.2 Favored 'General case' 0 N--CA 1.428 -1.568 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 171.697 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -66.65 -37.22 84.36 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 173.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.58 -31.74 4.13 Favored Glycine 0 N--CA 1.458 0.119 0 CA-C-N 115.471 -0.786 . . . . 0.0 113.985 172.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 2.7 ttm180 -61.55 -54.79 38.52 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 124.975 1.31 . . . . 0.0 111.401 -176.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.5 tt -84.82 141.55 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 CA-C-N 115.033 -0.985 . . . . 0.0 108.832 -176.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.7 mt-30 -143.0 -179.83 6.6 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 119.991 -0.684 . . . . 0.0 111.875 178.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.2 t -62.81 -30.69 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.701 178.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 35.3 m-80 -83.53 18.55 1.83 Allowed 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 113.252 0.834 . . . . 0.0 113.252 -175.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -104.57 175.43 5.49 Favored 'General case' 0 C--O 1.252 1.187 0 CA-C-O 121.491 0.662 . . . . 0.0 111.715 177.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.414 ' O ' HG23 ' A' ' 91' ' ' ILE . 62.3 tt0 -127.46 136.27 51.57 Favored 'General case' 0 N--CA 1.422 -1.827 0 CA-C-N 114.848 -1.069 . . . . 0.0 108.453 177.268 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.636 ' O ' HD11 ' A' ' 35' ' ' LEU . 49.0 mm -75.62 139.84 18.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 178.473 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.712 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 90.5 t -119.26 -53.71 3.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 CA-C-O 121.545 0.688 . . . . 0.0 109.805 177.57 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.563 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 32.0 tt0 -151.7 102.91 2.9 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 -177.617 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.449 HG23 HG23 ' A' ' 60' ' ' ILE . 7.8 t -96.41 127.61 48.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.762 -0.586 . . . . 0.0 111.38 179.185 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 35.2 t70 61.51 19.51 10.4 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 124.847 1.259 . . . . 0.0 111.17 173.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.17 20.24 79.69 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 114.891 -1.05 . . . . 0.0 112.505 -178.575 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.455 HD13 HG22 ' A' ' 79' ' ' VAL . 6.9 tt -81.33 -14.42 12.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 O-C-N 122.418 -0.46 . . . . 0.0 110.282 -179.269 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.42 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 17.8 m 45.33 81.23 0.04 OUTLIER 'General case' 0 C--N 1.351 0.642 0 C-N-CA 125.479 1.512 . . . . 0.0 112.172 -178.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.421 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.5 OUTLIER -91.4 18.31 7.36 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 121.88 0.848 . . . . 0.0 111.409 -174.901 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.409 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 57.2 t -57.95 104.67 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.941 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.264 173.426 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.47 29.27 6.36 Favored Glycine 0 N--CA 1.437 -1.261 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.633 179.028 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 68' ' ' LEU . 15.7 m -113.88 176.1 2.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 C-N-CA 120.166 -0.614 . . . . 0.0 110.735 176.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -104.06 173.27 6.38 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.734 178.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.28 -33.48 71.12 Favored 'General case' 0 C--O 1.204 -1.314 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.035 -176.616 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -66.09 -32.65 74.23 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 123.695 0.798 . . . . 0.0 111.967 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 51.3 t80 -78.92 -49.33 13.01 Favored 'General case' 0 N--CA 1.444 -0.752 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 177.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.42 -43.41 96.79 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.243 -177.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.446 ' O ' ' HB2' ' A' ' 81' ' ' ARG . . . -63.38 -22.59 66.97 Favored 'General case' 0 C--O 1.218 -0.592 0 CA-C-O 121.028 0.442 . . . . 0.0 110.798 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 52.9 m -80.96 -45.44 16.66 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.827 177.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.539 ' O ' HG23 ' A' ' 83' ' ' THR . 40.0 t -62.45 -52.71 56.63 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.571 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 178.338 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.45 HD12 HD11 ' A' ' 19' ' ' ILE . 3.7 mm? -70.13 6.82 1.14 Allowed 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 123.968 0.907 . . . . 0.0 112.213 -178.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.446 ' HB2' ' O ' ' A' ' 77' ' ' ALA . 41.5 ttt180 -109.12 -47.61 3.4 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 174.169 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -79.76 -10.76 59.83 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 113.99 -1.459 . . . . 0.0 114.021 -172.121 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.539 HG23 ' O ' ' A' ' 79' ' ' VAL . 12.5 p -63.14 138.43 58.55 Favored 'General case' 0 C--O 1.248 1.014 0 CA-C-O 120.418 0.151 . . . . 0.0 110.838 177.419 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.8 mmtt -131.17 132.38 44.69 Favored 'General case' 0 CA--C 1.487 -1.453 0 N-CA-C 113.516 0.932 . . . . 0.0 113.516 -175.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.46 -73.17 0.0 OUTLIER Glycine 0 CA--C 1.479 -2.179 0 C-N-CA 127.895 2.664 . . . . 0.0 115.079 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 19.2 m120 -102.53 100.19 10.27 Favored 'General case' 0 C--N 1.253 -3.63 0 CA-C-O 121.376 0.607 . . . . 0.0 109.417 -172.366 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.514 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 5.6 t -114.5 127.67 71.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.058 -172.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 37.7 mtm-85 -99.99 97.78 8.61 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-O 121.026 0.441 . . . . 0.0 109.942 175.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . 0.467 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 80.8 m-85 -87.56 100.75 13.02 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.494 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.712 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.4 t -85.66 94.25 4.02 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.634 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 175.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.414 HG23 ' O ' ' A' ' 59' ' ' GLN . 90.3 mt -112.84 158.58 13.17 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.257 0 CA-C-N 114.05 -1.432 . . . . 0.0 107.749 176.807 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.47 167.34 14.29 Favored Glycine 0 N--CA 1.405 -3.405 0 C-N-CA 118.903 -1.617 . . . . 0.0 112.276 -178.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 2.6 tmt_? -113.59 128.55 56.48 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 176.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 . . . . . 0 C--N 1.302 -1.477 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 178.236 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.507 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 35.3 tt0 . . . . . 0 CA--C 1.499 -0.988 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.451 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.0 mm? -87.85 117.34 26.63 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.409 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -132.38 140.67 38.66 Favored Pre-proline 0 C--N 1.294 -1.816 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -177.167 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.401 ' HA ' ' HA ' ' A' ' 90' ' ' VAL . 55.6 Cg_endo -77.78 125.0 7.16 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.525 2.15 . . . . 0.0 111.855 176.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 26.3 t -111.73 97.19 5.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.513 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -80.0 104.29 10.47 Favored 'General case' 0 N--CA 1.425 -1.691 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -98.4 141.22 31.55 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 -177.374 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -112.88 85.29 2.14 Favored 'General case' 0 N--CA 1.416 -2.133 0 C-N-CA 119.077 -1.049 . . . . 0.0 108.924 172.078 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.631 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 4.3 mmtt -68.69 168.67 12.72 Favored 'General case' 0 N--CA 1.409 -2.511 0 CA-C-N 114.402 -1.272 . . . . 0.0 114.398 -179.374 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.4 ' H ' ' CD ' ' A' ' 12' ' ' LYS . 6.3 m-20 -67.04 164.94 16.73 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 113.721 -1.582 . . . . 0.0 107.506 -178.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -70.25 -12.82 61.86 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.41 0.624 . . . . 0.0 111.712 -177.03 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -68.21 -43.87 77.06 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.186 174.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.464 ' O ' ' HD2' ' A' ' 12' ' ' LYS . . . 132.64 -152.48 20.29 Favored Glycine 0 N--CA 1.426 -1.98 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -176.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.574 ' O ' ' HB ' ' A' ' 43' ' ' THR . 22.8 mt -89.14 -49.49 6.72 Favored 'General case' 0 CA--C 1.489 -1.398 0 CA-C-N 117.678 0.739 . . . . 0.0 109.967 -177.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 73.11 23.82 76.93 Favored Glycine 0 N--CA 1.425 -2.054 0 CA-C-N 114.752 -1.113 . . . . 0.0 111.062 -174.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.469 HG22 ' HA ' ' A' ' 42' ' ' VAL . 19.5 pt -101.17 178.95 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.747 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.7 m -145.58 156.49 43.72 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.56 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -116.71 162.1 14.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 C-N-CA 122.83 0.452 . . . . 0.0 110.556 -176.065 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.4 tt -132.6 125.36 52.96 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.821 0 CA-C-O 120.965 0.412 . . . . 0.0 110.107 174.272 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.574 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.55 101.18 2.71 Favored Glycine 0 N--CA 1.417 -2.595 0 CA-C-N 115.743 -0.662 . . . . 0.0 112.013 -178.488 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 94.9 mmm -107.1 165.32 11.45 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 177.483 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.287 -2.166 0 C-N-CA 119.207 -1.473 . . . . 0.0 111.414 -179.852 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.516 ' CD2' ' HA ' ' A' ' 69' ' ' VAL . 1.6 pp . . . . . 0 N--CA 1.451 -0.411 0 CA-C-O 120.63 0.252 . . . . 0.0 110.867 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -106.52 30.19 9.88 Favored Glycine 0 N--CA 1.431 -1.662 0 C-N-CA 120.009 -1.091 . . . . 0.0 111.229 177.038 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.574 HD13 ' HA2' ' A' ' 23' ' ' GLY . 24.8 mm -82.83 100.68 6.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 121.537 0.684 . . . . 0.0 110.038 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -99.28 167.35 10.72 Favored 'General case' 0 C--N 1.277 -2.545 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.482 179.306 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.1 t -83.21 113.62 22.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 56.6 tptt -76.74 -45.73 28.05 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.897 -176.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.4 m -152.37 162.92 40.49 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -175.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.469 ' HA ' HG22 ' A' ' 19' ' ' ILE . 59.6 t -134.27 158.08 41.88 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.066 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.574 ' HB ' ' O ' ' A' ' 17' ' ' LEU . 10.1 t . . . . . 0 CA--C 1.546 0.792 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 171.025 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.631 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . . . . . . 0 C--O 1.201 -1.457 0 N-CA-C 115.254 1.575 . . . . 0.0 115.254 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.605 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -74.05 -58.99 2.93 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.217 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -69.84 -24.4 63.45 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 119.83 -0.748 . . . . 0.0 112.133 175.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.544 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 13.1 mmt180 -66.37 -36.77 83.72 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 174.017 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -57.23 -59.66 4.78 Favored 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.607 0.567 . . . . 0.0 109.728 177.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.06 -20.75 35.14 Favored Glycine 0 N--CA 1.437 -1.244 0 C-N-CA 120.222 -0.989 . . . . 0.0 114.442 174.37 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.553 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -77.11 -60.95 2.15 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.814 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.553 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 17.5 tt -69.08 140.75 18.33 Favored 'Isoleucine or valine' 0 C--O 1.245 0.831 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.428 -175.518 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 16.4 mm-40 -137.18 173.36 11.76 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-O 121.641 0.734 . . . . 0.0 111.669 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.6 p -81.77 23.75 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.227 0 CA-C-O 122.309 1.052 . . . . 0.0 110.362 -178.687 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -134.79 13.43 3.68 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 122.432 1.111 . . . . 0.0 108.816 -178.324 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.472 ' HB3' HG21 ' A' ' 91' ' ' ILE . 64.9 m-20 -92.47 -177.4 4.6 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.151 -0.932 . . . . 0.0 110.806 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.563 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 32.3 tt0 -134.31 125.02 26.81 Favored 'General case' 0 N--CA 1.434 -1.229 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.303 179.156 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.578 HG21 HD21 ' A' ' 80' ' ' LEU . 45.1 mm -77.63 113.8 17.29 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.908 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -177.143 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.668 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 84.9 t -97.17 -49.14 12.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-O 121.65 0.738 . . . . 0.0 111.093 -177.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.636 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 28.6 tt0 -149.39 115.77 5.82 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.9 t -108.9 125.95 65.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.688 176.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 21.1 t70 69.98 1.62 3.56 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 124.807 1.243 . . . . 0.0 112.162 173.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.54 16.84 38.31 Favored Glycine 0 N--CA 1.427 -1.908 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.608 -176.185 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.467 HG21 HG21 ' A' ' 79' ' ' VAL . 7.8 tt -74.24 -32.85 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.786 0 O-C-N 122.343 -0.504 . . . . 0.0 110.357 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.548 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 20.8 t 58.0 93.45 0.03 OUTLIER 'General case' 0 C--N 1.344 0.327 0 C-N-CA 125.015 1.326 . . . . 0.0 110.038 -176.207 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.54 HD21 HG22 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -105.27 21.0 17.91 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 121.747 0.784 . . . . 0.0 109.883 -174.954 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.516 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 21.4 t -56.31 96.22 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.287 -2.129 0 CA-C-N 114.532 -1.213 . . . . 0.0 112.046 179.091 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.49 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 108.49 6.86 30.77 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.859 175.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.463 HG22 ' O ' ' A' ' 68' ' ' LEU . 21.3 m -82.7 -177.26 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 117.245 0.522 . . . . 0.0 112.005 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 p -97.89 173.77 6.91 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.003 176.489 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.56 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -61.3 -35.11 76.47 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.437 -1.256 . . . . 0.0 111.706 179.044 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -71.33 -32.15 68.23 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 121.059 -0.257 . . . . 0.0 111.364 -178.547 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -70.75 -47.12 61.34 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 176.434 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.413 ' HA ' HG12 ' A' ' 79' ' ' VAL . . . -61.14 -42.88 99.35 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.915 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.411 ' O ' ' HB3' ' A' ' 81' ' ' ARG . . . -59.26 -38.08 79.18 Favored 'General case' 0 C--O 1.212 -0.911 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 176.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 88.1 m -65.15 -50.95 64.01 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.099 178.3 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.535 HG13 HD22 ' A' ' 80' ' ' LEU . 5.6 p -63.65 -45.2 98.15 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.577 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 178.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.578 HD21 HG21 ' A' ' 60' ' ' ILE . 4.0 mm? -67.29 -25.47 66.06 Favored 'General case' 0 C--O 1.216 -0.709 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.411 ' HB3' ' O ' ' A' ' 77' ' ' ALA . 0.4 OUTLIER -86.38 -23.54 26.11 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-O 120.857 0.36 . . . . 0.0 111.657 177.544 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -86.49 5.29 36.03 Favored 'General case' 0 N--CA 1.483 1.211 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 179.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.451 HG21 HD11 ' A' ' 17' ' ' LEU . 31.2 p -70.08 178.05 2.94 Favored 'General case' 0 C--N 1.291 -1.965 0 CA-C-O 121.711 0.767 . . . . 0.0 112.348 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.77 -159.04 0.97 Allowed 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 125.01 1.324 . . . . 0.0 108.045 -179.014 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.12 -76.01 0.22 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 114.467 0.547 . . . . 0.0 114.467 -179.223 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -78.75 112.14 15.58 Favored 'General case' 0 CA--C 1.497 -1.076 0 O-C-N 122.654 -0.321 . . . . 0.0 110.427 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 83.0 t -132.36 128.05 57.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.153 -178.374 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.68 108.38 19.78 Favored 'General case' 0 CA--C 1.496 -1.098 0 C-N-CA 119.715 -0.794 . . . . 0.0 109.903 172.133 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -93.63 98.92 11.46 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 174.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.668 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.7 t -84.55 96.39 4.58 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.06 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 176.062 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.472 HG21 ' HB3' ' A' ' 58' ' ' ASP . 95.0 mt -112.91 153.75 14.44 Favored 'Isoleucine or valine' 0 C--N 1.262 -3.202 0 CA-C-N 113.796 -1.547 . . . . 0.0 108.608 177.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -119.76 153.65 16.71 Favored Glycine 0 N--CA 1.403 -3.554 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 177.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.513 ' NH1' ' HG3' ' A' ' 94' ' ' GLU . 4.3 tmt_? -135.19 152.39 51.54 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -176.835 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.513 ' HG3' ' NH1' ' A' ' 93' ' ' ARG . 7.2 pt-20 . . . . . 0 C--N 1.321 -0.641 0 O-C-N 124.247 0.967 . . . . 0.0 110.771 177.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.19 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 17.8 p80 -146.15 142.05 28.1 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 54.7 ttp -77.99 109.44 12.06 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 121.295 0.569 . . . . 0.0 109.602 179.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.601 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 48.4 tt0 -87.9 114.47 24.55 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.904 -1.044 . . . . 0.0 108.737 -178.507 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -90.79 108.39 19.8 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.822 -1.548 . . . . 0.0 106.822 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -123.13 140.71 34.17 Favored Pre-proline 0 C--N 1.293 -1.881 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -171.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -86.7 131.71 3.37 Favored 'Trans proline' 0 C--N 1.314 -1.267 0 C-N-CA 123.05 2.5 . . . . 0.0 111.928 174.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.3 t -124.32 105.79 15.85 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.302 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 175.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.58 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.1 tt0 -91.32 103.33 16.0 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 175.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.489 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.2 OUTLIER -91.85 143.7 26.24 Favored 'General case' 0 N--CA 1.421 -1.884 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 -174.556 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -112.05 87.92 2.68 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.79 0.805 . . . . 0.0 109.684 175.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.474 ' HG2' HD12 ' A' ' 10' ' ' LEU . 2.1 mmtp -84.87 -178.95 6.98 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -178.222 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.402 ' CG ' ' H ' ' A' ' 14' ' ' GLU . 18.9 t70 -76.08 -176.7 3.61 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 113.568 -1.651 . . . . 0.0 109.845 -178.577 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.402 ' H ' ' CG ' ' A' ' 13' ' ' ASP . 12.0 pt-20 -82.02 -19.86 39.57 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.809 -1.087 . . . . 0.0 109.936 -176.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -69.26 -47.46 64.59 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.73 -128.31 4.4 Favored Glycine 0 N--CA 1.425 -2.039 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.078 -177.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.468 HD21 HG21 ' A' ' 87' ' ' VAL . 9.6 mt -103.81 -49.49 3.64 Favored 'General case' 0 CA--C 1.495 -1.139 0 O-C-N 122.351 -0.499 . . . . 0.0 110.151 -174.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 71.74 31.91 64.55 Favored Glycine 0 N--CA 1.428 -1.858 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -175.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.412 HG22 ' HA ' ' A' ' 42' ' ' VAL . 18.5 pt -111.01 167.82 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 C-N-CA 120.151 -0.62 . . . . 0.0 110.399 -179.077 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 37.4 m -131.47 154.38 48.78 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.303 -177.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.428 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -123.34 170.04 14.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 C-N-CA 123.334 0.654 . . . . 0.0 109.352 -178.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.421 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.1 tt -136.37 131.41 48.38 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 C-N-CA 120.569 -0.452 . . . . 0.0 110.208 176.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.631 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.63 104.24 3.08 Favored Glycine 0 CA--C 1.477 -2.305 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.428 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 19.4 ptm -145.75 98.17 3.08 Favored 'General case' 0 C--N 1.29 -1.992 0 CA-C-N 115.389 -0.406 . . . . 0.0 110.699 -179.049 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.7 111.36 1.2 Allowed Glycine 0 CA--C 1.497 -1.036 0 O-C-N 124.36 1.038 . . . . 0.0 111.32 -178.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -75.6 116.5 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.682 0 CA-C-O 121.779 0.8 . . . . 0.0 112.482 -174.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.73 75.07 2.05 Favored Glycine 0 N--CA 1.433 -1.538 0 N-CA-C 108.516 -1.834 . . . . 0.0 108.516 173.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.435 ' H ' ' HG2' ' A' ' 33' ' ' GLU . . . -58.13 -20.76 42.89 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 124.575 1.15 . . . . 0.0 113.554 -175.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.2 t70 76.13 -32.07 0.2 Allowed 'General case' 0 N--CA 1.495 1.825 0 C-N-CA 124.879 1.271 . . . . 0.0 111.681 176.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.419 ' H ' ' C ' ' A' ' 28' ' ' ALA . . . -60.76 -33.05 72.37 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 125.046 1.338 . . . . 0.0 111.596 178.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 123.71 -28.47 5.45 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 119.806 -1.188 . . . . 0.0 112.696 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.0 mp -71.94 -60.93 1.98 Allowed 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -177.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.435 ' HG2' ' H ' ' A' ' 28' ' ' ALA . 41.4 mt-10 60.03 75.79 0.39 Allowed 'General case' 0 CA--C 1.505 -0.753 0 CA-C-O 122.452 1.12 . . . . 0.0 110.31 176.236 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -72.06 -171.04 0.67 Allowed 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 113.161 -1.836 . . . . 0.0 111.175 -176.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.415 HD12 ' H ' ' A' ' 37' ' ' ILE . 3.4 pp -50.82 143.3 10.13 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.018 174.203 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -109.8 32.59 6.62 Favored Glycine 0 C--N 1.281 -2.509 0 C-N-CA 120.19 -1.005 . . . . 0.0 111.329 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.631 HD13 ' HA2' ' A' ' 23' ' ' GLY . 28.4 mm -93.06 100.4 11.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-O 121.732 0.777 . . . . 0.0 110.064 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -97.24 166.65 11.46 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.336 178.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.0 t -80.95 131.37 34.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 175.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.445 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -93.27 -49.61 5.88 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.477 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.3 m -150.69 161.03 43.4 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 -176.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.534 HG11 ' HG3' ' A' ' 49' ' ' GLN . 57.7 t -132.66 160.39 42.6 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.662 0 N-CA-C 104.9 -2.259 . . . . 0.0 104.9 175.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.1 t -59.31 155.6 14.2 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 173.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -48.54 -31.4 6.44 Favored 'General case' 0 C--O 1.241 0.613 0 C-N-CA 124.384 1.074 . . . . 0.0 112.826 -176.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -163.53 -62.53 0.02 OUTLIER Glycine 0 N--CA 1.417 -2.591 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.755 175.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 43.56 -112.12 0.51 Allowed Glycine 0 N--CA 1.421 -2.308 0 C-N-CA 125.28 1.419 . . . . 0.0 110.891 -170.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.485 ' O ' ' HB2' ' A' ' 51' ' ' ASP . . . -129.6 7.92 5.33 Favored 'General case' 0 C--N 1.258 -3.398 0 CA-C-N 112.853 -1.673 . . . . 0.0 108.938 175.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -95.95 -57.07 2.45 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -176.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.534 ' HG3' HG11 ' A' ' 42' ' ' VAL . 25.6 mt-30 -80.92 -12.99 59.31 Favored 'General case' 0 CA--C 1.502 -0.874 0 C-N-CA 119.349 -0.94 . . . . 0.0 109.853 177.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.48 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 5.8 mmp_? -92.17 -9.83 40.95 Favored 'General case' 0 N--CA 1.427 -1.599 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.891 173.062 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.485 ' HB2' ' O ' ' A' ' 47' ' ' ALA . 13.2 t70 -70.54 -64.74 0.84 Allowed 'General case' 0 N--CA 1.481 1.12 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 171.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 115.54 -25.66 9.55 Favored Glycine 0 N--CA 1.431 -1.655 0 C-N-CA 120.383 -0.913 . . . . 0.0 114.297 175.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -80.48 -36.0 34.04 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 117.903 0.851 . . . . 0.0 109.149 -177.581 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.4 tt -92.97 149.55 4.18 Favored 'Isoleucine or valine' 0 C--O 1.254 1.303 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 -178.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 23.5 mt-30 -130.8 167.43 18.91 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.156 0.503 . . . . 0.0 111.031 179.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.98 -8.81 11.48 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.165 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.641 178.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 10.3 p30 -106.38 12.62 29.59 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-O 121.423 0.63 . . . . 0.0 110.764 -177.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -91.28 -174.4 3.93 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.613 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.56 ' O ' HG23 ' A' ' 91' ' ' ILE . 30.6 tt0 -135.09 126.13 27.78 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.765 -176.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.542 HG22 HD11 ' A' ' 68' ' ' LEU . 47.0 mm -73.65 114.45 13.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.704 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 74.0 t -93.26 -49.95 12.5 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-O 121.675 0.75 . . . . 0.0 109.928 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.527 ' HG3' ' H ' ' A' ' 67' ' ' SER . 26.1 tt0 -151.27 126.73 10.06 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.464 178.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 5.0 t -118.43 130.65 72.96 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.048 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 174.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 16.6 t70 62.69 16.71 9.16 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 124.205 1.002 . . . . 0.0 111.623 174.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 79.89 15.81 78.37 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.209 -179.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.525 HD13 HG22 ' A' ' 79' ' ' VAL . 4.4 tt -79.86 -16.83 12.93 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.115 0 O-C-N 122.347 -0.502 . . . . 0.0 112.064 -175.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.527 ' H ' ' HG3' ' A' ' 62' ' ' GLU 0.282 0.8 OUTLIER 39.34 80.97 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 114.728 1.381 . . . . 0.0 114.728 -175.553 . . . . . . . . 4 4 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.62 ' H ' HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -92.24 36.78 0.99 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.859 -176.73 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 46.2 t -70.66 91.41 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.713 -177.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 107.4 33.17 3.21 Favored Glycine 0 C--N 1.303 -1.276 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.79 176.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.463 HG21 ' HB2' ' A' ' 68' ' ' LEU . 24.9 m -103.97 175.96 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 120.249 -0.58 . . . . 0.0 111.152 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 40.3 p -91.89 176.0 6.68 Favored 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 178.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.428 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -68.35 -25.18 64.96 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.404 179.86 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 -65.32 -48.16 74.04 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.488 ' O ' HG23 ' A' ' 79' ' ' VAL . 29.5 t80 -64.44 -51.85 61.07 Favored 'General case' 0 N--CA 1.432 -1.331 0 CA-C-N 114.577 -1.192 . . . . 0.0 109.124 -178.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.77 -44.99 96.05 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.558 -177.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.5 -34.1 73.58 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.039 0.447 . . . . 0.0 110.066 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.467 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 76.8 m -65.75 -45.06 84.01 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.525 176.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.525 HG22 HD13 ' A' ' 66' ' ' ILE . 41.1 t -60.62 -52.33 62.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 C-N-CA 122.229 0.212 . . . . 0.0 110.527 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -70.7 0.07 7.78 Favored 'General case' 0 CA--C 1.552 1.049 0 CA-C-O 121.406 0.622 . . . . 0.0 112.154 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.467 ' HB3' ' O ' ' A' ' 78' ' ' THR . 25.9 ttm180 -100.14 -38.18 8.63 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 124.024 0.93 . . . . 0.0 108.986 174.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.17 -10.26 59.3 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.122 -175.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 5.3 p -71.58 161.23 31.34 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 113.183 0.808 . . . . 0.0 113.183 -178.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -118.9 -161.24 0.84 Allowed 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.23 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.59 -63.42 5.3 Favored Glycine 0 N--CA 1.439 -1.12 0 O-C-N 123.544 0.528 . . . . 0.0 113.323 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.489 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 17.9 m120 -82.14 108.82 15.91 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.58 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.8 t -119.7 136.66 56.1 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.677 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.721 -176.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 84.2 mtt180 -102.63 97.38 7.58 Favored 'General case' 0 C--N 1.288 -2.103 0 CA-C-O 121.4 0.619 . . . . 0.0 109.993 173.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.458 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 92.8 m-85 -89.36 106.16 18.27 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.735 177.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.704 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.4 t -95.65 88.77 2.13 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.743 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 175.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.56 HG23 ' O ' ' A' ' 59' ' ' GLN . 82.2 mt -101.09 149.68 6.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.678 0 CA-C-N 114.613 -1.176 . . . . 0.0 108.566 179.094 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.601 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -138.05 128.73 4.32 Favored Glycine 1 N--CA 1.393 -4.196 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 -178.638 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 15.7 ttp180 -157.9 162.1 38.28 Favored 'General case' 0 N--CA 1.414 -2.24 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 -175.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.409 ' H ' ' CD ' ' A' ' 94' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--N 1.285 -2.212 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 175.367 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.496 -1.129 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 54.3 m80 55.42 63.41 2.09 Favored 'General case' 0 CA--C 1.508 -0.666 0 CA-C-O 121.73 0.776 . . . . 0.0 111.093 -177.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . 0.498 ' HA ' ' O ' ' A' ' 93' ' ' ARG 0.273 43.7 ttm 69.38 93.81 0.08 Allowed 'General case' 0 N--CA 1.432 -1.336 0 CA-C-N 113.736 -1.574 . . . . 0.0 113.236 -178.317 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.426 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 32.0 tt0 -85.25 115.46 23.03 Favored 'General case' 0 C--N 1.288 -2.09 0 CA-C-N 112.901 -1.954 . . . . 0.0 108.117 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.476 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.5 mm? -86.43 134.28 33.71 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 123.752 0.658 . . . . 0.0 109.884 -177.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 10.7 p90 -141.57 144.36 33.11 Favored Pre-proline 0 C--N 1.293 -1.865 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.802 -178.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -84.61 130.17 4.36 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 C-N-CA 122.57 2.18 . . . . 0.0 113.168 179.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.487 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 26.1 t -115.65 107.65 23.23 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.228 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 174.034 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -88.42 107.02 18.64 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 177.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.428 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -100.48 139.27 36.4 Favored 'General case' 0 N--CA 1.423 -1.802 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -176.157 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -109.76 81.77 1.49 Allowed 'General case' 0 N--CA 1.426 -1.641 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 173.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.632 ' HZ1' HG21 ' A' ' 43' ' ' THR . 2.0 mmtt -77.9 171.72 14.56 Favored 'General case' 0 N--CA 1.409 -2.52 0 CA-C-N 115.05 -0.977 . . . . 0.0 113.426 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -72.96 167.98 19.93 Favored 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 126.06 1.744 . . . . 0.0 108.617 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -68.58 -21.41 64.53 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-O 121.412 0.625 . . . . 0.0 110.289 179.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -64.14 -32.43 74.0 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.418 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.23 -158.8 14.05 Favored Glycine 0 N--CA 1.434 -1.472 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -178.501 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.455 HD11 HG21 ' A' ' 83' ' ' THR . 17.6 mt -83.64 -48.78 9.84 Favored 'General case' 0 CA--C 1.49 -1.352 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -177.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.32 32.01 71.85 Favored Glycine 0 N--CA 1.431 -1.67 0 O-C-N 124.515 1.134 . . . . 0.0 110.677 -175.093 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.414 HG23 ' HB3' ' A' ' 17' ' ' LEU . 26.8 pt -98.91 -177.79 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.567 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.403 -178.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.8 m -138.13 149.09 45.58 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 122.766 0.426 . . . . 0.0 110.011 -178.01 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.446 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.5 pp -119.04 161.39 18.15 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 C-N-CA 123.324 0.65 . . . . 0.0 109.73 -177.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.6 tt -128.94 128.72 67.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 174.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.588 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.71 96.39 2.07 Favored Glycine 0 N--CA 1.432 -1.61 0 C-N-CA 120.468 -0.872 . . . . 0.0 112.77 -175.526 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 91.9 mmm -104.15 164.52 11.66 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.8 73.97 0.36 Allowed Glycine 0 N--CA 1.421 -2.35 0 C-N-CA 119.969 -1.11 . . . . 0.0 110.653 177.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.4 p -101.33 94.77 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.405 0 CA-C-O 122.473 1.13 . . . . 0.0 108.939 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.487 ' CA ' ' HA ' ' A' ' 33' ' ' GLU . . . -148.13 -75.49 0.02 OUTLIER Glycine 0 N--CA 1.424 -2.154 0 C-N-CA 119.671 -1.252 . . . . 0.0 112.715 -173.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.32 -33.91 77.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.806 0.812 . . . . 0.0 109.81 -179.24 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -71.67 -19.22 62.12 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 114.225 -1.352 . . . . 0.0 111.481 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.99 -33.88 11.98 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 121.608 0.718 . . . . 0.0 109.241 177.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.14 -32.14 7.66 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.759 179.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.6 mp -78.83 -36.57 42.3 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.865 0.364 . . . . 0.0 110.991 -177.368 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.487 ' HA ' ' CA ' ' A' ' 27' ' ' GLY . 44.5 mt-10 64.22 97.15 0.04 OUTLIER 'General case' 0 CA--C 1.509 -0.605 0 C-N-CA 124.436 1.094 . . . . 0.0 113.393 -175.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -142.95 -179.42 6.34 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 172.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.484 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.6 pt? -57.71 151.56 17.2 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-O 121.738 0.78 . . . . 0.0 111.054 176.199 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -114.26 19.99 16.78 Favored Glycine 0 N--CA 1.412 -2.964 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 174.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.588 HD13 ' HA2' ' A' ' 23' ' ' GLY . 30.5 mm -77.7 116.53 21.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 177.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -114.92 165.88 12.39 Favored 'General case' 0 C--N 1.269 -2.924 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.7 t -77.96 132.37 32.66 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 176.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.518 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -95.89 -44.0 7.58 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 121.396 0.617 . . . . 0.0 110.049 -178.715 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.8 m -155.66 160.13 40.15 Favored 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 -178.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.41 ' HA ' HG22 ' A' ' 19' ' ' ILE . 64.0 t -129.11 148.8 33.29 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.621 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.632 HG21 ' HZ1' ' A' ' 12' ' ' LYS . 15.3 t -54.44 140.04 35.38 Favored 'General case' 0 C--O 1.254 1.292 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 176.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -68.89 -35.39 76.81 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -171.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -152.32 77.81 0.21 Allowed Glycine 0 CA--C 1.46 -3.373 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.289 -178.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -137.69 174.09 22.0 Favored Glycine 1 N--CA 1.366 -5.979 0 N-CA-C 103.422 -3.871 . . . . 0.0 103.422 173.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -61.73 -1.2 0.56 Allowed 'General case' 0 C--N 1.273 -2.74 0 N-CA-C 114.986 1.476 . . . . 0.0 114.986 -174.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.558 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -77.88 -57.34 3.85 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -75.16 -12.61 60.34 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 119.764 -0.774 . . . . 0.0 112.085 175.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.568 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 20.5 mmm180 -73.4 -40.99 63.88 Favored 'General case' 0 CA--C 1.507 -0.689 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -62.36 -57.69 10.39 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.965 0.79 . . . . 0.0 109.603 176.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 83.25 -5.74 75.49 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 115.539 0.976 . . . . 0.0 115.539 173.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -78.36 -30.99 48.29 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 178.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 19.7 tt -89.11 152.6 3.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 175.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -133.03 -177.57 4.57 Favored 'General case' 0 N--CA 1.42 -1.962 0 CA-C-O 121.508 0.67 . . . . 0.0 111.019 -179.297 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.9 p -97.9 -5.06 9.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 121.822 0.82 . . . . 0.0 109.548 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.402 HD22 ' HA ' ' A' ' 57' ' ' ASN . 2.1 t-20 -117.2 16.96 14.88 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.433 -174.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.426 ' OD1' HD13 ' A' ' 91' ' ' ILE . 3.0 p30 -100.66 -168.37 1.56 Allowed 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.167 177.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.476 ' O ' HG23 ' A' ' 91' ' ' ILE . 11.8 tt0 -131.39 117.6 19.11 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.374 -176.302 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.504 ' HA ' HG12 ' A' ' 91' ' ' ILE . 46.0 mm -68.83 106.85 1.24 Allowed 'Isoleucine or valine' 0 C--O 1.21 -1.024 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.778 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 89.3 t -87.76 -50.87 13.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-O 121.607 0.718 . . . . 0.0 110.326 -177.769 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.503 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.9 tt0 -145.62 133.32 21.04 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.7 t -126.31 129.56 71.98 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 176.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 31.3 t70 64.2 16.95 10.41 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 124.739 1.274 . . . . 0.0 111.143 172.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 72.2 26.03 73.16 Favored Glycine 0 N--CA 1.433 -1.525 0 CA-C-N 114.825 -1.08 . . . . 0.0 112.483 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.499 HD13 HG22 ' A' ' 79' ' ' VAL . 7.5 tt -85.09 -15.1 10.9 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 CA-C-O 121.417 0.627 . . . . 0.0 109.389 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.482 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 23.2 p 49.01 83.84 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 124.951 1.3 . . . . 0.0 112.704 -175.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.442 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.9 pp -97.88 14.02 28.6 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 122.22 1.01 . . . . 0.0 109.313 -177.682 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 22.4 t -56.13 93.43 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-N 113.836 -1.529 . . . . 0.0 110.356 176.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.484 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 106.74 14.52 19.24 Favored Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 116.032 -0.531 . . . . 0.0 113.3 176.571 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.442 HG22 ' O ' ' A' ' 68' ' ' LEU . 21.0 m -88.16 176.14 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 O-C-N 122.335 -0.509 . . . . 0.0 111.836 -179.426 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.6 p -92.16 176.72 6.39 Favored 'General case' 0 N--CA 1.428 -1.545 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.185 177.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.446 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -66.98 -23.87 65.98 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.07 179.895 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 19.6 m-80 -63.53 -50.92 67.68 Favored 'General case' 0 CA--C 1.484 -1.581 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.429 ' O ' HG23 ' A' ' 79' ' ' VAL . 38.8 t80 -68.5 -50.56 51.31 Favored 'General case' 0 N--CA 1.415 -2.182 0 CA-C-N 114.067 -1.424 . . . . 0.0 110.093 -175.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.5 -44.45 95.96 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.29 -16.48 64.07 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-O 121.232 0.539 . . . . 0.0 111.063 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.407 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 60.2 m -85.04 -42.22 15.06 Favored 'General case' 0 N--CA 1.417 -2.107 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.944 176.678 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.499 HG22 HD13 ' A' ' 66' ' ' ILE . 38.7 t -62.85 -53.14 50.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 122.211 0.204 . . . . 0.0 110.588 178.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.434 HD21 HG21 ' A' ' 60' ' ' ILE . 3.4 mm? -68.59 -1.93 7.86 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-O 121.571 0.701 . . . . 0.0 112.434 -179.367 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.407 ' HB3' ' O ' ' A' ' 78' ' ' THR . 33.4 ttm180 -97.34 -43.41 7.32 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-O 121.922 0.868 . . . . 0.0 108.93 174.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 11.5 m-80 -83.78 8.59 14.22 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 114.338 -1.301 . . . . 0.0 112.794 -174.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.455 HG21 HD11 ' A' ' 17' ' ' LEU . 2.2 p -65.6 176.99 1.31 Allowed 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 123.86 0.864 . . . . 0.0 112.679 177.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -139.25 -155.57 0.6 Allowed 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.31 -175.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -71.77 -68.77 1.53 Allowed Glycine 0 N--CA 1.444 -0.786 0 O-C-N 123.66 0.6 . . . . 0.0 111.834 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.428 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 43.8 m-80 -87.28 104.12 16.1 Favored 'General case' 0 CA--C 1.498 -1.044 0 CA-C-O 121.638 0.732 . . . . 0.0 110.079 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.42 ' HB ' ' CE1' ' A' ' 89' ' ' PHE . 3.0 t -116.74 133.17 64.25 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 CA-C-N 115.261 -0.881 . . . . 0.0 109.76 -175.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 70.0 mtp180 -97.79 101.97 13.6 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 173.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.487 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 91.1 m-85 -92.74 107.36 19.16 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 176.416 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.778 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 42.8 t -96.05 86.26 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.268 -2.951 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.504 HG12 ' HA ' ' A' ' 60' ' ' ILE . 88.8 mt -96.08 158.73 3.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.25 0 C-N-CA 125.314 1.445 . . . . 0.0 108.689 -179.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.476 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -136.53 149.32 20.11 Favored Glycine 0 N--CA 1.398 -3.884 0 C-N-CA 119.565 -1.303 . . . . 0.0 111.267 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.498 ' O ' ' HA ' ' A' ' 3' ' ' MET . 0.0 OUTLIER -115.23 135.18 54.44 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.078 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.291 -1.972 0 C-N-CA 124.335 1.054 . . . . 0.0 112.893 -175.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.28 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 31.2 t60 -154.19 139.73 17.84 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -178.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 49.7 ttm -160.41 112.09 1.94 Allowed 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 174.079 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -99.48 114.91 28.15 Favored 'General case' 0 C--N 1.285 -2.197 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.479 -178.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.54 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -87.31 128.6 35.17 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -140.43 144.08 35.49 Favored Pre-proline 0 C--N 1.307 -1.269 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -178.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -83.01 126.23 4.34 Favored 'Trans proline' 0 C--N 1.327 -0.594 0 C-N-CA 123.092 2.528 . . . . 0.0 113.393 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 41.4 t -118.05 99.94 9.08 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.018 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 175.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.489 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 34.0 tt0 -85.2 109.67 18.47 Favored 'General case' 0 N--CA 1.432 -1.372 0 C-N-CA 119.544 -0.863 . . . . 0.0 108.72 176.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.409 HD11 ' O ' ' A' ' 47' ' ' ALA . 0.1 OUTLIER -99.83 145.37 27.82 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -177.694 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -111.24 90.26 3.28 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 173.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.655 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 3.3 mtpm? -80.56 -176.63 5.84 Favored 'General case' 0 N--CA 1.423 -1.777 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -178.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -72.83 173.02 9.75 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 112.338 -2.21 . . . . 0.0 111.679 -173.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -61.29 -26.66 67.93 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.303 -0.862 . . . . 0.0 112.42 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -67.52 -45.52 75.51 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-O 121.494 0.664 . . . . 0.0 109.879 176.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.36 -114.3 2.34 Favored Glycine 0 N--CA 1.426 -2.025 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.73 -176.069 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.519 ' HG ' HG23 ' A' ' 19' ' ' ILE . 9.9 tp -108.1 -62.77 1.4 Allowed 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 117.349 0.575 . . . . 0.0 111.656 -173.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.87 36.25 92.87 Favored Glycine 0 N--CA 1.44 -1.034 0 O-C-N 123.889 0.743 . . . . 0.0 113.139 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.519 HG23 ' HG ' ' A' ' 17' ' ' LEU . 20.9 pt -102.17 178.48 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.519 177.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 13.8 m -130.79 148.79 52.61 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.53 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -118.66 162.86 16.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.453 -177.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.4 ' CG2' ' HB2' ' A' ' 38' ' ' PHE . 15.6 tt -126.9 125.55 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.938 0 C-N-CA 120.269 -0.573 . . . . 0.0 110.435 174.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.472 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -86.96 105.63 3.06 Favored Glycine 0 N--CA 1.431 -1.66 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.753 -178.417 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.462 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 9.0 ptp -137.03 176.96 8.24 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 122.668 0.387 . . . . 0.0 111.891 176.239 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.43 94.96 0.49 Allowed Glycine 0 C--N 1.303 -1.277 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.468 HG12 ' HA2' ' A' ' 36' ' ' GLY . 7.2 p -87.56 94.12 4.43 Favored 'Isoleucine or valine' 0 C--O 1.257 1.483 0 CA-C-O 122.238 1.018 . . . . 0.0 113.433 -176.031 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.4 76.31 0.59 Allowed Glycine 0 N--CA 1.435 -1.399 0 CA-C-N 114.182 -1.372 . . . . 0.0 115.724 173.235 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.76 -18.78 34.03 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 172.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -100.92 9.73 41.96 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.346 -1.297 . . . . 0.0 109.512 177.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.09 13.38 34.29 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 112.977 0.732 . . . . 0.0 112.977 -175.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.09 -50.91 3.42 Favored Glycine 0 C--N 1.306 -1.099 0 C-N-CA 119.948 -1.12 . . . . 0.0 114.821 174.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 26.8 mt -71.78 -44.92 63.17 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-O 120.623 0.249 . . . . 0.0 111.067 -173.227 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 54.64 77.32 0.21 Allowed 'General case' 0 CA--C 1.511 -0.52 0 O-C-N 124.301 1.0 . . . . 0.0 111.544 178.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.57 ' HD3' ' H ' ' A' ' 34' ' ' LYS . 0.0 OUTLIER -128.21 179.24 5.72 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.685 -178.786 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.419 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.6 pt? -53.73 155.71 3.07 Favored 'General case' 0 C--N 1.321 -0.638 0 O-C-N 124.413 1.071 . . . . 0.0 111.438 -179.191 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.468 ' HA2' HG12 ' A' ' 26' ' ' VAL . . . -124.41 33.0 3.94 Favored Glycine 0 N--CA 1.412 -2.909 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 174.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.542 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 32.8 mm -89.5 107.76 18.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 176.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.4 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 91.0 m-85 -104.21 168.66 8.96 Favored 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.9 t -78.72 121.63 32.16 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 176.014 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.524 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.1 OUTLIER -86.73 -49.19 7.65 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.503 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.09 157.65 43.68 Favored 'General case' 0 N--CA 1.417 -2.11 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.416 ' HA ' HG22 ' A' ' 19' ' ' ILE . 2.6 p -133.72 151.07 32.43 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.952 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 176.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.406 HG21 ' HE3' ' A' ' 12' ' ' LYS . 9.6 t -53.58 140.16 29.53 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-O 121.583 0.706 . . . . 0.0 112.132 -173.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -53.35 -44.12 68.28 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 126.184 1.793 . . . . 0.0 113.794 -174.091 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -159.76 36.66 0.47 Allowed Glycine 0 CA--C 1.458 -3.517 0 C-N-CA 118.541 -1.79 . . . . 0.0 113.997 -179.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -86.48 179.27 49.19 Favored Glycine 1 N--CA 1.365 -6.097 0 N-CA-C 106.497 -2.641 . . . . 0.0 106.497 170.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.655 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . -56.61 -8.12 0.52 Allowed 'General case' 0 C--N 1.259 -3.344 0 N-CA-C 115.301 1.593 . . . . 0.0 115.301 -174.265 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.29 -63.13 1.47 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 -70.6 -21.9 62.61 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 120.616 -0.434 . . . . 0.0 112.125 176.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.424 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 40.2 mmt180 -68.54 -33.71 74.58 Favored 'General case' 0 CA--C 1.522 -0.103 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -70.48 -64.98 0.79 Allowed 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.353 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.62 -10.97 57.84 Favored Glycine 0 N--CA 1.437 -1.278 0 C-N-CA 120.549 -0.834 . . . . 0.0 115.115 175.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.657 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -76.72 -33.63 58.16 Favored 'General case' 0 C--O 1.239 0.507 0 CA-C-N 118.65 1.225 . . . . 0.0 108.448 178.404 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.3 tt -90.82 154.47 3.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 178.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -134.96 -163.43 1.38 Allowed 'General case' 0 N--CA 1.428 -1.57 0 C-N-CA 119.772 -0.771 . . . . 0.0 110.972 -174.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.9 p -115.16 11.43 7.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-O 122.81 1.29 . . . . 0.0 107.564 176.25 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -121.94 -7.34 8.95 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.435 -1.257 . . . . 0.0 110.655 -174.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.511 ' OD1' HD13 ' A' ' 91' ' ' ILE . 3.9 p30 -86.92 -165.29 1.25 Allowed 'General case' 0 C--O 1.255 1.358 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.425 -177.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.542 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 62.9 tt0 -142.04 121.55 13.27 Favored 'General case' 0 N--CA 1.416 -2.14 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.38 -175.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.461 ' HA ' HG12 ' A' ' 91' ' ' ILE . 42.3 mm -70.16 107.0 1.71 Allowed 'Isoleucine or valine' 0 C--O 1.212 -0.872 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 179.149 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.698 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 93.5 t -88.28 -52.26 11.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 CA-C-O 121.649 0.738 . . . . 0.0 110.724 -177.178 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.585 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 29.4 tt0 -146.15 110.53 5.07 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.75 -178.199 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 t -105.15 131.0 55.44 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.919 0 O-C-N 122.033 -0.417 . . . . 0.0 111.455 176.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 33.5 t70 61.65 16.75 8.02 Favored 'General case' 0 N--CA 1.484 1.273 0 O-C-N 124.722 1.264 . . . . 0.0 111.242 174.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.37 19.01 75.05 Favored Glycine 0 N--CA 1.443 -0.898 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.232 -179.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.4 tt -80.18 -30.23 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 O-C-N 122.36 -0.494 . . . . 0.0 110.971 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.473 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 19.4 t 54.59 95.24 0.02 OUTLIER 'General case' 0 C--N 1.345 0.392 0 C-N-CA 125.035 1.334 . . . . 0.0 110.5 -175.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.466 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.7 OUTLIER -101.65 20.35 16.35 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 122.204 1.002 . . . . 0.0 109.734 -176.144 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 39.0 t -61.84 93.56 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-N 114.496 -1.229 . . . . 0.0 111.343 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.419 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 117.07 5.77 14.68 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.697 176.641 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.466 HG22 ' O ' ' A' ' 68' ' ' LEU . 16.3 m -87.72 179.51 0.49 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.57 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -177.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 14.9 p -94.21 176.18 6.41 Favored 'General case' 0 C--O 1.255 1.376 0 CA-C-O 121.463 0.649 . . . . 0.0 109.9 177.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.53 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -62.81 -38.37 90.44 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 114.713 -1.131 . . . . 0.0 111.246 178.071 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -68.65 -32.76 72.84 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 111.768 0.284 . . . . 0.0 111.768 -177.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -68.28 -51.83 40.59 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 176.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.418 ' CB ' HG21 ' A' ' 37' ' ' ILE . . . -59.84 -44.64 93.98 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.463 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.58 -18.48 63.93 Favored 'General case' 0 C--O 1.22 -0.467 0 C-N-CA 122.995 0.518 . . . . 0.0 111.266 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 78.3 m -83.67 -49.66 8.94 Favored 'General case' 0 N--CA 1.416 -2.125 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 175.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.441 ' O ' HG23 ' A' ' 83' ' ' THR . 38.4 t -59.57 -54.82 29.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 CA-C-O 120.462 0.172 . . . . 0.0 110.831 -178.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -67.95 -2.77 8.12 Favored 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 123.331 0.652 . . . . 0.0 112.033 -179.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 38.5 ttt180 -98.8 -43.46 6.76 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 174.221 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -73.08 -11.73 60.65 Favored 'General case' 0 C--O 1.24 0.588 0 CA-C-N 114.615 -1.175 . . . . 0.0 112.142 -174.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.441 HG23 ' O ' ' A' ' 79' ' ' VAL . 15.9 p -75.14 140.18 43.2 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-O 121.588 0.709 . . . . 0.0 112.464 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.464 ' O ' HG22 ' A' ' 87' ' ' VAL . 71.0 mmtt -107.07 -167.5 1.28 Allowed 'General case' 0 C--N 1.292 -1.908 0 CA-C-N 114.432 -1.258 . . . . 0.0 109.044 176.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -40.14 -58.57 2.33 Favored Glycine 0 C--O 1.216 -0.971 0 O-C-N 124.631 1.207 . . . . 0.0 115.761 -176.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -87.62 100.32 12.72 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 117.747 0.773 . . . . 0.0 111.399 -174.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.565 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 1.6 t -119.43 128.7 75.86 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.36 -175.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 42.3 mtp180 -92.31 99.46 12.23 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 173.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.565 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 97.1 m-85 -92.06 101.09 13.63 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 177.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.698 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.8 t -91.08 92.44 3.94 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 105.963 -1.865 . . . . 0.0 105.963 175.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.511 HD13 ' OD1' ' A' ' 58' ' ' ASP . 97.2 mt -110.56 153.39 12.35 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.777 0 CA-C-N 114.293 -1.321 . . . . 0.0 107.968 179.336 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.54 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -124.42 150.5 17.08 Favored Glycine 0 N--CA 1.401 -3.662 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.938 179.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 4.3 tmm_? -113.9 134.95 54.49 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 -177.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 . . . . . 0 C--N 1.309 -1.165 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.436 179.721 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.507 -0.457 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . 0.421 ' O ' ' HA ' ' A' ' 94' ' ' GLU . 59.9 m80 -68.78 131.87 45.87 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 177.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 45.0 ttp -137.59 132.89 33.75 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-O 121.089 0.471 . . . . 0.0 112.248 -174.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -102.14 120.0 39.73 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.474 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.1 mm? -90.45 120.39 31.52 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -135.1 146.64 59.21 Favored Pre-proline 0 C--N 1.304 -1.398 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -175.647 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -80.28 126.89 6.42 Favored 'Trans proline' 0 N--CA 1.444 -1.431 0 C-N-CA 122.244 1.963 . . . . 0.0 112.488 175.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 48.8 t -108.45 103.26 15.21 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.076 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 173.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.455 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.1 tt0 -88.17 103.57 15.89 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.49 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -98.28 145.71 26.38 Favored 'General case' 0 N--CA 1.426 -1.625 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 -175.819 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -116.48 95.85 5.25 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-O 121.66 0.743 . . . . 0.0 109.188 175.18 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.478 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 1.9 mmmp? -92.49 -169.96 2.35 Favored 'General case' 0 N--CA 1.419 -1.991 0 CA-C-N 114.911 -1.041 . . . . 0.0 112.564 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -78.49 167.19 21.66 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 113.864 -1.516 . . . . 0.0 107.805 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -67.88 -20.11 65.09 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.325 0.584 . . . . 0.0 109.807 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -65.69 -31.77 72.96 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 114.697 -1.138 . . . . 0.0 109.707 177.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.73 -130.4 9.06 Favored Glycine 0 N--CA 1.413 -2.838 0 CA-C-N 114.841 -1.072 . . . . 0.0 111.613 177.086 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.6 ' HB3' HG23 ' A' ' 19' ' ' ILE . 20.7 mt -108.49 -63.68 1.31 Allowed 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 120.348 -0.541 . . . . 0.0 110.836 -174.587 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.62 23.27 36.87 Favored Glycine 0 N--CA 1.424 -2.1 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -172.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.6 HG23 ' HB3' ' A' ' 17' ' ' LEU . 22.7 pt -89.23 178.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.349 0.547 0 C-N-CA 120.446 -0.502 . . . . 0.0 110.908 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.1 m -139.17 147.59 42.05 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.431 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -126.8 162.4 31.44 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 C-N-CA 122.814 0.446 . . . . 0.0 110.108 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.441 ' HB ' ' HG2' ' A' ' 40' ' ' LYS . 13.5 tt -130.96 135.0 60.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.473 174.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.576 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.18 102.48 2.86 Favored Glycine 0 N--CA 1.427 -1.945 0 C-N-CA 120.722 -0.751 . . . . 0.0 111.792 -178.017 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.641 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 93.8 mmm -116.87 93.48 4.21 Favored 'General case' 0 C--N 1.291 -1.96 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -179.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.93 107.07 0.56 Allowed Glycine 0 C--O 1.247 0.915 0 O-C-N 123.839 0.712 . . . . 0.0 111.743 -179.002 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.5 p -137.58 163.19 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -177.246 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 114.71 -9.49 21.61 Favored Glycine 0 N--CA 1.419 -2.471 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.7 177.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.92 -41.68 61.73 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -71.73 -30.96 66.19 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.921 0.867 . . . . 0.0 108.949 178.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.54 -29.28 66.83 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.403 175.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.53 24.43 28.46 Favored Glycine 0 N--CA 1.442 -0.934 0 C-N-CA 121.219 -0.515 . . . . 0.0 112.638 178.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -117.32 -38.94 3.25 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 122.546 -0.385 . . . . 0.0 111.013 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 54.45 82.88 0.09 Allowed 'General case' 0 C--O 1.238 0.495 0 CA-C-O 122.104 0.954 . . . . 0.0 110.377 -172.182 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -126.63 -155.6 0.7 Allowed 'General case' 0 C--N 1.297 -1.695 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.958 -175.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.465 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.5 pp -73.57 150.72 41.25 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 178.105 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.641 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -129.59 34.37 2.79 Favored Glycine 0 C--N 1.283 -2.38 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 172.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.576 HD13 ' HA2' ' A' ' 23' ' ' GLY . 26.8 mm -86.72 100.19 9.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.828 0 CA-C-O 121.556 0.693 . . . . 0.0 110.992 -175.405 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -93.16 160.3 14.91 Favored 'General case' 0 C--N 1.287 -2.134 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.211 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 49.3 t -83.63 130.52 35.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.441 ' HG2' ' HB ' ' A' ' 22' ' ' ILE . 20.3 mmmt -87.77 -53.09 4.95 Favored 'General case' 0 CA--C 1.491 -1.3 0 CA-C-O 121.661 0.743 . . . . 0.0 110.266 178.184 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -144.28 160.26 41.3 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 -176.107 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 60.9 t -131.53 86.95 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.473 -1.995 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -178.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.526 ' H ' ' HA ' ' A' ' 19' ' ' ILE 0.257 95.9 m 53.91 -170.5 0.05 Allowed 'General case' 0 CA--C 1.583 2.248 0 O-C-N 124.542 1.151 . . . . 0.0 110.182 179.381 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.486 ' N ' HG22 ' A' ' 43' ' ' THR . 11.8 pt-20 -81.84 -153.37 0.11 Allowed 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 104.887 -2.264 . . . . 0.0 104.887 161.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -93.78 57.41 2.22 Favored Glycine 0 C--N 1.287 -2.176 0 C-N-CA 118.796 -1.668 . . . . 0.0 111.047 177.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.449 ' O ' ' HG2' ' A' ' 50' ' ' ARG . . . -94.33 -160.38 34.41 Favored Glycine 1 N--CA 1.393 -4.215 0 N-CA-C 108.722 -1.751 . . . . 0.0 108.722 173.942 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.478 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . -58.67 -17.78 25.37 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 115.114 1.524 . . . . 0.0 115.114 -171.544 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.35 -60.42 2.25 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 179.075 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 44.1 mt-30 -70.64 -24.3 62.69 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.065 -0.516 . . . . 0.0 112.333 176.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.449 ' HG2' ' O ' ' A' ' 46' ' ' GLY . 40.0 mmt180 -69.72 -37.46 76.54 Favored 'General case' 0 CA--C 1.504 -0.806 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.589 174.771 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -59.81 -48.73 80.52 Favored 'General case' 0 C--N 1.352 0.691 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.61 -10.61 36.94 Favored Glycine 0 N--CA 1.439 -1.116 0 N-CA-C 115.286 0.874 . . . . 0.0 115.286 172.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.464 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.1 OUTLIER -75.46 -27.77 59.01 Favored 'General case' 0 C--O 1.221 -0.426 0 CA-C-N 118.57 1.185 . . . . 0.0 108.401 -179.782 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.0 tt -97.81 149.29 5.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 177.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 48.2 mt-30 -132.71 170.34 15.38 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-O 121.839 0.828 . . . . 0.0 112.499 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.4 p -83.26 -3.61 7.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.763 -179.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -103.85 15.98 27.42 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 122.6 1.191 . . . . 0.0 108.332 -178.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.512 ' HB3' HG21 ' A' ' 91' ' ' ILE . 68.5 m-20 -93.23 177.9 5.9 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.223 -0.899 . . . . 0.0 112.335 -178.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -136.7 122.46 19.89 Favored 'General case' 0 N--CA 1.416 -2.174 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.46 HG21 HD21 ' A' ' 80' ' ' LEU . 47.5 mm -74.11 111.95 10.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 -175.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.712 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 99.4 t -92.12 -51.22 11.77 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-O 121.771 0.796 . . . . 0.0 110.28 -177.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.527 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.4 tt0 -152.04 110.09 3.69 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.33 0.586 . . . . 0.0 111.066 -178.338 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.411 HG23 HG23 ' A' ' 60' ' ' ILE . 4.7 t -102.01 129.08 53.9 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 O-C-N 122.005 -0.434 . . . . 0.0 110.983 177.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 18.2 t70 65.11 10.52 6.42 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 124.764 1.226 . . . . 0.0 111.772 174.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.32 19.9 68.11 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.421 -177.428 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.517 HD13 HG22 ' A' ' 79' ' ' VAL . 9.7 tt -76.33 -18.96 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 CA-C-O 121.058 0.456 . . . . 0.0 110.357 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.518 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 31.4 p 48.2 84.96 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 124.875 1.27 . . . . 0.0 112.004 -175.189 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.447 HD21 HG22 ' A' ' 60' ' ' ILE . 1.5 pp -97.12 16.92 18.31 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.669 0.747 . . . . 0.0 110.084 -175.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.465 ' HA ' HD23 ' A' ' 35' ' ' LEU . 45.6 t -58.16 97.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.171 174.771 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.22 53.55 1.0 Allowed Glycine 0 N--CA 1.431 -1.652 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.551 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.6 m -134.32 173.87 13.91 Favored 'Isoleucine or valine' 0 C--O 1.244 0.796 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 176.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 14.5 p -92.45 175.53 6.8 Favored 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 122.873 0.469 . . . . 0.0 110.965 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.431 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -66.38 -31.17 71.77 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.276 -179.36 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -69.56 -36.94 76.77 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 120.783 -0.367 . . . . 0.0 111.166 -179.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.416 ' O ' HG23 ' A' ' 79' ' ' VAL . 44.1 t80 -68.02 -51.15 50.3 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.21 -47.14 86.45 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.036 -0.983 . . . . 0.0 111.693 -177.659 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.22 -37.07 74.12 Favored 'General case' 0 C--O 1.212 -0.9 0 O-C-N 122.94 0.15 . . . . 0.0 110.641 179.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 65.3 m -64.75 -42.75 94.93 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.088 176.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.517 HG22 HD13 ' A' ' 66' ' ' ILE . 47.8 t -61.12 -51.56 71.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 177.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.46 HD21 HG21 ' A' ' 60' ' ' ILE . 3.6 mm? -69.73 -2.34 11.63 Favored 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.448 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 3.4 tmt_? -99.51 -30.09 12.35 Favored 'General case' 0 C--N 1.312 -1.061 0 C-N-CA 123.667 0.787 . . . . 0.0 109.329 175.388 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -86.81 0.19 55.28 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 123.344 0.658 . . . . 0.0 112.004 -177.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.3 p -65.96 148.83 51.18 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.596 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.71 -157.48 0.72 Allowed 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 124.79 1.236 . . . . 0.0 108.587 178.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.27 -76.97 0.17 Allowed Glycine 0 C--N 1.315 -0.613 0 O-C-N 123.542 0.527 . . . . 0.0 113.963 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.49 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.3 m-80 -78.79 109.83 13.41 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.329 0.585 . . . . 0.0 111.537 -179.309 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.465 HG21 HD21 ' A' ' 17' ' ' LEU . 7.2 t -121.73 131.12 73.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.457 -178.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -98.58 98.71 9.84 Favored 'General case' 0 C--N 1.284 -2.271 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 174.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.442 ' CE1' ' HB ' ' A' ' 87' ' ' VAL . 89.8 m-85 -89.42 103.06 15.73 Favored 'General case' 0 CA--C 1.486 -1.481 0 CA-C-N 114.643 -1.162 . . . . 0.0 107.942 177.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.712 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.7 t -89.03 95.39 5.37 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.987 0 N-CA-C 106.6 -1.629 . . . . 0.0 106.6 177.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.512 HG21 ' HB3' ' A' ' 58' ' ' ASP . 96.7 mt -112.4 154.02 13.93 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.682 0 CA-C-N 114.143 -1.39 . . . . 0.0 108.248 176.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.474 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -120.91 149.72 17.38 Favored Glycine 0 N--CA 1.416 -2.657 0 C-N-CA 118.946 -1.597 . . . . 0.0 111.507 179.139 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 25.2 tpt180 -121.22 136.8 54.91 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 120.959 0.409 . . . . 0.0 110.859 179.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.421 ' HA ' ' O ' ' A' ' 2' ' ' HIS . 7.1 pt-20 . . . . . 0 N--CA 1.424 -1.755 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.171 176.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.503 -0.676 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 17.5 t-80 -92.61 10.02 32.27 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 122.858 1.314 . . . . 0.0 108.361 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 25.7 ttt -152.32 120.21 6.16 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 105.028 -2.212 . . . . 0.0 105.028 174.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.527 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 42.1 tt0 -88.22 104.4 16.68 Favored 'General case' 0 C--N 1.289 -2.054 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 -178.324 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -87.09 116.21 25.0 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 174.333 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -132.07 137.19 29.57 Favored Pre-proline 0 N--CA 1.417 -2.113 0 CA-C-O 121.896 0.855 . . . . 0.0 113.237 -173.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -82.31 128.47 5.57 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.972 2.448 . . . . 0.0 112.144 175.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.449 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 38.4 t -118.95 112.92 39.81 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.491 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 174.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.461 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 42.2 tt0 -96.11 105.2 17.22 Favored 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 176.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.429 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -92.93 143.46 26.23 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -175.02 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -108.34 90.73 3.38 Favored 'General case' 0 C--N 1.291 -1.941 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 174.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.8 mmmp? -87.05 -175.46 5.35 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 113.966 1.099 . . . . 0.0 113.966 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.439 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.2 p-10 -89.32 -172.39 3.61 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 126.285 1.834 . . . . 0.0 111.179 -178.248 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -82.1 -6.44 59.18 Favored 'General case' 0 N--CA 1.465 0.286 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -175.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.439 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 11.3 t70 -82.16 -34.09 29.24 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 122.005 0.907 . . . . 0.0 108.757 176.001 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 121.37 -109.95 1.59 Allowed Glycine 0 N--CA 1.415 -2.735 0 CA-C-N 114.146 -1.388 . . . . 0.0 110.118 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.763 ' HG ' HG23 ' A' ' 19' ' ' ILE . 14.1 tp -117.31 -62.75 1.53 Allowed 'General case' 0 C--N 1.291 -1.939 0 O-C-N 122.341 -0.505 . . . . 0.0 109.878 -177.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.56 33.55 55.75 Favored Glycine 0 N--CA 1.434 -1.496 0 O-C-N 124.175 0.922 . . . . 0.0 113.157 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.763 HG23 ' HG ' ' A' ' 17' ' ' LEU . 27.5 pt -101.02 172.6 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 C-N-CA 119.892 -0.723 . . . . 0.0 110.279 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 34.8 m -119.33 145.98 45.69 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -179.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.417 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -122.71 164.38 20.09 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -178.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.6 tt -132.53 132.78 60.09 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 174.361 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.629 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -95.58 105.73 3.29 Favored Glycine 0 N--CA 1.428 -1.9 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.926 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.469 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 16.7 ptm -143.65 85.22 1.82 Allowed 'General case' 0 C--N 1.291 -1.948 0 CA-C-O 121.585 0.707 . . . . 0.0 110.8 179.264 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.21 112.99 2.58 Favored Glycine 0 C--O 1.24 0.519 0 CA-C-N 114.013 -1.449 . . . . 0.0 113.845 -176.248 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.3 p -129.17 166.93 25.55 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 105.39 -18.49 41.64 Favored Glycine 0 N--CA 1.435 -1.411 0 C-N-CA 121.165 -0.54 . . . . 0.0 111.916 176.04 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.45 -39.84 74.08 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 120.649 0.261 . . . . 0.0 110.547 -177.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -65.91 -37.08 85.15 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.249 177.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.74 -26.73 66.28 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.998 178.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.78 -8.12 42.68 Favored Glycine 0 N--CA 1.443 -0.871 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.457 179.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.7 mp -84.89 -32.64 23.05 Favored 'General case' 0 C--N 1.312 -1.029 0 O-C-N 122.938 -0.154 . . . . 0.0 111.062 -178.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 57.77 78.46 0.24 Allowed 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 122.146 0.975 . . . . 0.0 110.01 -175.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.0 tptt -100.59 176.63 5.26 Favored 'General case' 0 N--CA 1.405 -2.7 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -175.243 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.478 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.0 OUTLIER -77.39 170.63 16.22 Favored 'General case' 0 N--CA 1.414 -2.253 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 170.197 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -131.67 35.48 2.39 Favored Glycine 0 N--CA 1.414 -2.781 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.039 176.255 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.629 HD13 ' HA2' ' A' ' 23' ' ' GLY . 26.7 mm -94.81 105.72 17.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 C-N-CA 119.405 -0.918 . . . . 0.0 109.547 -179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -102.17 161.54 13.61 Favored 'General case' 0 C--N 1.276 -2.604 0 CA-C-N 114.721 -1.127 . . . . 0.0 110.191 -179.171 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 29.0 t -77.5 117.81 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.087 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 176.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 56.3 tptt -84.64 -51.33 6.92 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -178.176 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -149.51 160.69 43.26 Favored 'General case' 0 N--CA 1.427 -1.61 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 -179.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.443 ' HB ' ' OE1' ' A' ' 49' ' ' GLN . 16.8 t -122.75 162.36 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.151 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 178.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.485 ' H ' HG22 ' A' ' 19' ' ' ILE . 9.1 t -74.48 141.36 44.94 Favored 'General case' 0 N--CA 1.422 -1.83 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.457 ' HA ' HE21 ' A' ' 49' ' ' GLN . 44.3 tt0 -95.91 -31.08 13.29 Favored 'General case' 0 C--N 1.27 -2.864 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -175.247 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -106.09 49.3 0.89 Allowed Glycine 0 CA--C 1.478 -2.273 0 CA-C-N 114.288 -1.324 . . . . 0.0 111.757 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -152.83 150.87 22.73 Favored Glycine 1 N--CA 1.368 -5.863 0 N-CA-C 107.309 -2.317 . . . . 0.0 107.309 178.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -58.59 0.59 0.07 Allowed 'General case' 0 C--N 1.279 -2.467 0 N-CA-C 115.424 1.638 . . . . 0.0 115.424 -176.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.89 -53.25 10.58 Favored 'General case' 0 N--CA 1.465 0.275 0 O-C-N 121.46 -0.775 . . . . 0.0 109.952 -178.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.457 HE21 ' HA ' ' A' ' 44' ' ' GLU . 27.8 mt-30 -78.46 -13.89 59.63 Favored 'General case' 0 CA--C 1.508 -0.66 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.739 176.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.478 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 13.5 mmm180 -74.45 -41.06 61.46 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 174.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.45 ' OD1' ' HB2' ' A' ' 53' ' ' ARG . 12.2 t70 -60.29 -59.03 6.06 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.461 177.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.4 -9.35 77.79 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 115.03 0.772 . . . . 0.0 115.03 174.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.45 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -69.35 -37.27 77.56 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.545 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.9 tt -81.93 152.33 4.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -178.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 30.3 mt-30 -127.88 161.6 28.69 Favored 'General case' 0 C--N 1.312 -1.061 0 C-N-CA 120.031 -0.668 . . . . 0.0 109.303 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.9 p -89.64 16.82 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 CA-C-O 121.747 0.784 . . . . 0.0 110.531 -177.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -137.59 20.38 2.9 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 122.236 1.017 . . . . 0.0 110.11 -177.021 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -103.72 -175.19 2.73 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.234 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.447 ' O ' HG23 ' A' ' 91' ' ' ILE . 33.6 tt0 -120.68 132.65 55.2 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.132 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.517 HG22 HD11 ' A' ' 68' ' ' LEU . 47.2 mm -76.73 101.45 2.91 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.128 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.722 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 81.2 t -80.8 -48.06 19.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 CA-C-O 121.233 0.539 . . . . 0.0 110.571 -175.32 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.481 ' HG3' ' H ' ' A' ' 67' ' ' SER . 39.5 tt0 -156.64 112.91 3.02 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-O 121.015 0.436 . . . . 0.0 110.639 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.435 ' C ' ' H ' ' A' ' 65' ' ' GLY . 4.8 t -102.26 131.08 51.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.566 175.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.3 t70 73.03 -22.56 0.23 Allowed 'General case' 0 N--CA 1.503 2.22 0 C-N-CA 125.747 1.619 . . . . 0.0 112.975 176.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 63' ' ' VAL . . . 110.36 12.41 17.4 Favored Glycine 0 C--N 1.274 -2.911 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -173.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.438 HD13 HG22 ' A' ' 79' ' ' VAL . 7.3 tt -70.02 -19.51 22.56 Favored 'Isoleucine or valine' 0 C--N 1.344 0.326 0 C-N-CA 122.885 0.474 . . . . 0.0 110.903 -178.119 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.481 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 12.3 p 49.03 81.57 0.05 Allowed 'General case' 0 C--O 1.233 0.19 0 C-N-CA 124.26 1.024 . . . . 0.0 112.88 -176.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.517 HD11 HG22 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -95.58 30.22 2.36 Favored 'General case' 0 N--CA 1.423 -1.778 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.381 -178.625 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 47.9 t -73.45 97.04 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-N 114.974 -1.012 . . . . 0.0 109.585 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.478 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 108.26 33.07 3.05 Favored Glycine 0 C--N 1.294 -1.799 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 176.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.471 HG21 ' HB2' ' A' ' 68' ' ' LEU . 19.7 m -109.39 174.53 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 119.917 -0.713 . . . . 0.0 111.461 -178.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 22.2 p -91.29 172.82 8.27 Favored 'General case' 0 N--CA 1.418 -2.049 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.794 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.417 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -66.97 -32.01 72.96 Favored 'General case' 0 C--O 1.204 -1.293 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.018 -179.682 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -71.44 -31.6 67.39 Favored 'General case' 0 CA--C 1.516 -0.362 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.82 -178.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -70.38 -51.67 28.03 Favored 'General case' 0 N--CA 1.443 -0.819 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 177.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.41 ' CB ' HG21 ' A' ' 37' ' ' ILE . . . -62.56 -42.16 99.37 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.031 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.09 -11.4 48.52 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 121.23 0.538 . . . . 0.0 111.102 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 58.0 m -89.75 -47.13 8.12 Favored 'General case' 0 N--CA 1.415 -2.204 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.862 174.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.494 ' O ' HG23 ' A' ' 83' ' ' THR . 31.4 t -61.86 -54.27 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.43 HD21 HG21 ' A' ' 60' ' ' ILE . 3.3 mm? -68.41 0.42 3.96 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.617 0.767 . . . . 0.0 112.716 -178.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -104.07 -45.95 4.59 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 174.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 -80.83 7.36 10.64 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 114.405 -1.27 . . . . 0.0 113.142 -173.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.494 HG23 ' O ' ' A' ' 79' ' ' VAL . 1.7 p -60.45 154.22 21.18 Favored 'General case' 0 C--N 1.29 -2.013 0 C-N-CA 124.854 1.261 . . . . 0.0 111.405 175.047 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.439 ' HD3' ' HA ' ' A' ' 84' ' ' LYS . 31.8 mmtp -111.51 -164.91 0.95 Allowed 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.061 178.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.32 -67.59 2.12 Favored Glycine 0 N--CA 1.439 -1.152 0 O-C-N 123.657 0.598 . . . . 0.0 112.886 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.429 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 15.6 m120 -82.52 117.07 22.25 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.461 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.2 t -125.04 127.79 72.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.453 -177.326 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -91.68 104.33 16.8 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-O 120.877 0.37 . . . . 0.0 110.169 172.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.449 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.7 m-85 -95.6 103.99 15.88 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 175.234 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.722 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 47.7 t -92.85 91.48 3.37 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.921 0 N-CA-C 104.781 -2.303 . . . . 0.0 104.781 174.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.492 HG12 ' HA ' ' A' ' 60' ' ' ILE . 74.8 mt -108.0 157.05 8.33 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.09 178.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -131.78 143.66 15.22 Favored Glycine 0 N--CA 1.397 -3.913 0 C-N-CA 119.404 -1.379 . . . . 0.0 111.093 177.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.42 ' C ' ' HD2' ' A' ' 93' ' ' ARG . 5.2 tmm_? -108.22 128.47 54.75 Favored 'General case' 0 C--N 1.291 -1.97 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -178.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 . . . . . 0 C--N 1.311 -1.095 0 O-C-N 123.353 0.408 . . . . 0.0 110.459 178.961 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.576 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 53.1 t-80 -128.91 127.22 41.35 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 117.351 0.576 . . . . 0.0 110.365 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 44.0 ttp -91.6 128.66 37.52 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.012 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.429 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 32.2 tt0 -88.3 109.43 19.95 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -179.168 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -91.72 127.87 37.34 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.761 -1.199 . . . . 0.0 107.761 173.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.494 ' O ' ' HA ' ' A' ' 90' ' ' VAL . 20.9 p90 -133.21 137.59 29.67 Favored Pre-proline 0 C--N 1.283 -2.295 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -175.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -84.21 121.67 2.75 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 123.472 2.781 . . . . 0.0 112.146 176.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 35.8 t -112.17 98.47 7.07 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.048 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 175.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.608 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 31.6 tt0 -83.8 101.54 11.69 Favored 'General case' 0 N--CA 1.421 -1.899 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 176.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.472 HD11 ' HA ' ' A' ' 48' ' ' ALA . 0.1 OUTLIER -93.23 133.67 36.21 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 -175.948 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -101.15 92.98 5.23 Favored 'General case' 0 N--CA 1.419 -2.016 0 CA-C-O 121.995 0.903 . . . . 0.0 109.282 175.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.572 ' CD ' ' HB3' ' A' ' 47' ' ' ALA . 2.0 mmmp? -92.95 -175.45 3.89 Favored 'General case' 0 N--CA 1.421 -1.921 0 CA-C-N 114.302 -1.317 . . . . 0.0 113.218 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.467 ' OD1' ' HB3' ' A' ' 15' ' ' ASP . 1.7 p30 -77.31 176.62 8.63 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-N 112.784 -2.007 . . . . 0.0 110.743 178.063 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -82.94 -6.65 59.56 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.612 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.467 ' HB3' ' OD1' ' A' ' 13' ' ' ASP . 9.6 t70 -81.77 -41.94 20.45 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 175.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.32 -123.26 2.6 Favored Glycine 0 N--CA 1.42 -2.381 0 C-N-CA 120.136 -1.031 . . . . 0.0 112.909 175.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.444 HD21 HG21 ' A' ' 87' ' ' VAL . 13.0 mt -108.36 -45.1 3.97 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 122.211 -0.582 . . . . 0.0 110.569 -172.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.67 28.45 70.89 Favored Glycine 0 N--CA 1.426 -2.014 0 O-C-N 124.336 1.023 . . . . 0.0 110.663 -174.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 20.4 pt -106.38 -176.95 0.58 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.293 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.797 -178.083 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 50.3 m -144.22 151.86 40.05 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.496 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.6 pp -125.0 162.67 26.84 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -178.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 12.1 tt -134.59 130.42 53.3 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.833 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 176.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.623 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -98.01 104.92 3.05 Favored Glycine 0 CA--C 1.481 -2.034 0 C-N-CA 120.357 -0.925 . . . . 0.0 111.744 -178.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.492 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 18.4 ptm -147.16 96.41 2.72 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 120.643 0.258 . . . . 0.0 111.562 -179.469 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.36 107.69 0.55 Allowed Glycine 0 C--O 1.243 0.704 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.315 -178.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -74.69 88.44 0.63 Allowed 'Isoleucine or valine' 0 C--O 1.252 1.201 0 N-CA-C 114.039 1.126 . . . . 0.0 114.039 -174.23 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 74.54 -71.96 1.53 Allowed Glycine 0 N--CA 1.439 -1.136 0 CA-C-N 114.376 -1.284 . . . . 0.0 115.926 171.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . 64.06 26.23 13.97 Favored 'General case' 0 C--N 1.35 0.597 0 CA-C-O 122.651 1.215 . . . . 0.0 107.979 -171.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -104.16 -42.45 5.52 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 113.775 -1.557 . . . . 0.0 111.594 -173.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.32 -29.7 70.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.897 -177.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.57 -20.29 10.25 Favored Glycine 0 CA--C 1.498 -1.011 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.78 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.2 mp -67.81 -47.14 69.88 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 53.66 72.84 0.41 Allowed 'General case' 0 C--O 1.247 0.955 0 C-N-CA 124.379 1.072 . . . . 0.0 112.081 174.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.2 ptpt -109.84 177.65 4.66 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 178.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.507 HD22 HG23 ' A' ' 69' ' ' VAL . 1.8 pt? -56.0 170.9 0.28 Allowed 'General case' 0 C--N 1.305 -1.346 0 CA-C-O 122.254 1.026 . . . . 0.0 111.985 173.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.492 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -131.66 32.04 2.99 Favored Glycine 0 N--CA 1.41 -3.076 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.873 175.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.623 HD13 ' HA2' ' A' ' 23' ' ' GLY . 23.8 mm -90.1 98.61 8.41 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 119.778 -0.769 . . . . 0.0 109.098 178.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -96.98 162.5 13.37 Favored 'General case' 0 C--N 1.273 -2.744 0 CA-C-N 115.047 -0.979 . . . . 0.0 108.914 -178.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 40.9 t -79.71 122.71 35.44 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.537 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -81.15 -49.92 10.24 Favored 'General case' 0 C--N 1.293 -1.86 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.331 -177.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -154.31 161.23 41.89 Favored 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 -178.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 51.0 t -136.25 147.54 27.88 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 N-CA-C 105.415 -2.068 . . . . 0.0 105.415 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.2 t -54.48 132.88 45.5 Favored 'General case' 0 C--O 1.257 1.465 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 173.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 16.5 tp10 -55.4 -58.34 8.15 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 124.759 1.223 . . . . 0.0 111.218 -172.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -144.36 39.36 1.24 Allowed Glycine 0 N--CA 1.421 -2.315 0 C-N-CA 120.094 -1.051 . . . . 0.0 112.744 179.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -63.39 -48.21 80.64 Favored Glycine 0 C--O 1.221 -0.667 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 175.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.572 ' HB3' ' CD ' ' A' ' 12' ' ' LYS . . . 170.44 -25.61 0.0 OUTLIER 'General case' 0 C--O 1.197 -1.704 0 C-N-CA 124.999 1.32 . . . . 0.0 109.797 177.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.472 ' HA ' HD11 ' A' ' 10' ' ' LEU . . . -64.42 -54.74 27.94 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.239 0.542 . . . . 0.0 110.662 -176.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 42.8 mt-30 -76.45 -7.79 55.81 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.772 178.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.415 ' HD3' ' HA ' ' A' ' 50' ' ' ARG . 23.4 mmt180 -90.44 -23.29 21.06 Favored 'General case' 0 N--CA 1.437 -1.085 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.12 176.56 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -61.01 -54.9 39.17 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 170.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 105.3 -26.55 21.46 Favored Glycine 0 N--CA 1.432 -1.576 0 CA-C-N 115.164 -0.925 . . . . 0.0 114.746 174.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -72.93 -31.5 64.66 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-N 118.446 1.123 . . . . 0.0 109.666 -176.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.9 tt -97.09 146.96 6.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -179.193 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . 0.424 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 97.0 mt-30 -136.57 162.52 32.9 Favored 'General case' 0 N--CA 1.436 -1.13 0 CA-C-O 121.331 0.586 . . . . 0.0 110.945 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.4 p -75.71 -15.34 15.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 C-N-CA 124.085 0.954 . . . . 0.0 111.298 -178.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -95.06 9.84 38.01 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.455 0.645 . . . . 0.0 111.557 -175.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.424 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 39.9 m-20 -97.84 -172.68 2.43 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.691 -177.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.564 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.6 tt0 -134.91 133.21 39.38 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.836 -177.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.461 ' HA ' HG12 ' A' ' 91' ' ' ILE . 44.1 mm -78.4 115.15 20.04 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.001 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 -177.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.657 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.2 t -94.49 -51.8 10.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-O 121.679 0.752 . . . . 0.0 110.552 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.609 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 21.4 tt0 -147.55 110.01 4.62 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.92 -177.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.5 t -103.39 126.54 57.78 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 O-C-N 122.018 -0.427 . . . . 0.0 110.204 175.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.5 t70 62.19 17.52 9.29 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 124.452 1.101 . . . . 0.0 112.215 174.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 83.09 8.75 85.15 Favored Glycine 0 N--CA 1.442 -0.915 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.975 -179.214 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.512 HD13 HG22 ' A' ' 79' ' ' VAL . 5.7 tt -75.25 -16.62 15.91 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 O-C-N 122.571 -0.37 . . . . 0.0 110.845 -176.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.43 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 31.3 m 49.09 79.71 0.07 Allowed 'General case' 0 N--CA 1.442 -0.848 0 C-N-CA 124.876 1.27 . . . . 0.0 112.706 -177.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.495 ' O ' HG22 ' A' ' 71' ' ' VAL . 2.3 pp -96.16 11.73 33.32 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 122.322 1.058 . . . . 0.0 110.074 -175.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.507 HG23 HD22 ' A' ' 35' ' ' LEU . 5.2 p -58.11 92.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.294 -1.841 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.497 173.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.489 ' N ' ' HB3' ' A' ' 35' ' ' LEU . . . 113.79 21.42 5.71 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.829 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.495 HG22 ' O ' ' A' ' 68' ' ' LEU . 20.4 m -103.48 176.97 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 O-C-N 121.978 -0.719 . . . . 0.0 110.965 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.3 p -93.7 171.71 8.71 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.026 177.034 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.496 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -64.78 -28.83 69.84 Favored 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.775 -176.337 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.82 -30.49 66.94 Favored 'General case' 0 CA--C 1.512 -0.492 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.358 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.451 ' O ' HG23 ' A' ' 79' ' ' VAL . 31.2 t80 -77.32 -52.01 9.91 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 177.686 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -56.25 -50.12 72.23 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.274 -0.876 . . . . 0.0 112.364 -177.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.15 -36.41 75.21 Favored 'General case' 0 C--O 1.214 -0.786 0 CA-C-O 120.505 0.193 . . . . 0.0 110.796 -179.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 84.0 m -62.88 -42.75 99.88 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.301 177.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.512 HG22 HD13 ' A' ' 66' ' ' ILE . 31.6 t -64.27 -51.78 64.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 178.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -63.58 -18.28 63.72 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.841 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.13 -26.44 23.62 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 123.276 0.631 . . . . 0.0 110.32 174.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -88.67 6.17 39.68 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-O 121.48 0.657 . . . . 0.0 112.251 -178.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 36.4 p -74.89 -178.2 3.64 Favored 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.043 177.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -154.18 -163.0 1.52 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.166 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -49.25 -73.3 0.37 Allowed Glycine 0 CA--C 1.531 1.036 0 O-C-N 123.884 0.74 . . . . 0.0 114.49 178.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.463 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 19.0 m120 -82.99 104.74 13.42 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 117.667 0.734 . . . . 0.0 111.628 -178.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.608 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -114.71 137.51 47.89 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.503 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 90.6 mtt180 -99.64 99.04 9.83 Favored 'General case' 0 C--N 1.283 -2.304 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.507 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 91.9 m-85 -92.2 101.45 13.96 Favored 'General case' 0 CA--C 1.489 -1.386 0 CA-C-N 114.895 -1.048 . . . . 0.0 108.555 177.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.657 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 60.8 t -92.32 94.76 4.96 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.89 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.47 HG23 ' O ' ' A' ' 59' ' ' GLN . 90.6 mt -106.3 163.19 4.92 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.929 0 CA-C-N 114.104 -1.407 . . . . 0.0 108.543 178.532 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -139.07 161.23 25.94 Favored Glycine 0 N--CA 1.412 -2.912 0 C-N-CA 119.489 -1.338 . . . . 0.0 112.162 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 37.0 ttp-105 -142.58 144.17 32.76 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 178.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 . . . . . 0 C--N 1.302 -1.485 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 176.291 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.5 -0.902 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 58.2 m80 -93.99 94.83 8.67 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 26.6 ttt -84.05 111.82 19.64 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 119.003 -1.079 . . . . 0.0 108.964 176.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -95.66 117.38 30.38 Favored 'General case' 0 C--N 1.287 -2.115 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 -179.148 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -93.1 127.55 38.68 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 175.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 19.6 p90 -137.25 141.34 33.79 Favored Pre-proline 0 C--N 1.297 -1.684 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -175.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -82.24 123.9 4.1 Favored 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 122.76 2.307 . . . . 0.0 112.21 177.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.415 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 38.9 t -109.44 95.99 4.29 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.688 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 174.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 29.7 tt0 -83.37 102.72 12.21 Favored 'General case' 0 N--CA 1.423 -1.825 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -98.44 140.43 32.7 Favored 'General case' 0 N--CA 1.411 -2.386 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 -175.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -108.86 95.74 5.85 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 173.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.539 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 1.9 mmmp? -84.72 174.21 10.09 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 114.381 1.252 . . . . 0.0 114.381 -178.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -92.12 179.91 5.45 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 112.714 -2.039 . . . . 0.0 111.032 -176.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -68.81 -15.51 63.52 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -173.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -77.3 -28.03 53.17 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 121.572 0.701 . . . . 0.0 109.411 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.12 -125.62 6.61 Favored Glycine 0 CA--C 1.482 -1.997 0 N-CA-C 108.513 -1.835 . . . . 0.0 108.513 -179.275 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt -103.79 -50.24 3.46 Favored 'General case' 0 CA--C 1.483 -1.609 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 176.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.94 27.33 64.77 Favored Glycine 0 N--CA 1.434 -1.491 0 O-C-N 124.642 1.214 . . . . 0.0 110.773 -176.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.499 HG22 ' HA ' ' A' ' 42' ' ' VAL . 21.6 pt -102.54 -179.51 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.817 -177.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.3 t -138.72 153.23 48.49 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -178.371 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.51 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.6 pp -125.75 163.43 27.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -177.304 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.615 ' HB ' ' HG2' ' A' ' 40' ' ' LYS . 11.3 tt -130.96 132.69 63.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-O 120.536 0.208 . . . . 0.0 110.686 174.503 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.519 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.15 103.83 3.1 Favored Glycine 0 N--CA 1.426 -1.978 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.5 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.42 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 16.5 ptm -143.94 91.3 2.21 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 178.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -51.82 109.98 0.98 Allowed Glycine 0 C--N 1.34 0.799 0 CA-C-N 114.184 -1.371 . . . . 0.0 113.018 -177.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -135.3 164.12 34.06 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.922 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -175.155 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 81.17 59.51 2.41 Favored Glycine 0 N--CA 1.432 -1.58 0 C-N-CA 121.22 -0.514 . . . . 0.0 113.381 173.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -109.04 -1.74 18.68 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 174.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -59.71 -41.2 90.26 Favored 'General case' 0 C--N 1.312 -1.023 0 C-N-CA 126.151 1.78 . . . . 0.0 111.909 -172.199 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.64 3.7 55.08 Favored 'General case' 0 C--N 1.31 -1.141 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.402 -178.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 89.83 8.79 66.91 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.831 -0.7 . . . . 0.0 114.02 177.025 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -90.77 -44.22 9.59 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 117.791 0.795 . . . . 0.0 113.057 -178.271 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 61.55 84.35 0.14 Allowed 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -171.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -96.38 -173.91 2.91 Favored 'General case' 0 N--CA 1.422 -1.865 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.266 -171.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.416 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 2.6 pp -64.95 146.35 55.1 Favored 'General case' 0 C--N 1.296 -1.735 0 CA-C-N 114.996 -1.002 . . . . 0.0 109.054 176.011 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -118.79 30.88 5.74 Favored Glycine 0 N--CA 1.417 -2.583 0 C-N-CA 119.684 -1.246 . . . . 0.0 110.303 176.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.519 HD13 ' HA2' ' A' ' 23' ' ' GLY . 30.3 mm -91.95 100.97 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.868 0 CA-C-O 121.553 0.692 . . . . 0.0 110.998 -176.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.419 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 96.2 m-85 -96.98 165.0 12.29 Favored 'General case' 0 C--N 1.285 -2.209 0 CA-C-N 115.075 -0.966 . . . . 0.0 108.532 177.567 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 47.1 t -81.41 128.17 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.14 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.615 ' HG2' ' HB ' ' A' ' 22' ' ' ILE . 15.9 mmmt -85.36 -57.34 3.11 Favored 'General case' 0 CA--C 1.473 -2.015 0 CA-C-O 121.567 0.698 . . . . 0.0 109.332 177.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.48 163.6 34.19 Favored 'General case' 0 C--N 1.291 -1.978 0 CA-C-N 114.241 -1.345 . . . . 0.0 107.789 -176.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.499 ' HA ' HG22 ' A' ' 19' ' ' ILE . 86.6 t -129.68 157.26 42.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.23 0 N-CA-C 104.9 -2.259 . . . . 0.0 104.9 174.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 14.9 t -61.54 150.9 34.59 Favored 'General case' 0 N--CA 1.435 -1.193 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 175.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -54.44 -30.99 54.4 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -172.06 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -149.74 -62.08 0.01 OUTLIER Glycine 0 N--CA 1.417 -2.573 0 C-N-CA 119.653 -1.26 . . . . 0.0 111.769 174.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 43.24 -103.99 0.05 OUTLIER Glycine 0 CA--C 1.477 -2.324 0 C-N-CA 125.325 1.441 . . . . 0.0 110.095 -170.096 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.539 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . -141.1 6.35 1.96 Allowed 'General case' 0 C--N 1.257 -3.419 0 CA-C-N 113.083 -1.559 . . . . 0.0 108.646 173.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -95.1 -55.8 2.95 Favored 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 115.795 -0.638 . . . . 0.0 109.608 -175.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -79.08 -16.19 57.1 Favored 'General case' 0 N--CA 1.438 -1.044 0 C-N-CA 119.301 -0.96 . . . . 0.0 110.037 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 36.0 mmt180 -78.43 -25.32 45.95 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.55 171.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -70.91 -61.0 1.92 Allowed 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 172.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.77 2.07 84.67 Favored Glycine 0 N--CA 1.437 -1.247 0 N-CA-C 115.055 0.782 . . . . 0.0 115.055 173.023 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -85.23 -36.37 20.99 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 176.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.6 tt -88.04 146.71 5.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -128.71 177.56 6.97 Favored 'General case' 0 N--CA 1.431 -1.377 0 C-N-CA 120.163 -0.615 . . . . 0.0 111.406 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 5.2 t -90.47 -9.99 10.29 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.774 0 CA-C-O 121.936 0.874 . . . . 0.0 109.46 -175.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -103.56 7.56 37.67 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.699 -176.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -83.25 -177.93 6.91 Favored 'General case' 0 C--O 1.247 0.954 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.537 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.426 ' O ' HG23 ' A' ' 91' ' ' ILE . 63.9 tt0 -133.32 128.3 35.41 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-N 115.112 -0.949 . . . . 0.0 108.746 -177.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.508 HG23 HG23 ' A' ' 63' ' ' VAL . 49.4 mm -76.83 109.99 11.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -176.165 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.677 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 88.1 t -92.64 -47.66 13.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 CA-C-O 121.242 0.544 . . . . 0.0 111.137 -176.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.532 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 38.7 tt0 -155.2 102.17 2.28 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-O 121.623 0.725 . . . . 0.0 110.541 -178.456 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.508 HG23 HG23 ' A' ' 60' ' ' ILE . 4.8 t -94.61 129.3 45.02 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 O-C-N 121.921 -0.487 . . . . 0.0 111.089 177.095 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 38.5 t70 65.32 11.72 7.52 Favored 'General case' 0 N--CA 1.487 1.394 0 CA-C-O 122.234 1.016 . . . . 0.0 111.55 172.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 80.35 15.47 78.31 Favored Glycine 0 N--CA 1.441 -1.026 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.084 -178.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.5 HD13 HG22 ' A' ' 79' ' ' VAL . 6.2 tt -76.41 -20.53 15.07 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.798 0 CA-C-O 121.215 0.531 . . . . 0.0 110.683 -177.694 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.529 ' H ' ' HG3' ' A' ' 62' ' ' GLU 0.267 13.1 p 47.97 76.48 0.11 Allowed 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 124.708 1.203 . . . . 0.0 113.879 -177.048 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.502 ' H ' HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -88.9 32.2 0.82 Allowed 'General case' 0 N--CA 1.432 -1.367 0 CA-C-N 114.432 -1.258 . . . . 0.0 111.287 -177.063 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 46.3 t -69.69 95.81 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 CA-C-N 114.799 -1.092 . . . . 0.0 110.385 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.416 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 105.44 19.74 10.24 Favored Glycine 0 C--N 1.31 -0.901 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.574 176.174 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.455 HG21 ' HB2' ' A' ' 68' ' ' LEU . 23.9 m -93.1 179.21 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 177.496 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.9 p -94.54 171.0 9.07 Favored 'General case' 0 N--CA 1.416 -2.163 0 CA-C-O 121.221 0.534 . . . . 0.0 110.349 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.51 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.17 -34.64 70.53 Favored 'General case' 0 C--N 1.294 -1.814 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.916 178.126 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.27 -36.97 74.75 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.332 -178.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.491 ' O ' HG23 ' A' ' 79' ' ' VAL . 45.9 t80 -66.99 -49.42 65.41 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.178 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.48 -45.58 93.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.758 -179.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -64.11 -16.84 62.67 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 120.915 0.388 . . . . 0.0 111.425 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 66.3 m -85.93 -44.81 12.08 Favored 'General case' 0 N--CA 1.426 -1.631 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.625 174.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.5 HG22 HD13 ' A' ' 66' ' ' ILE . 47.1 t -58.11 -51.5 70.15 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.627 0 N-CA-C 110.091 -0.336 . . . . 0.0 110.091 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -70.24 3.21 3.01 Favored 'General case' 0 CA--C 1.556 1.194 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.769 179.08 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 1.3 tmt_? -114.95 -17.76 11.43 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 123.373 0.669 . . . . 0.0 109.682 177.186 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -92.0 -7.46 48.83 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.279 0.632 . . . . 0.0 110.319 177.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.448 HG23 ' O ' ' A' ' 79' ' ' VAL . 2.5 p -64.5 161.48 17.21 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 115.061 -0.972 . . . . 0.0 113.444 -177.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 43.5 mmtm -113.42 -163.41 0.86 Allowed 'General case' 0 C--N 1.293 -1.875 0 CA-C-N 114.434 -1.257 . . . . 0.0 109.282 -178.066 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.87 -60.4 6.14 Favored Glycine 0 N--CA 1.424 -2.113 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 171.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -76.39 106.93 8.31 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-O 121.2 0.524 . . . . 0.0 110.168 177.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.0 t -121.87 132.36 71.05 Favored 'Isoleucine or valine' 0 CA--C 1.484 -1.571 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 -178.005 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 79.5 mtt180 -102.42 96.77 7.15 Favored 'General case' 0 C--N 1.283 -2.314 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 173.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.415 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 90.5 m-85 -87.35 102.53 14.61 Favored 'General case' 0 CA--C 1.491 -1.312 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 177.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.677 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.1 t -90.99 90.87 3.42 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.625 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 177.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.426 HG23 ' O ' ' A' ' 59' ' ' GLN . 86.2 mt -104.12 156.49 5.64 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.689 0 CA-C-N 114.248 -1.342 . . . . 0.0 108.189 179.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.65 166.81 22.89 Favored Glycine 0 N--CA 1.406 -3.344 0 C-N-CA 119.42 -1.371 . . . . 0.0 110.926 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 46.1 ttp180 -142.59 141.32 31.95 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 . . . . . 0 N--CA 1.431 -1.414 0 N-CA-C 106.087 -1.82 . . . . 0.0 106.087 170.204 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.503 -0.718 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 72.3 m-70 -103.54 104.16 14.19 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 117.228 0.514 . . . . 0.0 110.761 179.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 57.3 tpp -119.91 134.13 55.34 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -104.71 111.43 24.14 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.49 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.2 mm? -90.11 136.12 33.24 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.481 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 20.8 p90 -145.99 140.63 15.76 Favored Pre-proline 0 C--N 1.303 -1.421 0 CA-C-O 121.079 0.466 . . . . 0.0 112.141 -178.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -81.4 126.58 5.51 Favored 'Trans proline' 0 C--O 1.248 1.022 0 C-N-CA 123.29 2.66 . . . . 0.0 113.081 177.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.405 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 26.2 t -120.83 102.87 13.01 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 175.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 37.4 tt0 -84.24 105.98 15.5 Favored 'General case' 0 N--CA 1.427 -1.592 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.634 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 12.9 tp -89.91 155.08 19.37 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 -174.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -120.29 93.05 3.92 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 175.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.553 ' HG2' HD23 ' A' ' 10' ' ' LEU . 2.5 mmmp? -89.65 176.16 6.97 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 115.278 1.584 . . . . 0.0 115.278 -179.304 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -77.25 168.33 20.23 Favored 'General case' 0 N--CA 1.428 -1.547 0 CA-C-N 111.934 -2.393 . . . . 0.0 107.435 -179.275 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -74.01 -10.48 59.68 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-O 121.217 0.532 . . . . 0.0 110.967 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -63.55 -33.16 74.97 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 172.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.4 -130.87 9.08 Favored Glycine 0 N--CA 1.413 -2.897 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.509 ' HG ' HG23 ' A' ' 19' ' ' ILE . 13.7 tp -103.5 -61.51 1.41 Allowed 'General case' 0 C--N 1.285 -2.219 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 -177.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.462 ' O ' ' HB ' ' A' ' 43' ' ' THR . . . 71.32 37.85 62.88 Favored Glycine 0 N--CA 1.429 -1.786 0 O-C-N 124.284 0.99 . . . . 0.0 112.854 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.509 HG23 ' HG ' ' A' ' 17' ' ' LEU . 15.5 pt -107.95 167.51 3.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 118.949 -1.101 . . . . 0.0 111.435 176.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.3 m -117.08 148.54 41.43 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 -177.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -125.41 166.34 21.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -177.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 11.9 tt -130.35 132.15 65.03 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.877 0 C-N-CA 120.701 -0.4 . . . . 0.0 110.575 175.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.513 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.61 95.77 2.13 Favored Glycine 0 N--CA 1.424 -2.14 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.589 -178.58 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 95.1 mmm -109.3 173.72 6.19 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 176.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -130.31 61.74 0.66 Allowed Glycine 0 C--N 1.292 -1.916 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 177.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.43 HG12 ' HA2' ' A' ' 36' ' ' GLY . 10.7 p -69.17 133.4 31.93 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.394 0.616 . . . . 0.0 110.246 -177.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 78.06 0.45 76.35 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 115.848 -0.615 . . . . 0.0 113.277 178.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.49 -58.64 3.22 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 117.733 0.766 . . . . 0.0 110.517 -178.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -66.46 -29.96 70.2 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.515 178.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.64 -31.41 72.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.471 178.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 119.26 5.57 11.4 Favored Glycine 0 C--O 1.239 0.431 0 C-N-CA 119.389 -1.386 . . . . 0.0 114.851 176.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 4.4 mp -92.51 -47.82 6.94 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 117.386 0.593 . . . . 0.0 109.949 -178.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 60.01 82.86 0.15 Allowed 'General case' 0 C--O 1.248 1.001 0 C-N-CA 124.446 1.098 . . . . 0.0 111.081 -172.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 26.2 ttmt -128.41 176.26 7.86 Favored 'General case' 0 N--CA 1.385 -3.71 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 178.085 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.436 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.0 OUTLIER -68.74 147.65 51.5 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 120.806 0.336 . . . . 0.0 110.153 -178.718 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.43 ' HA2' HG12 ' A' ' 26' ' ' VAL . . . -124.07 25.13 6.15 Favored Glycine 0 N--CA 1.414 -2.771 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 174.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.513 HD13 ' HA2' ' A' ' 23' ' ' GLY . 33.4 mm -85.02 100.71 8.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 121.525 0.679 . . . . 0.0 109.524 -179.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -97.43 164.39 12.47 Favored 'General case' 0 C--N 1.278 -2.502 0 CA-C-N 115.252 -0.885 . . . . 0.0 108.917 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.565 ' HB ' ' O ' ' A' ' 56' ' ' VAL . 39.7 t -78.83 127.98 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.19 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 176.2 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 55.6 tptt -89.13 -44.13 10.55 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -178.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -161.18 162.82 31.42 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 89.1 t -127.35 152.52 35.49 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.167 0 N-CA-C 106.223 -1.769 . . . . 0.0 106.223 178.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.462 ' HB ' ' O ' ' A' ' 18' ' ' GLY . 10.6 t -63.6 143.63 57.67 Favored 'General case' 0 N--CA 1.428 -1.557 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.648 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.597 ' HA ' ' NE2' ' A' ' 49' ' ' GLN . 34.7 tt0 -79.54 -52.44 8.01 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -176.269 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -104.29 64.61 0.34 Allowed Glycine 0 CA--C 1.455 -3.707 0 CA-C-N 114.556 -1.202 . . . . 0.0 110.889 -178.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -145.33 148.51 20.3 Favored Glycine 1 N--CA 1.366 -6.002 0 N-CA-C 105.569 -3.012 . . . . 0.0 105.569 172.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.458 ' HA ' ' CG ' ' A' ' 50' ' ' ARG . . . -58.73 0.87 0.07 Allowed 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 115.542 1.682 . . . . 0.0 115.542 -175.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.97 -50.38 16.86 Favored 'General case' 0 C--O 1.215 -0.728 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.597 ' NE2' ' HA ' ' A' ' 44' ' ' GLU . 27.7 mt-30 -80.54 -3.59 50.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 120.285 -0.566 . . . . 0.0 111.101 176.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.458 ' CG ' ' HA ' ' A' ' 47' ' ' ALA . 36.1 mmt180 -82.65 -39.09 22.56 Favored 'General case' 0 CA--C 1.507 -0.691 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 171.283 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -53.83 -60.42 3.35 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 114.856 -1.065 . . . . 0.0 112.088 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.48 -17.56 56.55 Favored Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 120.316 -0.945 . . . . 0.0 114.353 175.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.432 ' HE ' ' C ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -88.69 -46.77 8.75 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.68 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.0 tt -73.67 145.13 11.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . 0.419 ' HB2' ' OD1' ' A' ' 58' ' ' ASP . 35.6 mt-30 -138.79 -172.66 3.36 Favored 'General case' 0 C--N 1.316 -0.868 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.843 -176.26 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.565 ' O ' ' HB ' ' A' ' 39' ' ' VAL . 49.0 t -93.22 -34.55 5.94 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.104 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.413 -178.258 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -92.24 20.67 5.79 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -174.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.419 ' OD1' ' HB2' ' A' ' 55' ' ' GLN . 4.2 m-20 -101.75 -172.9 2.23 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.967 177.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.467 ' O ' HG23 ' A' ' 91' ' ' ILE . 63.7 tt0 -128.54 126.51 40.52 Favored 'General case' 0 C--N 1.313 -0.995 0 O-C-N 122.089 -0.382 . . . . 0.0 111.328 -175.137 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.526 ' HA ' HG12 ' A' ' 91' ' ' ILE . 48.2 mm -74.93 104.36 3.27 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.016 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.749 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.2 t -91.41 -50.15 12.85 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-O 121.694 0.759 . . . . 0.0 111.315 -175.166 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.528 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 32.1 tt0 -149.0 105.74 3.56 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.398 0.618 . . . . 0.0 110.226 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.433 HG23 HG23 ' A' ' 60' ' ' ILE . 3.0 t -98.02 126.98 50.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.146 177.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 26.9 t70 71.42 -9.96 0.86 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 125.599 1.56 . . . . 0.0 112.702 173.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 103.61 12.96 29.21 Favored Glycine 0 N--CA 1.424 -2.151 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.126 -175.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.569 HD13 HG22 ' A' ' 79' ' ' VAL . 11.0 tt -72.98 -18.07 18.24 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-O 121.077 0.465 . . . . 0.0 111.198 -178.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.511 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 29.6 p 50.87 81.41 0.07 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.985 1.314 . . . . 0.0 112.92 -175.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.489 HD21 HG22 ' A' ' 60' ' ' ILE . 1.8 pp -96.12 14.91 22.33 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-O 122.092 0.948 . . . . 0.0 109.94 -176.114 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 61.2 t -57.62 98.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.427 174.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.436 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 103.51 35.03 3.68 Favored Glycine 0 N--CA 1.438 -1.223 0 CA-C-N 115.54 -0.754 . . . . 0.0 112.457 176.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.438 HG22 ' O ' ' A' ' 68' ' ' LEU . 20.6 m -115.02 177.55 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 117.14 0.47 . . . . 0.0 111.221 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 12.9 p -91.31 172.56 8.45 Favored 'General case' 0 N--CA 1.433 -1.318 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.605 178.609 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.445 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -65.37 -32.04 73.47 Favored 'General case' 0 C--O 1.205 -1.24 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.232 -178.638 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -71.58 -35.4 70.53 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 120.861 -0.336 . . . . 0.0 110.985 -178.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.493 ' O ' HG23 ' A' ' 79' ' ' VAL . 29.7 t80 -65.86 -52.19 52.39 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 176.472 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.83 -46.27 89.79 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.135 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.04 -33.96 69.56 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.795 0.331 . . . . 0.0 110.73 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 97.8 m -68.07 -45.57 73.46 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.069 176.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.569 HG22 HD13 ' A' ' 66' ' ' ILE . 32.7 t -61.56 -51.85 67.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 C-N-CA 122.632 0.373 . . . . 0.0 110.902 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.408 HD21 HG21 ' A' ' 60' ' ' ILE . 3.4 mm? -68.52 -4.57 15.59 Favored 'General case' 0 CA--C 1.542 0.65 0 CA-C-O 121.237 0.541 . . . . 0.0 112.364 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.403 ' HD3' ' C ' ' A' ' 81' ' ' ARG . 0.7 OUTLIER -99.73 -32.52 11.0 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.218 0.533 . . . . 0.0 109.796 172.868 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 8.7 m-80 -80.13 6.68 10.99 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 121.794 0.807 . . . . 0.0 111.856 -178.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.0 p -70.61 170.21 12.69 Favored 'General case' 0 N--CA 1.408 -2.551 0 CA-C-N 114.536 -1.211 . . . . 0.0 111.562 175.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.436 ' HE3' ' O ' ' A' ' 86' ' ' ASN . 0.0 OUTLIER -147.81 -161.3 1.31 Allowed 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 124.898 1.279 . . . . 0.0 107.831 -175.036 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -55.88 -75.15 0.26 Allowed Glycine 0 CA--C 1.525 0.696 0 O-C-N 123.524 0.515 . . . . 0.0 114.016 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.634 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.5 m120 -88.79 105.93 18.03 Favored 'General case' 0 CA--C 1.497 -1.061 0 CA-C-N 117.637 0.718 . . . . 0.0 111.482 -177.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.513 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.9 t -116.22 136.29 53.68 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.09 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.994 -175.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 46.8 mtp180 -92.89 99.97 12.52 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 175.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.503 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 97.3 m-85 -92.38 103.26 15.72 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 176.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.749 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 40.3 t -92.45 86.52 2.28 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.858 0 N-CA-C 104.984 -2.228 . . . . 0.0 104.984 175.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.526 HG12 ' HA ' ' A' ' 60' ' ' ILE . 64.1 mt -101.25 159.11 4.05 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 CA-C-N 113.989 -1.46 . . . . 0.0 109.174 -179.2 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.49 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -130.61 158.04 22.36 Favored Glycine 1 N--CA 1.385 -4.724 0 C-N-CA 119.85 -1.167 . . . . 0.0 110.329 176.83 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 4.9 tpp180 -133.31 138.79 46.54 Favored 'General case' 0 C--N 1.286 -2.154 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 . . . . . 0 N--CA 1.416 -2.167 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.051 174.098 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.289 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 39.6 m-70 69.53 102.64 0.06 Allowed 'General case' 0 CA--C 1.503 -0.844 0 C-N-CA 124.373 1.069 . . . . 0.0 113.354 -178.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 25.3 ttt 68.92 115.45 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 O-C-N 124.614 1.196 . . . . 0.0 112.361 176.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.431 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 32.0 tt0 -92.45 108.72 20.18 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.567 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -88.14 126.99 35.41 Favored 'General case' 0 C--O 1.249 1.052 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -138.97 142.73 34.45 Favored Pre-proline 0 C--N 1.306 -1.316 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -176.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -79.27 125.85 6.62 Favored 'Trans proline' 0 C--O 1.25 1.122 0 C-N-CA 122.929 2.419 . . . . 0.0 113.357 177.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.44 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 46.5 t -118.71 105.2 17.23 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 174.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -88.71 102.45 15.0 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.536 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 15.3 tp -90.94 153.13 20.4 Favored 'General case' 0 N--CA 1.422 -1.827 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 -176.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -125.39 78.41 1.72 Allowed 'General case' 0 C--N 1.289 -2.049 0 CA-C-O 122.062 0.934 . . . . 0.0 108.757 177.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.674 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 5.5 mmtt -68.92 -169.72 0.19 Allowed 'General case' 0 N--CA 1.402 -2.842 0 CA-C-N 113.56 -1.654 . . . . 0.0 113.047 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.478 ' H ' ' HD2' ' A' ' 12' ' ' LYS . 9.1 m-20 -91.79 176.37 6.55 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 124.619 1.168 . . . . 0.0 108.346 -174.231 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -63.61 -22.46 66.91 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -176.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -72.0 -32.53 67.29 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.62 0.724 . . . . 0.0 110.151 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.404 ' O ' ' HD2' ' A' ' 12' ' ' LYS . . . 108.82 -140.07 15.45 Favored Glycine 0 N--CA 1.414 -2.831 0 N-CA-C 107.49 -2.244 . . . . 0.0 107.49 -173.21 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.51 ' HB3' HG23 ' A' ' 19' ' ' ILE . 14.7 mt -91.18 -60.9 1.78 Allowed 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.208 179.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.58 33.92 60.45 Favored Glycine 0 N--CA 1.424 -2.117 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -173.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.51 HG23 ' HB3' ' A' ' 17' ' ' LEU . 30.6 pt -96.56 177.78 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 C-N-CA 120.369 -0.532 . . . . 0.0 111.018 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.4 m -120.4 150.11 41.3 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 115.252 -0.885 . . . . 0.0 109.092 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.465 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -125.84 162.98 28.17 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 -179.038 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.8 tt -136.13 126.31 41.1 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.256 176.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.578 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -85.37 104.95 2.86 Favored Glycine 0 N--CA 1.435 -1.38 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.657 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.583 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 89.6 mmm -120.98 88.92 3.03 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -56.11 112.09 3.0 Favored Glycine 0 C--N 1.314 -0.689 0 O-C-N 123.918 0.761 . . . . 0.0 112.528 -177.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.8 p -111.76 38.09 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 CA-C-O 123.284 1.516 . . . . 0.0 108.239 -178.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -62.09 130.87 45.07 Favored Glycine 0 N--CA 1.442 -0.922 0 CA-C-N 113.612 -1.631 . . . . 0.0 112.313 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.417 ' HA ' ' HG2' ' A' ' 33' ' ' GLU . . . 71.64 -47.2 0.66 Allowed 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 126.104 1.761 . . . . 0.0 113.679 179.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -73.13 5.57 3.36 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -176.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.31 -12.37 21.6 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 173.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 81.77 -53.24 4.69 Favored Glycine 0 C--N 1.335 0.481 0 CA-C-O 121.952 0.751 . . . . 0.0 111.342 -177.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.2 mp -78.2 -25.5 47.1 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 114.512 -0.844 . . . . 0.0 110.399 -179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.417 ' HG2' ' HA ' ' A' ' 28' ' ' ALA . 39.8 mt-10 55.85 92.12 0.03 OUTLIER 'General case' 0 C--N 1.349 0.567 0 C-N-CA 123.989 0.916 . . . . 0.0 111.261 -170.485 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.471 ' HD3' ' H ' ' A' ' 34' ' ' LYS . 0.1 OUTLIER -134.06 -176.02 4.05 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 177.855 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.49 HD12 ' HB ' ' A' ' 37' ' ' ILE . 1.1 pt? -58.97 161.01 5.34 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 124.136 0.897 . . . . 0.0 111.122 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.583 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -122.07 26.6 6.39 Favored Glycine 0 N--CA 1.417 -2.609 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 173.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.578 HD13 ' HA2' ' A' ' 23' ' ' GLY . 17.9 mm -85.36 101.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 121.547 0.689 . . . . 0.0 109.981 -178.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -95.12 161.93 13.92 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.315 179.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -77.6 122.85 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.202 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -85.54 -49.79 7.76 Favored 'General case' 0 C--N 1.291 -1.96 0 CA-C-O 121.333 0.587 . . . . 0.0 110.501 -177.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.434 ' O ' ' HB ' ' A' ' 19' ' ' ILE . 0.7 OUTLIER -150.84 156.49 41.34 Favored 'General case' 0 N--CA 1.421 -1.876 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.59 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 64.8 t -125.88 145.96 32.45 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.431 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 176.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 8.4 t -56.84 147.99 21.92 Favored 'General case' 0 C--O 1.253 1.289 0 O-C-N 123.556 0.535 . . . . 0.0 109.773 176.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -43.83 -68.62 0.18 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 126.73 2.012 . . . . 0.0 115.126 -169.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -154.35 53.17 0.45 Allowed Glycine 0 CA--C 1.471 -2.701 0 C-N-CA 118.828 -1.653 . . . . 0.0 113.756 -174.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -94.83 -165.26 35.66 Favored Glycine 1 N--CA 1.386 -4.664 0 N-CA-C 107.298 -2.321 . . . . 0.0 107.298 169.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.674 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . -74.82 33.54 0.1 Allowed 'General case' 0 C--N 1.27 -2.849 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -173.122 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.403 ' HA ' HD21 ' A' ' 10' ' ' LEU . . . -116.56 -65.56 1.17 Allowed 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 174.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -74.09 -26.06 60.15 Favored 'General case' 0 N--CA 1.464 0.239 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.111 175.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.561 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 2.0 mmp_? -69.09 -26.94 65.18 Favored 'General case' 0 CA--C 1.503 -0.828 0 CA-C-O 121.053 0.454 . . . . 0.0 110.058 173.128 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -73.74 -57.18 4.16 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 178.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.09 -20.73 48.79 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.505 -0.855 . . . . 0.0 114.262 174.68 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.52 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -73.66 -22.86 59.83 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-O 121.648 0.737 . . . . 0.0 109.114 -177.757 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.8 tt -104.85 148.98 8.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 26.7 mm-40 -129.54 165.98 20.6 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-O 121.168 0.509 . . . . 0.0 111.906 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -83.45 -8.94 11.49 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.892 0 CA-C-O 122.166 0.984 . . . . 0.0 108.621 176.195 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -102.43 16.85 25.1 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 122.286 1.041 . . . . 0.0 109.443 -175.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -102.05 -179.62 4.05 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.009 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.493 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 33.4 tt0 -128.72 124.96 36.93 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.477 HG22 HD11 ' A' ' 68' ' ' LEU . 46.1 mm -76.36 95.39 1.24 Allowed 'Isoleucine or valine' 0 C--O 1.206 -1.192 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 -176.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.697 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 60.6 t -79.42 -42.09 22.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 CA-C-O 121.59 0.71 . . . . 0.0 111.159 -175.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.562 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 36.8 tt0 -151.07 131.14 13.44 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.401 HG23 ' CG2' ' A' ' 60' ' ' ILE . 4.0 t -123.51 126.05 72.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 172.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 24.3 t70 69.47 5.47 5.18 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-O 122.356 1.074 . . . . 0.0 111.804 172.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.99 13.3 62.44 Favored Glycine 0 N--CA 1.434 -1.493 0 CA-C-N 115.362 -0.836 . . . . 0.0 111.624 -176.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.405 HD13 HG22 ' A' ' 79' ' ' VAL . 7.2 tt -77.34 -16.73 14.41 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.774 0 O-C-N 122.793 -0.239 . . . . 0.0 110.44 -178.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.467 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 8.6 m 39.74 80.67 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.985 1.714 . . . . 0.0 112.7 -176.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.498 ' H ' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -89.53 31.82 0.9 Allowed 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 122.216 1.007 . . . . 0.0 111.959 -175.606 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 47.8 t -70.52 106.16 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.075 0 CA-C-N 115.199 -0.91 . . . . 0.0 109.288 178.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.93 15.89 20.81 Favored Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.913 176.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.444 HG22 ' O ' ' A' ' 68' ' ' LEU . 19.1 m -96.63 175.83 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.973 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.711 178.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 8.4 p -91.54 172.86 8.22 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.99 178.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.465 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -61.24 -33.65 73.86 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.509 -179.488 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.9 p30 -73.09 -33.05 65.38 Favored 'General case' 0 CA--C 1.512 -0.507 0 C-N-CA 121.072 -0.251 . . . . 0.0 111.568 -176.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 33.4 t80 -69.94 -49.71 49.14 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 176.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -58.1 -49.22 77.7 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.516 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -55.87 -36.7 67.89 Favored 'General case' 0 C--O 1.216 -0.682 0 C-N-CA 122.467 0.307 . . . . 0.0 110.957 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 86.9 m -63.39 -45.51 90.75 Favored 'General case' 0 CA--C 1.55 0.957 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.086 176.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.405 HG22 HD13 ' A' ' 66' ' ' ILE . 31.0 t -65.1 -49.92 76.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.663 0.268 . . . . 0.0 110.788 178.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -69.77 -4.87 21.83 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.224 0.61 . . . . 0.0 111.993 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.41 ' HB3' ' O ' ' A' ' 78' ' ' THR . 59.5 ttt180 -92.15 -46.62 7.67 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 124.055 0.942 . . . . 0.0 108.541 174.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -77.41 5.68 8.33 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.326 -1.306 . . . . 0.0 113.366 -174.322 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.476 ' OG1' ' HG ' ' A' ' 17' ' ' LEU . 16.8 p -63.45 154.19 32.97 Favored 'General case' 0 C--N 1.294 -1.806 0 C-N-CA 123.832 0.853 . . . . 0.0 112.711 176.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.0 mmtt -120.24 -161.92 0.91 Allowed 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 114.567 -1.197 . . . . 0.0 108.501 176.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.05 -68.03 1.89 Allowed Glycine 0 N--CA 1.444 -0.824 0 O-C-N 123.818 0.699 . . . . 0.0 111.901 176.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.536 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 18.7 m120 -83.06 118.57 23.63 Favored 'General case' 0 C--N 1.307 -1.268 0 O-C-N 122.244 -0.562 . . . . 0.0 110.635 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.442 HG21 HD21 ' A' ' 17' ' ' LEU . 4.4 t -130.75 130.0 64.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.504 -176.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 22.1 mtp180 -94.33 100.59 12.6 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-O 121.186 0.517 . . . . 0.0 110.917 174.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.496 ' HB3' HG13 ' A' ' 91' ' ' ILE . 89.0 m-85 -95.12 112.0 23.76 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 176.101 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.697 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 10.7 t -100.48 65.54 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.496 HG13 ' HB3' ' A' ' 89' ' ' PHE . 76.4 mt -77.14 153.8 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.516 0 CA-C-N 112.796 -2.002 . . . . 0.0 109.909 -177.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.567 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -131.07 149.3 19.15 Favored Glycine 1 N--CA 1.385 -4.709 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 177.386 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -111.25 133.0 53.92 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 -178.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 . . . . . 0 C--N 1.309 -1.185 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 177.968 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.498 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -92.7 161.67 14.46 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 175.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . 0.408 ' O ' HD22 ' A' ' 5' ' ' LEU . 22.5 ttt -164.65 138.99 5.28 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 177.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -90.9 101.37 14.13 Favored 'General case' 0 C--N 1.294 -1.828 0 C-N-CA 119.396 -0.922 . . . . 0.0 108.898 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.527 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -87.86 125.17 34.33 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -132.02 140.66 38.81 Favored Pre-proline 0 C--N 1.287 -2.112 0 CA-C-O 121.461 0.648 . . . . 0.0 112.061 -176.286 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -83.11 125.85 4.18 Favored 'Trans proline' 0 C--N 1.301 -1.927 0 C-N-CA 122.535 2.157 . . . . 0.0 112.188 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.472 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 36.9 t -109.04 109.05 26.89 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.593 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 172.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.47 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 45.3 tt0 -92.89 103.23 15.58 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.51 HD21 ' HB2' ' A' ' 51' ' ' ASP . 0.5 OUTLIER -103.38 154.21 19.65 Favored 'General case' 0 N--CA 1.395 -3.182 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 -175.669 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.45 ' H ' HD23 ' A' ' 10' ' ' LEU . 42.2 tt0 -123.06 100.56 6.94 Favored 'General case' 0 N--CA 1.409 -2.483 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 177.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.65 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.3 mmmp? -92.48 178.92 5.67 Favored 'General case' 0 C--N 1.284 -2.282 0 CA-C-N 114.524 -1.217 . . . . 0.0 109.486 176.254 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.547 ' OD2' ' HG2' ' A' ' 14' ' ' GLU . 19.6 t70 -101.41 -160.01 0.77 Allowed 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -176.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.547 ' HG2' ' OD2' ' A' ' 13' ' ' ASP . 11.0 pt-20 -75.77 -13.08 60.29 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -171.305 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -71.07 -43.9 66.84 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.213 0.53 . . . . 0.0 110.254 177.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 125.1 -131.02 7.57 Favored Glycine 0 CA--C 1.481 -2.066 0 N-CA-C 108.28 -1.928 . . . . 0.0 108.28 -177.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 14.3 mt -100.7 -60.94 1.43 Allowed 'General case' 0 CA--C 1.476 -1.902 0 C-N-CA 119.012 -1.075 . . . . 0.0 109.462 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.12 29.94 39.65 Favored Glycine 0 N--CA 1.419 -2.472 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -174.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.435 HD11 HD12 ' A' ' 80' ' ' LEU . 24.5 pt -104.54 176.87 0.94 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.987 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.4 m -135.42 150.08 49.78 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 -177.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.588 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -120.16 166.02 15.0 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 C-N-CA 123.303 0.641 . . . . 0.0 110.098 -177.242 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 11.9 tt -140.94 127.93 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.014 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 174.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.51 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.57 109.48 3.81 Favored Glycine 0 CA--C 1.484 -1.869 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -177.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.626 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 88.7 mmm -125.99 92.92 3.69 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -56.74 97.9 0.06 OUTLIER Glycine 0 CA--C 1.52 0.397 0 N-CA-C 114.77 0.668 . . . . 0.0 114.77 -175.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.6 p -91.11 41.48 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 CA-C-O 123.18 1.467 . . . . 0.0 108.732 178.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.35 105.39 2.9 Favored Glycine 0 N--CA 1.432 -1.625 0 CA-C-N 114.367 -1.288 . . . . 0.0 110.904 -179.202 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.599 ' H ' ' HG3' ' A' ' 33' ' ' GLU . . . 68.44 66.09 0.32 Allowed 'General case' 0 CA--C 1.493 -1.232 0 C-N-CA 125.016 1.326 . . . . 0.0 109.766 -178.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -134.81 -64.63 0.66 Allowed 'General case' 0 N--CA 1.428 -1.538 0 CA-C-N 114.578 -1.192 . . . . 0.0 111.47 -174.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.36 9.94 7.3 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 -171.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.27 -7.93 48.07 Favored Glycine 0 CA--C 1.502 -0.721 0 C-N-CA 119.194 -1.479 . . . . 0.0 112.505 178.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.4 mp -80.61 -46.34 15.84 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.599 ' HG3' ' H ' ' A' ' 28' ' ' ALA . 0.4 OUTLIER 40.27 70.63 0.23 Allowed 'General case' 0 C--N 1.348 0.517 0 C-N-CA 124.871 1.268 . . . . 0.0 113.616 178.05 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 17.8 ptmt -160.02 -163.42 1.13 Allowed 'General case' 0 N--CA 1.424 -1.751 0 CA-C-N 115.158 -0.928 . . . . 0.0 108.94 -174.238 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.489 HD12 ' H ' ' A' ' 37' ' ' ILE . 2.3 pp -56.95 150.54 16.53 Favored 'General case' 0 N--CA 1.44 -0.927 0 O-C-N 124.175 0.922 . . . . 0.0 109.183 174.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.626 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -121.98 30.62 5.21 Favored Glycine 0 N--CA 1.422 -2.281 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.75 178.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.51 HD13 ' HA2' ' A' ' 23' ' ' GLY . 23.5 mm -82.25 103.65 9.74 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 CA-C-O 121.847 0.832 . . . . 0.0 110.537 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -99.32 164.33 12.16 Favored 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 41.0 t -82.6 131.04 34.69 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.484 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 177.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.556 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.4 OUTLIER -91.7 -45.39 8.47 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.137 0.494 . . . . 0.0 109.832 -178.692 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.0 m -154.66 162.24 41.21 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -127.11 160.98 35.13 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.15 0 N-CA-C 105.363 -2.088 . . . . 0.0 105.363 178.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.6 t -72.51 146.21 46.96 Favored 'General case' 0 C--N 1.293 -1.883 0 CA-C-O 121.908 0.861 . . . . 0.0 111.007 -178.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -102.78 -0.33 31.64 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-O 123.742 1.734 . . . . 0.0 107.305 176.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -70.28 -30.27 69.54 Favored Glycine 0 C--N 1.294 -1.776 0 CA-C-N 112.541 -2.118 . . . . 0.0 114.467 -177.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 142.81 150.63 5.34 Favored Glycine 0 N--CA 1.426 -2.031 0 C-N-CA 119.351 -1.404 . . . . 0.0 113.217 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.65 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . 73.92 -34.86 0.29 Allowed 'General case' 0 C--N 1.311 -1.088 0 C-N-CA 126.822 2.049 . . . . 0.0 115.685 171.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.455 ' HB2' ' CE ' ' A' ' 12' ' ' LYS . . . -82.38 -56.79 3.68 Favored 'General case' 0 N--CA 1.488 1.461 0 CA-C-N 118.974 0.806 . . . . 0.0 110.91 -176.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -73.9 -16.99 61.09 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.561 0.696 . . . . 0.0 110.45 177.055 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.508 ' HA ' ' NE ' ' A' ' 50' ' ' ARG . 3.9 mmp_? -83.14 -17.03 44.42 Favored 'General case' 0 N--CA 1.432 -1.353 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.092 174.073 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.51 ' HB2' HD21 ' A' ' 10' ' ' LEU . 11.7 t70 -61.43 -61.75 2.32 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.964 0.411 . . . . 0.0 109.987 173.584 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.92 -9.86 74.75 Favored Glycine 0 N--CA 1.44 -1.073 0 C-N-CA 120.575 -0.821 . . . . 0.0 114.849 173.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -89.35 -45.35 9.55 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 178.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.7 tt -74.9 150.51 6.96 Favored 'Isoleucine or valine' 0 C--O 1.252 1.225 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 176.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -134.87 160.35 38.51 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.7 p -73.27 -17.0 17.7 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.139 0 CA-C-O 121.79 0.805 . . . . 0.0 109.743 176.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -90.32 -6.37 55.16 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.389 -173.327 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -95.07 -176.12 3.73 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 113.249 0.833 . . . . 0.0 113.249 -174.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.503 ' O ' HG23 ' A' ' 91' ' ' ILE . 32.4 tt0 -116.99 127.43 54.18 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.102 -174.365 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.521 HG23 HG23 ' A' ' 63' ' ' VAL . 50.4 mm -73.4 105.57 2.87 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.627 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.644 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 97.9 t -90.04 -49.46 13.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 CA-C-O 121.664 0.745 . . . . 0.0 111.008 -176.006 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.516 ' HG3' ' H ' ' A' ' 67' ' ' SER . 37.4 tt0 -151.99 104.15 2.96 Favored 'General case' 0 C--N 1.296 -1.751 0 CA-C-O 121.518 0.675 . . . . 0.0 109.834 -178.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.521 HG23 HG23 ' A' ' 60' ' ' ILE . 3.8 t -91.75 123.04 43.73 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.061 0 CA-C-O 121.322 0.582 . . . . 0.0 111.717 176.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 24.5 t70 65.86 4.66 3.05 Favored 'General case' 0 C--N 1.311 -1.067 0 C-N-CA 126.813 2.045 . . . . 0.0 112.769 174.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.98 12.34 57.84 Favored Glycine 0 N--CA 1.429 -1.771 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.613 -177.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.469 HD13 HG22 ' A' ' 79' ' ' VAL . 9.6 tt -73.01 -17.8 18.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-O 121.185 0.517 . . . . 0.0 110.408 -179.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.516 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 9.7 p 49.69 82.83 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 124.826 1.25 . . . . 0.0 113.259 -176.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.536 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.8 pp -93.03 14.43 17.78 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.572 -177.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.41 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 58.6 t -57.75 102.5 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.5 176.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.467 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 113.62 -5.25 24.54 Favored Glycine 0 N--CA 1.442 -0.941 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.433 176.198 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.536 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.5 m -83.98 178.15 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.247 0.925 0 CA-C-O 121.245 0.545 . . . . 0.0 111.69 -175.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.4 p -101.12 170.53 8.2 Favored 'General case' 0 N--CA 1.415 -2.18 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.116 176.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.588 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -56.13 -33.5 65.21 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-N 114.51 -1.223 . . . . 0.0 112.256 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -74.4 -22.36 59.2 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 111.744 0.275 . . . . 0.0 111.744 -177.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.426 ' O ' ' HB ' ' A' ' 78' ' ' THR . 38.6 t80 -80.85 -50.14 10.17 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 174.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.64 -47.99 80.71 Favored 'General case' 0 C--O 1.22 -0.459 0 CA-C-N 114.719 -1.128 . . . . 0.0 112.12 -178.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -56.74 -33.22 66.34 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 120.89 0.376 . . . . 0.0 110.687 179.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.426 ' HB ' ' O ' ' A' ' 75' ' ' PHE . 53.0 m -68.62 -47.15 67.4 Favored 'General case' 0 N--CA 1.435 -1.205 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.904 176.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.469 HG22 HD13 ' A' ' 66' ' ' ILE . 44.3 t -58.82 -50.27 79.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 110.097 -0.335 . . . . 0.0 110.097 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.435 HD12 HD11 ' A' ' 19' ' ' ILE . 3.6 mm? -67.67 -10.62 53.93 Favored 'General case' 0 CA--C 1.551 1.014 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.681 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 81' ' ' ARG . 0.8 OUTLIER -97.7 -23.05 16.11 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.256 0.551 . . . . 0.0 110.43 176.082 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -83.84 -23.18 31.47 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.092 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.4 p -63.99 156.62 27.42 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 113.646 0.98 . . . . 0.0 113.646 -178.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.75 -145.97 0.36 Allowed 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 114.685 -1.143 . . . . 0.0 109.764 -176.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.8 -67.64 1.91 Allowed Glycine 0 C--N 1.295 -1.719 0 O-C-N 123.671 0.607 . . . . 0.0 112.603 -177.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -77.25 109.73 11.37 Favored 'General case' 0 CA--C 1.497 -1.079 0 C-N-CA 119.937 -0.705 . . . . 0.0 110.118 178.657 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.5 t -124.09 144.53 33.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.82 98.26 7.78 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 173.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.472 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 86.5 m-85 -90.42 98.4 11.75 Favored 'General case' 0 C--N 1.279 -2.498 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 178.134 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.644 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 58.9 t -89.3 91.8 3.77 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.433 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 178.168 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.503 HG23 ' O ' ' A' ' 59' ' ' GLN . 81.6 mt -106.52 156.67 7.04 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.073 0 CA-C-N 114.0 -1.454 . . . . 0.0 108.096 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.527 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -134.25 164.47 24.53 Favored Glycine 1 N--CA 1.393 -4.182 0 C-N-CA 119.566 -1.302 . . . . 0.0 109.931 178.595 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -149.46 131.06 14.91 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . 0.26 0.0 OUTLIER . . . . . 0 N--CA 1.411 -2.377 0 CA-C-O 118.436 -0.792 . . . . 0.0 110.671 175.218 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.428 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 36.6 t60 68.59 138.73 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 124.682 1.193 . . . . 0.0 109.827 -175.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . 0.419 ' O ' HD22 ' A' ' 5' ' ' LEU . 24.8 ttt -84.75 103.79 14.15 Favored 'General case' 0 N--CA 1.427 -1.595 0 C-N-CA 119.142 -1.023 . . . . 0.0 109.472 -179.319 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -79.86 104.56 10.52 Favored 'General case' 0 C--N 1.295 -1.801 0 CA-C-N 114.792 -1.094 . . . . 0.0 108.597 -179.211 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.42 HD12 HG21 ' A' ' 61' ' ' VAL . 1.8 mm? -81.73 130.55 35.1 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 178.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -137.11 141.53 34.84 Favored Pre-proline 0 C--N 1.284 -2.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.324 -179.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -77.89 128.71 9.4 Favored 'Trans proline' 0 N--CA 1.443 -1.474 0 C-N-CA 122.368 2.046 . . . . 0.0 112.418 178.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.416 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 21.7 t -119.11 94.99 3.34 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.258 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 174.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.512 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 40.7 tt0 -78.33 112.44 15.34 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 175.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -97.43 123.07 41.15 Favored 'General case' 0 N--CA 1.405 -2.701 0 N-CA-C 105.444 -2.058 . . . . 0.0 105.444 178.617 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.456 ' HG3' ' OD1' ' A' ' 86' ' ' ASN . 30.9 tt0 -94.44 90.45 6.23 Favored 'General case' 0 C--N 1.281 -2.373 0 CA-C-O 121.839 0.828 . . . . 0.0 109.005 179.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 2.8 mmmp? -93.82 -175.4 3.72 Favored 'General case' 0 N--CA 1.428 -1.563 0 CA-C-N 114.263 -1.335 . . . . 0.0 111.778 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.57 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.5 p-10 -88.27 -172.42 3.78 Favored 'General case' 0 C--N 1.28 -2.452 0 C-N-CA 126.8 2.04 . . . . 0.0 112.384 -177.386 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -77.45 -20.21 54.82 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 114.705 -1.134 . . . . 0.0 111.577 -179.458 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.57 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 18.8 t70 -73.95 -35.64 64.55 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 118.25 -124.58 6.11 Favored Glycine 0 CA--C 1.486 -1.747 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.661 172.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.525 ' HB3' HG23 ' A' ' 19' ' ' ILE . 31.7 mt -112.76 -54.54 2.61 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.1 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.55 27.51 69.32 Favored Glycine 0 N--CA 1.425 -2.062 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.818 -173.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.525 HG23 ' HB3' ' A' ' 17' ' ' LEU . 27.0 pt -94.67 176.32 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.26 -178.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 49.0 m -132.33 150.31 52.18 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.882 -178.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -120.05 159.89 20.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 15.4 tt -124.13 132.01 72.01 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 C-N-CA 120.063 -0.655 . . . . 0.0 110.045 175.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.539 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.82 92.45 1.78 Allowed Glycine 0 N--CA 1.427 -1.94 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.852 -177.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 91.8 mmm -108.26 -179.07 3.78 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -133.59 93.16 0.26 Allowed Glycine 0 C--N 1.284 -2.354 0 C-N-CA 120.087 -1.054 . . . . 0.0 112.333 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.433 HG12 ' HA2' ' A' ' 36' ' ' GLY . 11.1 p -97.68 75.21 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 123.601 1.667 . . . . 0.0 110.08 174.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.34 -164.52 15.53 Favored Glycine 0 N--CA 1.41 -3.058 0 CA-C-N 113.746 -1.57 . . . . 0.0 110.394 -178.429 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.52 ' H ' ' HG2' ' A' ' 33' ' ' GLU . . . 62.17 -83.57 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 125.125 1.37 . . . . 0.0 112.299 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -93.72 -12.5 29.08 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-O 122.409 1.1 . . . . 0.0 109.405 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.419 ' C ' ' H ' ' A' ' 32' ' ' LEU . . . -95.65 99.86 11.66 Favored 'General case' 0 N--CA 1.399 -2.98 0 N-CA-C 104.265 -2.495 . . . . 0.0 104.265 174.712 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -45.59 20.34 0.0 OUTLIER Glycine 0 N--CA 1.497 2.755 0 C-N-CA 128.608 3.004 . . . . 0.0 118.972 -175.519 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' A' ' 30' ' ' ALA . 19.8 mt -106.13 -37.56 6.56 Favored 'General case' 0 C--N 1.278 -2.515 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.097 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.52 ' HG2' ' H ' ' A' ' 28' ' ' ALA . 44.2 mt-10 49.5 73.88 0.22 Allowed 'General case' 0 C--O 1.247 0.97 0 CA-C-N 115.128 -0.942 . . . . 0.0 113.508 -179.076 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 17.7 ptmt -154.52 -172.03 4.06 Favored 'General case' 0 N--CA 1.406 -2.662 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 -179.211 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.653 HD23 ' HA ' ' A' ' 69' ' ' VAL . 3.2 pp -63.02 152.35 37.17 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 124.31 1.006 . . . . 0.0 110.066 179.066 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.433 ' HA2' HG12 ' A' ' 26' ' ' VAL . . . -116.47 32.54 5.51 Favored Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 175.172 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.539 HD13 ' HA2' ' A' ' 23' ' ' GLY . 29.7 mm -81.31 103.87 9.01 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.867 0 CA-C-O 121.624 0.726 . . . . 0.0 110.14 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -102.21 160.16 14.76 Favored 'General case' 0 C--N 1.275 -2.645 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.296 176.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 40.5 t -74.32 123.97 30.84 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 175.293 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.405 ' HB2' ' HB ' ' A' ' 22' ' ' ILE . 53.5 tptt -89.29 -48.61 7.25 Favored 'General case' 0 C--N 1.293 -1.871 0 CA-C-O 121.118 0.485 . . . . 0.0 110.28 -176.762 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -150.25 159.15 44.65 Favored 'General case' 0 N--CA 1.422 -1.874 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -177.401 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.517 HG11 ' HG3' ' A' ' 49' ' ' GLN . 23.3 t -121.24 174.16 6.17 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.522 0 N-CA-C 104.894 -2.261 . . . . 0.0 104.894 175.296 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.413 ' N ' HG12 ' A' ' 42' ' ' VAL . 3.2 t -61.07 178.23 0.27 Allowed 'General case' 0 CA--C 1.561 1.377 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 173.831 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -56.01 -31.09 62.77 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 124.065 0.946 . . . . 0.0 110.251 176.771 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.527 ' HA2' HE21 ' A' ' 49' ' ' GLN . . . -169.64 -73.87 0.04 OUTLIER Glycine 0 N--CA 1.402 -3.627 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.752 178.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 55.13 -177.51 0.42 Allowed Glycine 1 N--CA 1.382 -4.931 0 CA-C-O 123.398 1.554 . . . . 0.0 113.003 -173.163 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.434 ' O ' ' HB2' ' A' ' 51' ' ' ASP . . . -71.26 -4.93 28.5 Favored 'General case' 1 C--N 1.237 -4.291 0 CA-C-N 113.398 -1.401 . . . . 0.0 109.977 172.445 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.57 -60.11 2.44 Favored 'General case' 0 C--N 1.35 0.59 0 C-N-CA 123.551 0.74 . . . . 0.0 110.059 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.527 HE21 ' HA2' ' A' ' 45' ' ' GLY . 26.5 mt-30 -70.5 -27.46 64.22 Favored 'General case' 0 CA--C 1.511 -0.536 0 C-N-CA 120.14 -0.624 . . . . 0.0 111.029 178.087 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -78.45 -19.5 53.01 Favored 'General case' 0 N--CA 1.44 -0.975 0 C-N-CA 120.04 -0.664 . . . . 0.0 111.778 175.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.434 ' HB2' ' O ' ' A' ' 47' ' ' ALA . 11.1 t70 -66.7 -64.01 0.94 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 172.058 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.89 -10.11 70.4 Favored Glycine 0 N--CA 1.44 -1.092 0 C-N-CA 120.557 -0.83 . . . . 0.0 115.13 173.561 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.08 -21.56 43.2 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -179.817 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.6 tt -105.05 164.59 3.91 Favored 'Isoleucine or valine' 0 C--O 1.254 1.305 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 175.164 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 63.1 mt-30 -136.17 -156.72 0.73 Allowed 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 119.033 0.833 . . . . 0.0 110.923 -177.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.2 p -123.94 18.21 4.77 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 174.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -132.91 -8.43 3.09 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.758 0.789 . . . . 0.0 111.206 -174.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.564 ' OD2' HD13 ' A' ' 91' ' ' ILE . 7.1 p-10 -83.18 179.24 7.78 Favored 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 124.571 1.148 . . . . 0.0 110.919 -177.357 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.46 ' O ' HG23 ' A' ' 91' ' ' ILE . 31.1 tt0 -119.76 126.08 50.18 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.087 -176.054 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.538 HG21 HD21 ' A' ' 80' ' ' LEU . 50.8 mm -74.36 114.71 14.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.089 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.701 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 84.7 t -98.37 -48.92 11.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.85 0.834 . . . . 0.0 111.022 -178.164 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.576 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 26.9 tt0 -150.28 114.88 5.23 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -178.614 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.48 HG23 HG23 ' A' ' 60' ' ' ILE . 3.4 t -110.1 128.13 66.51 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.821 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.589 178.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.7 t70 72.58 -8.84 1.15 Allowed 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 125.265 1.426 . . . . 0.0 112.348 175.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.83 13.43 31.98 Favored Glycine 0 C--N 1.286 -2.203 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.686 -174.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.4 tt -74.97 -17.44 16.2 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.498 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 17.4 m 45.83 84.56 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 125.659 1.584 . . . . 0.0 111.585 -176.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.535 HD21 HG22 ' A' ' 60' ' ' ILE . 0.7 OUTLIER -93.06 20.98 6.19 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.659 0.742 . . . . 0.0 110.671 -175.317 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.653 ' HA ' HD23 ' A' ' 35' ' ' LEU . 59.1 t -52.77 100.63 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 CA-C-N 114.691 -1.141 . . . . 0.0 111.77 177.474 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 94.59 21.7 25.89 Favored Glycine 0 N--CA 1.443 -0.844 0 CA-C-N 115.47 -0.786 . . . . 0.0 114.131 174.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.418 ' CG2' ' HB2' ' A' ' 68' ' ' LEU . 20.5 m -93.43 -178.66 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 117.497 0.649 . . . . 0.0 111.173 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.9 p -98.37 178.97 4.87 Favored 'General case' 0 C--O 1.251 1.146 0 CA-C-O 121.037 0.446 . . . . 0.0 110.377 177.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.92 -25.31 66.3 Favored 'General case' 0 C--O 1.204 -1.337 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.337 179.638 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 25.6 m-80 -63.02 -48.57 78.22 Favored 'General case' 0 CA--C 1.483 -1.603 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.183 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -68.61 -47.79 65.78 Favored 'General case' 0 N--CA 1.426 -1.633 0 CA-C-N 114.76 -1.109 . . . . 0.0 109.698 -175.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.438 ' HA ' HG12 ' A' ' 79' ' ' VAL . . . -62.94 -40.29 97.21 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.167 -178.738 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -69.08 -18.19 63.97 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.229 0.537 . . . . 0.0 110.426 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 83.3 m -84.01 -47.5 10.91 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.457 176.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.542 HG13 HD22 ' A' ' 80' ' ' LEU . 3.9 p -62.78 -48.6 87.36 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 N-CA-C 112.943 0.72 . . . . 0.0 112.943 177.323 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.542 HD22 HG13 ' A' ' 79' ' ' VAL . 3.9 mm? -67.2 -12.22 59.48 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.531 0.682 . . . . 0.0 112.056 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -84.47 -46.05 12.04 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 176.249 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -79.56 -11.09 59.89 Favored 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 114.388 1.255 . . . . 0.0 114.388 -171.188 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.434 HG23 ' O ' ' A' ' 79' ' ' VAL . 12.0 p -68.45 140.7 55.76 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -135.93 141.75 44.54 Favored 'General case' 0 CA--C 1.482 -1.659 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.096 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 47.67 -88.13 0.01 OUTLIER Glycine 0 CA--C 1.474 -2.508 0 O-C-N 126.039 2.087 . . . . 0.0 113.696 178.081 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.456 ' OD1' ' HG3' ' A' ' 11' ' ' GLU . 3.0 m-20 -97.94 102.0 13.63 Favored 'General case' 0 C--N 1.247 -3.849 0 CA-C-N 113.804 -1.198 . . . . 0.0 110.52 -173.283 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 40.2 t -113.15 124.82 70.16 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.094 0 CA-C-N 115.021 -0.991 . . . . 0.0 111.611 -173.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.59 104.18 16.61 Favored 'General case' 0 CA--C 1.49 -1.364 0 C-N-CA 120.204 -0.598 . . . . 0.0 109.944 174.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.416 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 90.9 m-85 -93.49 100.19 12.52 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 175.697 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.701 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.8 t -89.5 92.99 4.13 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.82 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 177.282 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.564 HD13 ' OD2' ' A' ' 58' ' ' ASP . 96.5 mt -108.62 163.84 5.79 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.375 0 C-N-CA 125.485 1.514 . . . . 0.0 107.494 179.486 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -133.75 159.82 23.83 Favored Glycine 0 N--CA 1.411 -2.97 0 C-N-CA 118.557 -1.782 . . . . 0.0 113.301 -177.146 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 35.5 ttt180 -114.32 137.41 51.84 Favored 'General case' 0 C--N 1.307 -1.281 0 C-N-CA 123.321 0.648 . . . . 0.0 109.533 177.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? . . . . . 0 C--N 1.294 -1.834 0 CA-C-O 119.395 -0.336 . . . . 0.0 110.976 -178.445 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.359 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 32.4 m-70 -83.68 103.33 12.9 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-O 121.066 0.46 . . . . 0.0 110.732 176.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . 0.537 ' SD ' ' HG3' ' A' ' 94' ' ' GLU . 57.3 tpp -70.42 127.47 32.84 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 177.221 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.473 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 35.2 tt0 -85.61 102.52 13.63 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 177.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -84.14 131.89 34.74 Favored 'General case' 0 CA--C 1.5 -0.963 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -140.58 138.5 18.73 Favored Pre-proline 0 N--CA 1.42 -1.971 0 CA-C-O 121.507 0.67 . . . . 0.0 112.012 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -81.47 124.27 4.64 Favored 'Trans proline' 0 C--N 1.314 -1.263 0 C-N-CA 122.856 2.37 . . . . 0.0 112.781 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.445 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 25.0 t -113.61 106.14 20.13 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 175.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.492 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 30.8 tt0 -89.64 109.13 20.11 Favored 'General case' 0 N--CA 1.416 -2.132 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 177.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -100.91 149.34 23.99 Favored 'General case' 0 C--N 1.289 -2.063 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 -176.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -120.44 93.03 3.91 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 171.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.491 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.0 mmmp? -82.73 172.86 12.43 Favored 'General case' 0 N--CA 1.421 -1.92 0 CA-C-O 122.63 1.205 . . . . 0.0 114.177 -179.046 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -72.78 171.23 13.03 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 112.077 -2.329 . . . . 0.0 108.564 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -68.83 -16.93 63.92 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.345 0.593 . . . . 0.0 110.373 178.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.05 -33.02 72.65 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 122.023 0.916 . . . . 0.0 109.986 174.462 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.59 -138.38 14.93 Favored Glycine 0 N--CA 1.41 -3.095 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.414 HD21 HG21 ' A' ' 87' ' ' VAL . 16.8 mt -89.46 -43.91 10.52 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 119.734 -0.786 . . . . 0.0 109.735 -179.445 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 66.64 28.0 73.52 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 124.547 1.155 . . . . 0.0 111.013 -174.23 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.475 HD11 HD12 ' A' ' 80' ' ' LEU . 20.7 pt -109.0 177.07 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.452 -178.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 20.0 m -138.64 153.81 48.61 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -177.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.411 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -122.39 166.72 16.76 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 -178.204 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 13.7 tt -135.08 133.57 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.79 0 C-N-CA 120.026 -0.67 . . . . 0.0 111.435 176.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.537 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -92.93 103.44 3.05 Favored Glycine 0 N--CA 1.413 -2.886 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 18.1 ptm -140.85 86.94 2.08 Favored 'General case' 0 C--N 1.288 -2.079 0 CA-C-O 121.584 0.707 . . . . 0.0 109.77 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -57.98 110.08 2.22 Favored Glycine 0 N--CA 1.44 -1.09 0 CA-C-N 114.066 -1.425 . . . . 0.0 112.966 -176.058 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.1 p -97.23 146.66 7.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -100.71 -151.9 25.65 Favored Glycine 0 N--CA 1.422 -2.291 0 C-N-CA 120.269 -0.967 . . . . 0.0 113.618 -177.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.431 ' CB ' ' HG2' ' A' ' 33' ' ' GLU . . . -90.7 -17.32 26.97 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.438 -0.881 . . . . 0.0 111.39 -177.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -66.44 -33.02 74.76 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 121.713 0.768 . . . . 0.0 110.171 -174.203 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -84.38 -5.1 59.24 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.403 -179.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 87.94 11.21 68.08 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.103 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.488 ' O ' ' HE3' ' A' ' 34' ' ' LYS . 4.0 mm? -88.81 -59.22 2.29 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 120.858 -0.337 . . . . 0.0 111.452 -179.208 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.431 ' HG2' ' CB ' ' A' ' 28' ' ' ALA . 40.1 mt-10 62.32 33.22 16.62 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.254 0.622 . . . . 0.0 111.669 177.05 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.488 ' HE3' ' O ' ' A' ' 32' ' ' LEU . 15.0 ptpt -155.02 -164.41 1.79 Allowed 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.814 -175.622 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.437 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 0.8 OUTLIER -48.8 150.02 1.6 Allowed 'General case' 0 C--O 1.24 0.597 0 C-N-CA 124.984 1.314 . . . . 0.0 112.6 179.457 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -120.02 47.43 1.03 Allowed Glycine 0 N--CA 1.413 -2.877 0 N-CA-C 109.961 -1.255 . . . . 0.0 109.961 175.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.584 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 28.9 mm -109.12 111.43 36.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 177.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -110.49 170.41 8.1 Favored 'General case' 0 C--N 1.269 -2.909 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.385 -178.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 38.9 t -83.47 128.21 39.0 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.076 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.574 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -92.92 -47.12 7.17 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 120.944 0.402 . . . . 0.0 110.165 -176.884 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.1 m -150.36 163.46 38.3 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 -178.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 61.0 t -136.38 148.4 27.29 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 N-CA-C 105.007 -2.22 . . . . 0.0 105.007 178.347 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.6 t -59.34 142.04 53.06 Favored 'General case' 0 C--O 1.251 1.176 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 175.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.542 ' HA ' ' NE2' ' A' ' 49' ' ' GLN . 12.0 pt-20 -82.77 -27.51 30.97 Favored 'General case' 0 C--N 1.277 -2.568 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.261 -175.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -137.42 70.8 0.48 Allowed Glycine 0 CA--C 1.471 -2.696 0 CA-C-O 122.1 0.833 . . . . 0.0 112.402 -175.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -150.42 170.21 30.34 Favored Glycine 1 N--CA 1.372 -5.583 0 N-CA-C 105.032 -3.227 . . . . 0.0 105.032 174.77 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.543 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -59.59 -3.66 0.51 Allowed 'General case' 0 C--N 1.277 -2.557 0 N-CA-C 114.825 1.417 . . . . 0.0 114.825 -176.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.43 -59.33 2.82 Favored 'General case' 0 C--O 1.219 -0.535 0 O-C-N 121.745 -0.597 . . . . 0.0 109.993 -176.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.542 ' NE2' ' HA ' ' A' ' 44' ' ' GLU . 41.2 mt-30 -74.34 -15.12 60.96 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.387 175.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.543 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 24.2 mmm180 -73.12 -34.02 65.88 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 172.219 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -59.53 -58.63 7.75 Favored 'General case' 0 N--CA 1.473 0.681 0 O-C-N 123.565 0.54 . . . . 0.0 109.813 173.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.82 -12.81 67.68 Favored Glycine 0 C--N 1.312 -0.782 0 C-N-CA 120.319 -0.943 . . . . 0.0 114.879 173.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 63.5 ttt180 -80.18 -40.77 26.59 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.09 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.4 tt -86.23 143.73 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.99 0 CA-C-N 114.335 -1.302 . . . . 0.0 107.857 179.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -138.5 175.85 9.21 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-O 121.258 0.551 . . . . 0.0 110.665 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.7 p -81.38 -3.25 6.57 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.49 -177.05 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -105.38 6.89 32.97 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.638 0.732 . . . . 0.0 110.545 -174.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -93.01 -173.66 3.34 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 115.186 -0.916 . . . . 0.0 111.08 -176.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.584 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 27.5 tt0 -131.86 127.45 36.56 Favored 'General case' 0 C--N 1.322 -0.608 0 C-N-CA 123.488 0.715 . . . . 0.0 111.001 -177.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.549 HG22 HD21 ' A' ' 68' ' ' LEU . 48.9 mm -77.21 106.45 7.29 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.852 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.45 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.72 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 95.1 t -89.18 -49.5 13.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-O 122.219 1.009 . . . . 0.0 110.116 -176.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.558 ' HG3' ' H ' ' A' ' 67' ' ' SER . 23.8 tt0 -148.64 126.84 12.13 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.496 179.225 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.431 HG23 HG23 ' A' ' 60' ' ' ILE . 2.7 t -118.37 127.69 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.641 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.118 176.216 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.9 t70 63.94 15.15 8.95 Favored 'General case' 0 N--CA 1.477 0.886 0 O-C-N 124.744 1.277 . . . . 0.0 111.081 173.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.93 17.32 67.83 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.855 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.437 HG21 HG21 ' A' ' 79' ' ' VAL . 6.1 tt -77.23 -18.68 14.34 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.156 0 CA-C-N 117.166 0.483 . . . . 0.0 111.283 -179.098 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.558 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 16.8 p 49.56 83.88 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.419 1.488 . . . . 0.0 113.126 -174.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.549 HD21 HG22 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.87 17.36 18.34 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.582 0.706 . . . . 0.0 110.805 -175.894 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 44.6 t -57.06 94.13 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.134 174.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.437 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 102.96 52.74 0.93 Allowed Glycine 0 N--CA 1.436 -1.355 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.866 178.29 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 23.5 m -130.05 178.71 4.93 Favored 'Isoleucine or valine' 0 C--O 1.243 0.723 0 CA-C-O 120.97 0.414 . . . . 0.0 111.107 178.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 15.5 p -98.31 174.61 6.41 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.425 178.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.411 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -67.45 -27.38 66.99 Favored 'General case' 0 C--O 1.2 -1.541 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.395 -178.61 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -71.81 -30.87 65.96 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.064 -179.383 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -74.64 -48.39 26.57 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 176.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.429 ' HA ' HG12 ' A' ' 79' ' ' VAL . . . -61.72 -42.15 98.57 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.733 -179.115 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.1 -33.22 71.8 Favored 'General case' 0 C--O 1.204 -1.32 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 177.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 92.0 m -71.67 -48.7 45.8 Favored 'General case' 0 N--CA 1.434 -1.25 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.185 178.658 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.591 HG13 HD22 ' A' ' 80' ' ' LEU . 3.4 p -62.23 -45.59 98.4 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 178.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.591 HD22 HG13 ' A' ' 79' ' ' VAL . 3.8 mm? -70.68 -7.82 47.4 Favored 'General case' 0 CA--C 1.549 0.918 0 CA-C-O 121.053 0.454 . . . . 0.0 111.597 178.283 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.9 tmt_? -97.44 -28.12 14.14 Favored 'General case' 0 C--O 1.214 -0.799 0 C-N-CA 122.73 0.412 . . . . 0.0 110.773 176.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -84.92 -2.52 57.96 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -177.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.0 p -76.82 159.85 29.74 Favored 'General case' 0 C--N 1.288 -2.072 0 CA-C-O 121.655 0.741 . . . . 0.0 112.866 -177.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 33.2 mmtp -118.39 -162.51 0.89 Allowed 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 114.931 -1.031 . . . . 0.0 108.639 177.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -53.04 -62.71 5.69 Favored Glycine 0 C--O 1.217 -0.953 0 O-C-N 123.846 0.716 . . . . 0.0 113.228 174.258 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.16 115.2 18.67 Favored 'General case' 0 C--O 1.245 0.867 0 CA-C-N 117.597 0.699 . . . . 0.0 110.014 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 3.0 t -132.24 136.43 56.44 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.907 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.213 -177.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 65.2 mtp180 -99.2 99.71 10.72 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 171.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.445 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 95.9 m-85 -90.31 102.78 15.51 Favored 'General case' 0 CA--C 1.486 -1.493 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 175.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.72 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 47.5 t -93.65 87.28 2.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.694 0 N-CA-C 105.326 -2.102 . . . . 0.0 105.326 178.164 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.473 HG23 ' O ' ' A' ' 59' ' ' GLN . 76.9 mt -104.11 153.22 6.24 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.785 0 CA-C-N 113.684 -1.598 . . . . 0.0 109.223 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -126.08 155.74 19.37 Favored Glycine 1 N--CA 1.384 -4.778 0 N-CA-C 108.405 -1.878 . . . . 0.0 108.405 177.135 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 64.7 ttt-85 -141.03 137.48 32.98 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 119.169 -1.012 . . . . 0.0 112.83 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.537 ' HG3' ' SD ' ' A' ' 3' ' ' MET . 39.6 mt-10 . . . . . 0 C--N 1.311 -1.102 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 173.585 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.502 -0.722 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -70.43 102.28 2.15 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 26.1 ttt 71.47 118.86 0.04 OUTLIER 'General case' 0 C--N 1.342 0.281 0 C-N-CA 124.389 1.076 . . . . 0.0 111.19 -178.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.446 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 45.5 tt0 -85.26 106.47 16.7 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -178.511 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.462 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.7 mm? -85.54 130.98 34.45 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 176.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -138.79 142.41 33.83 Favored Pre-proline 0 C--N 1.288 -2.065 0 CA-C-O 121.214 0.531 . . . . 0.0 111.802 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -83.87 123.48 3.23 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.667 2.244 . . . . 0.0 112.732 177.21 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.4 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 40.2 t -114.65 105.38 18.55 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 174.316 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.487 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 27.6 tt0 -93.7 97.54 10.52 Favored 'General case' 0 N--CA 1.417 -2.121 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 -179.384 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.496 HD21 ' HB2' ' A' ' 51' ' ' ASP . 0.5 OUTLIER -87.67 158.36 18.86 Favored 'General case' 0 N--CA 1.397 -3.105 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -174.778 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.421 ' H ' HD23 ' A' ' 10' ' ' LEU . 48.1 tt0 -124.04 98.93 6.01 Favored 'General case' 0 C--N 1.274 -2.681 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.229 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 85' ' ' GLY . 2.3 mmmp? -100.73 -170.0 1.79 Allowed 'General case' 0 N--CA 1.409 -2.512 0 CA-C-N 114.518 -1.219 . . . . 0.0 112.696 -179.791 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.56 157.12 36.02 Favored 'General case' 0 N--CA 1.413 -2.312 0 CA-C-N 113.03 -1.896 . . . . 0.0 106.534 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -72.48 -8.95 57.75 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 121.438 0.637 . . . . 0.0 110.253 176.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -72.22 -38.47 68.97 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 175.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.59 -145.14 16.74 Favored Glycine 0 N--CA 1.42 -2.411 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.624 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.404 HD11 HG21 ' A' ' 83' ' ' THR . 18.3 mt -104.53 -46.47 4.35 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.44 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.85 29.7 37.82 Favored Glycine 0 N--CA 1.422 -2.242 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.874 -175.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.2 pt -102.42 -174.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 120.059 -0.656 . . . . 0.0 112.357 -177.293 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 21.8 m -135.66 153.04 51.75 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.589 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -126.63 164.99 25.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 123.393 0.677 . . . . 0.0 109.336 -177.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.9 tt -135.41 130.02 50.17 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-O 120.811 0.338 . . . . 0.0 110.487 175.062 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.505 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.33 107.28 3.32 Favored Glycine 0 N--CA 1.428 -1.861 0 C-N-CA 121.085 -0.578 . . . . 0.0 112.029 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.405 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.2 mmm -121.94 174.53 6.84 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.645 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.58 99.36 0.59 Allowed Glycine 0 C--N 1.29 -1.989 0 C-N-CA 119.418 -1.372 . . . . 0.0 112.171 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.0 p -96.63 91.9 2.89 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-O 122.723 1.249 . . . . 0.0 110.4 176.583 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.484 ' HA2' ' HA ' ' A' ' 33' ' ' GLU . . . -105.21 -116.81 4.26 Favored Glycine 0 N--CA 1.423 -2.213 0 CA-C-N 114.804 -1.089 . . . . 0.0 114.58 -174.194 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.97 -23.59 62.24 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 113.377 0.88 . . . . 0.0 113.377 -171.559 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -66.11 -28.14 68.58 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.476 0.655 . . . . 0.0 111.227 -177.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.2 -22.14 13.44 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.159 177.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.29 27.7 17.29 Favored Glycine 0 CA--C 1.494 -1.223 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -178.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.454 ' HB3' ' HG2' ' A' ' 34' ' ' LYS . 31.1 mt -109.75 -64.78 1.21 Allowed 'General case' 0 N--CA 1.423 -1.798 0 C-N-CA 120.051 -0.659 . . . . 0.0 111.541 -174.226 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.484 ' HA ' ' HA2' ' A' ' 27' ' ' GLY . 47.4 mt-10 65.93 35.21 6.65 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 122.414 1.102 . . . . 0.0 111.689 -178.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.454 ' HG2' ' HB3' ' A' ' 32' ' ' LEU . 2.5 ptpp? -111.48 -162.64 0.81 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-N 114.672 -1.149 . . . . 0.0 107.905 174.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.507 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.0 pp -57.56 145.67 32.8 Favored 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 123.904 0.882 . . . . 0.0 109.906 177.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -116.8 33.71 4.95 Favored Glycine 0 C--N 1.288 -2.103 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 173.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.522 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 26.3 mm -84.58 105.49 13.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 121.407 0.622 . . . . 0.0 110.337 -177.09 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -99.25 162.98 12.74 Favored 'General case' 0 C--N 1.279 -2.46 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 177.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.89 128.01 38.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.407 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.542 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -91.74 -39.07 12.02 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.303 0.573 . . . . 0.0 110.455 -177.049 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.7 m -159.65 161.0 34.9 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.441 HG11 ' HG3' ' A' ' 49' ' ' GLN . 17.5 t -117.62 167.73 10.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.216 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.9 t -68.86 -179.25 1.4 Allowed 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 123.044 0.538 . . . . 0.0 109.965 178.566 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -50.93 -64.29 0.86 Allowed 'General case' 0 C--O 1.225 -0.219 0 C-N-CA 124.112 0.965 . . . . 0.0 112.021 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.436 ' HA2' ' HB2' ' A' ' 49' ' ' GLN . . . 169.25 52.31 0.03 OUTLIER Glycine 0 N--CA 1.414 -2.802 0 C-N-CA 118.244 -1.931 . . . . 0.0 113.621 179.628 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.73 -149.01 15.95 Favored Glycine 0 N--CA 1.408 -3.215 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 170.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.462 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -58.44 -14.17 7.14 Favored 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 -172.241 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.55 -62.56 1.65 Allowed 'General case' 0 C--O 1.214 -0.807 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.441 ' HG3' HG11 ' A' ' 42' ' ' VAL . 27.4 mt-30 -72.73 -13.73 61.4 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.783 0.661 . . . . 0.0 112.783 176.208 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.462 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 27.4 mmt180 -81.17 -26.33 36.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 172.299 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.496 ' HB2' HD21 ' A' ' 10' ' ' LEU . 24.6 t70 -54.94 -57.55 11.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 123.743 0.652 . . . . 0.0 111.368 177.655 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.73 -13.15 56.48 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.225 -0.988 . . . . 0.0 114.352 175.322 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.579 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -93.74 -59.93 1.88 Allowed 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 118.082 0.941 . . . . 0.0 108.573 176.878 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.579 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 15.3 tt -64.29 143.67 15.47 Favored 'Isoleucine or valine' 0 C--O 1.246 0.893 0 O-C-N 123.707 0.63 . . . . 0.0 110.672 -175.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -142.52 172.76 12.26 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.029 0.442 . . . . 0.0 111.617 -178.377 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.7 p -76.68 -9.52 12.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.653 0 CA-C-O 121.889 0.852 . . . . 0.0 110.503 -177.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -92.22 -2.75 56.32 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.592 0.711 . . . . 0.0 110.288 -176.087 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.487 ' HB3' HG21 ' A' ' 91' ' ' ILE . 76.9 m-20 -82.29 174.94 10.68 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 121.988 0.899 . . . . 0.0 112.328 -176.173 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.522 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.3 tt0 -128.6 125.48 38.27 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.497 178.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.508 HG22 HD21 ' A' ' 68' ' ' LEU . 48.8 mm -77.16 104.74 5.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -178.582 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.779 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 86.1 t -87.13 -48.07 15.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.844 0.831 . . . . 0.0 110.82 -176.469 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.517 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 33.1 tt0 -151.66 125.95 9.35 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.442 HG23 HG23 ' A' ' 60' ' ' ILE . 3.0 t -115.64 128.05 73.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 175.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.1 t70 72.97 -9.15 1.16 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 125.23 1.412 . . . . 0.0 112.671 173.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.93 11.56 36.94 Favored Glycine 0 C--N 1.29 -2.011 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.763 -174.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.558 HD13 HG22 ' A' ' 79' ' ' VAL . 7.0 tt -70.95 -21.21 22.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-O 120.728 0.299 . . . . 0.0 111.36 -177.614 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.499 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 57.7 p 51.01 88.52 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.036 1.334 . . . . 0.0 112.192 -177.31 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.508 HD21 HG22 ' A' ' 60' ' ' ILE . 1.4 pp -100.29 17.9 20.22 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 122.29 1.043 . . . . 0.0 109.931 -175.595 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.507 ' HA ' HD23 ' A' ' 35' ' ' LEU . 39.2 t -60.69 98.49 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.297 178.234 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.411 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 112.75 9.67 18.34 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.609 177.538 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.7 m -95.56 174.21 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.485 -179.408 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 p -95.02 175.45 6.63 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.54 177.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.589 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.23 -34.35 72.1 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.628 -179.385 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.7 -36.87 73.48 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.439 -177.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.467 ' O ' HG23 ' A' ' 79' ' ' VAL . 35.4 t80 -70.68 -49.1 50.76 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.19 -45.07 94.38 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.399 -178.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -54.91 -43.29 73.14 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 122.716 0.406 . . . . 0.0 110.307 178.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 90.3 m -61.35 -41.78 97.61 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.981 177.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.558 HG22 HD13 ' A' ' 66' ' ' ILE . 47.4 t -62.98 -51.82 67.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 178.022 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.429 HD21 HG21 ' A' ' 60' ' ' ILE . 3.5 mm? -68.26 -5.36 17.99 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-O 121.342 0.591 . . . . 0.0 111.63 179.525 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -102.47 -22.44 14.05 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.901 0.881 . . . . 0.0 110.891 176.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -90.44 0.85 57.13 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 121.253 0.549 . . . . 0.0 111.628 178.295 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.404 HG21 HD11 ' A' ' 17' ' ' LEU . 15.6 p -61.83 155.38 23.33 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.172 -0.922 . . . . 0.0 112.739 178.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.49 -157.55 0.8 Allowed 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.626 -1.17 . . . . 0.0 108.241 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 12' ' ' LYS . . . -51.61 -82.04 0.05 OUTLIER Glycine 0 CA--C 1.531 1.033 0 N-CA-C 114.601 0.6 . . . . 0.0 114.601 177.489 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -77.12 102.13 6.42 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.122 0.486 . . . . 0.0 111.419 -176.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 41.8 t -115.52 119.42 61.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.16 -178.323 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.34 104.49 15.22 Favored 'General case' 0 CA--C 1.487 -1.447 0 C-N-CA 120.282 -0.567 . . . . 0.0 109.963 173.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.4 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.4 m-85 -93.33 101.33 13.57 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 174.445 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.779 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.9 t -91.53 85.77 2.3 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 N-CA-C 105.337 -2.098 . . . . 0.0 105.337 176.553 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.487 HG21 ' HB3' ' A' ' 58' ' ' ASP . 78.0 mt -102.68 155.37 5.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 CA-C-N 113.765 -1.561 . . . . 0.0 108.85 179.641 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.462 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -128.85 155.59 20.72 Favored Glycine 0 N--CA 1.4 -3.748 0 C-N-CA 119.747 -1.215 . . . . 0.0 110.479 177.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -132.15 152.17 51.41 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 121.551 0.691 . . . . 0.0 112.864 -178.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 . . . . . 0 C--N 1.299 -1.606 0 C-N-CA 127.231 2.212 . . . . 0.0 105.505 174.381 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.502 -0.722 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -70.43 102.28 2.15 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 26.1 ttt 71.47 118.86 0.04 OUTLIER 'General case' 0 C--N 1.342 0.281 0 C-N-CA 124.389 1.076 . . . . 0.0 111.19 -178.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.446 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 45.5 tt0 -85.26 106.47 16.7 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -178.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.462 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.7 mm? -85.54 130.98 34.45 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 176.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 14.5 p90 -138.79 142.41 33.83 Favored Pre-proline 0 C--N 1.288 -2.065 0 CA-C-O 121.214 0.531 . . . . 0.0 111.802 -179.176 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -83.87 123.48 3.23 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.667 2.244 . . . . 0.0 112.732 177.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.4 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 40.2 t -114.65 105.38 18.55 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.639 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 174.316 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.487 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 27.6 tt0 -93.7 97.54 10.52 Favored 'General case' 0 N--CA 1.417 -2.121 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 -179.384 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.496 HD21 ' HB2' ' A' ' 51' ' ' ASP . 0.5 OUTLIER -87.67 158.36 18.86 Favored 'General case' 0 N--CA 1.397 -3.105 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -174.778 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.421 ' H ' HD23 ' A' ' 10' ' ' LEU . 48.1 tt0 -124.04 98.93 6.01 Favored 'General case' 0 C--N 1.274 -2.681 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.229 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 85' ' ' GLY . 2.3 mmmp? -100.73 -170.0 1.79 Allowed 'General case' 0 N--CA 1.409 -2.512 0 CA-C-N 114.518 -1.219 . . . . 0.0 112.696 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.56 157.12 36.02 Favored 'General case' 0 N--CA 1.413 -2.312 0 CA-C-N 113.03 -1.896 . . . . 0.0 106.534 174.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -72.48 -8.95 57.75 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 121.438 0.637 . . . . 0.0 110.253 176.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -72.22 -38.47 68.97 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 175.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 137.59 -145.14 16.74 Favored Glycine 0 N--CA 1.42 -2.411 0 C-N-CA 120.665 -0.779 . . . . 0.0 111.624 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.404 HD11 HG21 ' A' ' 83' ' ' THR . 18.3 mt -104.53 -46.47 4.35 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.85 29.7 37.82 Favored Glycine 0 N--CA 1.422 -2.242 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.874 -175.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.2 pt -102.42 -174.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 120.059 -0.656 . . . . 0.0 112.357 -177.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 21.8 m -135.66 153.04 51.75 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.589 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.9 pp -126.63 164.99 25.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 123.393 0.677 . . . . 0.0 109.336 -177.539 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.9 tt -135.41 130.02 50.17 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-O 120.811 0.338 . . . . 0.0 110.487 175.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.505 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.33 107.28 3.32 Favored Glycine 0 N--CA 1.428 -1.861 0 C-N-CA 121.085 -0.578 . . . . 0.0 112.029 -178.292 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.405 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.2 mmm -121.94 174.53 6.84 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.58 99.36 0.59 Allowed Glycine 0 C--N 1.29 -1.989 0 C-N-CA 119.418 -1.372 . . . . 0.0 112.171 179.616 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.0 p -96.63 91.9 2.89 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 CA-C-O 122.723 1.249 . . . . 0.0 110.4 176.583 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.484 ' HA2' ' HA ' ' A' ' 33' ' ' GLU . . . -105.21 -116.81 4.26 Favored Glycine 0 N--CA 1.423 -2.213 0 CA-C-N 114.804 -1.089 . . . . 0.0 114.58 -174.194 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.97 -23.59 62.24 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 113.377 0.88 . . . . 0.0 113.377 -171.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -66.11 -28.14 68.58 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.476 0.655 . . . . 0.0 111.227 -177.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.2 -22.14 13.44 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.159 177.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.29 27.7 17.29 Favored Glycine 0 CA--C 1.494 -1.223 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.454 ' HB3' ' HG2' ' A' ' 34' ' ' LYS . 31.1 mt -109.75 -64.78 1.21 Allowed 'General case' 0 N--CA 1.423 -1.798 0 C-N-CA 120.051 -0.659 . . . . 0.0 111.541 -174.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.484 ' HA ' ' HA2' ' A' ' 27' ' ' GLY . 47.4 mt-10 65.93 35.21 6.65 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 122.414 1.102 . . . . 0.0 111.689 -178.485 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.454 ' HG2' ' HB3' ' A' ' 32' ' ' LEU . 2.5 ptpp? -111.48 -162.64 0.81 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-N 114.672 -1.149 . . . . 0.0 107.905 174.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.507 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.0 pp -57.56 145.67 32.8 Favored 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 123.904 0.882 . . . . 0.0 109.906 177.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -116.8 33.71 4.95 Favored Glycine 0 C--N 1.288 -2.103 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 173.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.522 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 26.3 mm -84.58 105.49 13.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 121.407 0.622 . . . . 0.0 110.337 -177.09 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -99.25 162.98 12.74 Favored 'General case' 0 C--N 1.279 -2.46 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 177.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.89 128.01 38.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.542 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.3 OUTLIER -91.74 -39.07 12.02 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.303 0.573 . . . . 0.0 110.455 -177.049 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.7 m -159.65 161.0 34.9 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.441 HG11 ' HG3' ' A' ' 49' ' ' GLN . 17.5 t -117.62 167.73 10.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.216 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.9 t -68.86 -179.25 1.4 Allowed 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 123.044 0.538 . . . . 0.0 109.965 178.566 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -50.93 -64.29 0.86 Allowed 'General case' 0 C--O 1.225 -0.219 0 C-N-CA 124.112 0.965 . . . . 0.0 112.021 -178.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.436 ' HA2' ' HB2' ' A' ' 49' ' ' GLN . . . 169.25 52.31 0.03 OUTLIER Glycine 0 N--CA 1.414 -2.802 0 C-N-CA 118.244 -1.931 . . . . 0.0 113.621 179.628 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.73 -149.01 15.95 Favored Glycine 0 N--CA 1.408 -3.215 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 170.699 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.462 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -58.44 -14.17 7.14 Favored 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 -172.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.55 -62.56 1.65 Allowed 'General case' 0 C--O 1.214 -0.807 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.441 ' HG3' HG11 ' A' ' 42' ' ' VAL . 27.4 mt-30 -72.73 -13.73 61.4 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.783 0.661 . . . . 0.0 112.783 176.208 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.462 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 27.4 mmt180 -81.17 -26.33 36.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 172.299 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.496 ' HB2' HD21 ' A' ' 10' ' ' LEU . 24.6 t70 -54.94 -57.55 11.22 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 123.743 0.652 . . . . 0.0 111.368 177.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.73 -13.15 56.48 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.225 -0.988 . . . . 0.0 114.352 175.322 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.579 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -93.74 -59.93 1.88 Allowed 'General case' 0 CA--C 1.499 -1.005 0 CA-C-N 118.082 0.941 . . . . 0.0 108.573 176.878 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.579 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 15.3 tt -64.29 143.67 15.47 Favored 'Isoleucine or valine' 0 C--O 1.246 0.893 0 O-C-N 123.707 0.63 . . . . 0.0 110.672 -175.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -142.52 172.76 12.26 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.029 0.442 . . . . 0.0 111.617 -178.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.7 p -76.68 -9.52 12.66 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.653 0 CA-C-O 121.889 0.852 . . . . 0.0 110.503 -177.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -92.22 -2.75 56.32 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.592 0.711 . . . . 0.0 110.288 -176.087 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.487 ' HB3' HG21 ' A' ' 91' ' ' ILE . 76.9 m-20 -82.29 174.94 10.68 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 121.988 0.899 . . . . 0.0 112.328 -176.173 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.522 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 31.3 tt0 -128.6 125.48 38.27 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.497 178.309 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.508 HG22 HD21 ' A' ' 68' ' ' LEU . 48.8 mm -77.16 104.74 5.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -178.582 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.779 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 86.1 t -87.13 -48.07 15.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.844 0.831 . . . . 0.0 110.82 -176.469 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.517 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 33.1 tt0 -151.66 125.95 9.35 Favored 'General case' 0 C--N 1.292 -1.934 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.782 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.442 HG23 HG23 ' A' ' 60' ' ' ILE . 3.0 t -115.64 128.05 73.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 175.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.1 t70 72.97 -9.15 1.16 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 125.23 1.412 . . . . 0.0 112.671 173.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.93 11.56 36.94 Favored Glycine 0 C--N 1.29 -2.011 0 CA-C-N 114.626 -1.17 . . . . 0.0 110.763 -174.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.558 HD13 HG22 ' A' ' 79' ' ' VAL . 7.0 tt -70.95 -21.21 22.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-O 120.728 0.299 . . . . 0.0 111.36 -177.614 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.499 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 57.7 p 51.01 88.52 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 125.036 1.334 . . . . 0.0 112.192 -177.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.508 HD21 HG22 ' A' ' 60' ' ' ILE . 1.4 pp -100.29 17.9 20.22 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 122.29 1.043 . . . . 0.0 109.931 -175.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.507 ' HA ' HD23 ' A' ' 35' ' ' LEU . 39.2 t -60.69 98.49 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.297 178.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.411 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 112.75 9.67 18.34 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.609 177.538 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 68' ' ' LEU . 11.7 m -95.56 174.21 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.482 -0.487 . . . . 0.0 111.485 -179.408 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 p -95.02 175.45 6.63 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.54 177.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.589 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.23 -34.35 72.1 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.628 -179.385 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -70.7 -36.87 73.48 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.439 -177.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.467 ' O ' HG23 ' A' ' 79' ' ' VAL . 35.4 t80 -70.68 -49.1 50.76 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.808 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.19 -45.07 94.38 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.399 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -54.91 -43.29 73.14 Favored 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 122.716 0.406 . . . . 0.0 110.307 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 90.3 m -61.35 -41.78 97.61 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.981 177.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.558 HG22 HD13 ' A' ' 66' ' ' ILE . 47.4 t -62.98 -51.82 67.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 178.022 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.429 HD21 HG21 ' A' ' 60' ' ' ILE . 3.5 mm? -68.26 -5.36 17.99 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-O 121.342 0.591 . . . . 0.0 111.63 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -102.47 -22.44 14.05 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.901 0.881 . . . . 0.0 110.891 176.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -90.44 0.85 57.13 Favored 'General case' 0 N--CA 1.476 0.866 0 CA-C-O 121.253 0.549 . . . . 0.0 111.628 178.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.404 HG21 HD11 ' A' ' 17' ' ' LEU . 15.6 p -61.83 155.38 23.33 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.172 -0.922 . . . . 0.0 112.739 178.578 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.49 -157.55 0.8 Allowed 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.626 -1.17 . . . . 0.0 108.241 179.377 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 12' ' ' LYS . . . -51.61 -82.04 0.05 OUTLIER Glycine 0 CA--C 1.531 1.033 0 N-CA-C 114.601 0.6 . . . . 0.0 114.601 177.489 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -77.12 102.13 6.42 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.122 0.486 . . . . 0.0 111.419 -176.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 41.8 t -115.52 119.42 61.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.16 -178.323 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.34 104.49 15.22 Favored 'General case' 0 CA--C 1.487 -1.447 0 C-N-CA 120.282 -0.567 . . . . 0.0 109.963 173.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.4 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 97.4 m-85 -93.33 101.33 13.57 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 174.445 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.779 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 43.9 t -91.53 85.77 2.3 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 N-CA-C 105.337 -2.098 . . . . 0.0 105.337 176.553 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.487 HG21 ' HB3' ' A' ' 58' ' ' ASP . 78.0 mt -102.68 155.37 5.14 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.417 0 CA-C-N 113.765 -1.561 . . . . 0.0 108.85 179.641 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.462 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -128.85 155.59 20.72 Favored Glycine 0 N--CA 1.4 -3.748 0 C-N-CA 119.747 -1.215 . . . . 0.0 110.479 177.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -132.15 152.17 51.41 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 121.551 0.691 . . . . 0.0 112.864 -178.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 . . . . . 0 C--N 1.299 -1.606 0 C-N-CA 127.231 2.212 . . . . 0.0 105.505 174.381 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.949 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 41.7 m80 -88.24 124.84 34.26 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.186 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 47.5 tpp -150.87 143.43 24.38 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 -176.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.468 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 40.9 tt0 -105.03 107.54 18.58 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 175.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -86.82 128.74 35.05 Favored 'General case' 0 C--N 1.313 -0.994 0 O-C-N 123.648 0.592 . . . . 0.0 110.007 -176.755 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 33.3 p90 -142.91 141.86 20.84 Favored Pre-proline 0 N--CA 1.423 -1.782 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -178.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -81.18 122.58 4.23 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.826 2.351 . . . . 0.0 112.107 176.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.524 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 47.2 t -103.03 100.35 10.23 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.98 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 174.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.485 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 35.9 tt0 -81.58 102.03 10.37 Favored 'General case' 0 N--CA 1.427 -1.587 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 174.174 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.522 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -104.04 134.49 47.22 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 -175.449 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -102.78 97.59 7.73 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 175.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.459 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.0 mmmp? -84.42 177.53 8.09 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 115.115 1.524 . . . . 0.0 115.115 -177.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -80.66 -174.47 4.73 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 112.759 -2.019 . . . . 0.0 110.457 -175.041 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -71.79 -26.62 62.49 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.742 176.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -59.11 -41.99 89.48 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.504 178.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 120.2 -114.12 2.61 Favored Glycine 0 N--CA 1.413 -2.888 0 N-CA-C 108.044 -2.023 . . . . 0.0 108.044 -175.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.515 ' HG ' HG23 ' A' ' 19' ' ' ILE . 10.5 tp -113.63 -64.41 1.31 Allowed 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -178.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 79.75 28.64 50.46 Favored Glycine 0 N--CA 1.437 -1.259 0 O-C-N 124.183 0.927 . . . . 0.0 113.014 177.021 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.515 HG23 ' HG ' ' A' ' 17' ' ' LEU . 18.0 pt -104.99 172.11 1.66 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.826 0 C-N-CA 119.543 -0.863 . . . . 0.0 111.278 179.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 24.1 m -123.81 147.4 47.61 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.854 -179.114 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.565 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.8 pp -117.66 162.2 15.87 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -178.248 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.438 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.9 tt -128.96 132.83 67.05 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.116 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 174.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.482 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -93.22 106.69 3.45 Favored Glycine 0 N--CA 1.42 -2.405 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.029 -177.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.419 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 94.7 mmm -115.82 156.2 26.5 Favored 'General case' 0 C--N 1.289 -2.052 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 177.414 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.92 76.31 0.23 Allowed Glycine 0 C--N 1.286 -2.195 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 176.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.6 p -84.8 95.58 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 122.628 1.204 . . . . 0.0 112.031 -176.511 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -94.03 -126.19 4.42 Favored Glycine 0 N--CA 1.424 -2.137 0 CA-C-N 114.48 -1.236 . . . . 0.0 110.575 179.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -93.02 99.68 12.26 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.77 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -140.93 -57.16 0.51 Allowed 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.54 -40.51 7.39 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.913 174.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.22 28.78 0.15 Allowed Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.842 178.69 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -95.12 -59.54 1.88 Allowed 'General case' 0 C--N 1.313 -0.991 0 O-C-N 122.483 -0.422 . . . . 0.0 111.835 -177.181 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 54.3 70.48 0.61 Allowed 'General case' 0 C--O 1.248 1.013 0 C-N-CA 123.505 0.722 . . . . 0.0 111.732 178.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 13.6 ptmt -165.54 -165.25 0.82 Allowed 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -176.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.52 HD22 ' HA ' ' A' ' 69' ' ' VAL . 1.0 OUTLIER -56.44 154.04 9.04 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 175.14 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.419 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -117.91 34.59 4.42 Favored Glycine 0 N--CA 1.416 -2.655 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.922 173.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.482 HD13 ' HA2' ' A' ' 23' ' ' GLY . 29.3 mm -87.15 99.04 7.88 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 119.83 -0.748 . . . . 0.0 109.868 179.491 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -97.09 159.34 14.97 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 115.13 -0.941 . . . . 0.0 109.724 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.7 t -77.17 115.41 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.544 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 176.563 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 83.0 tttt -87.15 -51.4 6.01 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.858 -175.229 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -143.43 157.16 44.68 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 -179.006 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.409 ' HA ' HG22 ' A' ' 19' ' ' ILE . 50.0 t -126.85 151.01 33.14 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 N-CA-C 105.984 -1.858 . . . . 0.0 105.984 175.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 9.4 t -64.29 144.08 57.42 Favored 'General case' 0 N--CA 1.433 -1.325 0 CA-C-O 121.869 0.842 . . . . 0.0 109.942 178.253 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -80.24 -27.8 38.64 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 114.533 -1.212 . . . . 0.0 108.393 179.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -123.45 66.18 0.51 Allowed Glycine 0 CA--C 1.453 -3.791 0 CA-C-N 115.019 -0.991 . . . . 0.0 111.59 -173.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -154.63 155.17 26.03 Favored Glycine 1 N--CA 1.349 -7.159 0 N-CA-C 107.799 -2.121 . . . . 0.0 107.799 175.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.531 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -61.32 -0.76 0.4 Allowed 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -179.356 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.06 -53.69 9.43 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -76.66 -6.31 51.56 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.743 175.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.531 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 1.8 mmp_? -86.95 -38.27 16.81 Favored 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 172.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.56 ' OD1' ' HB2' ' A' ' 53' ' ' ARG . 11.4 t70 -66.13 -46.0 79.06 Favored 'General case' 0 C--O 1.217 -0.631 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 176.523 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 80.86 -17.44 11.33 Favored Glycine 0 N--CA 1.469 0.841 0 N-CA-C 114.54 0.576 . . . . 0.0 114.54 173.096 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.56 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 6.7 ttm180 -64.05 -40.37 96.14 Favored 'General case' 0 C--N 1.316 -0.85 0 C-N-CA 124.285 1.034 . . . . 0.0 110.238 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.8 tt -83.04 162.54 3.19 Favored 'Isoleucine or valine' 0 C--O 1.257 1.451 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 -178.465 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -125.74 -171.74 2.45 Favored 'General case' 0 N--CA 1.423 -1.805 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.308 -178.309 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.9 p -123.51 16.46 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.042 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 173.312 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 34.9 p30 -134.4 16.23 3.72 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 122.591 1.186 . . . . 0.0 109.923 -174.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -112.89 -169.89 1.57 Allowed 'General case' 0 C--N 1.27 -2.865 0 CA-C-N 113.69 -1.596 . . . . 0.0 109.943 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.45 ' O ' HG23 ' A' ' 91' ' ' ILE . 62.7 tt0 -132.39 132.35 42.74 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 116.72 -0.218 . . . . 0.0 110.595 -173.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.49 HG21 HD21 ' A' ' 80' ' ' LEU . 50.5 mm -74.38 104.83 3.15 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.961 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.013 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.712 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 94.1 t -86.33 -49.22 15.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 121.292 0.568 . . . . 0.0 110.139 -176.622 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.506 ' HG3' ' H ' ' A' ' 67' ' ' SER . 34.8 tt0 -154.39 116.67 4.29 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.254 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.405 HG23 HG23 ' A' ' 60' ' ' ILE . 4.2 t -108.83 129.98 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.209 0 N-CA-C 111.765 0.283 . . . . 0.0 111.765 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 15.6 t70 62.09 17.06 8.79 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 124.922 1.289 . . . . 0.0 111.441 174.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.9 10.98 85.69 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 115.65 -0.705 . . . . 0.0 112.422 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.0 tt -73.83 -14.81 16.54 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 O-C-N 122.528 -0.395 . . . . 0.0 111.171 -176.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.506 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 8.9 p 42.95 79.59 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 124.801 1.24 . . . . 0.0 113.357 -176.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.464 ' O ' HG22 ' A' ' 71' ' ' VAL . 1.5 pp -90.84 14.14 14.46 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.739 -174.435 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.52 ' HA ' HD22 ' A' ' 35' ' ' LEU . 48.7 t -58.84 98.0 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 114.736 -1.12 . . . . 0.0 109.586 173.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.439 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 112.96 18.24 7.44 Favored Glycine 0 N--CA 1.435 -1.42 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.781 177.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.464 HG22 ' O ' ' A' ' 68' ' ' LEU . 15.6 m -105.33 175.72 1.13 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.518 0 CA-C-N 117.205 0.502 . . . . 0.0 110.578 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.6 p -94.65 179.37 5.28 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-O 121.633 0.73 . . . . 0.0 110.012 178.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.565 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -65.87 -35.29 80.23 Favored 'General case' 0 N--CA 1.419 -1.975 0 CA-C-N 114.803 -1.089 . . . . 0.0 111.055 -179.619 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -70.17 -27.68 64.72 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.492 -177.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 36.6 t80 -75.47 -51.8 12.18 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 175.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.2 -44.06 92.25 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.448 -0.797 . . . . 0.0 112.218 -178.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.46 -10.66 36.08 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.335 0.654 . . . . 0.0 111.59 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.423 ' O ' ' HB3' ' A' ' 81' ' ' ARG . 98.3 m -93.01 -49.18 6.15 Favored 'General case' 0 N--CA 1.412 -2.355 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.668 175.224 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.535 ' O ' HG23 ' A' ' 83' ' ' THR . 38.5 t -59.64 -52.07 65.34 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.649 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.49 HD21 HG21 ' A' ' 60' ' ' ILE . 3.6 mm? -68.62 3.39 1.88 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.611 0.764 . . . . 0.0 112.228 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.423 ' HB3' ' O ' ' A' ' 78' ' ' THR . 11.7 ttm180 -109.91 -41.02 4.6 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 121.99 0.9 . . . . 0.0 109.109 176.334 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -80.31 -4.83 54.92 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 114.496 -1.229 . . . . 0.0 112.182 -174.668 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 79' ' ' VAL . 7.5 p -60.7 147.68 41.3 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 123.759 0.824 . . . . 0.0 112.194 177.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.85 -172.88 2.17 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.852 177.157 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -38.93 -73.74 0.15 Allowed Glycine 0 C--O 1.217 -0.94 0 O-C-N 124.484 1.115 . . . . 0.0 115.067 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.522 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 36.3 m-80 -83.05 105.11 13.76 Favored 'General case' 0 CA--C 1.497 -1.062 0 CA-C-N 118.0 0.9 . . . . 0.0 110.956 -179.536 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.493 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 2.5 t -104.24 143.38 16.0 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 CA-C-N 115.44 -0.8 . . . . 0.0 108.927 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 60.3 mtp180 -107.27 97.28 7.06 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 173.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.524 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 81.6 m-85 -94.67 104.76 16.68 Favored 'General case' 0 CA--C 1.483 -1.6 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 177.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.712 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 62.5 t -87.65 94.74 4.71 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.609 0 N-CA-C 105.108 -2.182 . . . . 0.0 105.108 173.198 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.456 HG12 ' HA ' ' A' ' 60' ' ' ILE . 93.9 mt -114.49 153.76 15.95 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.671 0 CA-C-N 114.894 -1.048 . . . . 0.0 108.245 177.515 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -118.02 157.88 14.96 Favored Glycine 1 N--CA 1.393 -4.221 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.534 177.459 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.485 HH21 ' HG2' ' A' ' 94' ' ' GLU . 8.1 tpm_? -129.48 123.66 32.09 Favored 'General case' 0 C--N 1.29 -2.005 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.569 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.485 ' HG2' HH21 ' A' ' 93' ' ' ARG . 16.5 pt-20 . . . . . 0 N--CA 1.428 -1.567 0 N-CA-C 105.886 -1.894 . . . . 0.0 105.886 171.014 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.501 -0.826 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 41.5 m80 -113.74 18.23 17.58 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.975 0.387 . . . . 0.0 110.639 -178.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 25.4 ttt 71.76 117.25 0.05 OUTLIER 'General case' 0 CA--C 1.509 -0.613 0 C-N-CA 125.333 1.453 . . . . 0.0 109.606 -173.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.481 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 39.1 tt0 -87.4 107.81 18.71 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -177.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.437 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.7 mm? -89.93 120.33 31.06 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 177.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -131.63 143.64 50.01 Favored Pre-proline 0 C--N 1.29 -1.987 0 CA-C-O 121.322 0.582 . . . . 0.0 112.356 -174.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -84.01 127.45 4.1 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.914 2.409 . . . . 0.0 112.273 175.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.415 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 23.6 t -117.52 104.63 16.68 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.271 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 174.381 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.415 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 36.4 tt0 -91.48 102.41 15.08 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.497 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -91.23 144.51 25.54 Favored 'General case' 0 N--CA 1.422 -1.866 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 -173.983 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -113.12 84.54 2.01 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 170.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.538 ' HE2' ' H ' ' A' ' 48' ' ' ALA . 5.1 mmtt -71.89 165.5 24.04 Favored 'General case' 0 N--CA 1.417 -2.077 0 N-CA-C 114.071 1.137 . . . . 0.0 114.071 -179.243 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -84.38 -175.18 5.67 Favored 'General case' 0 N--CA 1.433 -1.308 0 CA-C-N 113.613 -1.631 . . . . 0.0 111.123 -176.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -78.21 -9.27 59.13 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 -172.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -77.72 -45.47 24.67 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 121.746 0.784 . . . . 0.0 108.889 176.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.85 -160.28 21.75 Favored Glycine 0 N--CA 1.422 -2.271 0 N-CA-C 108.551 -1.82 . . . . 0.0 108.551 -176.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.8 mt -75.52 -50.8 14.57 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 118.011 0.905 . . . . 0.0 109.599 -176.346 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 68.1 27.97 73.52 Favored Glycine 0 N--CA 1.433 -1.56 0 CA-C-N 114.695 -1.139 . . . . 0.0 110.453 -176.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.54 HD11 HD12 ' A' ' 80' ' ' LEU . 18.1 pt -99.57 171.02 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.832 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.165 -178.804 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.1 m -133.35 148.34 51.86 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -177.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -115.41 161.59 14.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.429 ' CG2' ' HB2' ' A' ' 38' ' ' PHE . 15.3 tt -129.14 131.84 67.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 C-N-CA 120.611 -0.436 . . . . 0.0 109.895 174.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.496 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -90.65 97.08 2.28 Favored Glycine 0 CA--C 1.494 -1.238 0 C-N-CA 120.974 -0.631 . . . . 0.0 112.138 -177.719 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.434 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 95.1 mmm -111.73 -175.72 2.76 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.01 86.45 0.2 Allowed Glycine 0 C--N 1.282 -2.43 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 174.107 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.2 p -89.67 120.32 38.23 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-O 121.727 0.775 . . . . 0.0 111.809 -175.298 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.572 ' HA2' ' HB3' ' A' ' 30' ' ' ALA . . . 70.36 20.55 76.91 Favored Glycine 0 N--CA 1.432 -1.574 0 CA-C-N 114.766 -1.106 . . . . 0.0 113.928 175.522 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.65 -39.57 94.67 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.453 0.644 . . . . 0.0 110.545 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.5 m-20 -114.08 12.15 17.82 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.003 -179.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.572 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . . . -109.0 7.51 25.88 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.019 -0.537 . . . . 0.0 112.341 -176.625 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.01 11.55 42.61 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 119.881 -1.152 . . . . 0.0 114.168 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.7 mp -107.41 -62.91 1.36 Allowed 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 117.384 0.592 . . . . 0.0 110.968 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 57.32 84.8 0.09 Allowed 'General case' 0 C--O 1.245 0.862 0 C-N-CA 124.134 0.974 . . . . 0.0 111.9 -172.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.3 ptmt -143.93 174.45 10.82 Favored 'General case' 0 N--CA 1.413 -2.324 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 178.419 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.678 HD22 HG23 ' A' ' 69' ' ' VAL . 2.2 pt? -56.57 145.34 28.56 Favored 'General case' 0 C--N 1.289 -2.06 0 O-C-N 124.205 0.941 . . . . 0.0 110.933 176.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -110.49 19.07 26.92 Favored Glycine 0 N--CA 1.417 -2.592 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 175.152 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.611 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 35.9 mm -85.73 104.04 13.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-O 121.498 0.666 . . . . 0.0 110.457 -177.551 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.429 ' HB2' ' CG2' ' A' ' 22' ' ' ILE . 96.6 m-85 -101.65 163.31 12.33 Favored 'General case' 0 C--N 1.281 -2.4 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.484 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 47.0 t -77.35 116.29 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 N-CA-C 106.935 -1.505 . . . . 0.0 106.935 175.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.532 ' HA ' ' HE3' ' A' ' 40' ' ' LYS . 0.2 OUTLIER -83.44 -39.03 21.11 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 -177.621 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -157.56 158.23 35.23 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.44 HG12 ' HB ' ' A' ' 56' ' ' VAL . 4.3 p -137.52 97.81 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 CA-C-O 121.456 0.646 . . . . 0.0 111.557 178.114 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.8 t 51.94 168.36 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.478 0 C-N-CA 127.221 2.208 . . . . 0.0 113.933 178.307 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -73.35 -28.79 62.24 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 173.693 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 143.4 38.03 0.07 OUTLIER Glycine 0 N--CA 1.415 -2.716 0 CA-C-N 114.105 -1.407 . . . . 0.0 111.172 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -84.82 -151.36 13.88 Favored Glycine 0 N--CA 1.41 -3.096 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 174.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.449 ' HB3' ' HD3' ' A' ' 12' ' ' LYS . . . -61.67 -10.57 8.79 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 115.178 1.547 . . . . 0.0 115.178 -172.518 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.538 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -80.48 -58.01 3.32 Favored 'General case' 0 C--O 1.214 -0.796 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 43.0 mt-30 -63.27 -29.83 71.09 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 119.903 -0.719 . . . . 0.0 111.948 173.421 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 31.0 mmm180 -66.78 -34.37 77.68 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 120.824 -0.35 . . . . 0.0 110.863 176.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.412 ' HB3' ' O ' ' A' ' 48' ' ' ALA . 11.6 t70 -56.3 -52.15 65.57 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.719 176.607 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.19 -7.14 72.83 Favored Glycine 0 C--N 1.313 -0.737 0 N-CA-C 114.944 0.737 . . . . 0.0 114.944 173.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -86.57 -43.69 12.5 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.3 tt -78.54 152.12 5.11 Favored 'Isoleucine or valine' 0 C--O 1.243 0.736 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 177.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . 0.541 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 19.5 mt-30 -140.69 171.06 14.63 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 121.02 0.438 . . . . 0.0 110.019 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.44 ' HB ' HG12 ' A' ' 42' ' ' VAL . 10.7 p -83.24 -11.91 11.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.419 1.104 . . . . 0.0 108.587 175.288 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -88.65 3.24 51.33 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.786 -172.152 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.541 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 13.0 m-20 -109.6 -165.99 1.06 Allowed 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -174.254 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.611 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 18.9 tt0 -136.41 129.19 30.82 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 123.683 0.793 . . . . 0.0 111.261 -176.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.541 ' HA ' HG12 ' A' ' 91' ' ' ILE . 46.9 mm -73.88 108.33 5.25 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.877 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -179.331 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.777 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 97.3 t -92.41 -49.87 12.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 CA-C-O 121.854 0.835 . . . . 0.0 110.403 -178.349 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.576 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 34.2 tt0 -146.13 127.89 15.3 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.457 HG21 HD11 ' A' ' 80' ' ' LEU . 2.7 t -117.78 126.39 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.917 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.612 175.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.4 t70 72.51 -13.67 0.62 Allowed 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 125.391 1.476 . . . . 0.0 112.97 173.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 111.0 11.41 18.68 Favored Glycine 0 C--N 1.288 -2.099 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.003 -176.177 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.417 HD13 HG22 ' A' ' 79' ' ' VAL . 7.5 tt -75.33 -18.35 15.96 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.733 0 CA-C-O 120.777 0.323 . . . . 0.0 110.617 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.57 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 25.7 m 49.19 87.15 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.257 1.423 . . . . 0.0 111.54 -176.262 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.445 ' O ' HG22 ' A' ' 71' ' ' VAL . 2.1 pp -103.93 15.58 28.29 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-O 122.246 1.022 . . . . 0.0 109.484 -176.009 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.678 HG23 HD22 ' A' ' 35' ' ' LEU . 6.3 p -62.66 79.62 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 114.001 -1.454 . . . . 0.0 111.324 175.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 118.17 49.35 0.37 Allowed Glycine 0 N--CA 1.433 -1.505 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.048 -178.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.445 HG22 ' O ' ' A' ' 68' ' ' LEU . 32.4 m -127.02 178.08 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.242 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 13.3 p -91.08 174.66 7.29 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 120.933 0.397 . . . . 0.0 111.27 179.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.42 ' HB3' ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -65.26 -35.35 80.76 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.026 -179.301 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -70.36 -31.14 68.28 Favored 'General case' 0 CA--C 1.511 -0.519 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.695 -177.604 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -71.52 -54.22 11.27 Favored 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.44 -48.25 79.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.419 -0.809 . . . . 0.0 112.022 -178.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.05 -25.75 65.59 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 -179.149 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 71.4 m -76.22 -44.14 39.01 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.485 176.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.417 HG22 HD13 ' A' ' 66' ' ' ILE . 33.5 t -61.75 -51.74 69.08 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.621 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.54 HD12 HD11 ' A' ' 19' ' ' ILE . 3.5 mm? -68.12 -3.82 11.67 Favored 'General case' 0 CA--C 1.556 1.188 0 CA-C-O 121.341 0.591 . . . . 0.0 112.448 -179.114 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 36.4 ttt180 -95.64 -40.79 9.23 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 175.642 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 23.1 m-80 -89.01 8.06 31.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 114.241 -1.345 . . . . 0.0 113.88 -171.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.415 HG23 ' O ' ' A' ' 79' ' ' VAL . 1.3 p -75.9 154.38 36.05 Favored 'General case' 0 C--N 1.28 -2.431 0 C-N-CA 123.596 0.758 . . . . 0.0 112.332 178.689 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.29 -170.38 1.63 Allowed 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.984 176.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -50.41 -62.87 4.79 Favored Glycine 0 N--CA 1.473 1.116 0 N-CA-C 115.341 0.896 . . . . 0.0 115.341 -176.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.497 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 20.7 m120 -81.49 104.6 12.04 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 117.436 0.618 . . . . 0.0 110.992 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.441 ' HB ' ' CE2' ' A' ' 89' ' ' PHE . 2.3 t -113.75 128.76 70.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.195 -176.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.14 104.23 16.26 Favored 'General case' 0 C--N 1.293 -1.872 0 C-N-CA 119.979 -0.689 . . . . 0.0 109.474 170.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.441 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 93.2 m-85 -94.8 100.66 12.51 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 174.53 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.777 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 27.2 t -93.62 83.82 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.434 0 N-CA-C 105.288 -2.116 . . . . 0.0 105.288 177.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.541 HG12 ' HA ' ' A' ' 60' ' ' ILE . 64.7 mt -97.61 158.36 3.31 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.588 0 CA-C-N 113.335 -1.757 . . . . 0.0 109.563 -178.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.481 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -133.3 147.83 19.13 Favored Glycine 1 N--CA 1.393 -4.187 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.607 176.836 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 24.8 tpt180 -115.73 119.2 35.27 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 . . . . . 0 N--CA 1.413 -2.315 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 173.717 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.501 -0.799 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -80.93 113.51 19.19 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.082 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 50.0 ttm -76.74 114.09 15.11 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-O 120.965 0.412 . . . . 0.0 110.896 -177.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.423 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 41.2 tt0 -83.58 110.5 18.29 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 115.332 -0.849 . . . . 0.0 108.894 178.475 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.442 HD13 ' HA3' ' A' ' 92' ' ' GLY . 1.9 mm? -85.32 130.37 34.61 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.245 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 24.8 p90 -139.37 139.85 24.0 Favored Pre-proline 0 N--CA 1.426 -1.667 0 CA-C-O 121.454 0.645 . . . . 0.0 112.157 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -82.77 121.94 3.37 Favored 'Trans proline' 0 N--CA 1.446 -1.273 0 C-N-CA 122.765 2.31 . . . . 0.0 112.844 177.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.0 t -111.28 105.08 18.11 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 176.24 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.602 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.1 tt0 -85.39 105.28 15.91 Favored 'General case' 0 N--CA 1.42 -1.956 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 174.674 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.551 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 15.9 tp -95.76 151.35 19.45 Favored 'General case' 0 N--CA 1.41 -2.471 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 -176.719 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -115.27 92.59 3.97 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 177.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.466 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 2.6 mmmp? -84.24 177.61 8.12 Favored 'General case' 0 C--N 1.289 -2.032 0 CA-C-O 122.498 1.142 . . . . 0.0 113.675 178.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.418 ' OD2' ' HB3' ' A' ' 15' ' ' ASP . 2.0 p-10 -88.86 172.06 9.46 Favored 'General case' 0 C--N 1.286 -2.178 0 CA-C-N 112.835 -1.984 . . . . 0.0 109.536 179.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -64.32 -18.22 64.42 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -174.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.418 ' HB3' ' OD2' ' A' ' 13' ' ' ASP . 23.3 t70 -68.61 -32.98 73.24 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.778 0.799 . . . . 0.0 110.209 178.652 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.97 -124.44 5.94 Favored Glycine 0 CA--C 1.477 -2.285 0 N-CA-C 108.706 -1.758 . . . . 0.0 108.706 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.488 HD21 HG21 ' A' ' 87' ' ' VAL . 25.7 mt -104.27 -52.58 2.89 Favored 'General case' 0 CA--C 1.462 -2.407 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.45 178.499 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.2 24.55 76.53 Favored Glycine 0 N--CA 1.426 -2.003 0 O-C-N 124.678 1.236 . . . . 0.0 110.911 -175.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 28.0 pt -101.27 176.48 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.482 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 23.7 m -132.65 148.59 52.35 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -176.489 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -119.82 167.11 13.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 13.2 tt -133.36 132.26 57.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.668 177.391 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.508 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.1 102.07 2.79 Favored Glycine 0 N--CA 1.435 -1.43 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.607 -177.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 95.5 mmm -115.68 173.41 6.56 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.04 85.21 0.37 Allowed Glycine 0 C--N 1.295 -1.702 0 C-N-CA 120.121 -1.038 . . . . 0.0 112.469 179.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.53 HG12 ' HA2' ' A' ' 36' ' ' GLY . 13.2 p -122.47 154.74 27.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.391 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.46 -37.62 3.09 Favored Glycine 0 N--CA 1.421 -2.354 0 C-N-CA 120.18 -1.01 . . . . 0.0 111.425 177.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.08 -30.46 60.96 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.759 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.4 p-10 -67.62 -40.02 84.68 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.47 175.174 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.93 -24.55 62.47 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 124.402 1.081 . . . . 0.0 111.945 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.15 6.54 68.92 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.399 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -101.46 -27.66 13.01 Favored 'General case' 0 C--N 1.314 -0.972 0 O-C-N 122.545 -0.385 . . . . 0.0 110.387 179.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 55.7 89.65 0.04 OUTLIER 'General case' 0 CA--C 1.514 -0.406 0 C-N-CA 124.557 1.143 . . . . 0.0 112.022 -176.292 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 21.9 ptmt -129.34 -173.05 2.9 Favored 'General case' 0 N--CA 1.411 -2.377 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.625 HD23 ' HA ' ' A' ' 69' ' ' VAL . 2.5 pp -72.23 149.63 44.39 Favored 'General case' 0 C--N 1.282 -2.337 0 O-C-N 123.956 0.785 . . . . 0.0 109.283 178.042 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.53 ' HA2' HG12 ' A' ' 26' ' ' VAL . . . -110.47 27.48 11.39 Favored Glycine 0 N--CA 1.423 -2.213 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 172.777 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.508 HD13 ' HA2' ' A' ' 23' ' ' GLY . 35.3 mm -83.67 102.84 10.18 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 CA-C-O 121.47 0.652 . . . . 0.0 110.068 -178.626 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -96.83 169.2 10.02 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 177.232 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.0 t -83.43 129.33 37.67 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 175.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 55.6 tptt -93.64 -46.37 7.3 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.248 -177.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.8 m -151.72 161.45 42.64 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 -179.258 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 40.6 t -137.58 141.4 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.115 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 177.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 14.1 t -83.25 149.24 26.91 Favored 'General case' 0 C--N 1.29 -1.98 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.115 -178.036 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -93.27 -19.72 21.11 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 174.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.75 25.69 2.47 Favored Glycine 0 C--N 1.31 -0.895 0 CA-C-N 114.04 -1.436 . . . . 0.0 113.262 179.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -156.42 159.62 29.59 Favored Glycine 1 N--CA 1.359 -6.492 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 178.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.604 ' HA ' ' HB2' ' A' ' 50' ' ' ARG . . . -67.36 30.14 0.02 OUTLIER 'General case' 0 C--N 1.28 -2.436 0 C-N-CA 125.844 1.658 . . . . 0.0 114.179 -177.283 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.437 ' HA ' HD21 ' A' ' 10' ' ' LEU . . . -98.23 -62.99 1.17 Allowed 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -75.87 -28.9 58.33 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.679 0.752 . . . . 0.0 109.312 176.543 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.604 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 19.1 mmm180 -63.35 -32.65 74.13 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 114.473 -1.239 . . . . 0.0 109.63 172.595 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -70.4 -63.21 1.13 Allowed 'General case' 0 C--O 1.241 0.64 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 173.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.26 -17.28 40.82 Favored Glycine 0 N--CA 1.436 -1.356 0 N-CA-C 115.435 0.934 . . . . 0.0 115.435 175.049 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.512 ' HD3' ' O ' ' A' ' 53' ' ' ARG . 0.3 OUTLIER -79.21 -25.69 42.66 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 118.816 1.308 . . . . 0.0 109.341 -177.914 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.9 tt -94.44 150.76 3.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . 0.596 ' HB2' ' OD2' ' A' ' 58' ' ' ASP . 23.6 mt-30 -136.64 166.11 24.3 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 121.232 0.539 . . . . 0.0 111.598 -176.327 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -86.88 -12.44 10.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.392 178.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -92.99 3.42 55.79 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 122.214 1.007 . . . . 0.0 110.647 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.596 ' OD2' ' HB2' ' A' ' 55' ' ' GLN . 24.9 m-20 -101.98 -174.54 2.61 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.268 -177.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.442 ' O ' HG23 ' A' ' 91' ' ' ILE . 61.5 tt0 -129.26 131.97 47.12 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.813 -176.017 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.456 HG22 HD11 ' A' ' 68' ' ' LEU . 49.1 mm -75.43 106.56 5.31 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.783 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 179.697 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.692 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 98.5 t -87.87 -44.65 15.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 120.967 0.413 . . . . 0.0 111.344 -177.09 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.557 ' HG3' ' H ' ' A' ' 67' ' ' SER . 37.6 tt0 -156.85 120.96 4.34 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 120.67 0.271 . . . . 0.0 110.544 178.281 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.3 t -112.62 129.04 68.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 111.575 0.213 . . . . 0.0 111.575 176.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.3 t70 66.95 7.52 5.41 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 125.737 1.615 . . . . 0.0 111.294 174.54 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.65 20.7 61.23 Favored Glycine 0 N--CA 1.434 -1.472 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.296 -175.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.437 HD13 HG22 ' A' ' 79' ' ' VAL . 6.4 tt -79.44 -22.68 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 CA-C-O 121.197 0.522 . . . . 0.0 110.267 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.557 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 63.8 p 48.68 81.95 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.356 1.462 . . . . 0.0 111.935 -176.003 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.456 HD11 HG22 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -87.33 30.71 0.77 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 122.515 1.15 . . . . 0.0 111.283 -175.997 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.625 ' HA ' HD23 ' A' ' 35' ' ' LEU . 42.4 t -74.71 103.87 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.585 -179.424 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.08 26.83 6.84 Favored Glycine 0 N--CA 1.434 -1.436 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.784 179.403 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.451 HG21 ' HB2' ' A' ' 68' ' ' LEU . 11.0 m -112.63 170.4 4.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 C-N-CA 120.391 -0.524 . . . . 0.0 110.071 177.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.9 p -93.6 172.2 8.41 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.323 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.535 ' N ' HE21 ' A' ' 73' ' ' GLN . 0.0 OUTLIER -60.98 -28.43 69.01 Favored 'General case' 0 C--O 1.205 -1.269 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.751 -179.141 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -73.44 -36.03 65.87 Favored 'General case' 0 CA--C 1.522 -0.122 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.557 -178.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.401 ' O ' HG23 ' A' ' 79' ' ' VAL . 30.1 t80 -70.43 -49.8 45.05 Favored 'General case' 0 CA--C 1.506 -0.712 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 178.189 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -59.29 -46.73 87.76 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.934 -178.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.48 -34.19 72.26 Favored 'General case' 0 C--O 1.209 -1.036 0 CA-C-O 120.472 0.177 . . . . 0.0 110.554 179.391 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 77.6 m -65.91 -44.45 85.16 Favored 'General case' 0 N--CA 1.435 -1.217 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.755 177.219 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.437 HG22 HD13 ' A' ' 66' ' ' ILE . 39.3 t -61.89 -53.08 52.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 178.553 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -67.98 -2.23 7.19 Favored 'General case' 0 CA--C 1.564 1.509 0 CA-C-O 121.393 0.616 . . . . 0.0 112.183 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.23 -34.02 10.51 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 123.556 0.743 . . . . 0.0 109.714 175.132 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -82.0 -13.68 57.06 Favored 'General case' 0 CA--C 1.498 -1.019 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -175.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.435 ' OG1' ' HG ' ' A' ' 17' ' ' LEU . 5.4 p -60.54 146.67 44.19 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.647 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.89 -161.28 0.75 Allowed 'General case' 0 C--N 1.297 -1.709 0 CA-C-N 114.88 -1.055 . . . . 0.0 109.238 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -51.21 -74.93 0.24 Allowed Glycine 0 CA--C 1.536 1.379 0 N-CA-C 115.399 0.92 . . . . 0.0 115.399 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.551 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 15.9 m120 -81.65 99.99 9.2 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 117.872 0.836 . . . . 0.0 112.18 -177.534 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.602 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.8 t -108.54 135.49 47.17 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.044 -175.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -94.05 101.49 13.52 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 172.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.513 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 98.8 m-85 -94.8 103.92 15.82 Favored 'General case' 0 CA--C 1.48 -1.741 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.206 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.692 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 60.8 t -88.81 93.31 4.26 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.89 0 N-CA-C 105.416 -2.068 . . . . 0.0 105.416 174.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.442 HG23 ' O ' ' A' ' 59' ' ' GLN . 88.7 mt -107.43 155.51 8.14 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.265 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.21 175.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.442 ' HA3' HD13 ' A' ' 5' ' ' LEU . . . -129.83 149.39 18.77 Favored Glycine 0 N--CA 1.406 -3.331 0 C-N-CA 119.376 -1.393 . . . . 0.0 111.673 -178.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 22.9 tpt180 -123.85 116.23 22.61 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 -178.313 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 . . . . . 0 N--CA 1.441 -0.92 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 173.879 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.507 -0.407 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 52.4 t60 -89.53 111.5 22.43 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.123 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 23.5 ttt -83.59 113.53 20.89 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.49 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 82.9 tt0 -92.59 111.49 23.11 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 -178.207 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.413 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.0 mm? -87.31 125.78 34.43 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -178.637 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -140.48 145.66 41.78 Favored Pre-proline 0 C--N 1.294 -1.845 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -176.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -82.64 125.48 4.35 Favored 'Trans proline' 0 N--CA 1.442 -1.511 0 C-N-CA 122.62 2.213 . . . . 0.0 112.202 175.635 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.422 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 23.7 t -111.14 102.77 14.44 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.58 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 175.297 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 28.7 tt0 -82.22 108.83 15.98 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 174.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 0.1 OUTLIER -103.79 135.97 44.34 Favored 'General case' 0 C--N 1.279 -2.469 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 -177.772 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -106.99 97.73 7.48 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.521 -1.289 . . . . 0.0 107.521 171.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.619 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 2.7 mmmp? -83.71 173.78 11.04 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-O 122.406 1.098 . . . . 0.0 113.839 -177.329 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -88.15 172.68 9.32 Favored 'General case' 0 N--CA 1.423 -1.803 0 CA-C-N 112.818 -1.992 . . . . 0.0 110.026 -178.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -67.75 -9.29 42.64 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 114.197 1.184 . . . . 0.0 114.197 -173.188 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -73.49 -34.05 65.13 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 175.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.95 -127.14 6.98 Favored Glycine 0 CA--C 1.475 -2.452 0 N-CA-C 107.533 -2.227 . . . . 0.0 107.533 -177.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 18.2 mt -99.65 -48.92 4.56 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 175.042 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 73.94 31.03 60.48 Favored Glycine 0 N--CA 1.418 -2.524 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 -177.038 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 22.2 pt -110.84 178.35 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.3 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.641 -178.44 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 34.8 m -140.09 154.65 47.1 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -178.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.9 pp -125.84 166.58 21.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -177.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 14.0 tt -140.23 134.6 35.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 C-N-CA 120.58 -0.448 . . . . 0.0 110.681 177.251 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.515 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -92.96 107.58 3.55 Favored Glycine 0 N--CA 1.425 -2.079 0 C-N-CA 120.965 -0.635 . . . . 0.0 111.794 -179.239 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.663 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 93.0 mmm -122.58 97.88 5.66 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.82 101.13 0.56 Allowed Glycine 0 C--N 1.308 -1.015 0 C-N-CA 120.98 -0.629 . . . . 0.0 113.428 -175.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.4 p -120.88 29.31 2.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-O 123.739 1.733 . . . . 0.0 106.525 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.633 ' O ' ' HA ' ' A' ' 33' ' ' GLU . . . -92.22 -19.26 39.62 Favored Glycine 0 N--CA 1.435 -1.373 0 CA-C-N 112.657 -2.065 . . . . 0.0 116.687 -168.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -130.86 -75.99 0.53 Allowed 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 119.328 1.564 . . . . 0.0 113.45 -175.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -61.51 -31.26 71.25 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.294 0.638 . . . . 0.0 111.954 -175.204 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.93 -26.54 68.86 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.428 -0.806 . . . . 0.0 112.424 -179.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.43 -3.61 79.32 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.551 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.9 mp -84.38 -38.02 20.8 Favored 'General case' 0 C--N 1.31 -1.135 0 O-C-N 122.478 -0.424 . . . . 0.0 110.617 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.633 ' HA ' ' O ' ' A' ' 27' ' ' GLY . 45.9 mt-10 53.89 76.72 0.21 Allowed 'General case' 0 C--O 1.244 0.772 0 O-C-N 124.56 1.163 . . . . 0.0 112.819 179.404 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.51 ' HE2' ' OE1' ' A' ' 59' ' ' GLN . 18.2 ptmt -162.03 168.65 22.38 Favored 'General case' 0 N--CA 1.42 -1.961 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 -178.54 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.458 ' HB3' ' H ' ' A' ' 70' ' ' GLY . 1.5 pp -59.47 150.32 27.08 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 123.736 0.647 . . . . 0.0 109.262 172.617 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.663 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -115.12 32.85 5.58 Favored Glycine 0 N--CA 1.424 -2.16 0 C-N-CA 118.919 -1.61 . . . . 0.0 111.797 178.14 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.531 ' O ' ' HG3' ' A' ' 59' ' ' GLN . 25.6 mm -91.04 98.73 8.71 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.779 0 CA-C-O 122.018 0.913 . . . . 0.0 110.117 -178.764 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -93.11 162.44 14.03 Favored 'General case' 0 C--N 1.277 -2.559 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.395 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 46.7 t -79.44 126.83 39.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 175.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 58.3 tptt -88.64 -50.45 6.25 Favored 'General case' 0 C--N 1.294 -1.811 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.806 -177.087 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -150.87 162.62 40.43 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 -177.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.422 HG11 ' HG3' ' A' ' 49' ' ' GLN . 61.4 t -128.02 159.55 38.93 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.134 0 N-CA-C 105.959 -1.867 . . . . 0.0 105.959 175.239 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 6.6 t -57.3 162.49 2.71 Favored 'General case' 0 CA--C 1.544 0.714 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 171.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -55.32 -34.67 64.39 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.116 0.484 . . . . 0.0 110.796 -176.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.489 ' HA2' ' HB2' ' A' ' 49' ' ' GLN . . . -162.89 -58.13 0.02 OUTLIER Glycine 0 N--CA 1.428 -1.847 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 176.313 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 47.06 -101.64 0.04 OUTLIER Glycine 0 CA--C 1.485 -1.823 0 C-N-CA 126.352 1.929 . . . . 0.0 111.084 -173.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.619 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . -139.73 2.77 2.01 Favored 'General case' 0 C--N 1.26 -3.317 0 CA-C-N 113.278 -1.461 . . . . 0.0 108.915 173.495 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.478 ' O ' ' HB3' ' A' ' 51' ' ' ASP . . . -87.55 -55.06 3.95 Favored 'General case' 0 CA--C 1.486 -1.483 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -175.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.489 ' HB2' ' HA2' ' A' ' 45' ' ' GLY . 41.2 mt-30 -76.46 -22.3 54.76 Favored 'General case' 0 N--CA 1.433 -1.319 0 C-N-CA 118.586 -1.246 . . . . 0.0 110.87 176.706 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 25.7 mmm180 -69.0 -23.59 64.12 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.192 171.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.478 ' HB3' ' O ' ' A' ' 48' ' ' ALA . 12.1 t70 -71.39 -64.92 0.82 Allowed 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.099 -1.075 . . . . 0.0 108.099 170.464 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.71 -5.54 84.63 Favored Glycine 0 C--O 1.245 0.794 0 C-N-CA 121.24 -0.505 . . . . 0.0 113.792 174.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.62 -32.85 21.82 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 178.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.6 tt -93.52 143.46 11.49 Favored 'Isoleucine or valine' 0 C--O 1.251 1.148 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 170.164 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 62.0 mt-30 -139.05 178.42 7.18 Favored 'General case' 0 C--N 1.308 -1.225 0 O-C-N 122.183 -0.323 . . . . 0.0 111.412 -179.513 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.2 p -84.64 -14.96 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-O 121.66 0.743 . . . . 0.0 110.838 -176.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -91.24 7.9 38.51 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-O 122.107 0.956 . . . . 0.0 109.502 -176.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.402 ' HB3' HG21 ' A' ' 91' ' ' ILE . 6.6 m-20 -88.47 -175.4 4.96 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.8 -176.063 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.531 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 30.9 tt0 -141.53 129.14 21.48 Favored 'General case' 0 N--CA 1.423 -1.795 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.007 -179.03 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.434 HG22 HD21 ' A' ' 68' ' ' LEU . 46.8 mm -77.2 105.31 5.96 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.786 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -178.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.766 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 94.2 t -85.07 -48.96 16.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-O 121.957 0.884 . . . . 0.0 109.357 -177.665 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.565 ' HG3' ' H ' ' A' ' 67' ' ' SER . 28.8 tt0 -150.87 135.1 16.89 Favored 'General case' 0 N--CA 1.419 -2.015 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.078 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 t -121.52 128.71 75.9 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 173.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 37.0 t70 71.23 -11.49 0.68 Allowed 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 125.3 1.44 . . . . 0.0 113.261 176.603 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.11 15.4 28.33 Favored Glycine 0 C--N 1.277 -2.729 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -174.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.425 HD13 HG22 ' A' ' 79' ' ' VAL . 9.3 tt -72.7 -21.02 19.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 CA-C-O 121.452 0.644 . . . . 0.0 110.046 -179.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.565 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 62.9 p 49.25 88.2 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 125.399 1.48 . . . . 0.0 111.89 -175.407 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.434 HD21 HG22 ' A' ' 60' ' ' ILE . 1.3 pp -98.11 20.1 12.94 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-O 122.429 1.109 . . . . 0.0 109.573 -176.775 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 50.4 t -57.6 94.26 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-N 114.025 -1.443 . . . . 0.0 110.944 175.549 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.458 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 107.77 27.35 5.21 Favored Glycine 0 N--CA 1.441 -1.003 0 CA-C-N 115.408 -0.815 . . . . 0.0 112.603 175.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.403 HG22 ' O ' ' A' ' 68' ' ' LEU . 20.2 m -105.73 176.15 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.885 -179.439 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 12.4 p -93.0 172.76 8.11 Favored 'General case' 0 C--O 1.254 1.327 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.546 179.08 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.97 -30.81 71.43 Favored 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.666 -178.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -73.73 -26.37 60.65 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.686 -177.5 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 40.3 t80 -75.27 -53.13 9.29 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -57.62 -48.8 78.42 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.054 -177.177 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -55.76 -36.96 67.89 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.642 0.258 . . . . 0.0 110.624 179.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 89.0 m -65.62 -44.64 85.85 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.854 177.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.425 HG22 HD13 ' A' ' 66' ' ' ILE . 34.7 t -61.93 -51.2 75.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 178.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -64.01 -20.2 65.73 Favored 'General case' 0 C--O 1.214 -0.794 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.423 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.82 -25.63 24.47 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 122.934 0.494 . . . . 0.0 110.927 177.177 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -89.02 3.62 51.06 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 112.747 0.647 . . . . 0.0 112.747 -178.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 38.9 p -73.49 -178.33 3.01 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.78 0.8 . . . . 0.0 111.846 177.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.23 -165.9 1.56 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 125.534 1.533 . . . . 0.0 107.045 -179.186 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -39.51 -78.27 0.06 OUTLIER Glycine 0 C--O 1.22 -0.719 0 O-C-N 124.504 1.128 . . . . 0.0 115.204 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.467 ' HA ' ' O ' ' A' ' 10' ' ' LEU . 20.9 m120 -81.57 114.97 20.63 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 118.075 0.938 . . . . 0.0 111.272 -177.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 2.4 t -124.37 140.48 47.54 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.458 -179.112 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 20.2 mtp85 -100.41 100.7 11.51 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 120.907 0.384 . . . . 0.0 110.831 171.35 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.456 ' CE2' ' HB ' ' A' ' 87' ' ' VAL . 95.4 m-85 -93.09 105.02 17.17 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 107.883 -1.154 . . . . 0.0 107.883 176.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.766 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 41.0 t -95.86 86.19 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.274 -2.686 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 178.369 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.402 HG21 ' HB3' ' A' ' 58' ' ' ASP . 94.0 mt -104.92 160.82 5.06 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.49 0 CA-C-N 113.841 -1.527 . . . . 0.0 109.252 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.49 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -122.47 152.88 16.86 Favored Glycine 0 N--CA 1.409 -3.134 0 C-N-CA 119.666 -1.254 . . . . 0.0 110.613 177.015 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 14.8 tpp180 -95.55 123.15 38.96 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -176.255 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 . . . . . 0 C--N 1.303 -1.449 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 172.354 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.505 -0.571 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -102.82 138.11 40.15 Favored 'General case' 0 CA--C 1.493 -1.215 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 175.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 18.8 ttt -118.49 117.56 29.36 Favored 'General case' 0 C--N 1.29 -2.021 0 C-N-CA 119.939 -0.704 . . . . 0.0 109.452 -176.455 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -91.19 109.15 20.4 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -85.87 123.52 31.31 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-O 120.877 0.37 . . . . 0.0 110.468 -177.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -133.5 143.71 49.11 Favored Pre-proline 0 C--N 1.29 -1.979 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.72 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.43 126.08 5.96 Favored 'Trans proline' 0 N--CA 1.437 -1.817 0 C-N-CA 122.148 1.899 . . . . 0.0 112.4 177.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.467 ' HB ' ' HB2' ' A' ' 89' ' ' PHE . 61.1 t -107.0 98.87 7.49 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.677 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 173.527 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.5 tt0 -88.72 103.38 15.9 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -99.36 137.74 37.44 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -173.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -100.28 103.98 15.43 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 171.286 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.754 ' HD2' ' HB3' ' A' ' 47' ' ' ALA . 3.9 mmmp? -98.35 173.57 6.91 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -175.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -63.05 167.2 5.07 Favored 'General case' 0 C--N 1.313 -0.996 0 C-N-CA 126.917 2.087 . . . . 0.0 109.069 178.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -64.47 -24.48 67.63 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.646 0.736 . . . . 0.0 109.719 176.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -58.78 -45.96 88.6 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 114.501 -1.227 . . . . 0.0 110.333 177.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.4 ' O ' ' HB3' ' A' ' 12' ' ' LYS . . . 124.74 -118.24 3.28 Favored Glycine 0 N--CA 1.413 -2.864 0 N-CA-C 107.834 -2.107 . . . . 0.0 107.834 -176.234 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.445 HD21 HG21 ' A' ' 87' ' ' VAL . 18.6 mt -105.76 -50.89 3.09 Favored 'General case' 0 CA--C 1.475 -1.911 0 CA-C-N 118.153 0.976 . . . . 0.0 110.305 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 71.27 30.49 67.15 Favored Glycine 0 N--CA 1.422 -2.291 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 -174.392 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.45 HD11 HD12 ' A' ' 80' ' ' LEU . 21.5 pt -107.32 172.04 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 119.708 -0.797 . . . . 0.0 110.195 179.166 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.3 m -124.67 150.53 46.0 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -177.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.7 pp -124.92 160.68 29.83 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 -177.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.3 tt -133.55 126.13 51.21 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 177.023 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.631 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -89.26 96.53 2.22 Favored Glycine 0 N--CA 1.429 -1.786 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.504 -176.184 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.473 ' O ' ' HA3' ' A' ' 36' ' ' GLY . 79.1 mmm -115.13 76.75 1.02 Allowed 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -49.01 108.63 0.44 Allowed Glycine 0 CA--C 1.504 -0.619 0 O-C-N 124.407 1.067 . . . . 0.0 113.093 -176.464 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -113.6 140.53 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.618 0 N-CA-C 107.969 -1.122 . . . . 0.0 107.969 179.723 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.401 ' O ' ' HA ' ' A' ' 33' ' ' GLU . . . -100.2 -104.47 2.63 Favored Glycine 0 N--CA 1.428 -1.865 0 N-CA-C 110.109 -1.197 . . . . 0.0 110.109 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.408 ' HA ' ' HG2' ' A' ' 33' ' ' GLU . . . -102.71 7.94 39.63 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.279 0.561 . . . . 0.0 110.163 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -59.1 -32.21 69.61 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.49 -172.299 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.14 2.08 31.49 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.184 0.516 . . . . 0.0 111.262 -177.623 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 86.56 -20.85 20.91 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 115.046 0.779 . . . . 0.0 115.046 176.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -85.04 -37.06 20.8 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 112.975 0.732 . . . . 0.0 112.975 -176.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.408 ' HG2' ' HA ' ' A' ' 28' ' ' ALA . 47.5 mt-10 64.79 91.68 0.08 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.063 0.945 . . . . 0.0 111.898 -178.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 7.3 ptpp? -161.29 -165.18 1.27 Allowed 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.636 HD11 ' O ' ' A' ' 60' ' ' ILE . 0.5 OUTLIER -58.2 158.75 6.68 Favored 'General case' 0 C--N 1.315 -0.899 0 O-C-N 124.192 0.932 . . . . 0.0 109.927 174.942 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.473 ' HA3' ' O ' ' A' ' 24' ' ' MET . . . -110.56 30.52 8.1 Favored Glycine 0 C--N 1.298 -1.569 0 C-N-CA 119.837 -1.173 . . . . 0.0 111.578 176.206 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.631 HD13 ' HA2' ' A' ' 23' ' ' GLY . 20.5 mm -90.56 112.03 24.35 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.125 0 CA-C-O 121.509 0.671 . . . . 0.0 110.628 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -104.92 159.88 15.46 Favored 'General case' 0 C--N 1.282 -2.341 0 CA-C-N 115.153 -0.93 . . . . 0.0 109.805 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 44.8 t -75.0 122.05 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 176.08 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 84.6 tttt -86.5 -47.8 8.94 Favored 'General case' 0 C--N 1.286 -2.178 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.623 -177.196 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.4 m -152.98 162.34 41.44 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 -179.268 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.431 HG11 ' HG3' ' A' ' 49' ' ' GLN . 47.8 t -130.02 151.84 36.48 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 177.052 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.2 t -61.29 151.23 32.47 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 176.629 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -48.36 -60.88 2.32 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 124.424 1.09 . . . . 0.0 113.14 -170.683 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 172.32 58.68 0.04 OUTLIER Glycine 0 C--N 1.29 -2.007 0 C-N-CA 118.428 -1.844 . . . . 0.0 114.1 179.416 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.47 -32.27 12.03 Favored Glycine 0 C--N 1.303 -1.298 0 C-N-CA 119.522 -1.323 . . . . 0.0 110.915 174.013 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.754 ' HB3' ' HD2' ' A' ' 12' ' ' LYS . . . -161.95 -41.74 0.04 OUTLIER 'General case' 0 C--O 1.209 -1.055 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -178.58 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.438 ' HB2' ' CE ' ' A' ' 12' ' ' LYS . . . -65.56 -59.59 3.81 Favored 'General case' 0 N--CA 1.504 2.274 0 CA-C-N 118.719 0.691 . . . . 0.0 110.423 -175.799 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.431 ' HG3' HG11 ' A' ' 42' ' ' VAL . 26.1 mt-30 -78.02 6.8 7.12 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.349 177.437 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 26.0 mmm180 -95.59 -27.72 15.2 Favored 'General case' 0 N--CA 1.428 -1.568 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 171.697 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -66.65 -37.22 84.36 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 173.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.58 -31.74 4.13 Favored Glycine 0 N--CA 1.458 0.119 0 CA-C-N 115.471 -0.786 . . . . 0.0 113.985 172.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 2.7 ttm180 -61.55 -54.79 38.52 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 124.975 1.31 . . . . 0.0 111.401 -176.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.5 tt -84.82 141.55 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 CA-C-N 115.033 -0.985 . . . . 0.0 108.832 -176.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.7 mt-30 -143.0 -179.83 6.6 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 119.991 -0.684 . . . . 0.0 111.875 178.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.2 t -62.81 -30.69 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.701 178.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 35.3 m-80 -83.53 18.55 1.83 Allowed 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 113.252 0.834 . . . . 0.0 113.252 -175.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -104.57 175.43 5.49 Favored 'General case' 0 C--O 1.252 1.187 0 CA-C-O 121.491 0.662 . . . . 0.0 111.715 177.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.414 ' O ' HG23 ' A' ' 91' ' ' ILE . 62.3 tt0 -127.46 136.27 51.57 Favored 'General case' 0 N--CA 1.422 -1.827 0 CA-C-N 114.848 -1.069 . . . . 0.0 108.453 177.268 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.636 ' O ' HD11 ' A' ' 35' ' ' LEU . 49.0 mm -75.62 139.84 18.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 178.473 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.712 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 90.5 t -119.26 -53.71 3.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 CA-C-O 121.545 0.688 . . . . 0.0 109.805 177.57 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.563 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 32.0 tt0 -151.7 102.91 2.9 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 -177.617 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.449 HG23 HG23 ' A' ' 60' ' ' ILE . 7.8 t -96.41 127.61 48.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.762 -0.586 . . . . 0.0 111.38 179.185 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 35.2 t70 61.51 19.51 10.4 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 124.847 1.259 . . . . 0.0 111.17 173.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 74.17 20.24 79.69 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 114.891 -1.05 . . . . 0.0 112.505 -178.575 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.455 HD13 HG22 ' A' ' 79' ' ' VAL . 6.9 tt -81.33 -14.42 12.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 O-C-N 122.418 -0.46 . . . . 0.0 110.282 -179.269 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.42 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 17.8 m 45.33 81.23 0.04 OUTLIER 'General case' 0 C--N 1.351 0.642 0 C-N-CA 125.479 1.512 . . . . 0.0 112.172 -178.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.421 ' O ' HG22 ' A' ' 71' ' ' VAL . 0.5 OUTLIER -91.4 18.31 7.36 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 121.88 0.848 . . . . 0.0 111.409 -174.901 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.409 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 57.2 t -57.95 104.67 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.941 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.264 173.426 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.47 29.27 6.36 Favored Glycine 0 N--CA 1.437 -1.261 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.633 179.028 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 68' ' ' LEU . 15.7 m -113.88 176.1 2.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 C-N-CA 120.166 -0.614 . . . . 0.0 110.735 176.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -104.06 173.27 6.38 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.734 178.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.28 -33.48 71.12 Favored 'General case' 0 C--O 1.204 -1.314 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.035 -176.616 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -66.09 -32.65 74.23 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 123.695 0.798 . . . . 0.0 111.967 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 51.3 t80 -78.92 -49.33 13.01 Favored 'General case' 0 N--CA 1.444 -0.752 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 177.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.42 -43.41 96.79 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.243 -177.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.446 ' O ' ' HB2' ' A' ' 81' ' ' ARG . . . -63.38 -22.59 66.97 Favored 'General case' 0 C--O 1.218 -0.592 0 CA-C-O 121.028 0.442 . . . . 0.0 110.798 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 52.9 m -80.96 -45.44 16.66 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.827 177.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.539 ' O ' HG23 ' A' ' 83' ' ' THR . 40.0 t -62.45 -52.71 56.63 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.571 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 178.338 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.45 HD12 HD11 ' A' ' 19' ' ' ILE . 3.7 mm? -70.13 6.82 1.14 Allowed 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 123.968 0.907 . . . . 0.0 112.213 -178.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.446 ' HB2' ' O ' ' A' ' 77' ' ' ALA . 41.5 ttt180 -109.12 -47.61 3.4 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 174.169 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -79.76 -10.76 59.83 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 113.99 -1.459 . . . . 0.0 114.021 -172.121 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.539 HG23 ' O ' ' A' ' 79' ' ' VAL . 12.5 p -63.14 138.43 58.55 Favored 'General case' 0 C--O 1.248 1.014 0 CA-C-O 120.418 0.151 . . . . 0.0 110.838 177.419 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 72.8 mmtt -131.17 132.38 44.69 Favored 'General case' 0 CA--C 1.487 -1.453 0 N-CA-C 113.516 0.932 . . . . 0.0 113.516 -175.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 49.46 -73.17 0.0 OUTLIER Glycine 0 CA--C 1.479 -2.179 0 C-N-CA 127.895 2.664 . . . . 0.0 115.079 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 19.2 m120 -102.53 100.19 10.27 Favored 'General case' 0 C--N 1.253 -3.63 0 CA-C-O 121.376 0.607 . . . . 0.0 109.417 -172.366 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.514 ' O ' ' HA ' ' A' ' 9' ' ' GLU . 5.6 t -114.5 127.67 71.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.058 -172.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 37.7 mtm-85 -99.99 97.78 8.61 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-O 121.026 0.441 . . . . 0.0 109.942 175.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.467 ' HB2' ' HB ' ' A' ' 8' ' ' VAL . 80.8 m-85 -87.56 100.75 13.02 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.494 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.712 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 57.4 t -85.66 94.25 4.02 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.634 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 175.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.414 HG23 ' O ' ' A' ' 59' ' ' GLN . 90.3 mt -112.84 158.58 13.17 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.257 0 CA-C-N 114.05 -1.432 . . . . 0.0 107.749 176.807 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.47 167.34 14.29 Favored Glycine 0 N--CA 1.405 -3.405 0 C-N-CA 118.903 -1.617 . . . . 0.0 112.276 -178.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 2.6 tmt_? -113.59 128.55 56.48 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 176.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 . . . . . 0 C--N 1.302 -1.477 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 178.236 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.496 -1.113 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 8.9 p80 -161.21 173.6 14.84 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -178.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 25.0 ttt -117.71 117.36 29.14 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 178.179 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.507 ' O ' ' HA2' ' A' ' 92' ' ' GLY . 35.3 tt0 -91.22 114.12 26.56 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.578 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.451 HD13 ' HA3' ' A' ' 92' ' ' GLY . 2.0 mm? -87.85 117.34 26.63 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.409 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -132.38 140.67 38.66 Favored Pre-proline 0 C--N 1.294 -1.816 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -177.167 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.401 ' HA ' ' HA ' ' A' ' 90' ' ' VAL . 55.6 Cg_endo -77.78 125.0 7.16 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.525 2.15 . . . . 0.0 111.855 176.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 26.3 t -111.73 97.19 5.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.513 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -80.0 104.29 10.47 Favored 'General case' 0 N--CA 1.425 -1.691 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -98.4 141.22 31.55 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 -177.374 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -112.88 85.29 2.14 Favored 'General case' 0 N--CA 1.416 -2.133 0 C-N-CA 119.077 -1.049 . . . . 0.0 108.924 172.078 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.631 ' HA ' ' HB3' ' A' ' 47' ' ' ALA . 4.3 mmtt -68.69 168.67 12.72 Favored 'General case' 0 N--CA 1.409 -2.511 0 CA-C-N 114.402 -1.272 . . . . 0.0 114.398 -179.374 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.4 ' H ' ' CD ' ' A' ' 12' ' ' LYS . 6.3 m-20 -67.04 164.94 16.73 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 113.721 -1.582 . . . . 0.0 107.506 -178.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -70.25 -12.82 61.86 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.41 0.624 . . . . 0.0 111.712 -177.03 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -68.21 -43.87 77.06 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.186 174.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.464 ' O ' ' HD2' ' A' ' 12' ' ' LYS . . . 132.64 -152.48 20.29 Favored Glycine 0 N--CA 1.426 -1.98 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -176.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.574 ' O ' ' HB ' ' A' ' 43' ' ' THR . 22.8 mt -89.14 -49.49 6.72 Favored 'General case' 0 CA--C 1.489 -1.398 0 CA-C-N 117.678 0.739 . . . . 0.0 109.967 -177.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 73.11 23.82 76.93 Favored Glycine 0 N--CA 1.425 -2.054 0 CA-C-N 114.752 -1.113 . . . . 0.0 111.062 -174.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.469 HG22 ' HA ' ' A' ' 42' ' ' VAL . 19.5 pt -101.17 178.95 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.747 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.7 m -145.58 156.49 43.72 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.56 ' CD1' ' HB2' ' A' ' 73' ' ' GLN . 2.7 pp -116.71 162.1 14.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 C-N-CA 122.83 0.452 . . . . 0.0 110.556 -176.065 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 15.4 tt -132.6 125.36 52.96 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.821 0 CA-C-O 120.965 0.412 . . . . 0.0 110.107 174.272 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.574 ' HA2' HD13 ' A' ' 37' ' ' ILE . . . -88.55 101.18 2.71 Favored Glycine 0 N--CA 1.417 -2.595 0 CA-C-N 115.743 -0.662 . . . . 0.0 112.013 -178.488 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 94.9 mmm -107.1 165.32 11.45 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 177.483 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.62 94.61 0.57 Allowed Glycine 0 C--N 1.287 -2.166 0 C-N-CA 119.207 -1.473 . . . . 0.0 111.414 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -93.93 113.09 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 CA-C-O 121.342 0.592 . . . . 0.0 109.65 178.5 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.03 -82.5 1.05 Allowed Glycine 0 N--CA 1.433 -1.551 0 CA-C-N 115.197 -0.911 . . . . 0.0 111.201 179.251 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.631 ' HA ' ' HG3' ' A' ' 33' ' ' GLU . . . -148.71 105.11 3.53 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -173.65 -42.71 0.01 OUTLIER 'General case' 0 CA--C 1.514 -0.423 0 O-C-N 123.885 0.741 . . . . 0.0 111.671 -177.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.32 -21.31 24.47 Favored 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 -170.088 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.01 -8.04 53.45 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -176.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -86.34 -48.47 8.45 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 114.58 -0.81 . . . . 0.0 109.434 179.493 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.631 ' HG3' ' HA ' ' A' ' 28' ' ' ALA . 1.0 OUTLIER 41.3 50.78 3.52 Favored 'General case' 0 C--O 1.243 0.76 0 N-CA-C 114.527 1.306 . . . . 0.0 114.527 176.522 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 6.9 ptpp? -150.57 -155.19 0.6 Allowed 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.516 ' CD2' ' HA ' ' A' ' 69' ' ' VAL . 1.6 pp -48.35 144.93 3.65 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 124.287 1.035 . . . . 0.0 110.867 175.019 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -106.52 30.19 9.88 Favored Glycine 0 N--CA 1.431 -1.662 0 C-N-CA 120.009 -1.091 . . . . 0.0 111.229 177.038 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.574 HD13 ' HA2' ' A' ' 23' ' ' GLY . 24.8 mm -82.83 100.68 6.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 121.537 0.684 . . . . 0.0 110.038 -179.44 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -99.28 167.35 10.72 Favored 'General case' 0 C--N 1.277 -2.545 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.482 179.306 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 45.1 t -83.21 113.62 22.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 56.6 tptt -76.74 -45.73 28.05 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.897 -176.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 2.4 m -152.37 162.92 40.49 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -175.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.469 ' HA ' HG22 ' A' ' 19' ' ' ILE . 59.6 t -134.27 158.08 41.88 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.066 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.574 ' HB ' ' O ' ' A' ' 17' ' ' LEU . 10.1 t -49.63 145.67 4.87 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 171.025 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -58.86 -39.14 80.43 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 123.178 0.591 . . . . 0.0 112.507 -174.649 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -175.55 44.56 0.12 Allowed Glycine 0 CA--C 1.471 -2.699 0 C-N-CA 119.784 -1.198 . . . . 0.0 112.567 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -89.05 -166.71 42.39 Favored Glycine 1 N--CA 1.381 -5.018 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 174.116 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.631 ' HB3' ' HA ' ' A' ' 12' ' ' LYS . . . -55.17 -17.98 5.1 Favored 'General case' 0 C--N 1.274 -2.711 0 N-CA-C 115.254 1.575 . . . . 0.0 115.254 -172.6 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.605 ' H ' ' HE2' ' A' ' 12' ' ' LYS . . . -74.05 -58.99 2.93 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.217 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -69.84 -24.4 63.45 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 119.83 -0.748 . . . . 0.0 112.133 175.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.544 ' HB2' ' HA ' ' A' ' 47' ' ' ALA . 13.1 mmt180 -66.37 -36.77 83.72 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 174.017 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -57.23 -59.66 4.78 Favored 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.607 0.567 . . . . 0.0 109.728 177.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.06 -20.75 35.14 Favored Glycine 0 N--CA 1.437 -1.244 0 C-N-CA 120.222 -0.989 . . . . 0.0 114.442 174.37 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.553 ' NH1' ' HA ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -77.11 -60.95 2.15 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.814 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.553 ' HA ' ' NH1' ' A' ' 53' ' ' ARG . 17.5 tt -69.08 140.75 18.33 Favored 'Isoleucine or valine' 0 C--O 1.245 0.831 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.428 -175.518 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 16.4 mm-40 -137.18 173.36 11.76 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-O 121.641 0.734 . . . . 0.0 111.669 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.6 p -81.77 23.75 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.227 0 CA-C-O 122.309 1.052 . . . . 0.0 110.362 -178.687 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -134.79 13.43 3.68 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 122.432 1.111 . . . . 0.0 108.816 -178.324 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.472 ' HB3' HG21 ' A' ' 91' ' ' ILE . 64.9 m-20 -92.47 -177.4 4.6 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.151 -0.932 . . . . 0.0 110.806 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.563 ' HG3' ' O ' ' A' ' 37' ' ' ILE . 32.3 tt0 -134.31 125.02 26.81 Favored 'General case' 0 N--CA 1.434 -1.229 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.303 179.156 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.578 HG21 HD21 ' A' ' 80' ' ' LEU . 45.1 mm -77.63 113.8 17.29 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.908 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -177.143 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.668 ' HB ' ' O ' ' A' ' 90' ' ' VAL . 84.9 t -97.17 -49.14 12.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-O 121.65 0.738 . . . . 0.0 111.093 -177.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.636 ' HB3' ' HB ' ' A' ' 90' ' ' VAL . 28.6 tt0 -149.39 115.77 5.82 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.9 t -108.9 125.95 65.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.688 176.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 21.1 t70 69.98 1.62 3.56 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 124.807 1.243 . . . . 0.0 112.162 173.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.54 16.84 38.31 Favored Glycine 0 N--CA 1.427 -1.908 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.608 -176.185 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.467 HG21 HG21 ' A' ' 79' ' ' VAL . 7.8 tt -74.24 -32.85 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.786 0 O-C-N 122.343 -0.504 . . . . 0.0 110.357 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.548 ' H ' ' HG3' ' A' ' 62' ' ' GLU . 20.8 t 58.0 93.45 0.03 OUTLIER 'General case' 0 C--N 1.344 0.327 0 C-N-CA 125.015 1.326 . . . . 0.0 110.038 -176.207 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.54 HD21 HG22 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -105.27 21.0 17.91 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 121.747 0.784 . . . . 0.0 109.883 -174.954 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.516 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 21.4 t -56.31 96.22 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.287 -2.129 0 CA-C-N 114.532 -1.213 . . . . 0.0 112.046 179.091 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.49 ' H ' ' HB3' ' A' ' 35' ' ' LEU . . . 108.49 6.86 30.77 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.859 175.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.463 HG22 ' O ' ' A' ' 68' ' ' LEU . 21.3 m -82.7 -177.26 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 117.245 0.522 . . . . 0.0 112.005 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 p -97.89 173.77 6.91 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.003 176.489 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.56 ' HB2' ' CD1' ' A' ' 21' ' ' ILE . 0.0 OUTLIER -61.3 -35.11 76.47 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.437 -1.256 . . . . 0.0 111.706 179.044 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -71.33 -32.15 68.23 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 121.059 -0.257 . . . . 0.0 111.364 -178.547 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -70.75 -47.12 61.34 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 176.434 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.413 ' HA ' HG12 ' A' ' 79' ' ' VAL . . . -61.14 -42.88 99.35 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.915 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.411 ' O ' ' HB3' ' A' ' 81' ' ' ARG . . . -59.26 -38.08 79.18 Favored 'General case' 0 C--O 1.212 -0.911 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 176.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 88.1 m -65.15 -50.95 64.01 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.099 178.3 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.535 HG13 HD22 ' A' ' 80' ' ' LEU . 5.6 p -63.65 -45.2 98.15 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.577 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 178.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.578 HD21 HG21 ' A' ' 60' ' ' ILE . 4.0 mm? -67.29 -25.47 66.06 Favored 'General case' 0 C--O 1.216 -0.709 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.411 ' HB3' ' O ' ' A' ' 77' ' ' ALA . 0.4 OUTLIER -86.38 -23.54 26.11 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-O 120.857 0.36 . . . . 0.0 111.657 177.544 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -86.49 5.29 36.03 Favored 'General case' 0 N--CA 1.483 1.211 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 179.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.451 HG21 HD11 ' A' ' 17' ' ' LEU . 31.2 p -70.08 178.05 2.94 Favored 'General case' 0 C--N 1.291 -1.965 0 CA-C-O 121.711 0.767 . . . . 0.0 112.348 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.77 -159.04 0.97 Allowed 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 125.01 1.324 . . . . 0.0 108.045 -179.014 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.12 -76.01 0.22 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 114.467 0.547 . . . . 0.0 114.467 -179.223 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -78.75 112.14 15.58 Favored 'General case' 0 CA--C 1.497 -1.076 0 O-C-N 122.654 -0.321 . . . . 0.0 110.427 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 83.0 t -132.36 128.05 57.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.153 -178.374 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.68 108.38 19.78 Favored 'General case' 0 CA--C 1.496 -1.098 0 C-N-CA 119.715 -0.794 . . . . 0.0 109.903 172.133 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -93.63 98.92 11.46 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 174.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.668 ' O ' ' HB ' ' A' ' 61' ' ' VAL . 61.7 t -84.55 96.39 4.58 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.06 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 176.062 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.472 HG21 ' HB3' ' A' ' 58' ' ' ASP . 95.0 mt -112.91 153.75 14.44 Favored 'Isoleucine or valine' 0 C--N 1.262 -3.202 0 CA-C-N 113.796 -1.547 . . . . 0.0 108.608 177.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 4' ' ' GLU . . . -119.76 153.65 16.71 Favored Glycine 0 N--CA 1.403 -3.554 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 177.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.513 ' NH1' ' HG3' ' A' ' 94' ' ' GLU . 4.3 tmt_? -135.19 152.39 51.54 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -176.835 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.513 ' HG3' ' NH1' ' A' ' 93' ' ' ARG . 7.2 pt-20 . . . . . 0 C--N 1.321 -0.641 0 O-C-N 124.247 0.967 . . . . 0.0 110.771 177.306 . . . . . . . . 1 1 . 1 stop_ save_